-- Adminer 3.3.3 MySQL dump

SET NAMES utf8;
SET foreign_key_checks = 0;
SET time_zone = 'SYSTEM';
SET sql_mode = 'NO_AUTO_VALUE_ON_ZERO';

DROP TABLE IF EXISTS `calzada_commentmeta`;
CREATE TABLE `calzada_commentmeta` (
  `meta_id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `comment_id` bigint(20) unsigned NOT NULL DEFAULT '0',
  `meta_key` varchar(255) DEFAULT NULL,
  `meta_value` longtext,
  PRIMARY KEY (`meta_id`),
  KEY `comment_id` (`comment_id`),
  KEY `meta_key` (`meta_key`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;


DROP TABLE IF EXISTS `calzada_comments`;
CREATE TABLE `calzada_comments` (
  `comment_ID` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `comment_post_ID` bigint(20) unsigned NOT NULL DEFAULT '0',
  `comment_author` tinytext NOT NULL,
  `comment_author_email` varchar(100) NOT NULL DEFAULT '',
  `comment_author_url` varchar(200) NOT NULL DEFAULT '',
  `comment_author_IP` varchar(100) NOT NULL DEFAULT '',
  `comment_date` datetime NOT NULL DEFAULT '0000-00-00 00:00:00',
  `comment_date_gmt` datetime NOT NULL DEFAULT '0000-00-00 00:00:00',
  `comment_content` text NOT NULL,
  `comment_karma` int(11) NOT NULL DEFAULT '0',
  `comment_approved` varchar(20) NOT NULL DEFAULT '1',
  `comment_agent` varchar(255) NOT NULL DEFAULT '',
  `comment_type` varchar(20) NOT NULL DEFAULT '',
  `comment_parent` bigint(20) unsigned NOT NULL DEFAULT '0',
  `user_id` bigint(20) unsigned NOT NULL DEFAULT '0',
  PRIMARY KEY (`comment_ID`),
  KEY `comment_approved` (`comment_approved`),
  KEY `comment_post_ID` (`comment_post_ID`),
  KEY `comment_approved_date_gmt` (`comment_approved`,`comment_date_gmt`),
  KEY `comment_date_gmt` (`comment_date_gmt`),
  KEY `comment_parent` (`comment_parent`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;


DROP TABLE IF EXISTS `calzada_links`;
CREATE TABLE `calzada_links` (
  `link_id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `link_url` varchar(255) NOT NULL DEFAULT '',
  `link_name` varchar(255) NOT NULL DEFAULT '',
  `link_image` varchar(255) NOT NULL DEFAULT '',
  `link_target` varchar(25) NOT NULL DEFAULT '',
  `link_description` varchar(255) NOT NULL DEFAULT '',
  `link_visible` varchar(20) NOT NULL DEFAULT 'Y',
  `link_owner` bigint(20) unsigned NOT NULL DEFAULT '1',
  `link_rating` int(11) NOT NULL DEFAULT '0',
  `link_updated` datetime NOT NULL DEFAULT '0000-00-00 00:00:00',
  `link_rel` varchar(255) NOT NULL DEFAULT '',
  `link_notes` mediumtext NOT NULL,
  `link_rss` varchar(255) NOT NULL DEFAULT '',
  PRIMARY KEY (`link_id`),
  KEY `link_visible` (`link_visible`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

INSERT INTO `calzada_links` (`link_id`, `link_url`, `link_name`, `link_image`, `link_target`, `link_description`, `link_visible`, `link_owner`, `link_rating`, `link_updated`, `link_rel`, `link_notes`, `link_rss`) VALUES
(1,	'http://codex.wordpress.org/',	'Documentation',	'',	'',	'',	'Y',	1,	0,	'0000-00-00 00:00:00',	'',	'',	''),
(2,	'http://wordpress.org/news/',	'WordPress Blog',	'',	'',	'',	'Y',	1,	0,	'0000-00-00 00:00:00',	'',	'',	'http://wordpress.org/news/feed/'),
(3,	'http://wordpress.org/extend/ideas/',	'Suggest Ideas',	'',	'',	'',	'Y',	1,	0,	'0000-00-00 00:00:00',	'',	'',	''),
(4,	'http://wordpress.org/support/',	'Support Forum',	'',	'',	'',	'Y',	1,	0,	'0000-00-00 00:00:00',	'',	'',	''),
(5,	'http://wordpress.org/extend/plugins/',	'Plugins',	'',	'',	'',	'Y',	1,	0,	'0000-00-00 00:00:00',	'',	'',	''),
(6,	'http://wordpress.org/extend/themes/',	'Themes',	'',	'',	'',	'Y',	1,	0,	'0000-00-00 00:00:00',	'',	'',	''),
(7,	'http://planet.wordpress.org/',	'WordPress Planet',	'',	'',	'',	'Y',	1,	0,	'0000-00-00 00:00:00',	'',	'',	'');

DROP TABLE IF EXISTS `calzada_options`;
CREATE TABLE `calzada_options` (
  `option_id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `blog_id` int(11) NOT NULL DEFAULT '0',
  `option_name` varchar(64) NOT NULL DEFAULT '',
  `option_value` longtext NOT NULL,
  `autoload` varchar(20) NOT NULL DEFAULT 'yes',
  PRIMARY KEY (`option_id`),
  UNIQUE KEY `option_name` (`option_name`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

INSERT INTO `calzada_options` (`option_id`, `blog_id`, `option_name`, `option_value`, `autoload`) VALUES
(3,	0,	'siteurl',	'http://calzada-wp.urldock.com',	'yes'),
(4,	0,	'blogname',	'Calzada Limited',	'yes'),
(5,	0,	'blogdescription',	'Calzada has 100% ownership of PolyNovo Biomaterials Pty Ltd and Metabolic Pharmaceuticals Pty Ltd. The company is listed on the Australian Stock Exchange (ASX Code CZD).',	'yes'),
(6,	0,	'users_can_register',	'0',	'yes'),
(7,	0,	'admin_email',	'piotr.kulpinski@xhtmlized.com',	'yes'),
(8,	0,	'start_of_week',	'1',	'yes'),
(9,	0,	'use_balanceTags',	'0',	'yes'),
(10,	0,	'use_smilies',	'1',	'yes'),
(11,	0,	'require_name_email',	'1',	'yes'),
(12,	0,	'comments_notify',	'1',	'yes'),
(13,	0,	'posts_per_rss',	'10',	'yes'),
(14,	0,	'rss_use_excerpt',	'0',	'yes'),
(15,	0,	'mailserver_url',	'mail.example.com',	'yes'),
(16,	0,	'mailserver_login',	'login@example.com',	'yes'),
(17,	0,	'mailserver_pass',	'password',	'yes'),
(18,	0,	'mailserver_port',	'110',	'yes'),
(19,	0,	'default_category',	'1',	'yes'),
(20,	0,	'default_comment_status',	'open',	'yes'),
(21,	0,	'default_ping_status',	'open',	'yes'),
(22,	0,	'default_pingback_flag',	'1',	'yes'),
(23,	0,	'default_post_edit_rows',	'20',	'yes'),
(24,	0,	'posts_per_page',	'10',	'yes'),
(25,	0,	'date_format',	'F j, Y',	'yes'),
(26,	0,	'time_format',	'g:i a',	'yes'),
(27,	0,	'links_updated_date_format',	'F j, Y g:i a',	'yes'),
(28,	0,	'links_recently_updated_prepend',	'<em>',	'yes'),
(29,	0,	'links_recently_updated_append',	'</em>',	'yes'),
(30,	0,	'links_recently_updated_time',	'120',	'yes'),
(31,	0,	'comment_moderation',	'0',	'yes'),
(32,	0,	'moderation_notify',	'1',	'yes'),
(33,	0,	'permalink_structure',	'/%postname%/',	'yes'),
(34,	0,	'gzipcompression',	'0',	'yes'),
(35,	0,	'hack_file',	'0',	'yes'),
(36,	0,	'blog_charset',	'UTF-8',	'yes'),
(37,	0,	'moderation_keys',	'',	'no'),
(38,	0,	'active_plugins',	'a:8:{i:0;s:33:\"admin-menu-editor/menu-editor.php\";i:1;s:30:\"advanced-custom-fields/acf.php\";i:2;s:39:\"ajax-campaign-monitor-forms/cm-ajax.php\";i:3;s:43:\"all-in-one-seo-pack/all_in_one_seo_pack.php\";i:4;s:27:\"backupbuddy/backupbuddy.php\";i:5;s:43:\"cm-subscriber-stats/cm-subscriber-stats.php\";i:6;s:29:\"j-shortcodes/j-shortcodes.php\";i:7;s:31:\"page-links-to/page-links-to.php\";}',	'yes'),
(39,	0,	'home',	'http://calzada-wp.urldock.com',	'yes'),
(40,	0,	'category_base',	'',	'yes'),
(41,	0,	'ping_sites',	'http://rpc.pingomatic.com/',	'yes'),
(42,	0,	'advanced_edit',	'0',	'yes'),
(43,	0,	'comment_max_links',	'2',	'yes'),
(44,	0,	'gmt_offset',	'0',	'yes'),
(45,	0,	'default_email_category',	'1',	'yes'),
(46,	0,	'recently_edited',	'a:5:{i:0;s:62:\"/var/www/vhosts/calzada-wp/wp-content/themes/calzada/style.css\";i:2;s:67:\"/var/www/vhosts/calzada-wp/wp-content/themes/calzada/front-page.php\";i:3;s:61:\"/var/www/vhosts/calzada-wp/wp-content/themes/calzada/page.php\";i:4;s:62:\"/var/www/vhosts/calzada-wp/wp-content/themes/calzada/index.php\";i:5;s:69:\"/var/www/vhosts/calzada-wp/wp-content/themes/calzada/_inc/widgets.php\";}',	'no'),
(47,	0,	'template',	'calzada',	'yes'),
(48,	0,	'stylesheet',	'calzada',	'yes'),
(49,	0,	'comment_whitelist',	'1',	'yes'),
(50,	0,	'blacklist_keys',	'',	'no'),
(51,	0,	'comment_registration',	'0',	'yes'),
(52,	0,	'rss_language',	'en',	'yes'),
(53,	0,	'html_type',	'text/html',	'yes'),
(54,	0,	'use_trackback',	'0',	'yes'),
(55,	0,	'default_role',	'subscriber',	'yes'),
(56,	0,	'db_version',	'19470',	'yes'),
(57,	0,	'uploads_use_yearmonth_folders',	'1',	'yes'),
(58,	0,	'upload_path',	'',	'yes'),
(59,	0,	'blog_public',	'1',	'yes'),
(60,	0,	'default_link_category',	'2',	'yes'),
(61,	0,	'show_on_front',	'page',	'yes'),
(62,	0,	'tag_base',	'',	'yes'),
(63,	0,	'show_avatars',	'1',	'yes'),
(64,	0,	'avatar_rating',	'G',	'yes'),
(65,	0,	'upload_url_path',	'',	'yes'),
(66,	0,	'thumbnail_size_w',	'150',	'yes'),
(67,	0,	'thumbnail_size_h',	'150',	'yes'),
(68,	0,	'thumbnail_crop',	'1',	'yes'),
(69,	0,	'medium_size_w',	'300',	'yes'),
(70,	0,	'medium_size_h',	'300',	'yes'),
(71,	0,	'avatar_default',	'mystery',	'yes'),
(72,	0,	'enable_app',	'0',	'yes'),
(73,	0,	'enable_xmlrpc',	'0',	'yes'),
(74,	0,	'large_size_w',	'1024',	'yes'),
(75,	0,	'large_size_h',	'1024',	'yes'),
(76,	0,	'image_default_link_type',	'file',	'yes'),
(77,	0,	'image_default_size',	'',	'yes'),
(78,	0,	'image_default_align',	'',	'yes'),
(79,	0,	'close_comments_for_old_posts',	'0',	'yes'),
(80,	0,	'close_comments_days_old',	'14',	'yes'),
(81,	0,	'thread_comments',	'1',	'yes'),
(82,	0,	'thread_comments_depth',	'5',	'yes'),
(83,	0,	'page_comments',	'0',	'yes'),
(84,	0,	'comments_per_page',	'50',	'yes'),
(85,	0,	'default_comments_page',	'newest',	'yes'),
(86,	0,	'comment_order',	'asc',	'yes'),
(87,	0,	'sticky_posts',	'a:0:{}',	'yes'),
(88,	0,	'widget_categories',	'a:2:{i:2;a:4:{s:5:\"title\";s:0:\"\";s:5:\"count\";i:0;s:12:\"hierarchical\";i:0;s:8:\"dropdown\";i:0;}s:12:\"_multiwidget\";i:1;}',	'yes'),
(89,	0,	'widget_text',	'a:1:{s:12:\"_multiwidget\";i:1;}',	'yes'),
(90,	0,	'widget_rss',	'a:0:{}',	'yes'),
(91,	0,	'timezone_string',	'',	'yes'),
(92,	0,	'embed_autourls',	'1',	'yes'),
(93,	0,	'embed_size_w',	'',	'yes'),
(94,	0,	'embed_size_h',	'600',	'yes'),
(95,	0,	'page_for_posts',	'0',	'yes'),
(96,	0,	'page_on_front',	'6',	'yes'),
(97,	0,	'default_post_format',	'0',	'yes'),
(98,	0,	'initial_db_version',	'19470',	'yes'),
(99,	0,	'calzada_user_roles',	'a:5:{s:13:\"administrator\";a:2:{s:4:\"name\";s:13:\"Administrator\";s:12:\"capabilities\";a:62:{s:13:\"switch_themes\";b:1;s:11:\"edit_themes\";b:1;s:16:\"activate_plugins\";b:1;s:12:\"edit_plugins\";b:1;s:10:\"edit_users\";b:1;s:10:\"edit_files\";b:1;s:14:\"manage_options\";b:1;s:17:\"moderate_comments\";b:1;s:17:\"manage_categories\";b:1;s:12:\"manage_links\";b:1;s:12:\"upload_files\";b:1;s:6:\"import\";b:1;s:15:\"unfiltered_html\";b:1;s:10:\"edit_posts\";b:1;s:17:\"edit_others_posts\";b:1;s:20:\"edit_published_posts\";b:1;s:13:\"publish_posts\";b:1;s:10:\"edit_pages\";b:1;s:4:\"read\";b:1;s:8:\"level_10\";b:1;s:7:\"level_9\";b:1;s:7:\"level_8\";b:1;s:7:\"level_7\";b:1;s:7:\"level_6\";b:1;s:7:\"level_5\";b:1;s:7:\"level_4\";b:1;s:7:\"level_3\";b:1;s:7:\"level_2\";b:1;s:7:\"level_1\";b:1;s:7:\"level_0\";b:1;s:17:\"edit_others_pages\";b:1;s:20:\"edit_published_pages\";b:1;s:13:\"publish_pages\";b:1;s:12:\"delete_pages\";b:1;s:19:\"delete_others_pages\";b:1;s:22:\"delete_published_pages\";b:1;s:12:\"delete_posts\";b:1;s:19:\"delete_others_posts\";b:1;s:22:\"delete_published_posts\";b:1;s:20:\"delete_private_posts\";b:1;s:18:\"edit_private_posts\";b:1;s:18:\"read_private_posts\";b:1;s:20:\"delete_private_pages\";b:1;s:18:\"edit_private_pages\";b:1;s:18:\"read_private_pages\";b:1;s:12:\"delete_users\";b:1;s:12:\"create_users\";b:1;s:17:\"unfiltered_upload\";b:1;s:14:\"edit_dashboard\";b:1;s:14:\"update_plugins\";b:1;s:14:\"delete_plugins\";b:1;s:15:\"install_plugins\";b:1;s:13:\"update_themes\";b:1;s:14:\"install_themes\";b:1;s:11:\"update_core\";b:1;s:10:\"list_users\";b:1;s:12:\"remove_users\";b:1;s:9:\"add_users\";b:1;s:13:\"promote_users\";b:1;s:18:\"edit_theme_options\";b:1;s:13:\"delete_themes\";b:1;s:6:\"export\";b:1;}}s:6:\"editor\";a:2:{s:4:\"name\";s:6:\"Editor\";s:12:\"capabilities\";a:34:{s:17:\"moderate_comments\";b:1;s:17:\"manage_categories\";b:1;s:12:\"manage_links\";b:1;s:12:\"upload_files\";b:1;s:15:\"unfiltered_html\";b:1;s:10:\"edit_posts\";b:1;s:17:\"edit_others_posts\";b:1;s:20:\"edit_published_posts\";b:1;s:13:\"publish_posts\";b:1;s:10:\"edit_pages\";b:1;s:4:\"read\";b:1;s:7:\"level_7\";b:1;s:7:\"level_6\";b:1;s:7:\"level_5\";b:1;s:7:\"level_4\";b:1;s:7:\"level_3\";b:1;s:7:\"level_2\";b:1;s:7:\"level_1\";b:1;s:7:\"level_0\";b:1;s:17:\"edit_others_pages\";b:1;s:20:\"edit_published_pages\";b:1;s:13:\"publish_pages\";b:1;s:12:\"delete_pages\";b:1;s:19:\"delete_others_pages\";b:1;s:22:\"delete_published_pages\";b:1;s:12:\"delete_posts\";b:1;s:19:\"delete_others_posts\";b:1;s:22:\"delete_published_posts\";b:1;s:20:\"delete_private_posts\";b:1;s:18:\"edit_private_posts\";b:1;s:18:\"read_private_posts\";b:1;s:20:\"delete_private_pages\";b:1;s:18:\"edit_private_pages\";b:1;s:18:\"read_private_pages\";b:1;}}s:6:\"author\";a:2:{s:4:\"name\";s:6:\"Author\";s:12:\"capabilities\";a:10:{s:12:\"upload_files\";b:1;s:10:\"edit_posts\";b:1;s:20:\"edit_published_posts\";b:1;s:13:\"publish_posts\";b:1;s:4:\"read\";b:1;s:7:\"level_2\";b:1;s:7:\"level_1\";b:1;s:7:\"level_0\";b:1;s:12:\"delete_posts\";b:1;s:22:\"delete_published_posts\";b:1;}}s:11:\"contributor\";a:2:{s:4:\"name\";s:11:\"Contributor\";s:12:\"capabilities\";a:5:{s:10:\"edit_posts\";b:1;s:4:\"read\";b:1;s:7:\"level_1\";b:1;s:7:\"level_0\";b:1;s:12:\"delete_posts\";b:1;}}s:10:\"subscriber\";a:2:{s:4:\"name\";s:10:\"Subscriber\";s:12:\"capabilities\";a:2:{s:4:\"read\";b:1;s:7:\"level_0\";b:1;}}}',	'yes'),
(100,	0,	'widget_search',	'a:2:{i:2;a:1:{s:5:\"title\";s:0:\"\";}s:12:\"_multiwidget\";i:1;}',	'yes'),
(101,	0,	'widget_recent-posts',	'a:4:{i:2;a:2:{s:5:\"title\";s:0:\"\";s:6:\"number\";i:5;}i:3;a:2:{s:5:\"title\";s:11:\"Latest News\";s:6:\"number\";i:4;}i:4;a:2:{s:5:\"title\";s:11:\"Latest News\";s:6:\"number\";i:4;}s:12:\"_multiwidget\";i:1;}',	'yes'),
(102,	0,	'widget_recent-comments',	'a:2:{i:2;a:2:{s:5:\"title\";s:0:\"\";s:6:\"number\";i:5;}s:12:\"_multiwidget\";i:1;}',	'yes'),
(103,	0,	'widget_archives',	'a:2:{i:2;a:3:{s:5:\"title\";s:0:\"\";s:5:\"count\";i:0;s:8:\"dropdown\";i:0;}s:12:\"_multiwidget\";i:1;}',	'yes'),
(104,	0,	'widget_meta',	'a:2:{i:2;a:1:{s:5:\"title\";s:0:\"\";}s:12:\"_multiwidget\";i:1;}',	'yes'),
(105,	0,	'sidebars_widgets',	'a:6:{s:18:\"orphaned_widgets_1\";a:6:{i:0;s:8:\"search-2\";i:1;s:14:\"recent-posts-2\";i:2;s:17:\"recent-comments-2\";i:3;s:10:\"archives-2\";i:4;s:12:\"categories-2\";i:5;s:6:\"meta-2\";}s:7:\"sidebar\";a:2:{i:0;s:21:\"stock_prices_widget-2\";i:1;s:20:\"latest_news_widget-2\";}s:19:\"wp_inactive_widgets\";a:0:{}s:12:\"main-sidebar\";a:4:{i:0;s:16:\"widget_cm_ajax-2\";i:1;s:21:\"stock_prices_widget-3\";i:2;s:14:\"recent-posts-3\";i:3;s:17:\"widget-rokstock-2\";}s:16:\"homepage-sidebar\";a:3:{i:0;s:14:\"recent-posts-4\";i:1;s:16:\"widget_cm_ajax-3\";i:2;s:21:\"stock_prices_widget-5\";}s:13:\"array_version\";i:3;}',	'yes'),
(106,	0,	'cron',	'a:3:{i:1346439617;a:3:{s:16:\"wp_version_check\";a:1:{s:32:\"40cd750bba9870f18aada2478b24840a\";a:3:{s:8:\"schedule\";s:10:\"twicedaily\";s:4:\"args\";a:0:{}s:8:\"interval\";i:43200;}}s:17:\"wp_update_plugins\";a:1:{s:32:\"40cd750bba9870f18aada2478b24840a\";a:3:{s:8:\"schedule\";s:10:\"twicedaily\";s:4:\"args\";a:0:{}s:8:\"interval\";i:43200;}}s:16:\"wp_update_themes\";a:1:{s:32:\"40cd750bba9870f18aada2478b24840a\";a:3:{s:8:\"schedule\";s:10:\"twicedaily\";s:4:\"args\";a:0:{}s:8:\"interval\";i:43200;}}}i:1346439653;a:1:{s:19:\"wp_scheduled_delete\";a:1:{s:32:\"40cd750bba9870f18aada2478b24840a\";a:3:{s:8:\"schedule\";s:5:\"daily\";s:4:\"args\";a:0:{}s:8:\"interval\";i:86400;}}}s:7:\"version\";i:2;}',	'yes'),
(108,	0,	'_site_transient_update_core',	'O:8:\"stdClass\":3:{s:7:\"updates\";a:1:{i:0;O:8:\"stdClass\":9:{s:8:\"response\";s:7:\"upgrade\";s:8:\"download\";s:40:\"http://wordpress.org/wordpress-3.4.1.zip\";s:6:\"locale\";s:5:\"en_US\";s:8:\"packages\";O:8:\"stdClass\":4:{s:4:\"full\";s:40:\"http://wordpress.org/wordpress-3.4.1.zip\";s:10:\"no_content\";s:51:\"http://wordpress.org/wordpress-3.4.1-no-content.zip\";s:11:\"new_bundled\";s:52:\"http://wordpress.org/wordpress-3.4.1-new-bundled.zip\";s:7:\"partial\";b:0;}s:7:\"current\";s:5:\"3.4.1\";s:11:\"php_version\";s:5:\"5.2.4\";s:13:\"mysql_version\";s:3:\"5.0\";s:11:\"new_bundled\";s:3:\"3.2\";s:15:\"partial_version\";s:0:\"\";}}s:12:\"last_checked\";i:1346406466;s:15:\"version_checked\";s:5:\"3.3.2\";}',	'yes'),
(110,	0,	'_site_transient_update_themes',	'O:8:\"stdClass\":3:{s:12:\"last_checked\";i:1346406466;s:7:\"checked\";a:2:{s:7:\"calzada\";s:3:\"1.0\";s:12:\"twentyeleven\";s:3:\"1.3\";}s:8:\"response\";a:1:{s:12:\"twentyeleven\";a:3:{s:11:\"new_version\";s:3:\"1.4\";s:3:\"url\";s:47:\"http://wordpress.org/extend/themes/twentyeleven\";s:7:\"package\";s:64:\"http://wordpress.org/extend/themes/download/twentyeleven.1.4.zip\";}}}',	'yes'),
(111,	0,	'_site_transient_timeout_browser_742fa94dc4080017a92b7961dab9ab9e',	'1338231659',	'yes'),
(112,	0,	'_site_transient_browser_742fa94dc4080017a92b7961dab9ab9e',	'a:9:{s:8:\"platform\";s:9:\"Macintosh\";s:4:\"name\";s:6:\"Chrome\";s:7:\"version\";s:11:\"16.0.912.75\";s:10:\"update_url\";s:28:\"http://www.google.com/chrome\";s:7:\"img_src\";s:49:\"http://s.wordpress.org/images/browsers/chrome.png\";s:11:\"img_src_ssl\";s:48:\"https://wordpress.org/images/browsers/chrome.png\";s:15:\"current_version\";s:2:\"18\";s:7:\"upgrade\";b:1;s:8:\"insecure\";b:0;}',	'yes'),
(113,	0,	'dashboard_widget_options',	'a:4:{s:25:\"dashboard_recent_comments\";a:1:{s:5:\"items\";i:5;}s:24:\"dashboard_incoming_links\";a:5:{s:4:\"home\";s:29:\"http://calzada-wp.urldock.com\";s:4:\"link\";s:105:\"http://blogsearch.google.com/blogsearch?scoring=d&partner=wordpress&q=link:http://calzada-wp.urldock.com/\";s:3:\"url\";s:138:\"http://blogsearch.google.com/blogsearch_feeds?scoring=d&ie=utf-8&num=10&output=rss&partner=wordpress&q=link:http://calzada-wp.urldock.com/\";s:5:\"items\";i:10;s:9:\"show_date\";b:0;}s:17:\"dashboard_primary\";a:7:{s:4:\"link\";s:26:\"http://wordpress.org/news/\";s:3:\"url\";s:31:\"http://wordpress.org/news/feed/\";s:5:\"title\";s:14:\"WordPress Blog\";s:5:\"items\";i:2;s:12:\"show_summary\";i:1;s:11:\"show_author\";i:0;s:9:\"show_date\";i:1;}s:19:\"dashboard_secondary\";a:7:{s:4:\"link\";s:28:\"http://planet.wordpress.org/\";s:3:\"url\";s:33:\"http://planet.wordpress.org/feed/\";s:5:\"title\";s:20:\"Other WordPress News\";s:5:\"items\";i:5;s:12:\"show_summary\";i:0;s:11:\"show_author\";i:0;s:9:\"show_date\";i:0;}}',	'yes'),
(115,	0,	'can_compress_scripts',	'1',	'yes'),
(150,	0,	'_site_transient_timeout_browser_92283a3167bcdd292a091e60e35f84bb',	'1338233632',	'yes'),
(151,	0,	'_site_transient_browser_92283a3167bcdd292a091e60e35f84bb',	'a:9:{s:8:\"platform\";s:9:\"Macintosh\";s:4:\"name\";s:6:\"Chrome\";s:7:\"version\";s:12:\"19.0.1084.46\";s:10:\"update_url\";s:28:\"http://www.google.com/chrome\";s:7:\"img_src\";s:49:\"http://s.wordpress.org/images/browsers/chrome.png\";s:11:\"img_src_ssl\";s:48:\"https://wordpress.org/images/browsers/chrome.png\";s:15:\"current_version\";s:2:\"18\";s:7:\"upgrade\";b:0;s:8:\"insecure\";b:0;}',	'yes'),
(156,	0,	'theme_mods_calzada',	'a:2:{i:0;b:0;s:18:\"nav_menu_locations\";a:2:{s:7:\"primary\";i:3;s:6:\"footer\";i:4;}}',	'yes'),
(157,	0,	'theme_switched',	'',	'yes'),
(158,	0,	'recently_activated',	'a:0:{}',	'yes'),
(159,	0,	'acf_version',	'3.2.5',	'yes'),
(160,	0,	'ws_menu_editor',	'a:4:{s:22:\"hide_advanced_settings\";b:1;s:19:\"menu_format_version\";i:4;s:21:\"display_survey_notice\";b:0;s:11:\"custom_menu\";a:15:{s:9:\"index.php\";a:14:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:9:\"css_class\";N;s:8:\"hookname\";N;s:8:\"icon_url\";N;s:6:\"custom\";N;s:8:\"defaults\";a:12:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:9:\"Dashboard\";s:12:\"access_level\";s:4:\"read\";s:4:\"file\";s:9:\"index.php\";s:9:\"css_class\";s:43:\"menu-top menu-top-first menu-icon-dashboard\";s:8:\"hookname\";s:14:\"menu-dashboard\";s:8:\"icon_url\";s:3:\"div\";s:8:\"position\";i:0;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:0;s:9:\"separator\";b:0;s:6:\"hidden\";b:0;s:5:\"items\";a:2:{s:9:\"index.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:4:\"Home\";s:12:\"access_level\";s:4:\"read\";s:4:\"file\";s:9:\"index.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:0;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:9:\"index.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:0;s:6:\"hidden\";b:0;}s:15:\"update-core.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:96:\"Updates <span class=\'update-plugins count-0\' title=\'\'><span class=\'update-count\'>0</span></span>\";s:12:\"access_level\";s:11:\"update_core\";s:4:\"file\";s:15:\"update-core.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:1;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:9:\"index.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:1;s:6:\"hidden\";b:0;}}}s:10:\"separator1\";a:14:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:9:\"css_class\";N;s:8:\"hookname\";N;s:8:\"icon_url\";N;s:6:\"custom\";N;s:8:\"defaults\";a:12:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:0:\"\";s:12:\"access_level\";s:4:\"read\";s:4:\"file\";s:10:\"separator1\";s:9:\"css_class\";s:17:\"wp-menu-separator\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:1;s:9:\"separator\";b:1;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:1;s:9:\"separator\";b:1;s:6:\"hidden\";b:0;s:5:\"items\";a:0:{}}s:8:\"edit.php\";a:14:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:9:\"css_class\";N;s:8:\"hookname\";N;s:8:\"icon_url\";N;s:6:\"custom\";N;s:8:\"defaults\";a:12:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:5:\"Posts\";s:12:\"access_level\";s:10:\"edit_posts\";s:4:\"file\";s:8:\"edit.php\";s:9:\"css_class\";s:37:\"open-if-no-js menu-top menu-icon-post\";s:8:\"hookname\";s:10:\"menu-posts\";s:8:\"icon_url\";s:3:\"div\";s:8:\"position\";i:2;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:2;s:9:\"separator\";b:0;s:6:\"hidden\";b:0;s:5:\"items\";a:4:{s:8:\"edit.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:9:\"All Posts\";s:12:\"access_level\";s:10:\"edit_posts\";s:4:\"file\";s:8:\"edit.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:0;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:8:\"edit.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:0;s:6:\"hidden\";b:0;}s:12:\"post-new.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:7:\"Add New\";s:12:\"access_level\";s:10:\"edit_posts\";s:4:\"file\";s:12:\"post-new.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:1;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:8:\"edit.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:1;s:6:\"hidden\";b:0;}s:31:\"edit-tags.php?taxonomy=category\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:10:\"Categories\";s:12:\"access_level\";s:17:\"manage_categories\";s:4:\"file\";s:31:\"edit-tags.php?taxonomy=category\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:2;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:8:\"edit.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:2;s:6:\"hidden\";b:0;}s:31:\"edit-tags.php?taxonomy=post_tag\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:4:\"Tags\";s:12:\"access_level\";s:17:\"manage_categories\";s:4:\"file\";s:31:\"edit-tags.php?taxonomy=post_tag\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:3;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:8:\"edit.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:3;s:6:\"hidden\";b:0;}}}s:23:\"edit.php?post_type=page\";a:14:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:9:\"css_class\";N;s:8:\"hookname\";N;s:8:\"icon_url\";N;s:6:\"custom\";N;s:8:\"defaults\";a:12:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:5:\"Pages\";s:12:\"access_level\";s:10:\"edit_pages\";s:4:\"file\";s:23:\"edit.php?post_type=page\";s:9:\"css_class\";s:23:\"menu-top menu-icon-page\";s:8:\"hookname\";s:10:\"menu-pages\";s:8:\"icon_url\";s:3:\"div\";s:8:\"position\";i:3;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:3;s:9:\"separator\";b:0;s:6:\"hidden\";b:0;s:5:\"items\";a:2:{s:23:\"edit.php?post_type=page\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:9:\"All Pages\";s:12:\"access_level\";s:10:\"edit_pages\";s:4:\"file\";s:23:\"edit.php?post_type=page\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:0;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:23:\"edit.php?post_type=page\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:0;s:6:\"hidden\";b:0;}s:27:\"post-new.php?post_type=page\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:7:\"Add New\";s:12:\"access_level\";s:10:\"edit_pages\";s:4:\"file\";s:27:\"post-new.php?post_type=page\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:1;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:23:\"edit.php?post_type=page\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:1;s:6:\"hidden\";b:0;}}}s:10:\"upload.php\";a:14:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:9:\"css_class\";N;s:8:\"hookname\";N;s:8:\"icon_url\";N;s:6:\"custom\";N;s:8:\"defaults\";a:12:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:5:\"Media\";s:12:\"access_level\";s:12:\"upload_files\";s:4:\"file\";s:10:\"upload.php\";s:9:\"css_class\";s:24:\"menu-top menu-icon-media\";s:8:\"hookname\";s:10:\"menu-media\";s:8:\"icon_url\";s:3:\"div\";s:8:\"position\";i:4;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:4;s:9:\"separator\";b:0;s:6:\"hidden\";b:0;s:5:\"items\";a:2:{s:10:\"upload.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:7:\"Library\";s:12:\"access_level\";s:12:\"upload_files\";s:4:\"file\";s:10:\"upload.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:0;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:10:\"upload.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:0;s:6:\"hidden\";b:0;}s:13:\"media-new.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:7:\"Add New\";s:12:\"access_level\";s:12:\"upload_files\";s:4:\"file\";s:13:\"media-new.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:1;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:10:\"upload.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:1;s:6:\"hidden\";b:0;}}}s:16:\"link-manager.php\";a:14:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:9:\"css_class\";N;s:8:\"hookname\";N;s:8:\"icon_url\";N;s:6:\"custom\";N;s:8:\"defaults\";a:12:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:5:\"Links\";s:12:\"access_level\";s:12:\"manage_links\";s:4:\"file\";s:16:\"link-manager.php\";s:9:\"css_class\";s:24:\"menu-top menu-icon-links\";s:8:\"hookname\";s:10:\"menu-links\";s:8:\"icon_url\";s:3:\"div\";s:8:\"position\";i:5;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:5;s:9:\"separator\";b:0;s:6:\"hidden\";b:1;s:5:\"items\";a:3:{s:16:\"link-manager.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:9:\"All Links\";s:12:\"access_level\";s:12:\"manage_links\";s:4:\"file\";s:16:\"link-manager.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:0;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:16:\"link-manager.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:0;s:6:\"hidden\";b:1;}s:12:\"link-add.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:7:\"Add New\";s:12:\"access_level\";s:12:\"manage_links\";s:4:\"file\";s:12:\"link-add.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:1;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:16:\"link-manager.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:1;s:6:\"hidden\";b:1;}s:36:\"edit-tags.php?taxonomy=link_category\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:15:\"Link Categories\";s:12:\"access_level\";s:17:\"manage_categories\";s:4:\"file\";s:36:\"edit-tags.php?taxonomy=link_category\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:2;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:16:\"link-manager.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:2;s:6:\"hidden\";b:1;}}}s:17:\"edit-comments.php\";a:14:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:9:\"css_class\";N;s:8:\"hookname\";N;s:8:\"icon_url\";N;s:6:\"custom\";N;s:8:\"defaults\";a:12:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:87:\"Comments <span class=\'awaiting-mod count-0\'><span class=\'pending-count\'>0</span></span>\";s:12:\"access_level\";s:10:\"edit_posts\";s:4:\"file\";s:17:\"edit-comments.php\";s:9:\"css_class\";s:27:\"menu-top menu-icon-comments\";s:8:\"hookname\";s:13:\"menu-comments\";s:8:\"icon_url\";s:3:\"div\";s:8:\"position\";i:6;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:6;s:9:\"separator\";b:0;s:6:\"hidden\";b:1;s:5:\"items\";a:1:{s:17:\"edit-comments.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:12:\"All Comments\";s:12:\"access_level\";s:10:\"edit_posts\";s:4:\"file\";s:17:\"edit-comments.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:0;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:17:\"edit-comments.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:0;s:6:\"hidden\";b:1;}}}s:29:\"edit.php?post_type=home-image\";a:14:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:9:\"css_class\";N;s:8:\"hookname\";N;s:8:\"icon_url\";N;s:6:\"custom\";N;s:8:\"defaults\";a:12:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:11:\"Home Images\";s:12:\"access_level\";s:10:\"edit_posts\";s:4:\"file\";s:29:\"edit.php?post_type=home-image\";s:9:\"css_class\";s:23:\"menu-top menu-icon-post\";s:8:\"hookname\";s:21:\"menu-posts-home-image\";s:8:\"icon_url\";s:3:\"div\";s:8:\"position\";i:7;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:7;s:9:\"separator\";b:0;s:6:\"hidden\";b:0;s:5:\"items\";a:2:{s:29:\"edit.php?post_type=home-image\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:11:\"Home Images\";s:12:\"access_level\";s:10:\"edit_posts\";s:4:\"file\";s:29:\"edit.php?post_type=home-image\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:0;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:29:\"edit.php?post_type=home-image\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:0;s:6:\"hidden\";b:0;}s:33:\"post-new.php?post_type=home-image\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:7:\"Add New\";s:12:\"access_level\";s:10:\"edit_posts\";s:4:\"file\";s:33:\"post-new.php?post_type=home-image\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:1;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:29:\"edit.php?post_type=home-image\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:1;s:6:\"hidden\";b:0;}}}s:10:\"separator2\";a:14:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:9:\"css_class\";N;s:8:\"hookname\";N;s:8:\"icon_url\";N;s:6:\"custom\";N;s:8:\"defaults\";a:12:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:0:\"\";s:12:\"access_level\";s:4:\"read\";s:4:\"file\";s:10:\"separator2\";s:9:\"css_class\";s:17:\"wp-menu-separator\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:8;s:9:\"separator\";b:1;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:8;s:9:\"separator\";b:1;s:6:\"hidden\";b:0;s:5:\"items\";a:0:{}}s:10:\"themes.php\";a:14:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:9:\"css_class\";N;s:8:\"hookname\";N;s:8:\"icon_url\";N;s:6:\"custom\";N;s:8:\"defaults\";a:12:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:10:\"Appearance\";s:12:\"access_level\";s:13:\"switch_themes\";s:4:\"file\";s:10:\"themes.php\";s:9:\"css_class\";s:29:\"menu-top menu-icon-appearance\";s:8:\"hookname\";s:15:\"menu-appearance\";s:8:\"icon_url\";s:3:\"div\";s:8:\"position\";i:9;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:9;s:9:\"separator\";b:0;s:6:\"hidden\";b:0;s:5:\"items\";a:4:{s:10:\"themes.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:6:\"Themes\";s:12:\"access_level\";s:13:\"switch_themes\";s:4:\"file\";s:10:\"themes.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:0;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:10:\"themes.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:0;s:6:\"hidden\";b:0;}s:11:\"widgets.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:7:\"Widgets\";s:12:\"access_level\";s:18:\"edit_theme_options\";s:4:\"file\";s:11:\"widgets.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:1;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:10:\"themes.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:1;s:6:\"hidden\";b:0;}s:13:\"nav-menus.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:5:\"Menus\";s:12:\"access_level\";s:18:\"edit_theme_options\";s:4:\"file\";s:13:\"nav-menus.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:2;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:10:\"themes.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:2;s:6:\"hidden\";b:0;}s:16:\"theme-editor.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:6:\"Editor\";s:10:\"menu_title\";s:6:\"Editor\";s:12:\"access_level\";s:11:\"edit_themes\";s:4:\"file\";s:16:\"theme-editor.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:3;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:10:\"themes.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:3;s:6:\"hidden\";b:0;}}}s:11:\"plugins.php\";a:14:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:9:\"css_class\";N;s:8:\"hookname\";N;s:8:\"icon_url\";N;s:6:\"custom\";N;s:8:\"defaults\";a:12:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:87:\"Plugins <span class=\'update-plugins count-0\'><span class=\'plugin-count\'>0</span></span>\";s:12:\"access_level\";s:16:\"activate_plugins\";s:4:\"file\";s:11:\"plugins.php\";s:9:\"css_class\";s:26:\"menu-top menu-icon-plugins\";s:8:\"hookname\";s:12:\"menu-plugins\";s:8:\"icon_url\";s:3:\"div\";s:8:\"position\";i:10;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:10;s:9:\"separator\";b:0;s:6:\"hidden\";b:0;s:5:\"items\";a:3:{s:11:\"plugins.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:17:\"Installed Plugins\";s:12:\"access_level\";s:16:\"activate_plugins\";s:4:\"file\";s:11:\"plugins.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:0;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:11:\"plugins.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:0;s:6:\"hidden\";b:0;}s:18:\"plugin-install.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:7:\"Add New\";s:12:\"access_level\";s:15:\"install_plugins\";s:4:\"file\";s:18:\"plugin-install.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:1;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:11:\"plugins.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:1;s:6:\"hidden\";b:0;}s:17:\"plugin-editor.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:6:\"Editor\";s:12:\"access_level\";s:12:\"edit_plugins\";s:4:\"file\";s:17:\"plugin-editor.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:2;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:11:\"plugins.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:2;s:6:\"hidden\";b:0;}}}s:9:\"users.php\";a:14:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:9:\"css_class\";N;s:8:\"hookname\";N;s:8:\"icon_url\";N;s:6:\"custom\";N;s:8:\"defaults\";a:12:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:5:\"Users\";s:12:\"access_level\";s:10:\"list_users\";s:4:\"file\";s:9:\"users.php\";s:9:\"css_class\";s:24:\"menu-top menu-icon-users\";s:8:\"hookname\";s:10:\"menu-users\";s:8:\"icon_url\";s:3:\"div\";s:8:\"position\";i:11;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:11;s:9:\"separator\";b:0;s:6:\"hidden\";b:1;s:5:\"items\";a:3:{s:9:\"users.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:9:\"All Users\";s:12:\"access_level\";s:10:\"list_users\";s:4:\"file\";s:9:\"users.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:0;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:9:\"users.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:0;s:6:\"hidden\";b:1;}s:12:\"user-new.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:7:\"Add New\";s:12:\"access_level\";s:12:\"create_users\";s:4:\"file\";s:12:\"user-new.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:1;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:9:\"users.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:1;s:6:\"hidden\";b:1;}s:11:\"profile.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:12:\"Your Profile\";s:12:\"access_level\";s:4:\"read\";s:4:\"file\";s:11:\"profile.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:2;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:9:\"users.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:2;s:6:\"hidden\";b:1;}}}s:9:\"tools.php\";a:14:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:9:\"css_class\";N;s:8:\"hookname\";N;s:8:\"icon_url\";N;s:6:\"custom\";N;s:8:\"defaults\";a:12:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:5:\"Tools\";s:12:\"access_level\";s:10:\"edit_posts\";s:4:\"file\";s:9:\"tools.php\";s:9:\"css_class\";s:24:\"menu-top menu-icon-tools\";s:8:\"hookname\";s:10:\"menu-tools\";s:8:\"icon_url\";s:3:\"div\";s:8:\"position\";i:12;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:12;s:9:\"separator\";b:0;s:6:\"hidden\";b:0;s:5:\"items\";a:3:{s:9:\"tools.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:15:\"Available Tools\";s:12:\"access_level\";s:10:\"edit_posts\";s:4:\"file\";s:9:\"tools.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:0;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:9:\"tools.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:0;s:6:\"hidden\";b:1;}s:10:\"import.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:6:\"Import\";s:12:\"access_level\";s:6:\"import\";s:4:\"file\";s:10:\"import.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:1;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:9:\"tools.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:1;s:6:\"hidden\";b:0;}s:10:\"export.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:6:\"Export\";s:12:\"access_level\";s:6:\"export\";s:4:\"file\";s:10:\"export.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:2;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:9:\"tools.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:2;s:6:\"hidden\";b:0;}}}s:19:\"options-general.php\";a:14:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:9:\"css_class\";N;s:8:\"hookname\";N;s:8:\"icon_url\";N;s:6:\"custom\";N;s:8:\"defaults\";a:12:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:8:\"Settings\";s:12:\"access_level\";s:14:\"manage_options\";s:4:\"file\";s:19:\"options-general.php\";s:9:\"css_class\";s:27:\"menu-top menu-icon-settings\";s:8:\"hookname\";s:13:\"menu-settings\";s:8:\"icon_url\";s:3:\"div\";s:8:\"position\";i:13;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:13;s:9:\"separator\";b:0;s:6:\"hidden\";b:0;s:5:\"items\";a:8:{s:19:\"options-general.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:7:\"General\";s:12:\"access_level\";s:14:\"manage_options\";s:4:\"file\";s:19:\"options-general.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:0;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:19:\"options-general.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:0;s:6:\"hidden\";b:0;}s:19:\"options-writing.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:7:\"Writing\";s:12:\"access_level\";s:14:\"manage_options\";s:4:\"file\";s:19:\"options-writing.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:1;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:19:\"options-general.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:1;s:6:\"hidden\";b:0;}s:19:\"options-reading.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:7:\"Reading\";s:12:\"access_level\";s:14:\"manage_options\";s:4:\"file\";s:19:\"options-reading.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:2;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:19:\"options-general.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:2;s:6:\"hidden\";b:0;}s:22:\"options-discussion.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:10:\"Discussion\";s:12:\"access_level\";s:14:\"manage_options\";s:4:\"file\";s:22:\"options-discussion.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:3;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:19:\"options-general.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:3;s:6:\"hidden\";b:0;}s:17:\"options-media.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:5:\"Media\";s:12:\"access_level\";s:14:\"manage_options\";s:4:\"file\";s:17:\"options-media.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:4;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:19:\"options-general.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:4;s:6:\"hidden\";b:0;}s:19:\"options-privacy.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:7:\"Privacy\";s:12:\"access_level\";s:14:\"manage_options\";s:4:\"file\";s:19:\"options-privacy.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:5;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:19:\"options-general.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:5;s:6:\"hidden\";b:0;}s:21:\"options-permalink.php\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:10:\"Permalinks\";s:12:\"access_level\";s:14:\"manage_options\";s:4:\"file\";s:21:\"options-permalink.php\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:6;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:19:\"options-general.php\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:6;s:6:\"hidden\";b:0;}s:11:\"menu_editor\";a:9:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:6:\"custom\";N;s:8:\"defaults\";a:13:{s:10:\"page_title\";s:11:\"Menu Editor\";s:10:\"menu_title\";s:11:\"Menu Editor\";s:12:\"access_level\";s:14:\"manage_options\";s:4:\"file\";s:11:\"menu_editor\";s:9:\"css_class\";s:0:\"\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:7;s:9:\"separator\";b:0;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:6:\"parent\";s:19:\"options-general.php\";s:14:\"is_plugin_page\";b:1;}s:8:\"position\";i:7;s:6:\"hidden\";b:0;}}}s:14:\"separator-last\";a:14:{s:10:\"menu_title\";N;s:12:\"access_level\";N;s:4:\"file\";N;s:10:\"page_title\";N;s:7:\"open_in\";N;s:9:\"css_class\";N;s:8:\"hookname\";N;s:8:\"icon_url\";N;s:6:\"custom\";N;s:8:\"defaults\";a:12:{s:10:\"page_title\";s:0:\"\";s:10:\"menu_title\";s:0:\"\";s:12:\"access_level\";s:4:\"read\";s:4:\"file\";s:14:\"separator-last\";s:9:\"css_class\";s:17:\"wp-menu-separator\";s:8:\"hookname\";s:0:\"\";s:8:\"icon_url\";s:0:\"\";s:8:\"position\";i:14;s:9:\"separator\";b:1;s:6:\"custom\";b:0;s:7:\"open_in\";s:11:\"same_window\";s:14:\"is_plugin_page\";b:0;}s:8:\"position\";i:14;s:9:\"separator\";b:1;s:6:\"hidden\";b:0;s:5:\"items\";a:0:{}}}}',	'yes'),
(161,	0,	'ossdl_off_cdn_url',	'http://calzada-wp.urldock.com',	'yes'),
(162,	0,	'ossdl_off_include_dirs',	'wp-content,wp-includes',	'yes'),
(163,	0,	'ossdl_off_exclude',	'.php',	'yes'),
(164,	0,	'ossdl_cname',	'',	'yes'),
(165,	0,	'uninstall_plugins',	'a:2:{i:0;b:0;s:39:\"options-framework/options-framework.php\";s:31:\"optionsframework_delete_options\";}',	'yes'),
(196,	0,	'nav_menu_options',	'a:2:{i:0;b:0;s:8:\"auto_add\";a:0:{}}',	'yes'),
(257,	0,	'theme_mods_twentyeleven',	'a:1:{s:16:\"sidebars_widgets\";a:2:{s:4:\"time\";i:1337807086;s:4:\"data\";a:6:{s:19:\"wp_inactive_widgets\";a:0:{}s:9:\"sidebar-1\";a:6:{i:0;s:8:\"search-2\";i:1;s:14:\"recent-posts-2\";i:2;s:17:\"recent-comments-2\";i:3;s:10:\"archives-2\";i:4;s:12:\"categories-2\";i:5;s:6:\"meta-2\";}s:9:\"sidebar-2\";a:0:{}s:9:\"sidebar-3\";a:0:{}s:9:\"sidebar-4\";a:0:{}s:9:\"sidebar-5\";a:0:{}}}}',	'yes'),
(258,	0,	'current_theme',	'Calzada',	'yes'),
(296,	0,	'widget_newsletter_widget',	'a:3:{i:2;a:3:{s:5:\"title\";s:19:\"Join Our Newsletter\";s:4:\"text\";s:130:\"Leave your name and email to join our electronic newsletter. We’ll be sending news and updates once a month about industry news.\";s:6:\"action\";s:1:\"#\";}i:4;a:3:{s:5:\"title\";s:19:\"Join Our Newsletter\";s:6:\"action\";s:1:\"#\";s:4:\"text\";s:130:\"Leave your name and email to join our electronic newsletter. We’ll be sending news and updates once a month about industry news.\";}s:12:\"_multiwidget\";i:1;}',	'yes'),
(297,	0,	'widget_stock_prices_widget',	'a:5:{i:2;a:2:{s:5:\"title\";s:12:\"Stock Prices\";s:4:\"text\";s:107:\"See the current share price of the CZD. You can also see further insights by <a href=\"#\">clicking here</a>.\";}i:3;a:2:{s:5:\"title\";s:12:\"Stock Prices\";s:4:\"text\";s:40:\"Current share price for Calzada Limited.\";}i:4;a:2:{s:5:\"title\";s:12:\"Stock Prices\";s:4:\"text\";s:107:\"See the current share price of the CZD. You can also see further insights by <a href=\"#\">clicking here</a>.\";}i:5;a:2:{s:5:\"title\";s:12:\"Stock Prices\";s:4:\"text\";s:39:\"Current share price for Calzada Limited\";}s:12:\"_multiwidget\";i:1;}',	'yes'),
(298,	0,	'widget_pages',	'a:1:{s:12:\"_multiwidget\";i:1;}',	'yes'),
(299,	0,	'widget_latest_news_widget',	'a:2:{i:2;a:2:{s:5:\"title\";s:11:\"Latest News\";s:6:\"number\";s:1:\"4\";}s:12:\"_multiwidget\";i:1;}',	'yes'),
(311,	0,	'widget_nav_menu',	'a:1:{s:12:\"_multiwidget\";i:1;}',	'yes'),
(324,	0,	'category_children',	'a:0:{}',	'yes'),
(335,	0,	'widget_widget_cm_ajax',	'a:3:{i:2;a:5:{s:5:\"title\";s:18:\"Sign Up for E-News\";s:7:\"pretext\";s:52:\"Leave your details to join our email news releases. \";s:15:\"account_api_key\";s:32:\"6ea825a8217fbcbd9e9e9bbd500e75f3\";s:12:\"list_api_key\";s:32:\"9f64d361ed00bd40377ea123f35d9714\";s:15:\"show_name_field\";b:1;}i:3;a:5:{s:5:\"title\";s:18:\"Sign Up for E-News\";s:7:\"pretext\";s:52:\"Leave your details to join our email news releases. \";s:15:\"account_api_key\";s:32:\"6ea825a8217fbcbd9e9e9bbd500e75f3\";s:12:\"list_api_key\";s:32:\"9f64d361ed00bd40377ea123f35d9714\";s:15:\"show_name_field\";b:1;}s:12:\"_multiwidget\";i:1;}',	'yes'),
(336,	0,	'cm_subscriber_stats_title',	'Campaign Monitor Subscriber Stats',	'yes'),
(337,	0,	'_site_transient_timeout_browser_a3fd3c81b01e934389c88afe4b60bc74',	'1338994573',	'yes'),
(338,	0,	'_site_transient_browser_a3fd3c81b01e934389c88afe4b60bc74',	'a:9:{s:8:\"platform\";s:9:\"Macintosh\";s:4:\"name\";s:6:\"Chrome\";s:7:\"version\";s:12:\"19.0.1084.52\";s:10:\"update_url\";s:28:\"http://www.google.com/chrome\";s:7:\"img_src\";s:49:\"http://s.wordpress.org/images/browsers/chrome.png\";s:11:\"img_src_ssl\";s:48:\"https://wordpress.org/images/browsers/chrome.png\";s:15:\"current_version\";s:2:\"18\";s:7:\"upgrade\";b:0;s:8:\"insecure\";b:0;}',	'yes'),
(359,	0,	'cm_subscriber_stats_intro',	'',	'yes'),
(360,	0,	'cm_subscriber_stats_feeds',	'https://calzada.createsend.com/rss/subscribers.aspx?listID=f684005763e1995f&d=j',	'yes'),
(392,	0,	'rokstock_options',	'a:8:{s:14:\"default_stocks\";s:17:\".DJI, .INX, .IXIC\";s:16:\"user_interaction\";s:1:\"1\";s:12:\"store_cookie\";s:1:\"1\";s:10:\"store_time\";s:2:\"30\";s:9:\"externals\";s:1:\"1\";s:15:\"show_main_chart\";s:1:\"1\";s:13:\"show_tooltips\";s:1:\"1\";s:12:\"time_display\";s:2:\"12\";}',	'yes'),
(393,	0,	'widget_widget-rokstock',	'a:2:{i:2;a:1:{s:5:\"title\";s:0:\"\";}s:12:\"_multiwidget\";i:1;}',	'yes'),
(403,	0,	'_site_transient_timeout_browser_ec00762ce8f87e1789d48f0bb3c77632',	'1339529165',	'yes'),
(404,	0,	'_site_transient_browser_ec00762ce8f87e1789d48f0bb3c77632',	'a:9:{s:8:\"platform\";s:9:\"Macintosh\";s:4:\"name\";s:6:\"Chrome\";s:7:\"version\";s:12:\"19.0.1084.53\";s:10:\"update_url\";s:28:\"http://www.google.com/chrome\";s:7:\"img_src\";s:49:\"http://s.wordpress.org/images/browsers/chrome.png\";s:11:\"img_src_ssl\";s:48:\"https://wordpress.org/images/browsers/chrome.png\";s:15:\"current_version\";s:2:\"18\";s:7:\"upgrade\";b:0;s:8:\"insecure\";b:0;}',	'yes'),
(407,	0,	'_transient_timeout_feed_03c8ce7c93f35fece01b3f0b9b41b3b8',	'1338967569',	'no'),
(408,	0,	'_transient_feed_03c8ce7c93f35fece01b3f0b9b41b3b8',	'a:4:{s:5:\"child\";a:1:{s:0:\"\";a:1:{s:3:\"rss\";a:1:{i:0;a:6:{s:4:\"data\";s:4:\"\n  \n\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:7:\"version\";s:3:\"2.0\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:1:{s:0:\"\";a:1:{s:7:\"channel\";a:1:{i:0;a:6:{s:4:\"data\";s:33:\"\n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:3:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"link:http://calzada-wp.urldock.com/ - Google Blog Search\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:95:\"http://www.google.com/search?ie=utf-8&q=link:http://calzada-wp.urldock.com/&tbm=blg&tbs=sbd:1\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:91:\"Your search - <b>link:http://calzada-wp.urldock.com/</b> - did not match any documents.  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://a9.com/-/spec/opensearch/1.1/\";a:3:{s:12:\"totalResults\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"0\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:10:\"startIndex\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"1\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:12:\"itemsPerPage\";a:1:{i:0;a:5:{s:4:\"data\";s:2:\"10\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}}}}}}}}s:4:\"type\";i:128;s:7:\"headers\";a:9:{s:12:\"content-type\";s:28:\"text/xml; charset=ISO-8859-1\";s:4:\"date\";s:29:\"Tue, 05 Jun 2012 19:26:09 GMT\";s:7:\"expires\";s:2:\"-1\";s:13:\"cache-control\";s:18:\"private, max-age=0\";s:10:\"set-cookie\";a:2:{i:0;s:143:\"PREF=ID=6dc6718103338b52:FF=0:TM=1338924369:LM=1338924370:S=H7SnhuPbh1klSnk3; expires=Thu, 05-Jun-2014 19:26:10 GMT; path=/; domain=.google.com\";i:1;s:212:\"NID=60=bYyevdt34efwYOHQcaQVbUaIxji_xFcBkvRW42_YdFwNdx85wRc6yP72GKgUT2yfK7pH0H43UpfVjA-2Ucsy4hhO9t4Fh9fIr1HAjTqByJY1IF7tDHY8twURCHLJPhI3; expires=Wed, 05-Dec-2012 19:26:10 GMT; path=/; domain=.google.com; HttpOnly\";}s:3:\"p3p\";s:122:\"CP=\"This is not a P3P policy! See http://www.google.com/support/accounts/bin/answer.py?hl=en&answer=151657 for more info.\"\";s:6:\"server\";s:3:\"gws\";s:16:\"x-xss-protection\";s:13:\"1; mode=block\";s:15:\"x-frame-options\";s:10:\"SAMEORIGIN\";}s:5:\"build\";s:14:\"20090627192103\";}',	'no'),
(409,	0,	'_transient_timeout_feed_mod_03c8ce7c93f35fece01b3f0b9b41b3b8',	'1338967569',	'no'),
(410,	0,	'_transient_feed_mod_03c8ce7c93f35fece01b3f0b9b41b3b8',	'1338924369',	'no'),
(471,	0,	'_site_transient_timeout_browser_f3ccaed0f2c445703b4810bf6e12ada1',	'1339732459',	'yes'),
(472,	0,	'_site_transient_browser_f3ccaed0f2c445703b4810bf6e12ada1',	'a:9:{s:8:\"platform\";s:7:\"Windows\";s:4:\"name\";s:7:\"Firefox\";s:7:\"version\";s:4:\"13.0\";s:10:\"update_url\";s:23:\"http://www.firefox.com/\";s:7:\"img_src\";s:50:\"http://s.wordpress.org/images/browsers/firefox.png\";s:11:\"img_src_ssl\";s:49:\"https://wordpress.org/images/browsers/firefox.png\";s:15:\"current_version\";s:2:\"12\";s:7:\"upgrade\";b:0;s:8:\"insecure\";b:0;}',	'yes'),
(696,	0,	'_site_transient_timeout_browser_300190862a78b6b16911d241196761d6',	'1340697899',	'yes'),
(697,	0,	'_site_transient_browser_300190862a78b6b16911d241196761d6',	'a:9:{s:8:\"platform\";s:9:\"Macintosh\";s:4:\"name\";s:6:\"Chrome\";s:7:\"version\";s:12:\"19.0.1084.56\";s:10:\"update_url\";s:28:\"http://www.google.com/chrome\";s:7:\"img_src\";s:49:\"http://s.wordpress.org/images/browsers/chrome.png\";s:11:\"img_src_ssl\";s:48:\"https://wordpress.org/images/browsers/chrome.png\";s:15:\"current_version\";s:2:\"18\";s:7:\"upgrade\";b:0;s:8:\"insecure\";b:0;}',	'yes'),
(753,	0,	'_site_transient_timeout_browser_b8b0b302356ed3165c699a19d84cb413',	'1341447912',	'yes'),
(754,	0,	'_site_transient_browser_b8b0b302356ed3165c699a19d84cb413',	'a:9:{s:8:\"platform\";s:9:\"Macintosh\";s:4:\"name\";s:6:\"Chrome\";s:7:\"version\";s:12:\"20.0.1132.43\";s:10:\"update_url\";s:28:\"http://www.google.com/chrome\";s:7:\"img_src\";s:49:\"http://s.wordpress.org/images/browsers/chrome.png\";s:11:\"img_src_ssl\";s:48:\"https://wordpress.org/images/browsers/chrome.png\";s:15:\"current_version\";s:2:\"18\";s:7:\"upgrade\";b:0;s:8:\"insecure\";b:0;}',	'yes'),
(839,	0,	'J-Shortcodes',	'a:6:{s:20:\"j-shortcodes-version\";s:5:\"1.405\";s:15:\"disable-wpautop\";s:1:\"0\";s:10:\"custom_css\";s:254:\".gallery img {border:none;}\r\n.gallery .nav-prev, .gallery .nav-next { width:auto;}\r\nul.filmstrip li { list-style: none; }\r\n.jayq-smoothness .ui-widget-content a { color: #FBB852;}\r\n.jayq-smoothness .ui-widget-content a hover {text-decoration: underline;}\";s:20:\"webmaster_subscribed\";s:0:\"\";s:13:\"jquery_themes\";a:5:{s:7:\"blitzer\";s:1:\"0\";s:9:\"cupertino\";s:1:\"0\";s:8:\"overcast\";s:1:\"0\";s:10:\"smoothness\";s:1:\"1\";s:5:\"vader\";s:1:\"0\";}s:16:\"jgallery_enabled\";s:1:\"1\";}',	'yes'),
(855,	0,	'_site_transient_timeout_browser_b4da43a5f894afcd1ca036d2a7fc18e4',	'1341472182',	'yes'),
(856,	0,	'_site_transient_browser_b4da43a5f894afcd1ca036d2a7fc18e4',	'a:9:{s:8:\"platform\";s:9:\"Macintosh\";s:4:\"name\";s:7:\"Firefox\";s:7:\"version\";s:6:\"13.0.1\";s:10:\"update_url\";s:23:\"http://www.firefox.com/\";s:7:\"img_src\";s:50:\"http://s.wordpress.org/images/browsers/firefox.png\";s:11:\"img_src_ssl\";s:49:\"https://wordpress.org/images/browsers/firefox.png\";s:15:\"current_version\";s:2:\"12\";s:7:\"upgrade\";b:0;s:8:\"insecure\";b:0;}',	'yes'),
(859,	0,	'_site_transient_timeout_browser_14808cd56d08e0286a721b44fd32699c',	'1341472938',	'yes'),
(860,	0,	'_site_transient_browser_14808cd56d08e0286a721b44fd32699c',	'a:9:{s:8:\"platform\";s:9:\"Macintosh\";s:4:\"name\";s:6:\"Safari\";s:7:\"version\";s:5:\"5.1.7\";s:10:\"update_url\";s:28:\"http://www.apple.com/safari/\";s:7:\"img_src\";s:49:\"http://s.wordpress.org/images/browsers/safari.png\";s:11:\"img_src_ssl\";s:48:\"https://wordpress.org/images/browsers/safari.png\";s:15:\"current_version\";s:3:\"5.1\";s:7:\"upgrade\";b:0;s:8:\"insecure\";b:0;}',	'yes'),
(866,	0,	'_site_transient_timeout_browser_1c656a8956f80883c5f0b640ea0ed2ae',	'1341795409',	'yes'),
(867,	0,	'_site_transient_browser_1c656a8956f80883c5f0b640ea0ed2ae',	'a:9:{s:8:\"platform\";s:9:\"Macintosh\";s:4:\"name\";s:6:\"Chrome\";s:7:\"version\";s:12:\"20.0.1132.47\";s:10:\"update_url\";s:28:\"http://www.google.com/chrome\";s:7:\"img_src\";s:49:\"http://s.wordpress.org/images/browsers/chrome.png\";s:11:\"img_src_ssl\";s:48:\"https://wordpress.org/images/browsers/chrome.png\";s:15:\"current_version\";s:2:\"18\";s:7:\"upgrade\";b:0;s:8:\"insecure\";b:0;}',	'yes'),
(905,	0,	'aioseop_options',	'a:38:{s:9:\"aiosp_can\";s:2:\"on\";s:12:\"aiosp_donate\";s:0:\"\";s:16:\"aiosp_home_title\";s:11:\"Calzada Ltd\";s:22:\"aiosp_home_description\";s:0:\"\";s:19:\"aiosp_home_keywords\";s:0:\"\";s:23:\"aiosp_max_words_excerpt\";s:0:\"\";s:20:\"aiosp_rewrite_titles\";s:2:\"on\";s:23:\"aiosp_post_title_format\";s:27:\"%post_title% | %blog_title%\";s:23:\"aiosp_page_title_format\";s:27:\"%page_title% | %blog_title%\";s:27:\"aiosp_category_title_format\";s:31:\"%category_title% | %blog_title%\";s:26:\"aiosp_archive_title_format\";s:21:\"%date% | %blog_title%\";s:22:\"aiosp_tag_title_format\";s:20:\"%tag% | %blog_title%\";s:25:\"aiosp_search_title_format\";s:23:\"%search% | %blog_title%\";s:24:\"aiosp_description_format\";s:13:\"%description%\";s:22:\"aiosp_404_title_format\";s:33:\"Nothing found for %request_words%\";s:18:\"aiosp_paged_format\";s:14:\" - Part %page%\";s:25:\"aiosp_google_analytics_id\";s:0:\"\";s:29:\"aiosp_ga_track_outbound_links\";s:0:\"\";s:20:\"aiosp_use_categories\";s:0:\"\";s:32:\"aiosp_dynamic_postspage_keywords\";s:2:\"on\";s:22:\"aiosp_category_noindex\";s:0:\"\";s:21:\"aiosp_archive_noindex\";s:0:\"\";s:18:\"aiosp_tags_noindex\";s:0:\"\";s:14:\"aiosp_cap_cats\";s:2:\"on\";s:27:\"aiosp_generate_descriptions\";s:0:\"\";s:16:\"aiosp_debug_info\";s:0:\"\";s:20:\"aiosp_post_meta_tags\";s:0:\"\";s:20:\"aiosp_page_meta_tags\";s:0:\"\";s:20:\"aiosp_home_meta_tags\";s:0:\"\";s:13:\"aiosp_enabled\";s:1:\"1\";s:17:\"aiosp_enablecpost\";s:0:\"\";s:26:\"aiosp_use_tags_as_keywords\";s:2:\"on\";s:16:\"aiosp_seopostcol\";s:0:\"\";s:18:\"aiosp_seocustptcol\";s:0:\"\";s:21:\"aiosp_posttypecolumns\";a:2:{i:0;s:4:\"post\";i:1;s:4:\"page\";}s:12:\"aiosp_do_log\";s:0:\"\";s:22:\"aiosp_google_publisher\";s:0:\"\";s:14:\"aiosp_ex_pages\";s:0:\"\";}',	'yes'),
(1014,	0,	'_site_transient_timeout_browser_475d1539fc446822d644e37254287eef',	'1342407181',	'yes'),
(1015,	0,	'_site_transient_browser_475d1539fc446822d644e37254287eef',	'a:9:{s:8:\"platform\";s:7:\"Windows\";s:4:\"name\";s:7:\"Firefox\";s:7:\"version\";s:6:\"13.0.1\";s:10:\"update_url\";s:23:\"http://www.firefox.com/\";s:7:\"img_src\";s:50:\"http://s.wordpress.org/images/browsers/firefox.png\";s:11:\"img_src_ssl\";s:49:\"https://wordpress.org/images/browsers/firefox.png\";s:15:\"current_version\";s:2:\"12\";s:7:\"upgrade\";b:0;s:8:\"insecure\";b:0;}',	'yes'),
(1055,	0,	'txfx_plt_schema_version',	'3',	'yes'),
(1218,	0,	'_site_transient_timeout_browser_727504993e58fa37cfa5eedb3ec2a0cf',	'1344401256',	'yes'),
(1219,	0,	'_site_transient_browser_727504993e58fa37cfa5eedb3ec2a0cf',	'a:9:{s:8:\"platform\";s:7:\"Windows\";s:4:\"name\";s:17:\"Internet Explorer\";s:7:\"version\";s:3:\"8.0\";s:10:\"update_url\";s:51:\"http://www.microsoft.com/windows/internet-explorer/\";s:7:\"img_src\";s:45:\"http://s.wordpress.org/images/browsers/ie.png\";s:11:\"img_src_ssl\";s:44:\"https://wordpress.org/images/browsers/ie.png\";s:15:\"current_version\";s:1:\"9\";s:7:\"upgrade\";b:1;s:8:\"insecure\";b:0;}',	'yes'),
(1326,	0,	'_site_transient_timeout_browser_c83370d39081a34be3744d3410d8f6e1',	'1344820752',	'yes'),
(1327,	0,	'_site_transient_browser_c83370d39081a34be3744d3410d8f6e1',	'a:9:{s:8:\"platform\";s:7:\"Windows\";s:4:\"name\";s:17:\"Internet Explorer\";s:7:\"version\";s:3:\"6.0\";s:10:\"update_url\";s:51:\"http://www.microsoft.com/windows/internet-explorer/\";s:7:\"img_src\";s:45:\"http://s.wordpress.org/images/browsers/ie.png\";s:11:\"img_src_ssl\";s:44:\"https://wordpress.org/images/browsers/ie.png\";s:15:\"current_version\";s:1:\"9\";s:7:\"upgrade\";b:1;s:8:\"insecure\";b:1;}',	'yes'),
(1364,	0,	'_site_transient_timeout_browser_6015033c7b3a9c4242cebd95e531b68c',	'1344822756',	'yes'),
(1365,	0,	'_site_transient_browser_6015033c7b3a9c4242cebd95e531b68c',	'a:9:{s:8:\"platform\";s:7:\"Windows\";s:4:\"name\";s:17:\"Internet Explorer\";s:7:\"version\";s:3:\"6.0\";s:10:\"update_url\";s:51:\"http://www.microsoft.com/windows/internet-explorer/\";s:7:\"img_src\";s:45:\"http://s.wordpress.org/images/browsers/ie.png\";s:11:\"img_src_ssl\";s:44:\"https://wordpress.org/images/browsers/ie.png\";s:15:\"current_version\";s:1:\"9\";s:7:\"upgrade\";b:1;s:8:\"insecure\";b:1;}',	'yes'),
(1516,	0,	'_site_transient_timeout_browser_395e85624d76b174592e94876474150a',	'1345673849',	'yes'),
(1517,	0,	'_site_transient_browser_395e85624d76b174592e94876474150a',	'a:9:{s:8:\"platform\";s:7:\"Windows\";s:4:\"name\";s:7:\"Firefox\";s:7:\"version\";s:6:\"14.0.1\";s:10:\"update_url\";s:23:\"http://www.firefox.com/\";s:7:\"img_src\";s:50:\"http://s.wordpress.org/images/browsers/firefox.png\";s:11:\"img_src_ssl\";s:49:\"https://wordpress.org/images/browsers/firefox.png\";s:15:\"current_version\";s:2:\"12\";s:7:\"upgrade\";b:0;s:8:\"insecure\";b:0;}',	'yes'),
(1557,	0,	'_site_transient_timeout_browser_a20b17151faba47d6d2f9ad7f33c4387',	'1345711962',	'yes'),
(1558,	0,	'_site_transient_browser_a20b17151faba47d6d2f9ad7f33c4387',	'a:9:{s:8:\"platform\";s:9:\"Macintosh\";s:4:\"name\";s:6:\"Chrome\";s:7:\"version\";s:12:\"21.0.1180.57\";s:10:\"update_url\";s:28:\"http://www.google.com/chrome\";s:7:\"img_src\";s:49:\"http://s.wordpress.org/images/browsers/chrome.png\";s:11:\"img_src_ssl\";s:48:\"https://wordpress.org/images/browsers/chrome.png\";s:15:\"current_version\";s:2:\"18\";s:7:\"upgrade\";b:0;s:8:\"insecure\";b:0;}',	'yes'),
(1561,	0,	'_site_transient_timeout_browser_6c928be94139168017d5e97a41d4cbc8',	'1345718769',	'yes'),
(1562,	0,	'_site_transient_browser_6c928be94139168017d5e97a41d4cbc8',	'a:9:{s:8:\"platform\";s:9:\"Macintosh\";s:4:\"name\";s:6:\"Safari\";s:7:\"version\";s:5:\"5.0.5\";s:10:\"update_url\";s:28:\"http://www.apple.com/safari/\";s:7:\"img_src\";s:49:\"http://s.wordpress.org/images/browsers/safari.png\";s:11:\"img_src_ssl\";s:48:\"https://wordpress.org/images/browsers/safari.png\";s:15:\"current_version\";s:3:\"5.1\";s:7:\"upgrade\";b:1;s:8:\"insecure\";b:0;}',	'yes'),
(1748,	0,	'_site_transient_timeout_wporg_theme_feature_list',	'1345622709',	'yes'),
(1749,	0,	'_site_transient_wporg_theme_feature_list',	'a:5:{s:6:\"Colors\";a:15:{i:0;s:5:\"black\";i:1;s:4:\"blue\";i:2;s:5:\"brown\";i:3;s:4:\"gray\";i:4;s:5:\"green\";i:5;s:6:\"orange\";i:6;s:4:\"pink\";i:7;s:6:\"purple\";i:8;s:3:\"red\";i:9;s:6:\"silver\";i:10;s:3:\"tan\";i:11;s:5:\"white\";i:12;s:6:\"yellow\";i:13;s:4:\"dark\";i:14;s:5:\"light\";}s:7:\"Columns\";a:6:{i:0;s:10:\"one-column\";i:1;s:11:\"two-columns\";i:2;s:13:\"three-columns\";i:3;s:12:\"four-columns\";i:4;s:12:\"left-sidebar\";i:5;s:13:\"right-sidebar\";}s:5:\"Width\";a:2:{i:0;s:11:\"fixed-width\";i:1;s:14:\"flexible-width\";}s:8:\"Features\";a:18:{i:0;s:8:\"blavatar\";i:1;s:10:\"buddypress\";i:2;s:17:\"custom-background\";i:3;s:13:\"custom-colors\";i:4;s:13:\"custom-header\";i:5;s:11:\"custom-menu\";i:6;s:12:\"editor-style\";i:7;s:21:\"featured-image-header\";i:8;s:15:\"featured-images\";i:9;s:20:\"front-page-post-form\";i:10;s:19:\"full-width-template\";i:11;s:12:\"microformats\";i:12;s:12:\"post-formats\";i:13;s:20:\"rtl-language-support\";i:14;s:11:\"sticky-post\";i:15;s:13:\"theme-options\";i:16;s:17:\"threaded-comments\";i:17;s:17:\"translation-ready\";}s:7:\"Subject\";a:3:{i:0;s:7:\"holiday\";i:1;s:13:\"photoblogging\";i:2;s:8:\"seasonal\";}}',	'yes'),
(1875,	0,	'_site_transient_timeout_browser_5bf5646da12ba232c3af7198fb2a134a',	'1346804191',	'yes'),
(1876,	0,	'_site_transient_browser_5bf5646da12ba232c3af7198fb2a134a',	'a:9:{s:8:\"platform\";s:7:\"Windows\";s:4:\"name\";s:17:\"Internet Explorer\";s:7:\"version\";s:3:\"8.0\";s:10:\"update_url\";s:51:\"http://www.microsoft.com/windows/internet-explorer/\";s:7:\"img_src\";s:45:\"http://s.wordpress.org/images/browsers/ie.png\";s:11:\"img_src_ssl\";s:44:\"https://wordpress.org/images/browsers/ie.png\";s:15:\"current_version\";s:1:\"9\";s:7:\"upgrade\";b:1;s:8:\"insecure\";b:0;}',	'yes'),
(1924,	0,	'_site_transient_timeout_browser_b62142a48ed49005fd38a0d2344d0a8a',	'1346954656',	'yes'),
(1925,	0,	'_site_transient_browser_b62142a48ed49005fd38a0d2344d0a8a',	'a:9:{s:8:\"platform\";s:7:\"Windows\";s:4:\"name\";s:6:\"Chrome\";s:7:\"version\";s:12:\"21.0.1180.83\";s:10:\"update_url\";s:28:\"http://www.google.com/chrome\";s:7:\"img_src\";s:49:\"http://s.wordpress.org/images/browsers/chrome.png\";s:11:\"img_src_ssl\";s:48:\"https://wordpress.org/images/browsers/chrome.png\";s:15:\"current_version\";s:2:\"18\";s:7:\"upgrade\";b:0;s:8:\"insecure\";b:0;}',	'yes'),
(1960,	0,	'_transient_timeout_plugin_slugs',	'1346505226',	'no'),
(1961,	0,	'_transient_plugin_slugs',	'a:13:{i:0;s:43:\"accordion-shortcode/accordion-shortcode.php\";i:1;s:33:\"admin-menu-editor/menu-editor.php\";i:2;s:30:\"advanced-custom-fields/acf.php\";i:3;s:43:\"all-in-one-seo-pack/all_in_one_seo_pack.php\";i:4;s:27:\"backupbuddy/backupbuddy.php\";i:5;s:39:\"ajax-campaign-monitor-forms/cm-ajax.php\";i:6;s:43:\"cm-subscriber-stats/cm-subscriber-stats.php\";i:7;s:29:\"j-shortcodes/j-shortcodes.php\";i:8;s:39:\"options-framework/options-framework.php\";i:9;s:31:\"page-links-to/page-links-to.php\";i:10;s:41:\"wordpress-importer/wordpress-importer.php\";i:11;s:43:\"wp-maintenance-mode/wp-maintenance-mode.php\";i:12;s:27:\"wp-super-cache/wp-cache.php\";}',	'no'),
(1964,	0,	'_site_transient_timeout_poptags_40cd750bba9870f18aada2478b24840a',	'1346360717',	'yes'),
(1965,	0,	'_site_transient_poptags_40cd750bba9870f18aada2478b24840a',	'a:40:{s:6:\"widget\";a:3:{s:4:\"name\";s:6:\"widget\";s:4:\"slug\";s:6:\"widget\";s:5:\"count\";s:4:\"3211\";}s:4:\"post\";a:3:{s:4:\"name\";s:4:\"Post\";s:4:\"slug\";s:4:\"post\";s:5:\"count\";s:4:\"2116\";}s:6:\"plugin\";a:3:{s:4:\"name\";s:6:\"plugin\";s:4:\"slug\";s:6:\"plugin\";s:5:\"count\";s:4:\"1981\";}s:5:\"admin\";a:3:{s:4:\"name\";s:5:\"admin\";s:4:\"slug\";s:5:\"admin\";s:5:\"count\";s:4:\"1623\";}s:5:\"posts\";a:3:{s:4:\"name\";s:5:\"posts\";s:4:\"slug\";s:5:\"posts\";s:5:\"count\";s:4:\"1562\";}s:7:\"sidebar\";a:3:{s:4:\"name\";s:7:\"sidebar\";s:4:\"slug\";s:7:\"sidebar\";s:5:\"count\";s:4:\"1387\";}s:8:\"comments\";a:3:{s:4:\"name\";s:8:\"comments\";s:4:\"slug\";s:8:\"comments\";s:5:\"count\";s:4:\"1109\";}s:7:\"twitter\";a:3:{s:4:\"name\";s:7:\"twitter\";s:4:\"slug\";s:7:\"twitter\";s:5:\"count\";s:4:\"1090\";}s:6:\"google\";a:3:{s:4:\"name\";s:6:\"google\";s:4:\"slug\";s:6:\"google\";s:5:\"count\";s:4:\"1084\";}s:6:\"images\";a:3:{s:4:\"name\";s:6:\"images\";s:4:\"slug\";s:6:\"images\";s:5:\"count\";s:4:\"1051\";}s:4:\"page\";a:3:{s:4:\"name\";s:4:\"page\";s:4:\"slug\";s:4:\"page\";s:5:\"count\";s:4:\"1006\";}s:5:\"image\";a:3:{s:4:\"name\";s:5:\"image\";s:4:\"slug\";s:5:\"image\";s:5:\"count\";s:3:\"923\";}s:5:\"links\";a:3:{s:4:\"name\";s:5:\"links\";s:4:\"slug\";s:5:\"links\";s:5:\"count\";s:3:\"845\";}s:3:\"seo\";a:3:{s:4:\"name\";s:3:\"seo\";s:4:\"slug\";s:3:\"seo\";s:5:\"count\";s:3:\"792\";}s:8:\"facebook\";a:3:{s:4:\"name\";s:8:\"Facebook\";s:4:\"slug\";s:8:\"facebook\";s:5:\"count\";s:3:\"746\";}s:9:\"shortcode\";a:3:{s:4:\"name\";s:9:\"shortcode\";s:4:\"slug\";s:9:\"shortcode\";s:5:\"count\";s:3:\"676\";}s:7:\"gallery\";a:3:{s:4:\"name\";s:7:\"gallery\";s:4:\"slug\";s:7:\"gallery\";s:5:\"count\";s:3:\"674\";}s:9:\"wordpress\";a:3:{s:4:\"name\";s:9:\"wordpress\";s:4:\"slug\";s:9:\"wordpress\";s:5:\"count\";s:3:\"660\";}s:3:\"rss\";a:3:{s:4:\"name\";s:3:\"rss\";s:4:\"slug\";s:3:\"rss\";s:5:\"count\";s:3:\"650\";}s:6:\"social\";a:3:{s:4:\"name\";s:6:\"social\";s:4:\"slug\";s:6:\"social\";s:5:\"count\";s:3:\"602\";}s:5:\"pages\";a:3:{s:4:\"name\";s:5:\"pages\";s:4:\"slug\";s:5:\"pages\";s:5:\"count\";s:3:\"579\";}s:7:\"widgets\";a:3:{s:4:\"name\";s:7:\"widgets\";s:4:\"slug\";s:7:\"widgets\";s:5:\"count\";s:3:\"565\";}s:4:\"ajax\";a:3:{s:4:\"name\";s:4:\"AJAX\";s:4:\"slug\";s:4:\"ajax\";s:5:\"count\";s:3:\"547\";}s:6:\"jquery\";a:3:{s:4:\"name\";s:6:\"jquery\";s:4:\"slug\";s:6:\"jquery\";s:5:\"count\";s:3:\"547\";}s:5:\"email\";a:3:{s:4:\"name\";s:5:\"email\";s:4:\"slug\";s:5:\"email\";s:5:\"count\";s:3:\"479\";}s:10:\"javascript\";a:3:{s:4:\"name\";s:10:\"javascript\";s:4:\"slug\";s:10:\"javascript\";s:5:\"count\";s:3:\"471\";}s:5:\"media\";a:3:{s:4:\"name\";s:5:\"media\";s:4:\"slug\";s:5:\"media\";s:5:\"count\";s:3:\"471\";}s:5:\"video\";a:3:{s:4:\"name\";s:5:\"video\";s:4:\"slug\";s:5:\"video\";s:5:\"count\";s:3:\"457\";}s:4:\"feed\";a:3:{s:4:\"name\";s:4:\"feed\";s:4:\"slug\";s:4:\"feed\";s:5:\"count\";s:3:\"456\";}s:10:\"buddypress\";a:3:{s:4:\"name\";s:10:\"buddypress\";s:4:\"slug\";s:10:\"buddypress\";s:5:\"count\";s:3:\"453\";}s:5:\"photo\";a:3:{s:4:\"name\";s:5:\"photo\";s:4:\"slug\";s:5:\"photo\";s:5:\"count\";s:3:\"437\";}s:7:\"content\";a:3:{s:4:\"name\";s:7:\"content\";s:4:\"slug\";s:7:\"content\";s:5:\"count\";s:3:\"419\";}s:6:\"photos\";a:3:{s:4:\"name\";s:6:\"photos\";s:4:\"slug\";s:6:\"photos\";s:5:\"count\";s:3:\"413\";}s:4:\"link\";a:3:{s:4:\"name\";s:4:\"link\";s:4:\"slug\";s:4:\"link\";s:5:\"count\";s:3:\"402\";}s:8:\"category\";a:3:{s:4:\"name\";s:8:\"category\";s:4:\"slug\";s:8:\"category\";s:5:\"count\";s:3:\"390\";}s:4:\"spam\";a:3:{s:4:\"name\";s:4:\"spam\";s:4:\"slug\";s:4:\"spam\";s:5:\"count\";s:3:\"388\";}s:5:\"stats\";a:3:{s:4:\"name\";s:5:\"stats\";s:4:\"slug\";s:5:\"stats\";s:5:\"count\";s:3:\"388\";}s:5:\"flash\";a:3:{s:4:\"name\";s:5:\"flash\";s:4:\"slug\";s:5:\"flash\";s:5:\"count\";s:3:\"367\";}s:7:\"comment\";a:3:{s:4:\"name\";s:7:\"comment\";s:4:\"slug\";s:7:\"comment\";s:5:\"count\";s:3:\"361\";}s:7:\"youtube\";a:3:{s:4:\"name\";s:7:\"youtube\";s:4:\"slug\";s:7:\"youtube\";s:5:\"count\";s:3:\"360\";}}',	'yes'),
(1966,	0,	'_site_transient_update_plugins',	'O:8:\"stdClass\":3:{s:12:\"last_checked\";i:1346418826;s:7:\"checked\";a:13:{s:43:\"accordion-shortcode/accordion-shortcode.php\";s:5:\"1.0.1\";s:33:\"admin-menu-editor/menu-editor.php\";s:5:\"1.1.7\";s:30:\"advanced-custom-fields/acf.php\";s:5:\"3.2.5\";s:43:\"all-in-one-seo-pack/all_in_one_seo_pack.php\";s:8:\"1.6.14.5\";s:27:\"backupbuddy/backupbuddy.php\";s:6:\"2.2.36\";s:39:\"ajax-campaign-monitor-forms/cm-ajax.php\";s:3:\"1.0\";s:43:\"cm-subscriber-stats/cm-subscriber-stats.php\";s:5:\"1.0.1\";s:29:\"j-shortcodes/j-shortcodes.php\";s:5:\"1.405\";s:39:\"options-framework/options-framework.php\";s:3:\"1.1\";s:31:\"page-links-to/page-links-to.php\";s:5:\"2.7.1\";s:41:\"wordpress-importer/wordpress-importer.php\";s:3:\"0.6\";s:43:\"wp-maintenance-mode/wp-maintenance-mode.php\";s:5:\"1.7.1\";s:27:\"wp-super-cache/wp-cache.php\";s:3:\"1.1\";}s:8:\"response\";a:4:{s:33:\"admin-menu-editor/menu-editor.php\";O:8:\"stdClass\":5:{s:2:\"id\";s:5:\"11743\";s:4:\"slug\";s:17:\"admin-menu-editor\";s:11:\"new_version\";s:6:\"1.1.10\";s:3:\"url\";s:54:\"http://wordpress.org/extend/plugins/admin-menu-editor/\";s:7:\"package\";s:66:\"http://downloads.wordpress.org/plugin/admin-menu-editor.1.1.10.zip\";}s:30:\"advanced-custom-fields/acf.php\";O:8:\"stdClass\":5:{s:2:\"id\";s:5:\"21367\";s:4:\"slug\";s:22:\"advanced-custom-fields\";s:11:\"new_version\";s:5:\"3.3.9\";s:3:\"url\";s:59:\"http://wordpress.org/extend/plugins/advanced-custom-fields/\";s:7:\"package\";s:64:\"http://downloads.wordpress.org/plugin/advanced-custom-fields.zip\";}s:43:\"all-in-one-seo-pack/all_in_one_seo_pack.php\";O:8:\"stdClass\":5:{s:2:\"id\";s:3:\"520\";s:4:\"slug\";s:19:\"all-in-one-seo-pack\";s:11:\"new_version\";s:6:\"1.6.15\";s:3:\"url\";s:56:\"http://wordpress.org/extend/plugins/all-in-one-seo-pack/\";s:7:\"package\";s:61:\"http://downloads.wordpress.org/plugin/all-in-one-seo-pack.zip\";}s:39:\"options-framework/options-framework.php\";O:8:\"stdClass\":5:{s:2:\"id\";s:5:\"21510\";s:4:\"slug\";s:17:\"options-framework\";s:11:\"new_version\";s:3:\"1.3\";s:3:\"url\";s:54:\"http://wordpress.org/extend/plugins/options-framework/\";s:7:\"package\";s:63:\"http://downloads.wordpress.org/plugin/options-framework.1.3.zip\";}}}',	'yes'),
(1967,	0,	'pluginbuddy_backupbuddy',	'a:35:{s:12:\"data_version\";s:1:\"2\";s:15:\"import_password\";s:8:\"adgo5f4c\";s:16:\"backup_reminders\";s:1:\"1\";s:16:\"edits_since_last\";i:0;s:11:\"last_backup\";i:1346350018;s:18:\"last_backup_serial\";s:10:\"gvxemg0sf1\";s:11:\"compression\";s:1:\"1\";s:19:\"force_compatibility\";s:1:\"0\";s:18:\"skip_database_dump\";s:1:\"0\";s:19:\"backup_nonwp_tables\";s:1:\"0\";s:14:\"include_tables\";a:0:{}s:14:\"exclude_tables\";a:0:{}s:15:\"integrity_check\";s:1:\"1\";s:9:\"schedules\";a:0:{}s:9:\"log_level\";s:1:\"1\";s:8:\"excludes\";s:7:\"/www/\r\n\";s:13:\"high_security\";i:0;s:19:\"next_schedule_index\";i:100;s:13:\"archive_limit\";s:1:\"0\";s:18:\"archive_limit_size\";s:1:\"0\";s:22:\"email_notify_scheduled\";s:0:\"\";s:19:\"email_notify_manual\";s:0:\"\";s:18:\"email_notify_error\";s:0:\"\";s:7:\"backups\";a:0:{}s:19:\"remote_destinations\";a:0:{}s:21:\"backup_file_integrity\";a:0:{}s:11:\"role_access\";s:13:\"administrator\";s:16:\"dropboxtemptoken\";s:0:\"\";s:11:\"backup_mode\";s:1:\"2\";s:16:\"multisite_export\";s:1:\"1\";s:16:\"backup_directory\";s:66:\"/var/www/vhosts/calzada-wp/wp-content/uploads/backupbuddy_backups/\";s:20:\"repairbuddy_password\";s:0:\"\";s:10:\"log_serial\";s:10:\"zth21rv6en\";s:17:\"temporary_options\";a:1:{s:16:\"experimental_zip\";s:1:\"0\";}i:0;b:0;}',	'yes'),
(1968,	0,	'pluginbuddy_plugins',	'a:1:{s:23:\"pluginbuddy_backupbuddy\";O:8:\"stdClass\":9:{s:3:\"url\";s:60:\"http://calzada-wp.urldock.com/wp-content/plugins/backupbuddy\";s:4:\"slug\";s:23:\"pluginbuddy_backupbuddy\";s:7:\"package\";s:0:\"\";s:11:\"new_version\";s:6:\"2.2.36\";s:11:\"last_update\";i:1346415457;s:2:\"id\";s:1:\"0\";s:3:\"key\";s:0:\"\";s:10:\"key_status\";s:7:\"invalid\";s:4:\"guid\";s:13:\"503fab99e1b7e\";}}',	'yes'),
(1969,	0,	'_transient_timeout_feed_94bc6e7dd050c2a74ce39668c35643cd',	'1346393184',	'no'),
(1970,	0,	'_transient_feed_94bc6e7dd050c2a74ce39668c35643cd',	'a:4:{s:5:\"child\";a:1:{s:0:\"\";a:1:{s:3:\"rss\";a:1:{i:0;a:6:{s:4:\"data\";s:3:\"\n\n\n\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:7:\"version\";s:3:\"2.0\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:1:{s:0:\"\";a:1:{s:7:\"channel\";a:1:{i:0;a:6:{s:4:\"data\";s:50:\"\n	\n	\n	\n	\n	\n	\n	\n	\n	\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n	\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:3:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:7:\"iThemes\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:18:\"http://ithemes.com\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:62:\"Your one-stop shop for WordPress themes, plugins and training.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:13:\"lastBuildDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 30 Aug 2012 15:22:33 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"language\";a:1:{i:0;a:5:{s:4:\"data\";s:2:\"en\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:9:\"generator\";a:1:{i:0;a:5:{s:4:\"data\";s:29:\"http://wordpress.org/?v=3.3.2\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"item\";a:10:{i:0;a:6:{s:4:\"data\";s:47:\"\n		\n		\n		\n		\n		\n				\n		\n		\n\n		\n		\n			\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:69:\"How To Pick Web Hosting Without a Computer Science Degree [New eBook]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:98:\"http://ithemes.com/2012/08/27/how-to-pick-web-hosting-without-a-computer-science-degree-new-ebook/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:107:\"http://ithemes.com/2012/08/27/how-to-pick-web-hosting-without-a-computer-science-degree-new-ebook/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 27 Aug 2012 13:00:44 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:3:{i:0;a:5:{s:4:\"data\";s:6:\"eBooks\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:1;a:5:{s:4:\"data\";s:7:\"hosting\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:2;a:5:{s:4:\"data\";s:17:\"WordPress hosting\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:27:\"http://ithemes.com/?p=13159\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:349:\"Web hosting is likely the most confusing, anxiety-ridden part of launching your own site. It’s highly technical, completely foreign to most people, and yet your entire site depends on it. Fun! But don’t worry. We have a brand new eBook that can help. In How To Pick Web Hosting Without a Computer Science Degree, we cover the basics of [...]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"Kristen Wright\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:1844:\"<p style=\"text-align: center;\"><a href=\"http://ithemes.com/publishing/how-to-pick-web-hosting-without-a-computer-science-degree/\"><img class=\"alignnone size-full wp-image-13171\" title=\"How to Pick Web Hosting Without a Computer Science Degree\" src=\"http://ithemes.com/wp-content/uploads/2012/08/Screen-shot-2012-08-24-at-10.56.22-AM.png\" alt=\"\" width=\"374\" height=\"480\" /></a></p>\n<p>Web hosting is likely the most confusing, anxiety-ridden part of launching your own site. It’s highly technical, completely foreign to most people, and yet your entire site depends on it. Fun!</p>\n<p>But don’t worry. We have a brand new eBook that can help. In <em><a href=\"http://ithemes.com/downloads/How-to-Pick-Web-Hosting-without-a-Computer-Science-Degree.pdf\">How To Pick Web Hosting Without a Computer Science Degree</a></em>, we cover the basics of web hosting and move through the technical lingo with easy-to-understand translations for those of us who don’t speak “server.” We’ll also cover many of the major considerations when looking for a host to help you figure out exactly what you need.</p>\n<h3>Topics covered:</h3>\n<ul>\n<li>Understanding your needs</li>\n<li>Types of hosting</li>\n<li>WordPress requirements &amp; recommendations</li>\n<li>Basic feature considerations</li>\n<li>Extra feature considerations</li>\n<li>Hosting wisdom from the pros</li>\n<li>BackupBuddy hosting Requirements</li>\n<li>Top 6 things to look for in a host</li>\n</ul>\n<h4><a href=\"http://ithemes.com/downloads/How-to-Pick-Web-Hosting-without-a-Computer-Science-Degree.pdf\">Download your copy now</a> and check out the rest of the <a href=\"http://ithemes.com/publishing\">iThemes eBook Library</a>.</h4>\n<p><a class=\"btn blue\" href=\"http://ithemes.com/downloads/How-to-Pick-Web-Hosting-without-a-Computer-Science-Degree.pdf\">Download the PDF</a></p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:103:\"http://ithemes.com/2012/08/27/how-to-pick-web-hosting-without-a-computer-science-degree-new-ebook/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"0\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:1;a:6:{s:4:\"data\";s:53:\"\n		\n		\n		\n		\n		\n				\n		\n		\n		\n		\n\n		\n		\n			\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:50:\"The All-New Getting Started with BackupBuddy eBook\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:81:\"http://ithemes.com/2012/08/21/the-all-new-getting-started-with-backupbuddy-ebook/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:90:\"http://ithemes.com/2012/08/21/the-all-new-getting-started-with-backupbuddy-ebook/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 21 Aug 2012 17:59:56 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:5:{i:0;a:5:{s:4:\"data\";s:11:\"BackupBuddy\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:1;a:5:{s:4:\"data\";s:6:\"eBooks\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:2;a:5:{s:4:\"data\";s:8:\"featured\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:3;a:5:{s:4:\"data\";s:17:\"BackupBuddy eBook\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:4;a:5:{s:4:\"data\";s:32:\"Getting Started with BackupBuddy\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:27:\"http://ithemes.com/?p=13053\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:379:\"Check it out. Our Getting Started with BackupBuddy handbook has just been completely updated to reflect all of the new features and UI enhancements in BackupBuddy 3.0. With a brand new eBook layout and helpful sections including &#8220;The First Four Critical Steps After Installing BackupBuddy,&#8221; this eBook presents a basic walk-through of using BackupBuddy for the [...]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"Kristen Wright\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:2504:\"<p style=\"text-align: center;\"><a href=\"http://ithemes.com/downloads/Getting-Started-with-BackupBuddy-3.02.pdf\"><img class=\"size-full wp-image-13089 aligncenter\" title=\"Getting-started-with-BackupBuddy\" src=\"http://ithemes.com/wp-content/uploads/2012/08/Screen-shot-2012-08-21-at-9.40.20-AM1.png\" alt=\"\" width=\"380\" height=\"486\" /></a></p>\n<p style=\"text-align: left;\">Check it out. Our <a href=\"http://ithemes.com/downloads/Getting-Started-with-BackupBuddy-3.02.pdf\"><em>Getting Started with BackupBuddy</em> handbook</a> has just been completely updated to reflect all of the new features and UI enhancements in <a href=\"http://ithemes.com/purchase/backupbuddy/\">BackupBuddy 3.0.</a></p>\n<p>With a brand new eBook layout and helpful sections including &#8220;The First Four Critical Steps After Installing BackupBuddy,&#8221; this eBook presents a basic walk-through of using BackupBuddy for the first time, plus an overview of BackupBuddy menu pages and key term definitions.</p>\n<h3>Part I: Getting Started</h3>\n<p>This section includes helpful &#8220;intro&#8221; info, including:</p>\n<ul>\n<li>The BackupBuddy Story</li>\n<li>BackupBuddy features</li>\n<li>Instructions for downloading and installing BackupBuddy</li>\n<li>Activating BackupBuddy on Multisite</li>\n<li>Common BackupBuddy mistakes</li>\n<li>BackupBuddy tips</li>\n</ul>\n<div>\n<h3>Part II: The First Four Critical Steps After Installing BackupBuddy</h3>\n<p>This quick-start guide offers a &#8220;checklist&#8221; of the four most important steps to complete after installing BackupBuddy.</p>\n<h3>Part III: The BackupBuddy Menu Overview</h3>\n<p>This section covers each page of the BackupBuddy menu, including:</p>\n<ul>\n<li>The <em>Getting Started</em> Page</li>\n<li>The <em>Backup</em> Page</li>\n<li>The <em>Migrate, Restore</em> Page</li>\n<li>The <em>Malware Scan</em> Page</li>\n<li>The <em>Server Informatio</em>n Page</li>\n<li>The <em>Scheduling</em> Page</li>\n<li>The <em>Settings</em> Page</li>\n</ul>\n</div>\n<h3>Part IV: Additional Resources</h3>\n<p>The last section includes an appendix for generating BackupBuddy license keys, links to helpful BackupBuddy resources and even an index.</p>\n<h4><a href=\"http://ithemes.com/downloads/Getting-Started-with-BackupBuddy-3.02.pdf\">Download your copy now</a> and check out the rest of the <a href=\"http://ithemes.com/publishing\">iThemes eBook Library</a>.</h4>\n<p><a class=\"btn blue\" href=\"http://ithemes.com/downloads/Getting-Started-with-BackupBuddy-3.02.pdf\">Download the PDF</a></p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:86:\"http://ithemes.com/2012/08/21/the-all-new-getting-started-with-backupbuddy-ebook/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"1\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:2;a:6:{s:4:\"data\";s:44:\"\n		\n		\n		\n		\n		\n				\n		\n\n		\n		\n			\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:55:\"The First 4 Critical Steps After Installing BackupBuddy\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:86:\"http://ithemes.com/2012/08/17/the-first-4-critical-steps-after-installing-backupbuddy/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:95:\"http://ithemes.com/2012/08/17/the-first-4-critical-steps-after-installing-backupbuddy/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 17 Aug 2012 17:08:54 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:2:{i:0;a:5:{s:4:\"data\";s:11:\"BackupBuddy\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:1;a:5:{s:4:\"data\";s:8:\"featured\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:27:\"http://ithemes.com/?p=12987\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:357:\"Having a solid backup strategy in place isn&#8217;t a choice, it&#8217;s absolutely vital for your WordPress site. And BackupBuddy is that all-in-one holistic solution &#8212; because you can easily backup your site (everything &#8211; all your settings, themes, plugins, content etc) &#8230; and then restore it if you have a crash … OR move it to [...]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:11:\"Cory Miller\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:7920:\"<h4>Having a solid backup strategy in place isn&#8217;t a choice, it&#8217;s absolutely vital for your WordPress site.</h4>\n<p>And <a title=\"backup buddy\" href=\"http://ithemes.com/purchase/backupbuddy/\">BackupBuddy</a> is that all-in-one holistic solution &#8212; because you can easily backup your site (<em>everything</em> &#8211; all your settings, themes, plugins, content etc) &#8230; and then restore it if you have a crash … OR move it to a new host or domain name.</p>\n<p>BackupBuddy is currently running on well over 100,000 sites &#8230; but we don&#8217;t want you to just buy it &#8230; we want you to USE it so your site is safely and securely backed up.</p>\n<h5>We highly recommend these first four steps after first installing BackupBuddy:</h5>\n<h3>1. Complete these key BackupBuddy settings.</h3>\n<div id=\"attachment_13002\" class=\'wp-caption alignnone\' style=\'width:1024px;\'><img class=\"size-large wp-image-13002\" title=\"BackupBuddy-settings\" src=\"http://ithemes.com/wp-content/uploads/2012/08/Screen-shot-2012-08-17-at-11.46.28-AM-1024x766.png\" alt=\"\" width=\"1024\" height=\"766\" /><p class=\'wp-caption-text\'>The BackupBuddy Settings Page</p></div>\n<h5>From the WordPress Dashboard, navigate to the BackupBuddy menu and go to the <em>Settings</em> page:</h5>\n<ol>\n<li>Make sure you set your <strong>ImportBuddy Password</strong> (so you can securely restore your site in the event of a crash).</li>\n<li>Put your email address in the “<strong>Error notification recipients”</strong> space (so you can be updated if backup errors occur).</li>\n<li>Setup your <strong>“Remote Destinations”</strong> (the best way to store your backups is off-site).</li>\n</ol>\n<p>Our recommended remote destination for backups is an affordable and reliable service like Amazon S3. Amazon S3 is backed by the enormous Amazon.com infrastructure that powers a lot of your favorite sites.</p>\n<p><a href=\"http://calculator.s3.amazonaws.com/calc5.html\">Here’s an Amazon S3 calculator to estimate your charges</a>. For example, we host our own backups with Amazon S3, and our bill is insanely cheap for what we store (everything). For 10GB of storage with 10GB of transfer (WAY more than the average WordPress site), the estimated bill is just 63 cents for the US region.</p>\n<p><a href=\"http://aws.amazon.com/s3/\">Signup for an Amazon S3 account (yes, different than regular Amazon.com)</a>.</p>\n<h3>2. Perform a backup to test your Remote Destination.</h3>\n<div id=\"attachment_13007\" class=\'wp-caption alignnone\' style=\'width:876px;\'><img class=\"size-full wp-image-13007\" title=\"BackupBuddy Backups Page\" src=\"http://ithemes.com/wp-content/uploads/2012/08/Screen-shot-2012-08-17-at-11.53.47-AM.png\" alt=\"\" width=\"876\" height=\"785\" /><p class=\'wp-caption-text\'>The BackupBuddy Backups Page</p></div>\n<p>After you&#8217;ve setup the key Settings above, you&#8217;ll want to do your first Database-Only Backup and Full Backup to ensure everything&#8217;s working properly.</p>\n<ol>\n<li>From the WordPress Dashboard, navigate to the BackupBuddy menu, then the <strong>Backup</strong> page.</li>\n<li>Select <em>Database</em>. BackupBuddy will start backing up only your database. Once the backup is complete, the blue lights will stop blinking and you&#8217;ll see a green light at the end of the progress bar.</li>\n<li>Go back to the <strong>Backup</strong> page and you should see your new backup file listed. Next to the file, you&#8217;ll see Statistics and Status of the file.</li>\n<li>If the backup is listed as &#8220;Good,&#8221; hover over the file name and click &#8220;<strong>Send file offsite&#8221;</strong>. A popup box will appear, select your Remote Destination, and click &#8220;<strong>Select this destination</strong>.&#8221;</li>\n<li>Once completed, a box will say that your file is in transfer. To verify the transfer and to see a list of backup files in your Remote Destinations, wait a few minutes (to allow the transfer to happen), then visit the <strong>Backup</strong> page and select the &#8220;<strong>Remote Destinations</strong>&#8221; tab.</li>\n<li>Click on the &#8220;<strong>Manage Remote Destinations &amp; Archives</strong>&#8221; button and select your Remote Destination (in this case Amazon S3) and hover over it to click &#8220;<strong>Select this destination.</strong>&#8220;</li>\n<li>The page will refresh and show you a complete file list. If you see your backup, you are good to go and can even download it to verify by clicking on &#8220;<strong>Copy to local</strong>.&#8221;</li>\n<li>Repeat this process for the Complete (Full) Backup.</li>\n<li>We also suggest on this first run through that you download a copy of your Database Only and Full Backups to your computer. Hover over the backup and select &#8220;<strong>Download file.</strong>&#8221; Create a folder on your computer called &#8220;BackupBuddy&#8221; or &#8220;WP Backups&#8221; and save it in there. This just gives you one more place to store your first backups.</li>\n</ol>\n<h3>3. Setup Schedules.</h3>\n<p>Once you have verified that BackupBuddy has backed up both types of backups and stored them safely to your Remote Destinations, you&#8217;ll want to setup your backup Schedules.</p>\n<div id=\"attachment_13011\" class=\'wp-caption alignnone\' style=\'width:1024px;\'><img class=\"size-large wp-image-13011\" title=\"BackupBuddy Scheduling\" src=\"http://ithemes.com/wp-content/uploads/2012/08/Screen-shot-2012-08-17-at-12.03.53-PM-1024x761.png\" alt=\"\" width=\"1024\" height=\"761\" /><p class=\'wp-caption-text\'>The BackupBuddy Scheduling Page</p></div>\n<p>In your WordPress dashboard, navigate to the BackupBuddy menu and click  &#8221;<strong>Scheduling</strong>.&#8221;</p>\n<h5>For most WordPress sites, we suggest these backup schedules below but you should make your own judgment on how frequent you should do your backups:</h5>\n<p>1. <strong>Database Only Backup running Once a Week</strong> &#8212; name it &#8220;Weekly Database,&#8221; then select &#8220;Database Only&#8221; and &#8220;Weekly&#8221; as the frequency. We suggest setting the &#8220;Date/time of next run&#8221; for a low trafficked part of your day, like after midnight.</p>\n<p>2. <strong>Full Database Backup running Twice Monthly</strong>&#8211; named it &#8220;Monthly Full Backup,&#8221; then select &#8220;Full Backup&#8221; and &#8220;Twice Monthly. Again, we suggest setting the &#8220;Date/time of next run&#8221; for a low trafficked part of your day, like after midnight.</p>\n<h3>4. Plan ahead to get the BEST SUPPORT from our team.</h3>\n<p>As always, our team is here for you if you have questions or get stumped along the way on our <a href=\"http://iThemes.com/forum\">Support Forum</a>… but please don&#8217;t wait until the last minute to migrate a site (especially if it is your first)!</p>\n<p>Finding out you don&#8217;t know how to do something or running into a technical problem 15 minutes before showing a site demo to a client is not fun and although our support is fast, we can&#8217;t help you fix something you needed 2 hours ago.</p>\n<h5>So please plan ahead so we can offer you the best support.</h5>\n<p>We highly recommend if you&#8217;re backing up, restoring or moving a critical site (or even a large one), that you consider our support hours so our awesome support ninjas can help you.</p>\n<p>Our support hours are 8 a.m. &#8211; 5 p.m. Central Standard Time, Monday-Friday (except on major U.S. holidays).</p>\n<p>Simply logon to the <a href=\"http://ithemes.com/forum/forum/74-backupbuddy/\">BackupBuddy Support Forum</a> with your iThemes username and password … search for a related subject, or post your issue giving as much details (with links) as you can in order to BEST serve you!</p>\n<h3>Watch the Video Tutorial: The First 4 Critical Steps After Installing BackupBuddy</h3>\n<p><iframe src=\"http://www.youtube.com/embed/-ZCer7STRks?rel=0\" frameborder=\"0\" width=\"560\" height=\"315\"></iframe></p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:91:\"http://ithemes.com/2012/08/17/the-first-4-critical-steps-after-installing-backupbuddy/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"7\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:3;a:6:{s:4:\"data\";s:41:\"\n		\n		\n		\n		\n		\n				\n\n		\n		\n			\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:51:\"Collaborate on Web Design Projects Easily with Cage\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:82:\"http://ithemes.com/2012/08/10/collaborate-on-web-design-projects-easily-with-cage/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:91:\"http://ithemes.com/2012/08/10/collaborate-on-web-design-projects-easily-with-cage/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 10 Aug 2012 21:29:19 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:1:{i:0;a:5:{s:4:\"data\";s:4:\"Blog\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:27:\"http://ithemes.com/?p=12859\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:343:\"This week my good friend, Sandip Patel, based here in Oklahoma City, walked me through the all-new Cage, an online collaboration software perfect for web designers, photographers, videographers or anyone wanting to be able to streamline the design input and feedback stage of client work. Go signup for a free trial today to take it for [...]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:11:\"Cory Miller\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:1169:\"<p>This week my good friend, Sandip Patel, based here in Oklahoma City, walked me through <a title=\"cage\" href=\"http://cageapp.com\">the all-new Cage</a>, an online collaboration software perfect for web designers, photographers, videographers or anyone wanting to be able to streamline the design input and feedback stage of client work.</p>\n<p>Go signup for a <a title=\"cage app\" href=\"http://cageapp.com/site/pricing\">free trial today</a> to take it for a test spin.</p>\n<p>Here&#8217;s the webinar walkthrough with Q&amp;A &#8230;</p>\n<p><iframe src=\"http://www.youtube.com/embed/VxDRsiezKHU?rel=0\" frameborder=\"0\" width=\"560\" height=\"315\"></iframe></p>\n<p>Also, Sandip has graciously offered a discount to the iThemes community for cage:</p>\n<h5>Through Sept.10, 2012, use coupon code <a href=\"http://cageapp.com\">ithemes</a> (all lowercase) for 20% off your first month of Cage.</h5>\n<p>Over the last year and a half since I met Sandip, I&#8217;ve been able to watch the progression of Cage and having talked extensively with him in that time, I&#8217;m pumped about Cage and their commitment to the customer experience. They love what they do and it shows.</p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:87:\"http://ithemes.com/2012/08/10/collaborate-on-web-design-projects-easily-with-cage/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"3\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:4;a:6:{s:4:\"data\";s:41:\"\n		\n		\n		\n		\n		\n				\n\n		\n		\n			\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:50:\"Two Great Podcast Interviews Featuring BackupBuddy\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:81:\"http://ithemes.com/2012/08/10/two-great-podcast-interviews-featuring-backupbuddy/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:90:\"http://ithemes.com/2012/08/10/two-great-podcast-interviews-featuring-backupbuddy/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 10 Aug 2012 14:26:17 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:1:{i:0;a:5:{s:4:\"data\";s:11:\"BackupBuddy\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:27:\"http://ithemes.com/?p=12853\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:317:\"I had the opportunity in the past couple of weeks to be a guest on two great podcasts to talk about BackupBuddy and wanted to share. First, Cliff Ravenscraft of Podcast Answer Man, who I found via Social Media Examiner, is doing some amazing things with WordPress podcasting. He is now using BackupBuddy to back [...]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:11:\"Cory Miller\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:1532:\"<p>I had the opportunity in the past couple of weeks to be a guest on two great podcasts to talk about <a title=\"backup buddy\" href=\"http://ithemes.com/purchase/backupbuddy/\">BackupBuddy</a> and wanted to share.</p>\n<p>First, Cliff Ravenscraft of <a title=\"podcast answer man\" href=\"http://podcastanswerman.com/271/\">Podcast Answer Man</a>, who I found via <a href=\"http://socialmediaexaminer.com\">Social Media Examiner</a>, is doing some amazing things with WordPress podcasting. He is now using BackupBuddy to back up all his sites (which as you might expect from a podcaster is HUGE) using Amazon S3 now.</p>\n<p>Check out our podcast interview at the <a title=\"podcast answer man 271 backupbuddy\" href=\"http://podcastanswerman.com/271/\">45-minute mark on Podcast Answer Man Episode 271</a>.</p>\n<p>Next up, I talked with Dustin Hartzler of <a href=\"http://yourwebsiteengineer.com/088-backup-your-wordpress-sites-with-backup-buddy/\">Your Website Engineer</a> about BackupBuddy. He had been recommending another free backup plugin and is now a BackupBuddy user and believer.</p>\n<p><a title=\"your website engineer podcast on backup buddy\" href=\"http://yourwebsiteengineer.com/088-backup-your-wordpress-sites-with-backup-buddy/#MustHavePlugin\">Check out our podcast interview</a> at Your Website Engineer here.</p>\n<p>If you&#8217;d like me or someone on our team to do an interview on your webinar or podcast, <a title=\"Contact iThemes\" href=\"http://ithttp://ithemes.com/contact/\">please let us know</a>. We love doing these!</p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:86:\"http://ithemes.com/2012/08/10/two-great-podcast-interviews-featuring-backupbuddy/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"0\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:5;a:6:{s:4:\"data\";s:47:\"\n		\n		\n		\n		\n		\n				\n		\n		\n\n		\n		\n			\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:40:\"PluginBuddy.com Merging with iThemes.com\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:71:\"http://ithemes.com/2012/08/07/pluginbuddy-com-merging-with-ithemes-com/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:80:\"http://ithemes.com/2012/08/07/pluginbuddy-com-merging-with-ithemes-com/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 07 Aug 2012 16:14:56 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:3:{i:0;a:5:{s:4:\"data\";s:4:\"Blog\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:1;a:5:{s:4:\"data\";s:15:\"iThemes plugins\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:2;a:5:{s:4:\"data\";s:11:\"PluginBuddy\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:27:\"http://ithemes.com/?p=12722\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:370:\"We briefly mentioned in the redesign announcement post that PluginBuddy, our plugin division, is now included in the new iThemes site. We&#8217;re hoping the iThemes and PluginBuddy site merge will reduce confusion about our products and make it easier for visitors to find and access everything they need from one place without having to switch between separate [...]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"Kristen Wright\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:3785:\"<p>We briefly mentioned in <a href=\"http://ithemes.com/2012/08/05/welcome-to-the-new-ithemes-com/\">the redesign announcement post</a> that PluginBuddy, our plugin division, is now included in the new iThemes site.</p>\n<p>We&#8217;re hoping the iThemes and PluginBuddy site merge will reduce confusion about our products and make it easier for visitors to find and access everything they need from one place without having to switch between separate domains.</p>\n<h2>Some background</h2>\n<p>iThemes and PluginBuddy have always been ONE company with ONE team of developers and staff.  In March of 2010, <a href=\"http://ithemes.com/2010/03/03/pluginbuddy-launches-march-4/\">we launched PluginBuddy</a> as our plugin division to provide professional plugins with guaranteed support and updates. In the two years since PluginBuddy first launched, our premium WordPress plugin library has grown to include over 20 premium plugins and our best-selling plugin, <a title=\"Backup Buddy\" href=\"http://ithemes.com/#\">BackupBuddy</a>.</p>\n<p>We were very <a href=\"http://corymiller.com/why-we-need-a-premium-wordpress-plugin-market/\">intentional about entering the plugin market</a>, because we wanted to provide solutions for issues we&#8217;d seen (and experienced ourselves) in the wide world of WordPress plugins.</p>\n<p>We launched PluginBuddy with these primary objectives:</p>\n<ul>\n<li><strong>Confidence and Quality</strong><strong> -</strong> Plugins made by experienced developers committed to high standards in coding practices</li>\n<li><strong>Support and Updates</strong> - Up-to-date, dependable plugins with an on-call support team</li>\n<li><strong>Less Filtering and Sifting</strong> &#8211; Plugins that would stand out among the thousands of plugins in the WordPress repo</li>\n</ul>\n<p>We&#8217;ve remained committed to these goals, but as we&#8217;ve grown, we&#8217;ve found it increasingly difficult to manage products and content between two separate domains. We saw the iThemes site redesign as an opportunity to evaluate our approach and become more efficient with a single, robust site.</p>\n<h2>How this affects you</h2>\n<h5>The new iThemes Plugins Store</h5>\n<p>PluginBuddy plugins are now included in the <a href=\"http://ithemes.com/find/plugins/\">iThemes Plugin store</a>. The new iThemes Plugin individual sales pages feature new layouts, feature overviews, plugin screenshots and videos. Now, you&#8217;ll be able to purchase or renew your plugin memberships directly from the iThemes.com site.</p>\n<h5>PluginBuddy.com URL redirects</h5>\n<p>We&#8217;ve redirected all URLs from PluginBuddy.com to corresponding iThemes.com pages and merged all previous posts from the PluginBuddy blog to iThemes.com.</p>\n<h5>PluginBuddy email newsletters</h5>\n<p>If you signed up for updates from PluginBuddy, we&#8217;ll be sending out a notification email about the iThemes/PluginBuddy merge. The content for these email updates will now include updates for all iThemes products (themes, plugins and training), resources and promotions.</p>\n<h5>Product downloads, support and membership terms</h5>\n<p>The iThemes/PluginBuddy site merge won&#8217;t effect your product downloads (still available from the <a href=\"http://ithemes.com/member/member.php\">iThemes Member Panel</a>), access to support (still located at <a href=\"http://ithemes.com/forum\">iThemes.com/support</a>) or your plugin membership terms.</p>\n<h3>Again, we hope this merge will enhance your customer experience and reduce confusion about our products.</h3>\n<p>We want to be your one-stop shop for WordPress themes, plugins and training and we believe this merge helps us serve you better.</p>\n<p>If you have any questions or concerns, <a href=\"http://ithemes.com/contact/\">please let us know</a>.</p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:76:\"http://ithemes.com/2012/08/07/pluginbuddy-com-merging-with-ithemes-com/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"1\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:6;a:6:{s:4:\"data\";s:41:\"\n		\n		\n		\n		\n		\n				\n\n		\n		\n			\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:30:\"Welcome to the New iThemes.com\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:61:\"http://ithemes.com/2012/08/05/welcome-to-the-new-ithemes-com/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:70:\"http://ithemes.com/2012/08/05/welcome-to-the-new-ithemes-com/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 06 Aug 2012 00:08:07 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:1:{i:0;a:5:{s:4:\"data\";s:8:\"featured\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:27:\"http://ithemes.com/?p=11639\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:329:\"The new iThemes.com is here. It&#8217;s been a long time coming (the previous design was 3 years old!) and we&#8217;re excited to share some of the new features that we hope will enhance your experience with the site. We&#8217;ve been intentional about the style and structure of the redesign, so every detail has a purpose [...]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"Kristen Wright\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:5730:\"<p><img class=\"size-medium wp-image-12330 aligncenter\" title=\"The-new-iThemes-site\" src=\"http://ithemes.com/wp-content/uploads/2012/08/Screen-shot-2012-08-05-at-6.06.00-PM-540x202.png\" alt=\"\" width=\"540\" height=\"202\" />The new iThemes.com is here. It&#8217;s been a long time coming (the previous design was 3 years old!) and we&#8217;re excited to share some of the new features that we hope will enhance your experience with the site.</p>\n<p>We&#8217;ve been intentional about the style and structure of the redesign, so every detail has a purpose and objective. iThemes has grown and changed dramatically in the years since we first launched, and we&#8217;ve badly needed a site that truly reflects who we are today by showcasing all of our products, services and content in a new way.</p>\n<p>You can check out <a href=\"http://ithemes.com/2012/07/20/some-qa-and-a-sneak-peek-of-the-new-ithemes-com/\">this Q&amp;A</a> with Brad (our designer) and Ty (from our <a title=\"WordPress design services\" href=\"http://creative.ithemes.com\">Creative Services</a> division) about their approach to the redesign and their favorite parts of the new site.</p>\n<p>We&#8217;re hoping you&#8217;ll enjoy the new iThemes.com as much as we do, as we&#8217;ve finally combined the two-fold purpose of an easy-to-manage site for us on the backend, with a beautiful, efficient site for you, our guests and community, on the front-end.</p>\n<p><strong>Here are a few features we want to highlight:</strong></p>\n<h2>It&#8217;s on Builder</h2>\n<p>iThemes.com is no ordinary WordPress site. More than 250 pages, countless blog posts, integrations with our eCommerce and forum software – all sorts of complications that make switching over to a new theme a big deal. Because of this complexity, we avoided a major theme redesign for a long time. The longer we waited, the more the old franken-theme grew. But we&#8217;re finally happy to announce that our site is using the theme we built for ourselves in 2009 – <a href=\"http://ithemes.com/purchase/builder-theme/\">Builder</a>. We&#8217;ve been drooling over the features and flexibility of Builder as we&#8217;ve added to it and created themes for it. We realized how much easier things would be if we could only use Builder. And now we can take full advantage of it. We&#8217;ll be publishing a series of blog posts about how we&#8217;re using Builder in the new site and how we made it responsive, in the coming weeks.</p>\n<h2>A single site for all of our WP themes and plugins</h2>\n<div  class=\'wp-caption alignnone\' style=\'width:540px;\'><img title=\"new-iThemes-nav\" src=\"http://ithemes.com/wp-content/uploads/2012/08/Screen-shot-2012-08-05-at-3.38.55-PM-540x174.png\" alt=\"\" width=\"540\" height=\"174\" /><p class=\'wp-caption-text\'>Welcome to the brand new iThemes.com</p></div>\n<p>In <a href=\"http://ithemes.com/2010/03/03/pluginbuddy-launches-march-4/\">March of 2010</a>, we launched PluginBuddy as our plugin division to provide professional plugins with guaranteed support and updates. Since then, our plugin library has grown to include over 20 premium plugins and our best-selling plugin, <a title=\"Backup Buddy\" href=\"http://ithemes.com/#\">BackupBuddy</a>.</p>\n<p>iThemes and PluginBuddy have always been ONE company with ONE team of developers and staff, but we&#8217;d found it increasingly difficult to manage products and content between two separate domains. With the launch of the new iThemes.com, we&#8217;ve created a single, robust site that includes all of our plugins and themes. Starting today, the PluginBuddy domain will be forwarded to corresponding URLs at iThemes.com:</p>\n<p><img title=\"new-plugin-store\" src=\"http://ithemes.com/wp-content/uploads/2012/08/new-plugin-store-391x540.jpg\" alt=\"\" width=\"313\" height=\"432\" /></p>\n<p>We&#8217;re hoping PluginBuddy&#8217;s merge into the iThemes.com site will reduce confusion about our products and make it easier for visitors to find and access everything they need from one place without having to switch between separate domains. You can check out the all-new iThemes (formerly PluginBuddy) plugin store <a href=\"http://ithemes.com/find/plugins/\">here</a>.</p>\n<h2>New, improved sales pages</h2>\n<div id=\"attachment_11692\" class=\'wp-caption alignnone\' style=\'width:540px;\'><img class=\"size-medium wp-image-11692 \" title=\"New-dev-suite\" src=\"http://ithemes.com/wp-content/uploads/2012/08/Screen-shot-2012-08-05-at-4.11.28-PM-540x318.png\" alt=\"\" width=\"540\" height=\"318\" /><p class=\'wp-caption-text\'>Our new Plugin Dev Suite sales page</p></div>\n<p>You&#8217;ll find completely redesigned sales pages for individual plugins, themes and combo packs with new feature overviews. Each of the DisplayBuddy plugins also feature new logos, feature overviews and FAQ sections, too.</p>\n<h2>The new theme sorter</h2>\n<div id=\"attachment_11667\" class=\'wp-caption alignnone\' style=\'width:540px;\'><img class=\"size-medium wp-image-11667\" title=\"New-theme-colorsorter\" src=\"http://ithemes.com/wp-content/uploads/2012/08/Screen-shot-2012-08-05-at-3.42.39-PM-540x300.png\" alt=\"\" width=\"540\" height=\"300\" /><p class=\'wp-caption-text\'>Easily sort themes by classification and color</p></div>\n<p>The new iThemes.com features a brand new way to view themes by type and color.  Check out the <a href=\"http://ithemes.com/find/themes/\">iThemes Themes</a> page to sort our themes according to color scheme and by classification as Builder child themes, Classic themes or Allure themes.</p>\n<h3>So, let us know what you think.</h3>\n<p>We&#8217;re eager to hear your feedback, so share your favorite part of the new site below or tweet us <a href=\"http://twitter.com/iThemes\">@iThemes</a>.  We&#8217;re really looking forward to hearing from you.</p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:66:\"http://ithemes.com/2012/08/05/welcome-to-the-new-ithemes-com/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:2:\"41\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:7;a:6:{s:4:\"data\";s:41:\"\n		\n		\n		\n		\n		\n				\n\n		\n		\n			\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:37:\"Get 30% Off Our All Access Theme Pass\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"http://ithemes.com/2012/07/24/get-30-our-all-access-theme-pass/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:72:\"http://ithemes.com/2012/07/24/get-30-our-all-access-theme-pass/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 24 Jul 2012 19:07:31 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:1:{i:0;a:5:{s:4:\"data\";s:4:\"Blog\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:27:\"http://ithemes.com/?p=11550\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:348:\"Since 2008, we&#8217;ve been building and sharing high-quality WordPress themes and now have well over 160+ themes in our inventory &#8212; a complete design palette to choose from for nearly every project you have! Until July 31, 2012, you can get all of our themes, including the iThemes Builder Developer Pack ($197),  FlexxThemes and all [...]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:11:\"Cory Miller\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:2028:\"<p><a href=\"http://ithemes.com/all-access-pass/\"><img class=\"alignright size-full wp-image-11554\" title=\"allaccess30\" src=\"http://ithemes.com/wp-content/uploads/2012/07/allaccess30.png\" alt=\"\" width=\"161\" height=\"160\" /></a>Since 2008, we&#8217;ve been building and sharing high-quality WordPress themes and now have well over 160+ themes in our inventory &#8212; a complete design palette to choose from for nearly every project you have!</p>\n<p>Until July 31, 2012, you can get all of our themes, including the iThemes Builder Developer Pack ($197),  FlexxThemes and all of our Classic Themes for 30% off on our <a title=\"wordpress themes\" href=\"http://ithemes.com/all-access-pass/\">All Access Theme Pass</a>.</p>\n<p>With this discount, you can get the <strong><a href=\"http://ithemes.com/member/signup.php?price_group=45&amp;product_id=117\">6-Month All Access Theme Pass Membership for just $208</a></strong> or <strong><a href=\"http://ithemes.com/member/signup.php?price_group=1\">1-Year All Access Pass Membership for just $271</a>.</strong></p>\n<p style=\"text-align: center;\"><strong>Use coupon code &#8212; ALLPASS30 &#8212; to get 30% off until midnight CDT, July 31, 2012</strong></p>\n<p style=\"text-align: left;\">By the way, this deal will be getting even better later this week as our Classic Themes prices are going to increase from $57 each to $70 each. Choose from popular Classic Themes like <a href=\"http://ithemes.com/purchase/wedding-wordpress-theme/\" target=\"_blank\">Save the Date</a>, <a href=\"http://ithemes.com/purchase/barista/\" target=\"_blank\">Barista Coffee</a> or <a href=\"http://ithemes.com/purchase/bsocial-premium-wordpress-social-magazine-theme/\" target=\"_blank\">bSocial Magazine</a> — <strong>just $57 </strong>until Friday, July 27, 2012. After that, prices of our Classic Themes go back up to $70.</p>\n<p style=\"text-align: left;\">So why not <a title=\"wordpress themes\" href=\"http://ithemes.com/all-access-pass/\">get the entire 160+ WordPress theme package today at 30% off!</a></p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:68:\"http://ithemes.com/2012/07/24/get-30-our-all-access-theme-pass/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"1\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:8;a:6:{s:4:\"data\";s:47:\"\n		\n		\n		\n		\n		\n				\n		\n		\n\n		\n		\n			\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:55:\"New BackupBuddy Support For ManageWP Automatic Upgrades\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:86:\"http://ithemes.com/2012/07/24/new-backupbuddy-support-for-managewp-automatic-upgrades/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:95:\"http://ithemes.com/2012/07/24/new-backupbuddy-support-for-managewp-automatic-upgrades/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 24 Jul 2012 14:44:51 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:3:{i:0;a:5:{s:4:\"data\";s:11:\"BackupBuddy\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:1;a:5:{s:4:\"data\";s:4:\"Blog\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:2;a:5:{s:4:\"data\";s:8:\"ManageWP\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:27:\"http://ithemes.com/?p=11544\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:363:\"We&#8217;ve had several requests on the BackupBuddy Forum (like this one) asking for plugin update integration with ManageWP. Since many of our customers use ManageWP to update all of their plugins across multiple sites, we wanted to make sure BackupBuddy was included in the convenience of the ManageWP automatic upgrades. With this update, BackupBuddy has [...]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"Kristen Wright\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:697:\"<p>We&#8217;ve had several requests on the BackupBuddy Forum (<a href=\"http://ithemes.com/forum/topic/22799-backupbuddy-doesnt-show-as-updatable-in-managewp/\">like this one</a>) asking for plugin update integration with <a href=\"http://managewp.com/\">ManageWP</a>.</p>\n<p>Since many of our customers use ManageWP to update all of their plugins across multiple sites, we wanted to make sure BackupBuddy was included in the convenience of the ManageWP automatic upgrades.</p>\n<p>With this update, BackupBuddy has been integrated with the ManageWP API so that ManageWP users can now see (and bulk update) all available BackupBuddy upgrades from within their ManageWP control panel.</p>\n<p>Enjoy!</p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:91:\"http://ithemes.com/2012/07/24/new-backupbuddy-support-for-managewp-automatic-upgrades/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"5\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:9;a:6:{s:4:\"data\";s:50:\"\n		\n		\n		\n		\n		\n				\n		\n		\n		\n\n		\n		\n			\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:48:\"Q&A with our Designers About the New iThemes.com\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:78:\"http://ithemes.com/2012/07/20/some-qa-and-a-sneak-peek-of-the-new-ithemes-com/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:87:\"http://ithemes.com/2012/07/20/some-qa-and-a-sneak-peek-of-the-new-ithemes-com/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 20 Jul 2012 16:26:14 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:4:{i:0;a:5:{s:4:\"data\";s:4:\"Blog\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:1;a:5:{s:4:\"data\";s:8:\"featured\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:2;a:5:{s:4:\"data\";s:13:\"Uncategorized\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:3;a:5:{s:4:\"data\";s:16:\"iThemes redesign\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:27:\"http://ithemes.com/?p=11484\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:321:\"We&#8217;re excited to finally share a preview of the iThemes.com redesign. We&#8217;ve been working on the redesign for months (and dreaming about it for years), and we hope you&#8217;ll be just as excited to see the new site as we are to get it launched. We plan to post more screenshots of the redesign over the [...]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"Kristen Wright\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:5583:\"<p>We&#8217;re excited to finally share a preview of the iThemes.com redesign. We&#8217;ve been working on the redesign for months (and dreaming about it for years), and we hope you&#8217;ll be just as excited to see the new site as we are to get it launched.</p>\n<p>We plan to post more screenshots of the redesign over the next few weeks, but we couldn&#8217;t wait to share a sneak peek of the new iThemes.com homepage today.</p>\n<h2>The new iThemes.com homepage</h2>\n<p><img class=\"alignnone size-full wp-image-11523\" title=\"new-iThemes-home\" src=\"http://ithemes.com/wp-content/uploads/2012/07/it539.png\" alt=\"\" width=\"539\" height=\"404\" /></p>\n<p>Brad (our designer) and Ty (from our <a href=\"http://creative.ithemes.com/\">Creative Services</a> division) have worked together on creating the design blueprint and styling the front-end. We sat down for a Q&amp;A time about the new iThemes.com:</p>\n<h3>Q. What are some of the objectives you hope to accomplish with the design of the new iThemes.com?</h3>\n<p><strong>Brad: </strong>It&#8217;s been 3 years since <a href=\"http://iThemes.com/\">iThemes.com</a> has had a fresh coat of paint. And over the years we&#8217;ve built things on top of older systems of organization and attached new things here and there. So we wanted to make sure we organized everything in a way that we could properly build on top of moving forward. We&#8217;ve built modified custom post types for a lot of the content on the site – products, team members and ebooks for now, and more coming in the future. We&#8217;re consolidating a lot of things and trying to make it easier for people to understand the connection between all the things we offer – themes, plugins and training. A redesign has always been a major project we&#8217;ve wanted to do, but hadn&#8217;t had time to tackle. And the longer we waited, the bigger the project got. So a few months ago we had the first talks about making it happen and making sure that everything we did would make the next iteration easier too.</p>\n<p><strong>Ty: </strong>For me it all boiled down to two basic objectives, one of which will benefit us and the other benefiting visitors of the site. The current iteration of <a href=\"http://iThemes.com/\">iThemes.com</a> has had a few years worth of adding and changing and building and it had become rather convoluted and difficult to keep updated. So the first objective, which helps us internally, was to reorganize content and design a better system for managing the site moving forward. Secondly, for the benefit of visitors/users of the website, we wanted to make it easier to understand all of the products and services that iThemes has to offer, which means we took a step back, looked at the big picture of what iThemes offers, and then laid it all out in a much more pleasant manner.</p>\n<h3>Q. What do you think users will appreciate most about the new site?</h3>\n<p><strong>Brad:</strong>  I think other than just the overall look, users will like the new theme sorter most. As well as the new login area. It&#8217;s going to be super cool.</p>\n<p><strong>Ty: </strong>I think that users will most appreciate the overall aesthetics and ease-of-use. The new site will provide all of the same information that we were already putting out there, but in a way that is much easier to find and dig into. I also believe we&#8217;ve done a great job of providing a fresh new look without losing the iThemes face that we all know and love.</p>\n<h3>Q. What&#8217;s your favorite part of the new site?</h3>\n<p><strong>Brad:</strong> My favorite part is that our site is finally going to be on Builder. We all love Builder and we use it for every new project around here, big and small. So we&#8217;re going to be &#8220;eating our own dogfood&#8221; soon and using it for our own site. It&#8217;s going to make the development and quick changes on the new site so much easier.</p>\n<p><strong>Ty:  </strong>My favorite part of the new site will be its interactions and responsiveness. The new look is basic and simple, but we&#8217;ve put a lot of time and care into the small details that will really keep a user engaged with the page. It&#8217;s going to be one of those sites that is enjoyable to just look around, move your mouse over things to see what new content or interaction you can find that you hadn&#8217;t seen before. That kind of stuff is super fun to me!</p>\n<h3>Q. What role has collaboration played in the redesign?</h3>\n<p><strong>Brad:</strong> It&#8217;s been great working with Ty on the new site. I can do a lot on my own. But Ty is a great designer, a much better coder than me, and he&#8217;s super fast. It&#8217;s nice to be able to pass off a .psd and a couple days later, work together to figure out how the interactions and responsiveness of the site will work. We also had Chris and Koop lend a hand with some of the post types and server setup. Koop built us an iThemes Builder Block for all our content needs. It&#8217;s so easy to work with on the back end.</p>\n<p><strong>Ty: </strong>I&#8217;m so thankful for the team that I get to work with on a daily basis. I&#8217;m consistently blown away by the amount of talent that resides inside these walls. My eyes would light up when Brad would send me a new Photoshop mockup of a page, and my chest leap as Koop would show me latest version of the iThemes Builder Block that he built for our custom post types. This will prove to be a project that I&#8217;m truly proud to be a part of!</p>\n<p><em>We expect to launch the new iThemes.com in August.</em></p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:83:\"http://ithemes.com/2012/07/20/some-qa-and-a-sneak-peek-of-the-new-ithemes-com/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"2\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}}}s:27:\"http://www.w3.org/2005/Atom\";a:1:{s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:1:{s:0:\"\";a:3:{s:4:\"href\";s:24:\"http://ithemes.com/feed/\";s:3:\"rel\";s:4:\"self\";s:4:\"type\";s:19:\"application/rss+xml\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:44:\"http://purl.org/rss/1.0/modules/syndication/\";a:2:{s:12:\"updatePeriod\";a:1:{i:0;a:5:{s:4:\"data\";s:6:\"hourly\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:15:\"updateFrequency\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"1\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}}}}}}}}s:4:\"type\";i:128;s:7:\"headers\";a:9:{s:4:\"date\";s:29:\"Thu, 30 Aug 2012 18:06:24 GMT\";s:6:\"server\";s:6:\"Apache\";s:12:\"x-powered-by\";s:9:\"PHP/5.3.4\";s:4:\"vary\";s:6:\"Cookie\";s:10:\"x-pingback\";s:29:\"http://ithemes.com/xmlrpc.php\";s:4:\"etag\";s:34:\"\"15378229d12def8d67451932823341d0\"\";s:13:\"last-modified\";s:29:\"Thu, 30 Aug 2012 15:22:33 GMT\";s:10:\"connection\";s:5:\"close\";s:12:\"content-type\";s:23:\"text/xml; charset=UTF-8\";}s:5:\"build\";s:14:\"20090627192103\";}',	'no'),
(1971,	0,	'_transient_timeout_feed_mod_94bc6e7dd050c2a74ce39668c35643cd',	'1346393184',	'no'),
(1972,	0,	'_transient_feed_mod_94bc6e7dd050c2a74ce39668c35643cd',	'1346349984',	'no'),
(1973,	0,	'_transient_timeout_94bc6e7dd050c2a74ce39668c35643cd',	'1346350284',	'no'),
(1974,	0,	'_transient_94bc6e7dd050c2a74ce39668c35643cd',	'<li>- <a href=\"http://ithemes.com/2012/08/27/how-to-pick-web-hosting-without-a-computer-science-degree-new-ebook/\">How To Pick Web Hosting Without  ...</a></li><li>- <a href=\"http://ithemes.com/2012/08/21/the-all-new-getting-started-with-backupbuddy-ebook/\">The All-New Getting Started with ...</a></li><li>- <a href=\"http://ithemes.com/2012/08/17/the-first-4-critical-steps-after-installing-backupbuddy/\">The First 4 Critical Steps After ...</a></li><li>- <a href=\"http://ithemes.com/2012/08/10/collaborate-on-web-design-projects-easily-with-cage/\">Collaborate on Web Design Projec ...</a></li><li>- <a href=\"http://ithemes.com/2012/08/10/two-great-podcast-interviews-featuring-backupbuddy/\">Two Great Podcast Interviews Fea ...</a></li>',	'no'),
(1975,	0,	'_transient_timeout_feed_2685d92621c4f83a0bac7ebffa7670ad',	'1346393184',	'no'),
(1976,	0,	'_transient_feed_2685d92621c4f83a0bac7ebffa7670ad',	'a:4:{s:5:\"child\";a:1:{s:0:\"\";a:1:{s:3:\"rss\";a:1:{i:0;a:6:{s:4:\"data\";s:4:\"\n  \n\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:7:\"version\";s:3:\"2.0\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:1:{s:0:\"\";a:1:{s:7:\"channel\";a:1:{i:0;a:6:{s:4:\"data\";s:93:\"\n    \n    \n    \n    \n    \n    \n  \n  \n  \n  \n  \n  \n  \n  \n  \n  \n  \n  \n  \n  \n  \n  \n  \n  \n  \n  \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:6:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:21:\"Twitter / pluginbuddy\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:30:\"http://twitter.com/pluginbuddy\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:52:\"Twitter updates from Pluginbuddy Team / pluginbuddy.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"language\";a:1:{i:0;a:5:{s:4:\"data\";s:5:\"en-us\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:3:\"ttl\";a:1:{i:0;a:5:{s:4:\"data\";s:2:\"40\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"item\";a:20:{i:0;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:90:\"pluginbuddy: http://t.co/Qyw1iPrH Merging with http://t.co/DblRQ9d7 - http://t.co/CqgblPhv\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:90:\"pluginbuddy: http://t.co/Qyw1iPrH Merging with http://t.co/DblRQ9d7 - http://t.co/CqgblPhv\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 07 Aug 2012 16:26:53 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/232875471694622720\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/232875471694622720\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:1;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:72:\"pluginbuddy: RT @granata: @pluginbuddy\'s #BackupBuddy is pretty awesome.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:72:\"pluginbuddy: RT @granata: @pluginbuddy\'s #BackupBuddy is pretty awesome.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Wed, 25 Jul 2012 19:22:15 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/228208562848014337\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/228208562848014337\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:2;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:137:\"pluginbuddy: @carapring - Sorry to hear that! Mind giving us a summary of the problem so we can help get it working? http://t.co/vhjq55zq\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:137:\"pluginbuddy: @carapring - Sorry to hear that! Mind giving us a summary of the problem so we can help get it working? http://t.co/vhjq55zq\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Wed, 25 Jul 2012 13:57:29 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/228126831197442049\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/228126831197442049\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:3;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:109:\"pluginbuddy: RT @wpkube: How to Backup Your WordPress site using BackupBuddy Plugin -... http://t.co/TM3mQjKG\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:109:\"pluginbuddy: RT @wpkube: How to Backup Your WordPress site using BackupBuddy Plugin -... http://t.co/TM3mQjKG\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 24 Jul 2012 15:15:53 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/227784172612239360\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/227784172612239360\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:4;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:94:\"pluginbuddy: @BFTrick - Let us know if we can help on the support forum - http://t.co/kmg2iz7H\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:94:\"pluginbuddy: @BFTrick - Let us know if we can help on the support forum - http://t.co/kmg2iz7H\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 12 Jul 2012 20:01:51 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/223507484260843521\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/223507484260843521\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:5;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:50:\"pluginbuddy: @astroboysoup - Sending you a DM now!\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:50:\"pluginbuddy: @astroboysoup - Sending you a DM now!\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Wed, 11 Jul 2012 22:04:12 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/223175884985741313\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/223175884985741313\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:6;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:133:\"pluginbuddy: @MagneticMMom - For the other plugins, check out the codex http://t.co/G2fNewIK and support forum - http://t.co/BYVz0Sce\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:133:\"pluginbuddy: @MagneticMMom - For the other plugins, check out the codex http://t.co/G2fNewIK and support forum - http://t.co/BYVz0Sce\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Wed, 11 Jul 2012 18:15:30 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/223118332855980032\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/223118332855980032\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:7;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:123:\"pluginbuddy: @MagneticMMom - Awesome! Here\'s a good summary of getting started with BackupBuddy info - http://t.co/ttj95GUq\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:123:\"pluginbuddy: @MagneticMMom - Awesome! Here\'s a good summary of getting started with BackupBuddy info - http://t.co/ttj95GUq\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Wed, 11 Jul 2012 18:09:15 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/223116759513833473\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/223116759513833473\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:8;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:108:\"pluginbuddy: @MagneticMMom - Hi! Which plugin did you purchase? We can send you some \"getting started\" info.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:108:\"pluginbuddy: @MagneticMMom - Hi! Which plugin did you purchase? We can send you some \"getting started\" info.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Wed, 11 Jul 2012 17:22:07 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/223104900182183936\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/223104900182183936\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:9;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:111:\"pluginbuddy: Just getting started with #BackupBuddy? Free intro webinar today @ 11am CDT - http://t.co/1o6O6FiI\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:111:\"pluginbuddy: Just getting started with #BackupBuddy? Free intro webinar today @ 11am CDT - http://t.co/1o6O6FiI\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 10 Jul 2012 15:25:38 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/222713197235417090\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/222713197235417090\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:10;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:93:\"pluginbuddy: @Opacreative - Yep, you can upgrade. Hope this info helps : http://t.co/jQY9gYNm\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:93:\"pluginbuddy: @Opacreative - Yep, you can upgrade. Hope this info helps : http://t.co/jQY9gYNm\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 09 Jul 2012 18:38:32 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/222399355448078336\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/222399355448078336\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:11;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:128:\"pluginbuddy: @jpelker - Ok, we\'ll look into it. Mind posting more details to the BackupBuddy support forum? http://t.co/vhjq55zq\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:128:\"pluginbuddy: @jpelker - Ok, we\'ll look into it. Mind posting more details to the BackupBuddy support forum? http://t.co/vhjq55zq\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 09 Jul 2012 18:35:04 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/222398482575667200\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/222398482575667200\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:12;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:116:\"pluginbuddy: Just released: #BackupBuddy 3.0.37, including new backup file notes and comments - http://t.co/0k2yO0AK\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:116:\"pluginbuddy: Just released: #BackupBuddy 3.0.37, including new backup file notes and comments - http://t.co/0k2yO0AK\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 02 Jul 2012 22:39:13 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/219923209330503680\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/219923209330503680\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:13;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:141:\"pluginbuddy: Just 12 hours left to save 30% on #BackupBuddy or the Dev Suite! 2 reasons to invest in #BackupBuddy today: http://t.co/paKPaIWu\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:141:\"pluginbuddy: Just 12 hours left to save 30% on #BackupBuddy or the Dev Suite! 2 reasons to invest in #BackupBuddy today: http://t.co/paKPaIWu\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Sat, 30 Jun 2012 17:09:24 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/219115433205309440\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/219115433205309440\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:14;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:148:\"pluginbuddy: @danieltakayama: Backupbuddy has features to combat that situation, but we can help in more detail from the forum: http://t.co/vhjq55zq\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:148:\"pluginbuddy: @danieltakayama: Backupbuddy has features to combat that situation, but we can help in more detail from the forum: http://t.co/vhjq55zq\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 29 Jun 2012 18:32:00 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/218773831790235648\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/218773831790235648\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:15;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:108:\"pluginbuddy: Add Notes/Comments to Backup Files in #BackupBuddy 3.0.37 - out next week! http://t.co/0k2yO0AK\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:108:\"pluginbuddy: Add Notes/Comments to Backup Files in #BackupBuddy 3.0.37 - out next week! http://t.co/0k2yO0AK\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 29 Jun 2012 15:58:39 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/218735239470649344\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/218735239470649344\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:16;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:153:\"pluginbuddy: RT @WebDesignCom: Take control of the #WordPress Loop! Webinar today @ 10am CDT on using LoopBuddy with custom post types and fields - h ...\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:153:\"pluginbuddy: RT @WebDesignCom: Take control of the #WordPress Loop! Webinar today @ 10am CDT on using LoopBuddy with custom post types and fields - h ...\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 28 Jun 2012 14:55:26 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/218356943822143490\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/218356943822143490\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:3:\"web\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:17;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:117:\"pluginbuddy: Glad to help! RT @iMotionvideo: You\'re BackupBuddy plugin saved my ass a couple weeks ago @pluginbuddy !\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:117:\"pluginbuddy: Glad to help! RT @iMotionvideo: You\'re BackupBuddy plugin saved my ass a couple weeks ago @pluginbuddy !\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 26 Jun 2012 19:32:37 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/217701923388792832\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/217701923388792832\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:18;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:88:\"pluginbuddy: Automatic updates for #BackupBuddy 3.0 now available - http://t.co/rsRh8d2r\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:88:\"pluginbuddy: Automatic updates for #BackupBuddy 3.0 now available - http://t.co/rsRh8d2r\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 25 Jun 2012 21:51:41 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/217374529998159874\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/217374529998159874\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:19;a:6:{s:4:\"data\";s:38:\"\n    \n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:155:\"pluginbuddy: Learn how to use LoopBuddy w/ Custom Post Types &amp; Custom Fields - free webinar via @webdesigncom, June 28 @ 10am CDT: http://t.co/lCwfvmMb\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:155:\"pluginbuddy: Learn how to use LoopBuddy w/ Custom Post Types &amp; Custom Fields - free webinar via @webdesigncom, June 28 @ 10am CDT: http://t.co/lCwfvmMb\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 25 Jun 2012 21:27:20 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/217368403541893120\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"http://twitter.com/pluginbuddy/statuses/217368403541893120\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:22:\"http://api.twitter.com\";a:2:{s:6:\"source\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"<a href=\"http://www.tweetdeck.com\" rel=\"nofollow\">TweetDeck</a>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:5:\"place\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}}}s:27:\"http://www.w3.org/2005/Atom\";a:1:{s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:1:{s:0:\"\";a:3:{s:4:\"type\";s:19:\"application/rss+xml\";s:3:\"rel\";s:4:\"self\";s:4:\"href\";s:55:\"http://twitter.com/statuses/user_timeline/108700480.rss\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}}}}}}}}s:4:\"type\";i:128;s:7:\"headers\";a:24:{s:4:\"date\";s:29:\"Thu, 30 Aug 2012 18:06:24 GMT\";s:6:\"status\";s:6:\"200 OK\";s:7:\"expires\";s:29:\"Tue, 31 Mar 1981 05:00:00 GMT\";s:17:\"x-ratelimit-limit\";s:3:\"150\";s:5:\"x-mid\";s:40:\"71bf8d619978b88ac9ee3ea58a12b531ffb50d11\";s:13:\"last-modified\";s:29:\"Thu, 30 Aug 2012 18:06:24 GMT\";s:15:\"x-frame-options\";s:10:\"SAMEORIGIN\";s:17:\"x-ratelimit-reset\";s:10:\"1346353584\";s:18:\"x-transaction-mask\";s:40:\"a6183ffa5f8ca943ff1b53b5644ef1141206a656\";s:17:\"x-ratelimit-class\";s:3:\"api\";s:13:\"cache-control\";s:62:\"no-cache, no-store, must-revalidate, pre-check=0, post-check=0\";s:9:\"x-runtime\";s:7:\"0.04766\";s:21:\"x-ratelimit-remaining\";s:3:\"149\";s:13:\"x-transaction\";s:16:\"92cb9b47a6fc5b8e\";s:6:\"pragma\";s:8:\"no-cache\";s:4:\"etag\";s:34:\"\"8835d6e63e0996f32dc352eaedb0a34c\"\";s:12:\"content-type\";s:34:\"application/rss+xml; charset=utf-8\";s:10:\"set-cookie\";a:3:{i:0;s:97:\"k=10.35.29.123.1346349984500768; path=/; expires=Thu, 06-Sep-12 18:06:24 GMT; domain=.twitter.com\";i:1;s:100:\"guest_id=v1%3A134634998451448712; domain=.twitter.com; path=/; expires=Sun, 31-Aug-2014 06:06:24 GMT\";i:2;s:265:\"_twitter_sess=BAh7CDoPY3JlYXRlZF9hdGwrCAVrtng5ASIKZmxhc2hJQzonQWN0aW9uQ29u%250AdHJvbGxlcjo6Rmxhc2g6OkZsYXNoSGFzaHsABjoKQHVzZWR7ADoHaWQiJTgz%250ANzk1ZTk3ZTZjNzE4MTc3NWZjNjY3NmZjMDMzY2Jm--cd9de99ca020eb816e8fd7af9a8dbc3b594611b4; domain=.twitter.com; path=/; HttpOnly\";}s:4:\"vary\";s:15:\"Accept-Encoding\";s:16:\"x-xss-protection\";s:13:\"1; mode=block\";s:10:\"connection\";s:10:\"keep-alive\";s:6:\"server\";s:3:\"tfe\";s:16:\"content-encoding\";s:7:\"deflate\";s:14:\"content-length\";s:4:\"2296\";}s:5:\"build\";s:14:\"20090627192103\";}',	'no'),
(1977,	0,	'_transient_timeout_feed_mod_2685d92621c4f83a0bac7ebffa7670ad',	'1346393184',	'no'),
(1978,	0,	'_transient_feed_mod_2685d92621c4f83a0bac7ebffa7670ad',	'1346349984',	'no'),
(1979,	0,	'_transient_timeout_2685d92621c4f83a0bac7ebffa7670ad',	'1346350284',	'no'),
(1980,	0,	'_transient_2685d92621c4f83a0bac7ebffa7670ad',	'<li>- <a href=\"http://twitter.com/pluginbuddy/statuses/232875471694622720\">http://t.co/Qyw1iPrH Merging wit ...</a></li><li>- <a href=\"http://twitter.com/pluginbuddy/statuses/228208562848014337\">RT @granata: @pluginbuddy\'s #Bac ...</a></li><li>- <a href=\"http://twitter.com/pluginbuddy/statuses/228126831197442049\">@carapring - Sorry to hear that! ...</a></li><li>- <a href=\"http://twitter.com/pluginbuddy/statuses/227784172612239360\">RT @wpkube: How to Backup Your W ...</a></li><li>- <a href=\"http://twitter.com/pluginbuddy/statuses/223507484260843521\">@BFTrick - Let us know if we can ...</a></li>',	'no'),
(1982,	0,	'_transient_timeout_pb_backupbuddy_malwarescan',	'1346353623',	'no'),
(1983,	0,	'_transient_pb_backupbuddy_malwarescan',	's:5200:\"a:5:{s:4:\"SCAN\";a:3:{s:4:\"SITE\";a:1:{i:0;s:31:\"http://calzada-wp.urldock.com  \";}s:6:\"DOMAIN\";a:1:{i:0;s:24:\"calzada-wp.urldock.com  \";}s:2:\"IP\";a:1:{i:0;s:13:\"74.50.54.37  \";}}s:6:\"SYSTEM\";a:1:{s:6:\"NOTICE\";a:3:{i:0;s:25:\"Running on: Apache/2.2.16\";i:1;s:23:\"System info:  (Debian)\r\";i:2;s:34:\"Powered by:  PHP/5.3.14-1~dotdeb.0\";}}s:6:\"WEBAPP\";a:4:{s:4:\"INFO\";a:1:{i:0;a:2:{i:0;s:28:\"Application: WordPress 3.3.2\";i:1;s:24:\"http://www.wordpress.org\";}}s:7:\"VERSION\";a:3:{i:0;s:35:\"WordPress version:  WordPress 3.3.2\";i:1;s:37:\" Wordpress version from source: 3.3.2\";i:2;s:111:\"Wordpress Version &gt;= 3.0 for: http://calzada-wp.urldock.com/wp-includes/js/scriptaculous/wp-scriptaculous.js\";}s:6:\"NOTICE\";a:1:{i:0;s:74:\"WordPress theme:  http://calzada-wp.urldock.com/wp-content/themes/calzada/\";}s:4:\"WARN\";a:1:{i:0;s:46:\"WordPress version outdated:  Upgrade required.\";}}s:5:\"LINKS\";a:3:{s:10:\"JSEXTERNAL\";a:4:{i:0;s:75:\"http://ajax.googleapis.com/ajax/libs/jquery/1.4.4/jquery.min.js?ver=3.3.2  \";i:1;s:80:\"http://ajax.googleapis.com/ajax/libs/jqueryui/1.8.9/jquery-ui.min.js?ver=3.3.2  \";i:2;s:52:\"http://html5shiv.googlecode.com/svn/trunk/html5.js  \";i:3;s:44:\"http://code.jquery.com/jquery-1.7.2.min.js  \";}s:7:\"JSLOCAL\";a:11:{i:0;s:76:\"http://calzada-wp.urldock.com/wp-includes/js/comment-reply.js?ver=20090102  \";i:1;s:73:\"http://calzada-wp.urldock.com/wp-content/plugins/j-shortcodes/js/jay.js  \";i:2;s:99:\"http://calzada-wp.urldock.com/wp-content/plugins/j-shortcodes/galleryview/js/jquery.easing.1.3.js  \";i:3;s:99:\"http://calzada-wp.urldock.com/wp-content/plugins/j-shortcodes/galleryview/js/jquery.timers-1.2.js  \";i:4;s:108:\"http://calzada-wp.urldock.com/wp-content/plugins/j-shortcodes/galleryview/js/jquery.galleryview-3.0.min.js  \";i:5;s:84:\"http://calzada-wp.urldock.com/wp-content/themes/calzada/_ui/js/jquery-1.7.2.min.js  \";i:6;s:91:\"http://calzada-wp.urldock.com/wp-content/themes/calzada/_ui/js/form.placeholder.jquery.js  \";i:7;s:88:\"http://calzada-wp.urldock.com/wp-content/themes/calzada/_ui/js/jquery.fancybox.pack.js  \";i:8;s:72:\"http://calzada-wp.urldock.com/wp-content/themes/calzada/_ui/js/main.js  \";i:9;s:91:\"http://calzada-wp.urldock.com/wp-includes/js/jquery/ui/jquery.ui.widget.min.js?ver=1.8.16  \";i:10;s:94:\"http://calzada-wp.urldock.com/wp-includes/js/jquery/ui/jquery.ui.accordion.min.js?ver=1.8.16  \";}s:3:\"URL\";a:23:{i:0;s:32:\"http://calzada-wp.urldock.com/  \";i:1;s:41:\"http://calzada-wp.urldock.com/about-us/  \";i:2;s:60:\"http://calzada-wp.urldock.com/about-us/board-of-directors/  \";i:3;s:58:\"http://calzada-wp.urldock.com/about-us/management-staff/  \";i:4;s:62:\"http://calzada-wp.urldock.com/about-us/corporate-governance/  \";i:5;s:66:\"http://calzada-wp.urldock.com/metabolic-pharmaceuticals-pty-ltd/  \";i:6;s:48:\"http://calzada-wp.urldock.com/investor-centre/  \";i:7;s:71:\"http://calzada-wp.urldock.com/investor-centre/annual-general-meeting/  \";i:8;s:63:\"http://calzada-wp.urldock.com/investor-centre/share-registry/  \";i:9;s:66:\"http://calzada-wp.urldock.com/investor-centre/financial-reports/  \";i:10;s:66:\"http://calzada-wp.urldock.com/investor-centre/asx-announcements/  \";i:11;s:62:\"http://calzada-wp.urldock.com/investor-centre/presentations/  \";i:12;s:43:\"http://calzada-wp.urldock.com/news-media/  \";i:13;s:55:\"http://calzada-wp.urldock.com/news-media/newsletters/  \";i:14;s:52:\"http://calzada-wp.urldock.com/news-media/articles/  \";i:15;s:49:\"http://calzada-wp.urldock.com/news-media/press/  \";i:16;s:60:\"http://calzada-wp.urldock.com/news-media/research-reports/  \";i:17;s:43:\"http://calzada-wp.urldock.com/contact-us/  \";i:18;s:67:\"http://calzada-wp.urldock.com/appendix-4e-and-2012-annual-report/  \";i:19;s:91:\"http://calzada-wp.urldock.com/polynovo-clinical-trial-and-composite-cultured-skin-update/  \";i:20;s:77:\"http://calzada-wp.urldock.com/dr-david-mcquillan-to-join-the-calzada-board/  \";i:21;s:59:\"http://calzada-wp.urldock.com/polynovo-us-patent-allowed/  \";i:22;s:62:\"http://calzada-wp.urldock.com/privacy-policy-and-disclaimer/  \";}}s:9:\"BLACKLIST\";a:1:{s:4:\"INFO\";a:8:{i:0;a:2:{i:0;s:60:\"Domain clean by Google Safe Browsing: calzada-wp.urldock.com\";i:1;s:90:\"http://safebrowsing.clients.google.com/safebrowsing/diagnostic?site=calzada-wp.urldock.com\";}i:1;a:2:{i:0;s:55:\"Domain clean by Norton Safe Web: calzada-wp.urldock.com\";i:1;s:64:\"http://safeweb.norton.com/report/show?url=calzada-wp.urldock.com\";}i:2;a:2:{i:0;s:50:\"Domain clean on Phish tank: calzada-wp.urldock.com\";i:1;s:25:\"http://www.phishtank.com/\";}i:3;a:2:{i:0;s:57:\"Domain clean on the Opera browser: calzada-wp.urldock.com\";i:1;s:17:\"http://opera.com/\";}i:4;a:2:{i:0;s:51:\"Domain clean by SiteAdvisor: calzada-wp.urldock.com\";i:1;s:55:\"http://www.siteadvisor.com/sites/calzada-wp.urldock.com\";}i:5;a:2:{i:0;s:71:\"Domain clean on Sucuri IP/URL malware blacklist: calzada-wp.urldock.com\";i:1;s:31:\"http://labs.sucuri.net/?malware\";}i:6;a:2:{i:0;s:73:\"Domain clean by the Sucuri Malware Labs blacklist: calzada-wp.urldock.com\";i:1;s:56:\"http://labs.sucuri.net/?blacklist=calzada-wp.urldock.com\";}i:7;a:2:{i:0;s:59:\"Domain clean on Yandex (via Sophos): calzada-wp.urldock.com\";i:1;s:69:\"http://www.yandex.com/infected?url=calzada-wp.urldock.com&amp;l10n=en\";}}}}\";',	'no'),
(1987,	0,	'rewrite_rules',	'a:84:{s:47:\"category/(.+?)/feed/(feed|rdf|rss|rss2|atom)/?$\";s:52:\"index.php?category_name=$matches[1]&feed=$matches[2]\";s:42:\"category/(.+?)/(feed|rdf|rss|rss2|atom)/?$\";s:52:\"index.php?category_name=$matches[1]&feed=$matches[2]\";s:35:\"category/(.+?)/page/?([0-9]{1,})/?$\";s:53:\"index.php?category_name=$matches[1]&paged=$matches[2]\";s:17:\"category/(.+?)/?$\";s:35:\"index.php?category_name=$matches[1]\";s:44:\"tag/([^/]+)/feed/(feed|rdf|rss|rss2|atom)/?$\";s:42:\"index.php?tag=$matches[1]&feed=$matches[2]\";s:39:\"tag/([^/]+)/(feed|rdf|rss|rss2|atom)/?$\";s:42:\"index.php?tag=$matches[1]&feed=$matches[2]\";s:32:\"tag/([^/]+)/page/?([0-9]{1,})/?$\";s:43:\"index.php?tag=$matches[1]&paged=$matches[2]\";s:14:\"tag/([^/]+)/?$\";s:25:\"index.php?tag=$matches[1]\";s:45:\"type/([^/]+)/feed/(feed|rdf|rss|rss2|atom)/?$\";s:50:\"index.php?post_format=$matches[1]&feed=$matches[2]\";s:40:\"type/([^/]+)/(feed|rdf|rss|rss2|atom)/?$\";s:50:\"index.php?post_format=$matches[1]&feed=$matches[2]\";s:33:\"type/([^/]+)/page/?([0-9]{1,})/?$\";s:51:\"index.php?post_format=$matches[1]&paged=$matches[2]\";s:15:\"type/([^/]+)/?$\";s:33:\"index.php?post_format=$matches[1]\";s:38:\"home-image/[^/]+/attachment/([^/]+)/?$\";s:32:\"index.php?attachment=$matches[1]\";s:48:\"home-image/[^/]+/attachment/([^/]+)/trackback/?$\";s:37:\"index.php?attachment=$matches[1]&tb=1\";s:68:\"home-image/[^/]+/attachment/([^/]+)/feed/(feed|rdf|rss|rss2|atom)/?$\";s:49:\"index.php?attachment=$matches[1]&feed=$matches[2]\";s:63:\"home-image/[^/]+/attachment/([^/]+)/(feed|rdf|rss|rss2|atom)/?$\";s:49:\"index.php?attachment=$matches[1]&feed=$matches[2]\";s:63:\"home-image/[^/]+/attachment/([^/]+)/comment-page-([0-9]{1,})/?$\";s:50:\"index.php?attachment=$matches[1]&cpage=$matches[2]\";s:31:\"home-image/([^/]+)/trackback/?$\";s:37:\"index.php?home-image=$matches[1]&tb=1\";s:51:\"home-image/([^/]+)/feed/(feed|rdf|rss|rss2|atom)/?$\";s:49:\"index.php?home-image=$matches[1]&feed=$matches[2]\";s:46:\"home-image/([^/]+)/(feed|rdf|rss|rss2|atom)/?$\";s:49:\"index.php?home-image=$matches[1]&feed=$matches[2]\";s:39:\"home-image/([^/]+)/page/?([0-9]{1,})/?$\";s:50:\"index.php?home-image=$matches[1]&paged=$matches[2]\";s:46:\"home-image/([^/]+)/comment-page-([0-9]{1,})/?$\";s:50:\"index.php?home-image=$matches[1]&cpage=$matches[2]\";s:31:\"home-image/([^/]+)(/[0-9]+)?/?$\";s:49:\"index.php?home-image=$matches[1]&page=$matches[2]\";s:27:\"home-image/[^/]+/([^/]+)/?$\";s:32:\"index.php?attachment=$matches[1]\";s:37:\"home-image/[^/]+/([^/]+)/trackback/?$\";s:37:\"index.php?attachment=$matches[1]&tb=1\";s:57:\"home-image/[^/]+/([^/]+)/feed/(feed|rdf|rss|rss2|atom)/?$\";s:49:\"index.php?attachment=$matches[1]&feed=$matches[2]\";s:52:\"home-image/[^/]+/([^/]+)/(feed|rdf|rss|rss2|atom)/?$\";s:49:\"index.php?attachment=$matches[1]&feed=$matches[2]\";s:52:\"home-image/[^/]+/([^/]+)/comment-page-([0-9]{1,})/?$\";s:50:\"index.php?attachment=$matches[1]&cpage=$matches[2]\";s:12:\"robots\\.txt$\";s:18:\"index.php?robots=1\";s:48:\".*wp-(atom|rdf|rss|rss2|feed|commentsrss2)\\.php$\";s:18:\"index.php?feed=old\";s:32:\"feed/(feed|rdf|rss|rss2|atom)/?$\";s:27:\"index.php?&feed=$matches[1]\";s:27:\"(feed|rdf|rss|rss2|atom)/?$\";s:27:\"index.php?&feed=$matches[1]\";s:20:\"page/?([0-9]{1,})/?$\";s:28:\"index.php?&paged=$matches[1]\";s:27:\"comment-page-([0-9]{1,})/?$\";s:38:\"index.php?&page_id=6&cpage=$matches[1]\";s:41:\"comments/feed/(feed|rdf|rss|rss2|atom)/?$\";s:42:\"index.php?&feed=$matches[1]&withcomments=1\";s:36:\"comments/(feed|rdf|rss|rss2|atom)/?$\";s:42:\"index.php?&feed=$matches[1]&withcomments=1\";s:29:\"comments/page/?([0-9]{1,})/?$\";s:28:\"index.php?&paged=$matches[1]\";s:44:\"search/(.+)/feed/(feed|rdf|rss|rss2|atom)/?$\";s:40:\"index.php?s=$matches[1]&feed=$matches[2]\";s:39:\"search/(.+)/(feed|rdf|rss|rss2|atom)/?$\";s:40:\"index.php?s=$matches[1]&feed=$matches[2]\";s:32:\"search/(.+)/page/?([0-9]{1,})/?$\";s:41:\"index.php?s=$matches[1]&paged=$matches[2]\";s:14:\"search/(.+)/?$\";s:23:\"index.php?s=$matches[1]\";s:47:\"author/([^/]+)/feed/(feed|rdf|rss|rss2|atom)/?$\";s:50:\"index.php?author_name=$matches[1]&feed=$matches[2]\";s:42:\"author/([^/]+)/(feed|rdf|rss|rss2|atom)/?$\";s:50:\"index.php?author_name=$matches[1]&feed=$matches[2]\";s:35:\"author/([^/]+)/page/?([0-9]{1,})/?$\";s:51:\"index.php?author_name=$matches[1]&paged=$matches[2]\";s:17:\"author/([^/]+)/?$\";s:33:\"index.php?author_name=$matches[1]\";s:69:\"([0-9]{4})/([0-9]{1,2})/([0-9]{1,2})/feed/(feed|rdf|rss|rss2|atom)/?$\";s:80:\"index.php?year=$matches[1]&monthnum=$matches[2]&day=$matches[3]&feed=$matches[4]\";s:64:\"([0-9]{4})/([0-9]{1,2})/([0-9]{1,2})/(feed|rdf|rss|rss2|atom)/?$\";s:80:\"index.php?year=$matches[1]&monthnum=$matches[2]&day=$matches[3]&feed=$matches[4]\";s:57:\"([0-9]{4})/([0-9]{1,2})/([0-9]{1,2})/page/?([0-9]{1,})/?$\";s:81:\"index.php?year=$matches[1]&monthnum=$matches[2]&day=$matches[3]&paged=$matches[4]\";s:39:\"([0-9]{4})/([0-9]{1,2})/([0-9]{1,2})/?$\";s:63:\"index.php?year=$matches[1]&monthnum=$matches[2]&day=$matches[3]\";s:56:\"([0-9]{4})/([0-9]{1,2})/feed/(feed|rdf|rss|rss2|atom)/?$\";s:64:\"index.php?year=$matches[1]&monthnum=$matches[2]&feed=$matches[3]\";s:51:\"([0-9]{4})/([0-9]{1,2})/(feed|rdf|rss|rss2|atom)/?$\";s:64:\"index.php?year=$matches[1]&monthnum=$matches[2]&feed=$matches[3]\";s:44:\"([0-9]{4})/([0-9]{1,2})/page/?([0-9]{1,})/?$\";s:65:\"index.php?year=$matches[1]&monthnum=$matches[2]&paged=$matches[3]\";s:26:\"([0-9]{4})/([0-9]{1,2})/?$\";s:47:\"index.php?year=$matches[1]&monthnum=$matches[2]\";s:43:\"([0-9]{4})/feed/(feed|rdf|rss|rss2|atom)/?$\";s:43:\"index.php?year=$matches[1]&feed=$matches[2]\";s:38:\"([0-9]{4})/(feed|rdf|rss|rss2|atom)/?$\";s:43:\"index.php?year=$matches[1]&feed=$matches[2]\";s:31:\"([0-9]{4})/page/?([0-9]{1,})/?$\";s:44:\"index.php?year=$matches[1]&paged=$matches[2]\";s:13:\"([0-9]{4})/?$\";s:26:\"index.php?year=$matches[1]\";s:27:\".?.+?/attachment/([^/]+)/?$\";s:32:\"index.php?attachment=$matches[1]\";s:37:\".?.+?/attachment/([^/]+)/trackback/?$\";s:37:\"index.php?attachment=$matches[1]&tb=1\";s:57:\".?.+?/attachment/([^/]+)/feed/(feed|rdf|rss|rss2|atom)/?$\";s:49:\"index.php?attachment=$matches[1]&feed=$matches[2]\";s:52:\".?.+?/attachment/([^/]+)/(feed|rdf|rss|rss2|atom)/?$\";s:49:\"index.php?attachment=$matches[1]&feed=$matches[2]\";s:52:\".?.+?/attachment/([^/]+)/comment-page-([0-9]{1,})/?$\";s:50:\"index.php?attachment=$matches[1]&cpage=$matches[2]\";s:20:\"(.?.+?)/trackback/?$\";s:35:\"index.php?pagename=$matches[1]&tb=1\";s:40:\"(.?.+?)/feed/(feed|rdf|rss|rss2|atom)/?$\";s:47:\"index.php?pagename=$matches[1]&feed=$matches[2]\";s:35:\"(.?.+?)/(feed|rdf|rss|rss2|atom)/?$\";s:47:\"index.php?pagename=$matches[1]&feed=$matches[2]\";s:28:\"(.?.+?)/page/?([0-9]{1,})/?$\";s:48:\"index.php?pagename=$matches[1]&paged=$matches[2]\";s:35:\"(.?.+?)/comment-page-([0-9]{1,})/?$\";s:48:\"index.php?pagename=$matches[1]&cpage=$matches[2]\";s:20:\"(.?.+?)(/[0-9]+)?/?$\";s:47:\"index.php?pagename=$matches[1]&page=$matches[2]\";s:27:\"[^/]+/attachment/([^/]+)/?$\";s:32:\"index.php?attachment=$matches[1]\";s:37:\"[^/]+/attachment/([^/]+)/trackback/?$\";s:37:\"index.php?attachment=$matches[1]&tb=1\";s:57:\"[^/]+/attachment/([^/]+)/feed/(feed|rdf|rss|rss2|atom)/?$\";s:49:\"index.php?attachment=$matches[1]&feed=$matches[2]\";s:52:\"[^/]+/attachment/([^/]+)/(feed|rdf|rss|rss2|atom)/?$\";s:49:\"index.php?attachment=$matches[1]&feed=$matches[2]\";s:52:\"[^/]+/attachment/([^/]+)/comment-page-([0-9]{1,})/?$\";s:50:\"index.php?attachment=$matches[1]&cpage=$matches[2]\";s:20:\"([^/]+)/trackback/?$\";s:31:\"index.php?name=$matches[1]&tb=1\";s:40:\"([^/]+)/feed/(feed|rdf|rss|rss2|atom)/?$\";s:43:\"index.php?name=$matches[1]&feed=$matches[2]\";s:35:\"([^/]+)/(feed|rdf|rss|rss2|atom)/?$\";s:43:\"index.php?name=$matches[1]&feed=$matches[2]\";s:28:\"([^/]+)/page/?([0-9]{1,})/?$\";s:44:\"index.php?name=$matches[1]&paged=$matches[2]\";s:35:\"([^/]+)/comment-page-([0-9]{1,})/?$\";s:44:\"index.php?name=$matches[1]&cpage=$matches[2]\";s:20:\"([^/]+)(/[0-9]+)?/?$\";s:43:\"index.php?name=$matches[1]&page=$matches[2]\";s:16:\"[^/]+/([^/]+)/?$\";s:32:\"index.php?attachment=$matches[1]\";s:26:\"[^/]+/([^/]+)/trackback/?$\";s:37:\"index.php?attachment=$matches[1]&tb=1\";s:46:\"[^/]+/([^/]+)/feed/(feed|rdf|rss|rss2|atom)/?$\";s:49:\"index.php?attachment=$matches[1]&feed=$matches[2]\";s:41:\"[^/]+/([^/]+)/(feed|rdf|rss|rss2|atom)/?$\";s:49:\"index.php?attachment=$matches[1]&feed=$matches[2]\";s:41:\"[^/]+/([^/]+)/comment-page-([0-9]{1,})/?$\";s:50:\"index.php?attachment=$matches[1]&cpage=$matches[2]\";}',	'yes'),
(1988,	0,	'_site_transient_timeout_browser_b0de9456e3669a47330909c804c82dcc',	'1347020257',	'yes'),
(1989,	0,	'_site_transient_browser_b0de9456e3669a47330909c804c82dcc',	'a:9:{s:8:\"platform\";s:7:\"Windows\";s:4:\"name\";s:7:\"Firefox\";s:7:\"version\";s:4:\"15.0\";s:10:\"update_url\";s:23:\"http://www.firefox.com/\";s:7:\"img_src\";s:50:\"http://s.wordpress.org/images/browsers/firefox.png\";s:11:\"img_src_ssl\";s:49:\"https://wordpress.org/images/browsers/firefox.png\";s:15:\"current_version\";s:2:\"12\";s:7:\"upgrade\";b:0;s:8:\"insecure\";b:0;}',	'yes'),
(1990,	0,	'_site_transient_timeout_theme_roots',	'1346422657',	'yes'),
(1991,	0,	'_site_transient_theme_roots',	'a:2:{s:7:\"calzada\";s:7:\"/themes\";s:12:\"twentyeleven\";s:7:\"/themes\";}',	'yes'),
(1992,	0,	'_transient_timeout_rss_bc0a9b71c0e85360d7c8dff980ccf7de',	'1346419058',	'no'),
(1993,	0,	'_transient_rss_bc0a9b71c0e85360d7c8dff980ccf7de',	'O:9:\"MagpieRSS\":17:{s:6:\"parser\";i:0;s:12:\"current_item\";a:0:{}s:5:\"items\";a:3:{i:0;a:5:{s:5:\"title\";s:29:\"Mon 6 Aug - 1 new subscribers\";s:11:\"description\";s:20:\"Today: 1<br>Total: 6\";s:7:\"pubdate\";s:31:\"Mon, 06 Aug 2012 00:00:00 +1000\";s:4:\"guid\";s:33:\"CM.406A061C46C89AC4.List.20120806\";s:7:\"summary\";s:20:\"Today: 1<br>Total: 6\";}i:1;a:5:{s:5:\"title\";s:30:\"Tue 26 Jun - 1 new subscribers\";s:11:\"description\";s:20:\"Today: 1<br>Total: 5\";s:7:\"pubdate\";s:31:\"Tue, 26 Jun 2012 00:00:00 +1000\";s:4:\"guid\";s:33:\"CM.406A061C46C89AC4.List.20120626\";s:7:\"summary\";s:20:\"Today: 1<br>Total: 5\";}i:2;a:5:{s:5:\"title\";s:30:\"Thu 31 May - 4 new subscribers\";s:11:\"description\";s:20:\"Today: 4<br>Total: 4\";s:7:\"pubdate\";s:31:\"Thu, 31 May 2012 00:00:00 +1000\";s:4:\"guid\";s:33:\"CM.406A061C46C89AC4.List.20120531\";s:7:\"summary\";s:20:\"Today: 4<br>Total: 4\";}}s:7:\"channel\";a:7:{s:5:\"title\";s:27:\"Calzada Limited Subscribers\";s:4:\"link\";s:78:\"http://calzada.createsend.com/rss/subscribers.aspx?listID=f684005763e1995f&d=j\";s:11:\"description\";s:27:\"Calzada Limited Subscribers\";s:8:\"language\";s:5:\"en-us\";s:7:\"pubdate\";s:31:\"Mon, 06 Aug 2012 00:00:00 +1000\";s:13:\"lastbuilddate\";s:31:\"Mon, 06 Aug 2012 00:00:00 +1000\";s:7:\"tagline\";s:27:\"Calzada Limited Subscribers\";}s:9:\"textinput\";a:0:{}s:5:\"image\";a:0:{}s:9:\"feed_type\";s:3:\"RSS\";s:12:\"feed_version\";s:3:\"2.0\";s:5:\"stack\";a:0:{}s:9:\"inchannel\";b:0;s:6:\"initem\";b:0;s:9:\"incontent\";b:0;s:11:\"intextinput\";b:0;s:7:\"inimage\";b:0;s:13:\"current_field\";s:0:\"\";s:17:\"current_namespace\";b:0;s:19:\"_CONTENT_CONSTRUCTS\";a:6:{i:0;s:7:\"content\";i:1;s:7:\"summary\";i:2;s:4:\"info\";i:3;s:5:\"title\";i:4;s:7:\"tagline\";i:5;s:9:\"copyright\";}}',	'no'),
(1994,	0,	'_transient_timeout_feed_ac0b00fe65abe10e0c5b588f3ed8c7ca',	'1346458662',	'no'),
(1995,	0,	'_transient_feed_ac0b00fe65abe10e0c5b588f3ed8c7ca',	'a:4:{s:5:\"child\";a:1:{s:0:\"\";a:1:{s:3:\"rss\";a:1:{i:0;a:6:{s:4:\"data\";s:3:\"\n\n\n\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:7:\"version\";s:3:\"2.0\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:1:{s:0:\"\";a:1:{s:7:\"channel\";a:1:{i:0;a:6:{s:4:\"data\";s:50:\"\n	\n	\n	\n	\n	\n	\n	\n	\n	\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n	\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:3:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"WordPress News\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:25:\"http://wordpress.org/news\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"WordPress News\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:13:\"lastBuildDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 13 Jul 2012 08:18:15 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"language\";a:1:{i:0;a:5:{s:4:\"data\";s:5:\"en-US\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:9:\"generator\";a:1:{i:0;a:5:{s:4:\"data\";s:39:\"http://wordpress.org/?v=3.5-alpha-21678\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"item\";a:10:{i:0;a:6:{s:4:\"data\";s:60:\"\n		\n		\n		\n		\n		\n				\n		\n		\n		\n		\n		\n		\n\n		\n		\n				\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:23:\"Event Organizers Unite!\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:57:\"http://wordpress.org/news/2012/07/event-organizers-unite/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:66:\"http://wordpress.org/news/2012/07/event-organizers-unite/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 13 Jul 2012 08:18:15 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:7:{i:0;a:5:{s:4:\"data\";s:9:\"Community\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:1;a:5:{s:4:\"data\";s:6:\"Events\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:2;a:5:{s:4:\"data\";s:7:\"classes\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:3;a:5:{s:4:\"data\";s:12:\"contributors\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:4;a:5:{s:4:\"data\";s:10:\"hackathons\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:5;a:5:{s:4:\"data\";s:7:\"meetups\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:6;a:5:{s:4:\"data\";s:9:\"WordCamps\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:33:\"http://wordpress.org/news/?p=2412\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:388:\"I&#8217;m happy to announce the formation of a new official contributor group within the WordPress project for the organizers of in-person events that promote WordPress. Though there are hundreds of people around the globe organizing WordCamps, WordPress meetups, hackathons, free classes and the like, since their &#8220;projects&#8221; were all happening locally there was never a [...]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:10:\"Jane Wells\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:3709:\"<p>I&#8217;m happy to announce the formation of a new official contributor group within the WordPress project for the organizers of in-person events that promote WordPress. Though there are hundreds of people around the globe organizing WordCamps, WordPress meetups, hackathons, free classes and the like, since their &#8220;projects&#8221; were all happening locally there was never a central hub of activity for these folks. Despite the many informal connections between community organizers, we weren&#8217;t taking advantage of the huge existing knowledge base as new organizers stepped up to the plate.</p>\n<p>With the creation of <a href=\"http://make.wordpress.org/events/\">this new contributor group</a>, we finally have a way to organize and recognize these kinds of contributions, a clear avenue for feedback and input when it comes to policies around official events, and the opportunity to create even more connections between community organizers through mentorship programs and group projects. I&#8217;m especially excited about the creation of this group because until now the role of community organizer, while one of the most important, has not gotten the same recognition as higher-profile contribution methods such as forum support or core code contribution. That is something I hope this group will change, and the local organizers can be recognized for the community leaders they are.*</p>\n<p>If you are the organizer of a local WordCamp, WordPress meetup, etc., head over to <a href=\"http://make.wordpress.org/events/\">http://make.wordpress.org/events/</a> and introduce yourself so we can include you in the fun!</p>\n<p>Speaking of meetups, an update on <a href=\"http://wordpress.org/news/2012/01/year-of-the-meetup/\">my last post about meetups</a> is long overdue. With around 500 meetup organizers (and/or potential organizers) responding to my last survey, it took much longer than anticipated to review all the responses. We&#8217;re working now with meetup.com to issue invitations to join a centralized WordPress Meetup account, so if you filled out the form earlier this year, you should be hearing from them soon. The first wave of existing meetup account transfers (for those who opted in) should happen in the next two weeks, with additional waves every 3 months thereafter (and new groups will be able to be created along the way).</p>\n<p>The <a href=\"http://wordpress.org/news/2012/05/calling-all-contributors-community-summit-2012/\">contributor summit</a> that is being planned for the end of October also generated hundreds of responses/nominations, so that review process is still happening, but we should be announcing some basic plans and issuing invitations soon.</p>\n<p>And finally, it would be impossible to talk about in-person WordPress events without mentioning the upcoming annual <a href=\"http://2012.sf.wordcamp.org\">WordCamp in San Francisco</a>. As the event that represents the worldwide project as a whole, it&#8217;s the perfect time to evaluate where we stand as a project and as a community, to help determine where we go next. If you&#8217;re a WordPress user, developer, or in any way a part of our vast and interconnected ecosystem, please take a moment to fill in the <a href=\"http://wpsurvey.polldaddy.com/s/wp-2012\">2nd annual WordPress survey</a>. It&#8217;s just a couple of questions, and your input would be greatly appreciated. The results of the survey will be announced at <a href=\"http://2012.sf.wordcamp.org\">WSCF</a>, and a report issued shortly thereafter.</p>\n<p>Thanks!</p>\n<p>*<em> I am also of the firm belief that academic and arts activities should earn varsity letters just like sports teams do &#8212; go mathletes! </em></p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:62:\"http://wordpress.org/news/2012/07/event-organizers-unite/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"0\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:1;a:6:{s:4:\"data\";s:45:\"\n		\n		\n		\n		\n		\n				\n		\n\n		\n		\n				\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:48:\"WordPress 3.4.1 Maintenance and Security Release\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:50:\"http://wordpress.org/news/2012/06/wordpress-3-4-1/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:59:\"http://wordpress.org/news/2012/06/wordpress-3-4-1/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Wed, 27 Jun 2012 19:57:46 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:2:{i:0;a:5:{s:4:\"data\";s:8:\"Releases\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:1;a:5:{s:4:\"data\";s:8:\"Security\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:33:\"http://wordpress.org/news/?p=2383\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:379:\"WordPress 3.4.1 is now available for download. WordPress 3.4 has been a very smooth release, and copies are flying off the shelf &#8212; 3 million downloads in two weeks! This maintenance release addresses 18 bugs with version 3.4, including: Fixes an issue where a theme&#8217;s page templates were sometimes not detected. Addresses problems with some category permalink [...]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:12:\"Andrew Nacin\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:1585:\"<p>WordPress 3.4.1 is now available for download. WordPress 3.4 has been a very smooth release, and copies are flying off the shelf &#8212; 3 million downloads in two weeks! This maintenance release addresses <a href=\"http://core.trac.wordpress.org/query?status=closed&amp;resolution=fixed&amp;milestone=3.4.1&amp;group=resolution&amp;order=severity&amp;desc=1\">18 bugs</a> with version 3.4, including:</p>\n<ul>\n<li>Fixes an issue where a theme&#8217;s page templates were sometimes not detected.</li>\n<li>Addresses problems with some category permalink structures.</li>\n<li>Better handling for plugins or themes loading JavaScript incorrectly.</li>\n<li>Adds early support for uploading images on iOS 6 devices.</li>\n<li>Allows for a technique commonly used by plugins to detect a network-wide activation.</li>\n<li>Better compatibility with servers running certain versions of PHP (5.2.4, 5.4) or with uncommon setups (safe mode, open_basedir), which had caused warnings or in some cases prevented emails from being sent.</li>\n</ul>\n<p>Version 3.4.1 also fixes a few security issues and contains some security hardening. The vulnerabilities included potential information disclosure as well as an bug that affects multisite installs with untrusted users. These issues were discovered and fixed by the WordPress security team.</p>\n<p><strong><a href=\"http://wordpress.org/download/\">Download 3.4.1</a> now or visit Dashboard → Updates in your site admin to update now.</strong></p>\n<p><em>Green was a bit green<br />\nWe have hardened it up some<br />\nUpdate WordPress now</em></p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:55:\"http://wordpress.org/news/2012/06/wordpress-3-4-1/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"0\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:2;a:6:{s:4:\"data\";s:42:\"\n		\n		\n		\n		\n		\n				\n\n		\n		\n				\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:25:\"WordPress 3.4 “Green”\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:40:\"http://wordpress.org/news/2012/06/green/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:49:\"http://wordpress.org/news/2012/06/green/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Wed, 13 Jun 2012 18:42:40 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:1:{i:0;a:5:{s:4:\"data\";s:8:\"Releases\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:33:\"http://wordpress.org/news/?p=2334\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:386:\"WordPress 3.4 is here and out the door. We&#8217;ve dubbed this release &#8220;Green&#8221; in honor of guitarist Grant Green whose soulful simplicity has kept many of us company during this release. This release includes significant improvements to theme customization, custom headers, Twitter embeds, and image captions &#8212; here&#8217;s a short clip with the highlights: For [...]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"Matt Mullenweg\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:15280:\"<p>WordPress 3.4 is <a href=\"http://wordpress.org/download/\">here and out the door</a>. We&#8217;ve dubbed this release &#8220;Green&#8221; in honor of guitarist <a href=\"http://en.wikipedia.org/wiki/Grant_Green\">Grant Green</a> whose soulful simplicity has kept many of us company during this release.</p>\n<p>This release includes significant improvements to theme customization, custom headers, Twitter embeds, and image captions &#8212; here&#8217;s a short clip with the highlights:</p>\n<div id=\"v-Gg0EFixV-1\" class=\"video-player\"><embed id=\"v-Gg0EFixV-1-video\" src=\"http://s0.videopress.com/player.swf?v=1.03&amp;guid=Gg0EFixV&amp;isDynamicSeeking=true\" type=\"application/x-shockwave-flash\" width=\"692\" height=\"388\" title=\"Introducing WordPress 3.4 &quot;Green&quot;\" wmode=\"direct\" seamlesstabbing=\"true\" allowfullscreen=\"true\" allowscriptaccess=\"always\" overstretch=\"true\"></embed></div>\n<h3>For Users</h3>\n<p>The biggest change in 3.4 is the <strong>theme customizer</strong> which allows you to play around with various looks and settings for your current theme or one you&#8217;re thinking about switching to without publishing those changes to the whole world. For themes that support it, you can change colors, backgrounds, and of course custom image headers. We have more planned for the customizer down the road.</p>\n<p>Throughout the rest of the admin you&#8217;ll notice tweaks to make your everyday life easier. For example, if you have lots of themes we&#8217;ve made it quicker to browse them all at once without paging. We&#8217;ve made it possible to use images from your media library to populate custom headers, and for you to choose the height and width of your header images.</p>\n<p>We&#8217;ve expanded our embed support to include tweets: just put a Twitter permalink on its own line in the post editor and we&#8217;ll turn it into a beautiful embedded Tweet. And finally, image captions have been improved to allow HTML, like links, in them.</p>\n<h3>For Developers</h3>\n<p>There are hundreds of under-the-hood improvements in this release, notably in the XML-RPC, themes, and custom header APIs, and significant performance improvements in WP_Query and the translation system. <a href=\"http://codex.wordpress.org/Version_3.4\">The Codex has a pretty good summary of the developer features</a>, and you can always <a href=\"http://core.trac.wordpress.org/milestone/3.4\">dive into Trac directly</a>.</p>\n<p>We&#8217;ve also <a href=\"http://wpdevel.wordpress.com/2012/06/07/wordpress-3-4-field-guide-for-developers/\">put together a busy developer&#8217;s field guide to the new APIs in 3.4</a>.</p>\n<h3>It takes a village</h3>\n<p>Here are some of the fine folks who were involved in bringing 3.4 to the world:</p>\n<p><a href=\"http://profiles.wordpress.org/082net\">082net</a>, <a href=\"http://profiles.wordpress.org/aaroncampbell\">Aaron D. Campbell</a>, <a href=\"http://profiles.wordpress.org/kawauso\">Adam Harley</a>, <a href=\"http://profiles.wordpress.org/ajacommerce\">AJ Acevedo</a>, <a href=\"http://profiles.wordpress.org/akshayagarwal\">akshayagarwal</a>, <a href=\"http://profiles.wordpress.org/xknown\">Alex Concha</a>, <a href=\"http://profiles.wordpress.org/alexkingorg\">Alex King</a>, <a href=\"http://profiles.wordpress.org/viper007bond\">Alex Mills (Viper007Bond)</a>, <a href=\"http://profiles.wordpress.org/ampt\">ampt</a>, <a href=\"http://profiles.wordpress.org/sabreuse\">Amy Hendrix</a>, <a href=\"http://profiles.wordpress.org/andrea_r\">Andrea Rennick</a>, <a href=\"http://profiles.wordpress.org/nacin\">Andrew Nacin</a>, <a href=\"http://profiles.wordpress.org/azaozz\">Andrew Ozz</a>, <a href=\"http://profiles.wordpress.org/andrewryno\">Andrew Ryno</a>, <a href=\"http://profiles.wordpress.org/andy\">Andy Skelton</a>, <a href=\"http://profiles.wordpress.org/arieputranto\">Arie Putranto</a>, <a href=\"http://profiles.wordpress.org/filosofo\">Austin Matzko</a>, <a href=\"http://profiles.wordpress.org/barry\">Barry</a>, <a href=\"http://profiles.wordpress.org/benchapman\">BenChapman</a>, <a href=\"http://profiles.wordpress.org/husobj\">Ben Huson</a>, <a href=\"http://profiles.wordpress.org/benbalter\">Benjamin J. Balter</a>, <a href=\"http://profiles.wordpress.org/billerickson\">Bill Erickson</a>, <a href=\"http://profiles.wordpress.org/bananastalktome\">Billy (bananastalktome)</a>, <a href=\"http://profiles.wordpress.org/boonebgorges\">Boone Gorges</a>, <a href=\"http://profiles.wordpress.org/camiloclc\">camiloclc</a>, <a href=\"http://profiles.wordpress.org/casben79\">casben79</a>, <a href=\"http://profiles.wordpress.org/caspie\">Caspie</a>, <a href=\"http://profiles.wordpress.org/ceefour\">ceefour</a>, <a href=\"http://profiles.wordpress.org/cheald\">cheald</a>, <a href=\"http://profiles.wordpress.org/chellycat\">chellycat</a>, <a href=\"http://profiles.wordpress.org/chexee\">Chelsea Otakan</a>, <a href=\"http://profiles.wordpress.org/chipbennett\">Chip Bennett</a>, <a href=\"http://profiles.wordpress.org/c3mdigital\">Chris Olbekson</a>, <a href=\"http://profiles.wordpress.org/coenjacobs\">Coen Jacobs</a>, <a href=\"http://profiles.wordpress.org/scribu\">Cristi Burc&#259;</a>, <a href=\"http://profiles.wordpress.org/cyapow\">Cyapow</a>, <a href=\"http://profiles.wordpress.org/djcp\">Dan Collis-Puro</a>, <a href=\"http://profiles.wordpress.org/danielbachhuber\">Daniel Bachhuber</a>, <a href=\"http://profiles.wordpress.org/convissor\">Daniel Convissor</a>, <a href=\"http://profiles.wordpress.org/redsweater\">Daniel Jalkut (Red Sweater)</a>, <a href=\"http://profiles.wordpress.org/daniloercoli\">daniloercoli</a>, <a href=\"http://profiles.wordpress.org/koopersmith\">Daryl Koopersmith</a>, <a href=\"http://profiles.wordpress.org/dgwyer\">David Gwyer</a>, <a href=\"http://profiles.wordpress.org/deltafactory\">deltafactory</a>, <a href=\"http://profiles.wordpress.org/demetris\">demetris</a>, <a href=\"http://profiles.wordpress.org/dd32\">Dion Hulse</a>, <a href=\"http://profiles.wordpress.org/dllh\">dllh</a>, <a href=\"http://profiles.wordpress.org/ocean90\">Dominik Schilling</a>, <a href=\"http://profiles.wordpress.org/dougwrites\">Doug Provencio</a>, <a href=\"http://profiles.wordpress.org/drewapicture\">Drew Jaynes (DrewAPicture)</a>, <a href=\"http://profiles.wordpress.org/ebababi\">ebababi</a>, <a href=\"http://profiles.wordpress.org/edward-mindreantre\">edward-mindreantre</a>, <a href=\"http://profiles.wordpress.org/emhr\">emhr</a>, <a href=\"http://profiles.wordpress.org/empireoflight\">Empireoflight</a>, <a href=\"http://profiles.wordpress.org/ericlewis\">Eric Andrew Lewis</a>, <a href=\"http://profiles.wordpress.org/ericmann\">Eric Mann</a>, <a href=\"http://profiles.wordpress.org/ejdanderson\">Evan Anderson</a>, <a href=\"http://profiles.wordpress.org/evansolomon\">Evan Solomon</a>, <a href=\"http://profiles.wordpress.org/fredwu\">Fred Wu</a>, <a href=\"http://profiles.wordpress.org/ounziw\">Fumito Mizuno</a>, <a href=\"http://profiles.wordpress.org/garyc40\">Gary Cao</a>, <a href=\"http://profiles.wordpress.org/garyj\">Gary Jones</a>, <a href=\"http://profiles.wordpress.org/gautamgupta\">Gautam</a>, <a href=\"http://profiles.wordpress.org/soulseekah\">Gennady Kovshenin</a>, <a href=\"http://profiles.wordpress.org/mamaduka\">George Mamadashvili</a>, <a href=\"http://profiles.wordpress.org/georgestephanis\">George Stephanis</a>, <a href=\"http://profiles.wordpress.org/webord\">Gustavo Bordoni</a>, <a href=\"http://profiles.wordpress.org/hearvox\">hearvox</a>, <a href=\"http://profiles.wordpress.org/helenyhou\">Helen Hou-Sandi</a>, <a href=\"http://profiles.wordpress.org/hugobaeta\">Hugo Baeta</a>, <a href=\"http://profiles.wordpress.org/iandstewart\">Ian Stewart</a>, <a href=\"http://profiles.wordpress.org/insertvisionhere\">insertvisionhere</a>, <a href=\"http://profiles.wordpress.org/ipstenu\">Ipstenu</a>, <a href=\"http://profiles.wordpress.org/master-jake\">Jacob Chappell</a>, <a href=\"http://profiles.wordpress.org/jane\">Jane Wells</a>, <a href=\"http://profiles.wordpress.org/japh\">Japh</a>, <a href=\"http://profiles.wordpress.org/jaquers\">jaquers</a>, <a href=\"http://profiles.wordpress.org/jarretc\">JarretC</a>, <a href=\"http://profiles.wordpress.org/jeremyclarke\">jeremyclarke</a>, <a href=\"http://profiles.wordpress.org/jeremyfelt\">Jeremy Felt</a>, <a href=\"http://profiles.wordpress.org/jayjdk\">Jesper Johansen (Jayjdk)</a>, <a href=\"http://profiles.wordpress.org/jiehanzheng\">Jiehan Zheng</a>, <a href=\"http://profiles.wordpress.org/intoxstudio\">Joachim Jensen (Intox Studio)</a>, <a href=\"http://profiles.wordpress.org/jkudish\">Joachim Kudish (jkudish)</a>, <a href=\"http://profiles.wordpress.org/johnbillion\">John Blackbourn (johnbillion)</a>, <a href=\"http://profiles.wordpress.org/aldenta\">John Ford</a>, <a href=\"http://profiles.wordpress.org/johnjamesjacoby\">John James Jacoby</a>, <a href=\"http://profiles.wordpress.org/duck_\">Jon Cave</a>, <a href=\"http://profiles.wordpress.org/joostdevalk\">Joost de Valk</a>, <a href=\"http://profiles.wordpress.org/koke\">Jorge Bernal</a>, <a href=\"http://profiles.wordpress.org/josephscott\">Joseph Scott</a>, <a href=\"http://profiles.wordpress.org/devesine\">Justin</a>, <a href=\"http://profiles.wordpress.org/justindgivens\">Justin Givens</a>, <a href=\"http://profiles.wordpress.org/trepmal\">Kailey Lampert (trepmal)</a>, <a href=\"http://profiles.wordpress.org/kenan3008\">Kenan Dervisevic</a>, <a href=\"http://profiles.wordpress.org/kovshenin\">Konstantin Kovshenin</a>, <a href=\"http://profiles.wordpress.org/kobenland\">Konstantin Obenland</a>, <a href=\"http://profiles.wordpress.org/klagraff\">Kristopher Lagraff</a>, <a href=\"http://profiles.wordpress.org/kurtpayne\">Kurt Payne</a>, <a href=\"http://profiles.wordpress.org/lancewillett\">Lance Willett</a>, <a href=\"http://profiles.wordpress.org/lardjo\">Lardjo</a>, <a href=\"http://profiles.wordpress.org/leewillis77\">Lee Willis (leewillis77)</a>, <a href=\"http://profiles.wordpress.org/linuxologos\">linuxologos</a>, <a href=\"http://profiles.wordpress.org/latz\">Lutz Schroer</a>, <a href=\"http://profiles.wordpress.org/settle\">Mantas Malcius</a>, <a href=\"http://profiles.wordpress.org/netweblogic\">Marcus</a>, <a href=\"http://profiles.wordpress.org/markjaquith\">Mark Jaquith</a>, <a href=\"http://profiles.wordpress.org/markoheijnen\">Marko Heijnen</a>, <a href=\"http://profiles.wordpress.org/markauk\">Mark Rowatt Anderson</a>, <a href=\"http://profiles.wordpress.org/matveb\">Matias Ventura</a>, <a href=\"http://profiles.wordpress.org/sivel\">Matt Martz</a>, <a href=\"http://profiles.wordpress.org/mattonomics\">mattonomics</a>, <a href=\"http://profiles.wordpress.org/iammattthomas\">Matt Thomas</a>, <a href=\"http://profiles.wordpress.org/mattwiebe\">Matt Wiebe</a>, <a href=\"http://profiles.wordpress.org/mattyrob\">MattyRob</a>, <a href=\"http://profiles.wordpress.org/maxcutler\">Max Cutler</a>, <a href=\"http://profiles.wordpress.org/merty\">Mert Yazicioglu</a>, <a href=\"http://profiles.wordpress.org/mgolawala\">mgolawala</a>, <a href=\"http://profiles.wordpress.org/mdawaffe\">Michael Adams (mdawaffe)</a>, <a href=\"http://profiles.wordpress.org/tw2113\">Michael Beckwith</a>, <a href=\"http://profiles.wordpress.org/mfields\">Michael Fields</a>, <a href=\"http://profiles.wordpress.org/mikeschinkel\">Mike Schinkel</a>, <a href=\"http://profiles.wordpress.org/dh-shredder\">Mike Schroder</a>, <a href=\"http://profiles.wordpress.org/toppa\">Mike Toppa</a>, <a href=\"http://profiles.wordpress.org/dimadin\">Milan Dinic</a>, <a href=\"http://profiles.wordpress.org/mitchoyoshitaka\">mitcho (Michael Yoshitaka Erlewine)</a>, <a href=\"http://profiles.wordpress.org/batmoo\">Mohammad Jangda</a>, <a href=\"http://profiles.wordpress.org/mrtorrent\">mrtorrent</a>, <a href=\"http://profiles.wordpress.org/namely\">Name.ly</a>, <a href=\"http://profiles.wordpress.org/Nao\">Naoko McCracken</a>, <a href=\"http://profiles.wordpress.org/alex-ye\">Nashwan Doaqan</a>, <a href=\"http://profiles.wordpress.org/niallkennedy\">Niall Kennedy</a>, <a href=\"http://profiles.wordpress.org/nikolayyordanov\">Nikolay Yordanov</a>, <a href=\"http://profiles.wordpress.org/norocketsurgeon\">norocketsurgeon</a>, <a href=\"http://profiles.wordpress.org/npetetin\">npetetin</a>, <a href=\"http://profiles.wordpress.org/nunomorgadinho\">Nuno Morgadinho</a>, <a href=\"http://profiles.wordpress.org/ocollet\">Olivier Collet</a>, <a href=\"http://profiles.wordpress.org/pbiron\">Paul Biron</a>, <a href=\"http://profiles.wordpress.org/pavelevap\">pavelevap</a>, <a href=\"http://profiles.wordpress.org/petemall\">Pete Mall</a>, <a href=\"http://profiles.wordpress.org/westi\">Peter Westwood</a>, <a href=\"http://profiles.wordpress.org/pishmishy\">pishmishy</a>, <a href=\"http://profiles.wordpress.org/nprasath002\">Prasath Nadarajah</a>, <a href=\"http://profiles.wordpress.org/prettyboymp\">prettyboymp</a>, <a href=\"http://profiles.wordpress.org/ptahdunbar\">Ptah Dunbar</a>, <a href=\"http://profiles.wordpress.org/pw201\">pw201</a>, <a href=\"http://profiles.wordpress.org/ramiy\">Rami Yushuvaev</a>, <a href=\"http://profiles.wordpress.org/rarst\">Rarst</a>, <a href=\"http://profiles.wordpress.org/arena\">RENAUT</a>, <a href=\"http://profiles.wordpress.org/greuben\">Reuben Gunday</a>, <a href=\"http://profiles.wordpress.org/roscius\">Roscius</a>, <a href=\"http://profiles.wordpress.org/rosshanney\">Ross Hanney</a>, <a href=\"http://profiles.wordpress.org/russellwwest\">russellwwest</a>, <a href=\"http://profiles.wordpress.org/ryan\">Ryan Boren</a>, <a href=\"http://profiles.wordpress.org/ryanduff\">Ryan Duff</a>, <a href=\"http://profiles.wordpress.org/rmccue\">Ryan McCue</a>, <a href=\"http://profiles.wordpress.org/zeo\">Safirul Alredha</a>, <a href=\"http://profiles.wordpress.org/solarissmoke\">Samir Shah</a>, <a href=\"http://profiles.wordpress.org/otto42\">Samuel &#8220;Otto&#8221; Wood</a>, <a href=\"http://profiles.wordpress.org/tenpura\">Seisuke Kuraishi</a>, <a href=\"http://profiles.wordpress.org/sergeybiryukov\">Sergey Biryukov</a>, <a href=\"http://profiles.wordpress.org/simonwheatley\">Simon Wheatley</a>, <a href=\"http://profiles.wordpress.org/sirzooro\">sirzooro</a>, <a href=\"http://profiles.wordpress.org/sksmatt\">sksmatt</a>, <a href=\"http://profiles.wordpress.org/sushkov\">Stas Su&#537;kov</a>, <a href=\"http://profiles.wordpress.org/stephdau\">Stephane Daury (stephdau)</a>, <a href=\"http://profiles.wordpress.org/tamlyn\">tamlyn</a>, <a href=\"http://profiles.wordpress.org/griffinjt\">Thomas Griffin</a>, <a href=\"http://profiles.wordpress.org/tott\">Thorsten Ott</a>, <a href=\"http://profiles.wordpress.org/tobiasbg\">TobiasBg</a>, <a href=\"http://profiles.wordpress.org/tomauger\">Tom Auger</a>, <a href=\"http://profiles.wordpress.org/skithund\">Toni Viemero</a>, <a href=\"http://profiles.wordpress.org/transom\">transom</a>, <a href=\"http://profiles.wordpress.org/sorich87\">Ulrich Sossou</a>, <a href=\"http://profiles.wordpress.org/utkarsh\">Utkarsh Kukreti</a>, <a href=\"http://profiles.wordpress.org/wojtekszkutnik\">Wojtek Szkutnik</a>, <a href=\"http://profiles.wordpress.org/wonderslug\">wonderslug</a>, <a href=\"http://profiles.wordpress.org/xibe\">Xavier Borderie</a>, <a href=\"http://profiles.wordpress.org/yoavf\">Yoav Farhi</a>, <a href=\"http://profiles.wordpress.org/thezman84\">Zach &#8220;The Z Man&#8221; Abernathy</a>, <a href=\"http://profiles.wordpress.org/tollmanz\">Zack Tollman</a>, <a href=\"http://profiles.wordpress.org/vanillalounge\">Ze Fontainhas</a>, and <a href=\"http://profiles.wordpress.org/zx2c4\">zx2c4</a>.</p>\n<p>See you next time!</p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:45:\"http://wordpress.org/news/2012/06/green/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"0\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:3;a:6:{s:4:\"data\";s:45:\"\n		\n		\n		\n		\n		\n				\n		\n\n		\n		\n				\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:33:\"WordPress 3.4 Release Candidate 3\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:68:\"http://wordpress.org/news/2012/06/wordpress-3-4-release-candidate-3/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:77:\"http://wordpress.org/news/2012/06/wordpress-3-4-release-candidate-3/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 12 Jun 2012 00:30:14 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:2:{i:0;a:5:{s:4:\"data\";s:11:\"Development\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:1;a:5:{s:4:\"data\";s:7:\"Testing\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:33:\"http://wordpress.org/news/?p=2326\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:325:\"The third release candidate for WordPress 3.4 is now available. Since RC2, we&#8217;ve fixed a few lingering issues with the new live preview feature, as well as with custom headers and backgrounds. There are no remaining issues, and we plan to release 3.4 in the coming days. But if you think you&#8217;ve found a bug, [...]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:12:\"Andrew Nacin\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:1376:\"<p>The third release candidate for WordPress 3.4 is now available. Since RC2, we&#8217;ve fixed a few lingering issues with the new live preview feature, as well as with custom headers and backgrounds.</p>\n<p>There are no remaining issues, and we plan to release 3.4 in the coming days. But if you think you&#8217;ve found a bug, you can post to the <a href=\"http://wordpress.org/support/forum/alphabeta\">Alpha/Beta area</a> in the support forums, or file a bug report on <a href=\"http://core.trac.wordpress.org/\">WordPress Trac</a>.</p>\n<p>To test WordPress 3.4, try the <a href=\"http://wordpress.org/extend/plugins/wordpress-beta-tester/\">WordPress Beta Tester</a> plugin (you’ll want &#8220;bleeding edge nightlies&#8221;). Or you can <a href=\"http://wordpress.org/wordpress-3.4-RC3.zip\">download the release candidate here</a> (zip). Be sure to visit <strong><img style=\"vertical-align: text-top\" src=\"http://wordpress.org/wp-content/themes/twentyten/images/wordpress.png\" alt=\"\" /> → About</strong> for an updated list of features and under-the-hood changes. As a reminder: We’ve published some resources on the <a href=\"http://wpdevel.wordpress.com/2012/06/07/wordpress-3-4-field-guide-for-developers/\">development blog</a> to help plugin and theme developers prepare.</p>\n<p><em>The new live preview<br />\nNearing perfection, and yet?<br />\nNot yet. RC3</em></p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:73:\"http://wordpress.org/news/2012/06/wordpress-3-4-release-candidate-3/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"0\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:4;a:6:{s:4:\"data\";s:48:\"\n		\n		\n		\n		\n		\n				\n		\n		\n\n		\n		\n				\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:33:\"WordPress 3.4 Release Candidate 2\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:68:\"http://wordpress.org/news/2012/06/wordpress-3-4-release-candidate-2/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:77:\"http://wordpress.org/news/2012/06/wordpress-3-4-release-candidate-2/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 07 Jun 2012 02:48:58 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:3:{i:0;a:5:{s:4:\"data\";s:11:\"Development\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:1;a:5:{s:4:\"data\";s:8:\"Releases\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:2;a:5:{s:4:\"data\";s:7:\"Testing\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:33:\"http://wordpress.org/news/?p=2318\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:331:\"The second release candidate for WordPress 3.4 is now available. Since RC1, we&#8217;ve made a few dozen final changes. Our goal is to release WordPress 3.4 early next week, so plugin and theme authors, this is likely your last chance to test your plugins and themes to find any compatibility issues before the final release. [...]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:12:\"Andrew Nacin\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:1713:\"<p>The second release candidate for WordPress 3.4 is now available. Since RC1, we&#8217;ve made a <a href=\"http://core.trac.wordpress.org/log/?action=stop_on_copy&amp;mode=stop_on_copy&amp;rev=21018&amp;stop_rev=20949&amp;limit=500\">few dozen final changes</a>.</p>\n<p>Our goal is to release WordPress 3.4 early next week, so plugin and theme authors, this is likely <strong>your last chance to test your plugins and themes to find any compatibility issues before the final release</strong>. We&#8217;ve published some resources on the <a href=\"http://wpdevel.wordpress.com/2012/06/07/wordpress-3-4-field-guide-for-developers/\">development blog</a> to help you prepare.</p>\n<p>If you think you’ve found a bug, you can post to the <a href=\"http://wordpress.org/support/forum/alphabeta\">Alpha/Beta area</a> in the support forums. Or, if you’re comfortable writing a reproducible bug report, <a href=\"http://core.trac.wordpress.org/\">file one on WordPress Trac</a>. Known issues that crop up will be listed <a href=\"http://core.trac.wordpress.org/report/6\">here</a>, but we&#8217;re hoping for a quiet few days so we can get some great features into your hands next week!</p>\n<p>To test WordPress 3.4, try the <a href=\"http://wordpress.org/extend/plugins/wordpress-beta-tester/\">WordPress Beta Tester</a> plugin (you’ll want &#8220;bleeding edge nightlies&#8221;). Or you can <a href=\"http://wordpress.org/wordpress-3.4-RC2.zip\">download the release candidate here</a> (zip). Be sure to visit <strong><img src=\"http://wordpress.org/wp-content/themes/twentyten/images/wordpress.png\" alt=\"\" style=\"vertical-align:text-top\" /> &rarr; About</strong> for an updated list of features and under-the-hood changes.</p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:73:\"http://wordpress.org/news/2012/06/wordpress-3-4-release-candidate-2/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"0\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:5;a:6:{s:4:\"data\";s:48:\"\n		\n		\n		\n		\n		\n				\n		\n		\n\n		\n		\n				\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"WordPress 3.4 Release Candidate\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:66:\"http://wordpress.org/news/2012/05/wordpress-3-4-release-candidate/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:75:\"http://wordpress.org/news/2012/05/wordpress-3-4-release-candidate/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Sun, 27 May 2012 17:18:30 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:3:{i:0;a:5:{s:4:\"data\";s:11:\"Development\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:1;a:5:{s:4:\"data\";s:8:\"Releases\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:2;a:5:{s:4:\"data\";s:7:\"Testing\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:33:\"http://wordpress.org/news/?p=2303\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:130:\"The first release candidate (RC1) for WordPress 3.4 is now available. If you haven’t tested WordPress 3.4 yet, now is the time! \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:12:\"Andrew Nacin\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:1871:\"<p>The first release candidate (RC1) for WordPress 3.4 is now available.</p>\n<p>An RC comes after the beta period and before final release. We think we&#8217;re done, but with millions of users and thousands of plugins and themes, it&#8217;s possible we&#8217;ve missed something. So if you haven’t tested WordPress 3.4 yet, now is the time! Please though, not on your live site unless you’re adventurous.</p>\n<p>With more than <a href=\"http://core.trac.wordpress.org/milestone/3.4\">500 tickets closed</a>, there are quite a few changes. <strong>Plugin and theme authors,</strong> please test your plugins and themes now, so that if there is a compatibility issue, we can figure it out before the final release.</p>\n<p>If you are testing the release candidate and think you&#8217;ve found a bug, please post to the <a href=\"http://wordpress.org/support/forum/alphabeta/\">Alpha/Beta area in the support forums</a>. If any known issues crop up, you’ll be able to <a href=\"http://core.trac.wordpress.org/report/5\">find them here</a>.</p>\n<p>To test WordPress 3.4, try the <a href=\"http://wordpress.org/extend/plugins/wordpress-beta-tester/\">WordPress Beta Tester</a> plugin (you&#8217;ll want &#8220;bleeding edge nightlies&#8221;). Or you can <a href=\"http://wordpress.org/wordpress-3.4-RC1.zip\">download the release candidate here (zip)</a>.</p>\n<p>If you&#8217;d like to know which levers to pull in your testing, visit the About page (<strong><img src=\"http://wordpress.org/wp-content/themes/twentyten/images/wordpress.png\" alt=\"\" style=\"vertical-align:text-top\" /> &rarr; About</strong> in the toolbar) and check out the list of features! You&#8217;ll definitely want to try the live theme previews.</p>\n<p><strong>Bonus:</strong> Happy birthday WordPress &#8212; <a href=\"http://wordpress.org/news/2003/05/wordpress-now-available/\">nine years old</a> today.</p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:71:\"http://wordpress.org/news/2012/05/wordpress-3-4-release-candidate/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"0\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:6;a:6:{s:4:\"data\";s:42:\"\n		\n		\n		\n		\n		\n				\n\n		\n		\n				\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:26:\"Plugin Directory Refreshed\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:52:\"http://wordpress.org/news/2012/05/plugins-refreshed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:61:\"http://wordpress.org/news/2012/05/plugins-refreshed/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Sat, 19 May 2012 18:56:27 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:1:{i:0;a:5:{s:4:\"data\";s:4:\"Meta\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:33:\"http://wordpress.org/news/?p=2291\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:333:\"Been hanging out with a few WordPress.org hackers &#8212; Scott, Nacin, and Otto &#8212; the last few days in a BBQ-fueled haze of hacking to make plugin directory better. There are over 19,000 plugins listed and they&#8217;re really the heart and soul of WordPress for many people, so they deserve a little tender loving care. [...]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"Matt Mullenweg\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:3324:\"<p>Been hanging out with a few WordPress.org hackers &#8212; Scott, Nacin, and Otto &#8212; the last few days in a BBQ-fueled haze of hacking to make plugin directory better. There are over <a href=\"http://wordpress.org/extend/plugins/\">19,000 plugins listed</a> and they&#8217;re really the heart and soul of WordPress for many people, so they deserve a little tender loving care. Here&#8217;s a quick before and after snapshot you can zoom in on to see a visual overview of some of the changes:</p>\n<p><a href=\"http://wpdotorg.files.wordpress.com/2012/05/contact-form-7.png\"><img src=\"http://s2.wp.com/imgpress?resize=690,350&amp;url=http://wpdotorg.files.wordpress.com/2012/05/contact-form-7.png&amp;unsharpmask=80,0.5,3\" alt=\"\" /></a></p>\n<p>Our first focus was around improving the discussion and support around plugins.</p>\n<p>You&#8217;ll now notice that threads about a plugin are pulled directly into a &#8220;support&#8221; tab on the plugin page &#8212; each plugin has its own forum. We&#8217;ve made authors much more prominent and with bigger Gravatars and better placement, so you can get a sense of who made the plugin you&#8217;re using. And finally to show how active and well-supported a plugin is, you can see  &#8221;16 of 75 support threads in the last two weeks have been resolved.&#8221; Finally, if you&#8217;re logged in you get access to the new &#8220;favorites&#8221; feature that lets you mark the plugins you use the most so you can share them on your profile page and find them quickly later. We soft-launched favorites a few days ago and there have already been 2,000 saved!</p>\n<p>If you&#8217;re a plugin author, we&#8217;ve started with a short threshold (2 weeks) for the resolved stats so it&#8217;s easy to catch up and stay on top of it. (It&#8217;ll eventually go to two months.) You also now have the ability to set stickies on your plugin forum to put FAQs or important information at the top, and of course any person you put as a committer on the plugin will have moderation access. People on the forum tag will see your custom header and links to the other resources attached to your plugin.</p>\n<p>We&#8217;ve tightened up the styling a bit on the forums and plugin pages, though still some cleanups to do there. Some older improvements you might have missed, but are still useful for users and developers alike:</p>\n<ul>\n<li>&#8220;Plugin headers&#8221; or those cool graphics you see at the top of plugin pages have really taken off, there are over 1,600 active now.</li>\n<li>You can now subscribe to get an email whenever a commit is made to a plugin repository even if it isn&#8217;t yours. There is no better way to follow the development of your favorite plugins. There&#8217;s nothing like the smell of fresh changesets in the morning.</li>\n<li>Behind the scenes, we&#8217;ve dramatically ramped up proactive scanning of the entire repository to help authors fix security and other problems they might not even know about yet. The quality level of the repo has gone way, way up.</li>\n</ul>\n<p>All of this will continue to evolve as we get feedback and see usage, but we&#8217;re happy to have been able to make some key improvements in just a few days while hanging out in Memphis. (This is why WordCamps usually have BBQ &#8212; it imparts magical coding powers.)</p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:57:\"http://wordpress.org/news/2012/05/plugins-refreshed/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"0\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:7;a:6:{s:4:\"data\";s:45:\"\n		\n		\n		\n		\n		\n				\n		\n\n		\n		\n				\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:47:\"Calling All Contributors: Community Summit 2012\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:81:\"http://wordpress.org/news/2012/05/calling-all-contributors-community-summit-2012/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:90:\"http://wordpress.org/news/2012/05/calling-all-contributors-community-summit-2012/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 15 May 2012 22:36:46 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:2:{i:0;a:5:{s:4:\"data\";s:9:\"Community\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:1;a:5:{s:4:\"data\";s:6:\"Events\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:33:\"http://wordpress.org/news/?p=2278\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:334:\"Each year, the WordPress core development team meets in person for a week to work together and discuss the vision for WordPress in the coming year. As annual events go, it&#8217;s easily my favorite. Don&#8217;t get me wrong, I love attending WordCamps and local WordPress meetups (which are awesome and you should try to attend [...]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:10:\"Jane Wells\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:5345:\"<p>Each year, the WordPress core development team meets in person for a week to work together and discuss the vision for WordPress in the coming year. As annual events go, it&#8217;s easily my favorite. Don&#8217;t get me wrong, I love attending <a title=\"WordCamp Central\" href=\"http://wordcamp.org\">WordCamps</a> and local <a title=\"WordPress on Meetup.com\" href=\"http://wordpress.meetup.com/\">WordPress meetups</a> (which are awesome and you should try to attend if you are able), but at the core team meetup, the focus on working together and getting things done is unique, as is the experience of every person in the room being so highly qualified. This year, instead of just planning a core team meetup, I&#8217;m aiming a little higher and shooting for a full-on contributor/community summit.</p>\n<p>Core code isn&#8217;t the only way to contribute to the WordPress project. We have an active <a title=\"Theme Review Team blog\" href=\"http://make.wordpress.org/themes/\">theme review team</a>, <a href=\"http://wordpress.org/support/\">support forum</a> volunteers, people writing <a href=\"http://codex.wordpress.org/Main_Page\">documentation</a>, plugin managers, community event organizers, translators, and more. The teams have been siloed for too long, so we&#8217;ve recently begun the process of bringing them together by having teams elect representatives to facilitate more communication between the contributor groups. These reps will form the nucleus of the contributor summit now being planned for a long weekend at the end of October in Tybee Island, GA. This is completely different from a WordCamp. It will be a combination of co-working, unconference, and discussions among the project leaders, and participation will be by invitation.</p>\n<p>In addition to bringing together the active contributor team reps to work together, I think it&#8217;s important to include community members who don&#8217;t fall into that category (at least not yet!). Successful WordPress-based business, authors of popular plugins and themes, and people using WordPress in unexpected but intriguing ways should have a place at the table, too. That said, part of the magic of the core team meetup is the small size; it allows every voice not only to be heard, but to engage. Since this is my first attempt at bringing together so many groups and points of view, I want to try and keep it small enough to retain that personal atmosphere while at the same time ensuring that the best possible mix of people and businesses in the WordPress ecosystem is represented. This is where you come in!</p>\n<p>Taking a cue from events with limited availability like <a title=\"AdaCamp\" href=\"http://dc.adacamp.org/\">AdaCamp</a> (attendance) and the <a title=\"jQuery Conference\" href=\"http://events.jquery.org/2012/sf/\">jQuery conference</a> (speaker roster), I want you to <a title=\"Nomination survey\" href=\"http://wordpressdotorg.polldaddy.com/s/2012-community-summit-nominations\">nominate people and/or WordPress-based businesses to participate in the summit</a>. Yes, you can nominate yourself.* You can nominate up to 10 additional people &#8212; be prepared to provide URLs and the reason you think they should participate. You can also nominate up to 10 WordPress-based businesses without naming individual people, so if there&#8217;s a theme or hosting company (for example) that you think should be there, you don&#8217;t need to go looking for employee names. This nomination process will hopefully ensure that we don&#8217;t overlook someone who is making a difference in our community when it comes time to issue invitations.</p>\n<p>Nominations will be open for a week, after which <a href=\"http://wordpressdotorg.polldaddy.com/s/2012-community-summit-nominations\">the survey</a> will be closed and the process of analyzing the results** will begin. The nominations process will lead to invitations in June, confirmations in July, planning in August and September, and the summit itself in October. Hopefully we can stream and/or record some of the activity to share online at <a href=\"http://wordpress.tv\">WordPress.tv</a>. Additional invitations may be extended up until the event if there are people/businesses that become more active in the community. If you&#8217;re thinking to yourself that maybe now&#8217;s the perfect time to start <a href=\"http://codex.wordpress.org/Contributing_to_WordPress\">contributing time to the WordPress project</a>, good thinking! In the meantime, if you want to weigh in, <a href=\"http://wordpressdotorg.polldaddy.com/s/2012-community-summit-nominations\">fill in the community summit nomination form</a>. Thanks, and wish us luck!</p>\n<p><em>* Nominating yourself: Do nominate yourself if you fall into one of the categories described in the post above, or if you believe that you have a unique point of view. Please do not nominate yourself if you just think it would be cool to hang out with this group. This is a working event, and everyone is expected to bring something special to the table.</em></p>\n<p><em>** I (and/or a helpful community volunteer) will sift through the nominations and compile a shortlist of the most-nominated people/businesses and the most intriguing underdogs. This list will be reviewed by the summit planning committee (made up of team reps) to create the invitation list.</em></p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:86:\"http://wordpress.org/news/2012/05/calling-all-contributors-community-summit-2012/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"0\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:8;a:6:{s:4:\"data\";s:42:\"\n		\n		\n		\n		\n		\n				\n\n		\n		\n				\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:20:\"WordPress 3.4 Beta 4\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:55:\"http://wordpress.org/news/2012/05/wordpress-3-4-beta-4/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:64:\"http://wordpress.org/news/2012/05/wordpress-3-4-beta-4/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 03 May 2012 02:52:28 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:1:{i:0;a:5:{s:4:\"data\";s:8:\"Releases\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:33:\"http://wordpress.org/news/?p=2273\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:123:\"Less bugs, more polish, the same beta disclaimers. Download, test, report bugs. Thanks much. /ryan #thewholebrevitything\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:10:\"Ryan Boren\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:190:\"<p>Less bugs, more polish, the same beta disclaimers. <a href=\"http://wordpress.org/wordpress-3.4-beta4.zip\">Download</a>, test, report bugs. Thanks much. /ryan #thewholebrevitything</p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:60:\"http://wordpress.org/news/2012/05/wordpress-3-4-beta-4/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"0\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:9;a:6:{s:4:\"data\";s:48:\"\n		\n		\n		\n		\n		\n				\n		\n		\n\n		\n		\n				\n			\n		\n		\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:5:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"WordPress 3.3.2 (and WordPress 3.4 Beta 3)\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:50:\"http://wordpress.org/news/2012/04/wordpress-3-3-2/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:59:\"http://wordpress.org/news/2012/04/wordpress-3-3-2/#comments\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 20 Apr 2012 15:10:37 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"category\";a:3:{i:0;a:5:{s:4:\"data\";s:11:\"Development\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:1;a:5:{s:4:\"data\";s:8:\"Releases\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}i:2;a:5:{s:4:\"data\";s:8:\"Security\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:33:\"http://wordpress.org/news/?p=2262\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:384:\"WordPress 3.3.2 is available now and is a security update for all previous versions. Three external libraries included in WordPress received security updates: Plupload (version 1.5.4), which WordPress uses for uploading media. SWFUpload, which WordPress previously used for uploading media, and may still be in use by plugins. SWFObject, which WordPress previously used to embed [...]\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:12:\"Andrew Nacin\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:40:\"http://purl.org/rss/1.0/modules/content/\";a:1:{s:7:\"encoded\";a:1:{i:0;a:5:{s:4:\"data\";s:3345:\"<p><a href=\"http://wordpress.org/download/\">WordPress 3.3.2</a> is available now and is a security update for all previous versions.</p>\n<p>Three external libraries included in WordPress received security updates:</p>\n<ul>\n<li>Plupload (version 1.5.4), which WordPress uses for uploading media.</li>\n<li>SWFUpload, which WordPress previously used for uploading media, and may still be in use by plugins.</li>\n<li>SWFObject, which WordPress previously used to embed Flash content, and may still be in use by plugins and themes.</li>\n</ul>\n<p>Thanks to <a href=\"https://nealpoole.com/blog/\">Neal Poole</a> and <a href=\"http://greywhind.wordpress.com/\">Nathan Partlan</a> for <a href=\"http://codex.wordpress.org/FAQ_Security\">responsibly disclosing</a> the bugs in Plupload and SWFUpload, and <a href=\"http://mars.iti.pk.edu.pl/~grucha/\">Szymon Gruszecki</a> for a separate bug in SWFUpload.</p>\n<p>WordPress 3.3.2 also addresses:</p>\n<ul>\n<li>Limited privilege escalation where a site administrator could deactivate network-wide plugins when running a WordPress network under particular circumstances, disclosed by <a href=\"http://joncave.co.uk/\">Jon Cave</a> of our WordPress core security team, and <a href=\"http://sixohthree.com/\">Adam Backstrom</a>.</li>\n<li>Cross-site scripting vulnerability when making URLs clickable, by Jon Cave.</li>\n<li>Cross-site scripting vulnerabilities in redirects after posting comments in older browsers, and when filtering URLs. Thanks to <a href=\"http://www.sneaked.net/\">Mauro Gentile</a> for responsibly disclosing these issues to the security team.</li>\n</ul>\n<p>These issues were fixed by the WordPress core security team. Five other bugs were also fixed in version 3.3.2. Consult the <a href=\"http://core.trac.wordpress.org/log/branches/3.3?rev=20552&amp;stop_rev=20087\">change log</a> for more details.</p>\n<p><a href=\"http://wordpress.org/download/\">Download WordPress 3.3.2</a> or update now from the Dashboard → Updates menu in your site&#8217;s admin area.</p>\n<hr />\n<h3>WordPress 3.4 Beta 3 also available</h3>\n<p>Our development of WordPress 3.4 development continues. Today we are proud to release Beta 3 for testing. <a href=\"http://core.trac.wordpress.org/log/trunk?rev=20552&amp;stop_rev=20450\">Nearly 90 changes</a> have been made since Beta 2, released 9 days ago. (We are aiming for a beta every week.)</p>\n<p>This is still beta software, so <strong>we don&#8217;t recommend that you use it on production sites</strong>. But if you&#8217;re a plugin developer, a theme developer, or a site administrator, <strong>you should be running this on your test environments</strong> and <a href=\"http://codex.wordpress.org/Reporting_Bugs\">reporting any bugs</a> you find. (See the <a href=\"http://core.trac.wordpress.org/report/5\">known issues here</a>.) If you&#8217;re a WordPress user who wants to open your presents early, take advantage of WordPress&#8217;s famous 5-minute install and spin up a secondary test site. <a href=\"http://wordpress.org/support/forum/alphabeta\">Let us know what you think</a>!</p>\n<p>Version 3.4 Beta 3 includes all of the fixes included in version 3.3.2. <a href=\"http://wordpress.org/wordpress-3.4-beta3.zip\">Download WordPress 3.4 Beta 3</a> or use the <a href=\"http://wordpress.org/extend/plugins/wordpress-beta-tester/\">WordPress Beta Tester</a> plugin.</p>\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://wellformedweb.org/CommentAPI/\";a:1:{s:10:\"commentRss\";a:1:{i:0;a:5:{s:4:\"data\";s:55:\"http://wordpress.org/news/2012/04/wordpress-3-3-2/feed/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:38:\"http://purl.org/rss/1.0/modules/slash/\";a:1:{s:8:\"comments\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"0\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}}}s:27:\"http://www.w3.org/2005/Atom\";a:1:{s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:1:{s:0:\"\";a:3:{s:4:\"href\";s:31:\"http://wordpress.org/news/feed/\";s:3:\"rel\";s:4:\"self\";s:4:\"type\";s:19:\"application/rss+xml\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:44:\"http://purl.org/rss/1.0/modules/syndication/\";a:2:{s:12:\"updatePeriod\";a:1:{i:0;a:5:{s:4:\"data\";s:6:\"hourly\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:15:\"updateFrequency\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"1\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}}}}}}}}s:4:\"type\";i:128;s:7:\"headers\";a:8:{s:6:\"server\";s:5:\"nginx\";s:4:\"date\";s:29:\"Fri, 31 Aug 2012 12:17:42 GMT\";s:12:\"content-type\";s:23:\"text/xml; charset=UTF-8\";s:10:\"connection\";s:5:\"close\";s:4:\"vary\";s:15:\"Accept-Encoding\";s:10:\"x-pingback\";s:36:\"http://wordpress.org/news/xmlrpc.php\";s:13:\"last-modified\";s:29:\"Fri, 13 Jul 2012 08:18:15 GMT\";s:4:\"x-nc\";s:11:\"HIT luv 139\";}s:5:\"build\";s:14:\"20090627192103\";}',	'no'),
(1996,	0,	'_transient_timeout_feed_mod_ac0b00fe65abe10e0c5b588f3ed8c7ca',	'1346458662',	'no'),
(1997,	0,	'_transient_feed_mod_ac0b00fe65abe10e0c5b588f3ed8c7ca',	'1346415462',	'no'),
(1998,	0,	'_transient_timeout_dash_4077549d03da2e451c8b5f002294ff51',	'1346458662',	'no'),
(1999,	0,	'_transient_dash_4077549d03da2e451c8b5f002294ff51',	'<div class=\"rss-widget\"><ul><li><a class=\'rsswidget\' href=\'http://wordpress.org/news/2012/07/event-organizers-unite/\' title=\'I’m happy to announce the formation of a new official contributor group within the WordPress project for the organizers of in-person events that promote WordPress. Though there are hundreds of people around the globe organizing WordCamps, WordPress meetups, hackathons, free classes and the like, since their “projects” were all happening locally there was nev [&hellip;]\'>Event Organizers Unite!</a> <span class=\"rss-date\">July 13, 2012</span><div class=\'rssSummary\'>I’m happy to announce the formation of a new official contributor group within the WordPress project for the organizers of in-person events that promote WordPress. Though there are hundreds of people around the globe organizing WordCamps, WordPress meetups, hackathons, free classes and the like, since their “projects” were all happening locally there was nev [&hellip;]</div></li><li><a class=\'rsswidget\' href=\'http://wordpress.org/news/2012/06/wordpress-3-4-1/\' title=\'WordPress 3.4.1 is now available for download. WordPress 3.4 has been a very smooth release, and copies are flying off the shelf — 3 million downloads in two weeks! This maintenance release addresses 18 bugs with version 3.4, including: Fixes an issue where a theme’s page templates were sometimes not detected. Addresses problems with some category permalink  [&hellip;]\'>WordPress 3.4.1 Maintenance and Security Release</a> <span class=\"rss-date\">June 27, 2012</span><div class=\'rssSummary\'>WordPress 3.4.1 is now available for download. WordPress 3.4 has been a very smooth release, and copies are flying off the shelf — 3 million downloads in two weeks! This maintenance release addresses 18 bugs with version 3.4, including: Fixes an issue where a theme’s page templates were sometimes not detected. Addresses problems with some category permalink  [&hellip;]</div></li></ul></div>',	'no'),
(2000,	0,	'_transient_timeout_feed_b31e65497fefe7e230773cc6c1a7deec',	'1346458662',	'no'),
(2001,	0,	'_transient_feed_b31e65497fefe7e230773cc6c1a7deec',	'a:4:{s:5:\"child\";a:1:{s:0:\"\";a:1:{s:3:\"rss\";a:1:{i:0;a:6:{s:4:\"data\";s:4:\"\n  \n\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:7:\"version\";s:3:\"2.0\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:1:{s:0:\"\";a:1:{s:7:\"channel\";a:1:{i:0;a:6:{s:4:\"data\";s:33:\"\n    \n    \n    \n    \n    \n    \n  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:3:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:56:\"link:http://calzada-wp.urldock.com/ - Google Blog Search\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:93:\"http://www.google.com/search?ie=utf-8&q=link:http://calzada-wp.urldock.com/&tbm=blg&tbs=sbd:1\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:89:\"Your search - <b>link:http://calzada-wp.urldock.com/</b> - did not match any documents.  \";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:36:\"http://a9.com/-/spec/opensearch/1.1/\";a:3:{s:12:\"totalResults\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"0\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:10:\"startIndex\";a:1:{i:0;a:5:{s:4:\"data\";s:1:\"1\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:12:\"itemsPerPage\";a:1:{i:0;a:5:{s:4:\"data\";s:2:\"10\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}}}}}}}}s:4:\"type\";i:128;s:7:\"headers\";a:9:{s:12:\"content-type\";s:28:\"text/xml; charset=ISO-8859-1\";s:4:\"date\";s:29:\"Fri, 31 Aug 2012 12:17:42 GMT\";s:7:\"expires\";s:2:\"-1\";s:13:\"cache-control\";s:18:\"private, max-age=0\";s:10:\"set-cookie\";a:2:{i:0;s:143:\"PREF=ID=dd72819edb124240:FF=0:TM=1346415462:LM=1346415462:S=HMGrqJbNUWULDask; expires=Sun, 31-Aug-2014 12:17:42 GMT; path=/; domain=.google.com\";i:1;s:212:\"NID=63=Wpu3qxc5kxSEtNqdYdjzABg0CD52W6r0bgkrCsYnYgsxoYhtCx75SGVF0YRTebD4Ode1XvuUngtZsVEf5BQSVv0QjJb3P14h3Y3H0pUrP8dMA-YPXtqU8UHI-Wizf3mQ; expires=Sat, 02-Mar-2013 12:17:42 GMT; path=/; domain=.google.com; HttpOnly\";}s:3:\"p3p\";s:122:\"CP=\"This is not a P3P policy! See http://www.google.com/support/accounts/bin/answer.py?hl=en&answer=151657 for more info.\"\";s:6:\"server\";s:3:\"gws\";s:16:\"x-xss-protection\";s:13:\"1; mode=block\";s:15:\"x-frame-options\";s:10:\"SAMEORIGIN\";}s:5:\"build\";s:14:\"20090627192103\";}',	'no'),
(2002,	0,	'_transient_timeout_feed_mod_b31e65497fefe7e230773cc6c1a7deec',	'1346458662',	'no'),
(2003,	0,	'_transient_feed_mod_b31e65497fefe7e230773cc6c1a7deec',	'1346415462',	'no'),
(2004,	0,	'_transient_timeout_dash_20494a3d90a6669585674ed0eb8dcd8f',	'1346458662',	'no'),
(2005,	0,	'_transient_dash_20494a3d90a6669585674ed0eb8dcd8f',	'<p>This dashboard widget queries <a href=\"http://blogsearch.google.com/\">Google Blog Search</a> so that when another blog links to your site it will show up here. It has found no incoming links&hellip; yet. It&#8217;s okay &#8212; there is no rush.</p>\n',	'no'),
(2006,	0,	'_transient_timeout_feed_a5420c83891a9c88ad2a4f04584a5efc',	'1346458662',	'no'),
(2007,	0,	'_transient_feed_a5420c83891a9c88ad2a4f04584a5efc',	'a:4:{s:5:\"child\";a:1:{s:0:\"\";a:1:{s:3:\"rss\";a:1:{i:0;a:6:{s:4:\"data\";s:3:\"\n	\n\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:7:\"version\";s:3:\"2.0\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:1:{s:0:\"\";a:1:{s:7:\"channel\";a:1:{i:0;a:6:{s:4:\"data\";s:72:\"\n		\n		\n		\n		\n		\n		\n				\n\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n\n	\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:39:\"WordPress Plugins » View: Most Popular\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:51:\"http://wordpress.org/extend/plugins/browse/popular/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:39:\"WordPress Plugins » View: Most Popular\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"language\";a:1:{i:0;a:5:{s:4:\"data\";s:5:\"en-US\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 31 Aug 2012 11:56:09 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:9:\"generator\";a:1:{i:0;a:5:{s:4:\"data\";s:25:\"http://bbpress.org/?v=1.1\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"item\";a:15:{i:0;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:19:\"Google XML Sitemaps\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:70:\"http://wordpress.org/extend/plugins/google-sitemap-generator/#post-132\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 09 Mar 2007 22:31:32 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:40:\"132@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:105:\"This plugin will generate a special XML sitemap which will help search engines to better index your blog.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:4:\"Arne\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:1;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:24:\"Jetpack by WordPress.com\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:55:\"http://wordpress.org/extend/plugins/jetpack/#post-23862\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 20 Jan 2011 02:21:38 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"23862@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:104:\"Supercharge your WordPress site with powerful features previously only available to WordPress.com users.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:24:\"Michael Adams (mdawaffe)\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:2;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:19:\"All in One SEO Pack\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:65:\"http://wordpress.org/extend/plugins/all-in-one-seo-pack/#post-753\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 30 Mar 2007 20:08:18 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:40:\"753@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:86:\"WordPress SEO plugin to automatically optimize your Wordpress blog for Search Engines.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:8:\"uberdose\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:3;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:22:\"WordPress SEO by Yoast\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:60:\"http://wordpress.org/extend/plugins/wordpress-seo/#post-8321\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 01 Jan 2009 20:34:44 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:41:\"8321@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:131:\"Improve your WordPress SEO: Write better content and have a fully optimized WordPress site using the WordPress SEO plugin by Yoast.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:13:\"Joost de Valk\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:4;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:15:\"NextGEN Gallery\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:62:\"http://wordpress.org/extend/plugins/nextgen-gallery/#post-1169\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 23 Apr 2007 20:08:06 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:41:\"1169@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:109:\"NextGEN Gallery is a fully integrated image gallery plugin for WordPress with dozens of options and features.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:9:\"Alex Rabe\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:5;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"Contact Form 7\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:61:\"http://wordpress.org/extend/plugins/contact-form-7/#post-2141\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 02 Aug 2007 12:45:03 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:41:\"2141@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:54:\"Just another contact form plugin. Simple but flexible.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:16:\"Takayuki Miyoshi\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:6;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:7:\"Akismet\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:52:\"http://wordpress.org/extend/plugins/akismet/#post-15\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 09 Mar 2007 22:11:30 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:39:\"15@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:98:\"Akismet checks your comments against the Akismet web service to see if they look like spam or not.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"Matt Mullenweg\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:7;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:11:\"WP-PageNavi\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:57:\"http://wordpress.org/extend/plugins/wp-pagenavi/#post-363\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 09 Mar 2007 23:17:57 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:40:\"363@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:49:\"Adds a more advanced paging navigation interface.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:11:\"Lester Chan\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:8;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:6:\"gtrans\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:54:\"http://wordpress.org/extend/plugins/gtrans/#post-30417\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 22 Sep 2011 11:48:04 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"30417@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"Make your website available to the world using Google Translate\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:7:\"kikadev\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:9;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:18:\"WordPress Importer\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:66:\"http://wordpress.org/extend/plugins/wordpress-importer/#post-18101\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 20 May 2010 17:42:45 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"18101@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:101:\"Import posts, pages, comments, custom fields, categories, tags and more from a WordPress export file.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"Brian Colinger\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:10;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:32:\"Yet Another Related Posts Plugin\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:79:\"http://wordpress.org/extend/plugins/yet-another-related-posts-plugin/#post-2769\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Wed, 02 Jan 2008 13:05:03 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:41:\"2769@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:120:\"Display a list of related entries on your site and feeds based on a unique algorithm. Now with custom post type support!\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:35:\"mitcho (Michael Yoshitaka Erlewine)\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:11;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:24:\"Fast Secure Contact Form\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"http://wordpress.org/extend/plugins/si-contact-form/#post-12636\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 27 Aug 2009 01:20:04 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"12636@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:131:\"A super customizable contact form that lets your visitors send you email. Blocks all automated spammers. No templates to mess with.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:12:\"Mike Challis\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:12;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"WP Super Cache\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:61:\"http://wordpress.org/extend/plugins/wp-super-cache/#post-2572\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 05 Nov 2007 11:40:04 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:41:\"2572@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:73:\"A very fast caching engine for WordPress that produces static html files.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:16:\"Donncha O Caoimh\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:13;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:19:\"Spam Free WordPress\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:67:\"http://wordpress.org/extend/plugins/spam-free-wordpress/#post-27649\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 21 Jun 2011 10:41:14 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"27649@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:113:\"Todd Lahman&#039;s comment spam blocking plugin that blocks 100% of the automated spam with zero false positives.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:11:\"Todd Lahman\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:14;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:33:\"WooCommerce - excelling eCommerce\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:59:\"http://wordpress.org/extend/plugins/woocommerce/#post-29860\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 05 Sep 2011 08:13:36 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"29860@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:97:\"WooCommerce is a powerful, extendable eCommerce plugin that helps you sell anything. Beautifully.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:9:\"WooThemes\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}}}s:27:\"http://www.w3.org/2005/Atom\";a:1:{s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:1:{s:0:\"\";a:3:{s:4:\"href\";s:52:\"http://wordpress.org/extend/plugins/rss/view/popular\";s:3:\"rel\";s:4:\"self\";s:4:\"type\";s:19:\"application/rss+xml\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}}}}}}}}s:4:\"type\";i:128;s:7:\"headers\";a:10:{s:6:\"server\";s:5:\"nginx\";s:4:\"date\";s:29:\"Fri, 31 Aug 2012 12:17:42 GMT\";s:12:\"content-type\";s:23:\"text/xml; charset=UTF-8\";s:10:\"connection\";s:5:\"close\";s:4:\"vary\";s:15:\"Accept-Encoding\";s:7:\"expires\";s:29:\"Fri, 31 Aug 2012 12:31:09 GMT\";s:13:\"cache-control\";s:0:\"\";s:6:\"pragma\";s:0:\"\";s:13:\"last-modified\";s:31:\"Fri, 31 Aug 2012 11:56:09 +0000\";s:4:\"x-nc\";s:11:\"HIT luv 139\";}s:5:\"build\";s:14:\"20090627192103\";}',	'no'),
(2008,	0,	'_transient_timeout_feed_mod_a5420c83891a9c88ad2a4f04584a5efc',	'1346458662',	'no'),
(2009,	0,	'_transient_feed_mod_a5420c83891a9c88ad2a4f04584a5efc',	'1346415462',	'no'),
(2010,	0,	'_transient_timeout_feed_867bd5c64f85878d03a060509cd2f92c',	'1346458662',	'no'),
(2011,	0,	'_transient_feed_867bd5c64f85878d03a060509cd2f92c',	'a:4:{s:5:\"child\";a:1:{s:0:\"\";a:1:{s:3:\"rss\";a:1:{i:0;a:6:{s:4:\"data\";s:3:\"\n\n\n\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:7:\"version\";s:3:\"2.0\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:1:{s:0:\"\";a:1:{s:7:\"channel\";a:1:{i:0;a:6:{s:4:\"data\";s:61:\"\n	\n	\n	\n	\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:1:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:16:\"WordPress Planet\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://planet.wordpress.org/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"language\";a:1:{i:0;a:5:{s:4:\"data\";s:2:\"en\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:47:\"WordPress Planet - http://planet.wordpress.org/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"item\";a:50:{i:0;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:59:\"Weblog Tools Collection: WordPress Plugin Releases for 8/29\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:41:\"http://weblogtoolscollection.com/?p=11884\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:73:\"http://feedproxy.google.com/~r/weblogtoolscollection/UXMP/~3/lu0a0iZ-0H8/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:1193:\"<h3>New plugins</h3>\n<p><a href=\"http://crosstec.de/en/wordpress-forms-download.html\"><strong>BreezingForms</strong></a> is an enterprise form builder.</p>\n<p><a href=\"http://www.moodthingy.com/\"><strong>MoodThingy</strong></a> is a plugin that any blogger can use to track the emotional feedback of an individual blog post or article.</p>\n<h3>Updated plugins</h3>\n<p><a href=\"http://jetpack.me/\"><strong>Jetpack</strong></a> allows you to supercharge your WordPress site with powerful features previously only available to WordPress.com users.</p>\n<p><a href=\"http://wordpress.org/extend/plugins/statpress-community-formerly-statcomm/\"><strong>StatComm</strong></a> provides realtime statistics on your blog, collecting information about visitors, spiders, search keywords, feeds, browsers, OS and more.</p>\n<p><a href=\"http://wordpress.org/extend/plugins/theme-check/\"><strong>Theme-Check</strong></a> allows you to run checks on the current theme before uploading to WordPress. This plugin uses the same API and is kept more or less in sync with the WordPress.org uploader tool.</p>\n<img src=\"http://feeds.feedburner.com/~r/weblogtoolscollection/UXMP/~4/lu0a0iZ-0H8\" height=\"1\" width=\"1\" />\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Wed, 29 Aug 2012 15:00:06 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:5:\"James\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:1;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:48:\"WordPress.tv: Adii Pienaar: The business of code\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12970\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:65:\"http://wordpress.tv/2012/08/28/adii-pienaar-the-business-of-code/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:650:\"<div id=\"v-L83k1ACk-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12970/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12970/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12970&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/28/adii-pienaar-the-business-of-code/\"><img alt=\"Adii Pienaar: The business of code\" src=\"http://videos.videopress.com/L83k1ACk/the-business-of-code_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 28 Aug 2012 19:50:31 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:2;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:44:\"WordPress.tv: Ryan Imel: The state of themes\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12978\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:61:\"http://wordpress.tv/2012/08/28/ryan-imel-the-state-of-themes/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:641:\"<div id=\"v-vatFaXvH-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12978/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12978/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12978&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/28/ryan-imel-the-state-of-themes/\"><img alt=\"Ryan Imel: The state of themes\" src=\"http://videos.videopress.com/vatFaXvH/the-state-of-themes_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 28 Aug 2012 13:49:59 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:3;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:36:\"Alex King: WordCamp Albuquerque 2012\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://alexking.org/?p=14277\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:61:\"http://alexking.org/blog/2012/08/27/wordcamp-albuquerque-2012\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:4755:\"<p>\n<a href=\"http://alexking.org/blog/2012/08/27/wordcamp-albuquerque-2012/paa-ko-ridge\" title=\"Paa Ko Ridge\"><img width=\"160\" height=\"120\" src=\"http://alexking.org/wp-content/uploads/2012/08/001-20120824-IMG_2582-160x120.jpg\" class=\"attachment-thumb-img\" alt=\"Paa Ko Ridge\" title=\"Paa Ko Ridge\" /></a>\n<a href=\"http://alexking.org/blog/2012/08/27/wordcamp-albuquerque-2012/cibola-national-forest\" title=\"Cibola National Forest\"><img width=\"160\" height=\"120\" src=\"http://alexking.org/wp-content/uploads/2012/08/002-20120826-IMG_2586-160x120.jpg\" class=\"attachment-thumb-img\" alt=\"Cibola National Forest\" title=\"Cibola National Forest\" /></a>\n<a href=\"http://alexking.org/blog/2012/08/27/wordcamp-albuquerque-2012/wheels-at-the-bottom\" title=\"Wheels at the Bottom\"><img width=\"160\" height=\"120\" src=\"http://alexking.org/wp-content/uploads/2012/08/003-20120826-IMG_2584-160x120.jpg\" class=\"attachment-thumb-img\" alt=\"Wheels at the Bottom\" title=\"Wheels at the Bottom\" /></a>\n<a href=\"http://alexking.org/blog/2012/08/27/wordcamp-albuquerque-2012/heading-up\" title=\"Heading Up\"><img width=\"160\" height=\"120\" src=\"http://alexking.org/wp-content/uploads/2012/08/004-20120826-IMG_2588-160x120.jpg\" class=\"attachment-thumb-img\" alt=\"Heading Up\" title=\"Heading Up\" /></a>\n<a href=\"http://alexking.org/blog/2012/08/27/wordcamp-albuquerque-2012/halfway\" title=\"Halfway\"><img width=\"160\" height=\"120\" src=\"http://alexking.org/wp-content/uploads/2012/08/005-20120826-IMG_2591-160x120.jpg\" class=\"attachment-thumb-img\" alt=\"Halfway\" title=\"Halfway\" /></a>\n<a href=\"http://alexking.org/blog/2012/08/27/wordcamp-albuquerque-2012/100ft-tall-trees\" title=\"100+ft Tall Trees\"><img width=\"160\" height=\"120\" src=\"http://alexking.org/wp-content/uploads/2012/08/006-20120826-IMG_2598-160x120.jpg\" class=\"attachment-thumb-img\" alt=\"100+ft Tall Trees\" title=\"100+ft Tall Trees\" /></a>\n<a href=\"http://alexking.org/blog/2012/08/27/wordcamp-albuquerque-2012/view-from-the-top\" title=\"View from the Top\"><img width=\"160\" height=\"120\" src=\"http://alexking.org/wp-content/uploads/2012/08/007-20120826-IMG_2599-160x120.jpg\" class=\"attachment-thumb-img\" alt=\"View from the Top\" title=\"View from the Top\" /></a>\n<a href=\"http://alexking.org/blog/2012/08/27/wordcamp-albuquerque-2012/wildflowers\" title=\"Wildflowers\"><img width=\"160\" height=\"120\" src=\"http://alexking.org/wp-content/uploads/2012/08/008-20120826-IMG_2600-160x120.jpg\" class=\"attachment-thumb-img\" alt=\"Wildflowers\" title=\"Wildflowers\" /></a>\n<a href=\"http://alexking.org/blog/2012/08/27/wordcamp-albuquerque-2012/wheels-at-the-top\" title=\"Wheels at the Top\"><img width=\"160\" height=\"120\" src=\"http://alexking.org/wp-content/uploads/2012/08/009-20120826-IMG_2604-160x120.jpg\" class=\"attachment-thumb-img\" alt=\"Wheels at the Top\" title=\"Wheels at the Top\" /></a>\n<a href=\"http://alexking.org/blog/2012/08/27/wordcamp-albuquerque-2012/sandia-mountains\" title=\"Sandia Mountains\"><img width=\"160\" height=\"120\" src=\"http://alexking.org/wp-content/uploads/2012/08/010-20120826-IMG_2590-160x120.jpg\" class=\"attachment-thumb-img\" alt=\"Sandia Mountains\" title=\"Sandia Mountains\" /></a>\n<a href=\"http://alexking.org/blog/2012/08/27/wordcamp-albuquerque-2012/connected\" title=\"Connected\"><img width=\"160\" height=\"120\" src=\"http://alexking.org/wp-content/uploads/2012/08/011-20120826-IMG_2608-160x120.jpg\" class=\"attachment-thumb-img\" alt=\"Connected\" title=\"Connected\" /></a>\n</p>\n<p>This past weekend I enjoyed my first trip to New Mexico to attend <a href=\"http://2012.albuquerque.wordcamp.org/\">WordCamp Albuquerque</a>. I&#8217;m not sure why it took me eight years after moving to Colorado to visit my neighboring state to the south, but WordCamp was a great excuse to get down for a visit.</p>\n<p>My thanks to the great folks in the New Mexico WordPress community for being wonderful hosts; in particular to <a href=\"http://karenalma.com/\">Karen Arnold</a>, <a href=\"http://www.evowebdev.com/about\">Ray Gulick</a> and the other WordCamp organizers for putting together a great event. Also, a particular thank you to my fellow speakers for their enjoyable camaraderie, discussion and debate.</p>\n<p>I thoroughly enjoyed giving <a href=\"http://2012.albuquerque.wordcamp.org/session/core-competency-things-you-might-not-know-about-how-wordpress-works-but-should/\">my presentation</a> (which I also plan to present at <a href=\"http://2012.denver.wordcamp.org/\">WordCamp Denver</a> in a few months) and was gratified to receive positive feedback from both long time WordPress developers and folks just getting their feet wet.</p>\n<p>I bookended the trip with a round of golf on Friday and a trip up the <a href=\"http://www.sandiapeak.com/\">Sandia Peak Tramway</a> on Sunday. Two beautiful places that demanded I take a few photos.</p>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 28 Aug 2012 05:32:11 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:4:\"Alex\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:4;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"Weblog Tools Collection: WordPress Theme Releases for 8/27\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:41:\"http://weblogtoolscollection.com/?p=11878\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:73:\"http://feedproxy.google.com/~r/weblogtoolscollection/UXMP/~3/TIanviRwbTA/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:881:\"<p><img class=\"alignnone size-full wp-image-11879\" title=\"blackmesa\" src=\"http://weblogtoolscollection.com/wp-content/uploads/2012/08/blackmesa.jpg\" alt=\"\" width=\"150\" height=\"113\" /></p>\n<p><a href=\"http://wordpress.org/extend/themes/blackmesa\"><strong>BlackMesa</strong></a> is a graphically intense theme with alternating, semitransparent headline-boxes, parallax moving backgrounds and beautiful text styles.</p>\n<p><img class=\"alignnone size-full wp-image-11880\" title=\"picturesque\" src=\"http://weblogtoolscollection.com/wp-content/uploads/2012/08/picturesque.jpg\" alt=\"\" width=\"150\" height=\"113\" /></p>\n<p><a href=\"http://wordpress.org/extend/themes/picturesque\"><strong>Picturesque</strong></a> is an elegant photoblogging theme that emphasizes your photography.</p>\n<img src=\"http://feeds.feedburner.com/~r/weblogtoolscollection/UXMP/~4/TIanviRwbTA\" height=\"1\" width=\"1\" />\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 27 Aug 2012 22:00:06 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:5:\"James\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:5;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:80:\"WordPress.tv: Andy Peatling: Mistakes I made using JQuery, and how to avoid them\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12961\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:96:\"http://wordpress.tv/2012/08/27/andy-peatling-mistakes-i-made-using-jquery-and-how-to-avoid-them/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:743:\"<div id=\"v-4LvqQkSN-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12961/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12961/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12961&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/27/andy-peatling-mistakes-i-made-using-jquery-and-how-to-avoid-them/\"><img alt=\"Andy Peatling: Mistakes I made using JQuery, and how to avoid them\" src=\"http://videos.videopress.com/4LvqQkSN/mistakes-i-made-using-jquery-and-how-to-avoid-them_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 27 Aug 2012 19:49:34 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:6;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:51:\"WordPress.tv: Michael Fields: Extendable Extensions\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12999\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:68:\"http://wordpress.tv/2012/08/27/michael-fields-extendable-extensions/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:669:\"<div id=\"v-2trWzass-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12999/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12999/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12999&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/27/michael-fields-extendable-extensions/\"><img alt=\"Michael Fields: Extendable Extensions\" src=\"http://videos.videopress.com/2trWzass/wcsf2012_fisher_02_michael_fields_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 27 Aug 2012 13:49:14 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:7;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:62:\"WordPress.tv: Chris Coyier: 10 Things to make your site faster\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12940\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:79:\"http://wordpress.tv/2012/08/26/chris-coyier-10-things-to-make-your-site-faster/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:693:\"<div id=\"v-ewwum1Wg-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12940/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12940/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12940&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/26/chris-coyier-10-things-to-make-your-site-faster/\"><img alt=\"Chris Coyier: 10 Things to make your site faster.\" src=\"http://videos.videopress.com/ewwum1Wg/10-things-to-make-your-site-faster_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 27 Aug 2012 03:48:42 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:8;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:59:\"WordPress.tv: Leo Babauta: Building an audience as a writer\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12943\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:76:\"http://wordpress.tv/2012/08/26/leo-babauta-building-an-audience-as-a-writer/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:685:\"<div id=\"v-jZobhHxF-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12943/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12943/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12943&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/26/leo-babauta-building-an-audience-as-a-writer/\"><img alt=\"Leo Babauta: Building an audience as a writer.\" src=\"http://videos.videopress.com/jZobhHxF/building-an-audience-as-a-writer_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Sun, 26 Aug 2012 19:48:21 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:9;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:43:\"Weblog Tools Collection: How Often You Blog\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:41:\"http://weblogtoolscollection.com/?p=11855\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:73:\"http://feedproxy.google.com/~r/weblogtoolscollection/UXMP/~3/oa1ruc7T32Q/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:1199:\"<p>Last month, we asked, <a href=\"http://weblogtoolscollection.com/archives/2012/07/19/how-often-do-you-blog/\">how often do you blog?</a> The responses were spread out quite a bit, with 28% blogging 1 to 3 times a month, 26% blogging every day, 24% blogging 1 to 3 times a week, 13% blogging 4 to 6 times a week, and 8% blogging less than once a month.</p>\n<p>I&#8217;m quite surprised to see the near tie between 1 to 3 times a month and every day, two frequencies which a quite different indeed. Rest-assured, most of you are blogging more than once a week, which is great news! You should enjoy blogging, and nothing says &#8220;I enjoy Blogging!&#8221; more than cranking out a few posts every week. Blogging shouldn&#8217;t be so difficult that you put it off. If you do, you&#8217;re doing it wrong. Try to find some little things to share, like a video you enjoyed watching or an article you enjoyed reading. The more you blog, the better you&#8217;ll get, and the more fun you&#8217;ll have.</p>\n<p>So, if you didn&#8217;t have a chance to tell us before, how often do you blog?</p>\n<img src=\"http://feeds.feedburner.com/~r/weblogtoolscollection/UXMP/~4/oa1ruc7T32Q\" height=\"1\" width=\"1\" />\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Sun, 26 Aug 2012 14:00:22 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:5:\"James\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:10;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:55:\"WordPress.tv: Sara Cannon: Designing for the modern web\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12946\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:72:\"http://wordpress.tv/2012/08/26/sara-cannon-designing-for-the-modern-web/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:672:\"<div id=\"v-MOyBk2xy-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12946/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12946/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12946&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/26/sara-cannon-designing-for-the-modern-web/\"><img alt=\"Sara Cannon: Designing for the modern web\" src=\"http://videos.videopress.com/MOyBk2xy/designing-for-the-modern-web_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Sun, 26 Aug 2012 13:47:54 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:11;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:72:\"WordPress.tv: Pete Davies: How to run a small country using the P2 theme\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12958\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:89:\"http://wordpress.tv/2012/08/25/pete-davies-how-to-run-a-small-country-using-the-p2-theme/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:723:\"<div id=\"v-ufvBU34X-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12958/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12958/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12958&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/25/pete-davies-how-to-run-a-small-country-using-the-p2-theme/\"><img alt=\"Pete Davies: How to run a small country using the P2 theme\" src=\"http://videos.videopress.com/ufvBU34X/how-to-run-a-small-country-using-the-p2-theme_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Sun, 26 Aug 2012 03:47:02 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:12;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:96:\"WordPress.tv: Nikolay Bachiyski: Selected pieces from “Elements of Style” translated to code\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12967\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:107:\"http://wordpress.tv/2012/08/25/nikolay-bachiyski-selected-pieces-from-elements-of-style-translated-to-code/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:797:\"<div id=\"v-6UXZJx29-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12967/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12967/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12967&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/25/nikolay-bachiyski-selected-pieces-from-elements-of-style-translated-to-code/\"><img alt=\"Nikolay Bachiyski: Selected pieces from &#8220;Elements of style&#8221; translated to code\" src=\"http://videos.videopress.com/6UXZJx29/selected-pieces-from-e2809celements-of-stylee2809d-translated-to-code_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Sat, 25 Aug 2012 19:46:40 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:13;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:59:\"Weblog Tools Collection: WordPress Plugin Releases for 8/25\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:41:\"http://weblogtoolscollection.com/?p=11863\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:73:\"http://feedproxy.google.com/~r/weblogtoolscollection/UXMP/~3/YkLQgtzxkmw/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:1136:\"<h3>New plugins</h3>\n<p><a href=\"http://wordpress.org/extend/plugins/polylang-simple-google-connect-compatibility/\"><strong>Polylang &#8211; Simple Google Connect compatibility</strong></a> ensures smooth operation when both Polylang and Simple Google Connect are active.</p>\n<p><a href=\"http://wordpress.org/extend/plugins/pushover-notifications/\"><strong>Pushover Notifications</strong></a> allows your WordPress blog to send push notifications for events happening on your blog straight to your iOS/Android device.</p>\n<h3>Updated plugins</h3>\n<p><a href=\"http://wordpress.org/extend/plugins/wp-conditional-captcha/\"><strong>Conditional CAPTCHA</strong></a> asks commenters to complete a simple CAPTCHA if Akismet thinks their comment is spam, eliminating false positives.</p>\n<p><a href=\"http://ottopress.com/wordpress-plugins/simple-facebook-connect/\"><strong>Simple Facebook Connect</strong></a> is a framework and series of sub-systems that let you add any sort of Facebook functionality you like to a WordPress blog.</p>\n<img src=\"http://feeds.feedburner.com/~r/weblogtoolscollection/UXMP/~4/YkLQgtzxkmw\" height=\"1\" width=\"1\" />\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Sat, 25 Aug 2012 14:45:04 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:5:\"James\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:14;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:70:\"WordPress.tv: John James Jacoby: bbPress: What’s all the buzz about?\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12988\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:82:\"http://wordpress.tv/2012/08/25/john-james-jacoby-bbpress-whats-all-the-buzz-about/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:703:\"<div id=\"v-jsRfb9hJ-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12988/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12988/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12988&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/25/john-james-jacoby-bbpress-whats-all-the-buzz-about/\"><img alt=\"John James Jacoby: BBpress: What&#8217;s all the buzz about?\" src=\"http://videos.videopress.com/jsRfb9hJ/wcsf2012_fisher_03_john_jacoby_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Sat, 25 Aug 2012 13:46:17 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:15;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:49:\"WordPress.tv: Paul Gibbs: The state of BuddyPress\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12991\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:66:\"http://wordpress.tv/2012/08/24/paul-gibbs-the-state-of-buddypress/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:661:\"<div id=\"v-YpZCYhzN-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12991/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12991/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12991&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/24/paul-gibbs-the-state-of-buddypress/\"><img alt=\"Paul Gibbs: The state of Buddypress\" src=\"http://videos.videopress.com/YpZCYhzN/wcsf2012_fisher_04_paul_gibbs_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Sat, 25 Aug 2012 03:45:55 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:16;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:52:\"WordPress.tv: James Pearce: Building a brave new web\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=13008\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:69:\"http://wordpress.tv/2012/08/24/james-pearce-building-a-brave-new-web/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:669:\"<div id=\"v-NRl9d1h6-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/13008/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/13008/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=13008&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/24/james-pearce-building-a-brave-new-web/\"><img alt=\"James Pearce: Building a brave new web\" src=\"http://videos.videopress.com/NRl9d1h6/wcsf2012_fisher_04_james_pearce_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 24 Aug 2012 21:45:29 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:17;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:53:\"WordPress.tv: Daniel Bachhuber: Zen of WP Development\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=13005\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:70:\"http://wordpress.tv/2012/08/24/daniel-bachhuber-zen-of-wp-development/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:675:\"<div id=\"v-JNcCUvAY-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/13005/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/13005/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=13005&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/24/daniel-bachhuber-zen-of-wp-development/\"><img alt=\"Daniel Bachhuber: Zen of WP Development\" src=\"http://videos.videopress.com/JNcCUvAY/wcsf2012_fisher_03_daniel_bachhuber_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 24 Aug 2012 16:42:10 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:18;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"Weblog Tools Collection: WordPress Theme Releases for 8/23\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:41:\"http://weblogtoolscollection.com/?p=11858\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:73:\"http://feedproxy.google.com/~r/weblogtoolscollection/UXMP/~3/6nx76h6z6KY/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:1144:\"<p><img class=\"alignnone size-full wp-image-11860\" title=\"dithewriter\" src=\"http://weblogtoolscollection.com/wp-content/uploads/2012/08/dithewriter.jpg\" alt=\"\" width=\"150\" height=\"113\" /></p>\n<p><a href=\"http://www.myokyawhtun.com/themes/di-the-writer\"><strong>Di the Writer</strong></a> is created for those who love writing with a minimalist style layout.</p>\n<p><img class=\"alignnone size-full wp-image-11859\" title=\"newsworthy\" src=\"http://weblogtoolscollection.com/wp-content/uploads/2012/08/newsworthy.jpg\" alt=\"\" width=\"150\" height=\"113\" /></p>\n<p><a href=\"http://wordpress.org/extend/themes/newsworthy\"><strong>Newsworthy</strong></a> is a simple theme with a cool design and beautiful color accents.</p>\n<p><img class=\"alignnone size-full wp-image-11861\" title=\"path\" src=\"http://weblogtoolscollection.com/wp-content/uploads/2012/08/path.jpg\" alt=\"\" width=\"150\" height=\"113\" /></p>\n<p><a href=\"http://wordpress.org/extend/themes/path\"><strong>Path</strong></a> is designed for multiauthor blogs and magazine style websites.</p>\n<img src=\"http://feeds.feedburner.com/~r/weblogtoolscollection/UXMP/~4/6nx76h6z6KY\" height=\"1\" width=\"1\" />\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 23 Aug 2012 15:00:06 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:5:\"James\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:19;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:50:\"Weblog Tools Collection: What you are Blogging For\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:41:\"http://weblogtoolscollection.com/?p=11852\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:73:\"http://feedproxy.google.com/~r/weblogtoolscollection/UXMP/~3/ycxCFI7v1S4/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:937:\"<p>Last month, we asked, <a href=\"http://weblogtoolscollection.com/archives/2012/07/17/what-do-you-blog-for/\">what do you blog for?</a> The break-down for the poll was very simple, either Personal, Business, or both. In the final tally after a month-long run, 45% of you blogged for both, 39% for Personal, and only 16% for Business.</p>\n<p>Putting those three reasons aside, one trend did emerge in the comments. Most of you blog because it&#8217;s fun. Sure, some of you blog for business and rarely have time for personal blogging, but it&#8217;s still fun, and that&#8217;s just great because if you consider blogging to be a chore, you&#8217;re doing it wrong. Even if it&#8217;s just for business, it should still be fun.</p>\n<p>So, if you didn&#8217;t have a chance to earlier, let us know here. What do you blog for?</p>\n<img src=\"http://feeds.feedburner.com/~r/weblogtoolscollection/UXMP/~4/ycxCFI7v1S4\" height=\"1\" width=\"1\" />\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Wed, 22 Aug 2012 15:15:07 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:5:\"James\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:20;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:69:\"WordPress.tv: Liz Manicatide: My Favorite Twenty Eleven Display Hacks\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12470\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:86:\"http://wordpress.tv/2012/08/21/liz-manicatide-my-favorite-twenty-eleven-display-hacks/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:695:\"<div id=\"v-uMSZPNat-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12470/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12470/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12470&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/21/liz-manicatide-my-favorite-twenty-eleven-display-hacks/\"><img alt=\"My Favorite Twenty Eleven Display Hacks\" src=\"http://videos.videopress.com/uMSZPNat/my-favorite-twenty-eleven-display-hacks_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Wed, 22 Aug 2012 01:54:18 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:15:\"WordCamp Boston\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:21;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:32:\"Matt: State of Password Cracking\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:21:\"http://ma.tt/?p=41771\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:48:\"http://ma.tt/2012/08/state-of-password-cracking/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:299:\"<p><a href=\"http://arstechnica.com/security/2012/08/passwords-under-assault/\">Why passwords have never been weaker—and crackers have never been stronger</a>, a great article from Ars Technica. Also emphasizes why two-factor authentication is going to become more important in the coming years.</p>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 21 Aug 2012 21:07:34 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:4:\"Matt\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:22;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:86:\"WordPress.tv: Aaron Jorbin: Developing An Automated Workflow For Front End Development\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12487\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:104:\"http://wordpress.tv/2012/08/21/aaron-jorbin-developing-an-automated-workflow-for-fronte-end-development/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:751:\"<div id=\"v-MaPvICW3-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12487/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12487/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12487&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/21/aaron-jorbin-developing-an-automated-workflow-for-fronte-end-development/\"><img alt=\"Developing an Automated Workflow for Front end Development\" src=\"http://videos.videopress.com/MaPvICW3/developing-an-automated-workflow-for-front-end-development_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 21 Aug 2012 19:04:43 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:15:\"WordCamp Boston\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:23;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:80:\"WordPress.tv: Randy Hoyt: Custom post type relationships: Subordinate post types\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12994\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:96:\"http://wordpress.tv/2012/08/21/randy-hoyt-custom-post-type-relationships-subordinate-post-types/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:723:\"<div id=\"v-skcpAH28-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12994/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12994/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12994&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/21/randy-hoyt-custom-post-type-relationships-subordinate-post-types/\"><img alt=\"Randy Hoyt: Custom post type relationships: Subordinate post types\" src=\"http://videos.videopress.com/skcpAH28/wcsf2012_fisher_01_randy_hoyt1_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 21 Aug 2012 18:38:36 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:24;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:74:\"WordPress.tv: Mika Epstein: Getting involved – Log on, jump in, hang out\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=13011\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:85:\"http://wordpress.tv/2012/08/21/mika-epstein-getting-involved-log-on-jump-in-hang-out/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:711:\"<div id=\"v-YhblAsZZ-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/13011/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/13011/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=13011&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/21/mika-epstein-getting-involved-log-on-jump-in-hang-out/\"><img alt=\"Mika Epstein: Getting involved &#8211; Log on, jump in, hang out\" src=\"http://videos.videopress.com/YhblAsZZ/wcsf2012_fisher_05_mika_epstein_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 21 Aug 2012 18:37:32 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:25;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:71:\"WordPress.tv: Trevor Trimm: Do WordPressers have the freedom of speech?\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=13014\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:87:\"http://wordpress.tv/2012/08/21/trevor-trimm-do-wordpressers-have-the-freedom-of-speech/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:702:\"<div id=\"v-QiSzmwdU-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/13014/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/13014/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=13014&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/21/trevor-trimm-do-wordpressers-have-the-freedom-of-speech/\"><img alt=\"Trevor Trimm: Do wordpressers have freedom of speech?\" src=\"http://videos.videopress.com/QiSzmwdU/wcsf2012_fisher_06_trevor_trimm_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 21 Aug 2012 18:36:14 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:26;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:83:\"WordPress.tv: Matt Perry: Dude, we are that frog : The story of grist and WordPress\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=13018\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:97:\"http://wordpress.tv/2012/08/21/matt-perry-dude-we-are-that-frog-the-story-of-grist-and-wordpress/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:726:\"<div id=\"v-RuwzBpzt-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/13018/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/13018/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=13018&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/21/matt-perry-dude-we-are-that-frog-the-story-of-grist-and-wordpress/\"><img alt=\"Matt Perry: Dude, we are that frog : The story of grist and wordpress\" src=\"http://videos.videopress.com/RuwzBpzt/wcsf2012_fisher_07_matt_perry_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 21 Aug 2012 18:34:32 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:27;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:99:\"WordPress.tv: Noel Tock: Happytables: Lessons learned creating a WordPress solution for restaurants\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=13021\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:115:\"http://wordpress.tv/2012/08/21/noel-tock-happytables-lessons-learned-creating-a-wordpress-solution-for-restaurants/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:759:\"<div id=\"v-jMXhfXPW-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/13021/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/13021/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=13021&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/21/noel-tock-happytables-lessons-learned-creating-a-wordpress-solution-for-restaurants/\"><img alt=\"Noel Tock: Happytables: Lessons learned creating a wordpress solution for restaurants\" src=\"http://videos.videopress.com/jMXhfXPW/wcsf2012_fisher_08_noel_tock_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 21 Aug 2012 18:31:38 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:28;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:100:\"WordPress.tv: Chuck Longanecker: How we built and grew the hello bar web application using WordPress\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=13024\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:117:\"http://wordpress.tv/2012/08/21/chuck-longanecker-how-we-built-and-grew-the-hello-bar-web-application-using-wordpress/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:770:\"<div id=\"v-zC0Nczeo-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/13024/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/13024/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=13024&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/21/chuck-longanecker-how-we-built-and-grew-the-hello-bar-web-application-using-wordpress/\"><img alt=\"Chuck Longanecker: How we built and grew the hello bar web application using WordPress\" src=\"http://videos.videopress.com/zC0Nczeo/wcsf2012_fisher_09_chuck_longanecker_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 21 Aug 2012 18:30:40 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:29;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:72:\"WordPress.tv: Scott Kingsley Clark: All-you-can-eat content-types buffet\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=13027\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:89:\"http://wordpress.tv/2012/08/21/scott-kingsley-clark-all-you-can-eat-content-types-buffet/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:717:\"<div id=\"v-voa65r9T-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/13027/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/13027/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=13027&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/21/scott-kingsley-clark-all-you-can-eat-content-types-buffet/\"><img alt=\"Scott Kingsley Clark: All-you-can-eat content-types buffet\" src=\"http://videos.videopress.com/voa65r9T/wcsf2012_fisher_10_scott_kingsley_clark_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 21 Aug 2012 18:29:06 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:30;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:83:\"WordPress.tv: Ilya Grigorik: Measure all things! Automate performance optimization!\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=13054\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:98:\"http://wordpress.tv/2012/08/21/ilya-grigorik-measure-all-things-automate-performance-optimization/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:754:\"<div id=\"v-LDorA4XW-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/13054/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/13054/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=13054&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/21/ilya-grigorik-measure-all-things-automate-performance-optimization/\"><img alt=\"Ilya Grigorik: Measure all things! Automate performance optimization!\" src=\"http://videos.videopress.com/LDorA4XW/measure-all-the-things-automate-performance-optimization_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 21 Aug 2012 18:27:54 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"blazestreaming\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:31;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:45:\"WordPress.tv: Justin Briggs: SEO for Bloggers\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12064\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:62:\"http://wordpress.tv/2012/08/21/justin-briggs-seo-for-bloggers/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:653:\"<div id=\"v-j2EE4QT9-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12064/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12064/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12064&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/21/justin-briggs-seo-for-bloggers/\"><img alt=\"SEO_for_bloggers_Justin_Briggs\" src=\"http://videos.videopress.com/j2EE4QT9/seo_for_bloggers_justin_briggs_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 21 Aug 2012 18:24:58 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:13:\"Grant Landram\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:32;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:59:\"Weblog Tools Collection: WordPress Plugin Releases for 8/21\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:41:\"http://weblogtoolscollection.com/?p=11848\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:73:\"http://feedproxy.google.com/~r/weblogtoolscollection/UXMP/~3/guk--bqOu1g/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:850:\"<h3>New plugins</h3>\n<p><a href=\"http://wordpress.org/extend/plugins/drag-drop-featured-image/\"><strong>Drag &amp; Drop Featured Image</strong></a> replaces the default &#8220;Set featured image&#8221; metabox with a drop zone for faster uploads.</p>\n<p><a href=\"http://wordpress.org/extend/plugins/oembed-in-comments/\"><strong>oEmbed in Comments</strong></a> adds oEmbed support to comments.</p>\n<h3>Updated plugins</h3>\n<p><a href=\"http://scribu.net/wordpress/posts-to-posts\"><strong>Posts 2 Posts</strong></a> allows you to create many-to-many connections between posts of all kinds.</p>\n<p><a href=\"http://www.duechiacchiere.it/wp-slimstat\"><strong>WP SlimStat</strong></a> is a simple but powerful web analytics plugin for WordPress.</p>\n<img src=\"http://feeds.feedburner.com/~r/weblogtoolscollection/UXMP/~4/guk--bqOu1g\" height=\"1\" width=\"1\" />\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 21 Aug 2012 15:00:08 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:5:\"James\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:33;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"WordPress.tv: Dave Ross: Microdata for SEO\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12490\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:59:\"http://wordpress.tv/2012/08/21/dave-ross-microdata-for-seo/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:624:\"<div id=\"v-E7XUgaJt-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12490/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12490/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12490&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/21/dave-ross-microdata-for-seo/\"><img alt=\"Microdata for SEO\" src=\"http://videos.videopress.com/E7XUgaJt/microdata-for-seo_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 21 Aug 2012 13:05:54 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:15:\"WordCamp Boston\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:34;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:54:\"WordPress.tv: Jake Goldman: Enterprise-class WordPress\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12492\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:71:\"http://wordpress.tv/2012/08/20/jake-goldman-enterprise-class-wordpress/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:654:\"<div id=\"v-vjawLLrC-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12492/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12492/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12492&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/20/jake-goldman-enterprise-class-wordpress/\"><img alt=\"Enterprize-class WordPress\" src=\"http://videos.videopress.com/vjawLLrC/enterprize-class-wordpress_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 21 Aug 2012 01:08:08 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:15:\"WordCamp Boston\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:35;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"WordPress.tv: Shane Pearlman: The Art & Science of Premium\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12432\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:73:\"http://wordpress.tv/2012/08/20/shane-pearlman-the-art-science-of-premium/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:664:\"<div id=\"v-yhA1fI9W-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12432/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12432/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12432&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/20/shane-pearlman-the-art-science-of-premium/\"><img alt=\"The_Art_and_Science_of_Premium\" src=\"http://videos.videopress.com/yhA1fI9W/the_art_and_science_of_premium_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 21 Aug 2012 01:04:19 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:13:\"Grant Landram\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:36;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:69:\"WordPress.tv: Kelli Wise: Using WordPress as Your Company’s Website\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12071\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:83:\"http://wordpress.tv/2012/08/20/kelli-wise-using-wordpress-as-your-companys-website/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:704:\"<div id=\"v-pZurw3pP-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12071/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12071/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12071&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/20/kelli-wise-using-wordpress-as-your-companys-website/\"><img alt=\"Using_WordPress_as_your_co_website_Kelli_Wise\" src=\"http://videos.videopress.com/pZurw3pP/using_wordpress_as_your_co_website_kelli_wise_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 20 Aug 2012 19:15:06 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:13:\"Grant Landram\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:37;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"WordPress.tv: Chris Cochran: Going Mobile: From 960 to 320\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12494\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:74:\"http://wordpress.tv/2012/08/20/chris-cochran-going-mobile-from-960-to-320/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:669:\"<div id=\"v-sq6fzBie-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12494/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12494/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12494&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/20/chris-cochran-going-mobile-from-960-to-320/\"><img alt=\"Going Mobile &#8211; From 960 to 320\" src=\"http://videos.videopress.com/sq6fzBie/going-mobile-from-960-to-320_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 20 Aug 2012 19:09:01 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:15:\"WordCamp Boston\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:38;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:93:\"WordPress.tv: Mark Root-Wiley and Christine Winckler: WYSI-WHA!?! Taming the WordPress Editor\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=13072\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:107:\"http://wordpress.tv/2012/08/20/mark-root-wiley-and-christine-winckler-wysi-wha-taming-the-wordpress-editor/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:788:\"<div id=\"v-n9sfo4eF-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/13072/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/13072/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=13072&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/20/mark-root-wiley-and-christine-winckler-wysi-wha-taming-the-wordpress-editor/\"><img alt=\"WYSI_WHA_Taming_the_WordPress_Editor_Mark_Root_Wiley_and_Christine_Winckler\" src=\"http://videos.videopress.com/n9sfo4eF/wysi_wha_taming_the_wordpress_editor_mark_root_wiley_and_christine_winckler_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 20 Aug 2012 17:36:31 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:13:\"Grant Landram\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:39;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:51:\"WordPress.tv: Andrew Villeneuve: WordPress Security\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=13077\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:68:\"http://wordpress.tv/2012/08/20/andrew-villeneuve-wordpress-security/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:671:\"<div id=\"v-KDHHrAdL-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/13077/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/13077/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=13077&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/20/andrew-villeneuve-wordpress-security/\"><img alt=\"WordPress_Security_Andrew_Villeneuve\" src=\"http://videos.videopress.com/KDHHrAdL/wordpress_security_andrew_villeneuve_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 20 Aug 2012 17:21:40 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:13:\"Grant Landram\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:40;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:71:\"WordPress.tv: Scott Berkun: Lessons From History and Blogging Every Day\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=13084\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:88:\"http://wordpress.tv/2012/08/20/scott-berkun-lessons-from-history-and-blogging-every-day/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:739:\"<div id=\"v-hWWhRfzq-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/13084/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/13084/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=13084&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/20/scott-berkun-lessons-from-history-and-blogging-every-day/\"><img alt=\"Lessons_From_History_Blogging_Every_Day_Keynote_Scott_Berkun\" src=\"http://videos.videopress.com/hWWhRfzq/lessons_from_history_blogging_every_day_keynote_scott_berkun_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 20 Aug 2012 17:21:11 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:13:\"Grant Landram\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:41;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:36:\"Joseph: A New, New Focus: VaultPress\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"https://josephscott.org/?p=6295\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:67:\"http://josephscott.org/archives/2012/08/a-new-new-focus-vaultpress/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:1977:\"<p>Two years ago I posted about &#8220;<a href=\"http://josephscott.org/archives/2010/07/a-new-focus/\">A New Focus</a>&#8220;, where my time at Automattic adjusted to be centered on Akismet.  Back then Akismet was catching <strong>500,000,000</strong> spam comments per month (see the sidebar chart at <a href=\"http://akismet.com/about/\">http://akismet.com/about/</a>).  Today it is catching just over <strong>2,000,000,000</strong> spam comments per month (with a peak of nearly <strong>2,500,000,000</strong> at the end of 2011).  Even with all that growth Akismet has continued to perform well, maintaining a high level of accuracy and performance, something that has been great to be a small part of.</p>\n<p>This summer I&#8217;ve been asked to shift my focus again, by joining the <a href=\"http://vaultpress.com/\">VaultPress</a> team.</p>\n<p><a href=\"http://vaultpress.com/\"><img src=\"https://lh6.googleusercontent.com/-SkboV9fXhuE/UDBTqUa4NJI/AAAAAAAAAbg/t8O-UxilJqE/s381/vaultpress-logo-home.png\" /></a></p>\n<p>If you aren&#8217;t familiar with VaultPress here is the elevator pitch: &#8220;VaultPress syncs the data from your WordPress site (posts, pages, comments, plugin &#038; theme files, and media uploads) as they are added.  On top of that VaultPress will scan your files for code vulnerabilities and changes to core WordPress files.&#8221; (more details are on the <a href=\"http://vaultpress.com/help/get-to-know/\">Get to know VaultPress</a> page)</p>\n<p>VaultPress also provides a restore process.  If your WordPress site gets vaporized for some reason doing a fresh install and activating the VaultPress plugin will allow VaultPress.com to push a backup snapshot back to your server.  There is also an option to manually download a backup snapshot, if you just want to pull out something specific.</p>\n<p>The last two years focused on Akismet have been great, and now it is exciting to be taking on the new challenge of helping VaultPress improve and grow.</p>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 20 Aug 2012 16:35:54 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:12:\"Joseph Scott\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:42;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:126:\"WordPress.tv: Meeky Hwang: Save Your Code: One Codebase, 9 Blogs With WordPress Multisite Using Sub-domains And Subdirectories\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12496\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:141:\"http://wordpress.tv/2012/08/20/meeky-hwang-save-your-code-one-codebase-9-blogs-with-wordpress-multisite-using-sub-domains-and-subdirectories/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:876:\"<div id=\"v-lkaI5cXV-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12496/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12496/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12496&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/20/meeky-hwang-save-your-code-one-codebase-9-blogs-with-wordpress-multisite-using-sub-domains-and-subdirectories/\"><img alt=\"Save Your Code &#8211; One Codebase &#8212; 9 Blogs with WordPress Multisite Using Sub-domains & Subdirectories\" src=\"http://videos.videopress.com/lkaI5cXV/save-your-code-one-codebase-9-blogs-with-wordpress-multisite-using-sub-domains-subdirectories_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 20 Aug 2012 13:10:15 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:15:\"WordCamp Boston\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:43;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:139:\"WordPress.tv: Jason Rivera: The Psychology of Social Media: Harnessing Psychological & Behavioral Connections To Develop Content Strategies\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12498\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:153:\"http://wordpress.tv/2012/08/19/jason-rivera-the-psychology-of-social-media-harnessing-psychological-behavioral-connections-to-develop-content-strategies/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:903:\"<div id=\"v-gyMCpZ3k-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12498/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12498/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12498&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/19/jason-rivera-the-psychology-of-social-media-harnessing-psychological-behavioral-connections-to-develop-content-strategies/\"><img alt=\"The Psychology of Social Media- harnessing Psychological & Bihavioral Connections to Develop content Strategies\" src=\"http://videos.videopress.com/gyMCpZ3k/the-psychology-of-social-media-harnessing-psychological-bihavioral-connections-to-develop-content-strategies_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 20 Aug 2012 01:11:38 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:15:\"WordCamp Boston\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:44;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:65:\"WordPress.tv: John Eckman: Why The @#@#$ Isn’t WordPress a CMS?\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12500\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:72:\"http://wordpress.tv/2012/08/19/john-eckman-why-the-isnt-wordpress-a-cms/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:672:\"<div id=\"v-glYrgVPE-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12500/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12500/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12500&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/19/john-eckman-why-the-isnt-wordpress-a-cms/\"><img alt=\"Why the @#@#$ Isn&#8217;t WordPress a CMS\" src=\"http://videos.videopress.com/glYrgVPE/why-the-isnt-wordpress-a-cms_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Sun, 19 Aug 2012 19:12:37 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:15:\"WordCamp Boston\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:45;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:58:\"Weblog Tools Collection: WordPress Theme Releases for 8/19\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:41:\"http://weblogtoolscollection.com/?p=11842\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:73:\"http://feedproxy.google.com/~r/weblogtoolscollection/UXMP/~3/5VSRj3BLcr0/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:1349:\"<p><img class=\"alignnone size-full wp-image-11845\" title=\"busybee\" src=\"http://weblogtoolscollection.com/wp-content/uploads/2012/08/busybee.jpg\" alt=\"\" width=\"150\" height=\"112\" /></p>\n<p><a href=\"http://emptynestthemes.com/2012/08/18/busy-bee-wordpress-theme/\"><strong>Busy Bee</strong></a> is a lovely theme suitable for any type of blog or website, taking advantage of new design features and elements including using Google web fonts to ensure a consistent look regardless of what fonts the viewer has installed on their computer.</p>\n<p><img class=\"alignnone size-full wp-image-11843\" title=\"snapshot\" src=\"http://weblogtoolscollection.com/wp-content/uploads/2012/08/snapshot.jpg\" alt=\"\" width=\"150\" height=\"113\" /></p>\n<p><a href=\"http://wordpress.org/extend/themes/snapshot\"><strong>Snapshot</strong></a> is a theme built for showing off your photography.</p>\n<p><img class=\"alignnone size-full wp-image-11844\" title=\"stack\" src=\"http://weblogtoolscollection.com/wp-content/uploads/2012/08/stack.jpg\" alt=\"\" width=\"150\" height=\"113\" /></p>\n<p><a href=\"http://wordpress.org/extend/themes/stack\"><strong>Stack</strong></a> is a paper-like Theme for WordPress heavily inspired by the popular &#8216;Stationary&#8217; theme for Tumblr.</p>\n<img src=\"http://feeds.feedburner.com/~r/weblogtoolscollection/UXMP/~4/5VSRj3BLcr0\" height=\"1\" width=\"1\" />\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Sun, 19 Aug 2012 18:41:54 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:5:\"James\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:46;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:64:\"WordPress.tv: Reiko Beach: Shopping For A Shopping Cart Solution\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12502\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:81:\"http://wordpress.tv/2012/08/19/reiko-beach-shopping-for-a-shopping-cart-solution/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:686:\"<div id=\"v-NuhdNx0H-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12502/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12502/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12502&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/19/reiko-beach-shopping-for-a-shopping-cart-solution/\"><img alt=\"Shopping for a Shopping Cart Solution\" src=\"http://videos.videopress.com/NuhdNx0H/shopping-for-a-shopping-cart-solution_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Sun, 19 Aug 2012 13:13:37 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:15:\"WordCamp Boston\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:47;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:82:\"WordPress.tv: Douglas Hanna: Engaging & Growing Your Audience Beyond The Blog Post\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12504\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:97:\"http://wordpress.tv/2012/08/18/douglas-hanna-engaging-growing-your-audience-beyond-the-blog-post/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:732:\"<div id=\"v-3EoVT9XR-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12504/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12504/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12504&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/18/douglas-hanna-engaging-growing-your-audience-beyond-the-blog-post/\"><img alt=\"Engaging & Growing Your Audience Beyond the Blog Post\" src=\"http://videos.videopress.com/3EoVT9XR/engaging-growing-your-audience-beyond-the-blog-post_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Sun, 19 Aug 2012 01:14:32 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:15:\"WordCamp Boston\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:48;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:78:\"WordPress.tv: Frederick Townes: 21 Optimization Secrets Of Top Media Companies\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12506\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:95:\"http://wordpress.tv/2012/08/18/frederick-townes-21-optimization-secrets-of-top-media-companies/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:718:\"<div id=\"v-2ET2b5Zn-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12506/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12506/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12506&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/18/frederick-townes-21-optimization-secrets-of-top-media-companies/\"><img alt=\"21 Optimization Secrets of Top Media Companies\" src=\"http://videos.videopress.com/2ET2b5Zn/21-optimization-secrets-of-top-media-companies_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Sat, 18 Aug 2012 19:15:22 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:15:\"WordCamp Boston\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:49;a:6:{s:4:\"data\";s:13:\"\n	\n	\n	\n	\n	\n	\n\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:78:\"WordPress.tv: Andrew Nacin: Developer: Andrew Nacin Presents Something Awesome\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"http://wordpress.tv/?p=12508\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:94:\"http://wordpress.tv/2012/08/18/andrew-nacin-developer-andrew-nacin-presents-something-awesome/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:703:\"<div id=\"v-H7hg5CcS-1\" class=\"video-player\">\n</div>\n<br />  <a rel=\"nofollow\" href=\"http://feeds.wordpress.com/1.0/gocomments/wptv.wordpress.com/12508/\"><img alt=\"\" border=\"0\" src=\"http://feeds.wordpress.com/1.0/comments/wptv.wordpress.com/12508/\" /></a> <img alt=\"\" border=\"0\" src=\"http://stats.wordpress.com/b.gif?host=wordpress.tv&blog=5089392&post=12508&subd=wptv&ref=&feed=1\" width=\"1\" height=\"1\" /><div><a href=\"http://wordpress.tv/2012/08/18/andrew-nacin-developer-andrew-nacin-presents-something-awesome/\"><img alt=\"Andrew Nacin Presents Something Awesome\" src=\"http://videos.videopress.com/H7hg5CcS/andrew-nacin-presents-something-awesome_std.original.jpg\" width=\"160\" height=\"120\" /></a></div>\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Sat, 18 Aug 2012 13:16:17 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:15:\"WordCamp Boston\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}}}}}}}}}}}}s:4:\"type\";i:128;s:7:\"headers\";a:9:{s:6:\"server\";s:5:\"nginx\";s:4:\"date\";s:29:\"Fri, 31 Aug 2012 12:17:42 GMT\";s:12:\"content-type\";s:8:\"text/xml\";s:14:\"content-length\";s:5:\"75842\";s:10:\"connection\";s:5:\"close\";s:4:\"vary\";s:15:\"Accept-Encoding\";s:13:\"last-modified\";s:29:\"Fri, 31 Aug 2012 12:00:11 GMT\";s:4:\"x-nc\";s:11:\"HIT luv 139\";s:13:\"accept-ranges\";s:5:\"bytes\";}s:5:\"build\";s:14:\"20090627192103\";}',	'no'),
(2012,	0,	'_transient_timeout_feed_mod_867bd5c64f85878d03a060509cd2f92c',	'1346458662',	'no'),
(2013,	0,	'_transient_feed_mod_867bd5c64f85878d03a060509cd2f92c',	'1346415462',	'no'),
(2014,	0,	'_transient_timeout_feed_57bc725ad6568758915363af670fd8bc',	'1346458662',	'no'),
(2015,	0,	'_transient_feed_57bc725ad6568758915363af670fd8bc',	'a:4:{s:5:\"child\";a:1:{s:0:\"\";a:1:{s:3:\"rss\";a:1:{i:0;a:6:{s:4:\"data\";s:3:\"\n	\n\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:7:\"version\";s:3:\"2.0\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:1:{s:0:\"\";a:1:{s:7:\"channel\";a:1:{i:0;a:6:{s:4:\"data\";s:72:\"\n		\n		\n		\n		\n		\n		\n				\n\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n\n	\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:33:\"WordPress Plugins » View: Newest\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:47:\"http://wordpress.org/extend/plugins/browse/new/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:33:\"WordPress Plugins » View: Newest\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"language\";a:1:{i:0;a:5:{s:4:\"data\";s:5:\"en-US\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 31 Aug 2012 11:45:04 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:9:\"generator\";a:1:{i:0;a:5:{s:4:\"data\";s:25:\"http://bbpress.org/?v=1.1\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"item\";a:15:{i:0;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:11:\"MFS MAILBOX\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:59:\"http://wordpress.org/extend/plugins/mfs-mailbox/#post-42526\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 30 Aug 2012 05:50:31 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42526@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:97:\"This Plugin is used for allowing one registered user to send mail(s) to other registered user(s).\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:18:\"Mindfire Solutions\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:1;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:33:\"Wordpress vTiger crm Lead Capture\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:56:\"http://wordpress.org/extend/plugins/wp-tiger/#post-41597\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 09 Aug 2012 14:43:06 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"41597@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:64:\"A easy plugin to integrate WordPress contact form to vtiger crm.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:11:\"smackcoders\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:2;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"Advanced WPMU Plugin Manager\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:76:\"http://wordpress.org/extend/plugins/advanced-wpmu-plugin-manager/#post-42531\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 30 Aug 2012 10:25:03 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42531@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:116:\"A plugin which Enable Network admin/Super admin to manage the Plugins for Individual Blog in the Multi site network.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:11:\"anthakkar08\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:3;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:16:\"Catalyst Connect\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:64:\"http://wordpress.org/extend/plugins/catalyst-connect/#post-42271\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 23 Aug 2012 16:23:48 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42271@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:144:\"Catalyst Connect is a simple, yet powerful Plugin that makes integrating\nthe BuddyPress, BBPress and WooCommerce Plugins with Catalyst a breeze.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:10:\"CobaltApps\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:4;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:16:\"Vbulletin widget\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:64:\"http://wordpress.org/extend/plugins/vbulletin-widget/#post-42502\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Wed, 29 Aug 2012 18:35:37 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42502@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:74:\"List latest threads, topics from vBulletin forum in wordpress sidebar area\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:8:\"Madchen1\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:5;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:9:\"Instagrab\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:57:\"http://wordpress.org/extend/plugins/instagrab/#post-42529\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 30 Aug 2012 08:44:27 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42529@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:119:\"Instagrab is a Wordpress plugin that grabs images from one or more Instagram hashtags and create a post for each image.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:10:\"olekenneth\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:6;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:33:\"Simple Count Eventbrite Attendees\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:81:\"http://wordpress.org/extend/plugins/simple-count-eventbrite-attendees/#post-42539\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 30 Aug 2012 13:41:30 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42539@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:96:\"Simple configurable widgetized plugin to display the number of atteendes of an Eventbrite event.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:15:\"Nuno Morgadinho\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:7;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:17:\"xTechnos Redirect\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:65:\"http://wordpress.org/extend/plugins/xtechnos-redirect/#post-42501\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Wed, 29 Aug 2012 17:57:56 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42501@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:149:\"Based on Redirect plugin, xTechnos Redirect plugin Simply redirect using Custom Fields with Homepage redirect bug fix. (How it works?: On the page or\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:13:\"zagham.naseem\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:8;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"Coupon Products for Jigoshop\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:72:\"http://wordpress.org/extend/plugins/jigoshop-coupon-products/#post-42532\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 30 Aug 2012 10:59:01 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42532@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:62:\"Extends JigoShop adding a new &#039;coupon&#039; product type.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:6:\"Carlos\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:9;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"WP Simple tabs\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:59:\"http://wordpress.org/extend/plugins/simple-tabs/#post-42495\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Wed, 29 Aug 2012 13:30:39 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42495@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:51:\"A Simple Accordion/tabs using wordpress custom post\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:11:\"renu sharma\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:10;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:15:\"PMC Post Savior\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:63:\"http://wordpress.org/extend/plugins/pmc-post-savior/#post-42291\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 23 Aug 2012 23:20:40 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42291@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:59:\"Never get unexpectedly logged out when saving a post again.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:12:\"Gabriel Koen\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:11;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:26:\"Pinterest for TheCartPress\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:74:\"http://wordpress.org/extend/plugins/pinterest-for-thecartpress/#post-42530\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 30 Aug 2012 10:18:54 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42530@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:148:\"Lets your customers share your products on the largest social pinboard for Shoppers.\n\nThe plugin allows to add the &#34;Pin it&#34; button in your p\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"Inigo Gonzalez\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:12;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:16:\"WP Custom Titles\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:64:\"http://wordpress.org/extend/plugins/wp-custom-titles/#post-42538\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 30 Aug 2012 13:30:10 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42538@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:67:\"One title for the navigation and one for the page (or post) itself.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:16:\"Callum Macdonald\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:13;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:20:\"Multidomain Redirect\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:68:\"http://wordpress.org/extend/plugins/multidomain-redirect/#post-42540\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 30 Aug 2012 13:43:54 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42540@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:150:\"Redirects visitors to the the site&#039;s URL as it appears in the WordPress database in case they&#039;re not already connecting through that domain.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:12:\"Joe Anzalone\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:14;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:12:\"Goodbye Bar!\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:59:\"http://wordpress.org/extend/plugins/goodbye-bar/#post-42292\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 24 Aug 2012 00:33:54 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42292@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:142:\"The WordPress Admin Bar has its uses... but not all users/roles need to see it. This plugin allows you to set who sees it and who doesn&#039;t\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:11:\"Sean Barton\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}}}s:27:\"http://www.w3.org/2005/Atom\";a:1:{s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:1:{s:0:\"\";a:3:{s:4:\"href\";s:48:\"http://wordpress.org/extend/plugins/rss/view/new\";s:3:\"rel\";s:4:\"self\";s:4:\"type\";s:19:\"application/rss+xml\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}}}}}}}}s:4:\"type\";i:128;s:7:\"headers\";a:10:{s:6:\"server\";s:5:\"nginx\";s:4:\"date\";s:29:\"Fri, 31 Aug 2012 12:17:42 GMT\";s:12:\"content-type\";s:23:\"text/xml; charset=UTF-8\";s:10:\"connection\";s:5:\"close\";s:4:\"vary\";s:15:\"Accept-Encoding\";s:7:\"expires\";s:29:\"Fri, 31 Aug 2012 12:20:04 GMT\";s:13:\"cache-control\";s:0:\"\";s:6:\"pragma\";s:0:\"\";s:13:\"last-modified\";s:31:\"Fri, 31 Aug 2012 11:45:04 +0000\";s:4:\"x-nc\";s:11:\"HIT luv 139\";}s:5:\"build\";s:14:\"20090627192103\";}',	'no'),
(2016,	0,	'_transient_timeout_feed_mod_57bc725ad6568758915363af670fd8bc',	'1346458663',	'no'),
(2017,	0,	'_transient_feed_mod_57bc725ad6568758915363af670fd8bc',	'1346415463',	'no'),
(2018,	0,	'_transient_timeout_feed_1a5f760f2e2b48827d4974a60857e7c2',	'1346458663',	'no'),
(2019,	0,	'_transient_feed_1a5f760f2e2b48827d4974a60857e7c2',	'a:4:{s:5:\"child\";a:1:{s:0:\"\";a:1:{s:3:\"rss\";a:1:{i:0;a:6:{s:4:\"data\";s:3:\"\n	\n\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:7:\"version\";s:3:\"2.0\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:1:{s:0:\"\";a:1:{s:7:\"channel\";a:1:{i:0;a:6:{s:4:\"data\";s:72:\"\n		\n		\n		\n		\n		\n		\n				\n\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n		\n\n	\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:7:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:43:\"WordPress Plugins » View: Recently Updated\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:51:\"http://wordpress.org/extend/plugins/browse/updated/\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:43:\"WordPress Plugins » View: Recently Updated\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:8:\"language\";a:1:{i:0;a:5:{s:4:\"data\";s:5:\"en-US\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Fri, 31 Aug 2012 11:45:23 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:9:\"generator\";a:1:{i:0;a:5:{s:4:\"data\";s:25:\"http://bbpress.org/?v=1.1\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"item\";a:15:{i:0;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:19:\"Ecwid Shopping Cart\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:67:\"http://wordpress.org/extend/plugins/ecwid-shopping-cart/#post-13603\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 15 Oct 2009 11:29:12 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"13603@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:121:\"Ecwid is a free full-featured shopping cart that can easily be added to any blog\nand takes less than 5 minutes to set up.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:5:\"ecwid\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:1;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:4:\"WPCB\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:52:\"http://wordpress.org/extend/plugins/wpcb/#post-28829\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 28 Jul 2011 22:09:17 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"28829@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:150:\"Paiement par cartes bancaires (majoritée des banques françaises), paypal, chèques et virement pour le plugin WP e-Commerce.\nCalcul de frais de port\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:4:\"6WWW\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:2;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:28:\"Coupon Products for Jigoshop\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:72:\"http://wordpress.org/extend/plugins/jigoshop-coupon-products/#post-42532\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 30 Aug 2012 10:59:01 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42532@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:62:\"Extends JigoShop adding a new &#039;coupon&#039; product type.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:6:\"Carlos\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:3;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:25:\"Wpshop - simple eCommerce\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:54:\"http://wordpress.org/extend/plugins/wpshop/#post-27342\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 09 Jun 2011 15:30:03 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"27342@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:138:\"Wpshop une extension e-commerce 100% libre, gratuite et d&#233;velopp&#233;e en France. Inclus un th&#232;me adapt&#233; pour les mobiles.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:30:\"Agence web Eoxia - Montpellier\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:4;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:22:\"Acobot Live Chat Robot\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:54:\"http://wordpress.org/extend/plugins/acobot/#post-33193\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 22 Dec 2011 07:39:02 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"33193@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:145:\"Enhance your Wordpress with Acobot live chat robot in 3 minutes or less. Boost online results like never before. It&#039;s simple, easy and FREE.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:6:\"acobot\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:5;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:11:\"MFS MAILBOX\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:59:\"http://wordpress.org/extend/plugins/mfs-mailbox/#post-42526\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 30 Aug 2012 05:50:31 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42526@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:97:\"This Plugin is used for allowing one registered user to send mail(s) to other registered user(s).\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:18:\"Mindfire Solutions\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:6;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:33:\"Wordpress vTiger crm Lead Capture\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:56:\"http://wordpress.org/extend/plugins/wp-tiger/#post-41597\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 09 Aug 2012 14:43:06 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"41597@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:64:\"A easy plugin to integrate WordPress contact form to vtiger crm.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:11:\"smackcoders\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:7;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:8:\"Easy Ads\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:61:\"http://wordpress.org/extend/plugins/easy-ads-lite/#post-36795\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Sun, 15 Apr 2012 23:21:43 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"36795@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:143:\"Easy Ads displays AdSense and its alternatives on your blog pages and sidebar widgets: Chitika, BidVertiser, Clicksor etc. Simple yet flexible.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:7:\"manojtd\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:8;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:26:\"Related Content by Zemanta\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:54:\"http://wordpress.org/extend/plugins/zemanta/#post-5788\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Thu, 29 May 2008 20:51:56 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:41:\"5788@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:135:\"Zemanta finds related posts, images, links and tags while you write your post. Just pick and choose which you like with a single click!\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:26:\"Related Content by Zemanta\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:9;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:14:\"Newsgrape Sync\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:62:\"http://wordpress.org/extend/plugins/newsgrape-sync/#post-37010\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Mon, 23 Apr 2012 13:13:18 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"37010@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:46:\"Syncs your Wordpress articles to Newsgrape.com\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:3:\"sk7\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:10;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:24:\"aliyun oss for WordPress\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:54:\"http://wordpress.org/extend/plugins/oss4wp/#post-42484\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Wed, 29 Aug 2012 01:30:34 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42484@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:123:\"上传您博客的图片到阿里云的开放储存服务，享受阿里云带给您的高速稳定的云中漫步快感。\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:5:\"enj0y\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:11;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:12:\"Captcha Code\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:75:\"http://wordpress.org/extend/plugins/captcha-code-authentication/#post-40649\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 17 Jul 2012 12:04:54 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"40649@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:149:\"Adds Captcha Code anti-spam methods to WordPress forms. Forms include comments form, registration form, lost passwordform and login form. In order to\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:13:\"Vinoj Cardoza\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:12;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:21:\"Widgetize Pages Light\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:69:\"http://wordpress.org/extend/plugins/widgetize-pages-light/#post-41812\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Tue, 14 Aug 2012 11:11:45 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"41812@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:127:\"Drop widgets in page or post content area. Widgetized pages. Build your custom page layout in no time. No coding, easy and fun!\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:9:\"OTWthemes\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:13;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:20:\"Widget Manager Light\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:68:\"http://wordpress.org/extend/plugins/widget-manager-light/#post-42219\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Wed, 22 Aug 2012 16:19:39 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42219@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:114:\"Get control over widgets visibility. Show or hide widgets. Display relevant content in the sidebars of your pages.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:9:\"OTWthemes\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}i:14;a:6:{s:4:\"data\";s:30:\"\n			\n			\n			\n			\n			\n			\n					\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";s:5:\"child\";a:2:{s:0:\"\";a:5:{s:5:\"title\";a:1:{i:0;a:5:{s:4:\"data\";s:21:\"Sidebar Manager Light\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:69:\"http://wordpress.org/extend/plugins/sidebar-manager-light/#post-42218\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:7:\"pubDate\";a:1:{i:0;a:5:{s:4:\"data\";s:31:\"Wed, 22 Aug 2012 16:18:24 +0000\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:4:\"guid\";a:1:{i:0;a:5:{s:4:\"data\";s:42:\"42218@http://wordpress.org/extend/plugins/\";s:7:\"attribs\";a:1:{s:0:\"\";a:1:{s:11:\"isPermaLink\";s:5:\"false\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}s:11:\"description\";a:1:{i:0;a:5:{s:4:\"data\";s:126:\"Create custom sidebars (widget areas) and replace any existing sidebar so you can display relevant content on different pages.\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}s:32:\"http://purl.org/dc/elements/1.1/\";a:1:{s:7:\"creator\";a:1:{i:0;a:5:{s:4:\"data\";s:9:\"OTWthemes\";s:7:\"attribs\";a:0:{}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}}}s:27:\"http://www.w3.org/2005/Atom\";a:1:{s:4:\"link\";a:1:{i:0;a:5:{s:4:\"data\";s:0:\"\";s:7:\"attribs\";a:1:{s:0:\"\";a:3:{s:4:\"href\";s:52:\"http://wordpress.org/extend/plugins/rss/view/updated\";s:3:\"rel\";s:4:\"self\";s:4:\"type\";s:19:\"application/rss+xml\";}}s:8:\"xml_base\";s:0:\"\";s:17:\"xml_base_explicit\";b:0;s:8:\"xml_lang\";s:0:\"\";}}}}}}}}}}}}s:4:\"type\";i:128;s:7:\"headers\";a:10:{s:6:\"server\";s:5:\"nginx\";s:4:\"date\";s:29:\"Fri, 31 Aug 2012 12:17:43 GMT\";s:12:\"content-type\";s:23:\"text/xml; charset=UTF-8\";s:10:\"connection\";s:5:\"close\";s:4:\"vary\";s:15:\"Accept-Encoding\";s:7:\"expires\";s:29:\"Fri, 31 Aug 2012 12:20:23 GMT\";s:13:\"cache-control\";s:0:\"\";s:6:\"pragma\";s:0:\"\";s:13:\"last-modified\";s:31:\"Fri, 31 Aug 2012 11:45:23 +0000\";s:4:\"x-nc\";s:11:\"HIT luv 139\";}s:5:\"build\";s:14:\"20090627192103\";}',	'no'),
(2020,	0,	'_transient_timeout_dash_aa95765b5cc111c56d5993d476b1c2f0',	'1346458663',	'no'),
(2021,	0,	'_transient_timeout_feed_mod_1a5f760f2e2b48827d4974a60857e7c2',	'1346458663',	'no'),
(2022,	0,	'_transient_dash_aa95765b5cc111c56d5993d476b1c2f0',	'<div class=\"rss-widget\"><ul><li><a class=\'rsswidget\' href=\'http://feedproxy.google.com/~r/weblogtoolscollection/UXMP/~3/lu0a0iZ-0H8/\' title=\'New plugins BreezingForms is an enterprise form builder. MoodThingy is a plugin that any blogger can use to track the emotional feedback of an individual blog post or article. Updated plugins Jetpack allows you to supercharge your WordPress site with powerful features previously only available to WordPress.com users. StatComm provides realtime statistics on  [&hellip;]\'>Weblog Tools Collection: WordPress Plugin Releases for 8/29</a></li><li><a class=\'rsswidget\' href=\'http://wordpress.tv/2012/08/28/adii-pienaar-the-business-of-code/\' title=\' [&hellip;]\'>WordPress.tv: Adii Pienaar: The business of code</a></li><li><a class=\'rsswidget\' href=\'http://wordpress.tv/2012/08/28/ryan-imel-the-state-of-themes/\' title=\' [&hellip;]\'>WordPress.tv: Ryan Imel: The state of themes</a></li><li><a class=\'rsswidget\' href=\'http://alexking.org/blog/2012/08/27/wordcamp-albuquerque-2012\' title=\'This past weekend I enjoyed my first trip to New Mexico to attend WordCamp Albuquerque. I’m not sure why it took me eight years after moving to Colorado to visit my neighboring state to the south, but WordCamp was a great excuse to get down for a visit. My thanks to the great folks in the New Mexico WordPress community for being wonderful hosts; in particula [&hellip;]\'>Alex King: WordCamp Albuquerque 2012</a></li><li><a class=\'rsswidget\' href=\'http://feedproxy.google.com/~r/weblogtoolscollection/UXMP/~3/TIanviRwbTA/\' title=\'BlackMesa is a graphically intense theme with alternating, semitransparent headline-boxes, parallax moving backgrounds and beautiful text styles. Picturesque is an elegant photoblogging theme that emphasizes your photography. [&hellip;]\'>Weblog Tools Collection: WordPress Theme Releases for 8/27</a></li></ul></div>',	'no'),
(2023,	0,	'_transient_feed_mod_1a5f760f2e2b48827d4974a60857e7c2',	'1346415463',	'no'),
(2024,	0,	'_transient_timeout_dash_de3249c4736ad3bd2cd29147c4a0d43e',	'1346458663',	'no'),
(2025,	0,	'_transient_dash_de3249c4736ad3bd2cd29147c4a0d43e',	'<h4>Most Popular</h4>\n<h5><a href=\'http://wordpress.org/extend/plugins/jetpack/\'>Jetpack by WordPress.com</a></h5>&nbsp;<span>(<a href=\'plugin-install.php?tab=plugin-information&amp;plugin=jetpack&amp;_wpnonce=a7c7362666&amp;TB_iframe=true&amp;width=600&amp;height=800\' class=\'thickbox\' title=\'Jetpack by WordPress.com\'>Install</a>)</span>\n<p>Supercharge your WordPress site with powerful features previously only available to WordPress.com users.</p>\n<h4>Newest Plugins</h4>\n<h5><a href=\'http://wordpress.org/extend/plugins/jigoshop-coupon-products/\'>Coupon Products for Jigoshop</a></h5>&nbsp;<span>(<a href=\'plugin-install.php?tab=plugin-information&amp;plugin=jigoshop-coupon-products&amp;_wpnonce=ddb0cac807&amp;TB_iframe=true&amp;width=600&amp;height=800\' class=\'thickbox\' title=\'Coupon Products for Jigoshop\'>Install</a>)</span>\n<p>Extends JigoShop adding a new &#039;coupon&#039; product type.</p>\n<h4>Recently Updated</h4>\n<h5><a href=\'http://wordpress.org/extend/plugins/jigoshop-coupon-products/\'>Coupon Products for Jigoshop</a></h5>&nbsp;<span>(<a href=\'plugin-install.php?tab=plugin-information&amp;plugin=jigoshop-coupon-products&amp;_wpnonce=ddb0cac807&amp;TB_iframe=true&amp;width=600&amp;height=800\' class=\'thickbox\' title=\'Coupon Products for Jigoshop\'>Install</a>)</span>\n<p>Extends JigoShop adding a new &#039;coupon&#039; product type.</p>\n',	'no'),
(2026,	0,	'_transient_random_seed',	'69966c9b387ebb9da166e2bdf53e320b',	'yes');

DROP TABLE IF EXISTS `calzada_postmeta`;
CREATE TABLE `calzada_postmeta` (
  `meta_id` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `post_id` bigint(20) unsigned NOT NULL DEFAULT '0',
  `meta_key` varchar(255) DEFAULT NULL,
  `meta_value` longtext,
  PRIMARY KEY (`meta_id`),
  KEY `post_id` (`post_id`),
  KEY `meta_key` (`meta_key`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

INSERT INTO `calzada_postmeta` (`meta_id`, `post_id`, `meta_key`, `meta_value`) VALUES
(7,	6,	'_edit_last',	'1'),
(8,	6,	'_edit_lock',	'1345786506:1'),
(9,	8,	'_edit_last',	'1'),
(10,	8,	'_edit_lock',	'1345779870:1'),
(13,	13,	'_edit_last',	'1'),
(14,	13,	'_edit_lock',	'1345512373:1'),
(15,	15,	'_edit_last',	'1'),
(16,	15,	'_edit_lock',	'1344315920:1'),
(17,	17,	'_edit_last',	'1'),
(18,	17,	'_edit_lock',	'1346199820:1'),
(21,	23,	'_edit_last',	'1'),
(22,	23,	'_edit_lock',	'1345697672:1'),
(23,	25,	'_edit_last',	'1'),
(24,	25,	'_edit_lock',	'1344230988:1'),
(25,	27,	'_edit_last',	'1'),
(26,	27,	'_edit_lock',	'1344391876:1'),
(27,	29,	'_menu_item_type',	'post_type'),
(28,	29,	'_menu_item_menu_item_parent',	'0'),
(29,	29,	'_menu_item_object_id',	'27'),
(30,	29,	'_menu_item_object',	'page'),
(31,	29,	'_menu_item_target',	''),
(32,	29,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(33,	29,	'_menu_item_xfn',	''),
(34,	29,	'_menu_item_url',	''),
(36,	30,	'_menu_item_type',	'post_type'),
(37,	30,	'_menu_item_menu_item_parent',	'0'),
(38,	30,	'_menu_item_object_id',	'25'),
(39,	30,	'_menu_item_object',	'page'),
(40,	30,	'_menu_item_target',	''),
(41,	30,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(42,	30,	'_menu_item_xfn',	''),
(43,	30,	'_menu_item_url',	''),
(45,	31,	'_menu_item_type',	'post_type'),
(46,	31,	'_menu_item_menu_item_parent',	'0'),
(47,	31,	'_menu_item_object_id',	'23'),
(48,	31,	'_menu_item_object',	'page'),
(49,	31,	'_menu_item_target',	''),
(50,	31,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(51,	31,	'_menu_item_xfn',	''),
(52,	31,	'_menu_item_url',	''),
(63,	33,	'_menu_item_type',	'post_type'),
(64,	33,	'_menu_item_menu_item_parent',	'0'),
(65,	33,	'_menu_item_object_id',	'8'),
(66,	33,	'_menu_item_object',	'page'),
(67,	33,	'_menu_item_target',	''),
(68,	33,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(69,	33,	'_menu_item_xfn',	''),
(70,	33,	'_menu_item_url',	''),
(72,	34,	'_menu_item_type',	'post_type'),
(73,	34,	'_menu_item_menu_item_parent',	'33'),
(74,	34,	'_menu_item_object_id',	'17'),
(75,	34,	'_menu_item_object',	'page'),
(76,	34,	'_menu_item_target',	''),
(77,	34,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(78,	34,	'_menu_item_xfn',	''),
(79,	34,	'_menu_item_url',	''),
(81,	35,	'_menu_item_type',	'post_type'),
(82,	35,	'_menu_item_menu_item_parent',	'33'),
(83,	35,	'_menu_item_object_id',	'15'),
(84,	35,	'_menu_item_object',	'page'),
(85,	35,	'_menu_item_target',	''),
(86,	35,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(87,	35,	'_menu_item_xfn',	''),
(88,	35,	'_menu_item_url',	''),
(90,	36,	'_menu_item_type',	'post_type'),
(91,	36,	'_menu_item_menu_item_parent',	'33'),
(92,	36,	'_menu_item_object_id',	'13'),
(93,	36,	'_menu_item_object',	'page'),
(94,	36,	'_menu_item_target',	''),
(95,	36,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(96,	36,	'_menu_item_xfn',	''),
(97,	36,	'_menu_item_url',	''),
(108,	38,	'_menu_item_type',	'post_type'),
(109,	38,	'_menu_item_menu_item_parent',	'0'),
(110,	38,	'_menu_item_object_id',	'6'),
(111,	38,	'_menu_item_object',	'page'),
(112,	38,	'_menu_item_target',	''),
(113,	38,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(114,	38,	'_menu_item_xfn',	''),
(115,	38,	'_menu_item_url',	''),
(117,	40,	'_edit_last',	'1'),
(118,	40,	'_edit_lock',	'1345611705:1'),
(119,	43,	'_edit_last',	'1'),
(120,	43,	'_edit_lock',	'1341191165:1'),
(121,	45,	'_edit_last',	'1'),
(122,	45,	'_edit_lock',	'1345610767:1'),
(123,	47,	'_edit_last',	'1'),
(124,	47,	'_edit_lock',	'1341191114:1'),
(152,	52,	'_menu_item_type',	'post_type'),
(153,	52,	'_menu_item_menu_item_parent',	'0'),
(154,	52,	'_menu_item_object_id',	'40'),
(155,	52,	'_menu_item_object',	'page'),
(156,	52,	'_menu_item_target',	''),
(157,	52,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(158,	52,	'_menu_item_xfn',	''),
(159,	52,	'_menu_item_url',	''),
(161,	53,	'_menu_item_type',	'post_type'),
(162,	53,	'_menu_item_menu_item_parent',	'0'),
(163,	53,	'_menu_item_object_id',	'27'),
(164,	53,	'_menu_item_object',	'page'),
(165,	53,	'_menu_item_target',	''),
(166,	53,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(167,	53,	'_menu_item_xfn',	''),
(168,	53,	'_menu_item_url',	''),
(169,	54,	'_wp_attached_file',	'2012/05/pic_page-banner-02.jpg'),
(170,	54,	'_wp_attachment_metadata',	'a:6:{s:5:\"width\";s:3:\"632\";s:6:\"height\";s:3:\"233\";s:14:\"hwstring_small\";s:23:\"height=\'47\' width=\'128\'\";s:4:\"file\";s:30:\"2012/05/pic_page-banner-02.jpg\";s:5:\"sizes\";a:2:{s:9:\"thumbnail\";a:3:{s:4:\"file\";s:30:\"pic_page-banner-02-150x150.jpg\";s:5:\"width\";s:3:\"150\";s:6:\"height\";s:3:\"150\";}s:6:\"medium\";a:3:{s:4:\"file\";s:30:\"pic_page-banner-02-300x110.jpg\";s:5:\"width\";s:3:\"300\";s:6:\"height\";s:3:\"110\";}}s:10:\"image_meta\";a:10:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";}}'),
(171,	8,	'_thumbnail_id',	'54'),
(180,	60,	'_wp_attached_file',	'2012/05/pic_page-banner-011.jpg'),
(181,	60,	'_wp_attachment_metadata',	'a:6:{s:5:\"width\";s:3:\"960\";s:6:\"height\";s:3:\"368\";s:14:\"hwstring_small\";s:23:\"height=\'49\' width=\'128\'\";s:4:\"file\";s:31:\"2012/05/pic_page-banner-011.jpg\";s:5:\"sizes\";a:3:{s:9:\"thumbnail\";a:3:{s:4:\"file\";s:31:\"pic_page-banner-011-150x150.jpg\";s:5:\"width\";s:3:\"150\";s:6:\"height\";s:3:\"150\";}s:6:\"medium\";a:3:{s:4:\"file\";s:31:\"pic_page-banner-011-300x115.jpg\";s:5:\"width\";s:3:\"300\";s:6:\"height\";s:3:\"115\";}s:11:\"page-images\";a:3:{s:4:\"file\";s:31:\"pic_page-banner-011-632x233.jpg\";s:5:\"width\";s:3:\"632\";s:6:\"height\";s:3:\"233\";}}s:10:\"image_meta\";a:10:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";}}'),
(183,	68,	'_edit_last',	'1'),
(186,	68,	'_edit_lock',	'1341803657:1'),
(187,	70,	'_edit_last',	'1'),
(188,	70,	'_edit_lock',	'1341803534:1'),
(191,	72,	'_edit_last',	'1'),
(192,	72,	'_edit_lock',	'1341803386:1'),
(195,	74,	'_edit_last',	'1'),
(196,	74,	'_edit_lock',	'1343799925:1'),
(199,	77,	'_edit_last',	'1'),
(200,	77,	'field_4fc24b44558b0',	'a:9:{s:3:\"key\";s:19:\"field_4fc24b44558b0\";s:5:\"label\";s:13:\"Company Title\";s:4:\"name\";s:13:\"company_title\";s:4:\"type\";s:4:\"text\";s:12:\"instructions\";s:0:\"\";s:8:\"required\";s:1:\"1\";s:13:\"default_value\";s:0:\"\";s:10:\"formatting\";s:4:\"html\";s:8:\"order_no\";s:1:\"0\";}'),
(201,	77,	'field_4fc24b445aae8',	'a:9:{s:3:\"key\";s:19:\"field_4fc24b445aae8\";s:5:\"label\";s:19:\"Company Description\";s:4:\"name\";s:19:\"company_description\";s:4:\"type\";s:7:\"wysiwyg\";s:12:\"instructions\";s:0:\"\";s:8:\"required\";s:1:\"1\";s:7:\"toolbar\";s:5:\"basic\";s:12:\"media_upload\";s:2:\"no\";s:8:\"order_no\";s:1:\"1\";}'),
(202,	77,	'allorany',	'all'),
(204,	77,	'position',	'normal'),
(205,	77,	'layout',	'default'),
(207,	77,	'_edit_lock',	'1343798820:1'),
(208,	77,	'field_4fc24b6d9d622',	'a:9:{s:5:\"label\";s:13:\"Markets Title\";s:4:\"name\";s:13:\"markets_title\";s:4:\"type\";s:4:\"text\";s:12:\"instructions\";s:0:\"\";s:8:\"required\";s:1:\"1\";s:13:\"default_value\";s:0:\"\";s:10:\"formatting\";s:4:\"html\";s:3:\"key\";s:19:\"field_4fc24b6d9d622\";s:8:\"order_no\";s:1:\"2\";}'),
(209,	77,	'field_4fc24b6da534e',	'a:9:{s:5:\"label\";s:19:\"Markets Description\";s:4:\"name\";s:19:\"markets_description\";s:4:\"type\";s:7:\"wysiwyg\";s:12:\"instructions\";s:0:\"\";s:8:\"required\";s:1:\"1\";s:7:\"toolbar\";s:5:\"basic\";s:12:\"media_upload\";s:2:\"no\";s:3:\"key\";s:19:\"field_4fc24b6da534e\";s:8:\"order_no\";s:1:\"3\";}'),
(210,	77,	'rule',	'a:4:{s:5:\"param\";s:4:\"page\";s:8:\"operator\";s:2:\"==\";s:5:\"value\";s:1:\"6\";s:8:\"order_no\";s:1:\"0\";}'),
(211,	6,	'company_title',	'Calzada Limited'),
(212,	6,	'_company_title',	'field_4fc24b44558b0'),
(213,	6,	'company_description',	'Calzada Limited is a biotechnology company with two wholly owned subsidiaries (PolyNovo Biomaterials and Metabolic Pharmaceuticals), both with high potential and maturing products reaching major value inflexion points during 2012 &amp; 2013.\r\n\r\n&nbsp;\r\n\r\nCalzada is listed on the Australian Securities Exchange (Code CZD).'),
(214,	6,	'_company_description',	'field_4fc24b445aae8'),
(215,	6,	'markets_title',	'Our Markets'),
(216,	6,	'_markets_title',	'field_4fc24b6d9d622'),
(217,	6,	'markets_description',	'PolyNovo has developed a unique biodegradable polymer platform technology (NovoSorb™) designed to be used in medical devices and for tissue engineering scaffolds. \r\n\r\nMetabolic is seeking to derive value from the Company\'s past investment of over $50 million in the pharmaceutical development AOD9604.'),
(218,	6,	'_markets_description',	'field_4fc24b6da534e'),
(221,	86,	'_menu_item_type',	'post_type'),
(222,	86,	'_menu_item_menu_item_parent',	'33'),
(223,	86,	'_menu_item_object_id',	'8'),
(224,	86,	'_menu_item_object',	'page'),
(225,	86,	'_menu_item_target',	''),
(226,	86,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(227,	86,	'_menu_item_xfn',	''),
(228,	86,	'_menu_item_url',	''),
(229,	25,	'_thumbnail_id',	'54'),
(230,	102,	'_wp_attached_file',	'2012/05/650x100.gif'),
(231,	102,	'_wp_attachment_metadata',	'a:6:{s:5:\"width\";s:3:\"650\";s:6:\"height\";s:3:\"100\";s:14:\"hwstring_small\";s:23:\"height=\'19\' width=\'128\'\";s:4:\"file\";s:19:\"2012/05/650x100.gif\";s:5:\"sizes\";a:3:{s:9:\"thumbnail\";a:3:{s:4:\"file\";s:19:\"650x100-150x100.gif\";s:5:\"width\";s:3:\"150\";s:6:\"height\";s:3:\"100\";}s:6:\"medium\";a:3:{s:4:\"file\";s:18:\"650x100-300x46.gif\";s:5:\"width\";s:3:\"300\";s:6:\"height\";s:2:\"46\";}s:11:\"page-images\";a:3:{s:4:\"file\";s:19:\"650x100-632x100.gif\";s:5:\"width\";s:3:\"632\";s:6:\"height\";s:3:\"100\";}}s:10:\"image_meta\";a:10:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";}}'),
(232,	102,	'_wp_attachment_image_alt',	'Integer posuere erat a ante venenatis dapibus posuere velit aliquet.'),
(233,	123,	'_wp_attached_file',	'2012/05/calzada_logo.jpg'),
(234,	123,	'_wp_attachment_metadata',	'a:6:{s:5:\"width\";s:3:\"225\";s:6:\"height\";s:3:\"120\";s:14:\"hwstring_small\";s:23:\"height=\'68\' width=\'128\'\";s:4:\"file\";s:24:\"2012/05/calzada_logo.jpg\";s:5:\"sizes\";a:1:{s:9:\"thumbnail\";a:3:{s:4:\"file\";s:24:\"calzada_logo-150x120.jpg\";s:5:\"width\";s:3:\"150\";s:6:\"height\";s:3:\"120\";}}s:10:\"image_meta\";a:10:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";}}'),
(235,	124,	'_wp_attached_file',	'2012/05/polynovologo.jpg'),
(236,	124,	'_wp_attachment_metadata',	'a:6:{s:5:\"width\";s:3:\"225\";s:6:\"height\";s:3:\"120\";s:14:\"hwstring_small\";s:23:\"height=\'68\' width=\'128\'\";s:4:\"file\";s:24:\"2012/05/polynovologo.jpg\";s:5:\"sizes\";a:1:{s:9:\"thumbnail\";a:3:{s:4:\"file\";s:24:\"polynovologo-150x120.jpg\";s:5:\"width\";s:3:\"150\";s:6:\"height\";s:3:\"120\";}}s:10:\"image_meta\";a:10:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";}}'),
(237,	126,	'_wp_attached_file',	'2012/05/metaboliclogo.jpg'),
(238,	126,	'_wp_attachment_metadata',	'a:6:{s:5:\"width\";s:3:\"225\";s:6:\"height\";s:3:\"120\";s:14:\"hwstring_small\";s:23:\"height=\'68\' width=\'128\'\";s:4:\"file\";s:25:\"2012/05/metaboliclogo.jpg\";s:5:\"sizes\";a:1:{s:9:\"thumbnail\";a:3:{s:4:\"file\";s:25:\"metaboliclogo-150x120.jpg\";s:5:\"width\";s:3:\"150\";s:6:\"height\";s:3:\"120\";}}s:10:\"image_meta\";a:10:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";}}'),
(239,	130,	'_wp_attached_file',	'2012/05/Share_Registry_s.jpg'),
(240,	130,	'_wp_attachment_metadata',	'a:5:{s:5:\"width\";s:3:\"140\";s:6:\"height\";s:2:\"84\";s:14:\"hwstring_small\";s:23:\"height=\'76\' width=\'128\'\";s:4:\"file\";s:28:\"2012/05/Share_Registry_s.jpg\";s:10:\"image_meta\";a:10:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";}}'),
(241,	133,	'_edit_last',	'1'),
(242,	133,	'_edit_lock',	'1345785602:1'),
(243,	135,	'_menu_item_type',	'post_type'),
(244,	135,	'_menu_item_menu_item_parent',	'31'),
(245,	135,	'_menu_item_object_id',	'133'),
(246,	135,	'_menu_item_object',	'page'),
(247,	135,	'_menu_item_target',	''),
(248,	135,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(249,	135,	'_menu_item_xfn',	''),
(250,	135,	'_menu_item_url',	''),
(251,	137,	'_edit_last',	'1'),
(252,	137,	'_edit_lock',	'1340012475:1'),
(253,	139,	'_edit_last',	'1'),
(254,	139,	'_edit_lock',	'1345780784:1'),
(255,	141,	'_edit_last',	'1'),
(256,	141,	'_edit_lock',	'1345779708:1'),
(257,	143,	'_edit_last',	'1'),
(258,	143,	'_edit_lock',	'1345779489:1'),
(259,	145,	'_edit_last',	'1'),
(260,	145,	'_edit_lock',	'1344315750:1'),
(261,	147,	'_edit_last',	'1'),
(262,	147,	'_edit_lock',	'1341191512:1'),
(263,	149,	'_menu_item_type',	'post_type'),
(264,	149,	'_menu_item_menu_item_parent',	'31'),
(265,	149,	'_menu_item_object_id',	'147'),
(266,	149,	'_menu_item_object',	'page'),
(267,	149,	'_menu_item_target',	''),
(268,	149,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(269,	149,	'_menu_item_xfn',	''),
(270,	149,	'_menu_item_url',	''),
(272,	150,	'_menu_item_type',	'post_type'),
(273,	150,	'_menu_item_menu_item_parent',	'31'),
(274,	150,	'_menu_item_object_id',	'145'),
(275,	150,	'_menu_item_object',	'page'),
(276,	150,	'_menu_item_target',	''),
(277,	150,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(278,	150,	'_menu_item_xfn',	''),
(279,	150,	'_menu_item_url',	''),
(281,	151,	'_menu_item_type',	'post_type'),
(282,	151,	'_menu_item_menu_item_parent',	'31'),
(283,	151,	'_menu_item_object_id',	'143'),
(284,	151,	'_menu_item_object',	'page'),
(285,	151,	'_menu_item_target',	''),
(286,	151,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(287,	151,	'_menu_item_xfn',	''),
(288,	151,	'_menu_item_url',	''),
(290,	152,	'_menu_item_type',	'post_type'),
(291,	152,	'_menu_item_menu_item_parent',	'31'),
(292,	152,	'_menu_item_object_id',	'141'),
(293,	152,	'_menu_item_object',	'page'),
(294,	152,	'_menu_item_target',	''),
(295,	152,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(296,	152,	'_menu_item_xfn',	''),
(297,	152,	'_menu_item_url',	''),
(299,	153,	'_menu_item_type',	'post_type'),
(300,	153,	'_menu_item_menu_item_parent',	'0'),
(301,	153,	'_menu_item_object_id',	'139'),
(302,	153,	'_menu_item_object',	'page'),
(303,	153,	'_menu_item_target',	''),
(304,	153,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(305,	153,	'_menu_item_xfn',	''),
(306,	153,	'_menu_item_url',	''),
(317,	155,	'_edit_last',	'1'),
(318,	155,	'_edit_lock',	'1341191636:1'),
(319,	157,	'_edit_last',	'1'),
(320,	157,	'_edit_lock',	'1341191661:1'),
(321,	159,	'_edit_last',	'1'),
(322,	159,	'_edit_lock',	'1341191679:1'),
(323,	161,	'_edit_last',	'1'),
(324,	161,	'_edit_lock',	'1341191700:1'),
(325,	163,	'_menu_item_type',	'post_type'),
(326,	163,	'_menu_item_menu_item_parent',	'30'),
(327,	163,	'_menu_item_object_id',	'155'),
(328,	163,	'_menu_item_object',	'page'),
(329,	163,	'_menu_item_target',	''),
(330,	163,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(331,	163,	'_menu_item_xfn',	''),
(332,	163,	'_menu_item_url',	''),
(334,	164,	'_menu_item_type',	'post_type'),
(335,	164,	'_menu_item_menu_item_parent',	'30'),
(336,	164,	'_menu_item_object_id',	'157'),
(337,	164,	'_menu_item_object',	'page'),
(338,	164,	'_menu_item_target',	''),
(339,	164,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(340,	164,	'_menu_item_xfn',	''),
(341,	164,	'_menu_item_url',	''),
(343,	165,	'_menu_item_type',	'post_type'),
(344,	165,	'_menu_item_menu_item_parent',	'30'),
(345,	165,	'_menu_item_object_id',	'159'),
(346,	165,	'_menu_item_object',	'page'),
(347,	165,	'_menu_item_target',	''),
(348,	165,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(349,	165,	'_menu_item_xfn',	''),
(350,	165,	'_menu_item_url',	''),
(352,	166,	'_menu_item_type',	'post_type'),
(353,	166,	'_menu_item_menu_item_parent',	'30'),
(354,	166,	'_menu_item_object_id',	'161'),
(355,	166,	'_menu_item_object',	'page'),
(356,	166,	'_menu_item_target',	''),
(357,	166,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(358,	166,	'_menu_item_xfn',	''),
(359,	166,	'_menu_item_url',	''),
(361,	169,	'_wp_attached_file',	'2012/06/BIO_CEO_OBESITY-SESSION_NY_FEB2006.pdf'),
(362,	169,	'_wp_attachment_metadata',	'a:0:{}'),
(363,	170,	'_wp_attached_file',	'2012/06/BostonBio2005CorporatePresentation_June2005.pdf'),
(364,	170,	'_wp_attachment_metadata',	'a:0:{}'),
(365,	171,	'_wp_attached_file',	'2012/06/BostonBio2005DiabetesSession_June2005.pdf'),
(366,	171,	'_wp_attachment_metadata',	'a:0:{}'),
(367,	172,	'_wp_attached_file',	'2012/06/CEOPresentationRodmanRenshaw_7Nov2005.pdf'),
(368,	172,	'_wp_attachment_metadata',	'a:0:{}'),
(369,	173,	'_wp_attached_file',	'2012/06/CEOUSbiotechpresentation_5April2006.pdf'),
(370,	173,	'_wp_attachment_metadata',	'a:0:{}'),
(371,	174,	'_wp_attached_file',	'2012/06/CurrentCorporatePresentation_January2007.pdf'),
(372,	174,	'_wp_attachment_metadata',	'a:0:{}'),
(373,	175,	'_wp_attached_file',	'2012/06/HeffernanUK.pdf'),
(374,	175,	'_wp_attachment_metadata',	'a:0:{}'),
(375,	176,	'_wp_attached_file',	'2012/06/IntersuissePresentation_October2006.pdf'),
(376,	176,	'_wp_attachment_metadata',	'a:0:{}'),
(377,	177,	'_wp_attached_file',	'2012/06/InvestorRoadshowPresentation_8Feb2006.pdf'),
(378,	177,	'_wp_attachment_metadata',	'a:0:{}'),
(379,	178,	'_wp_attached_file',	'2012/06/MBPCorporatePresentation_June-2005.pdf'),
(380,	178,	'_wp_attachment_metadata',	'a:0:{}'),
(381,	179,	'_wp_attached_file',	'2012/06/Metabolic-2007-AGM-Presentation.pdf'),
(382,	179,	'_wp_attachment_metadata',	'a:0:{}'),
(383,	180,	'_wp_attached_file',	'2012/06/Metabolic-Corporate-Presentation.pdf'),
(384,	180,	'_wp_attachment_metadata',	'a:0:{}'),
(385,	181,	'_wp_attached_file',	'2012/06/MetabolicDomesticRoadshow_November2006.pdf'),
(386,	181,	'_wp_attachment_metadata',	'a:0:{}'),
(387,	182,	'_wp_attached_file',	'2012/06/NAASO_2005presentation.pdf'),
(388,	182,	'_wp_attachment_metadata',	'a:0:{}'),
(389,	183,	'_wp_attached_file',	'2012/06/PacificGrowthEquities_USA-conference.pdf'),
(390,	183,	'_wp_attachment_metadata',	'a:0:{}'),
(391,	184,	'_wp_attached_file',	'2012/06/SouthernCrossEquitiesRS_7Sept2005.pdf'),
(392,	184,	'_wp_attachment_metadata',	'a:0:{}'),
(393,	185,	'_wp_attached_file',	'2012/06/TIDES-2004-Conference.pdf'),
(394,	185,	'_wp_attachment_metadata',	'a:0:{}'),
(395,	186,	'_wp_attached_file',	'2012/06/TIDES-ACV1_2ndMay2005.pdf'),
(396,	186,	'_wp_attachment_metadata',	'a:0:{}'),
(397,	187,	'_wp_attached_file',	'2012/06/UBSPresentation28Sept2006.ppt'),
(398,	187,	'_wp_attachment_metadata',	'a:0:{}'),
(399,	188,	'_wp_attached_file',	'2012/06/UKRoadshowPresentation_July2006.pdf'),
(400,	188,	'_wp_attachment_metadata',	'a:0:{}'),
(401,	189,	'_wp_attached_file',	'2012/06/UpdateOralPeptideDeliveryPlatform_20Sept2007.pdf'),
(402,	189,	'_wp_attachment_metadata',	'a:0:{}'),
(403,	190,	'_wp_attached_file',	'2012/06/USPresentations_June-2005.pdf'),
(404,	190,	'_wp_attachment_metadata',	'a:0:{}'),
(405,	191,	'_wp_attached_file',	'2012/06/WilsonHTMConference_RS_10Oct2005.pdf'),
(406,	191,	'_wp_attachment_metadata',	'a:0:{}'),
(407,	192,	'_wp_attached_file',	'2012/06/0823-ASX-Announcement-Corporate-Presentation-Acquisition-of-PolyNovo-18-July-2008.pdf'),
(408,	192,	'_wp_attachment_metadata',	'a:0:{}'),
(409,	193,	'_wp_attached_file',	'2012/06/0823-ASX-Announcement-Corporate-Presentation-Acquisition-of-PolyNovo-18-July-2008_001.pdf'),
(410,	193,	'_wp_attachment_metadata',	'a:0:{}'),
(411,	194,	'_wp_attached_file',	'2012/06/914346.pdf'),
(412,	194,	'_wp_attachment_metadata',	'a:0:{}'),
(413,	195,	'_wp_attached_file',	'2012/06/ACV1_PosterVenomstoDrugs_Sept2005.pdf'),
(414,	195,	'_wp_attachment_metadata',	'a:0:{}'),
(415,	196,	'_wp_attached_file',	'2012/06/ADAposter_June2005.pdf'),
(416,	196,	'_wp_attachment_metadata',	'a:0:{}'),
(417,	197,	'_wp_attached_file',	'2012/06/AGMCEOPresentation_27October2006.pdf'),
(418,	197,	'_wp_attachment_metadata',	'a:0:{}'),
(419,	198,	'_wp_attached_file',	'2012/06/AGMCEOPresentation_27October2006_001.pdf'),
(420,	198,	'_wp_attachment_metadata',	'a:0:{}'),
(421,	199,	'_wp_attached_file',	'2012/06/AGMPresentation_28Oct2005.pdf'),
(422,	199,	'_wp_attachment_metadata',	'a:0:{}'),
(423,	200,	'_wp_attached_file',	'2012/06/ASX_May23RoadshowPresentation.pdf'),
(424,	200,	'_wp_attachment_metadata',	'a:0:{}'),
(425,	201,	'_wp_attached_file',	'2012/06/BBY_Jeffries_Conference_Sydney19Oct05.pdf'),
(426,	201,	'_wp_attachment_metadata',	'a:0:{}'),
(427,	210,	'_wp_attached_file',	'2012/06/USPresentations_June-20051.pdf'),
(428,	210,	'_wp_attachment_metadata',	'a:0:{}'),
(429,	213,	'_wp_attached_file',	'2012/06/ADAposter_June20051.pdf'),
(430,	213,	'_wp_attachment_metadata',	'a:0:{}'),
(431,	220,	'_wp_attached_file',	'2012/06/2010_Annual_Report.pdf'),
(432,	220,	'_wp_attachment_metadata',	'a:0:{}'),
(433,	221,	'_wp_attached_file',	'2012/06/2011_Annual_Report_Calzada_FY11_FINAL_version.pdf'),
(434,	221,	'_wp_attachment_metadata',	'a:0:{}'),
(435,	222,	'_wp_attached_file',	'2012/06/31_December_2010_Financial_statements_FINAL.pdf'),
(436,	222,	'_wp_attachment_metadata',	'a:0:{}'),
(437,	226,	'_wp_attached_file',	'2012/06/132F042F2012103A213A23PM.pdf'),
(438,	226,	'_wp_attachment_metadata',	'a:0:{}'),
(439,	227,	'_wp_attached_file',	'2012/06/132F042F2012103A223A05PM.pdf'),
(440,	227,	'_wp_attachment_metadata',	'a:0:{}'),
(441,	228,	'_wp_attached_file',	'2012/06/132F042F2012103A223A30PM.pdf'),
(442,	228,	'_wp_attachment_metadata',	'a:0:{}'),
(443,	229,	'_wp_attached_file',	'2012/06/1899_Calzada_Shareholder_Newsletter_FINAL.pdf'),
(444,	229,	'_wp_attachment_metadata',	'a:0:{}'),
(445,	230,	'_wp_attached_file',	'2012/06/947775.pdf'),
(446,	230,	'_wp_attachment_metadata',	'a:0:{}'),
(447,	231,	'_wp_attached_file',	'2012/06/953112.pdf'),
(448,	231,	'_wp_attachment_metadata',	'a:0:{}'),
(449,	232,	'_wp_attached_file',	'2012/06/962429.pdf'),
(450,	232,	'_wp_attachment_metadata',	'a:0:{}'),
(451,	233,	'_wp_attached_file',	'2012/06/962630.pdf'),
(452,	233,	'_wp_attachment_metadata',	'a:0:{}'),
(453,	234,	'_wp_attached_file',	'2012/06/963942.pdf'),
(454,	234,	'_wp_attachment_metadata',	'a:0:{}'),
(455,	235,	'_wp_attached_file',	'2012/06/967193.pdf'),
(456,	235,	'_wp_attachment_metadata',	'a:0:{}'),
(457,	236,	'_wp_attached_file',	'2012/06/979227.pdf'),
(458,	236,	'_wp_attachment_metadata',	'a:0:{}'),
(459,	237,	'_wp_attached_file',	'2012/06/980299.pdf'),
(460,	237,	'_wp_attachment_metadata',	'a:0:{}'),
(461,	238,	'_wp_attached_file',	'2012/06/1007282.pdf'),
(462,	238,	'_wp_attachment_metadata',	'a:0:{}'),
(463,	239,	'_wp_attached_file',	'2012/06/1030228.pdf'),
(464,	239,	'_wp_attachment_metadata',	'a:0:{}'),
(465,	240,	'_wp_attached_file',	'2012/06/1030275.pdf'),
(466,	240,	'_wp_attachment_metadata',	'a:0:{}'),
(467,	241,	'_wp_attached_file',	'2012/06/1065480.pdf'),
(468,	241,	'_wp_attachment_metadata',	'a:0:{}'),
(469,	242,	'_wp_attached_file',	'2012/06/1074690.pdf'),
(470,	242,	'_wp_attachment_metadata',	'a:0:{}'),
(471,	243,	'_wp_attached_file',	'2012/06/1073489.pdf'),
(472,	243,	'_wp_attachment_metadata',	'a:0:{}'),
(473,	245,	'_wp_attached_file',	'2012/06/1899_Calzada_Shareholder_Newsletter_FINAL1.pdf'),
(474,	245,	'_wp_attachment_metadata',	'a:0:{}'),
(475,	246,	'_wp_attached_file',	'2012/06/Major_Milestone_for_PolyNovo_and_NovoSorbTM.pdf'),
(476,	246,	'_wp_attachment_metadata',	'a:0:{}'),
(477,	247,	'_wp_attached_file',	'2012/06/Notice_of_Annual_General_Meeting_and_Proxy_Form.pdf'),
(478,	247,	'_wp_attachment_metadata',	'a:0:{}'),
(479,	248,	'_wp_attached_file',	'2012/06/POH_Annoucnement.pdf'),
(480,	248,	'_wp_attachment_metadata',	'a:0:{}'),
(481,	249,	'_wp_attached_file',	'2012/06/Successful_Proof_of_Concept_for_Synthetic_Skin.pdf'),
(482,	249,	'_wp_attachment_metadata',	'a:0:{}'),
(483,	254,	'_wp_attached_file',	'2012/06/0605-ASX-Announcement-6-Feb-Qty-Investor-Update-FINAL.pdf'),
(484,	254,	'_wp_attachment_metadata',	'a:0:{}'),
(485,	255,	'_wp_attached_file',	'2012/06/0619-ASX-Announcement-10-May-Quarterly-Update-FINAL.pdf'),
(486,	255,	'_wp_attachment_metadata',	'a:0:{}'),
(487,	256,	'_wp_attached_file',	'2012/06/1899_Calzada_Shareholder_Newsletter_FINAL2.pdf'),
(488,	256,	'_wp_attachment_metadata',	'a:0:{}'),
(489,	257,	'_wp_attached_file',	'2012/06/051026-ASX-Announcement-Quarterly-Investor-Update-Octo..pdf'),
(490,	257,	'_wp_attachment_metadata',	'a:0:{}'),
(491,	258,	'_wp_attached_file',	'2012/06/ASX-Investor-Update-4-June-2004.pdf'),
(492,	258,	'_wp_attachment_metadata',	'a:0:{}'),
(493,	259,	'_wp_attached_file',	'2012/06/ASX-Investor-Update-8-Mar-2005.pdf'),
(494,	259,	'_wp_attachment_metadata',	'a:0:{}'),
(495,	260,	'_wp_attached_file',	'2012/06/ASX-Investor-Update-5-7-05.pdf'),
(496,	260,	'_wp_attachment_metadata',	'a:0:{}'),
(497,	261,	'_wp_attached_file',	'2012/06/ASX-Investor-Update-March-2004.pdf'),
(498,	261,	'_wp_attachment_metadata',	'a:0:{}'),
(499,	262,	'_wp_attached_file',	'2012/06/ASX_InvestorQuarterlyUpdate_July2006.pdf'),
(500,	262,	'_wp_attachment_metadata',	'a:0:{}'),
(501,	263,	'_wp_attached_file',	'2012/06/ASX_QuarterlyInvestorUpdate_17October2006.pdf'),
(502,	263,	'_wp_attachment_metadata',	'a:0:{}'),
(503,	264,	'_wp_attached_file',	'2012/06/ASX_QuarterlyInvestorUpdate_22ndJanuary2007.pdf'),
(504,	264,	'_wp_attachment_metadata',	'a:0:{}'),
(505,	265,	'_wp_attached_file',	'2012/06/ASX_QuarterlyInvestorUpdateQ0207_25July2007.pdf'),
(506,	265,	'_wp_attachment_metadata',	'a:0:{}'),
(507,	266,	'_wp_attached_file',	'2012/06/ASX_QuarterlyInvestorUpdateQ0307_October2007.pdf'),
(508,	266,	'_wp_attachment_metadata',	'a:0:{}'),
(509,	267,	'_wp_attached_file',	'2012/06/ASX_QuarterlyInvestorUpdateQ407_1Feb2008.pdf'),
(510,	267,	'_wp_attachment_metadata',	'a:0:{}'),
(511,	268,	'_wp_attached_file',	'2012/06/Investor-Update-22-September-2004.pdf'),
(512,	268,	'_wp_attachment_metadata',	'a:0:{}'),
(513,	269,	'_wp_attached_file',	'2012/06/ASX_QuarterlyInvestorUpdateQ107_5April2007.pdf'),
(514,	269,	'_wp_attachment_metadata',	'a:0:{}'),
(517,	137,	'_wp_page_template',	'default'),
(518,	279,	'_wp_attached_file',	'2012/06/1046682.pdf'),
(519,	279,	'_wp_attachment_metadata',	'a:0:{}'),
(520,	280,	'_wp_attached_file',	'2012/06/1046745.pdf'),
(521,	280,	'_wp_attachment_metadata',	'a:0:{}'),
(522,	281,	'_wp_attached_file',	'2012/06/AGM-2006-Chairman_s-address.pdf'),
(523,	281,	'_wp_attachment_metadata',	'a:0:{}'),
(524,	282,	'_wp_attached_file',	'2012/06/AGM-2006-Poll-Results.pdf'),
(525,	282,	'_wp_attachment_metadata',	'a:0:{}'),
(526,	283,	'_wp_attached_file',	'2012/06/AGM-2006-Presentation.pdf'),
(527,	283,	'_wp_attachment_metadata',	'a:0:{}'),
(528,	284,	'_wp_attached_file',	'2012/06/ASX-Annual-Report-2004-23-9-04.pdf'),
(529,	284,	'_wp_attachment_metadata',	'a:0:{}'),
(530,	285,	'_wp_attached_file',	'2012/06/ASX-AGM-Results-29-10-04.pdf'),
(531,	285,	'_wp_attachment_metadata',	'a:0:{}'),
(532,	286,	'_wp_attached_file',	'2012/06/ASX-Chairmans-Address-AGM-2004.pdf'),
(533,	286,	'_wp_attachment_metadata',	'a:0:{}'),
(534,	287,	'_wp_attached_file',	'2012/06/ASX_2007AGM_Results.pdf'),
(535,	287,	'_wp_attachment_metadata',	'a:0:{}'),
(536,	288,	'_wp_attached_file',	'2012/06/ASX_2008AGM_Chairman_address.pdf'),
(537,	288,	'_wp_attachment_metadata',	'a:0:{}'),
(538,	289,	'_wp_attached_file',	'2012/06/ASX_2008AGM_Presentation.pdf'),
(539,	289,	'_wp_attachment_metadata',	'a:0:{}'),
(540,	290,	'_wp_attached_file',	'2012/06/ASX_2008AGM_Results.pdf'),
(541,	290,	'_wp_attachment_metadata',	'a:0:{}'),
(542,	291,	'_wp_attached_file',	'2012/06/Metabolic-2007-AGM-Presentation1.pdf'),
(543,	291,	'_wp_attachment_metadata',	'a:0:{}'),
(544,	292,	'_wp_attached_file',	'2012/06/MPL_NOM_Final.pdf'),
(545,	292,	'_wp_attachment_metadata',	'a:0:{}'),
(546,	293,	'_wp_attached_file',	'2012/06/Notice_of_Annual_General_Meeting.pdf'),
(547,	293,	'_wp_attachment_metadata',	'a:0:{}'),
(548,	294,	'_wp_attached_file',	'2012/06/Notice_of_Annual_General_Meeting_and_Proxy_Form1.pdf'),
(549,	294,	'_wp_attachment_metadata',	'a:0:{}'),
(550,	295,	'_wp_attached_file',	'2012/06/2006-Notice-of-AGM-and-Proxy-Form.pdf'),
(551,	295,	'_wp_attachment_metadata',	'a:0:{}'),
(552,	296,	'_wp_attached_file',	'2012/06/2007-AGM-Chairmans-Address.pdf'),
(553,	296,	'_wp_attachment_metadata',	'a:0:{}'),
(554,	297,	'_wp_attached_file',	'2012/06/2007-Sample-Proxy-Form.pdf'),
(555,	297,	'_wp_attachment_metadata',	'a:0:{}'),
(556,	298,	'_wp_attached_file',	'2012/06/050927-ASX-Announcement-Annual-Report-and-Notice-of-AGM-2005.pdf'),
(557,	298,	'_wp_attachment_metadata',	'a:0:{}'),
(558,	299,	'_wp_attached_file',	'2012/06/051028b-ASX-Announcement-AGM-Results.pdf'),
(559,	299,	'_wp_attachment_metadata',	'a:0:{}'),
(560,	300,	'_wp_attached_file',	'2012/06/051028c-ASX-Announcement-AGM-address.pdf'),
(561,	300,	'_wp_attachment_metadata',	'a:0:{}'),
(562,	301,	'_wp_attached_file',	'2012/06/051028d-ASX-Announcement-AGM-preso.pdf'),
(563,	301,	'_wp_attachment_metadata',	'a:0:{}'),
(564,	302,	'_wp_attached_file',	'2012/06/1046608.pdf'),
(565,	302,	'_wp_attachment_metadata',	'a:0:{}'),
(566,	310,	'_wp_attached_file',	'2012/06/ASX_NoticeofAGMandProxyForm_28October2008.pdf'),
(567,	310,	'_wp_attachment_metadata',	'a:0:{}'),
(568,	312,	'_wp_attached_file',	'2012/05/Banner.jpg'),
(569,	312,	'_wp_attachment_metadata',	'a:6:{s:5:\"width\";s:3:\"960\";s:6:\"height\";s:3:\"368\";s:14:\"hwstring_small\";s:23:\"height=\'49\' width=\'128\'\";s:4:\"file\";s:18:\"2012/05/Banner.jpg\";s:5:\"sizes\";a:3:{s:9:\"thumbnail\";a:3:{s:4:\"file\";s:18:\"Banner-150x150.jpg\";s:5:\"width\";s:3:\"150\";s:6:\"height\";s:3:\"150\";}s:6:\"medium\";a:3:{s:4:\"file\";s:18:\"Banner-300x115.jpg\";s:5:\"width\";s:3:\"300\";s:6:\"height\";s:3:\"115\";}s:11:\"page-images\";a:3:{s:4:\"file\";s:18:\"Banner-632x233.jpg\";s:5:\"width\";s:3:\"632\";s:6:\"height\";s:3:\"233\";}}s:10:\"image_meta\";a:10:{s:8:\"aperture\";s:1:\"0\";s:6:\"credit\";s:0:\"\";s:6:\"camera\";s:0:\"\";s:7:\"caption\";s:0:\"\";s:17:\"created_timestamp\";s:1:\"0\";s:9:\"copyright\";s:0:\"\";s:12:\"focal_length\";s:1:\"0\";s:3:\"iso\";s:1:\"0\";s:13:\"shutter_speed\";s:1:\"0\";s:5:\"title\";s:0:\"\";}}'),
(570,	6,	'_thumbnail_id',	'312'),
(571,	314,	'_menu_item_type',	'custom'),
(572,	314,	'_menu_item_menu_item_parent',	'0'),
(573,	314,	'_menu_item_object_id',	'314'),
(574,	314,	'_menu_item_object',	'custom'),
(575,	314,	'_menu_item_target',	''),
(576,	314,	'_menu_item_classes',	'a:1:{i:0;s:0:\"\";}'),
(577,	314,	'_menu_item_xfn',	''),
(578,	314,	'_menu_item_url',	'http://polynovo.com/'),
(580,	319,	'_wp_attached_file',	'2012/06/1059707.pdf'),
(581,	319,	'_wp_attachment_metadata',	'a:0:{}'),
(582,	322,	'_wp_attached_file',	'2012/06/943726.pdf'),
(583,	322,	'_wp_attachment_metadata',	'a:0:{}'),
(584,	324,	'_wp_attached_file',	'2012/06/p2.pdf'),
(585,	324,	'_wp_attachment_metadata',	'a:0:{}'),
(586,	326,	'_wp_attached_file',	'2012/06/p3.pdf'),
(587,	326,	'_wp_attachment_metadata',	'a:0:{}'),
(588,	328,	'_wp_attached_file',	'2012/06/p4.pdf'),
(589,	328,	'_wp_attachment_metadata',	'a:0:{}'),
(590,	330,	'_wp_attached_file',	'2012/06/p5.pdf'),
(591,	330,	'_wp_attachment_metadata',	'a:0:{}'),
(592,	332,	'_wp_attached_file',	'2012/06/p6.pdf'),
(593,	332,	'_wp_attachment_metadata',	'a:0:{}'),
(594,	334,	'_wp_attached_file',	'2012/06/p7.pdf'),
(595,	334,	'_wp_attachment_metadata',	'a:0:{}'),
(596,	336,	'_wp_attached_file',	'2012/06/p8.pdf'),
(597,	336,	'_wp_attachment_metadata',	'a:0:{}'),
(598,	338,	'_wp_attached_file',	'2012/06/p9.pdf'),
(599,	338,	'_wp_attachment_metadata',	'a:0:{}'),
(600,	340,	'_wp_attached_file',	'2012/06/p10.pdf'),
(601,	340,	'_wp_attachment_metadata',	'a:0:{}'),
(602,	342,	'_wp_attached_file',	'2012/06/p11.pdf'),
(603,	342,	'_wp_attachment_metadata',	'a:0:{}'),
(604,	344,	'_wp_attached_file',	'2012/06/p12.pdf'),
(605,	344,	'_wp_attachment_metadata',	'a:0:{}'),
(606,	346,	'_wp_attached_file',	'2012/06/p13.pdf'),
(607,	346,	'_wp_attachment_metadata',	'a:0:{}'),
(608,	348,	'_wp_attached_file',	'2012/06/p14.pdf'),
(609,	348,	'_wp_attachment_metadata',	'a:0:{}'),
(610,	350,	'_wp_attached_file',	'2012/06/p15.pdf'),
(611,	350,	'_wp_attachment_metadata',	'a:0:{}'),
(612,	352,	'_wp_attached_file',	'2012/06/p16.pdf'),
(613,	352,	'_wp_attachment_metadata',	'a:0:{}'),
(614,	354,	'_wp_attached_file',	'2012/06/p17.pdf'),
(615,	354,	'_wp_attachment_metadata',	'a:0:{}'),
(616,	356,	'_wp_attached_file',	'2012/06/p18.pdf'),
(617,	356,	'_wp_attachment_metadata',	'a:0:{}'),
(618,	358,	'_wp_attached_file',	'2012/06/p19.pdf'),
(619,	358,	'_wp_attachment_metadata',	'a:0:{}'),
(620,	360,	'_wp_attached_file',	'2012/06/p20.pdf'),
(621,	360,	'_wp_attachment_metadata',	'a:0:{}'),
(622,	362,	'_wp_attached_file',	'2012/06/p21.pdf'),
(623,	362,	'_wp_attachment_metadata',	'a:0:{}'),
(624,	364,	'_wp_attached_file',	'2012/06/p22.pdf'),
(625,	364,	'_wp_attachment_metadata',	'a:0:{}'),
(626,	366,	'_wp_attached_file',	'2012/06/p23.pdf'),
(627,	366,	'_wp_attachment_metadata',	'a:0:{}'),
(628,	368,	'_wp_attached_file',	'2012/06/pp1.pdf'),
(629,	368,	'_wp_attachment_metadata',	'a:0:{}'),
(630,	370,	'_wp_attached_file',	'2012/06/pp2.pdf'),
(631,	370,	'_wp_attachment_metadata',	'a:0:{}'),
(632,	372,	'_wp_attached_file',	'2012/06/pp3.pdf'),
(633,	372,	'_wp_attachment_metadata',	'a:0:{}'),
(634,	374,	'_wp_attached_file',	'2012/06/pp4.pdf'),
(635,	374,	'_wp_attachment_metadata',	'a:0:{}'),
(636,	375,	'_wp_attached_file',	'2012/06/pp5.pdf'),
(637,	375,	'_wp_attachment_metadata',	'a:0:{}'),
(638,	376,	'_wp_attached_file',	'2012/06/pp6.pdf'),
(639,	376,	'_wp_attachment_metadata',	'a:0:{}'),
(640,	377,	'_wp_attached_file',	'2012/06/pp7.pdf'),
(641,	377,	'_wp_attachment_metadata',	'a:0:{}'),
(642,	378,	'_wp_attached_file',	'2012/06/pp8.pdf'),
(643,	378,	'_wp_attachment_metadata',	'a:0:{}'),
(644,	379,	'_wp_attached_file',	'2012/06/pp9.pdf'),
(645,	379,	'_wp_attachment_metadata',	'a:0:{}'),
(646,	380,	'_wp_attached_file',	'2012/06/pp10.pdf'),
(647,	380,	'_wp_attachment_metadata',	'a:0:{}'),
(648,	381,	'_wp_attached_file',	'2012/06/pp11.pdf'),
(649,	381,	'_wp_attachment_metadata',	'a:0:{}'),
(650,	382,	'_wp_attached_file',	'2012/06/pp12.pdf'),
(651,	382,	'_wp_attachment_metadata',	'a:0:{}'),
(652,	384,	'_wp_attached_file',	'2012/06/pp13.pdf'),
(653,	384,	'_wp_attachment_metadata',	'a:0:{}'),
(654,	386,	'_wp_attached_file',	'2012/06/pp14.pdf'),
(655,	386,	'_wp_attachment_metadata',	'a:0:{}'),
(656,	387,	'_wp_attached_file',	'2012/06/pp15.pdf'),
(657,	387,	'_wp_attachment_metadata',	'a:0:{}'),
(658,	388,	'_wp_attached_file',	'2012/06/pp16.pdf'),
(659,	388,	'_wp_attachment_metadata',	'a:0:{}'),
(660,	389,	'_wp_attached_file',	'2012/06/pp17.pdf'),
(661,	389,	'_wp_attachment_metadata',	'a:0:{}'),
(662,	390,	'_wp_attached_file',	'2012/06/pp18.pdf'),
(663,	390,	'_wp_attachment_metadata',	'a:0:{}'),
(664,	391,	'_wp_attached_file',	'2012/06/pp19.pdf'),
(665,	391,	'_wp_attachment_metadata',	'a:0:{}'),
(666,	392,	'_wp_attached_file',	'2012/06/pp20.pdf'),
(667,	392,	'_wp_attachment_metadata',	'a:0:{}'),
(668,	393,	'_wp_attached_file',	'2012/06/pp21.pdf'),
(669,	393,	'_wp_attachment_metadata',	'a:0:{}'),
(670,	394,	'_wp_attached_file',	'2012/06/pp22.pdf'),
(671,	394,	'_wp_attachment_metadata',	'a:0:{}'),
(672,	77,	'hide_on_screen',	'a:0:{}'),
(707,	47,	'_aioseop_description',	'Nullam quis risus eget urna mollis ornare vel eu leo. Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Etiam porta sem malesuada magna mollis euismod. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Curabitur blandit tempus porttitor. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.\r\n\r\nCum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec ullamcorper nulla non metus auctor fringilla.'),
(708,	47,	'_aioseop_title',	'Employment'),
(713,	43,	'_aioseop_description',	'Lorem ipsum dolor sit amet'),
(714,	43,	'_aioseop_title',	'Footer to go here'),
(761,	147,	'_aioseop_description',	'2011 Annual General Meeting\r\n\r\nThe 2011 Annual General Meeting of Calzada Limited will be held at Unit 2, 320 Lorimer Street, Port Melbourne, Victoria, at 10:00am (Melbourne time)on the 15th of November 2011.\r\n\r\nNotice of AGM\r\nChairmans Address\r\nResults of Meeting\r\nNotice of AGM\r\n'),
(762,	147,	'_aioseop_title',	'Annual General Meeting	'),
(785,	155,	'_aioseop_description',	' 	 \r\n \r\n 	Calzada Shareholder Newsletter June 2011\r\n 	 \r\n \r\n 	February 2008 - Quarterly Investor Update - Fourth Quarter 2007\r\n 	 \r\n \r\n 	October 2007 - Quarterly Investor Update - Third Quarter 2007\r\n 	 \r\n \r\n 	July 2007 - Quarterly Investor Update - Second Quarter 2007\r\n 	 \r\n \r\n 	April 2007 - Quarterly Investor Update - First Quarter 2007\r\n 	 \r\n \r\n 	January 2007 - Quarterly Investor Update - Fourth Quarter 2006\r\n 	 \r\n \r\n 	October 2006 - Quarterly Investor Update - Third Quarter 2006\r\n 	 \r\n \r\n 	July 2006 - Quarterly Investor Update - Second Quarter 2006\r\n 	 \r\n '),
(786,	155,	'_aioseop_title',	'Newsletters'),
(789,	157,	'_aioseop_title',	'Articles'),
(792,	159,	'_aioseop_title',	'Press'),
(795,	161,	'_aioseop_title',	'Research Reports'),
(866,	452,	'_wp_attached_file',	'2012/07/Bioshares450rbpCZD.pdf'),
(867,	452,	'_wp_attachment_metadata',	'a:0:{}'),
(868,	453,	'_edit_last',	'1'),
(873,	453,	'_edit_lock',	'1343799864:1'),
(876,	456,	'_wp_attached_file',	'2012/07/132F042F2012103A223A30PM.pdf'),
(877,	456,	'_wp_attachment_metadata',	'a:0:{}'),
(886,	462,	'_wp_attached_file',	'2012/07/132F042F2012103A223A05PM.pdf'),
(887,	462,	'_wp_attachment_metadata',	'a:0:{}'),
(890,	464,	'_wp_attached_file',	'2012/07/132F042F2012103A213A23PM.pdf'),
(891,	464,	'_wp_attachment_metadata',	'a:0:{}'),
(894,	468,	'_wp_attached_file',	'2012/07/1074690.pdf'),
(895,	468,	'_wp_attachment_metadata',	'a:0:{}'),
(896,	469,	'_wp_attached_file',	'2012/07/10746901.pdf'),
(897,	469,	'_wp_attachment_metadata',	'a:0:{}'),
(926,	15,	'_aioseop_description',	'Mr Laurent Fossaert\r\n\r\nCHIEF EXECUTIVE OFFICER – POLYNOVO BIOMATERIALS PTY LTD\r\n\r\nLF to provide wording.\r\n\r\nXXXXX\r\n\r\n\r\n\r\nMr David Kenley\r\n\r\nCHIEF EXECUTIVE OFFICER – metabolic pharmaceuticals PTY LTD\r\n\r\nDavid Kenley has a Masters degree in Entrepreneurship & Innovation, a Bachelor of Economics and is a member of the Australian Institute of Company Directors.  Over the last 25 years his career has focussed on the commercialisation of research results from Australia’s leading research institutions including CSIRO.  He has gained considerable experience in the establishment of spin-off companies and the licensing of research in many fields of science and over the last 14 years has focussed on the biotechnology sector.'),
(927,	15,	'_aioseop_title',	'Management & Staff'),
(940,	476,	'_wp_attached_file',	'2012/06/ASX-Ann_30-Jul-12.pdf'),
(941,	476,	'_wp_attachment_metadata',	'a:0:{}'),
(958,	477,	'_edit_last',	'1'),
(959,	477,	'_edit_lock',	'1343868016:1'),
(1122,	25,	'_aioseop_description',	'Donec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.\r\n\r\n[listing type=\"post\" title=\"News Listing\" count=\"5\"]\r\n'),
(1123,	25,	'_aioseop_title',	'News & Media'),
(1124,	493,	'_edit_last',	'1'),
(1125,	493,	'_edit_lock',	'1344303958:1'),
(1132,	496,	'_wp_attached_file',	'2012/08/PolyNovo-US-Patent-Allowed_7-Aug-12.pdf'),
(1133,	496,	'_wp_attachment_metadata',	'a:0:{}'),
(1148,	500,	'_wp_attached_file',	'2012/06/PolyNovo-US-Patent-Allowed_7-Aug-12.pdf'),
(1149,	500,	'_wp_attachment_metadata',	'a:0:{}'),
(1166,	8,	'_aioseop_description',	'Calzada has two wholly owned subsidiaries, PolyNovo Biomaterials Pty Ltd (“PolyNovo”) and Metabolic Pharmaceuticals Pty Ltd (“Metabolic”), both have high potential and maturing products reaching major value inflexion points.'),
(1167,	8,	'_aioseop_title',	'About Us'),
(1184,	145,	'_aioseop_description',	'Share Register Enquiries\r\n\r\nTo view information relating to your securityholding, or to update your securityholding details, please visit www.investorcentre.com or click here.\r\n\r\nFor shareholder related enquiries, such as changing your address or consolidating your holdings, please direct enquiries to:\r\n'),
(1185,	145,	'_aioseop_title',	'Share Registry'),
(1278,	27,	'_aioseop_description',	'Calzada Limited\r\n\r\n\r\n\r\nWendy Townsend\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia	Phone:+61 (0) 3 8681 4050\r\nFax:+61 (0) 3 8681 4099\r\nEmail:wtownsend@calzada.com.au\r\nPolyNovo Biomaterials Pty Ltd\r\n\r\n\r\n\r\nChief Executive Officer\r\nMr. Laurent Fossaert\r\nPolyNovo Biomaterials Pty Ltd\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia	Phone:+61 (0) 3 8681 4050\r\nFax:+61 (0) 3 8681 4099\r\nEmail:info@polynovo.com\r\nMetabolic Pharmaceuticals Pty Ltd\r\n\r\n\r\n\r\nChief Executive Officer\r\nMr. David Kenley\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia	Phone:+61 (0) 3 8681 4050\r\nFax:+61 (0) 3 8681 4099\r\nEmail:dkenley@calzada.com.au'),
(1279,	27,	'_aioseop_title',	'Contact Us'),
(1280,	514,	'_edit_last',	'1'),
(1281,	514,	'_edit_lock',	'1344392235:1'),
(1282,	515,	'_wp_attached_file',	'2012/08/Dr-David-McQuillan-to-Join-the-Calzada-Board_8-Aug-12.pdf'),
(1283,	515,	'_wp_attachment_metadata',	'a:0:{}'),
(1476,	13,	'_aioseop_description',	'Mr David Franklyn (BEcon)\r\n\r\nNON-EXECUTIVE CHAIRMAN\r\n\r\nMr Franklyn is Chairman of Calzada and its 100% owned subsidiary PolyNovo Biomaterials Pty Ltd and has held that title since 16th April 2009.\r\n\r\nMr Franklyn holds an Economics degree from the University of Western Australia and has completed the Graduate Diploma in Applied Finance and Investment from the Securities Institute of Australia, now FINSIA.\r\n'),
(1477,	13,	'_aioseop_title',	'Board of Directors'),
(1478,	554,	'_wp_attached_file',	'2012/05/Corporate-Governance-Statement-30-June-2012.pdf'),
(1479,	554,	'_wp_attachment_metadata',	'a:0:{}'),
(1486,	556,	'_wp_attached_file',	'2012/05/Market-Disclosure-Protocol-June-12.pdf'),
(1487,	556,	'_wp_attachment_metadata',	'a:0:{}'),
(1488,	557,	'_wp_attached_file',	'2012/05/Market-Disclosure-Protocol-June-121.pdf'),
(1489,	557,	'_wp_attachment_metadata',	'a:0:{}'),
(1490,	558,	'_wp_attached_file',	'2012/05/CZD-BOARD-CHARTER-June-2012.pdf'),
(1491,	558,	'_wp_attachment_metadata',	'a:0:{}'),
(1492,	559,	'_wp_attached_file',	'2012/05/Risk-Management-Policy-June-2012.pdf'),
(1493,	559,	'_wp_attachment_metadata',	'a:0:{}'),
(1494,	560,	'_wp_attached_file',	'2012/05/Calzada-Share-Trading-Policy-21-Dec-10.pdf'),
(1495,	560,	'_wp_attachment_metadata',	'a:0:{}'),
(1496,	561,	'_wp_attached_file',	'2012/05/Communications-Policy-June-2012-v2.pdf'),
(1497,	561,	'_wp_attachment_metadata',	'a:0:{}'),
(1498,	562,	'_wp_attached_file',	'2012/05/Audit-Committee-Charter-June-12.pdf'),
(1499,	562,	'_wp_attachment_metadata',	'a:0:{}'),
(1500,	563,	'_wp_attached_file',	'2012/05/CZD-CODE-OF-CONDUCT-Final-FY12.pdf'),
(1501,	563,	'_wp_attachment_metadata',	'a:0:{}'),
(1502,	564,	'_wp_attached_file',	'2012/05/Calzada-Gender-Diversity-Policy-June-12.pdf'),
(1503,	564,	'_wp_attachment_metadata',	'a:0:{}'),
(1512,	565,	'_wp_attached_file',	'2012/05/Calzada-Share-Trading-Policy-21-Dec-101.pdf'),
(1513,	565,	'_wp_attachment_metadata',	'a:0:{}'),
(1514,	566,	'_wp_attached_file',	'2012/05/CZD-BOARD-CHARTER-June-20121.pdf'),
(1515,	566,	'_wp_attachment_metadata',	'a:0:{}'),
(1516,	567,	'_wp_attached_file',	'2012/05/Communications-Policy-June-2012-v21.pdf'),
(1517,	567,	'_wp_attachment_metadata',	'a:0:{}'),
(1528,	569,	'_wp_attached_file',	'2012/05/CZD-CODE-OF-CONDUCT-Final-FY121.pdf'),
(1529,	569,	'_wp_attachment_metadata',	'a:0:{}'),
(1536,	571,	'_wp_attached_file',	'2012/05/CZD-CODE-OF-CONDUCT-Final-FY122.pdf'),
(1537,	571,	'_wp_attachment_metadata',	'a:0:{}'),
(1548,	17,	'_aioseop_description',	'Introduction\r\n\r\nThe Board of Calzada is responsible for the corporate governance of the Group and guides and monitors the business on behalf of its shareholders. The Board has strived to reach a balance between industry best practice and appropriate policies for Calzada in terms of its size, stage of development and role in the biotechnology industry. Calzada performed a review of its Board policies and governance practices with reference to the eight Principles of Good Corporate Governance and the Best Practice Recommendations (Recommendations) established by the ASX Corporate Governance Council. The Recommendations are not mandatory and cannot, in themselves, prevent corporate failure or poor corporate decision-making. They are intended to provide a reference point for companies about their corporate governance structures and practices.\r\n'),
(1549,	17,	'_aioseop_title',	'Corporate Governance'),
(1626,	23,	'_aioseop_description',	'Share Register Enquiries\r\n\r\nTo view information relating to your securityholding, or to update your securityholding details, please visit www.investorcentre.com or click here.\r\n\r\nFor shareholder related enquiries, such as changing your address or consolidating your holdings, please direct enquiries to:\r\n\r\nComputershare Investor Services\r\n\r\nYarra Falls\r\n452 Johnston Street\r\nAbbotsford Victoria 3067\r\nAustralia\r\n\r\nPhone: 1300 850 505\r\nFax: +61 3 9473 2500\r\nEmail: Web.queries@computershare.com.au'),
(1627,	23,	'_aioseop_title',	'Investor Centre'),
(1628,	585,	'_wp_attached_file',	'2012/08/POlyNovo-Clinical-Trial-and-Composite-Cultured-Skin-Update.pdf'),
(1629,	585,	'_wp_attachment_metadata',	'a:0:{}'),
(1630,	584,	'_edit_last',	'1'),
(1631,	584,	'_edit_lock',	'1345769620:1'),
(1638,	591,	'_wp_attached_file',	'2012/06/Dr-David-McQuillan-to-Join-the-Calzada-Board_8-Aug-12.pdf'),
(1639,	591,	'_wp_attachment_metadata',	'a:0:{}'),
(1650,	593,	'_wp_attached_file',	'2012/06/POlyNovo-Clinical-Trial-and-Composite-Cultured-Skin-Update.pdf'),
(1651,	593,	'_wp_attachment_metadata',	'a:0:{}'),
(1662,	596,	'_wp_attached_file',	'2012/08/Annual-Report-2012.pdf'),
(1663,	596,	'_wp_attachment_metadata',	'a:0:{}'),
(1664,	595,	'_edit_last',	'1'),
(1665,	595,	'_edit_lock',	'1345778670:1'),
(1668,	599,	'_wp_attached_file',	'2012/06/ASX-Annoucnement-half-year-results-Dec-11.pdf'),
(1669,	599,	'_wp_attachment_metadata',	'a:0:{}'),
(1674,	600,	'_wp_attached_file',	'2012/06/31-December-2011-Financial-statements-Final.pdf'),
(1675,	600,	'_wp_attachment_metadata',	'a:0:{}'),
(1676,	601,	'_wp_attached_file',	'2012/06/2012-Annual-Report_ONLY.pdf'),
(1677,	601,	'_wp_attachment_metadata',	'a:0:{}'),
(1686,	143,	'_aioseop_description',	'Annual Reports\r\n\r\nRelated Files:\r\n2010_Annual_Report.pdf\r\n31_December_2010_Financial_statements_FINAL.pdf\r\n2011_Annual_Report_Calzada_FY11_FINAL_version.pdf'),
(1687,	143,	'_aioseop_title',	'Financial Reports'),
(1688,	603,	'_wp_attached_file',	'2012/06/Annual-Report-2012.pdf'),
(1689,	603,	'_wp_attachment_metadata',	'a:0:{}'),
(1698,	141,	'_aioseop_description',	'Click on a year to view links to PDFs\r\n\r\n2012 ASX Releases 2012\r\n\r\n\r\n 	\r\nASX Releases 2012\r\n\r\n\r\n \r\n 	PolyNovo human Trial Update\r\n 	PolyNovo human Trial Update\r\n \r\n 	AOD positive in Cartilage and Muscle Repair\r\n 	AOD positive in Cartilage and Muscle Repair\r\n \r\n 	PolyNovo Commences Second Human Trial\r\n 	PolyNovo Commences Second Human Trial\r\n \r\n 	PolyNovo to Commence Human Trial\r\n 	PolyNovo to Commence Human Trial\r\n \r\n 	PolyNovo’s US Collaboration Update\r\n 	PolyNovo’s US Collaboration Update\r\n \r\n 	Update on US Partner Collaboration\r\n 	Update on US Partner Collaboration\r\n \r\n'),
(1699,	141,	'_aioseop_title',	'ASX Announcements'),
(1712,	139,	'_aioseop_description',	'Metabolic Pharmaceuticals Pty Ltd'),
(1713,	139,	'_aioseop_title',	'Metabolic'),
(1720,	608,	'_wp_attached_file',	'2012/06/Calzada-AGM-Presentation_Nov-2011.pdf'),
(1721,	608,	'_wp_attachment_metadata',	'a:0:{}'),
(1726,	609,	'_wp_attached_file',	'2012/06/Calzada-AGM-Presentation_Nov-20111.pdf'),
(1727,	609,	'_wp_attachment_metadata',	'a:0:{}'),
(1728,	610,	'_wp_attached_file',	'2012/06/Calzada-AGM-Presentation_Nov-20112.pdf'),
(1729,	610,	'_wp_attachment_metadata',	'a:0:{}'),
(1748,	133,	'_aioseop_description',	'Presentations\r\n\r\n\r\n\r\n15th April 2011\r\nAGM Presentation 2010\r\nClick here to download presentation (1.7mb)\r\n\r\n18th July 2008\r\nCorporate Presentation: Metabolic\'s acquisition of PolyNovo\r\nRob Stewart, Chairman of Metabolic and Ian Griffiths, CEO of PolyNovo\r\nClick here to download presentation (495 kb)\r\n\r\n2nd November 2007\r\n2007 AGM Presentation\r\nRob Stewart, Chairman and Roland Scollay, CEO\r\nClick here to download presentation (432 kb)\r\n\r\n'),
(1749,	133,	'_aioseop_title',	'Presentations'),
(1776,	6,	'_aioseop_description',	'Calzada Limited is a biotechnology company that provides investment exposure to two wholly owned subsidiaries with high potential and maturing products reaching major value inflexion points.\r\n\r\nCalzada is listed on the Australian Securities Exchange (Code CZD).'),
(1777,	6,	'_aioseop_title',	'Home');

DROP TABLE IF EXISTS `calzada_posts`;
CREATE TABLE `calzada_posts` (
  `ID` bigint(20) unsigned NOT NULL AUTO_INCREMENT,
  `post_author` bigint(20) unsigned NOT NULL DEFAULT '0',
  `post_date` datetime NOT NULL DEFAULT '0000-00-00 00:00:00',
  `post_date_gmt` datetime NOT NULL DEFAULT '0000-00-00 00:00:00',
  `post_content` longtext NOT NULL,
  `post_title` text NOT NULL,
  `post_excerpt` text NOT NULL,
  `post_status` varchar(20) NOT NULL DEFAULT 'publish',
  `comment_status` varchar(20) NOT NULL DEFAULT 'open',
  `ping_status` varchar(20) NOT NULL DEFAULT 'open',
  `post_password` varchar(20) NOT NULL DEFAULT '',
  `post_name` varchar(200) NOT NULL DEFAULT '',
  `to_ping` text NOT NULL,
  `pinged` text NOT NULL,
  `post_modified` datetime NOT NULL DEFAULT '0000-00-00 00:00:00',
  `post_modified_gmt` datetime NOT NULL DEFAULT '0000-00-00 00:00:00',
  `post_content_filtered` text NOT NULL,
  `post_parent` bigint(20) unsigned NOT NULL DEFAULT '0',
  `guid` varchar(255) NOT NULL DEFAULT '',
  `menu_order` int(11) NOT NULL DEFAULT '0',
  `post_type` varchar(20) NOT NULL DEFAULT 'post',
  `post_mime_type` varchar(100) NOT NULL DEFAULT '',
  `comment_count` bigint(20) NOT NULL DEFAULT '0',
  PRIMARY KEY (`ID`),
  KEY `post_name` (`post_name`),
  KEY `type_status_date` (`post_type`,`post_status`,`post_date`,`ID`),
  KEY `post_parent` (`post_parent`),
  KEY `post_author` (`post_author`)
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

INSERT INTO `calzada_posts` (`ID`, `post_author`, `post_date`, `post_date_gmt`, `post_content`, `post_title`, `post_excerpt`, `post_status`, `comment_status`, `ping_status`, `post_password`, `post_name`, `to_ping`, `pinged`, `post_modified`, `post_modified_gmt`, `post_content_filtered`, `post_parent`, `guid`, `menu_order`, `post_type`, `post_mime_type`, `comment_count`) VALUES
(6,	1,	'2012-05-21 20:19:01',	'2012-05-21 20:19:01',	'',	'Home',	'',	'publish',	'open',	'open',	'',	'home',	'',	'',	'2012-08-24 05:35:05',	'2012-08-24 05:35:05',	'',	0,	'http://calzada-wp.urldock.com/?page_id=6',	0,	'page',	'',	0),
(7,	1,	'2012-05-21 20:18:55',	'2012-05-21 20:18:55',	'',	'Auto Draft',	'',	'inherit',	'open',	'open',	'',	'6-revision',	'',	'',	'2012-05-21 20:18:55',	'2012-05-21 20:18:55',	'',	6,	'http://calzada-wp.urldock.com/6-revision/',	0,	'revision',	'',	0),
(8,	1,	'2012-05-21 20:20:53',	'2012-05-21 20:20:53',	'Calzada has two wholly owned subsidiaries, PolyNovo Biomaterials Pty Ltd (“PolyNovo”) and Metabolic Pharmaceuticals Pty Ltd (“Metabolic”), both have high potential and maturing products reaching major value inflexion points.\n<h3>PolyNovo</h3>\n<a title=\"PolyNovo Biomaterials\" href=\"http://polynovo.com/\">PolyNovo Biomaterials</a> has developed a unique biodegradable polymer platform technology (NovoSorb™) designed to be used in medical devices and for tissue engineering scaffolds. The potential applications include reconstructive surgery and repair in a diverse range of fields including wounds, burns, cardiovascular, orthopaedic, periodontal, cartilage and drug delivery.\n\nPolyNovo is developing two lead products with world leading burns surgeon, Associate Professor John Greenwood AM (20% interest).\n<h3>Metabolic</h3>\nMetabolic Pharmaceuticals is seeking to derive value from the past investment of over $50mill in the pharmaceutical development of AOD9604. The peptide has proven to be safe and well tolerated in a total of 6 human clinical trials involving 925 humans.\n<h3>Corporate</h3>\nThe corporate head office takes responsibility for group strategy, capital allocation, identification and analysis of investment opportunities and investor and media relations.\n\nFor further information on Calzada please <a title=\"Contact Us\" href=\"http://calzada-wp.urldock.com/contact-us/\">contact us</a>.',	'About Us',	'',	'publish',	'open',	'open',	'',	'about-us',	'',	'',	'2012-08-06 04:55:30',	'2012-08-06 04:55:30',	'',	0,	'http://calzada-wp.urldock.com/?page_id=8',	0,	'page',	'',	0),
(9,	1,	'2012-05-21 20:20:45',	'2012-05-21 20:20:45',	'',	'Auto Draft',	'',	'inherit',	'open',	'open',	'',	'8-revision',	'',	'',	'2012-05-21 20:20:45',	'2012-05-21 20:20:45',	'',	8,	'http://calzada-wp.urldock.com/8-revision/',	0,	'revision',	'',	0),
(13,	1,	'2012-05-21 20:22:03',	'2012-05-21 20:22:03',	'<h3>Mr David Franklyn (BEcon)</h3>\r\n<h4>NON-EXECUTIVE CHAIRMAN</h4>\r\nMr Franklyn is Chairman of Calzada and its 100% owned subsidiary PolyNovo Biomaterials Pty Ltd and has held that title since 16th April 2009.\r\n\r\nMr Franklyn holds an Economics degree from the University of Western Australia and has completed the Graduate Diploma in Applied Finance and Investment from the Securities Institute of Australia, now FINSIA.\r\n\r\nMr Franklyn has been involved in the financial services industry for over twenty years. He has extensive experience in the financial analysis of companies, funds management, corporate finance, business management and investor relations. His previous roles include being Head of Research for a national stockbroker and General Manager Corporate Communications for an ASX 200 company.\r\n\r\nMr Franklyn is currently Managing Director of Entrust Funds Management Ltd, a Western Australian based boutique funds management business, and an Executive Director of ASX Listed Nomad Building Solutions Ltd.\r\n<h3>Dr David McQuillan (PhD)</h3>\r\n<h4><strong>NON-EXECUTIVE DIRECTOR </strong></h4>\r\nDr McQuillan was appointed a Director of Calzada on 6th August 2012.\r\n\r\nDr McQuillan possesses extensive technical, medical, scientific and regulatory knowledge as well as significant mergers and acquisition expertise.\r\n\r\nIn 2000, Dr McQuillan joined LifeCell Corporation as the Vice-President for Research and Development (R &amp; D). He led LifeCell’s R &amp; D team focusing on the creation of market-leading products for reconstructive and plastic surgery applications.  Following marketing approval in 2008 for its new reconstructive tissue matrix StratticeTM, LifeCell was acquired by Kinetic Concepts Inc (“KCI”) for US$1.8 billion. Following the acquisition, Dr McQuillan became the Senior Vice President of the Advanced Research and Technology unit at KCI.  Dr McQuillan left KCI in 2011 after its acquisition by a private consortium for US$6.7 billion.\r\n\r\nDr McQuillan is currently a consultant to several leading US based Healthcare Investment Funds that are focused in the fields of regenerative medicine, medical devices and tissue engineering.  He is also the Chief Scientific Officer of Humacyte, Inc., Durham, NC.\r\n<h3>Mr Bruce Rathie (BComm, LLB, MBA, FAIM, FAICD)</h3>\r\n<h4>NON-EXECUTIVE DIRECTOR</h4>\r\nMr Rathie was appointed a Director of Calzada on 18th February 2010.\r\n\r\nMr Rathie holds degrees in law, commerce and business and has considerable experience as a lawyer having practiced as a solicitor and partner in a major Brisbane based legal firm and then as Senior in-house Counsel to Bell Resources Limited from 1980 to 1985 in aggregate.\r\n\r\nHe studied for his MBA in Geneva and then went into investment banking in 1986 which subsequently took him to New York returning to Sydney in 1990.\r\n\r\nHe spent the 1990\'s in investment banking in Sydney, the last 5 years as a Director of Investment Banking at Salomon Brothers/ Salomon Smith Barney where he was Head of the Industrial Franchise Group and also led Salomon\'s roles in the Federal Government\'s privatisation of Qantas, Commonwealth Bank (CBA3) and Telstra (T1).\r\n\r\nMr Rathie currently is, in addition to his Non-Executive Director role at Calzada, a Non-Executive Director of ASX listed companies Mungana Goldmines Limited (a gold mining company) and DataDot Technology Limited (an industrial security products company) which he Chairs. He is also a Non-Executive Director of Capricorn Society Limited the largest auto parts cooperative in the Southern Hemisphere with operations in Australia, South Africa and New Zealand, and is also Chairman of EFTPOS Payments Australia Limited the Australian debit card payment company. In the past, he has served on the Boards of other ASX listed medical device companies being Anteo Diagnostics Limited (2006 - 2009), Compumedics Limited (2004 - 2006) and USCOM Limited (2006 – 2011).\r\n<h3>Dr John Chiplin, Ph.D.</h3>\r\n<h4>NON-EXECUTIVE DIRECTOR</h4>\r\nDr Chiplin was appointed a Director of Calzada on 18th October 2010.\r\n\r\nDr Chiplin is one of the most successful life sciences professionals in the Australian biotech industry. His most recent accomplishment was the corporate re-engineering of Arana Therapeutics (Arana), a world leading antibody developer, which resulted in the mid 2009 acquisition of Arana by Cephalon for $329 million at a 70 percent premium to the market valuation. Immediately prior to running Arana, Dr Chiplin was head of the $300 million ITI Life Sciences investment fund in the United Kingdom and prior to this was co-founder and Chief Executive officer of Geneformatics Inc.\r\n\r\nDr Chiplin brings considerable international biotechnology industry experience, deep technical medical and scientific knowledge and extensive mergers and acquisition and investment expertise.\r\n\r\nDr Chiplin is a current Non-Executive Director of ASX listed Benitec Ltd, Healthlinx Ltd and a Director of ScienceMedia.',	'Board of Directors',	'',	'publish',	'open',	'open',	'',	'board-of-directors',	'',	'',	'2012-08-21 01:18:06',	'2012-08-21 01:18:06',	'',	8,	'http://calzada-wp.urldock.com/?page_id=13',	0,	'page',	'',	0),
(14,	1,	'2012-05-21 20:21:44',	'2012-05-21 20:21:44',	'',	'Auto Draft',	'',	'inherit',	'open',	'open',	'',	'13-revision',	'',	'',	'2012-05-21 20:21:44',	'2012-05-21 20:21:44',	'',	13,	'http://calzada-wp.urldock.com/13-revision/',	0,	'revision',	'',	0),
(15,	1,	'2012-05-21 20:22:20',	'2012-05-21 20:22:20',	'<h3>Mr Laurent Fossaert</h3>\r\n<h4>CHIEF EXECUTIVE OFFICER – POLYNOVO BIOMATERIALS PTY LTD</h4>\r\nMr Fossaert has worked in the polymer industry for over 20 years in a number of technical and management roles.\r\n\r\nMr Fossaert\'s involvement with medical polymers started in 1988 at Elastomedic Pty Ltd.  He joined PolyNovo in July 2007 as its Chief Operating Officer, with the main task of setting up PolyNovo\'s new facility in Port Melbourne and refocusing the organisation on commercial outcomes.  Since Mr Fossaert became PolyNovo\'s CEO (in May 2009), he has continued to streamline the business and progressed the development of the company\'s own devices.\r\n\r\nMr Fossaert graduated in Polymer Technology in France in 1989.\r\n<h3> </h3>\r\n<h3>Mr David Kenley</h3>\r\n<h4>CHIEF EXECUTIVE OFFICER – METABOLIC PHARMACEUTICALS PTY LTD</h4>\r\nDavid Kenley has a Masters degree in Entrepreneurship &amp; Innovation, a Bachelor of Economics and is a member of the Australian Institute of Company Directors.  Over the last 25 years his career has focussed on the commercialisation of research results from Australia’s leading research institutions including CSIRO.  He has gained considerable experience in the establishment of spin-off companies and the licensing of research in many fields of science and over the last 14 years has focussed on the biotechnology sector.\r\n\r\nMr Kenley was a Director of Calzada Ltd until his resignation in early 2010 to become the CEO of Metabolic Pharmaceuticals Pty Ltd, the subsidiary established to house Calzada’s AOD and other drug development assets.\r\n\r\nPrior to this role David was the Managing Director of Xceed Capital Ltd where he worked closely with the CEO of the subsidiary, PolyNovo Biomaterials Pty Ltd, in commercialising that company’s novel biodegradable polymer technology.  He also orchestrated the restructuring and significant turnaround in financial performance of the fully owned subsidiary, Boron Molecular Pty Ltd.\r\n\r\nPreviously David was one of the Founders and the Vice President, Corporate Development of Metabolic Pharmaceuticals Ltd (now Calzada) where he worked as the 2IC until mid 2005.  He has also previously been a senior executive of Axon Instruments, Inc. (a Silicon Valley based designer and manufacturer of scientific instruments and drug discovery equipment) and Corporate Development Manager of Circadian Technologies Ltd, Australia’s first listed biotechnology company.  Over a period of nearly ten years he was Licensing &amp; Finance Manager of Sirotech Ltd, the commercial arm of CSIRO, where he managed the organisation’s licence portfolio, the largest in the southern hemisphere, and all its equity based interests.\r\n\r\nMr Kenley has significant experience in starting and growing entrepreneurial growth companies, the capital markets and in the running of publicly listed entities.\r\n<h3 id=\"greenwood\">Dr Tim Moore</h3>\r\n<h4>PRINCIPAL SCIENTIST</h4>\r\nDr. Moore completed a Bachelor of Applied Science (Chemistry) degree at Swinburne University of Technology, followed by an honours degree and PhD degree. Dr. Moore’s PhD dissertation was in the field of biodegradable polyurethanes; the title was “Design and Synthesis of Biodegradable Thermoplastic Polyurethanes for Tissue Engineering”.\r\n\r\nDr. Moore has been involved with PolyNovo since its inception and is a co-inventor of some of the variants of NovoSorb™. He has been working on the development of biodegradable polymers for medical devices for over ten years. His main area of expertise is in polyurethanes and the development of biomaterials for use in medical devices. He developed a novel range of biodegradable chain extenders which is included in several of PolyNovo’s patent applications. Dr. Moore is involved in project management and product development in PolyNovo’s leading applications. Dr. Moore is also responsible for the maintenance of PolyNovo’s extensive Intellectual Property Portfolio. He is co-author on a number of peer-reviewed papers and patent applications. He was a co-recipient of the CSIRO Molecular Science Divisional Strategic Action Plan Award for Innovation (2004) and of the CSIRO medal in Research Achievement category (2005).\r\n<h3>Mr Chris Mews (CPA, ACIS)</h3>\r\n<h4>COMPANY SECRETARY/CHIEF FINANCIAL OFFICER</h4>\r\nMr Mews was appointed Company Secretary of Calzada Ltd on 16th April 2009 and was appointed Chief Financial Officer on 1st September 2009.\r\n\r\nMr Mews has been involved in the financial services industry for over 10 years.  Mr Mews is a Certified Practicing Accountant and Chartered Company Secretary and has been Company Secretary and Chief Financial Officer of various listed and unlisted companies.',	'Management & Staff',	'',	'publish',	'open',	'open',	'',	'management-staff',	'',	'',	'2012-08-01 04:57:04',	'2012-08-01 04:57:04',	'',	8,	'http://calzada-wp.urldock.com/?page_id=15',	0,	'page',	'',	0),
(16,	1,	'2012-05-21 20:22:15',	'2012-05-21 20:22:15',	'',	'Management & Staff',	'',	'inherit',	'open',	'open',	'',	'15-revision',	'',	'',	'2012-05-21 20:22:15',	'2012-05-21 20:22:15',	'',	15,	'http://calzada-wp.urldock.com/15-revision/',	0,	'revision',	'',	0),
(17,	1,	'2012-05-21 20:22:47',	'2012-05-21 20:22:47',	'<a title=\"Corporate Governance Statement\" href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/Corporate-Governance-Statement-30-June-2012.pdf\">Corporate Governance Statement</a>\r\n\r\n<a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/CZD-BOARD-CHARTER-June-20121.pdf\">Board Charter</a>\r\n\r\n<a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/Market-Disclosure-Protocol-June-121.pdf\">Market Disclosure Protocol</a>\r\n\r\n<a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/Risk-Management-Policy-June-2012.pdf\">Risk Management Policy</a>\r\n\r\n<a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/Calzada-Share-Trading-Policy-21-Dec-101.pdf\">Share Trading Policy </a>\r\n\r\n<a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/Communications-Policy-June-2012-v21.pdf\">Communications Policy</a>\r\n\r\n<a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/Audit-Committee-Charter-June-12.pdf\">Audit Committee Charter</a>\r\n\r\n<a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/CZD-CODE-OF-CONDUCT-Final-FY122.pdf\">Code of Conduct</a>\r\n\r\n<a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/Calzada-Gender-Diversity-Policy-June-12.pdf\">Calzada Gender Diversity Policy</a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;',	'Corporate Governance',	'',	'publish',	'open',	'open',	'',	'corporate-governance',	'',	'',	'2012-08-21 03:44:11',	'2012-08-21 03:44:11',	'',	8,	'http://calzada-wp.urldock.com/?page_id=17',	0,	'page',	'',	0),
(18,	1,	'2012-05-21 20:22:28',	'2012-05-21 20:22:28',	'',	'Auto Draft',	'',	'inherit',	'open',	'open',	'',	'17-revision',	'',	'',	'2012-05-21 20:22:28',	'2012-05-21 20:22:28',	'',	17,	'http://calzada-wp.urldock.com/17-revision/',	0,	'revision',	'',	0),
(23,	1,	'2012-05-21 20:23:47',	'2012-05-21 20:23:47',	'<h2>Share Register Enquiries</h2>\r\n<img class=\"alignleft size-full wp-image-130\" style=\"margin-right: 15px;\" title=\"Share_Registry_s\" src=\"/wp-content/uploads/2012/05/Share_Registry_s.jpg\" alt=\"investor center\" width=\"140\" height=\"84\" />\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\nTo view information relating to your securityholding, or to update your securityholding details, please visit www.investorcentre.com or <a href=\"http://www.investorcentre.com\">click here</a>.\r\n\r\nFor shareholder related enquiries, such as changing your address or consolidating your holdings, please direct enquiries to:\r\n<h2>Computershare Investor Services</h2>\r\nYarra Falls\r\n452 Johnston Street\r\nAbbotsford Victoria 3067\r\nAustralia\r\n\r\nPhone: 1300 850 505\r\nFax: +61 3 9473 2500\r\nEmail: <a href=\"mailto:Web.queries@computershare.com.au\">Web.queries@computershare.com.au</a>',	'Investor Centre',	'',	'publish',	'open',	'open',	'',	'investor-centre',	'',	'',	'2012-08-23 04:39:03',	'2012-08-23 04:39:03',	'',	0,	'http://calzada-wp.urldock.com/?page_id=23',	0,	'page',	'',	0),
(24,	1,	'2012-05-21 20:23:39',	'2012-05-21 20:23:39',	'',	'Auto Draft',	'',	'inherit',	'open',	'open',	'',	'23-revision',	'',	'',	'2012-05-21 20:23:39',	'2012-05-21 20:23:39',	'',	23,	'http://calzada-wp.urldock.com/23-revision/',	0,	'revision',	'',	0),
(25,	1,	'2012-05-21 20:24:00',	'2012-05-21 20:24:00',	'',	'News & Media',	'',	'publish',	'open',	'open',	'',	'news-media',	'',	'',	'2012-08-06 05:23:44',	'2012-08-06 05:23:44',	'',	0,	'http://calzada-wp.urldock.com/?page_id=25',	0,	'page',	'',	0),
(26,	1,	'2012-05-21 20:23:50',	'2012-05-21 20:23:50',	'',	'Auto Draft',	'',	'inherit',	'open',	'open',	'',	'25-revision',	'',	'',	'2012-05-21 20:23:50',	'2012-05-21 20:23:50',	'',	25,	'http://calzada-wp.urldock.com/25-revision/',	0,	'revision',	'',	0),
(27,	1,	'2012-05-21 20:24:07',	'2012-05-21 20:24:07',	'<table>\r\n<tbody>\r\n<tr>\r\n<td>\r\n<h2 style=\"margin-top: 40px;\">Calzada Limited</h2>\r\n<img class=\"alignnone size-thumbnail wp-image-123\" title=\"calzada_logo\" src=\"/wp-content/uploads/2012/05/calzada_logo\" alt=\"contact Calzada\" /></td>\r\n</tr>\r\n<tr>\r\n<td>Wendy Townsend\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia</td>\r\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\r\n<strong>Fax:</strong>+61 (0) 3 8681 4099\r\n<strong>Email:</strong><a href=\"mailTo:wtownsend@calzada.com.au\">wtownsend@calzada.com.au</a></td>\r\n</tr>\r\n<tr>\r\n<td>\r\n<h2 style=\"margin-top: 70px;\">PolyNovo Biomaterials Pty Ltd</h2>\r\n<img class=\"alignnone size-full wp-image-124\" style=\"margin-top: 30px; margin-bottom: 30px; border: 0px none;\" title=\"polynovo\" src=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/polynovologo.jpg\" alt=\"polynovo\" width=\"225\" height=\"120\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td>Chief Executive Officer\r\nMr. Laurent Fossaert\r\nPolyNovo Biomaterials Pty Ltd\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia</td>\r\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\r\n<strong>Fax:</strong>+61 (0) 3 8681 4099\r\n<strong>Email:</strong><a href=\"mailTo:info@polynovo.com\">info@polynovo.com</a></td>\r\n</tr>\r\n<tr>\r\n<td>\r\n<h2 style=\"margin-top: 70px;\">Metabolic Pharmaceuticals Pty Ltd</h2>\r\n<img class=\"alignnone size-full wp-image-126\" style=\"margin-top: 30px; margin-bottom: 30px; border: 0px none;\" title=\"metaboliclogo\" src=\"/wp-content/uploads/2012/05/metaboliclogo.jpg\" alt=\"metaboloic\" width=\"225\" height=\"120\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td>Chief Executive Officer\r\nMr. David Kenley\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia</td>\r\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\r\n<strong>Fax:</strong>+61 (0) 3 8681 4099\r\n<strong>Email:</strong><a href=\"mailto:dkenley@calzada.com.au\">dkenley@calzada.com.au</a></td>\r\n</tr>\r\n</tbody>\r\n</table>',	'Contact Us',	'',	'publish',	'open',	'open',	'',	'contact-us',	'',	'',	'2012-08-07 07:11:25',	'2012-08-07 07:11:25',	'',	0,	'http://calzada-wp.urldock.com/?page_id=27',	0,	'page',	'',	0),
(28,	1,	'2012-05-21 20:24:02',	'2012-05-21 20:24:02',	'',	'Auto Draft',	'',	'inherit',	'open',	'open',	'',	'27-revision',	'',	'',	'2012-05-21 20:24:02',	'2012-05-21 20:24:02',	'',	27,	'http://calzada-wp.urldock.com/27-revision/',	0,	'revision',	'',	0),
(29,	1,	'2012-05-21 20:25:47',	'2012-05-21 20:25:47',	' ',	'',	'',	'publish',	'open',	'open',	'',	'29',	'',	'',	'2012-07-06 00:13:20',	'2012-07-06 00:13:20',	'',	0,	'http://calzada-wp.urldock.com/?p=29',	20,	'nav_menu_item',	'',	0),
(30,	1,	'2012-05-21 20:25:47',	'2012-05-21 20:25:47',	' ',	'',	'',	'publish',	'open',	'open',	'',	'30',	'',	'',	'2012-07-06 00:13:20',	'2012-07-06 00:13:20',	'',	0,	'http://calzada-wp.urldock.com/?p=30',	15,	'nav_menu_item',	'',	0),
(31,	1,	'2012-05-21 20:25:47',	'2012-05-21 20:25:47',	' ',	'',	'',	'publish',	'open',	'open',	'',	'31',	'',	'',	'2012-07-06 00:13:20',	'2012-07-06 00:13:20',	'',	0,	'http://calzada-wp.urldock.com/?p=31',	9,	'nav_menu_item',	'',	0),
(33,	1,	'2012-05-21 20:25:46',	'2012-05-21 20:25:46',	' ',	'',	'',	'publish',	'open',	'open',	'',	'33',	'',	'',	'2012-07-06 00:13:19',	'2012-07-06 00:13:19',	'',	0,	'http://calzada-wp.urldock.com/?p=33',	2,	'nav_menu_item',	'',	0),
(34,	1,	'2012-05-21 20:25:47',	'2012-05-21 20:25:47',	' ',	'',	'',	'publish',	'open',	'open',	'',	'34',	'',	'',	'2012-07-06 00:13:19',	'2012-07-06 00:13:19',	'',	8,	'http://calzada-wp.urldock.com/?p=34',	6,	'nav_menu_item',	'',	0),
(35,	1,	'2012-05-21 20:25:46',	'2012-05-21 20:25:46',	' ',	'',	'',	'publish',	'open',	'open',	'',	'35',	'',	'',	'2012-07-06 00:13:19',	'2012-07-06 00:13:19',	'',	8,	'http://calzada-wp.urldock.com/?p=35',	5,	'nav_menu_item',	'',	0),
(36,	1,	'2012-05-21 20:25:46',	'2012-05-21 20:25:46',	' ',	'',	'',	'publish',	'open',	'open',	'',	'36',	'',	'',	'2012-07-06 00:13:19',	'2012-07-06 00:13:19',	'',	8,	'http://calzada-wp.urldock.com/?p=36',	4,	'nav_menu_item',	'',	0),
(38,	1,	'2012-05-21 20:25:46',	'2012-05-21 20:25:46',	' ',	'',	'',	'publish',	'open',	'open',	'',	'38',	'',	'',	'2012-07-06 00:13:19',	'2012-07-06 00:13:19',	'',	0,	'http://calzada-wp.urldock.com/?p=38',	1,	'nav_menu_item',	'',	0),
(40,	1,	'2012-05-21 20:27:03',	'2012-05-21 20:27:03',	'<h2>Privacy Notice</h2>\r\nCalzada Limited is committed to protecting the privacy of the individuals it deals with. This statement outlines our policies on how we collect online information and how we use that information. It is important that you read and understand this information.\r\n\r\nCollection and retention of details\r\nWe may ask you for personal details such as your name, telephone number, email address, postal address, user name or password if you wish to use a service on this website. You may decline to provide this information, however if you do not provide the information we may not be able to provide you with that particular service.\r\n\r\nWe may also collect information about you from a third party. For example we may obtain details from our share registry to contact you and send communications to you in relation to your shareholding.\r\n\r\nWe may retain any such information and we may store and access that information indefinitely.\r\n\r\n<strong>Use of data</strong>\r\n\r\nWe only use the information for the purpose for which it was provided. We do not provide personal information to third parties except:\r\n<ul>\r\n	<li>government and regulatory authorities where we are legally obliged to do so</li>\r\n	<li>related companies where necessary to fulfil our purposes</li>\r\n	<li>contracted service providers engaged to provide certain of our services to you, for example mail out companies, information technology services, data processing services and share registry services</li>\r\n	<li>your representatives (your authorised representatives or legal advisers)</li>\r\n	<li>our professional advisers, including our accountants, auditors and lawyers.</li>\r\n</ul>\r\n<strong>For example</strong>\r\n<ul>\r\n	<li>if you subscribe to our email information service, we use your email address in order to deliver information and company announcements to you</li>\r\n	<li>if you contact us through this website, we use information such as your name and contact details to respond to your request</li>\r\n</ul>\r\n<strong>Log files</strong>\r\n\r\nAs part of the operation of this website, we and our web hosting provider automatically track certain information about you. This information includes your domain name and IP address, your browser version, your operating system, the URL you came from, and the pages you visit within the site. We use this information (in an aggregate and non-identifying form only) to monitor site performance, utilisation of features and services, traffic trends, user demographics, and to assist in the administration of the website. IP addresses are not linked to any personally identifiable information.\r\n\r\nWe do not use cookies on this website (a cookie is a piece of data containing information about the user that is sent to your browser and stored in the browser directory of your computer\'s hard drive).\r\n\r\n<strong>Linked sites</strong>\r\n\r\nThe site includes links to other websites. We do not share personally identifiable information about users with the operators of these sites. We are not responsible for the privacy practices of any of these sites.\r\n\r\n<strong>Security</strong>\r\n\r\nWhile we take reasonable steps to ensure that your personal information is stored securely, no data transmission over the Internet can be totally secure. Although we aim to protect your personal information from misuse, loss and unauthorised access, we cannot guarantee the security of any information you transmit or receive from our website or via email.\r\n\r\nBy using this website, you acknowledge that you are aware of security and privacy limitations, including but not limited to possible limitations or failures of security, privacy and authentication measures and features in this system and that data or information may be subject to third party eavesdropping or tampering.\r\n\r\n<strong>Contacting us</strong>\r\n\r\nIf you have a complaint, wish to gain access to your personal information, or want to know more about our information handling processes or give us suggestions about them, please contact us. We will respond to your query or complaint as soon as possible.?\r\n\r\nIf you wish to access or modify personal information which you have provided via our website, but are unable to access that information at our website, please contact us.\r\n\r\nWe take reasonable steps to ensure that your personal information is accurate, complete, and up-to-date whenever we collect or use it. If the personal information we hold about you is inaccurate, incomplete or out-of-date, please contact us and we will take reasonable steps to correct this information.\r\n\r\n<strong>Changes to policy</strong>\r\n\r\nWe may change the terms of this privacy policy at any time. If we change this policy we will post the revised policy document on this website. We therefore recommend that you review the privacy policy whenever you visit our website.\r\n<h2><strong>Website Disclaimer</strong></h2>\r\nWhile Calzada Limited has taken all reasonable care in preparing the information contained on this website, you should not rely solely on its contents.\r\n\r\nThe information is for your personal and/or educational use only and is provided in good faith without any express or implied warranty. Commercial use of the information contained on this website is expressly prohibited. To the extent permitted by law, Calzada Limited makes no representations, warranties, or assurances as to the accuracy, currency or completeness of the information, which may include technical inaccuracies or typographical errors.\r\n\r\nCalzada Limited reserves the right to make additions, deletions, or modifications to the information contained on this website at any time without any prior notification. The matters covered by this website are subject to change without notice, and may not be current at the time this website is accessed as there may be delays, errors or omissions.\r\n\r\nTo the extent permitted by law, Calzada Limited is not responsible to you or anyone else for any loss, damage or injury resulting from your access to, or inability to access, this website, or from your reliance on any information provided on this website. This includes, but is not limited to, the transmission of any computer virus. We recommend that prior to using any downloaded file, you carry out an appropriate virus check, and we will not be responsible for any virus or similar problem transmitted through this website.\r\n\r\nAny reference to any specific product, process or service by provider manufacturer or distributor does not constitute or imply its endorsement or recommendation by Calzada Limited.\r\n\r\nCalzada Limited has provided hypertext links to a number of other websites as a service to users of this website. This service does not mean that Calzada Limited endorses those sites or material on them in any way, and Calzada Limited makes no representation as to the accuracy or any other aspect of the information contained on those websites.\r\n\r\nBy accessing or using this website, you agree to the terms and conditions for using this website including our legal disclaimer.\r\n\r\nThe information contained on this website is for Australian residents only and is governed by Australian law.',	'Privacy Policy and Disclaimer',	'',	'publish',	'open',	'open',	'',	'privacy-policy-and-disclaimer',	'',	'',	'2012-08-22 05:00:02',	'2012-08-22 05:00:02',	'',	0,	'http://calzada-wp.urldock.com/?page_id=40',	0,	'page',	'',	0),
(41,	1,	'2012-05-21 20:27:00',	'2012-05-21 20:27:00',	'',	'Privacy Policy and Disclaimer',	'',	'inherit',	'open',	'open',	'',	'40-revision',	'',	'',	'2012-05-21 20:27:00',	'2012-05-21 20:27:00',	'',	40,	'http://calzada-wp.urldock.com/40-revision/',	0,	'revision',	'',	0),
(43,	1,	'2012-05-21 20:27:29',	'2012-05-21 20:27:29',	'Lorem ipsum dolor sit amet',	'Footer to go here',	'',	'publish',	'open',	'open',	'',	'footer-to-go-here',	'',	'',	'2012-07-02 01:07:42',	'2012-07-02 01:07:42',	'',	0,	'http://calzada-wp.urldock.com/?page_id=43',	0,	'page',	'',	0),
(44,	1,	'2012-05-21 20:27:21',	'2012-05-21 20:27:21',	'',	'Auto Draft',	'',	'inherit',	'open',	'open',	'',	'43-revision',	'',	'',	'2012-05-21 20:27:21',	'2012-05-21 20:27:21',	'',	43,	'http://calzada-wp.urldock.com/43-revision/',	0,	'revision',	'',	0),
(45,	1,	'2012-05-21 20:27:43',	'2012-05-21 20:27:43',	'<h2>Privacy Notice</h2>\r\nCalzada Limited is committed to protecting the privacy of the individuals it deals with. This statement outlines our policies on how we collect online information and how we use that information. It is important that you read and understand this information.\r\n\r\n<strong>Collection and retention of details</strong>\r\nWe may ask you for personal details such as your name, telephone number, email address, postal address, user name or password if you wish to use a service on this website. You may decline to provide this information, however if you do not provide the information we may not be able to provide you with that particular service.\r\n\r\nWe may also collect information about you from a third party. For example we may obtain details from our share registry to contact you and send communications to you in relation to your shareholding.\r\n\r\nWe may retain any such information and we may store and access that information indefinitely.\r\n\r\n<strong>Use of data</strong>\r\n\r\nWe only use the information for the purpose for which it was provided. We do not provide personal information to third parties except:\r\n<ul>\r\n	<li>government and regulatory authorities where we are legally obliged to do so</li>\r\n	<li>related companies where necessary to fulfil our purposes</li>\r\n	<li>contracted service providers engaged to provide certain of our services to you, for example mail out companies, information technology services, data processing services and share registry services</li>\r\n	<li>your representatives (your authorised representatives or legal advisers)</li>\r\n	<li>our professional advisers, including our accountants, auditors and lawyers.</li>\r\n</ul>\r\nFor example\r\n<ul>\r\n	<li>if you subscribe to our email information service, we use your email address in order to deliver information and company announcements to you</li>\r\n	<li>if you contact us through this website, we use information such as your name and contact details to respond to your request</li>\r\n</ul>\r\n<strong>Log files</strong>\r\nAs part of the operation of this website, we and our web hosting provider automatically track certain information about you. This information includes your domain name and IP address, your browser version, your operating system, the URL you came from, and the pages you visit within the site. We use this information (in an aggregate and non-identifying form only) to monitor site performance, utilisation of features and services, traffic trends, user demographics, and to assist in the administration of the website. IP addresses are not linked to any personally identifiable information.\r\n\r\nWe do not use cookies on this website (a cookie is a piece of data containing information about the user that is sent to your browser and stored in the browser directory of your computer\'s hard drive).\r\n\r\n<strong>Linked sites</strong>\r\nThe site includes links to other websites. We do not share personally identifiable information about users with the operators of these sites. We are not responsible for the privacy practices of any of these sites.\r\n\r\n<strong>Security</strong>\r\nWhile we take reasonable steps to ensure that your personal information is stored securely, no data transmission over the Internet can be totally secure. Although we aim to protect your personal information from misuse, loss and unauthorised access, we cannot guarantee the security of any information you transmit or receive from our website or via email.\r\n\r\nBy using this website, you acknowledge that you are aware of security and privacy limitations, including but not limited to possible limitations or failures of security, privacy and authentication measures and features in this system and that data or information may be subject to third party eavesdropping or tampering.\r\n\r\n<strong>Contacting us</strong>\r\nIf you have a complaint, wish to gain access to your personal information, or want to know more about our information handling processes or give us suggestions about them, please contact us. We will respond to your query or complaint as soon as possible.?\r\n\r\nIf you wish to access or modify personal information which you have provided via our website, but are unable to access that information at our website, please contact us.\r\n\r\nWe take reasonable steps to ensure that your personal information is accurate, complete, and up-to-date whenever we collect or use it. If the personal information we hold about you is inaccurate, incomplete or out-of-date, please contact us and we will take reasonable steps to correct this information.\r\n\r\n<strong>Changes to policy</strong>\r\nWe may change the terms of this privacy policy at any time. If we change this policy we will post the revised policy document on this website. We therefore recommend that you review the privacy policy whenever you visit our website.\r\n\r\n<strong>Website Disclaimer</strong>\r\n\r\nWhile Calzada Limited has taken all reasonable care in preparing the information contained on this website, you should not rely solely on its contents.\r\n\r\nThe information is for your personal and/or educational use only and is provided in good faith without any express or implied warranty. Commercial use of the information contained on this website is expressly prohibited. To the extent permitted by law, Calzada Limited makes no representations, warranties, or assurances as to the accuracy, currency or completeness of the information, which may include technical inaccuracies or typographical errors.\r\n\r\nCalzada Limited reserves the right to make additions, deletions, or modifications to the information contained on this website at any time without any prior notification. The matters covered by this website are subject to change without notice, and may not be current at the time this website is accessed as there may be delays, errors or omissions.\r\n\r\nTo the extent permitted by law, Calzada Limited is not responsible to you or anyone else for any loss, damage or injury resulting from your access to, or inability to access, this website, or from your reliance on any information provided on this website. This includes, but is not limited to, the transmission of any computer virus. We recommend that prior to using any downloaded file, you carry out an appropriate virus check, and we will not be responsible for any virus or similar problem transmitted through this website.\r\n\r\nAny reference to any specific product, process or service by provider manufacturer or distributor does not constitute or imply its endorsement or recommendation by Calzada Limited.\r\n\r\nCalzada Limited has provided hypertext links to a number of other websites as a service to users of this website. This service does not mean that Calzada Limited endorses those sites or material on them in any way, and Calzada Limited makes no representation as to the accuracy or any other aspect of the information contained on those websites.\r\n\r\nBy accessing or using this website, you agree to the terms and conditions for using this website including our legal disclaimer.\r\n\r\nThe information contained on this website is for Australian residents only and is governed by Australian law.',	'Privacy',	'',	'publish',	'open',	'open',	'',	'privacy',	'',	'',	'2012-08-21 00:56:05',	'2012-08-21 00:56:05',	'',	0,	'http://calzada-wp.urldock.com/?page_id=45',	0,	'page',	'',	0),
(46,	1,	'2012-05-21 20:27:35',	'2012-05-21 20:27:35',	'',	'Auto Draft',	'',	'inherit',	'open',	'open',	'',	'45-revision',	'',	'',	'2012-05-21 20:27:35',	'2012-05-21 20:27:35',	'',	45,	'http://calzada-wp.urldock.com/45-revision/',	0,	'revision',	'',	0),
(47,	1,	'2012-05-21 20:27:55',	'2012-05-21 20:27:55',	'Nullam quis risus eget urna mollis ornare vel eu leo. Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Etiam porta sem malesuada magna mollis euismod. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Curabitur blandit tempus porttitor. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.\r\n\r\nCum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec ullamcorper nulla non metus auctor fringilla.\r\n\r\nCum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Sed posuere consectetur est at lobortis. Aenean lacinia bibendum nulla sed consectetur. Donec sed odio dui. Etiam porta sem malesuada magna mollis euismod.\r\n\r\nAenean eu leo quam. Pellentesque ornare sem lacinia quam venenatis vestibulum. Maecenas faucibus mollis interdum. Curabitur blandit tempus porttitor. Nullam id dolor id nibh ultricies vehicula ut id elit. Nullam id dolor id nibh ultricies vehicula ut id elit. Nulla vitae elit libero, a pharetra augue. Lorem ipsum dolor sit amet, consectetur adipiscing elit.',	'Employment',	'',	'publish',	'open',	'open',	'',	'employment',	'',	'',	'2012-07-02 01:07:04',	'2012-07-02 01:07:04',	'',	0,	'http://calzada-wp.urldock.com/?page_id=47',	0,	'page',	'',	0),
(48,	1,	'2012-05-21 20:27:49',	'2012-05-21 20:27:49',	'',	'Auto Draft',	'',	'inherit',	'open',	'open',	'',	'47-revision',	'',	'',	'2012-05-21 20:27:49',	'2012-05-21 20:27:49',	'',	47,	'http://calzada-wp.urldock.com/47-revision/',	0,	'revision',	'',	0),
(52,	1,	'2012-05-21 20:28:52',	'2012-05-21 20:28:52',	' ',	'',	'',	'publish',	'open',	'open',	'',	'52',	'',	'',	'2012-06-11 05:26:38',	'2012-06-11 05:26:38',	'',	0,	'http://calzada-wp.urldock.com/?p=52',	1,	'nav_menu_item',	'',	0),
(53,	1,	'2012-05-21 20:28:52',	'2012-05-21 20:28:52',	' ',	'',	'',	'publish',	'open',	'open',	'',	'53',	'',	'',	'2012-06-11 05:26:38',	'2012-06-11 05:26:38',	'',	0,	'http://calzada-wp.urldock.com/?p=53',	2,	'nav_menu_item',	'',	0),
(54,	1,	'2012-05-23 20:34:57',	'2012-05-23 20:34:57',	'',	'Porta Ornare Dapibus Elit Malesuada',	'',	'inherit',	'open',	'open',	'',	'pic_page-banner-02',	'',	'',	'2012-05-23 20:34:57',	'2012-05-23 20:34:57',	'',	8,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/05/pic_page-banner-02.jpg',	0,	'attachment',	'image/jpeg',	0),
(55,	1,	'2012-05-21 20:20:53',	'2012-05-21 20:20:53',	'',	'About Us',	'',	'inherit',	'open',	'open',	'',	'8-revision-2',	'',	'',	'2012-05-21 20:20:53',	'2012-05-21 20:20:53',	'',	8,	'http://calzada-wp.urldock.com/8-revision-2/',	0,	'revision',	'',	0),
(57,	1,	'2012-05-21 20:19:01',	'2012-05-21 20:19:01',	'',	'Home',	'',	'inherit',	'open',	'open',	'',	'6-revision-2',	'',	'',	'2012-05-21 20:19:01',	'2012-05-21 20:19:01',	'',	6,	'http://calzada-wp.urldock.com/6-revision-2/',	0,	'revision',	'',	0),
(60,	1,	'2012-05-23 20:49:11',	'2012-05-23 20:49:11',	'',	'Cras Risus Mollis Vestibulum Vulputate',	'',	'inherit',	'open',	'open',	'',	'pic_page-banner-01-2',	'',	'',	'2012-05-23 20:49:11',	'2012-05-23 20:49:11',	'',	6,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/05/pic_page-banner-011.jpg',	0,	'attachment',	'image/jpeg',	0),
(61,	1,	'2012-05-23 20:47:25',	'2012-05-23 20:47:25',	'',	'Home',	'',	'inherit',	'open',	'open',	'',	'6-revision-3',	'',	'',	'2012-05-23 20:47:25',	'2012-05-23 20:47:25',	'',	6,	'http://calzada-wp.urldock.com/6-revision-3/',	0,	'revision',	'',	0),
(62,	1,	'2012-05-23 20:35:26',	'2012-05-23 20:35:26',	'',	'About Us',	'',	'inherit',	'open',	'open',	'',	'8-revision-3',	'',	'',	'2012-05-23 20:35:26',	'2012-05-23 20:35:26',	'',	8,	'http://calzada-wp.urldock.com/8-revision-3/',	0,	'revision',	'',	0),
(63,	1,	'2012-08-24 03:45:42',	'2012-08-24 03:45:42',	'Calzada has two wholly owned subsidiaries, PolyNovo Biomaterials Pty Ltd (“PolyNovo”) and Metabolic Pharmaceuticals Pty Ltd (“Metabolic”), both have high potential and maturing products reaching major value inflexion points.\n<h3>PolyNovo</h3>\n<a title=\"PolyNovo Biomaterials\" href=\"http://polynovo.com/\">PolyNovo Biomaterials</a> has developed a unique biodegradable polymer platform technology (NovoSorb™) designed to be used in medical devices and for tissue engineering scaffolds. The potential applications include reconstructive surgery and repair in a diverse range of fields including wounds, burns, cardiovascular, orthopaedic, periodontal, cartilage and drug delivery.\n\nPolyNovo is developing two lead products with world leading burns surgeon, Associate Professor John Greenwood AM (20% interest).\n<h3>Metabolic</h3>\nMetabolic Pharmaceuticals is seeking to derive value from the past investment of over $50mill in the pharmaceutical development of AOD9604. The peptide has proven to be safe and well tolerated in a total of 6 human clinical trials involving 925 humans.\n<h3>Corporate</h3>\nThe corporate head office takes responsibility for group strategy, capital allocation, identification and analysis of investment opportunities and investor and media relations.\n\nFor further information on Calzada please <a title=\"Contact Us\" href=\"http://calzada-wp.urldock.com/contact-us/\">contact us</a>.',	'About Us',	'',	'inherit',	'open',	'open',	'',	'8-autosave',	'',	'',	'2012-08-24 03:45:42',	'2012-08-24 03:45:42',	'',	8,	'http://calzada-wp.urldock.com/8-autosave/',	0,	'revision',	'',	0),
(64,	1,	'2012-05-21 20:22:47',	'2012-05-21 20:22:47',	'',	'Corporate Governance',	'',	'inherit',	'open',	'open',	'',	'17-revision-2',	'',	'',	'2012-05-21 20:22:47',	'2012-05-21 20:22:47',	'',	17,	'http://calzada-wp.urldock.com/17-revision-2/',	0,	'revision',	'',	0),
(65,	1,	'2012-08-29 00:18:21',	'2012-08-29 00:18:21',	'<a title=\"Corporate Governance Statement\" href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/Corporate-Governance-Statement-30-June-2012.pdf\">Corporate Governance Statement</a>\n\n<a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/CZD-BOARD-CHARTER-June-20121.pdf\">Board Charter</a>\n\n<a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/Market-Disclosure-Protocol-June-121.pdf\">Market Disclosure Protocol</a>\n\n<a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/Risk-Management-Policy-June-2012.pdf\">Risk Management Policy</a>\n\n<a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/Calzada-Share-Trading-Policy-21-Dec-101.pdf\">Share Trading Policy </a>\n\n<a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/Communications-Policy-June-2012-v21.pdf\">Communications Policy</a>\n\n<a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/Audit-Committee-Charter-June-12.pdf\">Audit Committee Charter</a>\n\n<a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/CZD-CODE-OF-CONDUCT-Final-FY122.pdf\">Code of Conduct</a>\n\n<a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/Calzada-Gender-Diversity-Policy-June-12.pdf\">Calzada Gender Diversity Policy</a>\n\n&nbsp;\n\n&nbsp;',	'Corporate Governance',	'',	'inherit',	'open',	'open',	'',	'17-autosave',	'',	'',	'2012-08-29 00:18:21',	'2012-08-29 00:18:21',	'',	17,	'http://calzada-wp.urldock.com/17-autosave/',	0,	'revision',	'',	0),
(66,	1,	'2012-05-23 20:51:03',	'2012-05-23 20:51:03',	'Calzada has 100% ownership of PolyNovo Biomaterials Pty Ltd and Metabolic Pharmaceuticals Pty Ltd. The company is listed on the Australian Stock Exchange (ASX Code CZD).\r\n\r\nThe corporate head office takes responsibility for group strategy, capital allocation, identification and analysis of investment opportunities and investor and media relations.\r\n\r\nMr Franklyn is Chairman of Calzada and its 100% owned subsidiary PolyNovo Biomaterials Pty Ltd and has held that title since 16th April 2009.\r\n\r\nMr Franklyn holds an Economics degree from the University of Western Australia and has completed the Graduate Diploma in Applied Finance and Investment from the Securities Institute of Australia, now FINSIA.\r\n\r\nMr Franklyn has been involved in the financial services industry for over twenty years. He has extensive experience in the financial analysis of companies, funds management, corporate finance, business management and investor relations. His previous roles include being Head of Research for a national stockbroker and General Manager Corporate Communications for an ASX 200 company.\r\n<h2>Sub Heading to go here - h2</h2>\r\nMr Franklyn is currently Managing Director of Entrust Funds Management Ltd, a Western Australian based boutique funds management business, and a Non-Executive Director of ASX Listed Nomad Building Solutions Ltd. Mr Franklyn resigned as Non-Executive Director of GoldLink Income Plus on 27th March 2009.\r\n\r\nMr Bruce Rathie (BComm, LLB, MBA, FAIM, FAICD)\r\n\r\nNON-EXECUTIVE DIRECTOR\r\n\r\nMr Rathie was appointed a Director of Calzada on 18th February 2010.\r\n\r\nMr Rathie holds degrees in law, commerce and business and has considerable experience as a lawyer having practiced as a solicitor and partner in a major Brisbane based legal firm and then as Senior in-house Counsel to Bell Resources Limited from 1980 to 1985 in aggregate.\r\n\r\nHe studied for his MBA in Geneva and then went into investment banking in 1986 which subsequently took him to New York for over 2 years returning to Sydney in 1990.\r\n\r\nHe spent the 90\'s in investment banking in Sydney, the last 5 years as a Director of Investment Banking at Salomon Brothers/ Salomon Smith Barney where he was Head of the Industrial Franchise Group and also led Salomon\'s roles in the Federal Government\'s privatisation of Qantas, Commonwealth Bank (CBA3) and Telstra (T1).\r\n\r\nMr Rathie currently is, in addition to his Non-Executive Director role at Calzada, a Non-Executive Director of ASX listed companies USCOM Limited (a medical devices company), Mungana Goldmines Limited (a gold mining company) and DataDot Technology Limited (an industrial security products company) which he Chairs. He is also a Non-Executive Director of Capricorn Society Limited the largest auto parts cooperative in the Southern Hemisphere with operations in Australia, South Africa and New Zealand, and is also Deputy Chairman of EFTPOS Payments Australia Limited the Australian debit card payment company. Mr Rathie resigned as Director of Anteo Diagnostics Limited on 31st August 2009.\r\n\r\nDr John Chiplin (PhD)',	'About Us',	'',	'inherit',	'open',	'open',	'',	'8-revision-4',	'',	'',	'2012-05-23 20:51:03',	'2012-05-23 20:51:03',	'',	8,	'http://calzada-wp.urldock.com/8-revision-4/',	0,	'revision',	'',	0),
(67,	1,	'2012-05-23 21:09:43',	'2012-05-23 21:09:43',	'<h3>Introduction</h3>\r\nThe Board of Calzada is responsible for the corporate governance of the Group and guides and monitors the business on behalf of its shareholders. The Board has strived to reach a balance between industry best practice and appropriate policies for Calzada in terms of its size, stage of development and role in the biotechnology industry. Calzada performed a review of its Board policies and governance practices with reference to the eight Principles of Good Corporate Governance and the Best Practice Recommendations (Recommendations) established by the ASX Corporate Governance Council. The Recommendations are not mandatory and cannot, in themselves, prevent corporate failure or poor corporate decision-making. They are intended to provide a reference point for companies about their corporate governance structures and practices.\r\n\r\nThe Directors have considered each of the core Principles and Recommendations during the period under review. There are instances where the Company would not benefit from compliance with the Recommendations, and in some instances the Company has not had the resources to comply. The Recommendations that were not adopted are discussed in this Corporate Governance Statement.\r\n<h3>Principle 1: Lay solid foundations for management and oversight</h3>\r\n<h4>Recommendation 1.1</h4>\r\nThe role of the Board is to represent the interests of shareholders, by providing the Group with good governance and strategic direction. Calzada has adopted a Board Charter setting out the matters reserved to them, including their function and responsibilities. The Board Charter is available at <a href=\"http://www.calzada.com.au/CALZADA/Corporate-Governance/ANNUAL-CORPORATE-GOVERNANCE-STATEMENT.asp\">www.calzada.com.au</a> in the Corporate Governance section.\r\n\r\nCalzada delegates authority to Senior Management for the day-to-day running of the business as per agreed delegations.\r\n\r\nCurrently Calzada has no full time employees however Calzada has a full time CFO /Company Secretary employed under a contract arrangement, a part time Executive Chairman and a part time Senior Executive employed on a contract basis. Calzadas 100% owned subsidiary PolyNovo employs 5 full time staff and 2 part time staff. Senior Management of PolyNovo report directly to the Calzada board. Metabolic Pharmaceuticals Pty Ltd has a full time CEO.\r\n<h4>Recommendation 1.2</h4>\r\nCalzada does not conduct a formal review of the Senior Executives within the group. The Chairman reviews the performance of the executives on an ongoing basis throughout the year. A Remuneration Committee has been formally established by the Board. The Charter of the Remuneration Committee includes the evaluation of the performance of Senior Management and Executives in consultation with the Board.\r\n<h3>Principle 2: Structure the Board to add value</h3>\r\n<h4>Recommendation 2.1</h4>\r\nThe Board has adopted the Councils recommended criteria for assessing Director independence. To be assessed as independent, a Director must fulfill a number of criteria as outlined in the ASX Corporate Governance Principles.\r\n\r\nGiven the small size of the Company, it is not possible to consistently maintain a majority of independent Directors. The Company has been proactive in providing the Board with access to independent professional advice. In the furtherance of their duties, Directors have access to seek independent professional advice at the Companys expense, unless the Board determines otherwise.\r\n\r\nMr Franklyn is an officer of an associated entity that is a substantial shareholder of Calzada and as such cannot be considered independent. Mr Rathie has no commercial agreements with Calzada and is not a substantial holder of shares in the Company. As such Mr Rathie is considered independent. Mr Cameron-Dow is an associate of SG Corporate Pty Ltd which is engaged to assist in the ongoing operations of the Company. Fees are paid by Calzada monthly. For this reason Mr Cameron-Dow is not considered independent. Mr Stevens is an employee of an associated entity that is a substantial holder of Calzada shares and therefore cannot be considered independent. As at the date of this Directors Report, the Board of Calzada is comprised of four Directors, with a combination of commercial acumen and experience in the biotechnology industry. The relevant qualifications and details of each Director are documented in this Directors Report under the section titled Board of Directors and Senior Management.',	'Corporate Governance',	'',	'inherit',	'open',	'open',	'',	'17-revision-3',	'',	'',	'2012-05-23 21:09:43',	'2012-05-23 21:09:43',	'',	17,	'http://calzada-wp.urldock.com/17-revision-3/',	0,	'revision',	'',	0),
(68,	1,	'2012-05-27 14:00:59',	'2012-05-27 14:00:59',	'PolyNovo to Commence First Human Trial\r\n\r\nRecruitment underway for first NovoSorbTM human clinical trial. \r\nAim is to test NovoSorbTM to repair full thickness wounds.\r\n\r\n<a href=\"/wp-content/uploads/2012/07/1074690.pdf\" target=\"_blank\">Click for details (PDF)</a>',	'PolyNovo to Commence Human Trial',	'',	'publish',	'open',	'open',	'',	'polynovo-to-commence-human-trial',	'',	'',	'2012-07-09 03:16:05',	'2012-07-09 03:16:05',	'',	0,	'http://calzada-wp.urldock.com/?p=68',	0,	'post',	'',	0),
(69,	1,	'2012-05-27 13:59:38',	'2012-05-27 13:59:38',	'',	'Auto Draft',	'',	'inherit',	'open',	'open',	'',	'68-revision',	'',	'',	'2012-05-27 13:59:38',	'2012-05-27 13:59:38',	'',	68,	'http://calzada-wp.urldock.com/68-revision/',	0,	'revision',	'',	0),
(70,	1,	'2012-05-27 14:01:17',	'2012-05-27 14:01:17',	'PolyNovo Commences Human Trial for Full Thickness Wounds\r\n\r\n• Recruitment is underway for PolyNovo’s 2nd human clinical trial\r\n• Aim is to test NovoSorbTM to repair full thickness wounds\r\n\r\n<a href=\"/wp-content/uploads/2012/07/132F042F2012103A213A23PM.pdf\">Click here for details (PDF)</a>',	'PolyNovo Commences Second Human Trial',	'',	'publish',	'open',	'open',	'',	'polynovo-commences-second-human-trial',	'',	'',	'2012-07-09 03:13:29',	'2012-07-09 03:13:29',	'',	0,	'http://calzada-wp.urldock.com/?p=70',	0,	'post',	'',	0),
(71,	1,	'2012-05-27 14:01:12',	'2012-05-27 14:01:12',	'',	'PolyNovo Commences Second Human Trial',	'',	'inherit',	'open',	'open',	'',	'70-revision',	'',	'',	'2012-05-27 14:01:12',	'2012-05-27 14:01:12',	'',	70,	'http://calzada-wp.urldock.com/70-revision/',	0,	'revision',	'',	0),
(72,	1,	'2012-05-27 14:01:29',	'2012-05-27 14:01:29',	'Calzada Ltd’s (‘Calzada’) wholly owned subsidiary, Metabolic Pharmaceuticals Pty Ltd (‘Metabolic’), is pleased\r\nto announce that it has received positive results from in-vitro tests conducted on its peptide compound.\r\n\r\n<a href=\"/wp-content/uploads/2012/07/132F042F2012103A223A05PM.pdf\" target=\"_blank\">Click here for details (PDF)</a>',	'AOD Positive In Cartilage and Muscle Repair',	'',	'publish',	'open',	'open',	'',	'aod-positive-in-cartilage-and-muscle-repair',	'',	'',	'2012-07-09 03:11:32',	'2012-07-09 03:11:32',	'',	0,	'http://calzada-wp.urldock.com/?p=72',	0,	'post',	'',	0),
(73,	1,	'2012-05-27 14:01:28',	'2012-05-27 14:01:28',	'Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Donec ullamcorper nulla non metus auctor fringilla. Etiam porta sem malesuada magna mollis euismod.\n\nPraesent commodo cursus magna, vel scelerisque nisl consectetur et. Nullam id dolor id nibh ultricies vehicula ut id elit. Donec ullamcorper nulla non metus auctor fringilla. Cras justo odio, dapibus ac facilisis in, egestas eget quam.\n\nCurabitur blandit tempus porttitor. Etiam porta sem malesuada magna mollis euismod. Vestibulum id ligula porta felis euismod semper. Donec ullamcorper nulla non metus auctor fringilla. Donec id elit non mi porta gravida at eget metus.',	'AOD positive in Cartilage and Muscle Repair',	'',	'inherit',	'open',	'open',	'',	'72-revision',	'',	'',	'2012-05-27 14:01:28',	'2012-05-27 14:01:28',	'',	72,	'http://calzada-wp.urldock.com/72-revision/',	0,	'revision',	'',	0),
(74,	1,	'2012-05-27 14:02:27',	'2012-05-27 14:02:27',	'Calzada Ltd’s wholly owned subsidiary, PolyNovo Biomaterials Pty Ltd (‘PolyNovo’) is pleased to report that\r\nthe VAC human clinical trial, as announced on February 6th 2012, is well underway. This is the first human\r\nclinical trial involving NovoSorbTM.\r\n\r\n<a href=\"/wp-content/uploads/2012/07/132F042F2012103A223A30PM.pdf\" target=\"_blank\">Click here for details (PDF)</a>',	'PolyNovo Human Trial Update',	'',	'publish',	'open',	'open',	'',	'polynovo-human-trial-update',	'',	'',	'2012-07-09 03:03:54',	'2012-07-09 03:03:54',	'',	0,	'http://calzada-wp.urldock.com/?p=74',	0,	'post',	'',	0),
(75,	1,	'2012-05-27 14:02:26',	'2012-05-27 14:02:26',	'',	'PolyNovo human Trial Update',	'',	'inherit',	'open',	'open',	'',	'74-revision',	'',	'',	'2012-05-27 14:02:26',	'2012-05-27 14:02:26',	'',	74,	'http://calzada-wp.urldock.com/74-revision/',	0,	'revision',	'',	0),
(77,	1,	'2012-05-27 15:41:56',	'2012-05-27 15:41:56',	'',	'Homepage Extra Content',	'',	'publish',	'closed',	'closed',	'',	'acf_homepage-extra-content',	'',	'',	'2012-05-27 15:42:37',	'2012-05-27 15:42:37',	'',	0,	'http://calzada-wp.urldock.com/?post_type=acf&#038;p=77',	0,	'acf',	'',	0),
(78,	1,	'2012-05-23 20:49:18',	'2012-05-23 20:49:18',	'',	'Home',	'',	'inherit',	'open',	'open',	'',	'6-revision-4',	'',	'',	'2012-05-23 20:49:18',	'2012-05-23 20:49:18',	'',	6,	'http://calzada-wp.urldock.com/6-revision-4/',	0,	'revision',	'',	0),
(79,	1,	'2012-05-27 15:43:18',	'2012-05-27 15:43:18',	'',	'Home',	'',	'inherit',	'open',	'open',	'',	'6-revision-5',	'',	'',	'2012-05-27 15:43:18',	'2012-05-27 15:43:18',	'',	6,	'http://calzada-wp.urldock.com/6-revision-5/',	0,	'revision',	'',	0),
(81,	1,	'2012-05-21 20:22:03',	'2012-05-21 20:22:03',	'',	'Board of Directors',	'',	'inherit',	'open',	'open',	'',	'13-revision-2',	'',	'',	'2012-05-21 20:22:03',	'2012-05-21 20:22:03',	'',	13,	'http://calzada-wp.urldock.com/13-revision-2/',	0,	'revision',	'',	0),
(82,	1,	'2012-05-21 20:22:20',	'2012-05-21 20:22:20',	'',	'Management & Staff',	'',	'inherit',	'open',	'open',	'',	'15-revision-2',	'',	'',	'2012-05-21 20:22:20',	'2012-05-21 20:22:20',	'',	15,	'http://calzada-wp.urldock.com/15-revision-2/',	0,	'revision',	'',	0),
(83,	1,	'2012-05-28 17:57:24',	'2012-05-28 17:57:24',	'Nullam quis risus eget urna mollis ornare vel eu leo. Vestibulum id ligula porta felis euismod semper. Etiam porta sem malesuada magna mollis euismod. Maecenas sed diam eget risus varius blandit sit amet non magna.\r\n\r\nNullam id dolor id nibh ultricies vehicula ut id elit. Sed posuere consectetur est at lobortis. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Nullam quis risus eget urna mollis ornare vel eu leo. Cras mattis consectetur purus sit amet fermentum. Sed posuere consectetur est at lobortis.\r\n\r\nDuis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Donec id elit non mi porta gravida at eget metus. Nulla vitae elit libero, a pharetra augue. Cras mattis consectetur purus sit amet fermentum. Aenean eu leo quam. Pellentesque ornare sem lacinia quam venenatis vestibulum. Vestibulum id ligula porta felis euismod semper.\r\n\r\nDonec id elit non mi porta gravida at eget metus. Nulla vitae elit libero, a pharetra augue. Aenean lacinia bibendum nulla sed consectetur. Integer posuere erat a ante venenatis dapibus posuere velit aliquet. Cras justo odio, dapibus ac facilisis in, egestas eget quam.',	'Board of Directors',	'',	'inherit',	'open',	'open',	'',	'13-revision-3',	'',	'',	'2012-05-28 17:57:24',	'2012-05-28 17:57:24',	'',	13,	'http://calzada-wp.urldock.com/13-revision-3/',	0,	'revision',	'',	0),
(84,	1,	'2012-08-01 04:56:09',	'2012-08-01 04:56:09',	'<h3>Mr Laurent Fossaert</h3>\n<h4>CHIEF EXECUTIVE OFFICER – POLYNOVO BIOMATERIALS PTY LTD</h4>\nMr Fossaert has worked in the polymer industry for over 20 years in a number of technical and management roles.\n\nMr Fossaert\'s involvement with medical polymers started in 1988 at Elastomedic Pty Ltd.  He joined PolyNovo in July 2007 as its Chief Operating Officer, with the main task of setting up PolyNovo\'s new facility in Port Melbourne and refocusing the organisation on commercial outcomes.  Since Mr Fossaert became PolyNovo\'s CEO (in May 2009), he has continued to streamline the business and progressed the development of the company\'s own devices.\n\nMr Fossaert graduated in Polymer Technology in France in 1989.\n<h3> </h3>\n<h3>Mr David Kenley</h3>\n<h4>CHIEF EXECUTIVE OFFICER – METABOLIC PHARMACEUTICALS PTY LTD</h4>\nDavid Kenley has a Masters degree in Entrepreneurship &amp; Innovation, a Bachelor of Economics and is a member of the Australian Institute of Company Directors.  Over the last 25 years his career has focussed on the commercialisation of research results from Australia’s leading research institutions including CSIRO.  He has gained considerable experience in the establishment of spin-off companies and the licensing of research in many fields of science and over the last 14 years has focussed on the biotechnology sector.\n\nMr Kenley was a Director of Calzada Ltd until his resignation in early 2010 to become the CEO of Metabolic Pharmaceuticals Pty Ltd, the subsidiary established to house Calzada’s AOD and other drug development assets.\n\nPrior to this role David was the Managing Director of Xceed Capital Ltd where he worked closely with the CEO of the subsidiary, PolyNovo Biomaterials Pty Ltd, in commercialising that company’s novel biodegradable polymer technology.  He also orchestrated the restructuring and significant turnaround in financial performance of the fully owned subsidiary, Boron Molecular Pty Ltd.\n\nPreviously David was one of the Founders and the Vice President, Corporate Development of Metabolic Pharmaceuticals Ltd (now Calzada) where he worked as the 2IC until mid 2005.  He has also previously been a senior executive of Axon Instruments, Inc. (a Silicon Valley based designer and manufacturer of scientific instruments and drug discovery equipment) and Corporate Development Manager of Circadian Technologies Ltd, Australia’s first listed biotechnology company.  Over a period of nearly ten years he was Licensing &amp; Finance Manager of Sirotech Ltd, the commercial arm of CSIRO, where he managed the organisation’s licence portfolio, the largest in the southern hemisphere, and all its equity based interests.\n\nMr Kenley has significant experience in starting and growing entrepreneurial growth companies, the capital markets and in the running of publicly listed entities.\n<h3 id=\"greenwood\">Dr Tim Moore</h3>\n<h4>PRINCIPAL SCIENTIST</h4>\nDr. Moore completed a Bachelor of Applied Science (Chemistry) degree at Swinburne University of Technology, followed by an honours degree and PhD degree. Dr. Moore’s PhD dissertation was in the field of biodegradable polyurethanes; the title was “Design and Synthesis of Biodegradable Thermoplastic Polyurethanes for Tissue Engineering”.\n\nDr. Moore has been involved with PolyNovo since its inception and is a co-inventor of some of the variants of NovoSorb™. He has been working on the development of biodegradable polymers for medical devices for over ten years. His main area of expertise is in polyurethanes and the development of biomaterials for use in medical devices. He developed a novel range of biodegradable chain extenders which is included in several of PolyNovo’s patent applications. Dr. Moore is involved in project management and product development in PolyNovo’s leading applications. Dr. Moore is also responsible for the maintenance of PolyNovo’s extensive Intellectual Property Portfolio. He is co-author on a number of peer-reviewed papers and patent applications. He was a co-recipient of the CSIRO Molecular Science Divisional Strategic Action Plan Award for Innovation (2004) and of the CSIRO medal in Research Achievement category (2005).\n<h3>Mr Chris Mews (CPA, ACIS)</h3>\n<h4>COMPANY SECRETARY/CHIEF FINANCIAL OFFICER</h4>\nMr Mews was appointed Company Secretary of Calzada Ltd on 16th April 2009 and was appointed Chief Financial Officer on 1st September 2009.\n\nMr Mews has been involved in the financial services industry for over 10 years.  Mr Mews is a Certified Practicing Accountant and Chartered Company Secretary and has been Company Secretary and Chief Financial Officer of various listed and unlisted companies.',	'Management & Staff',	'',	'inherit',	'open',	'open',	'',	'15-autosave',	'',	'',	'2012-08-01 04:56:09',	'2012-08-01 04:56:09',	'',	15,	'http://calzada-wp.urldock.com/15-autosave/',	0,	'revision',	'',	0),
(86,	1,	'2012-05-28 17:59:20',	'2012-05-28 17:59:20',	'',	'Calzada',	'',	'publish',	'open',	'open',	'',	'calzada-2',	'',	'',	'2012-07-06 00:13:19',	'2012-07-06 00:13:19',	'',	0,	'http://calzada-wp.urldock.com/?p=86',	3,	'nav_menu_item',	'',	0),
(87,	1,	'2012-08-21 01:19:09',	'2012-08-21 01:19:09',	'<h3>Mr David Franklyn (BEcon)</h3>\n<h4>NON-EXECUTIVE CHAIRMAN</h4>\nMr Franklyn is Chairman of Calzada and its 100% owned subsidiary PolyNovo Biomaterials Pty Ltd and has held that title since 16th April 2009.\n\nMr Franklyn holds an Economics degree from the University of Western Australia and has completed the Graduate Diploma in Applied Finance and Investment from the Securities Institute of Australia, now FINSIA.\n\nMr Franklyn has been involved in the financial services industry for over twenty years. He has extensive experience in the financial analysis of companies, funds management, corporate finance, business management and investor relations. His previous roles include being Head of Research for a national stockbroker and General Manager Corporate Communications for an ASX 200 company.\n\nMr Franklyn is currently Managing Director of Entrust Funds Management Ltd, a Western Australian based boutique funds management business, and an Executive Director of ASX Listed Nomad Building Solutions Ltd.\n<h3>Dr David McQuillan (PhD)</h3>\n<h4><strong>NON-EXECUTIVE DIRECTOR </strong></h4>\nDr McQuillan was appointed a Director of Calzada on 6th August 2012.\n\nDr McQuillan possesses extensive technical, medical, scientific and regulatory knowledge as well as significant mergers and acquisition expertise.\n\nIn 2000, Dr McQuillan joined LifeCell Corporation as the Vice-President for Research and Development (R &amp; D). He led LifeCell’s R &amp; D team focusing on the creation of market-leading products for reconstructive and plastic surgery applications.  Following marketing approval in 2008 for its new reconstructive tissue matrix StratticeTM, LifeCell was acquired by Kinetic Concepts Inc (“KCI”) for US$1.8 billion. Following the acquisition, Dr McQuillan became the Senior Vice President of the Advanced Research and Technology unit at KCI.  Dr McQuillan left KCI in 2011 after its acquisition by a private consortium for US$6.7 billion.\n\nDr McQuillan is currently a consultant to several leading US based Healthcare Investment Funds that are focused in the fields of regenerative medicine, medical devices and tissue engineering.  He is also the Chief Scientific Officer of Humacyte, Inc., Durham, NC.\n<h3>Mr Bruce Rathie (BComm, LLB, MBA, FAIM, FAICD)</h3>\n<h4>NON-EXECUTIVE DIRECTOR</h4>\nMr Rathie was appointed a Director of Calzada on 18th February 2010.\n\nMr Rathie holds degrees in law, commerce and business and has considerable experience as a lawyer having practiced as a solicitor and partner in a major Brisbane based legal firm and then as Senior in-house Counsel to Bell Resources Limited from 1980 to 1985 in aggregate.\n\nHe studied for his MBA in Geneva and then went into investment banking in 1986 which subsequently took him to New York returning to Sydney in 1990.\n\nHe spent the 1990\'s in investment banking in Sydney, the last 5 years as a Director of Investment Banking at Salomon Brothers/ Salomon Smith Barney where he was Head of the Industrial Franchise Group and also led Salomon\'s roles in the Federal Government\'s privatisation of Qantas, Commonwealth Bank (CBA3) and Telstra (T1).\n\nMr Rathie currently is, in addition to his Non-Executive Director role at Calzada, a Non-Executive Director of ASX listed companies Mungana Goldmines Limited (a gold mining company) and DataDot Technology Limited (an industrial security products company) which he Chairs. He is also a Non-Executive Director of Capricorn Society Limited the largest auto parts cooperative in the Southern Hemisphere with operations in Australia, South Africa and New Zealand, and is also Chairman of EFTPOS Payments Australia Limited the Australian debit card payment company. In the past, he has served on the Boards of other ASX listed medical device companies being Anteo Diagnostics Limited (2006 - 2009), Compumedics Limited (2004 - 2006) and USCOM Limited (2006 – 2011).\n<h3>Dr John Chiplin, Ph.D.</h3>\n<h4>NON-EXECUTIVE DIRECTOR</h4>\nDr Chiplin was appointed a Director of Calzada on 18th October 2010.\n\nDr Chiplin is one of the most successful life sciences professionals in the Australian biotech industry. His most recent accomplishment was the corporate re-engineering of Arana Therapeutics (Arana), a world leading antibody developer, which resulted in the mid 2009 acquisition of Arana by Cephalon for $329 million at a 70 percent premium to the market valuation. Immediately prior to running Arana, Dr Chiplin was head of the $300 million ITI Life Sciences investment fund in the United Kingdom and prior to this was co-founder and Chief Executive officer of Geneformatics Inc.\n\nDr Chiplin brings considerable international biotechnology industry experience, deep technical medical and scientific knowledge and extensive mergers and acquisition and investment expertise.\n\nDr Chiplin is a current Non-Executive Director of ASX listed Benitec Ltd, Healthlinx Ltd and a Director of ScienceMedia.',	'Board of Directors',	'',	'inherit',	'open',	'open',	'',	'13-autosave',	'',	'',	'2012-08-21 01:19:09',	'2012-08-21 01:19:09',	'',	13,	'http://calzada-wp.urldock.com/13-autosave/',	0,	'revision',	'',	0),
(88,	1,	'2012-05-21 20:27:03',	'2012-05-21 20:27:03',	'',	'Privacy Policy and Disclaimer',	'',	'inherit',	'open',	'open',	'',	'40-revision-2',	'',	'',	'2012-05-21 20:27:03',	'2012-05-21 20:27:03',	'',	40,	'http://calzada-wp.urldock.com/40-revision-2/',	0,	'revision',	'',	0),
(89,	1,	'2012-05-21 20:27:43',	'2012-05-21 20:27:43',	'',	'Privacy',	'',	'inherit',	'open',	'open',	'',	'45-revision-2',	'',	'',	'2012-05-21 20:27:43',	'2012-05-21 20:27:43',	'',	45,	'http://calzada-wp.urldock.com/45-revision-2/',	0,	'revision',	'',	0),
(91,	1,	'2012-05-21 20:27:29',	'2012-05-21 20:27:29',	'',	'Footer to go here',	'',	'inherit',	'open',	'open',	'',	'43-revision-2',	'',	'',	'2012-05-21 20:27:29',	'2012-05-21 20:27:29',	'',	43,	'http://calzada-wp.urldock.com/43-revision-2/',	0,	'revision',	'',	0),
(92,	1,	'2012-05-21 20:23:47',	'2012-05-21 20:23:47',	'',	'Investor Centre',	'',	'inherit',	'open',	'open',	'',	'23-revision-2',	'',	'',	'2012-05-21 20:23:47',	'2012-05-21 20:23:47',	'',	23,	'http://calzada-wp.urldock.com/23-revision-2/',	0,	'revision',	'',	0),
(93,	1,	'2012-05-21 20:27:55',	'2012-05-21 20:27:55',	'',	'Employment',	'',	'inherit',	'open',	'open',	'',	'47-revision-2',	'',	'',	'2012-05-21 20:27:55',	'2012-05-21 20:27:55',	'',	47,	'http://calzada-wp.urldock.com/47-revision-2/',	0,	'revision',	'',	0),
(94,	1,	'2012-05-21 20:24:07',	'2012-05-21 20:24:07',	'',	'Contact Us',	'',	'inherit',	'open',	'open',	'',	'27-revision-2',	'',	'',	'2012-05-21 20:24:07',	'2012-05-21 20:24:07',	'',	27,	'http://calzada-wp.urldock.com/27-revision-2/',	0,	'revision',	'',	0),
(95,	1,	'2012-05-21 20:24:00',	'2012-05-21 20:24:00',	'',	'News & Media',	'',	'inherit',	'open',	'open',	'',	'25-revision-2',	'',	'',	'2012-05-21 20:24:00',	'2012-05-21 20:24:00',	'',	25,	'http://calzada-wp.urldock.com/25-revision-2/',	0,	'revision',	'',	0),
(96,	1,	'2012-05-30 16:08:21',	'2012-05-30 16:08:21',	'Donec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.\r\n[news-listing title=\"News Listing\"]\r\nCras mattis consectetur purus sit amet fermentum. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nulla vitae elit libero, a pharetra augue. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.\r\n[media-listing title=\"Media Listing\"]\r\nDonec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.',	'News & Media',	'',	'inherit',	'open',	'open',	'',	'25-revision-3',	'',	'',	'2012-05-30 16:08:21',	'2012-05-30 16:08:21',	'',	25,	'http://calzada-wp.urldock.com/25-revision-3/',	0,	'revision',	'',	0),
(97,	1,	'2012-08-06 05:23:13',	'2012-08-06 05:23:13',	'',	'News & Media',	'',	'inherit',	'open',	'open',	'',	'25-autosave',	'',	'',	'2012-08-06 05:23:13',	'2012-08-06 05:23:13',	'',	25,	'http://calzada-wp.urldock.com/25-autosave/',	0,	'revision',	'',	0),
(98,	1,	'2012-05-30 16:09:26',	'2012-05-30 16:09:26',	'Donec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.\r\n\r\n[news-listing title=\"News Listing\"]\r\n\r\nCras mattis consectetur purus sit amet fermentum. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nulla vitae elit libero, a pharetra augue. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.\r\n\r\n[media-listing title=\"Media Listing\"]\r\n\r\nDonec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.',	'News & Media',	'',	'inherit',	'open',	'open',	'',	'25-revision-4',	'',	'',	'2012-05-30 16:09:26',	'2012-05-30 16:09:26',	'',	25,	'http://calzada-wp.urldock.com/25-revision-4/',	0,	'revision',	'',	0),
(99,	1,	'2012-05-30 16:11:20',	'2012-05-30 16:11:20',	'Donec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.\r\n\r\n[news-listing title=\"News Listing\"]\r\n\r\nCras mattis consectetur purus sit amet fermentum. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nulla vitae elit libero, a pharetra augue. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.\r\n\r\n[media-listing title=\"Media Listing\"]\r\n\r\nDonec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.',	'News & Media',	'',	'inherit',	'open',	'open',	'',	'25-revision-5',	'',	'',	'2012-05-30 16:11:20',	'2012-05-30 16:11:20',	'',	25,	'http://calzada-wp.urldock.com/25-revision-5/',	0,	'revision',	'',	0),
(100,	1,	'2012-05-30 16:24:29',	'2012-05-30 16:24:29',	'Donec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.\r\n\r\n[listing type=\"post\" title=\"News Listing\" count=\"5\"]\r\n\r\nCras mattis consectetur purus sit amet fermentum. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nulla vitae elit libero, a pharetra augue. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.\r\n\r\n[listing type=\"attachment\" title=\"Media Listing\" count=\"5\"]\r\n\r\nDonec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.',	'News & Media',	'',	'inherit',	'open',	'open',	'',	'25-revision-6',	'',	'',	'2012-05-30 16:24:29',	'2012-05-30 16:24:29',	'',	25,	'http://calzada-wp.urldock.com/25-revision-6/',	0,	'revision',	'',	0),
(101,	1,	'2012-05-30 16:24:43',	'2012-05-30 16:24:43',	'Donec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.\r\n\r\n[listing type=\"page\" title=\"News Listing\" count=\"5\"]\r\n\r\nCras mattis consectetur purus sit amet fermentum. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nulla vitae elit libero, a pharetra augue. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.\r\n\r\n[listing type=\"attachment\" title=\"Media Listing\" count=\"5\"]\r\n\r\nDonec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.',	'News & Media',	'',	'inherit',	'open',	'open',	'',	'25-revision-7',	'',	'',	'2012-05-30 16:24:43',	'2012-05-30 16:24:43',	'',	25,	'http://calzada-wp.urldock.com/25-revision-7/',	0,	'revision',	'',	0),
(102,	1,	'2012-05-30 16:25:35',	'2012-05-30 16:25:35',	'Integer posuere erat a ante venenatis dapibus posuere velit aliquet.',	'Integer posuere erat a ante venenatis dapibus posuere velit aliquet.',	'',	'inherit',	'open',	'open',	'',	'650x100',	'',	'',	'2012-05-30 16:25:35',	'2012-05-30 16:25:35',	'',	0,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/05/650x100.gif',	0,	'attachment',	'image/gif',	0),
(103,	1,	'2012-05-30 16:24:53',	'2012-05-30 16:24:53',	'Donec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.\r\n\r\n[listing type=\"post\" title=\"News Listing\" count=\"5\"]\r\n\r\nCras mattis consectetur purus sit amet fermentum. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nulla vitae elit libero, a pharetra augue. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.\r\n\r\n[listing type=\"attachment\" title=\"Media Listing\" count=\"5\"]\r\n\r\nDonec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.',	'News & Media',	'',	'inherit',	'open',	'open',	'',	'25-revision-8',	'',	'',	'2012-05-30 16:24:53',	'2012-05-30 16:24:53',	'',	25,	'http://calzada-wp.urldock.com/25-revision-8/',	0,	'revision',	'',	0),
(104,	1,	'2012-05-30 16:29:05',	'2012-05-30 16:29:05',	'Donec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.\r\n\r\n[listing type=\"post\" title=\"News Listing\" count=\"5\"]\r\n\r\nCras mattis consectetur purus sit amet fermentum. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nulla vitae elit libero, a pharetra augue. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.\r\n\r\n[listing type=\"page\" title=\"Media Listing\" count=\"5\"]\r\n\r\nDonec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.',	'News & Media',	'',	'inherit',	'open',	'open',	'',	'25-revision-9',	'',	'',	'2012-05-30 16:29:05',	'2012-05-30 16:29:05',	'',	25,	'http://calzada-wp.urldock.com/25-revision-9/',	0,	'revision',	'',	0),
(105,	1,	'2012-05-30 16:37:23',	'2012-05-30 16:37:23',	'Donec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.\r\n\r\n[listing type=\"post\" title=\"News Listing\" count=\"5\"]\r\n\r\nCras mattis consectetur purus sit amet fermentum. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nulla vitae elit libero, a pharetra augue. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.\r\n\r\n[listing type=\"attachment\" title=\"Media Listing\" count=\"5\"]\r\n\r\nDonec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.',	'News & Media',	'',	'inherit',	'open',	'open',	'',	'25-revision-10',	'',	'',	'2012-05-30 16:37:23',	'2012-05-30 16:37:23',	'',	25,	'http://calzada-wp.urldock.com/25-revision-10/',	0,	'revision',	'',	0),
(106,	1,	'2012-05-30 16:37:29',	'2012-05-30 16:37:29',	'Donec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.\r\n\r\n[listing type=\"post\" title=\"News Listing\" count=\"5\"]\r\n\r\nCras mattis consectetur purus sit amet fermentum. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nulla vitae elit libero, a pharetra augue. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.\r\n\r\n[listing type=\"attachment\" title=\"Media Listing\" count=\"5\"]\r\n\r\nDonec ullamcorper nulla non metus auctor fringilla. Vestibulum id ligula porta felis euismod semper. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Etiam porta sem malesuada magna mollis euismod. Cras mattis consectetur purus sit amet fermentum. Maecenas faucibus mollis interdum.',	'News & Media',	'',	'inherit',	'open',	'open',	'',	'25-revision-11',	'',	'',	'2012-05-30 16:37:29',	'2012-05-30 16:37:29',	'',	25,	'http://calzada-wp.urldock.com/25-revision-11/',	0,	'revision',	'',	0),
(107,	1,	'2012-05-27 14:02:27',	'2012-05-27 14:02:27',	'Donec id elit non mi porta gravida at eget metus. Cras mattis consectetur purus sit amet fermentum. Integer posuere erat a ante venenatis dapibus posuere velit aliquet. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Praesent commodo cursus magna, vel scelerisque nisl consectetur et.\r\n\r\nLorem ipsum dolor sit amet, consectetur adipiscing elit. Cras mattis consectetur purus sit amet fermentum. Nullam quis risus eget urna mollis ornare vel eu leo. Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Aenean eu leo quam. Pellentesque ornare sem lacinia quam venenatis vestibulum.',	'PolyNovo human Trial Update',	'',	'inherit',	'open',	'open',	'',	'74-revision-2',	'',	'',	'2012-05-27 14:02:27',	'2012-05-27 14:02:27',	'',	74,	'http://calzada-wp.urldock.com/74-revision-2/',	0,	'revision',	'',	0),
(108,	1,	'2012-07-09 03:04:58',	'2012-07-09 03:04:58',	'Calzada Ltd’s wholly owned subsidiary, PolyNovo Biomaterials Pty Ltd (‘PolyNovo’) is pleased to report that\nthe VAC human clinical trial, as announced on February 6th 2012, is well underway. This is the first human\nclinical trial involving NovoSorbTM.\n\n<a href=\"/wp-content/uploads/2012/07/132F042F2012103A223A30PM.pdf\" target=\"_blank\">Click here for details (PDF)</a>',	'PolyNovo Human Trial Update',	'',	'inherit',	'open',	'open',	'',	'74-autosave',	'',	'',	'2012-07-09 03:04:58',	'2012-07-09 03:04:58',	'',	74,	'http://calzada-wp.urldock.com/74-autosave/',	0,	'revision',	'',	0),
(109,	1,	'2012-05-30 17:41:09',	'2012-05-30 17:41:09',	'Donec id elit non mi porta gravida at eget metus. Cras mattis consectetur purus sit amet fermentum. Integer posuere erat a ante venenatis dapibus posuere velit aliquet. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Praesent commodo cursus magna, vel scelerisque nisl consectetur et.\r\n\r\nLorem ipsum dolor sit amet, consectetur adipiscing elit. Cras mattis consectetur purus sit amet fermentum. Nullam quis risus eget urna mollis ornare vel eu leo. Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Aenean eu leo quam. Pellentesque ornare sem lacinia quam venenatis vestibulum.\r\nMaecenas sed diam eget risus varius blandit sit amet non magna. Donec sed odio dui. Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Nullam quis risus eget urna mollis ornare vel eu leo. Aenean eu leo quam. Pellentesque ornare sem lacinia quam venenatis vestibulum. Donec sed odio dui. Nulla vitae elit libero, a pharetra augue.\r\n\r\nCurabitur blandit tempus porttitor. Cras justo odio, dapibus ac facilisis in, egestas eget quam. Donec id elit non mi porta gravida at eget metus. Aenean lacinia bibendum nulla sed consectetur. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Nullam quis risus eget urna mollis ornare vel eu leo. Etiam porta sem malesuada magna mollis euismod.\r\n\r\nAenean lacinia bibendum nulla sed consectetur. Curabitur blandit tempus porttitor. Praesent commodo cursus magna, vel scelerisque nisl consectetur et. Maecenas faucibus mollis interdum.\r\n\r\nVestibulum id ligula porta felis euismod semper. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam porta sem malesuada magna mollis euismod. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Curabitur blandit tempus porttitor. Etiam porta sem malesuada magna mollis euismod.Maecenas sed diam eget risus varius blandit sit amet non magna. Donec sed odio dui. Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Nullam quis risus eget urna mollis ornare vel eu leo. Aenean eu leo quam. Pellentesque ornare sem lacinia quam venenatis vestibulum. Donec sed odio dui. Nulla vitae elit libero, a pharetra augue.\r\n\r\nCurabitur blandit tempus porttitor. Cras justo odio, dapibus ac facilisis in, egestas eget quam. Donec id elit non mi porta gravida at eget metus. Aenean lacinia bibendum nulla sed consectetur. Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Nullam quis risus eget urna mollis ornare vel eu leo. Etiam porta sem malesuada magna mollis euismod.\r\n\r\nAenean lacinia bibendum nulla sed consectetur. Curabitur blandit tempus porttitor. Praesent commodo cursus magna, vel scelerisque nisl consectetur et. Maecenas faucibus mollis interdum.\r\n\r\nVestibulum id ligula porta felis euismod semper. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam porta sem malesuada magna mollis euismod. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Curabitur blandit tempus porttitor. Etiam porta sem malesuada magna mollis euismod.',	'PolyNovo human Trial Update',	'',	'inherit',	'open',	'open',	'',	'74-revision-3',	'',	'',	'2012-05-30 17:41:09',	'2012-05-30 17:41:09',	'',	74,	'http://calzada-wp.urldock.com/74-revision-3/',	0,	'revision',	'',	0),
(110,	1,	'2012-05-27 15:57:32',	'2012-05-27 15:57:32',	'',	'Home',	'',	'inherit',	'open',	'open',	'',	'6-revision-6',	'',	'',	'2012-05-27 15:57:32',	'2012-05-27 15:57:32',	'',	6,	'http://calzada-wp.urldock.com/6-revision-6/',	0,	'revision',	'',	0),
(111,	1,	'2012-05-28 17:58:11',	'2012-05-28 17:58:11',	'<h3>Mr David Franklyn (BEcon)</h3>\r\n<h4>NON-EXECUTIVE CHAIRMAN (EXECUTIVE CHAIRMAN 1ST FEBRUARY 2010 TO 31ST MARCH 2011)</h4>\r\n<span style=\"font-family: Verdana, Helvetica, Arial;\">Mr Franklyn is Chairman of Calzada and its 100% owned subsidiary PolyNovo Biomaterials Pty Ltd and has held that title since 16th April 2009.</span>\r\n\r\n<span style=\"font-family: Verdana, Helvetica, Arial;\">Mr Franklyn holds an Economics degree from the University of Western Australia and has completed the Graduate Diploma in Applied Finance and Investment from the Securities Institute of Australia, now FINSIA.</span>\r\n\r\n<span style=\"font-family: Verdana, Helvetica, Arial;\">Mr Franklyn has been involved in the financial services industry for over twenty years. He has extensive experience in the financial analysis of companies, funds management, corporate finance, business management and investor relations. His previous roles include being Head of Research for a national stockbroker and General Manager Corporate Communications for an ASX 200 company.</span>\r\n\r\n<span style=\"font-family: Verdana, Helvetica, Arial;\">Mr Franklyn is currently Managing Director of Entrust Funds Management Ltd, a Western Australian based boutique funds management business, and a Non-Executive Director of ASX Listed Nomad Building Solutions Ltd. Mr Franklyn resigned as Non-Executive Director of GoldLink Income Plus on 27th March 2009.</span>\r\n<h3>Mr Bruce Rathie (BComm, LLB, MBA, FAIM, FAICD)</h3>\r\n<h4>NON-EXECUTIVE DIRECTOR</h4>\r\n<span style=\"font-family: Verdana, Helvetica, Arial;\">Mr Rathie was appointed a Director of Calzada on 18th February 2010.</span>\r\n\r\n<span style=\"font-family: Verdana, Helvetica, Arial;\">Mr Rathie holds degrees in law, commerce and business and has considerable experience as a lawyer having practiced as a solicitor and partner in a major Brisbane based legal firm and then as Senior in-house Counsel to Bell Resources Limited from 1980 to 1985 in aggregate.</span>\r\n\r\n<span style=\"font-family: Verdana, Helvetica, Arial;\">He studied for his MBA in Geneva and then went into investment banking in 1986 which subsequently took him to New York for over 2 years returning to Sydney in 1990.</span>\r\n\r\n<span style=\"font-family: Verdana, Helvetica, Arial;\">He spent the 90\'s in investment banking in Sydney, the last 5 years as a Director of Investment Banking at Salomon Brothers/ Salomon Smith Barney where he was Head of the Industrial Franchise Group and also led Salomon\'s roles in the Federal Government\'s privatisation of Qantas, Commonwealth Bank (CBA3) and Telstra (T1).</span>\r\n\r\n<span style=\"font-family: Verdana, Helvetica, Arial;\">Mr Rathie currently is, in addition to his Non-Executive Director role at Calzada, a Non-Executive Director of ASX listed companies USCOM Limited (a medical devices company), Mungana Goldmines Limited (a gold mining company) and DataDot Technology Limited (an industrial security products company) which he Chairs. He is also a Non-Executive Director of Capricorn Society Limited the largest auto parts cooperative in the Southern Hemisphere with operations in Australia, South Africa and New Zealand, and is also Deputy Chairman of EFTPOS Payments Australia Limited the Australian debit card payment company. Mr Rathie resigned as Director of Anteo Diagnostics Limited on 31st August 2009.</span>\r\n<h3>Dr John Chiplin (PhD)</h3>\r\n<h4>NON-EXECUTIVE DIRECTOR</h4>\r\n<span style=\"font-family: Verdana, Helvetica, Arial;\">Dr Chiplin was appointed a Director of Calzada on 18th October 2010.</span>\r\n\r\n<span style=\"font-family: Verdana, Helvetica, Arial;\">Dr Chiplin is one of the most successful life sciences professionals in the Australian biotech industry. His most recent accomplishment was the corporate re-engineering of Arana Therapeutics (Arana), a world leading antibody developer, which resulted in the mid 2009 acquisition of Arana by Cephalon for $329 million at a 70 percent premium to the market valuation. Immediately prior to running Arana, Dr Chiplin was head of the $300 million ITI Life Sciences investment fund in the United Kingdom and prior to this was co-founder and Chief Executive officer of Geneformatics Inc.</span>\r\n\r\n<span style=\"font-family: Verdana, Helvetica, Arial;\">Dr Chiplin brings considerable international biotechnology industry experience, deep technical medical and scientific knowledge and extensive mergers and acquisition and investment expertise.</span>\r\n\r\n<span style=\"font-family: Verdana, Helvetica, Arial;\">Dr Chiplin is a current Non-Executive Director of ASX listed Benitec Ltd, Healthlinx Ltd and a Director of ScienceMedia. He resigned as Non-Executive Director of Progen Pharmaceuticals in August 2011.</span>',	'Board of Directors',	'',	'inherit',	'open',	'open',	'',	'13-revision-4',	'',	'',	'2012-05-28 17:58:11',	'2012-05-28 17:58:11',	'',	13,	'http://calzada-wp.urldock.com/13-revision-4/',	0,	'revision',	'',	0),
(112,	1,	'2012-06-05 19:29:29',	'2012-06-05 19:29:29',	'<h3>Mr David Franklyn (BEcon)</h3>\r\n<h4>NON-Executive Chairman</h4>\r\nMr Franklyn is Chairman of Calzada and its 100% owned subsidiary PolyNovo Biomaterials Pty Ltd and has held that title since 16th April 2009.\r\n\r\nMr Franklyn holds an Economics degree from the University of Western Australia and has completed the Graduate Diploma in Applied Finance and Investment from the Securities Institute of Australia, now FINSIA.\r\n\r\nMr Franklyn has been involved in the financial services industry for over twenty years. He has extensive experience in the financial analysis of companies, funds management, corporate finance, business management and investor relations. His previous roles include being Head of Research for a national stockbroker and General Manager Corporate Communications for an ASX 200 company.\r\n\r\nMr Franklyn is currently Managing Director of Entrust Funds Management Ltd, a Western Australian based boutique funds management business, and an Executive Director of ASX Listed Nomad Building Solutions Ltd.\r\n<h3>Mr Bruce Rathie (BComm, LLB, MBA, FAIM, FAICD)</h3>\r\n<h4>Non-executive Director</h4>\r\nMr Rathie was appointed a Director of Calzada on 18th February 2010.\r\n\r\nMr Rathie holds degrees in law, commerce and business and has considerable experience as a lawyer having practiced as a solicitor and partner in a major Brisbane based legal firm and then as Senior in-house Counsel to Bell Resources Limited from 1980 to 1985 in aggregate.\r\n\r\nHe studied for his MBA in Geneva and then went into investment banking in 1986 which subsequently took him to New York returning to Sydney in 1990.\r\n\r\nHe spent the 1990\'s in investment banking in Sydney, the last 5 years as a Director of Investment Banking at Salomon Brothers/ Salomon Smith Barney where he was Head of the Industrial Franchise Group and also led Salomon\'s roles in the Federal Government\'s privatisation of Qantas, Commonwealth Bank (CBA3) and Telstra (T1).\r\n\r\nMr Rathie currently is, in addition to his Non-Executive Director role at Calzada, a Non-Executive Director of ASX listed companies Mungana Goldmines Limited (a gold mining company) and DataDot Technology Limited (an industrial security products company) which he Chairs. He is also a Non-Executive Director of Capricorn Society Limited the largest auto parts cooperative in the Southern Hemisphere with operations in Australia, South Africa and New Zealand, and is also Chairman of EFTPOS Payments Australia Limited the Australian debit card payment company. In the past, he has served on the Boards of other ASX listed medical device companies being Anteo Diagnostics Limited (2006 - 2009), Compumedics Limited (2004 - 2006) and USCOM Limited (2006 – 2011).\r\n<h3>Dr John Chiplin, Ph.D.</h3>\r\n<h4>Non-executive Director</h4>\r\nDr Chiplin was appointed a Director of Calzada on 18th October 2010.\r\n\r\nDr Chiplin is one of the most successful life sciences professionals in the Australian biotech industry. His most recent accomplishment was the corporate re-engineering of Arana Therapeutics (Arana), a world leading antibody developer, which resulted in the mid 2009 acquisition of Arana by Cephalon for $329 million at a 70 percent premium to the market valuation. Immediately prior to running Arana, Dr Chiplin was head of the $300 million ITI Life Sciences investment fund in the United Kingdom and prior to this was co-founder and Chief Executive officer of Geneformatics Inc.\r\n\r\nDr Chiplin brings considerable international biotechnology industry experience, deep technical medical and scientific knowledge and extensive mergers and acquisition and investment expertise.\r\n\r\nDr Chiplin is a current Non-Executive Director of ASX listed Benitec Ltd, Healthlinx Ltd and a Director of ScienceMedia.',	'Board of Directors',	'',	'inherit',	'open',	'open',	'',	'13-revision-5',	'',	'',	'2012-06-05 19:29:29',	'2012-06-05 19:29:29',	'',	13,	'http://calzada-wp.urldock.com/13-revision-5/',	0,	'revision',	'',	0),
(113,	1,	'2012-05-28 17:57:27',	'2012-05-28 17:57:27',	'Nullam quis risus eget urna mollis ornare vel eu leo. Vestibulum id ligula porta felis euismod semper. Etiam porta sem malesuada magna mollis euismod. Maecenas sed diam eget risus varius blandit sit amet non magna.\r\n\r\nNullam id dolor id nibh ultricies vehicula ut id elit. Sed posuere consectetur est at lobortis. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Nullam quis risus eget urna mollis ornare vel eu leo. Cras mattis consectetur purus sit amet fermentum. Sed posuere consectetur est at lobortis.\r\n\r\nDuis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Donec id elit non mi porta gravida at eget metus. Nulla vitae elit libero, a pharetra augue. Cras mattis consectetur purus sit amet fermentum. Aenean eu leo quam. Pellentesque ornare sem lacinia quam venenatis vestibulum. Vestibulum id ligula porta felis euismod semper.\r\n\r\nDonec id elit non mi porta gravida at eget metus. Nulla vitae elit libero, a pharetra augue. Aenean lacinia bibendum nulla sed consectetur. Integer posuere erat a ante venenatis dapibus posuere velit aliquet. Cras justo odio, dapibus ac facilisis in, egestas eget quam.',	'Management & Staff',	'',	'inherit',	'open',	'open',	'',	'15-revision-3',	'',	'',	'2012-05-28 17:57:27',	'2012-05-28 17:57:27',	'',	15,	'http://calzada-wp.urldock.com/15-revision-3/',	0,	'revision',	'',	0),
(114,	1,	'2012-06-05 19:37:02',	'2012-06-05 19:37:02',	'<h3>Mr Laurent Fossaert</h3>\r\n<h4>CHIEF EXECUTIVE OFFICER – POLYNOVO BIOMATERIALS PTY LTD</h4>\r\nLF to provide wording.\r\n\r\nXXXXX\r\n<h3></h3>\r\n<h3>Mr David Kenley</h3>\r\n<h4>CHIEF EXECUTIVE OFFICER – metabolic pharmaceuticals PTY LTD</h4>\r\nDavid Kenley has a Masters degree in Entrepreneurship &amp; Innovation, a Bachelor of Economics and is a member of the Australian Institute of Company Directors.  Over the last 25 years his career has focussed on the commercialisation of research results from Australia’s leading research institutions including CSIRO.  He has gained considerable experience in the establishment of spin-off companies and the licensing of research in many fields of science and over the last 14 years has focussed on the biotechnology sector.\r\n\r\nMr Kenley was a Director of Calzada Ltd until his resignation in early 2010 to become the CEO of Metabolic Pharmaceuticals Pty Ltd, the subsidiary established to house Calzada’s AOD and other drug development assets.\r\n\r\nPrior to this role David was the Managing Director of Xceed Capital Ltd where he worked closely with the CEO of the subsidiary, PolyNovo Biomaterials Pty Ltd, in commercialising that company’s novel biodegradable polymer technology.  He also orchestrated the restructuring and significant turnaround in financial performance of the fully owned subsidiary, Boron Molecular Pty Ltd.\r\n\r\nPreviously David was one of the Founders and the Vice President, Corporate Development of Metabolic Pharmaceuticals Ltd (now Calzada) where he worked as the 2IC until mid 2005.  He has also previously been a senior executive of Axon Instruments, Inc. (a Silicon Valley based designer and manufacturer of scientific instruments and drug discovery equipment) and Corporate Development Manager of Circadian Technologies Ltd, Australia’s first listed biotechnology company.  Over a period of nearly ten years he was Licensing &amp; Finance Manager of Sirotech Ltd, the commercial arm of CSIRO, where he managed the organisation’s licence portfolio, the largest in the southern hemisphere, and all its equity based interests.\r\n\r\nMr Kenley has significant experience in starting and growing entrepreneurial growth companies, the capital markets and in the running of publicly listed entities.\r\n<h3>A/Prof John Greenwood AM</h3>\r\n<h4>Chief Medical Officer</h4>\r\n<strong>Director, Adult Burns Service, Royal Adelaide Hospital </strong>\r\n\r\n<strong>Director, Skin Engineering Laboratory, Hanson Institute </strong>\r\n\r\n<strong>Associate Professor, Department of Surgery, University of Adelaide</strong>\r\n\r\nAssociate Professor John Greenwood AM is an English-trained plastic surgeon who works full-time in burn care as the Medical Director of the Adult Burn Centre of the Royal Adelaide Hospital in Adelaide, South Australia. This is currently the only ABA/ACS Verified Burn Centre outside the United States. His other posts include Director of the Skin Engineering Laboratory (one of only two Australian laboratories licensed by the Therapeutic Goods Administration (TGA – Australia’s equivalent of the FDA) for the commercial processing of cultured skin cellular products, and Associate Professor in the Discipline of Surgery, School of Medicine, University of Adelaide.\r\n\r\nHe has been working on the development of skin replacement products utilising the NovoSorb biodegradable polyurethane platform since 2004, following a structured programme of studies, both <em>in-vitro</em> and <em>in-vivo</em>, collecting data and generating impressive results which have been rewarded with approval for human trials in Australia.\r\n\r\nHe is a member of both the American Burn Association and the Australian and New Zealand Burn Association and an international editor for the Journal of Burn Care and Research. Although a single-handed burn surgeon, his laboratory and clinical research programmes and general insights have been rewarded with 81 publications including 6 book chapters and 51 papers in peer-reviewed journals. His recent work with the polymer BTM earned him the inaugural Burke-Yannas Bioengineering Award, presented at the ABA Meeting in Chicago earlier this year.\r\n\r\nIn addition to his basic medical degree (MBChB – Bachelor of Medicine, Bachelor of Surgery), he holds a Bachelor of Science with honours degree by thesis in anatomy and a Doctor of Medicine post-graduate degree, also by thesis. His other qualifications are specialist plastic surgery fellowships with the Intercollegiate Board of the Colleges of Surgery of England, Scotland and Ireland and more recently specialist plastic surgery fellowship of the Royal Australasian College of Surgeons. The post-nominal immediately after his name (AM) is membership of the Order of Australia, an honour bestowed on him by the Queen following his work leading Australia’s only Burns Assessment Team after the carnage of the 2002 Bali Bombings which killed 202 civilians.\r\n<h3>Dr Tim Moore</h3>\r\n<h4>Principal Scientist</h4>\r\nDr. Moore completed a Bachelor of Applied Science (Chemistry) degree at Swinburne University of Technology, followed by an honours degree and PhD degree. Dr. Moore’s PhD dissertation was in the field of biodegradable polyurethanes; the title was “Design and Synthesis of Biodegradable Thermoplastic Polyurethanes for Tissue Engineering”.\r\n\r\nDr. Moore has been involved with PolyNovo since its inception and is a co-inventor of some of the variants of NovoSorb™. He has been working on the development of biodegradable polymers for medical devices for over ten years. His main area of expertise is in polyurethanes and the development of biomaterials for use in medical devices. He developed a novel range of biodegradable chain extenders which is included in several of PolyNovo’s patent applications. Dr. Moore is involved in project management and product development in PolyNovo’s leading applications. Dr. Moore is also responsible for the maintenance of PolyNovo’s extensive Intellectual Property Portfolio. He is co-author on a number of peer-reviewed papers and patent applications. He was a co-recipient of the CSIRO Molecular Science Divisional Strategic Action Plan Award for Innovation (2004) and of the CSIRO medal in Research Achievement category (2005).\r\n<h3>Mr Chris Mews (CPA, ACIS)</h3>\r\n<h4>Company Secretary/Chief Financial Officer</h4>\r\nMr Mews was appointed Company Secretary of Calzada Ltd on 16th April 2009 and was appointed Chief Financial Officer on 1st September 2009.\r\n\r\nMr Mews has been involved in the financial services industry for over 10 years.  Mr Mews is a Certified Practicing Accountant and Chartered Company Secretary and has been Company Secretary and Chief Financial Officer of various listed and unlisted companies.',	'Management & Staff',	'',	'inherit',	'open',	'open',	'',	'15-revision-4',	'',	'',	'2012-06-05 19:37:02',	'2012-06-05 19:37:02',	'',	15,	'http://calzada-wp.urldock.com/15-revision-4/',	0,	'revision',	'',	0),
(115,	1,	'2012-05-23 21:16:12',	'2012-05-23 21:16:12',	'Calzada has 100% ownership of PolyNovo Biomaterials Pty Ltd and Metabolic Pharmaceuticals Pty Ltd. The company is listed on the Australian Stock Exchange (ASX Code CZD).\r\n\r\nThe corporate head office takes responsibility for group strategy, capital allocation, identification and analysis of investment opportunities and investor and media relations.\r\n\r\nMr Franklyn is Chairman of Calzada and its 100% owned subsidiary PolyNovo Biomaterials Pty Ltd and has held that title since 16th April 2009.\r\n\r\nMr Franklyn holds an Economics degree from the University of Western Australia and has completed the Graduate Diploma in Applied Finance and Investment from the Securities Institute of Australia, now FINSIA.\r\n\r\nMr Franklyn has been involved in the financial services industry for over twenty years. He has extensive experience in the financial analysis of companies, funds management, corporate finance, business management and investor relations. His previous roles include being Head of Research for a national stockbroker and General Manager Corporate Communications for an ASX 200 company.\r\n<h2>Sub Heading to go here - h2</h2>\r\nMr Franklyn is currently Managing Director of Entrust Funds Management Ltd, a Western Australian based boutique funds management business, and a Non-Executive Director of ASX Listed Nomad Building Solutions Ltd. Mr Franklyn resigned as Non-Executive Director of GoldLink Income Plus on 27th March 2009.\r\n\r\nMr Bruce Rathie (BComm, LLB, MBA, FAIM, FAICD)\r\n\r\nNON-EXECUTIVE DIRECTOR\r\n\r\nMr Rathie was appointed a Director of Calzada on 18th February 2010.\r\n\r\nMr Rathie holds degrees in law, commerce and business and has considerable experience as a lawyer having practiced as a solicitor and partner in a major Brisbane based legal firm and then as Senior in-house Counsel to Bell Resources Limited from 1980 to 1985 in aggregate.\r\n\r\nHe studied for his MBA in Geneva and then went into investment banking in 1986 which subsequently took him to New York for over 2 years returning to Sydney in 1990.\r\n\r\nHe spent the 90\'s in investment banking in Sydney, the last 5 years as a Director of Investment Banking at Salomon Brothers/ Salomon Smith Barney where he was Head of the Industrial Franchise Group and also led Salomon\'s roles in the Federal Government\'s privatisation of Qantas, Commonwealth Bank (CBA3) and Telstra (T1).\r\n\r\nMr Rathie currently is, in addition to his Non-Executive Director role at Calzada, a Non-Executive Director of ASX listed companies USCOM Limited (a medical devices company), Mungana Goldmines Limited (a gold mining company) and DataDot Technology Limited (an industrial security products company) which he Chairs. He is also a Non-Executive Director of Capricorn Society Limited the largest auto parts cooperative in the Southern Hemisphere with operations in Australia, South Africa and New Zealand, and is also Deputy Chairman of EFTPOS Payments Australia Limited the Australian debit card payment company. Mr Rathie resigned as Director of Anteo Diagnostics Limited on 31st August 2009.\r\n\r\nDr John Chiplin (PhD)',	'About Us',	'',	'inherit',	'open',	'open',	'',	'8-revision-5',	'',	'',	'2012-05-23 21:16:12',	'2012-05-23 21:16:12',	'',	8,	'http://calzada-wp.urldock.com/8-revision-5/',	0,	'revision',	'',	0),
(116,	1,	'2012-06-05 19:47:45',	'2012-06-05 19:47:45',	'<div>Calzada has two wholly owned subsidiaries, PolyNovo Biomaterials Pty Ltd (“PolyNovo”)and Metabolic Pharmaceuticals Pty Ltd (“Metabolic”), both have high potential and maturing products reaching major value inflexion points.</div>\r\n<h3><em>PolyNovo</em></h3>\r\n<div>PolyNovo Biomaterials [link to PNV websitre] has developed a unique biodegradable polymer platform technology (NovoSorb™) designed to be used in medical devices and for tissue engineering scaffolds. The potential applications include reconstructive surgery and repair in a diverse range of fields including wounds, burns, cardiovascular, orthopaedic, periodontal, cartilage and drug delivery.</div>\r\n<div></div>\r\n<div>PolyNovo is developing two lead products with world leading burns surgeon, Associate Professor John Greenwood AM (20% interest). [link to description of John Greenwood]</div>\r\n<h3><em>Metabolic</em></h3>\r\n<div>Metabolic Pharmaceuticals is seeking to derive value from the past investment of over $50mill in the pharmaceutical development of AOD9604. The peptide has proven to be safe and well tolerated in a total of 6 human clinical trials involving 925 humans. [link to metabolic section of website]</div>\r\n<h3><em>Corporate</em></h3>\r\n<div>The corporate head office takes responsibility for group strategy, capital allocation, identification and analysis of investment opportunities and investor and media relations.</div>\r\n<div></div>\r\n<div>For further information on Calzada please <a href=\"http://www.calzada.com.au/html/s08_contact/default.asp\">contact us</a>. – [link this through to the contact us section]</div>',	'About Us',	'',	'inherit',	'open',	'open',	'',	'8-revision-6',	'',	'',	'2012-06-05 19:47:45',	'2012-06-05 19:47:45',	'',	8,	'http://calzada-wp.urldock.com/8-revision-6/',	0,	'revision',	'',	0),
(117,	1,	'2012-06-05 19:48:22',	'2012-06-05 19:48:22',	'Calzada has two wholly owned subsidiaries, PolyNovo Biomaterials Pty Ltd (“PolyNovo”) and Metabolic Pharmaceuticals Pty Ltd (“Metabolic”), both have high potential and maturing products reaching major value inflexion points.\r\n<h3>PolyNovo</h3>\r\n<div>PolyNovo Biomaterials [link to PNV websitre] has developed a unique biodegradable polymer platform technology (NovoSorb™) designed to be used in medical devices and for tissue engineering scaffolds. The potential applications include reconstructive surgery and repair in a diverse range of fields including wounds, burns, cardiovascular, orthopaedic, periodontal, cartilage and drug delivery.</div>\r\n<div></div>\r\n<div>PolyNovo is developing two lead products with world leading burns surgeon, Associate Professor John Greenwood AM (20% interest). [link to description of John Greenwood]</div>\r\n<h3>Metabolic</h3>\r\n<div>Metabolic Pharmaceuticals is seeking to derive value from the past investment of over $50mill in the pharmaceutical development of AOD9604. The peptide has proven to be safe and well tolerated in a total of 6 human clinical trials involving 925 humans. [link to metabolic section of website]</div>\r\n<h3>Corporate</h3>\r\n<div>The corporate head office takes responsibility for group strategy, capital allocation, identification and analysis of investment opportunities and investor and media relations.</div>\r\n<div></div>\r\n<div>For further information on Calzada please <a href=\"http://www.calzada.com.au/html/s08_contact/default.asp\">contact us</a>. – [link this through to the contact us section]</div>',	'About Us',	'',	'inherit',	'open',	'open',	'',	'8-revision-7',	'',	'',	'2012-06-05 19:48:22',	'2012-06-05 19:48:22',	'',	8,	'http://calzada-wp.urldock.com/8-revision-7/',	0,	'revision',	'',	0),
(118,	1,	'2012-06-05 19:48:50',	'2012-06-05 19:48:50',	'Calzada has two wholly owned subsidiaries, PolyNovo Biomaterials Pty Ltd (“PolyNovo”) and Metabolic Pharmaceuticals Pty Ltd (“Metabolic”), both have high potential and maturing products reaching major value inflexion points.\r\n<h3>PolyNovo</h3>\r\nPolyNovo Biomaterials [link to PNV websitre] has developed a unique biodegradable polymer platform technology (NovoSorb™) designed to be used in medical devices and for tissue engineering scaffolds. The potential applications include reconstructive surgery and repair in a diverse range of fields including wounds, burns, cardiovascular, orthopaedic, periodontal, cartilage and drug delivery.\r\n\r\nPolyNovo is developing two lead products with world leading burns surgeon, Associate Professor John Greenwood AM (20% interest). [link to description of John Greenwood]\r\n<h3>Metabolic</h3>\r\nMetabolic Pharmaceuticals is seeking to derive value from the past investment of over $50mill in the pharmaceutical development of AOD9604. The peptide has proven to be safe and well tolerated in a total of 6 human clinical trials involving 925 humans. [link to metabolic section of website]\r\n<h3>Corporate</h3>\r\nThe corporate head office takes responsibility for group strategy, capital allocation, identification and analysis of investment opportunities and investor and media relations.\r\n\r\nFor further information on Calzada please <a href=\"http://www.calzada.com.au/html/s08_contact/default.asp\">contact us</a>. – [link this through to the contact us section]',	'About Us',	'',	'inherit',	'open',	'open',	'',	'8-revision-8',	'',	'',	'2012-06-05 19:48:50',	'2012-06-05 19:48:50',	'',	8,	'http://calzada-wp.urldock.com/8-revision-8/',	0,	'revision',	'',	0),
(119,	1,	'2012-06-05 19:50:41',	'2012-06-05 19:50:41',	'Calzada has two wholly owned subsidiaries, PolyNovo Biomaterials Pty Ltd (“PolyNovo”) and Metabolic Pharmaceuticals Pty Ltd (“Metabolic”), both have high potential and maturing products reaching major value inflexion points.\r\n<h3>PolyNovo</h3>\r\n<a title=\"PolyNovo Biomaterials\" href=\"http://polynovo.com/\">PolyNovo Biomaterials</a> has developed a unique biodegradable polymer platform technology (NovoSorb™) designed to be used in medical devices and for tissue engineering scaffolds. The potential applications include reconstructive surgery and repair in a diverse range of fields including wounds, burns, cardiovascular, orthopaedic, periodontal, cartilage and drug delivery.\r\n\r\nPolyNovo is developing two lead products with world leading burns surgeon, Associate Professor John Greenwood AM (20% interest). [link to description of John Greenwood]\r\n<h3>Metabolic</h3>\r\nMetabolic Pharmaceuticals is seeking to derive value from the past investment of over $50mill in the pharmaceutical development of AOD9604. The peptide has proven to be safe and well tolerated in a total of 6 human clinical trials involving 925 humans. [link to metabolic section of website]\r\n<h3>Corporate</h3>\r\nThe corporate head office takes responsibility for group strategy, capital allocation, identification and analysis of investment opportunities and investor and media relations.\r\n\r\nFor further information on Calzada please <a title=\"Contact Us\" href=\"http://calzada-wp.urldock.com/contact-us/\">contact us</a>.',	'About Us',	'',	'inherit',	'open',	'open',	'',	'8-revision-9',	'',	'',	'2012-06-05 19:50:41',	'2012-06-05 19:50:41',	'',	8,	'http://calzada-wp.urldock.com/8-revision-9/',	0,	'revision',	'',	0),
(120,	1,	'2012-06-05 19:37:36',	'2012-06-05 19:37:36',	'<h3>Mr Laurent Fossaert</h3>\r\n<h4>CHIEF EXECUTIVE OFFICER – POLYNOVO BIOMATERIALS PTY LTD</h4>\r\nLF to provide wording.\r\n\r\nXXXXX\r\n<h3></h3>\r\n<h3>Mr David Kenley</h3>\r\n<h4>CHIEF EXECUTIVE OFFICER – metabolic pharmaceuticals PTY LTD</h4>\r\nDavid Kenley has a Masters degree in Entrepreneurship &amp; Innovation, a Bachelor of Economics and is a member of the Australian Institute of Company Directors.  Over the last 25 years his career has focussed on the commercialisation of research results from Australia’s leading research institutions including CSIRO.  He has gained considerable experience in the establishment of spin-off companies and the licensing of research in many fields of science and over the last 14 years has focussed on the biotechnology sector.\r\n\r\nMr Kenley was a Director of Calzada Ltd until his resignation in early 2010 to become the CEO of Metabolic Pharmaceuticals Pty Ltd, the subsidiary established to house Calzada’s AOD and other drug development assets.\r\n\r\nPrior to this role David was the Managing Director of Xceed Capital Ltd where he worked closely with the CEO of the subsidiary, PolyNovo Biomaterials Pty Ltd, in commercialising that company’s novel biodegradable polymer technology.  He also orchestrated the restructuring and significant turnaround in financial performance of the fully owned subsidiary, Boron Molecular Pty Ltd.\r\n\r\nPreviously David was one of the Founders and the Vice President, Corporate Development of Metabolic Pharmaceuticals Ltd (now Calzada) where he worked as the 2IC until mid 2005.  He has also previously been a senior executive of Axon Instruments, Inc. (a Silicon Valley based designer and manufacturer of scientific instruments and drug discovery equipment) and Corporate Development Manager of Circadian Technologies Ltd, Australia’s first listed biotechnology company.  Over a period of nearly ten years he was Licensing &amp; Finance Manager of Sirotech Ltd, the commercial arm of CSIRO, where he managed the organisation’s licence portfolio, the largest in the southern hemisphere, and all its equity based interests.\r\n\r\nMr Kenley has significant experience in starting and growing entrepreneurial growth companies, the capital markets and in the running of publicly listed entities.\r\n<h3>A/Prof John Greenwood AM</h3>\r\n<h4>Chief Medical Officer</h4>\r\n<strong>Director, Adult Burns Service, Royal Adelaide Hospital</strong><br /><strong>Director, Skin Engineering Laboratory, Hanson Institute</strong><br /><strong>Associate Professor, Department of Surgery, University of Adelaide</strong>\r\n\r\nAssociate Professor John Greenwood AM is an English-trained plastic surgeon who works full-time in burn care as the Medical Director of the Adult Burn Centre of the Royal Adelaide Hospital in Adelaide, South Australia. This is currently the only ABA/ACS Verified Burn Centre outside the United States. His other posts include Director of the Skin Engineering Laboratory (one of only two Australian laboratories licensed by the Therapeutic Goods Administration (TGA – Australia’s equivalent of the FDA) for the commercial processing of cultured skin cellular products, and Associate Professor in the Discipline of Surgery, School of Medicine, University of Adelaide.\r\n\r\nHe has been working on the development of skin replacement products utilising the NovoSorb biodegradable polyurethane platform since 2004, following a structured programme of studies, both <em>in-vitro</em> and <em>in-vivo</em>, collecting data and generating impressive results which have been rewarded with approval for human trials in Australia.\r\n\r\nHe is a member of both the American Burn Association and the Australian and New Zealand Burn Association and an international editor for the Journal of Burn Care and Research. Although a single-handed burn surgeon, his laboratory and clinical research programmes and general insights have been rewarded with 81 publications including 6 book chapters and 51 papers in peer-reviewed journals. His recent work with the polymer BTM earned him the inaugural Burke-Yannas Bioengineering Award, presented at the ABA Meeting in Chicago earlier this year.\r\n\r\nIn addition to his basic medical degree (MBChB – Bachelor of Medicine, Bachelor of Surgery), he holds a Bachelor of Science with honours degree by thesis in anatomy and a Doctor of Medicine post-graduate degree, also by thesis. His other qualifications are specialist plastic surgery fellowships with the Intercollegiate Board of the Colleges of Surgery of England, Scotland and Ireland and more recently specialist plastic surgery fellowship of the Royal Australasian College of Surgeons. The post-nominal immediately after his name (AM) is membership of the Order of Australia, an honour bestowed on him by the Queen following his work leading Australia’s only Burns Assessment Team after the carnage of the 2002 Bali Bombings which killed 202 civilians.\r\n<h3>Dr Tim Moore</h3>\r\n<h4>Principal Scientist</h4>\r\nDr. Moore completed a Bachelor of Applied Science (Chemistry) degree at Swinburne University of Technology, followed by an honours degree and PhD degree. Dr. Moore’s PhD dissertation was in the field of biodegradable polyurethanes; the title was “Design and Synthesis of Biodegradable Thermoplastic Polyurethanes for Tissue Engineering”.\r\n\r\nDr. Moore has been involved with PolyNovo since its inception and is a co-inventor of some of the variants of NovoSorb™. He has been working on the development of biodegradable polymers for medical devices for over ten years. His main area of expertise is in polyurethanes and the development of biomaterials for use in medical devices. He developed a novel range of biodegradable chain extenders which is included in several of PolyNovo’s patent applications. Dr. Moore is involved in project management and product development in PolyNovo’s leading applications. Dr. Moore is also responsible for the maintenance of PolyNovo’s extensive Intellectual Property Portfolio. He is co-author on a number of peer-reviewed papers and patent applications. He was a co-recipient of the CSIRO Molecular Science Divisional Strategic Action Plan Award for Innovation (2004) and of the CSIRO medal in Research Achievement category (2005).\r\n<h3>Mr Chris Mews (CPA, ACIS)</h3>\r\n<h4>Company Secretary/Chief Financial Officer</h4>\r\nMr Mews was appointed Company Secretary of Calzada Ltd on 16th April 2009 and was appointed Chief Financial Officer on 1st September 2009.\r\n\r\nMr Mews has been involved in the financial services industry for over 10 years.  Mr Mews is a Certified Practicing Accountant and Chartered Company Secretary and has been Company Secretary and Chief Financial Officer of various listed and unlisted companies.',	'Management & Staff',	'',	'inherit',	'open',	'open',	'',	'15-revision-5',	'',	'',	'2012-06-05 19:37:36',	'2012-06-05 19:37:36',	'',	15,	'http://calzada-wp.urldock.com/15-revision-5/',	0,	'revision',	'',	0),
(121,	1,	'2012-06-05 19:51:51',	'2012-06-05 19:51:51',	'Calzada has two wholly owned subsidiaries, PolyNovo Biomaterials Pty Ltd (“PolyNovo”) and Metabolic Pharmaceuticals Pty Ltd (“Metabolic”), both have high potential and maturing products reaching major value inflexion points.\r\n<h3>PolyNovo</h3>\r\n<a title=\"PolyNovo Biomaterials\" href=\"http://polynovo.com/\">PolyNovo Biomaterials</a> has developed a unique biodegradable polymer platform technology (NovoSorb™) designed to be used in medical devices and for tissue engineering scaffolds. The potential applications include reconstructive surgery and repair in a diverse range of fields including wounds, burns, cardiovascular, orthopaedic, periodontal, cartilage and drug delivery.\r\n\r\nPolyNovo is developing two lead products with world leading burns surgeon, <a title=\"Management &amp; Staff\" href=\"http://calzada-wp.urldock.com/about-us/management-staff/#greenwood\">Associate Professor John Greenwood </a>AM (20% interest).\r\n<h3>Metabolic</h3>\r\nMetabolic Pharmaceuticals is seeking to derive value from the past investment of over $50mill in the pharmaceutical development of AOD9604. The peptide has proven to be safe and well tolerated in a total of 6 human clinical trials involving 925 humans.\r\n<h3>Corporate</h3>\r\nThe corporate head office takes responsibility for group strategy, capital allocation, identification and analysis of investment opportunities and investor and media relations.\r\n\r\nFor further information on Calzada please <a title=\"Contact Us\" href=\"http://calzada-wp.urldock.com/contact-us/\">contact us</a>.',	'About Us',	'',	'inherit',	'open',	'open',	'',	'8-revision-10',	'',	'',	'2012-06-05 19:51:51',	'2012-06-05 19:51:51',	'',	8,	'http://calzada-wp.urldock.com/8-revision-10/',	0,	'revision',	'',	0),
(122,	1,	'2012-08-08 01:57:26',	'2012-08-08 01:57:26',	'<table>\n<tbody>\n<tr>\n<td>\n<h2 style=\"margin-top: 40px;\">Calzada Limited</h2>\n<img class=\"alignnone size-thumbnail wp-image-123\" title=\"calzada_logo\" src=\"/wp-content/uploads/2012/05/calzada_logo\" alt=\"contact Calzada\" /></td>\n</tr>\n<tr>\n<td>Wendy Townsend\n2/320 Lorimer Street\nPort Melbourne VIC 3207\nAustralia</td>\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\n<strong>Fax:</strong>+61 (0) 3 8681 4099\n<strong>Email:</strong><a href=\"mailTo:wtownsend@calzada.com.au\">wtownsend@calzada.com.au</a></td>\n</tr>\n<tr>\n<td>\n<h2 style=\"margin-top: 70px;\">PolyNovo Biomaterials Pty Ltd</h2>\n<img class=\"alignnone size-full wp-image-124\" style=\"margin-top: 30px; margin-bottom: 30px; border: 0px none;\" title=\"polynovo\" src=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/polynovologo.jpg\" alt=\"polynovo\" width=\"225\" height=\"120\" border=\"0\" /></td>\n</tr>\n<tr>\n<td>Chief Executive Officer\nMr. Laurent Fossaert\nPolyNovo Biomaterials Pty Ltd\n2/320 Lorimer Street\nPort Melbourne VIC 3207\nAustralia</td>\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\n<strong>Fax:</strong>+61 (0) 3 8681 4099\n<strong>Email:</strong><a href=\"mailTo:info@polynovo.com\">info@polynovo.com</a></td>\n</tr>\n<tr>\n<td>\n<h2 style=\"margin-top: 70px;\">Metabolic Pharmaceuticals Pty Ltd</h2>\n<img class=\"alignnone size-full wp-image-126\" style=\"margin-top: 30px; margin-bottom: 30px; border: 0px none;\" title=\"metaboliclogo\" src=\"/wp-content/uploads/2012/05/metaboliclogo.jpg\" alt=\"metaboloic\" width=\"225\" height=\"120\" border=\"0\" /></td>\n</tr>\n<tr>\n<td>Chief Executive Officer\nMr. David Kenley\n2/320 Lorimer Street\nPort Melbourne VIC 3207\nAustralia</td>\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\n<strong>Fax:</strong>+61 (0) 3 8681 4099\n<strong>Email:</strong><a href=\"mailto:dkenley@calzada.com.au\">dkenley@calzada.com.au</a></td>\n</tr>\n</tbody>\n</table>',	'Contact Us',	'',	'inherit',	'open',	'open',	'',	'27-autosave',	'',	'',	'2012-08-08 01:57:26',	'2012-08-08 01:57:26',	'',	27,	'http://calzada-wp.urldock.com/27-autosave/',	0,	'revision',	'',	0),
(123,	1,	'2012-06-11 04:28:52',	'2012-06-11 04:28:52',	'',	'calzada_logo',	'',	'inherit',	'open',	'open',	'',	'calzada_logo',	'',	'',	'2012-06-11 04:28:52',	'2012-06-11 04:28:52',	'',	27,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/05/calzada_logo.jpg',	0,	'attachment',	'image/jpeg',	0),
(124,	1,	'2012-06-11 04:42:05',	'2012-06-11 04:42:05',	'',	'polynovologo',	'',	'inherit',	'open',	'open',	'',	'polynovologo',	'',	'',	'2012-06-11 04:42:05',	'2012-06-11 04:42:05',	'',	27,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/05/polynovologo.jpg',	0,	'attachment',	'image/jpeg',	0),
(125,	1,	'2012-05-28 18:03:03',	'2012-05-28 18:03:03',	'Nullam quis risus eget urna mollis ornare vel eu leo. Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Etiam porta sem malesuada magna mollis euismod. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Curabitur blandit tempus porttitor. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.\r\n\r\nCum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec ullamcorper nulla non metus auctor fringilla.\r\n\r\nCum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Sed posuere consectetur est at lobortis. Aenean lacinia bibendum nulla sed consectetur. Donec sed odio dui. Etiam porta sem malesuada magna mollis euismod.\r\n\r\nAenean eu leo quam. Pellentesque ornare sem lacinia quam venenatis vestibulum. Maecenas faucibus mollis interdum. Curabitur blandit tempus porttitor. Nullam id dolor id nibh ultricies vehicula ut id elit. Nullam id dolor id nibh ultricies vehicula ut id elit. Nulla vitae elit libero, a pharetra augue. Lorem ipsum dolor sit amet, consectetur adipiscing elit.',	'Contact Us',	'',	'inherit',	'open',	'open',	'',	'27-revision-3',	'',	'',	'2012-05-28 18:03:03',	'2012-05-28 18:03:03',	'',	27,	'http://calzada-wp.urldock.com/27-revision-3/',	0,	'revision',	'',	0),
(126,	1,	'2012-06-11 04:48:56',	'2012-06-11 04:48:56',	'',	'metaboliclogo',	'',	'inherit',	'open',	'open',	'',	'metaboliclogo',	'',	'',	'2012-06-11 04:48:56',	'2012-06-11 04:48:56',	'',	27,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/05/metaboliclogo.jpg',	0,	'attachment',	'image/jpeg',	0),
(127,	1,	'2012-06-11 04:44:42',	'2012-06-11 04:44:42',	'<table><tbody><tr>\r\n<td>\r\n<h2>Calzada Limited</h2>\r\n<p><img alt=\"Calzada Limited\" src=\"/wp-content/uploads/2012/05/calzada_logo\" alt=\"contact Calzada\" title=\"calzada_logo\" class=\"alignnone size-thumbnail wp-image-123\" /></p></td></tr>\r\n<tr><td>\r\n<p>Wendy Townsend<br>2/320 Lorimer Street<br>Port Melbourne VIC 3207<br>Australia<br>\r\n</p></td><td><p><b>Phone:</b>+61 (0) 3 8681 4050<br /><b>Fax:</b>+61 (0) 3 8681 4099<br /><b>Email:</b><a href=\"mailTo:wtownsend@calzada.com.au\">wtownsend@calzada.com.au</a></td></tr>\r\n<tr><td>\r\n<h2>Polynovo</h2>\r\n<img src=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/polynovologo.jpg\" title=\"polynovo\" width=\"225\" height=\"120\" class=\"alignnone size-full wp-image-124\" border=\"0\">\r\nPolyNovo Biomaterials Pty Ltd<br><br>Chief Executive Officer<br>Mr. Laurent Fossaert<br><br>PolyNovo Biomaterials Pty Ltd<br>2/320 Lorimer Street<br>Port Melbourne VIC 3207<br>Australia<br><br>\r\n<b>Phone:</b>+61 (0) 3 8681 4050<br /><b>Fax:</b>+61 (0) 3 8681 4099<br /><b>Email:</b><a href=\"mailTo:info@polynovo.com\">info@polynovo.com</a></td></tr>\r\n<tr><td>\r\n<h2>Metabolic</h2><br>\r\n<p><img alt=\"Metabolic Logo\" src=\"../files/ZT9HVEXI0Q/metabolic_logo.JPG\" border=\"0\" width=\"100\"></p>\r\n<p>Metabolic Pharmaceuticals Limited <br><br>Chief Executive Officer<br>Mr. David Kenley<br><br>2/320 Lorimer Street<br>Port Melbourne VIC 3207<br>Australia<br><br>\r\n<b>Phone:</b>+61 (0) 3 8681 4050<br /><b>Fax:</b>+61 (0) 3 8681 4099</td></tr>\r\n</tbody></table>',	'Contact Us',	'',	'inherit',	'open',	'open',	'',	'27-revision-4',	'',	'',	'2012-06-11 04:44:42',	'2012-06-11 04:44:42',	'',	27,	'http://calzada-wp.urldock.com/27-revision-4/',	0,	'revision',	'',	0),
(128,	1,	'2012-06-11 04:51:14',	'2012-06-11 04:51:14',	'<table>\r\n<tbody>\r\n<tr>\r\n<td>\r\n<h2>Calzada Limited</h2>\r\n<img class=\"alignnone size-thumbnail wp-image-123\" title=\"calzada_logo\" src=\"/wp-content/uploads/2012/05/calzada_logo\" alt=\"contact Calzada\" /></td>\r\n</tr>\r\n<tr>\r\n<td>Wendy Townsend\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia</td>\r\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\r\n<strong>Fax:</strong>+61 (0) 3 8681 4099\r\n<strong>Email:</strong><a href=\"mailTo:wtownsend@calzada.com.au\">wtownsend@calzada.com.au</a></td>\r\n</tr>\r\n<tr>\r\n<td>\r\n<h2>PolyNovo Biomaterials Pty Ltd</h2>\r\n<img class=\"alignnone size-full wp-image-124\" title=\"polynovo\" src=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/polynovologo.jpg\" alt=\"\" width=\"225\" height=\"120\" border=\"0\" />\r\n</td></tr>\r\n<tr><td>\r\nChief Executive Officer\r\nMr. Laurent Fossaert\r\nPolyNovo Biomaterials Pty Ltd\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia\r\n</td><td>\r\n<strong>Phone:</strong>+61 (0) 3 8681 4050\r\n<strong>Fax:</strong>+61 (0) 3 8681 4099\r\n<strong>Email:</strong><a href=\"mailTo:info@polynovo.com\">info@polynovo.com</a></td>\r\n</tr>\r\n<tr>\r\n<td>\r\n<h2>Metabolic Pharmaceuticals Limited</h2>\r\n<img src=\"/wp-content/uploads/2012/05/metaboliclogo.jpg\" alt=\"metaboloic\" title=\"metaboliclogo\" width=\"225\" height=\"120\" class=\"alignnone size-full wp-image-126\" border=\"0\" />\r\n</td></tr><tr>\r\n<td>Chief Executive Officer\r\nMr. David Kenley\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia\r\n</td><td>\r\n<strong>Phone:</strong>+61 (0) 3 8681 4050\r\n<strong>Fax:</strong>+61 (0) 3 8681 4099</td>\r\n</tr>\r\n</tbody>\r\n</table>',	'Contact Us',	'',	'inherit',	'open',	'open',	'',	'27-revision-5',	'',	'',	'2012-06-11 04:51:14',	'2012-06-11 04:51:14',	'',	27,	'http://calzada-wp.urldock.com/27-revision-5/',	0,	'revision',	'',	0),
(129,	1,	'2012-06-11 04:52:52',	'2012-06-11 04:52:52',	'<table>\r\n<tbody>\r\n<tr>\r\n<td>\r\n<h2>Calzada Limited</h2>\r\n<img class=\"alignnone size-thumbnail wp-image-123\" title=\"calzada_logo\" src=\"/wp-content/uploads/2012/05/calzada_logo\" alt=\"contact Calzada\" /></td>\r\n</tr>\r\n<tr>\r\n<td>Wendy Townsend\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia\r\n\r\n&nbsp;\r\n\r\n&nbsp;</td>\r\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\r\n<strong>Fax:</strong>+61 (0) 3 8681 4099\r\n<strong>Email:</strong><a href=\"mailTo:wtownsend@calzada.com.au\">wtownsend@calzada.com.au</a></td>\r\n</tr>\r\n<tr>\r\n<td>\r\n<h2>PolyNovo Biomaterials Pty Ltd</h2>\r\n<img class=\"alignnone size-full wp-image-124\" title=\"polynovo\" src=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/polynovologo.jpg\" alt=\"\" width=\"225\" height=\"120\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td>Chief Executive Officer\r\nMr. Laurent Fossaert\r\nPolyNovo Biomaterials Pty Ltd\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia\r\n\r\n&nbsp;\r\n\r\n&nbsp;</td>\r\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\r\n<strong>Fax:</strong>+61 (0) 3 8681 4099\r\n<strong>Email:</strong><a href=\"mailTo:info@polynovo.com\">info@polynovo.com</a></td>\r\n</tr>\r\n<tr>\r\n<td>\r\n<h2>Metabolic Pharmaceuticals Limited</h2>\r\n<img class=\"alignnone size-full wp-image-126\" title=\"metaboliclogo\" src=\"/wp-content/uploads/2012/05/metaboliclogo.jpg\" alt=\"metaboloic\" width=\"225\" height=\"120\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td>Chief Executive Officer\r\nMr. David Kenley\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia</td>\r\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\r\n<strong>Fax:</strong>+61 (0) 3 8681 4099</td>\r\n</tr>\r\n</tbody>\r\n</table>',	'Contact Us',	'',	'inherit',	'open',	'open',	'',	'27-revision-6',	'',	'',	'2012-06-11 04:52:52',	'2012-06-11 04:52:52',	'',	27,	'http://calzada-wp.urldock.com/27-revision-6/',	0,	'revision',	'',	0),
(130,	1,	'2012-06-11 05:22:09',	'2012-06-11 05:22:09',	'',	'Share_Registry_s',	'',	'inherit',	'open',	'open',	'',	'share_registry_s',	'',	'',	'2012-06-11 05:22:09',	'2012-06-11 05:22:09',	'',	23,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/05/Share_Registry_s.jpg',	0,	'attachment',	'image/jpeg',	0),
(131,	1,	'2012-08-23 04:40:06',	'2012-08-23 04:40:06',	'<h2>Share Register Enquiries</h2>\n<img class=\"alignleft size-full wp-image-130\" style=\"margin-right: 15px;\" title=\"Share_Registry_s\" src=\"/wp-content/uploads/2012/05/Share_Registry_s.jpg\" alt=\"investor center\" width=\"140\" height=\"84\" />\n\n&nbsp;\n\n&nbsp;\n\n&nbsp;\n\nTo view information relating to your securityholding, or to update your securityholding details, please visit www.investorcentre.com or <a href=\"http://www.investorcentre.com\">click here</a>.\n\nFor shareholder related enquiries, such as changing your address or consolidating your holdings, please direct enquiries to:\n<h2>Computershare Investor Services</h2>\nYarra Falls\n452 Johnston Street\nAbbotsford Victoria 3067\nAustralia\n\nPhone: 1300 850 505\nFax: +61 3 9473 2500\nEmail: <a href=\"mailto:Web.queries@computershare.com.au\">Web.queries@computershare.com.au</a>',	'Investor Centre',	'',	'inherit',	'open',	'open',	'',	'23-autosave',	'',	'',	'2012-08-23 04:40:06',	'2012-08-23 04:40:06',	'',	23,	'http://calzada-wp.urldock.com/23-autosave/',	0,	'revision',	'',	0),
(132,	1,	'2012-05-28 18:02:53',	'2012-05-28 18:02:53',	'Nullam quis risus eget urna mollis ornare vel eu leo. Morbi leo risus, porta ac consectetur ac, vestibulum at eros. Etiam porta sem malesuada magna mollis euismod. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Curabitur blandit tempus porttitor. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.\r\n\r\nCum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec ullamcorper nulla non metus auctor fringilla.\r\n\r\nCum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Sed posuere consectetur est at lobortis. Aenean lacinia bibendum nulla sed consectetur. Donec sed odio dui. Etiam porta sem malesuada magna mollis euismod.\r\n\r\nAenean eu leo quam. Pellentesque ornare sem lacinia quam venenatis vestibulum. Maecenas faucibus mollis interdum. Curabitur blandit tempus porttitor. Nullam id dolor id nibh ultricies vehicula ut id elit. Nullam id dolor id nibh ultricies vehicula ut id elit. Nulla vitae elit libero, a pharetra augue. Lorem ipsum dolor sit amet, consectetur adipiscing elit.',	'Investor Centre',	'',	'inherit',	'open',	'open',	'',	'23-revision-3',	'',	'',	'2012-05-28 18:02:53',	'2012-05-28 18:02:53',	'',	23,	'http://calzada-wp.urldock.com/23-revision-3/',	0,	'revision',	'',	0),
(133,	1,	'2012-06-11 05:27:54',	'2012-06-11 05:27:54',	'<h2 class=\"feSubHeading\">Presentations</h2>\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" />\r\n\r\n15th November 2011\r\n<span style=\"color: #333399;\">AGM Presentation 2011</span>\r\n<a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/Calzada-AGM-Presentation_Nov-20112.pdf\">Click here to download presentation (835kb)</a>\r\n\r\n22nd November 2010\r\n<span style=\"color: #000099;\">AGM Presentation 2010</span>\r\n<a href=\"/wp-content/uploads/2012/06/914346.pdf\" target=\"_blank\">Click here to download presentation (1.7mb)</a>\r\n\r\n18th July 2008\r\n<span style=\"color: #000099;\">Corporate Presentation: Metabolic\'s acquisition of PolyNovo\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman of Metabolic </em>and <em>Ian Griffiths, CEO of PolyNovo\r\n</em><a href=\"/wp-content/uploads/2012/06/0823-ASX-Announcement-Corporate-Presentation-Acquisition-of-PolyNovo-18-July-2008_001.pdf\">Click here to download presentation (495 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman </em>and <em>Roland Scollay, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation.pdf\" target=\"_blank\">Click here to download presentation (432 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman</em> and <em>Roland Scollay, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/32241/wmp/poxf1u5rb8\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n20th September 2007\r\n<span style=\"color: #000099;\">Update on Oral Peptide Delivery Platform\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/UpdateOralPeptideDeliveryPlatform_20Sept2007.pdf\" target=\"_blank\">Click here to download presentation ( 347 kb)</a></span>\r\n\r\n9th May 2007\r\n<span style=\"color: #003399;\">Corporate Update - May 2007</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic-Corporate-Presentation.pdf\" target=\"_blank\">Click here to download presentation (577kb)</a>\r\n\r\n24th January 2007\r\n<span style=\"color: #000099;\">Corporate Update - January 2007\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CurrentCorporatePresentation_January2007.pdf\" target=\"_blank\">Click here to download presentation (518kb)</a></span>\r\n\r\n27th November 2006\r\n<span style=\"color: #000099;\">Metabolic Domestic Roadshow - November 2006\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MetabolicDomesticRoadshow_November2006.pdf\" target=\"_blank\">Click here to download presentation (266kb)</a>\r\n\r\n30th October 2006\r\n<span style=\"color: #0000cc;\">2006 AGM:  CEO\'s presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/16722/wmp/siqi3bsv8o\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n27th October 2006\r\n<span style=\"color: #000099;\">2006 AGM: CEO\'s presentation</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMCEOPresentation_27October2006.pdf\" target=\"_blank\">Click here to download presentation (507kb) </a>\r\n\r\n12 October 2006\r\n<span style=\"color: #000099;\">Asia Pacific Life Sciences Forum (London) 12 Ocotber 2006\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em></span><span style=\"color: #000000;\"><a href=\"/wp-content/uploads/2012/06/IntersuissePresentation_October2006.pdf\" target=\"_blank\">Click here to download presentation (425kb)</a></span>\r\n\r\n28th September 2006\r\n<span style=\"color: #000099;\">UBS Global Life Sciences Conference\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<span style=\"color: #000099;\"><a href=\"/wp-content/uploads/2012/06/UBSPresentation28Sept2006.ppt\">Click here to download presentation (4.82mb)</a></span>\r\n\r\n3rd July 2006\r\n<span style=\"color: #000099;\">Investor Roadshow (UK &amp; Europe) presentation - company update - July 2006</span>\r\n<span style=\"color: #000099;\"><em><span style=\"color: #000000;\">Roland Scollay, PhD, CEO</span>\r\n</em><a href=\"/wp-content/uploads/2012/06/UKRoadshowPresentation_July2006.pdf\" target=\"_blank\">Click here to download report (301kb)</a></span>\r\n\r\n14th June 2006\r\n<span style=\"color: #000099;\">Presentation at the Pacific Growth Equities\' <em>2006 Life Sciences Growth Conferences </em>(USA)</span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/PacificGrowthEquities_USA%20conference.pdf\" target=\"_blank\">Click here to download presentation (313kb)</a>\r\n\r\n23rd May 2006\r\n<span style=\"color: #000099;\">Roadshow presentation - company update - May 2006\r\n</span><span style=\"color: #000099;\"><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO</em> </span>\r\n</span><a href=\"/wp-content/uploads/2012/06/ASX_May23RoadshowPresentation.pdf\" target=\"_blank\">Click here to download report (323kb)</a>\r\n\r\n5th April 2006\r\n<span style=\"color: #000099;\">Presentation at US biotech conferences, 5th - 7th April 2006</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CEOUSbiotechpresentation_5April2006.pdf\" target=\"_blank\">Click here to download report (211kb)</a>\r\n\r\n14th February 2006\r\n<span style=\"color: #000099;\">Presentation to BIO-CEO Obesity Session, New York, 14th February 2006\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"New Advances in Obesity Drugs\"\r\n<a href=\"/wp-content/uploads/2012/06/BIO_CEO_OBESITY-SESSION_NY_FEB2006.pdf\" target=\"_blank\">Click here to download report (142kb)</a>\r\n\r\n8th February 2006\r\n<span style=\"color: #000099;\">Investor Roadshow Presentation, 8th February 2006 </span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/InvestorRoadshowPresentation_8Feb2006.pdf\" target=\"_blank\">Click here to download report (183kb)</a>\r\n\r\n4th November 2005\r\n<span style=\"color: #000099;\">CEO Presentation at Rodman and Renshaw Conference New York, 7 November 2005 </span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/CEOPresentationRodmanRenshaw_7Nov2005.pdf\" target=\"_blank\">Click here to download report (202kb)</a>\r\n\r\n28th October 2005\r\n<span style=\"color: #000099;\">CEO Presentation at AGM October 2005 </span>\r\n<em>Roland Scollay PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMPresentation_28Oct2005.pdf\" target=\"_blank\">Click here to download report (168kb)</a>\r\n\r\n19th October 2005\r\n<span style=\"color: #000099;\">BBY/Jeffries Health Care and Life Sciences Conference</span>\r\n<em>Roland Scollay PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/BBY_Jeffries_Conference_Sydney19Oct05.pdf\" target=\"_blank\">Click here to download report (1mb)</a>\r\n\r\n18th October 2005\r\n<span style=\"color: #000099;\">NAASO 2005 Annual Scientific Meeting</span>\r\n<em>Caroline Herd PhD </em>\r\n\"The Effect of AOD9604 on Weight Loss in Obese Adults\"\r\n<a href=\"/wp-content/uploads/2012/06/NAASO_2005presentation.pdf\" target=\"_blank\">Click here to download report (371kb)</a>\r\n\r\n10th October 2005\r\n<span style=\"color: #000099;\">Wilson HTM Biotechnology Conference</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em>\"Products to Profits\"\r\n<a href=\"/wp-content/uploads/2012/06/WilsonHTMConference_RS_10Oct2005.pdf\" target=\"_blank\">Click here to download report (96kb)</a>\r\n\r\n7th September 2005\r\n<span style=\"color: #000099;\">Southern Cross Equities Biotechnology conference\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"DNA, Devices and Dealers\"\r\n<a href=\"/wp-content/uploads/2012/06/SouthernCrossEquitiesRS_7Sept2005.pdf\" target=\"_blank\">Click here to download report (3.63mb)</a>\r\n\r\n2nd September 2005\r\n<span style=\"color: #000099;\">Venom to Drugs 2005, Conference, Heron Island</span>\r\n<em>Daniel McIntosh </em>\r\n<a href=\"/wp-content/uploads/2012/06/ACV1_PosterVenomstoDrugs_Sept2005.pdf\" target=\"_blank\">Click here to download report (123kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">US Presentations June 2005</span>\r\n<em>Roland Scollay PhD CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/USPresentations_June-20051.pdf\" target=\"_blank\">Click here to download report (264kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Boston Bio-Relationships 2005\r\n</span><em>Roland Scollay PhD CEO\r\n</em>Presentation 1: Corporate Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005CorporatePresentation_June2005.pdf\" target=\"_blank\">Click to download report (132kb)</a>\r\n\r\nPresentation 2: Diabetes Session Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005DiabetesSession_June2005.pdf\" target=\"_blank\">Click to download report (127kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">American Diabetes Association 65th Scientific Sessions San Diego</span>\r\n<em>Prof. Gary Wittert </em>\r\nAOD9604, an Orally Active Peptide for the Treatment of Obesity: Results of a Phase 2b Study\r\n<a href=\"/wp-content/uploads/2012/06/ADAposter_June20051.pdf\" target=\"_blank\">Click here to download report (106kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Share Placement Corporate Presentation June 2005</span>\r\n<em>Roland Scollay PhD CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/ADAposter_June2005.pdf\" target=\"_blank\">Click here to download Presentation (1.78mb)</a>\r\n\r\n2nd May 2005\r\n<span style=\"color: #000099;\">TIDES 2005 Conference Presentation, Boston</span>\r\n<em>Dr Andrea McCracken\r\n</em>Development of the Conopeptide ACV1 for the Treatment of Neuropathic Pain\r\n<a href=\"/wp-content/uploads/2012/06/TIDES-ACV1_2ndMay2005.pdf\" target=\"_blank\">Click here to download the Presentation (4.65mb)</a>\r\n\r\n3rd May 2004\r\n<span style=\"color: #000099;\">TIDES 2004 Conference Presentation, Las Vegas </span>\r\n<em>Dr Caroline Herd\r\n</em>AOD9604 - An Orally Active Peptide for the Treatment of Obesity\r\n<a href=\"/wp-content/uploads/2012/06/TIDES-2004-Conference.pdf\" target=\"_blank\">Click to download Presentation (2.33mb)</a>\r\n\r\n17th February 2003\r\n<span style=\"color: #000099;\">Conference Presentation\r\n</span><em>Mark Heffernan</em>\r\nPresentation at the Obesity and Metabolic disorders conference, London\r\n<a href=\"/wp-content/uploads/2012/06/HeffernanUK.pdf\" target=\"_blank\">Click to download Presentation (396kb)</a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<em>Please Note:\r\nThese files are provided in Adobe PDF format, requiring the Adobe PDF Reader application to view them. This application is available to download from <span style=\"text-decoration: underline;\"><strong><a href=\"http://www.adobe.com/\" target=\"_blank\">http://www.adobe.com</a></strong></span></em>\r\n\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"15\" border=\"0\" />',	'Presentations',	'',	'publish',	'open',	'open',	'',	'presentations',	'',	'',	'2012-08-24 05:18:39',	'2012-08-24 05:18:39',	'',	23,	'http://calzada-wp.urldock.com/?page_id=133',	0,	'page',	'',	0),
(134,	1,	'2012-06-11 05:27:46',	'2012-06-11 05:27:46',	'',	'Presentations',	'',	'inherit',	'open',	'open',	'',	'133-revision',	'',	'',	'2012-06-11 05:27:46',	'2012-06-11 05:27:46',	'',	133,	'http://calzada-wp.urldock.com/133-revision/',	0,	'revision',	'',	0),
(135,	1,	'2012-06-11 05:28:24',	'2012-06-11 05:28:24',	' ',	'',	'',	'publish',	'open',	'open',	'',	'135',	'',	'',	'2012-07-06 00:13:20',	'2012-07-06 00:13:20',	'',	23,	'http://calzada-wp.urldock.com/?p=135',	14,	'nav_menu_item',	'',	0),
(137,	1,	'2012-06-18 02:46:34',	'2012-06-18 02:46:34',	'',	'PolyNovo',	'',	'publish',	'open',	'closed',	'',	'polynovo-biomaterials-pty-ltd',	'',	'',	'2012-06-18 09:41:15',	'2012-06-18 09:41:15',	'',	0,	'http://calzada-wp.urldock.com/?page_id=137',	0,	'page',	'',	0),
(138,	1,	'2012-06-18 02:46:24',	'2012-06-18 02:46:24',	'',	'PolyNovo Biomaterials Pty Ltd',	'',	'inherit',	'open',	'open',	'',	'137-revision',	'',	'',	'2012-06-18 02:46:24',	'2012-06-18 02:46:24',	'',	137,	'http://calzada-wp.urldock.com/137-revision/',	0,	'revision',	'',	0),
(139,	1,	'2012-06-18 02:46:52',	'2012-06-18 02:46:52',	'<h2><big><span style=\"color: #000080;\"><strong>Metabolic Pharmaceuticals Pty Ltd (Metabolic)</strong></span></big></h2>\r\nMetabolic is seeking to derive value from the Company’s past investment of over $50 million in the pharmaceutical development of AOD9604. The peptide has proven to be safe and well tolerated in a total of 6 human clinical trials involving 925 humans.\r\n<div>\r\n\r\nPotential means of deriving value from AOD9604 currently being actively pursued include seeking partners and licensing interest for the use of AOD9604 in:\r\n\r\n</div>\r\n<div>\r\n<h3><span style=\"color: #000080;\">(i) Over the counter (OTC) products in the United States for fat reduction under a self-affirmed GRAS status.</span></h3>\r\n<span style=\"color: #000000;\">Metabolic has recently achieved a self-affirmed GRAS (Generally Recognised As Safe) status which allows the marketing of AOD9604 into the US market. This means that AOD9604 can be legally added to foods, drinks, nutraceuticals &amp; dietary supplements.</span></div>\r\n<div>\r\n\r\nThe key advantages of this approach are:\r\n\r\n</div>\r\n<div>\r\n\r\n• OTC products are faster and cheaper to get to market than pharmaceuticals undertaking the extensive clinical development route.\r\n\r\n</div>\r\n<div>\r\n\r\n• The nutraceutical market for fat reduction, health and well being is large and growing. With success in the US market, it is planned to pursue expansion into European OTC markets via a novel food application and possibly into Australia and key Asian markets.\r\n\r\n</div>\r\n<div>\r\n<h3><span style=\"color: #000080;\">(ii) The treatment of bone diseases and in bone repair applications.</span></h3>\r\n</div>\r\n<div>\r\n\r\nIn February 2011, Metabolic received positive in-vitro data from Mt Sini hospital in Toronto, Canada confirming that AOD9604 has an ability to stimulate bone formation in cell cultures utilizing human mesenchymal stem cells. Metabolic has previously received positive in-vivo results in four separate rat models of osteoporosis. Utilising these positive results together with the existing substantial human clinical safety data enables Metabolic to seek partnering interest in bone disease and repair applications. Examples might include use as a biologic, such as a bone morphogenic protein (BMP) type product, a stem cell growth factor or coatings to improve the fixation of medical devices.\r\n\r\n</div>\r\n<div>\r\n<h3><span style=\"color: #000080;\">(iii) The promotion of cartilage and muscle creation and repair.</span></h3>\r\n</div>\r\n<div>\r\n\r\nAOD9604 has shown positive results in cartilage and muscle repair in in-vitro tests completed in March 2012 at the Mt. Sinai Hospital. The studies were conducted in separate cartilage and muscle cell experiments. The positive results mean that AOD9604 has the potential to promote cartilage creation and repair and may have a capacity to repair muscle and enhance muscle formation. This may be particularly useful in pharmaceutical development to treat diseases such as osteoarthritis and in applications where muscle mass loss is a dominant factor. Utilising this new data together with the existing substantial human clinical safety data provides AOD9604 with the potential to proceed straight to the phase 2 human clinical development stage.\r\n\r\n</div>\r\n<div>\r\n<h3><span style=\"color: #000080;\">(iv) Veterinary applications.</span></h3>\r\n</div>\r\n<div>\r\n\r\nMany of the diseases and applications identified above also have relevance to domestic pets. Two prime examples with large markets include obesity and osteoarthritis. Due to the comprehensive safety package already established, it may be possible to seek regulatory approval for the use of AOD9604 in a veterinary product after completing just one successful proof of concept trial in a domestic pet model.\r\n\r\n</div>\r\n<div>\r\n\r\nThe uses of AOD9604 outlined above target potential application in various conditions, trauma and injuries with $multi-million markets and where there are limited or inadequate treatment options. Metabolic is utilizing a low cost out-licensing and partnering strategy to unlock value in AOD9604 with the aim of generating substantial royalty and partnering income from one or more of these opportunities.\r\n\r\n</div>\r\n<div>\r\n\r\nAOD9604 in cosmetics – first product launched by Phosphagenics (ASX:POH) in 2011.\r\n\r\n</div>\r\n<div>\r\n\r\nAOD9604 has been licensed to Phosphagenics for use in their topical cosmetic cellulite cream (‘BodyShaper™’) launched in May 2011. It is anticipated that the royalties received by Metabolic will increase with successful world-wide marketing/product sales penetration and also with an extended product range. BodyShaper™ is now being sold throughout Australia in Myer stores, David Jones, Pulse Pharmacies, Priceline, Terry White Chemists and on the TVSN shopping network. It has also been launched in Asia through the A.S. Watson Group and distribution networks in South Korea and northern Asia. Metabolic already receives royalties from Phosphagenics on worldwide sales of BodyShaper™ and a share of any sub-licensing revenue that may be received\r\n\r\n</div>',	'Metabolic',	'',	'publish',	'open',	'open',	'',	'metabolic-pharmaceuticals-pty-ltd',	'',	'',	'2012-08-24 03:49:56',	'2012-08-24 03:49:56',	'',	0,	'http://calzada-wp.urldock.com/?page_id=139',	0,	'page',	'',	0),
(140,	1,	'2012-06-18 02:46:48',	'2012-06-18 02:46:48',	'',	'Metabolic Pharmaceuticals Pty Ltd',	'',	'inherit',	'open',	'open',	'',	'139-revision',	'',	'',	'2012-06-18 02:46:48',	'2012-06-18 02:46:48',	'',	139,	'http://calzada-wp.urldock.com/139-revision/',	0,	'revision',	'',	0),
(141,	1,	'2012-06-18 02:47:54',	'2012-06-18 02:47:54',	'Click on a year to view links to PDFs\r\n[jaccordion size=\"xsmall\" theme=\"smoothness\" active=\"0\"]\r\nASX Releases 2012::\r\n<table id=\"theTable3\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td colspan=\"2\"><img src=\"../../html/images/trans.gif\" alt=\"\" width=\"9\" height=\"1\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>\r\n<h2 class=\"feSubHeading\">ASX Releases 2012</h2>\r\n</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"><img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/Annual-Report-2012.pdf\">Appendix 4E and 2012 Annual Report</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Appendix 4E and 2012 Annual Report</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/POlyNovo-Clinical-Trial-and-Composite-Cultured-Skin-Update.pdf\">PolyNovo Clinical Trial and Composite Cultured Skin Update</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>PolyNovo Clinical Trial and Composite Cultured Skin Update</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/Dr-David-McQuillan-to-Join-the-Calzada-Board_8-Aug-12.pdf\">Dr David McQuillan to Join the Calzada Board</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Dr David McQuillan to Join the Calzada Board</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/PolyNovo-US-Patent-Allowed_7-Aug-12.pdf\">PolyNovo US Patent Allowed</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>PolyNovo US Patent Allowed</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX-Ann_30-Jul-12.pdf\">NovoSorb Vac Human Clinical Trial Update</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>NovoSorb Vac Human Clinical Trial Update</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/132F042F2012103A223A30PM.pdf\">PolyNovo human Trial Update</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>PolyNovo human Trial Update</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/132F042F2012103A223A05PM.pdf\">AOD positive in Cartilage and Muscle Repair</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>AOD positive in Cartilage and Muscle Repair</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/132F042F2012103A213A23PM.pdf\">PolyNovo Commences Second Human Trial</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>PolyNovo Commences Second Human Trial</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1074690.pdf\" target=\"_blank\">PolyNovo to Commence Human Trial </a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>PolyNovo to Commence Human Trial</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1073489.pdf\" target=\"_blank\">PolyNovo’s US Collaboration Update</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>PolyNovo’s US Collaboration Update</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1065480.pdf\" target=\"_blank\">Update on US Partner Collaboration </a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Update on US Partner Collaboration</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n[jacc/]\r\nASX Releases 2011::\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td> </td>\r\n<td>\r\n<h2 class=\"feSubHeading\">ASX Releases 2011</h2>\r\n</td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1059707.pdf\" target=\"_blank\">New Applications for AOD9604</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>New Applications for AOD9604</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/Successful_Proof_of_Concept_for_Synthetic_Skin.pdf\" target=\"_blank\">Successful Proof of Concept for Synthetic Skin</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Successful Proof of Concept for Synthetic Skin</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1030228.pdf\" target=\"_blank\">Changes to Executive Structure</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Changes to Executive Structure</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1030275.pdf\" target=\"_blank\">Cancellation of Options </a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Cancellation of Options</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p9.pdf\" target=\"_blank\">Notice of Annual General Meeting and Proxy Form</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Notice of Annual General Meeting and Proxy Form</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/Major_Milestone_for_PolyNovo_and_NovoSorbTM.pdf\" target=\"_blank\">Major Milestone for PolyNovo and NovoSorbTM : First Human Study</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Major Milestone for PolyNovo and NovoSorbTM : First Human Study</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1007282.pdf\" target=\"_blank\">Operational Update and Financial Result Guidance </a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Operational Update and Financial Result Guidance</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1899_Calzada_Shareholder_Newsletter_FINAL1.pdf\" target=\"_blank\">Calzada Shareholder Newsletter</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Calzada Shareholder Newsletter</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/980299.pdf\" target=\"_blank\">Metabolic’s Osteoporosis Patent Allowed in US </a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Metabolic’s Osteoporosis Patent Allowed in US</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/979227.pdf\" target=\"_blank\">Phosphagenics Bodyshaper Update</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Phosphagenics Bodyshaper Update</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/POH_Annoucnement.pdf\" target=\"_blank\">Phosphagenics to launch new cellulite cosmetics</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Phosphagenics to launch new cellulite cosmetics</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/967193.pdf\" target=\"_blank\">Calzada Transfers Neural Regeneration Peptides Technology</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Calzada Transfers Neural Regeneration Peptides Technology</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/963942.pdf\" target=\"_blank\">First PolyNovo Patent Allowed in US</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>First PolyNovo Patent Allowed in US</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/962630.pdf\" target=\"_blank\">Burn Surgeon John Greenwood receives the inaugural Burke/Yannas prize at the American Burn Association conference</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Burn Surgeon John Greenwood receives the inaugural Burke/Yannas prize at the American Burn Association conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/963942.pdf\" target=\"_blank\">Board Changes</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Board Changes</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/953112.pdf\" target=\"_blank\">PolyNovo successfully completes pivotal animal study on burns device</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>PolyNovo successfully completes pivotal animal study on burns device</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/947775.pdf\" target=\"_blank\">Results for the Half Year Ended 31 December 2010</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Half year results and accounts</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/943726.pdf\">AOD9604 shows positive results in human stem cell assay for bone growth</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>AOD9604 shows positive results in human stem cell assay for bone growth</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p2.pdf\">Feasibility study extended by 12 months</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Feasibility study extended by 12 months</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p3.pdf\">Update of Black Market Sales of AOD</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Update of Black Market Sales of AOD</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p4.pdf\">Appointment of Dr Stewart Washer</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Appointment of Dr Stewart Washer</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n[jacc/]\r\nASX Releases 2010::\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td> </td>\r\n<td>\r\n<h2 class=\"feSubHeading\">ASX Releases 2010</h2>\r\n</td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p5.pdf\">Calzada sells Avexa Shares</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Calzada sells Avexa Shares</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p6.pdf\">Calzada signs Licensing Agreement with Phosphagenics</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Calzada signs Licensing Agreement with Phosphagenics</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p7.pdf\">Dr John Chiplin appointed to Calzada Board</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Dr John Chiplin appointed to Calzada Board</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p8.pdf\">Calzada - 2010 Annual Report</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Calzada - 2010 Annual Report</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=750&amp;nav_cat_id=205&amp;nav_top_id=58\">Notice of Annual General Meeting</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Notice of Annual General Meeting</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p10.pdf\">Calzada responds to claims made by Avexa Limited</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Calzada responds to claims made by Avexa Limited</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p11.pdf\">Email correspondence with Avexa – combining Avexa EGM with Avexa AGM </a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Email correspondence with Avexa – combining Avexa EGM with Avexa AGM</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p12.pdf\">Phosphagenics exercises option to licence AOD9604 to develop topical cellulite product</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Phosphagenics exercises option to licence AOD9604 to develop topical cellulite product</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p13.pdf\">Calzada to vend Metabolic into ATOS Wellness </a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Calzada to vend Metabolic into ATOS Wellness</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p14.pdf\">Change of Director\'s Interest NoticeChange of Director\'s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Change of Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p15.pdf\">Replacement response to the Age newspaper articleReplacement response to the Age newspaper article</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Replacement response to the Age newspaper article</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p16.pdf\">Calzada responds to The Age newspaper article</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Calzada responds to The Age newspaper article</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p17.pdf\">Half Year Report and Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Half Year Report and Accounts</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p18.pdf\">Final Director\'s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Final Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p19.pdf\">Initial Director\'s Interest Notice </a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Initial Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p20.pdf\">Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Appendix 3B</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p21.pdf\">Calzada moves to 100% ownership of PolyNovo </a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Calzada moves to 100% ownership of PolyNovo</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p22.pdf\">Change in substantial holding Change in substantial holding </a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Change in substantial holding</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/p23.pdf\">Becoming a substantial holder from XCD </a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Becoming a substantial holder from XCD</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n[jacc/]\r\nASX Releases 2009::\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td> </td>\r\n<td>\r\n<h2 class=\"feSubHeading\">ASX Releases 2012</h2>\r\n</td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp1.pdf\">Initial Director\'s Interest Notice - Oliver Stevens</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Initial Director\'s Interest Notice - Oliver Stevens</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp2.pdf\">Initial Director\' Interest Notice - David Franklyn</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Initial Director\' Interest Notice - David Franklyn</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp3.pdf\">Initial Director\'s Interest Notice - George Cameron-Dow</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Initial Director\'s Interest Notice - George Cameron-Dow</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp4.pdf\">Initial Director\'s Interest Notice - David Kenley</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Initial Director\'s Interest Notice - David Kenley</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp5.pdf\">Changes to Company Board</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Changes to Company Board</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp6.pdf\">Appendix 3Z - I Kirkwood</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Appendix 3Z - I Kirkwood</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp7.pdf\">Appendix 3Z - Paul Lappin</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Final Directors interest Notice - P Lappin</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp8.pdf\">7 April 09 Initial Substantial Holder - Entrust </a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>7 April 09 Initial Substantil Holder - Entrust picks up 19.81%</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp9.pdf\">7 Aprl 09 - Ceasing o be a substantal holder - Tony Moore</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Ceasingto be a substantil holder - Tony Moore</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp10.pdf\">2 April 2009 Substantial Shareholder Notice - Tony Moore</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Tony Moore purchases substantial shareholding</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp11.pdf\">31 March 2009 Final Directors Interest Notice 3Z F. Brazil</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>31 March 2009 Final Directors Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp12.pdf\">Changes to Metabolic Board</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Board Changes</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp13.pdf\">10th March 2009 Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td>Options expiry</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp14.pdf\">10 March 2009 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td> </td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp15.pdf\">6 March 2009 - Changes to PolyNovo Board and Management</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td> </td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp16.pdf\">4 March 2009 - First NovoSorb Patent Granted in Australia</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td> </td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp17.pdf\">26 February 2009 - Appendix 4D Half Yearly Report and Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td> </td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp18.pdf\">23 February 2009 - Changes to Metabolic Chairman and Company Secretary</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td> </td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp19.pdf\">23 February 2009 - Appendix 3Z - Final Director\'s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td> </td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp20.pdf\">2 February 2009 - Changes to Metabolic and PolyNovo Board</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td> </td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp21.pdf\">30 January 2009 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td> </td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"> </td>\r\n</tr>\r\n<tr>\r\n<td> </td>\r\n<td><a href=\"/wp-content/uploads/2012/06/pp22.pdf\">9th January 2009 - Change of Registered Office and Place of Business Address</a></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n[/jaccordion]',	'ASX Announcements',	'',	'publish',	'open',	'open',	'',	'asx-announcements',	'',	'',	'2012-08-24 03:43:32',	'2012-08-24 03:43:32',	'',	23,	'http://calzada-wp.urldock.com/?page_id=141',	0,	'page',	'',	0),
(142,	1,	'2012-06-18 02:47:43',	'2012-06-18 02:47:43',	'',	'ASX Announcements',	'',	'inherit',	'open',	'open',	'',	'141-revision',	'',	'',	'2012-06-18 02:47:43',	'2012-06-18 02:47:43',	'',	141,	'http://calzada-wp.urldock.com/141-revision/',	0,	'revision',	'',	0),
(143,	1,	'2012-06-18 02:48:10',	'2012-06-18 02:48:10',	'<table>\r\n<tbody>\r\n<tr>\r\n<td>\r\n<h2 class=\"feSubHeading\">Annual Reports</h2>\r\n</td>\r\n</tr>\r\n<tr>\r\n<td>Related Files:</td>\r\n</tr>\r\n<tr>\r\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/2010_Annual_Report.pdf\">Annual Report - for Year Ended 30 June 2010</a></td>\r\n</tr>\r\n<tr>\r\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/31_December_2010_Financial_statements_FINAL.pdf\">Half Year Financial Report - for half Year Ended 31 Dec 2010</a></td>\r\n</tr>\r\n<tr>\r\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/2011_Annual_Report_Calzada_FY11_FINAL_version.pdf\">Annual Report - for Year Ended 30 June 2011</a></td>\r\n</tr>\r\n<tr>\r\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/31-December-2011-Financial-statements-Final.pdf\">Half Year Financial Report - for half Year Ended 31 Dec 2011</a></td>\r\n</tr>\r\n<tr>\r\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/2012-Annual-Report_ONLY.pdf\">Annual Report - For Year ended 30 June 2012</a></td>\r\n</tr>\r\n</tbody>\r\n</table>',	'Financial Reports',	'',	'publish',	'open',	'open',	'',	'financial-reports',	'',	'',	'2012-08-24 03:39:53',	'2012-08-24 03:39:53',	'',	23,	'http://calzada-wp.urldock.com/?page_id=143',	1,	'page',	'',	0),
(144,	1,	'2012-06-18 02:48:05',	'2012-06-18 02:48:05',	'',	'Financial Reports',	'',	'inherit',	'open',	'open',	'',	'143-revision',	'',	'',	'2012-06-18 02:48:05',	'2012-06-18 02:48:05',	'',	143,	'http://calzada-wp.urldock.com/143-revision/',	0,	'revision',	'',	0),
(145,	1,	'2012-06-18 02:48:26',	'2012-06-18 02:48:26',	'<div>\r\n<h2>Share Register Enquiries</h2>\r\n<img title=\"Share_Registry_s\" src=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/Share_Registry_s.jpg\" alt=\"investor center\" width=\"182\" height=\"111\" />\r\n\r\nTo view information relating to your securityholding, or to update your securityholding details, please visit www.investorcentre.com or <a href=\"https://www-au.computershare.com/investor/default.asp?bhjs=1&amp;fla=1&amp;cc=au\" target=\"_blank\">click here</a>.\r\n\r\nFor shareholder related enquiries, such as changing your address or consolidating your holdings, please direct enquiries to:\r\n<h2>Computershare Investor Services</h2>\r\nYarra Falls\r\n452 Johnston Street\r\nAbbotsford Victoria 3067\r\nAustralia\r\n\r\nPhone: 1300 850 505\r\nFax: +61 3 9473 2500\r\nEmail: <a href=\"mailto:Web.queries@computershare.com.au\">Web.queries@computershare.com.au</a>\r\n\r\n</div>',	'Share Registry',	'',	'publish',	'open',	'open',	'',	'share-registry',	'',	'',	'2012-08-07 05:04:17',	'2012-08-07 05:04:17',	'',	23,	'http://calzada-wp.urldock.com/?page_id=145',	2,	'page',	'',	0),
(146,	1,	'2012-06-18 02:48:21',	'2012-06-18 02:48:21',	'',	'Share Registry',	'',	'inherit',	'open',	'open',	'',	'145-revision',	'',	'',	'2012-06-18 02:48:21',	'2012-06-18 02:48:21',	'',	145,	'http://calzada-wp.urldock.com/145-revision/',	0,	'revision',	'',	0),
(147,	1,	'2012-06-18 02:48:41',	'2012-06-18 02:48:41',	'<strong>2011 Annual General Meeting</strong>\r\n\r\nThe 2011 Annual General Meeting of Calzada Limited will be held at Unit 2, 320 Lorimer Street, Port Melbourne, Victoria, at 10:00am (Melbourne time)on the 15th of November 2011.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting_and_Proxy_Form1.pdf\" target=\"_blank\">Notice of AGM</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046608.pdf\" target=\"_blank\">Chairmans Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046682.pdf\" target=\"_blank\">Results of Meeting</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046745.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2010 Annual General Meeting</strong>\r\n\r\nThe 2010 Annual General Meeting of Calzada Limited will be held at RACV Club, 501 Bourke Street, Melbourne, Victoria, at 10:30am (Melbourne time) on the 22nd of November 2010.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2009 Annual General Meeting</strong>\r\n\r\nThe 2009 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at Level 1, 320 Lorimer St. Port Melbourne Victoria at 10:30am (Melbourne time) on Monday the 23rd of November 2009.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/MPL_NOM_Final.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2008 Annual General Meeting</strong>\r\n\r\nThe 2008 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at the offices of Minter Ellison Lawyers at Level 23, North Tower, Rialto, 525 Collins Street, Melbourne, Victoria at 2pm (Melbourne time) on Thursday 27 November, 2008.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Presentation.pdf\" target=\"_blank\">AGM Presentation</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Chairman_address.pdf\" target=\"_blank\">AGM Chairman\'s Address</a>\r\n<a title=\"2008 Notice of AGM and Sample Proxy Form\" href=\"/wp-content/uploads/2012/06/ASX_NoticeofAGMandProxyForm_28October2008.pdf\">Notice of AGM and Sample Proxy Form</a>\r\n\r\n<strong>2007 Annual General Meeting</strong>\r\n\r\nThe 2007 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Computershare Conference Centre, Yarra Falls, 452 Johnston Street, Abbotsford, Vic  3067 on Friday, 2 November 2007.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2007AGM_Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/2007-AGM-Chairmans-Address.pdf\" target=\"_blank\">Chairman\'s Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation1.pdf\" target=\"_blank\">AGM presentation - Full slide show</a>\r\n<a href=\"/wp-content/uploads/2012/06/2007-Sample-Proxy-Form.pdf\" target=\"_blank\">Sample Proxy Form</a>\r\n\r\n<strong>2006 Annual General Meeting</strong>\r\n\r\nThe 2006 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Level 23, Rialto South Tower, 525 Collins Street Melbourne on 27 October 2006\r\n\r\n<a href=\"/wp-content/uploads/2012/06/AGM-2006-Poll-Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/AGM-2006-Chairman_s-address.pdf\" target=\"_blank\">Chairman\'s Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/AGM-2006-Presentation.pdf\" target=\"_blank\">AGM Presentation - Full Slide Show</a>\r\n<a href=\"/wp-content/uploads/2012/06/2006-Notice-of-AGM-and-Proxy-Form.pdf\" target=\"_blank\">2006 Notice of Meeting and Proxy Form</a>\r\n\r\n<strong>2005 Annual General Meeting</strong>\r\n\r\nThe 2005 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 28 October, 2005.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/051028b-ASX-Announcement-AGM-Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/051028c-ASX-Announcement-AGM-address.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>\r\n<a href=\"/wp-content/uploads/2012/06/051028d-ASX-Announcement-AGM-preso.pdf\" target=\"_blank\">Presentation Full Slide Show</a>\r\n<a href=\"/wp-content/uploads/2012/06/050927-ASX-Announcement-Annual-Report-and-Notice-of-AGM-2005.pdf\" target=\"_blank\">2005 Notice of Meeting, Letter to Shareholders and Proxy Form</a>\r\n\r\n<strong>2004 Annual General Meeting</strong>\r\n\r\nThe 2004 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 29 October, 2004.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX-AGM-Results-29-10-04.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX-Chairmans-Address-AGM-2004.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX-Annual-Report-2004-23-9-04.pdf\" target=\"_blank\">2004 Notice of Meeting and Letter to Shareholders</a>',	'Annual General Meeting	',	'',	'publish',	'open',	'open',	'',	'annual-general-meeting',	'',	'',	'2012-07-02 01:13:42',	'2012-07-02 01:13:42',	'',	23,	'http://calzada-wp.urldock.com/?page_id=147',	3,	'page',	'',	0),
(148,	1,	'2012-06-18 02:48:37',	'2012-06-18 02:48:37',	'',	'Annual General Meeting	',	'',	'inherit',	'open',	'open',	'',	'147-revision',	'',	'',	'2012-06-18 02:48:37',	'2012-06-18 02:48:37',	'',	147,	'http://calzada-wp.urldock.com/147-revision/',	0,	'revision',	'',	0),
(149,	1,	'2012-06-18 02:53:47',	'2012-06-18 02:53:47',	' ',	'',	'',	'publish',	'open',	'open',	'',	'149',	'',	'',	'2012-07-06 00:13:20',	'2012-07-06 00:13:20',	'',	23,	'http://calzada-wp.urldock.com/?p=149',	10,	'nav_menu_item',	'',	0),
(150,	1,	'2012-06-18 02:53:47',	'2012-06-18 02:53:47',	' ',	'',	'',	'publish',	'open',	'open',	'',	'150',	'',	'',	'2012-07-06 00:13:20',	'2012-07-06 00:13:20',	'',	23,	'http://calzada-wp.urldock.com/?p=150',	11,	'nav_menu_item',	'',	0),
(151,	1,	'2012-06-18 02:53:47',	'2012-06-18 02:53:47',	' ',	'',	'',	'publish',	'open',	'open',	'',	'151',	'',	'',	'2012-07-06 00:13:20',	'2012-07-06 00:13:20',	'',	23,	'http://calzada-wp.urldock.com/?p=151',	12,	'nav_menu_item',	'',	0),
(152,	1,	'2012-06-18 02:53:48',	'2012-06-18 02:53:48',	' ',	'',	'',	'publish',	'open',	'open',	'',	'152',	'',	'',	'2012-07-06 00:13:20',	'2012-07-06 00:13:20',	'',	23,	'http://calzada-wp.urldock.com/?p=152',	13,	'nav_menu_item',	'',	0),
(153,	1,	'2012-06-18 02:53:47',	'2012-06-18 02:53:47',	' ',	'',	'',	'publish',	'open',	'open',	'',	'153',	'',	'',	'2012-07-06 00:13:20',	'2012-07-06 00:13:20',	'',	0,	'http://calzada-wp.urldock.com/?p=153',	8,	'nav_menu_item',	'',	0),
(155,	1,	'2012-06-18 02:54:08',	'2012-06-18 02:54:08',	'<table>\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1899_Calzada_Shareholder_Newsletter_FINAL2.pdf\">Calzada Shareholder Newsletter June 2011</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ407_1Feb2008.pdf\">February 2008 - Quarterly Investor Update - Fourth Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ0307_October2007.pdf\">October 2007 - Quarterly Investor Update - Third Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ0207_25July2007.pdf\">July 2007 - Quarterly Investor Update - Second Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ107_5April2007.pdf\">April 2007 - Quarterly Investor Update - First Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdate_22ndJanuary2007.pdf\">January 2007 - Quarterly Investor Update - Fourth Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdate_17October2006.pdf\">October 2006 - Quarterly Investor Update - Third Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_InvestorQuarterlyUpdate_July2006.pdf\">July 2006 - Quarterly Investor Update - Second Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/0619-ASX-Announcement-10-May-Quarterly-Update-FINAL.pdf\">May 2006 - Quarterly Investor Update - First Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/0605-ASX-Announcement-6-Feb-Qty-Investor-Update-FINAL.pdf\">Feb 2006 - Quarterly Investor Update - Fourth Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/051026-ASX-Announcement-Quarterly-Investor-Update-Octo..pdf\">Oct 2005 - Quarterly Investor Update - Third Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX-Investor-Update-5-7-05.pdf\">Jul 2005 - Quarterly Investor Update - Second Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX-Investor-Update-8-Mar-2005.pdf\">Mar 2005 - Quarterly Investor Update - First Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/Investor-Update-22-September-2004.pdf\">Sep 2004 - Quarterly Investor Update - Third Quarter 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX-Investor-Update-4-June-2004.pdf\">Jun 2004 - Quarterly Investor Update - Second Quarter 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX-Investor-Update-March-2004.pdf\">Mar 2004 - Quarterly Investor Update - First Quarter 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>',	'Newsletters',	'',	'publish',	'open',	'open',	'',	'newsletters',	'',	'',	'2012-07-02 01:15:46',	'2012-07-02 01:15:46',	'',	25,	'http://calzada-wp.urldock.com/?page_id=155',	0,	'page',	'',	0),
(156,	1,	'2012-06-18 02:54:00',	'2012-06-18 02:54:00',	'',	'Newsletters',	'',	'inherit',	'open',	'open',	'',	'155-revision',	'',	'',	'2012-06-18 02:54:00',	'2012-06-18 02:54:00',	'',	155,	'http://calzada-wp.urldock.com/155-revision/',	0,	'revision',	'',	0),
(157,	1,	'2012-06-18 02:54:27',	'2012-06-18 02:54:27',	'',	'Articles',	'',	'publish',	'open',	'open',	'',	'articles',	'',	'',	'2012-07-02 01:16:12',	'2012-07-02 01:16:12',	'',	25,	'http://calzada-wp.urldock.com/?page_id=157',	1,	'page',	'',	0),
(158,	1,	'2012-06-18 02:54:22',	'2012-06-18 02:54:22',	'',	'Articles',	'',	'inherit',	'open',	'open',	'',	'157-revision',	'',	'',	'2012-06-18 02:54:22',	'2012-06-18 02:54:22',	'',	157,	'http://calzada-wp.urldock.com/157-revision/',	0,	'revision',	'',	0),
(159,	1,	'2012-06-18 02:54:42',	'2012-06-18 02:54:42',	'',	'Press',	'',	'publish',	'open',	'open',	'',	'press',	'',	'',	'2012-07-02 01:16:31',	'2012-07-02 01:16:31',	'',	25,	'http://calzada-wp.urldock.com/?page_id=159',	2,	'page',	'',	0),
(160,	1,	'2012-06-18 02:54:38',	'2012-06-18 02:54:38',	'',	'Press',	'',	'inherit',	'open',	'open',	'',	'159-revision',	'',	'',	'2012-06-18 02:54:38',	'2012-06-18 02:54:38',	'',	159,	'http://calzada-wp.urldock.com/159-revision/',	0,	'revision',	'',	0),
(161,	1,	'2012-06-18 02:54:57',	'2012-06-18 02:54:57',	'',	'Research Reports',	'',	'publish',	'open',	'open',	'',	'research-reports',	'',	'',	'2012-07-02 01:16:49',	'2012-07-02 01:16:49',	'',	25,	'http://calzada-wp.urldock.com/?page_id=161',	3,	'page',	'',	0),
(162,	1,	'2012-06-18 02:54:53',	'2012-06-18 02:54:53',	'',	'Research Reports',	'',	'inherit',	'open',	'open',	'',	'161-revision',	'',	'',	'2012-06-18 02:54:53',	'2012-06-18 02:54:53',	'',	161,	'http://calzada-wp.urldock.com/161-revision/',	0,	'revision',	'',	0),
(163,	1,	'2012-06-18 02:55:59',	'2012-06-18 02:55:59',	' ',	'',	'',	'publish',	'open',	'open',	'',	'163',	'',	'',	'2012-07-06 00:13:20',	'2012-07-06 00:13:20',	'',	25,	'http://calzada-wp.urldock.com/?p=163',	16,	'nav_menu_item',	'',	0),
(164,	1,	'2012-06-18 02:55:59',	'2012-06-18 02:55:59',	' ',	'',	'',	'publish',	'open',	'open',	'',	'164',	'',	'',	'2012-07-06 00:13:20',	'2012-07-06 00:13:20',	'',	25,	'http://calzada-wp.urldock.com/?p=164',	17,	'nav_menu_item',	'',	0),
(165,	1,	'2012-06-18 02:55:59',	'2012-06-18 02:55:59',	' ',	'',	'',	'publish',	'open',	'open',	'',	'165',	'',	'',	'2012-07-06 00:13:20',	'2012-07-06 00:13:20',	'',	25,	'http://calzada-wp.urldock.com/?p=165',	18,	'nav_menu_item',	'',	0),
(166,	1,	'2012-06-18 02:55:59',	'2012-06-18 02:55:59',	' ',	'',	'',	'publish',	'open',	'open',	'',	'166',	'',	'',	'2012-07-06 00:13:20',	'2012-07-06 00:13:20',	'',	25,	'http://calzada-wp.urldock.com/?p=166',	19,	'nav_menu_item',	'',	0),
(167,	1,	'2012-08-24 05:19:43',	'2012-08-24 05:19:43',	'<h2 class=\"feSubHeading\">Presentations</h2>\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" />\n\n15th November 2011\n<span style=\"color: #333399;\">AGM Presentation 2011</span>\n<a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/Calzada-AGM-Presentation_Nov-20112.pdf\">Click here to download presentation (835kb)</a>\n\n22nd November 2010\n<span style=\"color: #000099;\">AGM Presentation 2010</span>\n<a href=\"/wp-content/uploads/2012/06/914346.pdf\" target=\"_blank\">Click here to download presentation (1.7mb)</a>\n\n18th July 2008\n<span style=\"color: #000099;\">Corporate Presentation: Metabolic\'s acquisition of PolyNovo\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman of Metabolic </em>and <em>Ian Griffiths, CEO of PolyNovo\n</em><a href=\"/wp-content/uploads/2012/06/0823-ASX-Announcement-Corporate-Presentation-Acquisition-of-PolyNovo-18-July-2008_001.pdf\">Click here to download presentation (495 kb)</a></span>\n\n2nd November 2007\n<span style=\"color: #000099;\">2007 AGM Presentation\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman </em>and <em>Roland Scollay, CEO\n</em><a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation.pdf\" target=\"_blank\">Click here to download presentation (432 kb)</a></span>\n\n2nd November 2007\n<span style=\"color: #000099;\">2007 AGM Presentation (AUDIO WEBCAST)\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman</em> and <em>Roland Scollay, CEO\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/32241/wmp/poxf1u5rb8\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\n\n20th September 2007\n<span style=\"color: #000099;\">Update on Oral Peptide Delivery Platform\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\n</em><a href=\"/wp-content/uploads/2012/06/UpdateOralPeptideDeliveryPlatform_20Sept2007.pdf\" target=\"_blank\">Click here to download presentation ( 347 kb)</a></span>\n\n9th May 2007\n<span style=\"color: #003399;\">Corporate Update - May 2007</span>\n<em>Roland Scollay, PhD, CEO</em>\n<a href=\"/wp-content/uploads/2012/06/Metabolic-Corporate-Presentation.pdf\" target=\"_blank\">Click here to download presentation (577kb)</a>\n\n24th January 2007\n<span style=\"color: #000099;\">Corporate Update - January 2007\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\n</em><a href=\"/wp-content/uploads/2012/06/CurrentCorporatePresentation_January2007.pdf\" target=\"_blank\">Click here to download presentation (518kb)</a></span>\n\n27th November 2006\n<span style=\"color: #000099;\">Metabolic Domestic Roadshow - November 2006\n</span><em>Roland Scollay, PhD, CEO</em>\n<a href=\"/wp-content/uploads/2012/06/MetabolicDomesticRoadshow_November2006.pdf\" target=\"_blank\">Click here to download presentation (266kb)</a>\n\n30th October 2006\n<span style=\"color: #0000cc;\">2006 AGM:  CEO\'s presentation (AUDIO WEBCAST)\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/16722/wmp/siqi3bsv8o\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\n\n27th October 2006\n<span style=\"color: #000099;\">2006 AGM: CEO\'s presentation</span>\n<em>Roland Scollay, PhD, CEO</em>\n<a href=\"/wp-content/uploads/2012/06/AGMCEOPresentation_27October2006.pdf\" target=\"_blank\">Click here to download presentation (507kb) </a>\n\n12 October 2006\n<span style=\"color: #000099;\">Asia Pacific Life Sciences Forum (London) 12 Ocotber 2006\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\n</em></span><span style=\"color: #000000;\"><a href=\"/wp-content/uploads/2012/06/IntersuissePresentation_October2006.pdf\" target=\"_blank\">Click here to download presentation (425kb)</a></span>\n\n28th September 2006\n<span style=\"color: #000099;\">UBS Global Life Sciences Conference\n</span><em>Roland Scollay, PhD, CEO</em>\n<span style=\"color: #000099;\"><a href=\"/wp-content/uploads/2012/06/UBSPresentation28Sept2006.ppt\">Click here to download presentation (4.82mb)</a></span>\n\n3rd July 2006\n<span style=\"color: #000099;\">Investor Roadshow (UK &amp; Europe) presentation - company update - July 2006</span>\n<span style=\"color: #000099;\"><em><span style=\"color: #000000;\">Roland Scollay, PhD, CEO</span>\n</em><a href=\"/wp-content/uploads/2012/06/UKRoadshowPresentation_July2006.pdf\" target=\"_blank\">Click here to download report (301kb)</a></span>\n\n14th June 2006\n<span style=\"color: #000099;\">Presentation at the Pacific Growth Equities\' <em>2006 Life Sciences Growth Conferences </em>(USA)</span>\n<em>Roland Scollay, PhD, CEO </em>\n<a href=\"/wp-content/uploads/2012/06/PacificGrowthEquities_USA%20conference.pdf\" target=\"_blank\">Click here to download presentation (313kb)</a>\n\n23rd May 2006\n<span style=\"color: #000099;\">Roadshow presentation - company update - May 2006\n</span><span style=\"color: #000099;\"><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO</em> </span>\n</span><a href=\"/wp-content/uploads/2012/06/ASX_May23RoadshowPresentation.pdf\" target=\"_blank\">Click here to download report (323kb)</a>\n\n5th April 2006\n<span style=\"color: #000099;\">Presentation at US biotech conferences, 5th - 7th April 2006</span>\n<em>Roland Scollay, PhD, CEO\n</em><a href=\"/wp-content/uploads/2012/06/CEOUSbiotechpresentation_5April2006.pdf\" target=\"_blank\">Click here to download report (211kb)</a>\n\n14th February 2006\n<span style=\"color: #000099;\">Presentation to BIO-CEO Obesity Session, New York, 14th February 2006\n</span><em>Roland Scollay, PhD, CEO\n</em>\"New Advances in Obesity Drugs\"\n<a href=\"/wp-content/uploads/2012/06/BIO_CEO_OBESITY-SESSION_NY_FEB2006.pdf\" target=\"_blank\">Click here to download report (142kb)</a>\n\n8th February 2006\n<span style=\"color: #000099;\">Investor Roadshow Presentation, 8th February 2006 </span>\n<em>Roland Scollay, PhD, CEO </em>\n<a href=\"/wp-content/uploads/2012/06/InvestorRoadshowPresentation_8Feb2006.pdf\" target=\"_blank\">Click here to download report (183kb)</a>\n\n4th November 2005\n<span style=\"color: #000099;\">CEO Presentation at Rodman and Renshaw Conference New York, 7 November 2005 </span>\n<em>Roland Scollay, PhD, CEO</em>\n<a href=\"/wp-content/uploads/2012/06/CEOPresentationRodmanRenshaw_7Nov2005.pdf\" target=\"_blank\">Click here to download report (202kb)</a>\n\n28th October 2005\n<span style=\"color: #000099;\">CEO Presentation at AGM October 2005 </span>\n<em>Roland Scollay PhD, CEO </em>\n<a href=\"/wp-content/uploads/2012/06/AGMPresentation_28Oct2005.pdf\" target=\"_blank\">Click here to download report (168kb)</a>\n\n19th October 2005\n<span style=\"color: #000099;\">BBY/Jeffries Health Care and Life Sciences Conference</span>\n<em>Roland Scollay PhD, CEO\n</em><a href=\"/wp-content/uploads/2012/06/BBY_Jeffries_Conference_Sydney19Oct05.pdf\" target=\"_blank\">Click here to download report (1mb)</a>\n\n18th October 2005\n<span style=\"color: #000099;\">NAASO 2005 Annual Scientific Meeting</span>\n<em>Caroline Herd PhD </em>\n\"The Effect of AOD9604 on Weight Loss in Obese Adults\"\n<a href=\"/wp-content/uploads/2012/06/NAASO_2005presentation.pdf\" target=\"_blank\">Click here to download report (371kb)</a>\n\n10th October 2005\n<span style=\"color: #000099;\">Wilson HTM Biotechnology Conference</span>\n<em>Roland Scollay, PhD, CEO\n</em>\"Products to Profits\"\n<a href=\"/wp-content/uploads/2012/06/WilsonHTMConference_RS_10Oct2005.pdf\" target=\"_blank\">Click here to download report (96kb)</a>\n\n7th September 2005\n<span style=\"color: #000099;\">Southern Cross Equities Biotechnology conference\n</span><em>Roland Scollay, PhD, CEO\n</em>\"DNA, Devices and Dealers\"\n<a href=\"/wp-content/uploads/2012/06/SouthernCrossEquitiesRS_7Sept2005.pdf\" target=\"_blank\">Click here to download report (3.63mb)</a>\n\n2nd September 2005\n<span style=\"color: #000099;\">Venom to Drugs 2005, Conference, Heron Island</span>\n<em>Daniel McIntosh </em>\n<a href=\"/wp-content/uploads/2012/06/ACV1_PosterVenomstoDrugs_Sept2005.pdf\" target=\"_blank\">Click here to download report (123kb)</a>\n\n14th June 2005\n<span style=\"color: #000099;\">US Presentations June 2005</span>\n<em>Roland Scollay PhD CEO\n</em><a href=\"/wp-content/uploads/2012/06/USPresentations_June-20051.pdf\" target=\"_blank\">Click here to download report (264kb)</a>\n\n14th June 2005\n<span style=\"color: #000099;\">Boston Bio-Relationships 2005\n</span><em>Roland Scollay PhD CEO\n</em>Presentation 1: Corporate Presentation\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005CorporatePresentation_June2005.pdf\" target=\"_blank\">Click to download report (132kb)</a>\n\nPresentation 2: Diabetes Session Presentation\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005DiabetesSession_June2005.pdf\" target=\"_blank\">Click to download report (127kb)</a>\n\n14th June 2005\n<span style=\"color: #000099;\">American Diabetes Association 65th Scientific Sessions San Diego</span>\n<em>Prof. Gary Wittert </em>\nAOD9604, an Orally Active Peptide for the Treatment of Obesity: Results of a Phase 2b Study\n<a href=\"/wp-content/uploads/2012/06/ADAposter_June20051.pdf\" target=\"_blank\">Click here to download report (106kb)</a>\n\n14th June 2005\n<span style=\"color: #000099;\">Share Placement Corporate Presentation June 2005</span>\n<em>Roland Scollay PhD CEO</em>\n<a href=\"/wp-content/uploads/2012/06/ADAposter_June2005.pdf\" target=\"_blank\">Click here to download Presentation (1.78mb)</a>\n\n2nd May 2005\n<span style=\"color: #000099;\">TIDES 2005 Conference Presentation, Boston</span>\n<em>Dr Andrea McCracken\n</em>Development of the Conopeptide ACV1 for the Treatment of Neuropathic Pain\n<a href=\"/wp-content/uploads/2012/06/TIDES-ACV1_2ndMay2005.pdf\" target=\"_blank\">Click here to download the Presentation (4.65mb)</a>\n\n3rd May 2004\n<span style=\"color: #000099;\">TIDES 2004 Conference Presentation, Las Vegas </span>\n<em>Dr Caroline Herd\n</em>AOD9604 - An Orally Active Peptide for the Treatment of Obesity\n<a href=\"/wp-content/uploads/2012/06/TIDES-2004-Conference.pdf\" target=\"_blank\">Click to download Presentation (2.33mb)</a>\n\n17th February 2003\n<span style=\"color: #000099;\">Conference Presentation\n</span><em>Mark Heffernan</em>\nPresentation at the Obesity and Metabolic disorders conference, London\n<a href=\"/wp-content/uploads/2012/06/HeffernanUK.pdf\" target=\"_blank\">Click to download Presentation (396kb)</a>\n\n&nbsp;\n\n&nbsp;\n\n<em>Please Note:\nThese files are provided in Adobe PDF format, requiring the Adobe PDF Reader application to view them. This application is available to download from <span style=\"text-decoration: underline;\"><strong><a href=\"http://www.adobe.com/\" target=\"_blank\">http://www.adobe.com</a></strong></span></em>\n\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"15\" border=\"0\" />',	'Presentations',	'',	'inherit',	'open',	'open',	'',	'133-autosave',	'',	'',	'2012-08-24 05:19:43',	'2012-08-24 05:19:43',	'',	133,	'http://calzada-wp.urldock.com/133-autosave/',	0,	'revision',	'',	0),
(168,	1,	'2012-06-11 05:27:54',	'2012-06-11 05:27:54',	'',	'Presentations',	'',	'inherit',	'open',	'open',	'',	'133-revision-2',	'',	'',	'2012-06-11 05:27:54',	'2012-06-11 05:27:54',	'',	133,	'http://calzada-wp.urldock.com/133-revision-2/',	0,	'revision',	'',	0),
(169,	1,	'2012-06-18 04:58:07',	'2012-06-18 04:58:07',	'',	'BIO_CEO_OBESITY SESSION_NY_FEB2006',	'',	'inherit',	'open',	'open',	'',	'bio_ceo_obesity-session_ny_feb2006',	'',	'',	'2012-06-18 04:58:07',	'2012-06-18 04:58:07',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/BIO_CEO_OBESITY-SESSION_NY_FEB2006.pdf',	0,	'attachment',	'application/pdf',	0),
(170,	1,	'2012-06-18 04:58:10',	'2012-06-18 04:58:10',	'',	'BostonBio2005CorporatePresentation_June2005',	'',	'inherit',	'open',	'open',	'',	'bostonbio2005corporatepresentation_june2005',	'',	'',	'2012-06-18 04:58:10',	'2012-06-18 04:58:10',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/BostonBio2005CorporatePresentation_June2005.pdf',	0,	'attachment',	'application/pdf',	0),
(171,	1,	'2012-06-18 04:58:12',	'2012-06-18 04:58:12',	'',	'BostonBio2005DiabetesSession_June2005',	'',	'inherit',	'open',	'open',	'',	'bostonbio2005diabetessession_june2005',	'',	'',	'2012-06-18 04:58:12',	'2012-06-18 04:58:12',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/BostonBio2005DiabetesSession_June2005.pdf',	0,	'attachment',	'application/pdf',	0),
(172,	1,	'2012-06-18 04:58:18',	'2012-06-18 04:58:18',	'',	'CEOPresentationRodmanRenshaw_7Nov2005',	'',	'inherit',	'open',	'open',	'',	'ceopresentationrodmanrenshaw_7nov2005',	'',	'',	'2012-06-18 04:58:18',	'2012-06-18 04:58:18',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/CEOPresentationRodmanRenshaw_7Nov2005.pdf',	0,	'attachment',	'application/pdf',	0),
(173,	1,	'2012-06-18 04:58:22',	'2012-06-18 04:58:22',	'',	'CEOUSbiotechpresentation_5April2006',	'',	'inherit',	'open',	'open',	'',	'ceousbiotechpresentation_5april2006',	'',	'',	'2012-06-18 04:58:22',	'2012-06-18 04:58:22',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/CEOUSbiotechpresentation_5April2006.pdf',	0,	'attachment',	'application/pdf',	0),
(174,	1,	'2012-06-18 04:58:31',	'2012-06-18 04:58:31',	'',	'CurrentCorporatePresentation_January2007',	'',	'inherit',	'open',	'open',	'',	'currentcorporatepresentation_january2007',	'',	'',	'2012-06-18 04:58:31',	'2012-06-18 04:58:31',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/CurrentCorporatePresentation_January2007.pdf',	0,	'attachment',	'application/pdf',	0),
(175,	1,	'2012-06-18 04:58:38',	'2012-06-18 04:58:38',	'',	'HeffernanUK',	'',	'inherit',	'open',	'open',	'',	'heffernanuk',	'',	'',	'2012-06-18 04:58:38',	'2012-06-18 04:58:38',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/HeffernanUK.pdf',	0,	'attachment',	'application/pdf',	0),
(176,	1,	'2012-06-18 04:58:44',	'2012-06-18 04:58:44',	'',	'IntersuissePresentation_October2006',	'',	'inherit',	'open',	'open',	'',	'intersuissepresentation_october2006',	'',	'',	'2012-06-18 04:58:44',	'2012-06-18 04:58:44',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/IntersuissePresentation_October2006.pdf',	0,	'attachment',	'application/pdf',	0),
(177,	1,	'2012-06-18 04:58:48',	'2012-06-18 04:58:48',	'',	'InvestorRoadshowPresentation_8Feb2006',	'',	'inherit',	'open',	'open',	'',	'investorroadshowpresentation_8feb2006',	'',	'',	'2012-06-18 04:58:48',	'2012-06-18 04:58:48',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/InvestorRoadshowPresentation_8Feb2006.pdf',	0,	'attachment',	'application/pdf',	0),
(178,	1,	'2012-06-18 04:59:18',	'2012-06-18 04:59:18',	'',	'MBPCorporatePresentation_June 2005',	'',	'inherit',	'open',	'open',	'',	'mbpcorporatepresentation_june-2005',	'',	'',	'2012-06-18 04:59:18',	'2012-06-18 04:59:18',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/MBPCorporatePresentation_June-2005.pdf',	0,	'attachment',	'application/pdf',	0),
(179,	1,	'2012-06-18 04:59:30',	'2012-06-18 04:59:30',	'',	'Metabolic 2007 AGM Presentation',	'',	'inherit',	'open',	'open',	'',	'metabolic-2007-agm-presentation',	'',	'',	'2012-06-18 04:59:30',	'2012-06-18 04:59:30',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation.pdf',	0,	'attachment',	'application/pdf',	0),
(180,	1,	'2012-06-18 04:59:41',	'2012-06-18 04:59:41',	'',	'Metabolic Corporate Presentation',	'',	'inherit',	'open',	'open',	'',	'metabolic-corporate-presentation',	'',	'',	'2012-06-18 04:59:41',	'2012-06-18 04:59:41',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/Metabolic-Corporate-Presentation.pdf',	0,	'attachment',	'application/pdf',	0),
(181,	1,	'2012-06-18 04:59:45',	'2012-06-18 04:59:45',	'',	'MetabolicDomesticRoadshow_November2006',	'',	'inherit',	'open',	'open',	'',	'metabolicdomesticroadshow_november2006',	'',	'',	'2012-06-18 04:59:45',	'2012-06-18 04:59:45',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/MetabolicDomesticRoadshow_November2006.pdf',	0,	'attachment',	'application/pdf',	0),
(182,	1,	'2012-06-18 04:59:52',	'2012-06-18 04:59:52',	'',	'NAASO_2005presentation',	'',	'inherit',	'open',	'open',	'',	'naaso_2005presentation',	'',	'',	'2012-06-18 04:59:52',	'2012-06-18 04:59:52',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/NAASO_2005presentation.pdf',	0,	'attachment',	'application/pdf',	0),
(183,	1,	'2012-06-18 04:59:56',	'2012-06-18 04:59:56',	'',	'PacificGrowthEquities_USA conference',	'',	'inherit',	'open',	'open',	'',	'pacificgrowthequities_usa-conference',	'',	'',	'2012-06-18 04:59:56',	'2012-06-18 04:59:56',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/PacificGrowthEquities_USA-conference.pdf',	0,	'attachment',	'application/pdf',	0),
(184,	1,	'2012-06-18 05:00:54',	'2012-06-18 05:00:54',	'',	'SouthernCrossEquitiesRS_7Sept2005',	'',	'inherit',	'open',	'open',	'',	'southerncrossequitiesrs_7sept2005',	'',	'',	'2012-06-18 05:00:54',	'2012-06-18 05:00:54',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/SouthernCrossEquitiesRS_7Sept2005.pdf',	0,	'attachment',	'application/pdf',	0),
(185,	1,	'2012-06-18 05:01:29',	'2012-06-18 05:01:29',	'',	'TIDES 2004 Conference',	'',	'inherit',	'open',	'open',	'',	'tides-2004-conference',	'',	'',	'2012-06-18 05:01:29',	'2012-06-18 05:01:29',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/TIDES-2004-Conference.pdf',	0,	'attachment',	'application/pdf',	0),
(186,	1,	'2012-06-18 05:02:44',	'2012-06-18 05:02:44',	'',	'TIDES ACV1_2ndMay2005',	'',	'inherit',	'open',	'open',	'',	'tides-acv1_2ndmay2005',	'',	'',	'2012-06-18 05:02:44',	'2012-06-18 05:02:44',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/TIDES-ACV1_2ndMay2005.pdf',	0,	'attachment',	'application/pdf',	0),
(187,	1,	'2012-06-18 05:03:39',	'2012-06-18 05:03:39',	'',	'UBSPresentation28Sept2006',	'',	'inherit',	'open',	'open',	'',	'ubspresentation28sept2006',	'',	'',	'2012-06-18 05:03:39',	'2012-06-18 05:03:39',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/UBSPresentation28Sept2006.ppt',	0,	'attachment',	'application/vnd.ms-powerpoint',	0),
(188,	1,	'2012-06-18 05:03:44',	'2012-06-18 05:03:44',	'',	'UKRoadshowPresentation_July2006',	'',	'inherit',	'open',	'open',	'',	'ukroadshowpresentation_july2006',	'',	'',	'2012-06-18 05:03:44',	'2012-06-18 05:03:44',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/UKRoadshowPresentation_July2006.pdf',	0,	'attachment',	'application/pdf',	0),
(189,	1,	'2012-06-18 05:03:54',	'2012-06-18 05:03:54',	'',	'UpdateOralPeptideDeliveryPlatform_20Sept2007',	'',	'inherit',	'open',	'open',	'',	'updateoralpeptidedeliveryplatform_20sept2007',	'',	'',	'2012-06-18 05:03:54',	'2012-06-18 05:03:54',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/UpdateOralPeptideDeliveryPlatform_20Sept2007.pdf',	0,	'attachment',	'application/pdf',	0),
(190,	1,	'2012-06-18 05:03:59',	'2012-06-18 05:03:59',	'',	'USPresentations_June 2005',	'',	'inherit',	'open',	'open',	'',	'uspresentations_june-2005',	'',	'',	'2012-06-18 05:03:59',	'2012-06-18 05:03:59',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/USPresentations_June-2005.pdf',	0,	'attachment',	'application/pdf',	0),
(191,	1,	'2012-06-18 05:04:01',	'2012-06-18 05:04:01',	'',	'WilsonHTMConference_RS_10Oct2005',	'',	'inherit',	'open',	'open',	'',	'wilsonhtmconference_rs_10oct2005',	'',	'',	'2012-06-18 05:04:01',	'2012-06-18 05:04:01',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/WilsonHTMConference_RS_10Oct2005.pdf',	0,	'attachment',	'application/pdf',	0),
(192,	1,	'2012-06-18 05:04:11',	'2012-06-18 05:04:11',	'',	'0823 ASX Announcement Corporate Presentation - Acquisition of PolyNovo 18 July 2008',	'',	'inherit',	'open',	'open',	'',	'0823-asx-announcement-corporate-presentation-acquisition-of-polynovo-18-july-2008',	'',	'',	'2012-06-18 05:04:11',	'2012-06-18 05:04:11',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/0823-ASX-Announcement-Corporate-Presentation-Acquisition-of-PolyNovo-18-July-2008.pdf',	0,	'attachment',	'application/pdf',	0),
(193,	1,	'2012-06-18 05:04:18',	'2012-06-18 05:04:18',	'',	'0823 ASX Announcement Corporate Presentation - Acquisition of PolyNovo 18 July 2008_001',	'',	'inherit',	'open',	'open',	'',	'0823-asx-announcement-corporate-presentation-acquisition-of-polynovo-18-july-2008_001',	'',	'',	'2012-06-18 05:04:18',	'2012-06-18 05:04:18',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/0823-ASX-Announcement-Corporate-Presentation-Acquisition-of-PolyNovo-18-July-2008_001.pdf',	0,	'attachment',	'application/pdf',	0),
(194,	1,	'2012-06-18 05:04:51',	'2012-06-18 05:04:51',	'',	'914346',	'',	'inherit',	'open',	'open',	'',	'914346',	'',	'',	'2012-06-18 05:04:51',	'2012-06-18 05:04:51',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/914346.pdf',	0,	'attachment',	'application/pdf',	0),
(195,	1,	'2012-06-18 05:04:54',	'2012-06-18 05:04:54',	'',	'ACV1_PosterVenomstoDrugs_Sept2005',	'',	'inherit',	'open',	'open',	'',	'acv1_postervenomstodrugs_sept2005',	'',	'',	'2012-06-18 05:04:54',	'2012-06-18 05:04:54',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ACV1_PosterVenomstoDrugs_Sept2005.pdf',	0,	'attachment',	'application/pdf',	0),
(196,	1,	'2012-06-18 05:04:59',	'2012-06-18 05:04:59',	'',	'ADAposter_June2005',	'',	'inherit',	'open',	'open',	'',	'adaposter_june2005',	'',	'',	'2012-06-18 05:04:59',	'2012-06-18 05:04:59',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ADAposter_June2005.pdf',	0,	'attachment',	'application/pdf',	0),
(197,	1,	'2012-06-18 05:05:11',	'2012-06-18 05:05:11',	'',	'AGMCEOPresentation_27October2006',	'',	'inherit',	'open',	'open',	'',	'agmceopresentation_27october2006',	'',	'',	'2012-06-18 05:05:11',	'2012-06-18 05:05:11',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/AGMCEOPresentation_27October2006.pdf',	0,	'attachment',	'application/pdf',	0),
(198,	1,	'2012-06-18 05:05:20',	'2012-06-18 05:05:20',	'',	'AGMCEOPresentation_27October2006_001',	'',	'inherit',	'open',	'open',	'',	'agmceopresentation_27october2006_001',	'',	'',	'2012-06-18 05:05:20',	'2012-06-18 05:05:20',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/AGMCEOPresentation_27October2006_001.pdf',	0,	'attachment',	'application/pdf',	0),
(199,	1,	'2012-06-18 05:05:23',	'2012-06-18 05:05:23',	'',	'AGMPresentation_28Oct2005',	'',	'inherit',	'open',	'open',	'',	'agmpresentation_28oct2005',	'',	'',	'2012-06-18 05:05:23',	'2012-06-18 05:05:23',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/AGMPresentation_28Oct2005.pdf',	0,	'attachment',	'application/pdf',	0),
(200,	1,	'2012-06-18 05:05:27',	'2012-06-18 05:05:27',	'',	'ASX_May23RoadshowPresentation',	'',	'inherit',	'open',	'open',	'',	'asx_may23roadshowpresentation',	'',	'',	'2012-06-18 05:05:27',	'2012-06-18 05:05:27',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX_May23RoadshowPresentation.pdf',	0,	'attachment',	'application/pdf',	0),
(201,	1,	'2012-06-18 05:05:48',	'2012-06-18 05:05:48',	'',	'BBY_Jeffries_Conference_Sydney19Oct05',	'',	'inherit',	'open',	'open',	'',	'bby_jeffries_conference_sydney19oct05',	'',	'',	'2012-06-18 05:05:48',	'2012-06-18 05:05:48',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/BBY_Jeffries_Conference_Sydney19Oct05.pdf',	0,	'attachment',	'application/pdf',	0),
(202,	1,	'2012-06-18 03:01:03',	'2012-06-18 03:01:03',	'<h2 class=\"feSubHeading\">Presentations</h2></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"><img src=\"../../html/images/trans.gif\" alt=\"\" border=\"0\" height=\"10\" width=\"1\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td id=\"theCell1\" width=\"100%\">\r\n<p>15th&nbsp;April 2011<br><font color=\"#000099\">AGM Presentation 2010</font><br><a href=\"../../files/FYIZQVO1AC/914346.pdf\" target=\"_blank\">Click here to download presentation (1.7mb)</a></p>\r\n<p>18th July 2008<br><font color=\"#000099\">Corporate P<a href=\"../../files/CHZ65N42VF/0823%20ASX%20Announcement%20Corporate%20Presentation%20-%20Acquisition%20of%20PolyNovo%2018%20July%202008.pdf\"></a>resentation: Metabolic\'s acquisition of PolyNovo<br></font><font color=\"#000000\"><em>Rob Stewart, Chairman of Metabolic </em>and <em>Ian Griffiths, CEO of PolyNovo<br></em><a href=\"../../files/TWALY1I6M1/0823%20ASX%20Announcement%20Corporate%20Presentation%20-%20Acquisition%20of%20PolyNovo%2018%20July%202008.pdf\">Click here to download presentation (495 kb)</a></font></p>\r\n<p>2nd November 2007<br><font color=\"#000099\">2007 AGM Presentation<br></font><font color=\"#000000\"><em>Rob Stewart, Chairman </em>and <em>Roland Scollay, CEO<br></em><a href=\"../../files/K6VMK8VF1A/Metabolic%202007%20AGM%20Presentation.pdf\" target=\"_blank\">Click here to download presentation (432 kb)</a></font></p>\r\n<p>2nd November 2007<br><font color=\"#000099\">2007 AGM Presentation (AUDIO WEBCAST)<br></font><font color=\"#000000\"><em>Rob Stewart, Chairman</em>&nbsp;and <em>Roland Scollay, CEO<br></em><a href=\"http://www.brr.com.au/event/MBP/1281/32241/wmp/poxf1u5rb8\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></font></p>\r\n<p>20th September 2007<br><font color=\"#000099\">Update on Oral Peptide Delivery Platform<br></font><font color=\"#000000\"><em>Roland Scollay, PhD, CEO<br></em><a href=\"../../files/CRHORJBYVO/UpdateOralPeptideDeliveryPlatform_20Sept2007.pdf\" target=\"_blank\">Click here to download presentation ( 347 kb)</a></font></p>\r\n<p>9th May 2007<br><font color=\"#003399\">Corporate Update - May 2007</font> <br><em>Roland Scollay, PhD, CEO</em> <br><a href=\"../../files/89KVZHJ8BI/Metabolic%20Corporate%20Presentation.pdf\" target=\"_blank\">Click here to download presentation (577kb)</a> </p>\r\n<p>24th January 2007<br><font color=\"#000099\">Corporate Update - January 2007<br></font><font color=\"#000000\"><em>Roland Scollay, PhD, CEO<br></em><a href=\"../../files/E5LPNYTC6D/CurrentCorporatePresentation_January2007.pdf\" target=\"_blank\">Click here to download presentation (518kb)</a></font></p>\r\n<p>27th November 2006<br><font color=\"#000099\">Metabolic Domestic Roadshow - November 2006<br></font><em>Roland Scollay, PhD, CEO</em><br><a href=\"../../files/WC0C0Z7IEB/MetabolicDomesticRoadshow_November2006.pdf\" target=\"_blank\">Click here to download presentation (266kb)</a></p>\r\n<p>30th October 2006<br><font color=\"#0000cc\">2006 AGM:&nbsp; CEO\'s presentation (AUDIO WEBCAST)<br></font><font color=\"#000000\"><em>Roland Scollay, PhD, CEO<br></em><a href=\"http://www.brr.com.au/event/MBP/1281/16722/wmp/siqi3bsv8o\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></font></p>\r\n<p>27th October 2006<a href=\"../../files/OPPWJX0IBT/AGMCEOPresentation_27October2006.pdf\" target=\"_blank\"></a><br><font color=\"#000099\">2006 AGM: CEO\'s presentation</font><br><em>Roland Scollay, PhD, CEO</em><br><a href=\"../../files/E75PIOMUTZ/AGMCEOPresentation_27October2006.pdf\" target=\"_blank\">Click here to download presentation (507kb) </a></p>\r\n<p>12 October 2006<br><font color=\"#000099\">Asia Pacific Life Sciences Forum (London) 12 Ocotber 2006<br></font><font color=\"#000000\"><em>Roland Scollay, PhD, CEO<br></em></font><font color=\"#000000\"><a href=\"../../files/EXVWZ830LV/IntersuissePresentation_October2006.pdf\" target=\"_blank\">Click here to download presentation (425kb)</a></font></p>\r\n<p>28th September 2006<br><font color=\"#000099\">UBS Global Life Sciences Conference<br></font><em>Roland Scollay, PhD, CEO</em><br><font color=\"#000099\"><a href=\"../../files/OSBFMF1LLH/UBSPresentation28Sept2006.ppt\">Click here to download presentation&nbsp;(4.82mb)</a></font></p>\r\n<p>3rd July 2006<br><font color=\"#000099\">Investor Roadshow (UK &amp; Europe) presentation - company update - July 2006</font><br><font color=\"#000099\"><em><font color=\"#000000\">Roland Scollay, PhD, CEO</font><br></em><a href=\"../../files/RIA90SL67O/UKRoadshowPresentation_July2006.pdf\" target=\"_blank\">Click here to download report (301kb)</a></font></p>\r\n<p>14th June 2006 <br><font color=\"#000099\">Presentation at the Pacific Growth Equities\' <em>2006 Life Sciences Growth Conferences </em>(USA)</font> <br><em>Roland Scollay, PhD, CEO </em><br><a href=\"../../files/C7UOJV7LYC/PacificGrowthEquities_USA%20conference.pdf\" target=\"_blank\">Click here to download presentation (313kb)</a></p>\r\n<p>23rd May 2006 <br><font color=\"#000099\">Roadshow presentation - company update - May 2006 <br></font><font color=\"#000099\"><font color=\"#000000\"><em>Roland Scollay, PhD, CEO</em> </font><br></font><a href=\"../../files/CFEG1WM0SM/ASX_May23RoadshowPresentation.pdf\" target=\"_blank\">Click here to download report (323kb)</a></p>\r\n<p>5th April 2006 <br><font color=\"#000099\">Presentation at US biotech conferences, 5th - 7th April 2006</font> <br><em>Roland Scollay, PhD, CEO <br></em><a href=\"../../files/SFL9G67Y1N/CEOUSbiotechpresentation_5April2006.pdf\" target=\"_blank\">Click here to download report (211kb)</a></p>\r\n<p>14th February 2006 <br><font color=\"#000099\">Presentation to BIO-CEO Obesity Session, New York, 14th February 2006 <br></font><em>Roland Scollay, PhD, CEO <br></em>\"New Advances in Obesity Drugs\" <br><a href=\"../../files/6BJI9VQE91/BIO_CEO_OBESITY%20SESSION_NY_FEB2006.pdf\" target=\"_blank\">Click here to download report (142kb)</a></p>\r\n<p>8th February 2006 <br><font color=\"#000099\">Investor Roadshow Presentation, 8th February 2006 </font><br><em>Roland Scollay, PhD, CEO </em><br><a href=\"../../files/3ZEBQVN35T/InvestorRoadshowPresentation_8Feb2006.pdf\" target=\"_blank\">Click here to download report (183kb)</a></p>\r\n<p>4th November 2005 <br><font color=\"#000099\">CEO Presentation at Rodman and Renshaw Conference New York, 7 November 2005 </font><br><em>Roland Scollay, PhD, CEO</em> <br><a href=\"../../files/61AFYHW5H4/CEOPresentationRodmanRenshaw_7Nov2005.pdf\" target=\"_blank\">Click here to download report (202kb)</a></p>\r\n<p><a href=\"http://wsw.com/webcast/rrshq7/metabolic/\" target=\"_blank\">http://wsw.com/webcast/rrshq7/metabolic/</a> <br>Click link above for Live webcast Tuesday 8 November 2005 10am aest</p>\r\n<p>28th October 2005 <br><font color=\"#000099\">CEO Presentation at AGM October 2005 </font><br><em>Roland Scollay PhD, CEO </em><br><a href=\"../../files/DEBYNKZPC0/AGMPresentation_28Oct2005.pdf\" target=\"_blank\">Click here to download report (168kb)</a></p>\r\n<p>19th October 2005 <br><font color=\"#000099\">BBY/Jeffries Health Care and Life Sciences Conference</font> <br><em>Roland Scollay PhD, CEO <br></em><a href=\"../../files/CWRZFNLAHY/BBY_Jeffries_Conference_Sydney19Oct05.pdf\" target=\"_blank\">Click here to download report (1mb)</a></p>\r\n<p>18th October 2005 <br><font color=\"#000099\">NAASO 2005 Annual Scientific Meeting</font> <br><em>Caroline Herd PhD </em><br>\"The Effect of AOD9604 on Weight Loss in Obese Adults\" <br><a href=\"../../files/FXP0ZBOTGC/NAASO_2005presentation.pdf\" target=\"_blank\">Click here to download report (371kb)</a></p>\r\n<p>10th October 2005 <br><font color=\"#000099\">Wilson HTM Biotechnology Conference</font> <br><em>Roland Scollay, PhD, CEO <br></em>\"Products to Profits\" <br><a href=\"../../files/9334N827JA/WilsonHTMConference_RS_10Oct2005.pdf\" target=\"_blank\">Click here to download report (96kb)</a></p>\r\n<p>7th September 2005 <br><font color=\"#000099\">Southern Cross Equities Biotechnology conference <br></font><em>Roland Scollay, PhD, CEO <br></em>\"DNA, Devices and Dealers\" <br><a href=\"../../files/WXI1A0PJ0L/SouthernCrossEquitiesRS_7Sept2005.pdf\" target=\"_blank\">Click here to download report (3.63mb)</a></p>\r\n<p>2nd September 2005 <br><font color=\"#000099\">Venom to Drugs 2005, Conference, Heron Island</font> <br><em>Daniel McIntosh </em><br><a href=\"../../files/RJ1EARA7L0/ACV1_PosterVenomstoDrugs_Sept2005.pdf\" target=\"_blank\">Click here to download report (123kb)</a></p>\r\n<p>14th June 2005 <br><font color=\"#000099\">US Presentations June 2005</font><br><em>Roland Scollay PhD CEO <br></em><a href=\"../../files/RPYEAX67IF/USPresentations_June%202005.pdf\" target=\"_blank\">Click here to download report (264kb)</a></p>\r\n<p>14th June 2005 <br><font color=\"#000099\">Boston Bio-Relationships 2005<br></font><em>Roland Scollay PhD CEO <br></em>Presentation 1: Corporate Presentation <br><a href=\"../../files/NHGJWYDSBH/BostonBio2005CorporatePresentation_June2005.pdf\" target=\"_blank\">Click to download report (132kb)</a></p>\r\n<p>Presentation 2: Diabetes Session Presentation <br><a href=\"../../files/D92OHAGKYK/BostonBio2005DiabetesSession_June2005.pdf\" target=\"_blank\">Click to download report (127kb)</a></p>\r\n<p>14th June 2005 <br><font color=\"#000099\">American Diabetes Association 65th Scientific Sessions San Diego</font> <br><em>Prof. Gary Wittert </em><br>AOD9604, an Orally Active Peptide for the Treatment of Obesity: Results of a Phase 2b Study <br><a href=\"../../files/ISW4JYRJF0/ADAposter_June2005.pdf\" target=\"_blank\">Click here to download report (106kb)</a></p>\r\n<p>14th June 2005 <br><font color=\"#000099\">Share Placement Corporate Presentation June 2005</font> <br><em>Roland Scollay PhD CEO</em> <br><a href=\"../../files/LR5QIIJTN3/MBPCorporatePresentation_June%202005.pdf\" target=\"_blank\">Click here to download Presentation (1.78mb)</a></p>\r\n<p>2nd May 2005 <br><font color=\"#000099\">TIDES 2005 Conference Presentation, Boston</font> <br><em>Dr Andrea McCracken <br></em>Development of the Conopeptide ACV1 for the Treatment of Neuropathic Pain <br><a href=\"../../files/6MSAE99WO4/TIDES%20ACV1_2ndMay2005.pdf\" target=\"_blank\">Click here to download the Presentation (4.65mb)</a></p>\r\n<p>3rd May 2004 <br><font color=\"#000099\">TIDES 2004 Conference Presentation, Las Vegas </font><br><em>Dr Caroline Herd <br></em>AOD9604 - An Orally Active Peptide for the Treatment of Obesity <br><a href=\"../../files/ZWYPDH2VK4/TIDES%202004%20Conference.pdf\" target=\"_blank\">Click to download Presentation (2.33mb)</a></p>\r\n<p>17th February 2003 <br><font color=\"#000099\">Conference Presentation <br></font><em>Mark Heffernan</em><br>Presentation at the Obesity and Metabolic disorders conference, London <br><a href=\"../../files/KLI223405C/HeffernanUK.pdf\" target=\"_blank\">Click to download Presentation (396kb)</a></p>\r\n<p>&nbsp;</p>\r\n<p>&nbsp;</p>\r\n<p><em>Please Note: <br>These files are provided in Adobe PDF format, requiring the Adobe PDF Reader application to view them. This application is available to download from <u><strong><a href=\"http://www.adobe.com/\" target=\"_blank\">http://www.adobe.com</a></strong></u></em></p>\r\n\r\n</td>\r\n</tr>\r\n\r\n<tr>\r\n<td colspan=\"2\"><img src=\"../../html/images/trans.gif\" alt=\"\" border=\"0\" height=\"15\" width=\"1\">',	'Presentations',	'',	'inherit',	'open',	'open',	'',	'133-revision-3',	'',	'',	'2012-06-18 03:01:03',	'2012-06-18 03:01:03',	'',	133,	'http://calzada-wp.urldock.com/133-revision-3/',	0,	'revision',	'',	0),
(203,	1,	'2012-06-18 05:22:46',	'2012-06-18 05:22:46',	'<h2 class=\"feSubHeading\">Presentations</h2>\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" />\r\n\r\n15th April 2011\r\n<span style=\"color: #000099;\">AGM Presentation 2010</span>\r\n<a href=\"/wp-content/uploads/2012/06/914346.pdf\" target=\"_blank\">Click here to download presentation (1.7mb)</a>\r\n\r\n18th July 2008\r\n<span style=\"color: #000099;\">Corporate Presentation: Metabolic\'s acquisition of PolyNovo\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman of Metabolic </em>and <em>Ian Griffiths, CEO of PolyNovo\r\n</em><a href=\"/wp-content/uploads/2012/06/0823%20ASX%20Announcement%20Corporate%20Presentation%20-%20Acquisition%20of%20PolyNovo%2018%20July%202008.pdf\">Click here to download presentation (495 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman </em>and <em>Roland Scollay, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/Metabolic%202007%20AGM%20Presentation.pdf\" target=\"_blank\">Click here to download presentation (432 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman</em> and <em>Roland Scollay, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/32241/wmp/poxf1u5rb8\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n20th September 2007\r\n<span style=\"color: #000099;\">Update on Oral Peptide Delivery Platform\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"../../files/CRHORJBYVO/UpdateOralPeptideDeliveryPlatform_20Sept2007.pdf\" target=\"_blank\">Click here to download presentation ( 347 kb)</a></span>\r\n\r\n9th May 2007\r\n<span style=\"color: #003399;\">Corporate Update - May 2007</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"../../files/89KVZHJ8BI/Metabolic%20Corporate%20Presentation.pdf\" target=\"_blank\">Click here to download presentation (577kb)</a>\r\n\r\n24th January 2007\r\n<span style=\"color: #000099;\">Corporate Update - January 2007\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"../../files/E5LPNYTC6D/CurrentCorporatePresentation_January2007.pdf\" target=\"_blank\">Click here to download presentation (518kb)</a></span>\r\n\r\n27th November 2006\r\n<span style=\"color: #000099;\">Metabolic Domestic Roadshow - November 2006\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"../../files/WC0C0Z7IEB/MetabolicDomesticRoadshow_November2006.pdf\" target=\"_blank\">Click here to download presentation (266kb)</a>\r\n\r\n30th October 2006\r\n<span style=\"color: #0000cc;\">2006 AGM:  CEO\'s presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/16722/wmp/siqi3bsv8o\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n27th October 2006\r\n<span style=\"color: #000099;\">2006 AGM: CEO\'s presentation</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"../../files/E75PIOMUTZ/AGMCEOPresentation_27October2006.pdf\" target=\"_blank\">Click here to download presentation (507kb) </a>\r\n\r\n12 October 2006\r\n<span style=\"color: #000099;\">Asia Pacific Life Sciences Forum (London) 12 Ocotber 2006\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em></span><span style=\"color: #000000;\"><a href=\"../../files/EXVWZ830LV/IntersuissePresentation_October2006.pdf\" target=\"_blank\">Click here to download presentation (425kb)</a></span>\r\n\r\n28th September 2006\r\n<span style=\"color: #000099;\">UBS Global Life Sciences Conference\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<span style=\"color: #000099;\"><a href=\"../../files/OSBFMF1LLH/UBSPresentation28Sept2006.ppt\">Click here to download presentation (4.82mb)</a></span>\r\n\r\n3rd July 2006\r\n<span style=\"color: #000099;\">Investor Roadshow (UK &amp; Europe) presentation - company update - July 2006</span>\r\n<span style=\"color: #000099;\"><em><span style=\"color: #000000;\">Roland Scollay, PhD, CEO</span>\r\n</em><a href=\"../../files/RIA90SL67O/UKRoadshowPresentation_July2006.pdf\" target=\"_blank\">Click here to download report (301kb)</a></span>\r\n\r\n14th June 2006\r\n<span style=\"color: #000099;\">Presentation at the Pacific Growth Equities\' <em>2006 Life Sciences Growth Conferences </em>(USA)</span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"../../files/C7UOJV7LYC/PacificGrowthEquities_USA%20conference.pdf\" target=\"_blank\">Click here to download presentation (313kb)</a>\r\n\r\n23rd May 2006\r\n<span style=\"color: #000099;\">Roadshow presentation - company update - May 2006\r\n</span><span style=\"color: #000099;\"><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO</em> </span>\r\n</span><a href=\"../../files/CFEG1WM0SM/ASX_May23RoadshowPresentation.pdf\" target=\"_blank\">Click here to download report (323kb)</a>\r\n\r\n5th April 2006\r\n<span style=\"color: #000099;\">Presentation at US biotech conferences, 5th - 7th April 2006</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em><a href=\"../../files/SFL9G67Y1N/CEOUSbiotechpresentation_5April2006.pdf\" target=\"_blank\">Click here to download report (211kb)</a>\r\n\r\n14th February 2006\r\n<span style=\"color: #000099;\">Presentation to BIO-CEO Obesity Session, New York, 14th February 2006\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"New Advances in Obesity Drugs\"\r\n<a href=\"../../files/6BJI9VQE91/BIO_CEO_OBESITY%20SESSION_NY_FEB2006.pdf\" target=\"_blank\">Click here to download report (142kb)</a>\r\n\r\n8th February 2006\r\n<span style=\"color: #000099;\">Investor Roadshow Presentation, 8th February 2006 </span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"../../files/3ZEBQVN35T/InvestorRoadshowPresentation_8Feb2006.pdf\" target=\"_blank\">Click here to download report (183kb)</a>\r\n\r\n4th November 2005\r\n<span style=\"color: #000099;\">CEO Presentation at Rodman and Renshaw Conference New York, 7 November 2005 </span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"../../files/61AFYHW5H4/CEOPresentationRodmanRenshaw_7Nov2005.pdf\" target=\"_blank\">Click here to download report (202kb)</a>\r\n\r\n<a href=\"http://wsw.com/webcast/rrshq7/metabolic/\" target=\"_blank\">http://wsw.com/webcast/rrshq7/metabolic/</a>\r\nClick link above for Live webcast Tuesday 8 November 2005 10am aest\r\n\r\n28th October 2005\r\n<span style=\"color: #000099;\">CEO Presentation at AGM October 2005 </span>\r\n<em>Roland Scollay PhD, CEO </em>\r\n<a href=\"../../files/DEBYNKZPC0/AGMPresentation_28Oct2005.pdf\" target=\"_blank\">Click here to download report (168kb)</a>\r\n\r\n19th October 2005\r\n<span style=\"color: #000099;\">BBY/Jeffries Health Care and Life Sciences Conference</span>\r\n<em>Roland Scollay PhD, CEO\r\n</em><a href=\"../../files/CWRZFNLAHY/BBY_Jeffries_Conference_Sydney19Oct05.pdf\" target=\"_blank\">Click here to download report (1mb)</a>\r\n\r\n18th October 2005\r\n<span style=\"color: #000099;\">NAASO 2005 Annual Scientific Meeting</span>\r\n<em>Caroline Herd PhD </em>\r\n\"The Effect of AOD9604 on Weight Loss in Obese Adults\"\r\n<a href=\"../../files/FXP0ZBOTGC/NAASO_2005presentation.pdf\" target=\"_blank\">Click here to download report (371kb)</a>\r\n\r\n10th October 2005\r\n<span style=\"color: #000099;\">Wilson HTM Biotechnology Conference</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em>\"Products to Profits\"\r\n<a href=\"../../files/9334N827JA/WilsonHTMConference_RS_10Oct2005.pdf\" target=\"_blank\">Click here to download report (96kb)</a>\r\n\r\n7th September 2005\r\n<span style=\"color: #000099;\">Southern Cross Equities Biotechnology conference\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"DNA, Devices and Dealers\"\r\n<a href=\"../../files/WXI1A0PJ0L/SouthernCrossEquitiesRS_7Sept2005.pdf\" target=\"_blank\">Click here to download report (3.63mb)</a>\r\n\r\n2nd September 2005\r\n<span style=\"color: #000099;\">Venom to Drugs 2005, Conference, Heron Island</span>\r\n<em>Daniel McIntosh </em>\r\n<a href=\"../../files/RJ1EARA7L0/ACV1_PosterVenomstoDrugs_Sept2005.pdf\" target=\"_blank\">Click here to download report (123kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">US Presentations June 2005</span>\r\n<em>Roland Scollay PhD CEO\r\n</em><a href=\"../../files/RPYEAX67IF/USPresentations_June%202005.pdf\" target=\"_blank\">Click here to download report (264kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Boston Bio-Relationships 2005\r\n</span><em>Roland Scollay PhD CEO\r\n</em>Presentation 1: Corporate Presentation\r\n<a href=\"../../files/NHGJWYDSBH/BostonBio2005CorporatePresentation_June2005.pdf\" target=\"_blank\">Click to download report (132kb)</a>\r\n\r\nPresentation 2: Diabetes Session Presentation\r\n<a href=\"../../files/D92OHAGKYK/BostonBio2005DiabetesSession_June2005.pdf\" target=\"_blank\">Click to download report (127kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">American Diabetes Association 65th Scientific Sessions San Diego</span>\r\n<em>Prof. Gary Wittert </em>\r\nAOD9604, an Orally Active Peptide for the Treatment of Obesity: Results of a Phase 2b Study\r\n<a href=\"../../files/ISW4JYRJF0/ADAposter_June2005.pdf\" target=\"_blank\">Click here to download report (106kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Share Placement Corporate Presentation June 2005</span>\r\n<em>Roland Scollay PhD CEO</em>\r\n<a href=\"../../files/LR5QIIJTN3/MBPCorporatePresentation_June%202005.pdf\" target=\"_blank\">Click here to download Presentation (1.78mb)</a>\r\n\r\n2nd May 2005\r\n<span style=\"color: #000099;\">TIDES 2005 Conference Presentation, Boston</span>\r\n<em>Dr Andrea McCracken\r\n</em>Development of the Conopeptide ACV1 for the Treatment of Neuropathic Pain\r\n<a href=\"../../files/6MSAE99WO4/TIDES%20ACV1_2ndMay2005.pdf\" target=\"_blank\">Click here to download the Presentation (4.65mb)</a>\r\n\r\n3rd May 2004\r\n<span style=\"color: #000099;\">TIDES 2004 Conference Presentation, Las Vegas </span>\r\n<em>Dr Caroline Herd\r\n</em>AOD9604 - An Orally Active Peptide for the Treatment of Obesity\r\n<a href=\"../../files/ZWYPDH2VK4/TIDES%202004%20Conference.pdf\" target=\"_blank\">Click to download Presentation (2.33mb)</a>\r\n\r\n17th February 2003\r\n<span style=\"color: #000099;\">Conference Presentation\r\n</span><em>Mark Heffernan</em>\r\nPresentation at the Obesity and Metabolic disorders conference, London\r\n<a href=\"../../files/KLI223405C/HeffernanUK.pdf\" target=\"_blank\">Click to download Presentation (396kb)</a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<em>Please Note:\r\nThese files are provided in Adobe PDF format, requiring the Adobe PDF Reader application to view them. This application is available to download from <span style=\"text-decoration: underline;\"><strong><a href=\"http://www.adobe.com/\" target=\"_blank\">http://www.adobe.com</a></strong></span></em>\r\n\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"15\" border=\"0\" />',	'Presentations',	'',	'inherit',	'open',	'open',	'',	'133-revision-4',	'',	'',	'2012-06-18 05:22:46',	'2012-06-18 05:22:46',	'',	133,	'http://calzada-wp.urldock.com/133-revision-4/',	0,	'revision',	'',	0),
(204,	1,	'2012-06-18 05:26:32',	'2012-06-18 05:26:32',	'<h2 class=\"feSubHeading\">Presentations</h2>\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" />\r\n\r\n15th April 2011\r\n<span style=\"color: #000099;\">AGM Presentation 2010</span>\r\n<a href=\"/wp-content/uploads/2012/06/914346.pdf\" target=\"_blank\">Click here to download presentation (1.7mb)</a>\r\n\r\n18th July 2008\r\n<span style=\"color: #000099;\">Corporate Presentation: Metabolic\'s acquisition of PolyNovo\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman of Metabolic </em>and <em>Ian Griffiths, CEO of PolyNovo\r\n</em><a href=\"/wp-content/uploads/2012/06/0823-ASX-Announcement-Corporate-Presentation-Acquisition-of-PolyNovo-18-July-2008_001.pdf\">Click here to download presentation (495 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman </em>and <em>Roland Scollay, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation.pdf\" target=\"_blank\">Click here to download presentation (432 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman</em> and <em>Roland Scollay, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/32241/wmp/poxf1u5rb8\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n20th September 2007\r\n<span style=\"color: #000099;\">Update on Oral Peptide Delivery Platform\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/UpdateOralPeptideDeliveryPlatform_20Sept2007.pdf\" target=\"_blank\">Click here to download presentation ( 347 kb)</a></span>\r\n\r\n9th May 2007\r\n<span style=\"color: #003399;\">Corporate Update - May 2007</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"../../files/89KVZHJ8BI/Metabolic%20Corporate%20Presentation.pdf\" target=\"_blank\">Click here to download presentation (577kb)</a>\r\n\r\n24th January 2007\r\n<span style=\"color: #000099;\">Corporate Update - January 2007\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"../../files/E5LPNYTC6D/CurrentCorporatePresentation_January2007.pdf\" target=\"_blank\">Click here to download presentation (518kb)</a></span>\r\n\r\n27th November 2006\r\n<span style=\"color: #000099;\">Metabolic Domestic Roadshow - November 2006\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"../../files/WC0C0Z7IEB/MetabolicDomesticRoadshow_November2006.pdf\" target=\"_blank\">Click here to download presentation (266kb)</a>\r\n\r\n30th October 2006\r\n<span style=\"color: #0000cc;\">2006 AGM:  CEO\'s presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/16722/wmp/siqi3bsv8o\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n27th October 2006\r\n<span style=\"color: #000099;\">2006 AGM: CEO\'s presentation</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"../../files/E75PIOMUTZ/AGMCEOPresentation_27October2006.pdf\" target=\"_blank\">Click here to download presentation (507kb) </a>\r\n\r\n12 October 2006\r\n<span style=\"color: #000099;\">Asia Pacific Life Sciences Forum (London) 12 Ocotber 2006\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em></span><span style=\"color: #000000;\"><a href=\"../../files/EXVWZ830LV/IntersuissePresentation_October2006.pdf\" target=\"_blank\">Click here to download presentation (425kb)</a></span>\r\n\r\n28th September 2006\r\n<span style=\"color: #000099;\">UBS Global Life Sciences Conference\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<span style=\"color: #000099;\"><a href=\"../../files/OSBFMF1LLH/UBSPresentation28Sept2006.ppt\">Click here to download presentation (4.82mb)</a></span>\r\n\r\n3rd July 2006\r\n<span style=\"color: #000099;\">Investor Roadshow (UK &amp; Europe) presentation - company update - July 2006</span>\r\n<span style=\"color: #000099;\"><em><span style=\"color: #000000;\">Roland Scollay, PhD, CEO</span>\r\n</em><a href=\"../../files/RIA90SL67O/UKRoadshowPresentation_July2006.pdf\" target=\"_blank\">Click here to download report (301kb)</a></span>\r\n\r\n14th June 2006\r\n<span style=\"color: #000099;\">Presentation at the Pacific Growth Equities\' <em>2006 Life Sciences Growth Conferences </em>(USA)</span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"../../files/C7UOJV7LYC/PacificGrowthEquities_USA%20conference.pdf\" target=\"_blank\">Click here to download presentation (313kb)</a>\r\n\r\n23rd May 2006\r\n<span style=\"color: #000099;\">Roadshow presentation - company update - May 2006\r\n</span><span style=\"color: #000099;\"><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO</em> </span>\r\n</span><a href=\"../../files/CFEG1WM0SM/ASX_May23RoadshowPresentation.pdf\" target=\"_blank\">Click here to download report (323kb)</a>\r\n\r\n5th April 2006\r\n<span style=\"color: #000099;\">Presentation at US biotech conferences, 5th - 7th April 2006</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em><a href=\"../../files/SFL9G67Y1N/CEOUSbiotechpresentation_5April2006.pdf\" target=\"_blank\">Click here to download report (211kb)</a>\r\n\r\n14th February 2006\r\n<span style=\"color: #000099;\">Presentation to BIO-CEO Obesity Session, New York, 14th February 2006\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"New Advances in Obesity Drugs\"\r\n<a href=\"../../files/6BJI9VQE91/BIO_CEO_OBESITY%20SESSION_NY_FEB2006.pdf\" target=\"_blank\">Click here to download report (142kb)</a>\r\n\r\n8th February 2006\r\n<span style=\"color: #000099;\">Investor Roadshow Presentation, 8th February 2006 </span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"../../files/3ZEBQVN35T/InvestorRoadshowPresentation_8Feb2006.pdf\" target=\"_blank\">Click here to download report (183kb)</a>\r\n\r\n4th November 2005\r\n<span style=\"color: #000099;\">CEO Presentation at Rodman and Renshaw Conference New York, 7 November 2005 </span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"../../files/61AFYHW5H4/CEOPresentationRodmanRenshaw_7Nov2005.pdf\" target=\"_blank\">Click here to download report (202kb)</a>\r\n\r\n<a href=\"http://wsw.com/webcast/rrshq7/metabolic/\" target=\"_blank\">http://wsw.com/webcast/rrshq7/metabolic/</a>\r\nClick link above for Live webcast Tuesday 8 November 2005 10am aest\r\n\r\n28th October 2005\r\n<span style=\"color: #000099;\">CEO Presentation at AGM October 2005 </span>\r\n<em>Roland Scollay PhD, CEO </em>\r\n<a href=\"../../files/DEBYNKZPC0/AGMPresentation_28Oct2005.pdf\" target=\"_blank\">Click here to download report (168kb)</a>\r\n\r\n19th October 2005\r\n<span style=\"color: #000099;\">BBY/Jeffries Health Care and Life Sciences Conference</span>\r\n<em>Roland Scollay PhD, CEO\r\n</em><a href=\"../../files/CWRZFNLAHY/BBY_Jeffries_Conference_Sydney19Oct05.pdf\" target=\"_blank\">Click here to download report (1mb)</a>\r\n\r\n18th October 2005\r\n<span style=\"color: #000099;\">NAASO 2005 Annual Scientific Meeting</span>\r\n<em>Caroline Herd PhD </em>\r\n\"The Effect of AOD9604 on Weight Loss in Obese Adults\"\r\n<a href=\"../../files/FXP0ZBOTGC/NAASO_2005presentation.pdf\" target=\"_blank\">Click here to download report (371kb)</a>\r\n\r\n10th October 2005\r\n<span style=\"color: #000099;\">Wilson HTM Biotechnology Conference</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em>\"Products to Profits\"\r\n<a href=\"../../files/9334N827JA/WilsonHTMConference_RS_10Oct2005.pdf\" target=\"_blank\">Click here to download report (96kb)</a>\r\n\r\n7th September 2005\r\n<span style=\"color: #000099;\">Southern Cross Equities Biotechnology conference\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"DNA, Devices and Dealers\"\r\n<a href=\"../../files/WXI1A0PJ0L/SouthernCrossEquitiesRS_7Sept2005.pdf\" target=\"_blank\">Click here to download report (3.63mb)</a>\r\n\r\n2nd September 2005\r\n<span style=\"color: #000099;\">Venom to Drugs 2005, Conference, Heron Island</span>\r\n<em>Daniel McIntosh </em>\r\n<a href=\"../../files/RJ1EARA7L0/ACV1_PosterVenomstoDrugs_Sept2005.pdf\" target=\"_blank\">Click here to download report (123kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">US Presentations June 2005</span>\r\n<em>Roland Scollay PhD CEO\r\n</em><a href=\"../../files/RPYEAX67IF/USPresentations_June%202005.pdf\" target=\"_blank\">Click here to download report (264kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Boston Bio-Relationships 2005\r\n</span><em>Roland Scollay PhD CEO\r\n</em>Presentation 1: Corporate Presentation\r\n<a href=\"../../files/NHGJWYDSBH/BostonBio2005CorporatePresentation_June2005.pdf\" target=\"_blank\">Click to download report (132kb)</a>\r\n\r\nPresentation 2: Diabetes Session Presentation\r\n<a href=\"../../files/D92OHAGKYK/BostonBio2005DiabetesSession_June2005.pdf\" target=\"_blank\">Click to download report (127kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">American Diabetes Association 65th Scientific Sessions San Diego</span>\r\n<em>Prof. Gary Wittert </em>\r\nAOD9604, an Orally Active Peptide for the Treatment of Obesity: Results of a Phase 2b Study\r\n<a href=\"../../files/ISW4JYRJF0/ADAposter_June2005.pdf\" target=\"_blank\">Click here to download report (106kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Share Placement Corporate Presentation June 2005</span>\r\n<em>Roland Scollay PhD CEO</em>\r\n<a href=\"../../files/LR5QIIJTN3/MBPCorporatePresentation_June%202005.pdf\" target=\"_blank\">Click here to download Presentation (1.78mb)</a>\r\n\r\n2nd May 2005\r\n<span style=\"color: #000099;\">TIDES 2005 Conference Presentation, Boston</span>\r\n<em>Dr Andrea McCracken\r\n</em>Development of the Conopeptide ACV1 for the Treatment of Neuropathic Pain\r\n<a href=\"../../files/6MSAE99WO4/TIDES%20ACV1_2ndMay2005.pdf\" target=\"_blank\">Click here to download the Presentation (4.65mb)</a>\r\n\r\n3rd May 2004\r\n<span style=\"color: #000099;\">TIDES 2004 Conference Presentation, Las Vegas </span>\r\n<em>Dr Caroline Herd\r\n</em>AOD9604 - An Orally Active Peptide for the Treatment of Obesity\r\n<a href=\"../../files/ZWYPDH2VK4/TIDES%202004%20Conference.pdf\" target=\"_blank\">Click to download Presentation (2.33mb)</a>\r\n\r\n17th February 2003\r\n<span style=\"color: #000099;\">Conference Presentation\r\n</span><em>Mark Heffernan</em>\r\nPresentation at the Obesity and Metabolic disorders conference, London\r\n<a href=\"../../files/KLI223405C/HeffernanUK.pdf\" target=\"_blank\">Click to download Presentation (396kb)</a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<em>Please Note:\r\nThese files are provided in Adobe PDF format, requiring the Adobe PDF Reader application to view them. This application is available to download from <span style=\"text-decoration: underline;\"><strong><a href=\"http://www.adobe.com/\" target=\"_blank\">http://www.adobe.com</a></strong></span></em>\r\n\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"15\" border=\"0\" />',	'Presentations',	'',	'inherit',	'open',	'open',	'',	'133-revision-5',	'',	'',	'2012-06-18 05:26:32',	'2012-06-18 05:26:32',	'',	133,	'http://calzada-wp.urldock.com/133-revision-5/',	0,	'revision',	'',	0),
(205,	1,	'2012-06-18 05:31:00',	'2012-06-18 05:31:00',	'<h2 class=\"feSubHeading\">Presentations</h2>\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" />\r\n\r\n15th April 2011\r\n<span style=\"color: #000099;\">AGM Presentation 2010</span>\r\n<a href=\"/wp-content/uploads/2012/06/914346.pdf\" target=\"_blank\">Click here to download presentation (1.7mb)</a>\r\n\r\n18th July 2008\r\n<span style=\"color: #000099;\">Corporate Presentation: Metabolic\'s acquisition of PolyNovo\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman of Metabolic </em>and <em>Ian Griffiths, CEO of PolyNovo\r\n</em><a href=\"/wp-content/uploads/2012/06/0823-ASX-Announcement-Corporate-Presentation-Acquisition-of-PolyNovo-18-July-2008_001.pdf\">Click here to download presentation (495 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman </em>and <em>Roland Scollay, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation.pdf\" target=\"_blank\">Click here to download presentation (432 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman</em> and <em>Roland Scollay, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/32241/wmp/poxf1u5rb8\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n20th September 2007\r\n<span style=\"color: #000099;\">Update on Oral Peptide Delivery Platform\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/UpdateOralPeptideDeliveryPlatform_20Sept2007.pdf\" target=\"_blank\">Click here to download presentation ( 347 kb)</a></span>\r\n\r\n9th May 2007\r\n<span style=\"color: #003399;\">Corporate Update - May 2007</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic%20Corporate%20Presentation.pdf\" target=\"_blank\">Click here to download presentation (577kb)</a>\r\n\r\n24th January 2007\r\n<span style=\"color: #000099;\">Corporate Update - January 2007\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CurrentCorporatePresentation_January2007.pdf\" target=\"_blank\">Click here to download presentation (518kb)</a></span>\r\n\r\n27th November 2006\r\n<span style=\"color: #000099;\">Metabolic Domestic Roadshow - November 2006\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MetabolicDomesticRoadshow_November2006.pdf\" target=\"_blank\">Click here to download presentation (266kb)</a>\r\n\r\n30th October 2006\r\n<span style=\"color: #0000cc;\">2006 AGM:  CEO\'s presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/16722/wmp/siqi3bsv8o\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n27th October 2006\r\n<span style=\"color: #000099;\">2006 AGM: CEO\'s presentation</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMCEOPresentation_27October2006.pdf\" target=\"_blank\">Click here to download presentation (507kb) </a>\r\n\r\n12 October 2006\r\n<span style=\"color: #000099;\">Asia Pacific Life Sciences Forum (London) 12 Ocotber 2006\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em></span><span style=\"color: #000000;\"><a href=\"/wp-content/uploads/2012/06/IntersuissePresentation_October2006.pdf\" target=\"_blank\">Click here to download presentation (425kb)</a></span>\r\n\r\n28th September 2006\r\n<span style=\"color: #000099;\">UBS Global Life Sciences Conference\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<span style=\"color: #000099;\"><a href=\"/wp-content/uploads/2012/06/UBSPresentation28Sept2006.ppt\">Click here to download presentation (4.82mb)</a></span>\r\n\r\n3rd July 2006\r\n<span style=\"color: #000099;\">Investor Roadshow (UK &amp; Europe) presentation - company update - July 2006</span>\r\n<span style=\"color: #000099;\"><em><span style=\"color: #000000;\">Roland Scollay, PhD, CEO</span>\r\n</em><a href=\"/wp-content/uploads/2012/06/UKRoadshowPresentation_July2006.pdf\" target=\"_blank\">Click here to download report (301kb)</a></span>\r\n\r\n14th June 2006\r\n<span style=\"color: #000099;\">Presentation at the Pacific Growth Equities\' <em>2006 Life Sciences Growth Conferences </em>(USA)</span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/PacificGrowthEquities_USA%20conference.pdf\" target=\"_blank\">Click here to download presentation (313kb)</a>\r\n\r\n23rd May 2006\r\n<span style=\"color: #000099;\">Roadshow presentation - company update - May 2006\r\n</span><span style=\"color: #000099;\"><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO</em> </span>\r\n</span><a href=\"/wp-content/uploads/2012/06/ASX_May23RoadshowPresentation.pdf\" target=\"_blank\">Click here to download report (323kb)</a>\r\n\r\n5th April 2006\r\n<span style=\"color: #000099;\">Presentation at US biotech conferences, 5th - 7th April 2006</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CEOUSbiotechpresentation_5April2006.pdf\" target=\"_blank\">Click here to download report (211kb)</a>\r\n\r\n14th February 2006\r\n<span style=\"color: #000099;\">Presentation to BIO-CEO Obesity Session, New York, 14th February 2006\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"New Advances in Obesity Drugs\"\r\n<a href=\"/wp-content/uploads/2012/06/BIO_CEO_OBESITY%20SESSION_NY_FEB2006.pdf\" target=\"_blank\">Click here to download report (142kb)</a>\r\n\r\n8th February 2006\r\n<span style=\"color: #000099;\">Investor Roadshow Presentation, 8th February 2006 </span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/InvestorRoadshowPresentation_8Feb2006.pdf\" target=\"_blank\">Click here to download report (183kb)</a>\r\n\r\n4th November 2005\r\n<span style=\"color: #000099;\">CEO Presentation at Rodman and Renshaw Conference New York, 7 November 2005 </span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/CEOPresentationRodmanRenshaw_7Nov2005.pdf\" target=\"_blank\">Click here to download report (202kb)</a>\r\n\r\n<a href=\"http://wsw.com/webcast/rrshq7/metabolic/\" target=\"_blank\">http://wsw.com/webcast/rrshq7/metabolic/</a>\r\nClick link above for Live webcast Tuesday 8 November 2005 10am aest\r\n\r\n28th October 2005\r\n<span style=\"color: #000099;\">CEO Presentation at AGM October 2005 </span>\r\n<em>Roland Scollay PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMPresentation_28Oct2005.pdf\" target=\"_blank\">Click here to download report (168kb)</a>\r\n\r\n19th October 2005\r\n<span style=\"color: #000099;\">BBY/Jeffries Health Care and Life Sciences Conference</span>\r\n<em>Roland Scollay PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/BBY_Jeffries_Conference_Sydney19Oct05.pdf\" target=\"_blank\">Click here to download report (1mb)</a>\r\n\r\n18th October 2005\r\n<span style=\"color: #000099;\">NAASO 2005 Annual Scientific Meeting</span>\r\n<em>Caroline Herd PhD </em>\r\n\"The Effect of AOD9604 on Weight Loss in Obese Adults\"\r\n<a href=\"/wp-content/uploads/2012/06/NAASO_2005presentation.pdf\" target=\"_blank\">Click here to download report (371kb)</a>\r\n\r\n10th October 2005\r\n<span style=\"color: #000099;\">Wilson HTM Biotechnology Conference</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em>\"Products to Profits\"\r\n<a href=\"/wp-content/uploads/2012/06/WilsonHTMConference_RS_10Oct2005.pdf\" target=\"_blank\">Click here to download report (96kb)</a>\r\n\r\n7th September 2005\r\n<span style=\"color: #000099;\">Southern Cross Equities Biotechnology conference\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"DNA, Devices and Dealers\"\r\n<a href=\"/wp-content/uploads/2012/06/SouthernCrossEquitiesRS_7Sept2005.pdf\" target=\"_blank\">Click here to download report (3.63mb)</a>\r\n\r\n2nd September 2005\r\n<span style=\"color: #000099;\">Venom to Drugs 2005, Conference, Heron Island</span>\r\n<em>Daniel McIntosh </em>\r\n<a href=\"/wp-content/uploads/2012/06/ACV1_PosterVenomstoDrugs_Sept2005.pdf\" target=\"_blank\">Click here to download report (123kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">US Presentations June 2005</span>\r\n<em>Roland Scollay PhD CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/USPresentations_June%202005.pdf\" target=\"_blank\">Click here to download report (264kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Boston Bio-Relationships 2005\r\n</span><em>Roland Scollay PhD CEO\r\n</em>Presentation 1: Corporate Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005CorporatePresentation_June2005.pdf\" target=\"_blank\">Click to download report (132kb)</a>\r\n\r\nPresentation 2: Diabetes Session Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005DiabetesSession_June2005.pdf\" target=\"_blank\">Click to download report (127kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">American Diabetes Association 65th Scientific Sessions San Diego</span>\r\n<em>Prof. Gary Wittert </em>\r\nAOD9604, an Orally Active Peptide for the Treatment of Obesity: Results of a Phase 2b Study\r\n<a href=\"/wp-content/uploads/2012/06/ISW4JYRJF0/ADAposter_June2005.pdf\" target=\"_blank\">Click here to download report (106kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Share Placement Corporate Presentation June 2005</span>\r\n<em>Roland Scollay PhD CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MBPCorporatePresentation_June%202005.pdf\" target=\"_blank\">Click here to download Presentation (1.78mb)</a>\r\n\r\n2nd May 2005\r\n<span style=\"color: #000099;\">TIDES 2005 Conference Presentation, Boston</span>\r\n<em>Dr Andrea McCracken\r\n</em>Development of the Conopeptide ACV1 for the Treatment of Neuropathic Pain\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%20ACV1_2ndMay2005.pdf\" target=\"_blank\">Click here to download the Presentation (4.65mb)</a>\r\n\r\n3rd May 2004\r\n<span style=\"color: #000099;\">TIDES 2004 Conference Presentation, Las Vegas </span>\r\n<em>Dr Caroline Herd\r\n</em>AOD9604 - An Orally Active Peptide for the Treatment of Obesity\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%202004%20Conference.pdf\" target=\"_blank\">Click to download Presentation (2.33mb)</a>\r\n\r\n17th February 2003\r\n<span style=\"color: #000099;\">Conference Presentation\r\n</span><em>Mark Heffernan</em>\r\nPresentation at the Obesity and Metabolic disorders conference, London\r\n<a href=\"/wp-content/uploads/2012/06/HeffernanUK.pdf\" target=\"_blank\">Click to download Presentation (396kb)</a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<em>Please Note:\r\nThese files are provided in Adobe PDF format, requiring the Adobe PDF Reader application to view them. This application is available to download from <span style=\"text-decoration: underline;\"><strong><a href=\"http://www.adobe.com/\" target=\"_blank\">http://www.adobe.com</a></strong></span></em>\r\n\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"15\" border=\"0\" />',	'Presentations',	'',	'inherit',	'open',	'open',	'',	'133-revision-6',	'',	'',	'2012-06-18 05:31:00',	'2012-06-18 05:31:00',	'',	133,	'http://calzada-wp.urldock.com/133-revision-6/',	0,	'revision',	'',	0),
(206,	1,	'2012-06-18 05:32:40',	'2012-06-18 05:32:40',	'<h2 class=\"feSubHeading\">Presentations</h2>\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" />\r\n\r\n15th April 2011\r\n<span style=\"color: #000099;\">AGM Presentation 2010</span>\r\n<a href=\"/wp-content/uploads/2012/06/914346.pdf\" target=\"_blank\">Click here to download presentation (1.7mb)</a>\r\n\r\n18th July 2008\r\n<span style=\"color: #000099;\">Corporate Presentation: Metabolic\'s acquisition of PolyNovo\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman of Metabolic </em>and <em>Ian Griffiths, CEO of PolyNovo\r\n</em><a href=\"/wp-content/uploads/2012/06/0823-ASX-Announcement-Corporate-Presentation-Acquisition-of-PolyNovo-18-July-2008_001.pdf\">Click here to download presentation (495 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman </em>and <em>Roland Scollay, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation.pdf\" target=\"_blank\">Click here to download presentation (432 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman</em> and <em>Roland Scollay, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/32241/wmp/poxf1u5rb8\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n20th September 2007\r\n<span style=\"color: #000099;\">Update on Oral Peptide Delivery Platform\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/UpdateOralPeptideDeliveryPlatform_20Sept2007.pdf\" target=\"_blank\">Click here to download presentation ( 347 kb)</a></span>\r\n\r\n9th May 2007\r\n<span style=\"color: #003399;\">Corporate Update - May 2007</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic-Corporate-Presentation.pdf\" target=\"_blank\">Click here to download presentation (577kb)</a>\r\n\r\n24th January 2007\r\n<span style=\"color: #000099;\">Corporate Update - January 2007\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CurrentCorporatePresentation_January2007.pdf\" target=\"_blank\">Click here to download presentation (518kb)</a></span>\r\n\r\n27th November 2006\r\n<span style=\"color: #000099;\">Metabolic Domestic Roadshow - November 2006\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MetabolicDomesticRoadshow_November2006.pdf\" target=\"_blank\">Click here to download presentation (266kb)</a>\r\n\r\n30th October 2006\r\n<span style=\"color: #0000cc;\">2006 AGM:  CEO\'s presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/16722/wmp/siqi3bsv8o\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n27th October 2006\r\n<span style=\"color: #000099;\">2006 AGM: CEO\'s presentation</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMCEOPresentation_27October2006.pdf\" target=\"_blank\">Click here to download presentation (507kb) </a>\r\n\r\n12 October 2006\r\n<span style=\"color: #000099;\">Asia Pacific Life Sciences Forum (London) 12 Ocotber 2006\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em></span><span style=\"color: #000000;\"><a href=\"/wp-content/uploads/2012/06/IntersuissePresentation_October2006.pdf\" target=\"_blank\">Click here to download presentation (425kb)</a></span>\r\n\r\n28th September 2006\r\n<span style=\"color: #000099;\">UBS Global Life Sciences Conference\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<span style=\"color: #000099;\"><a href=\"/wp-content/uploads/2012/06/UBSPresentation28Sept2006.ppt\">Click here to download presentation (4.82mb)</a></span>\r\n\r\n3rd July 2006\r\n<span style=\"color: #000099;\">Investor Roadshow (UK &amp; Europe) presentation - company update - July 2006</span>\r\n<span style=\"color: #000099;\"><em><span style=\"color: #000000;\">Roland Scollay, PhD, CEO</span>\r\n</em><a href=\"/wp-content/uploads/2012/06/UKRoadshowPresentation_July2006.pdf\" target=\"_blank\">Click here to download report (301kb)</a></span>\r\n\r\n14th June 2006\r\n<span style=\"color: #000099;\">Presentation at the Pacific Growth Equities\' <em>2006 Life Sciences Growth Conferences </em>(USA)</span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/PacificGrowthEquities_USA%20conference.pdf\" target=\"_blank\">Click here to download presentation (313kb)</a>\r\n\r\n23rd May 2006\r\n<span style=\"color: #000099;\">Roadshow presentation - company update - May 2006\r\n</span><span style=\"color: #000099;\"><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO</em> </span>\r\n</span><a href=\"/wp-content/uploads/2012/06/ASX_May23RoadshowPresentation.pdf\" target=\"_blank\">Click here to download report (323kb)</a>\r\n\r\n5th April 2006\r\n<span style=\"color: #000099;\">Presentation at US biotech conferences, 5th - 7th April 2006</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CEOUSbiotechpresentation_5April2006.pdf\" target=\"_blank\">Click here to download report (211kb)</a>\r\n\r\n14th February 2006\r\n<span style=\"color: #000099;\">Presentation to BIO-CEO Obesity Session, New York, 14th February 2006\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"New Advances in Obesity Drugs\"\r\n<a href=\"/wp-content/uploads/2012/06/BIO_CEO_OBESITY%20SESSION_NY_FEB2006.pdf\" target=\"_blank\">Click here to download report (142kb)</a>\r\n\r\n8th February 2006\r\n<span style=\"color: #000099;\">Investor Roadshow Presentation, 8th February 2006 </span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/InvestorRoadshowPresentation_8Feb2006.pdf\" target=\"_blank\">Click here to download report (183kb)</a>\r\n\r\n4th November 2005\r\n<span style=\"color: #000099;\">CEO Presentation at Rodman and Renshaw Conference New York, 7 November 2005 </span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/CEOPresentationRodmanRenshaw_7Nov2005.pdf\" target=\"_blank\">Click here to download report (202kb)</a>\r\n\r\n<a href=\"http://wsw.com/webcast/rrshq7/metabolic/\" target=\"_blank\">http://wsw.com/webcast/rrshq7/metabolic/</a>\r\nClick link above for Live webcast Tuesday 8 November 2005 10am aest\r\n\r\n28th October 2005\r\n<span style=\"color: #000099;\">CEO Presentation at AGM October 2005 </span>\r\n<em>Roland Scollay PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMPresentation_28Oct2005.pdf\" target=\"_blank\">Click here to download report (168kb)</a>\r\n\r\n19th October 2005\r\n<span style=\"color: #000099;\">BBY/Jeffries Health Care and Life Sciences Conference</span>\r\n<em>Roland Scollay PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/BBY_Jeffries_Conference_Sydney19Oct05.pdf\" target=\"_blank\">Click here to download report (1mb)</a>\r\n\r\n18th October 2005\r\n<span style=\"color: #000099;\">NAASO 2005 Annual Scientific Meeting</span>\r\n<em>Caroline Herd PhD </em>\r\n\"The Effect of AOD9604 on Weight Loss in Obese Adults\"\r\n<a href=\"/wp-content/uploads/2012/06/NAASO_2005presentation.pdf\" target=\"_blank\">Click here to download report (371kb)</a>\r\n\r\n10th October 2005\r\n<span style=\"color: #000099;\">Wilson HTM Biotechnology Conference</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em>\"Products to Profits\"\r\n<a href=\"/wp-content/uploads/2012/06/WilsonHTMConference_RS_10Oct2005.pdf\" target=\"_blank\">Click here to download report (96kb)</a>\r\n\r\n7th September 2005\r\n<span style=\"color: #000099;\">Southern Cross Equities Biotechnology conference\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"DNA, Devices and Dealers\"\r\n<a href=\"/wp-content/uploads/2012/06/SouthernCrossEquitiesRS_7Sept2005.pdf\" target=\"_blank\">Click here to download report (3.63mb)</a>\r\n\r\n2nd September 2005\r\n<span style=\"color: #000099;\">Venom to Drugs 2005, Conference, Heron Island</span>\r\n<em>Daniel McIntosh </em>\r\n<a href=\"/wp-content/uploads/2012/06/ACV1_PosterVenomstoDrugs_Sept2005.pdf\" target=\"_blank\">Click here to download report (123kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">US Presentations June 2005</span>\r\n<em>Roland Scollay PhD CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/USPresentations_June%202005.pdf\" target=\"_blank\">Click here to download report (264kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Boston Bio-Relationships 2005\r\n</span><em>Roland Scollay PhD CEO\r\n</em>Presentation 1: Corporate Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005CorporatePresentation_June2005.pdf\" target=\"_blank\">Click to download report (132kb)</a>\r\n\r\nPresentation 2: Diabetes Session Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005DiabetesSession_June2005.pdf\" target=\"_blank\">Click to download report (127kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">American Diabetes Association 65th Scientific Sessions San Diego</span>\r\n<em>Prof. Gary Wittert </em>\r\nAOD9604, an Orally Active Peptide for the Treatment of Obesity: Results of a Phase 2b Study\r\n<a href=\"/wp-content/uploads/2012/06/ISW4JYRJF0/ADAposter_June2005.pdf\" target=\"_blank\">Click here to download report (106kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Share Placement Corporate Presentation June 2005</span>\r\n<em>Roland Scollay PhD CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MBPCorporatePresentation_June%202005.pdf\" target=\"_blank\">Click here to download Presentation (1.78mb)</a>\r\n\r\n2nd May 2005\r\n<span style=\"color: #000099;\">TIDES 2005 Conference Presentation, Boston</span>\r\n<em>Dr Andrea McCracken\r\n</em>Development of the Conopeptide ACV1 for the Treatment of Neuropathic Pain\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%20ACV1_2ndMay2005.pdf\" target=\"_blank\">Click here to download the Presentation (4.65mb)</a>\r\n\r\n3rd May 2004\r\n<span style=\"color: #000099;\">TIDES 2004 Conference Presentation, Las Vegas </span>\r\n<em>Dr Caroline Herd\r\n</em>AOD9604 - An Orally Active Peptide for the Treatment of Obesity\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%202004%20Conference.pdf\" target=\"_blank\">Click to download Presentation (2.33mb)</a>\r\n\r\n17th February 2003\r\n<span style=\"color: #000099;\">Conference Presentation\r\n</span><em>Mark Heffernan</em>\r\nPresentation at the Obesity and Metabolic disorders conference, London\r\n<a href=\"/wp-content/uploads/2012/06/HeffernanUK.pdf\" target=\"_blank\">Click to download Presentation (396kb)</a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<em>Please Note:\r\nThese files are provided in Adobe PDF format, requiring the Adobe PDF Reader application to view them. This application is available to download from <span style=\"text-decoration: underline;\"><strong><a href=\"http://www.adobe.com/\" target=\"_blank\">http://www.adobe.com</a></strong></span></em>\r\n\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"15\" border=\"0\" />',	'Presentations',	'',	'inherit',	'open',	'open',	'',	'133-revision-7',	'',	'',	'2012-06-18 05:32:40',	'2012-06-18 05:32:40',	'',	133,	'http://calzada-wp.urldock.com/133-revision-7/',	0,	'revision',	'',	0),
(207,	1,	'2012-06-18 05:35:14',	'2012-06-18 05:35:14',	'<h2 class=\"feSubHeading\">Presentations</h2>\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" />\r\n\r\n15th April 2011\r\n<span style=\"color: #000099;\">AGM Presentation 2010</span>\r\n<a href=\"/wp-content/uploads/2012/06/914346.pdf\" target=\"_blank\">Click here to download presentation (1.7mb)</a>\r\n\r\n18th July 2008\r\n<span style=\"color: #000099;\">Corporate Presentation: Metabolic\'s acquisition of PolyNovo\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman of Metabolic </em>and <em>Ian Griffiths, CEO of PolyNovo\r\n</em><a href=\"/wp-content/uploads/2012/06/0823-ASX-Announcement-Corporate-Presentation-Acquisition-of-PolyNovo-18-July-2008_001.pdf\">Click here to download presentation (495 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman </em>and <em>Roland Scollay, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation.pdf\" target=\"_blank\">Click here to download presentation (432 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman</em> and <em>Roland Scollay, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/32241/wmp/poxf1u5rb8\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n20th September 2007\r\n<span style=\"color: #000099;\">Update on Oral Peptide Delivery Platform\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/UpdateOralPeptideDeliveryPlatform_20Sept2007.pdf\" target=\"_blank\">Click here to download presentation ( 347 kb)</a></span>\r\n\r\n9th May 2007\r\n<span style=\"color: #003399;\">Corporate Update - May 2007</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic-Corporate-Presentation.pdf\" target=\"_blank\">Click here to download presentation (577kb)</a>\r\n\r\n24th January 2007\r\n<span style=\"color: #000099;\">Corporate Update - January 2007\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CurrentCorporatePresentation_January2007.pdf\" target=\"_blank\">Click here to download presentation (518kb)</a></span>\r\n\r\n27th November 2006\r\n<span style=\"color: #000099;\">Metabolic Domestic Roadshow - November 2006\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MetabolicDomesticRoadshow_November2006.pdf\" target=\"_blank\">Click here to download presentation (266kb)</a>\r\n\r\n30th October 2006\r\n<span style=\"color: #0000cc;\">2006 AGM:  CEO\'s presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/16722/wmp/siqi3bsv8o\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n27th October 2006\r\n<span style=\"color: #000099;\">2006 AGM: CEO\'s presentation</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMCEOPresentation_27October2006.pdf\" target=\"_blank\">Click here to download presentation (507kb) </a>\r\n\r\n12 October 2006\r\n<span style=\"color: #000099;\">Asia Pacific Life Sciences Forum (London) 12 Ocotber 2006\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em></span><span style=\"color: #000000;\"><a href=\"/wp-content/uploads/2012/06/IntersuissePresentation_October2006.pdf\" target=\"_blank\">Click here to download presentation (425kb)</a></span>\r\n\r\n28th September 2006\r\n<span style=\"color: #000099;\">UBS Global Life Sciences Conference\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<span style=\"color: #000099;\"><a href=\"/wp-content/uploads/2012/06/UBSPresentation28Sept2006.ppt\">Click here to download presentation (4.82mb)</a></span>\r\n\r\n3rd July 2006\r\n<span style=\"color: #000099;\">Investor Roadshow (UK &amp; Europe) presentation - company update - July 2006</span>\r\n<span style=\"color: #000099;\"><em><span style=\"color: #000000;\">Roland Scollay, PhD, CEO</span>\r\n</em><a href=\"/wp-content/uploads/2012/06/UKRoadshowPresentation_July2006.pdf\" target=\"_blank\">Click here to download report (301kb)</a></span>\r\n\r\n14th June 2006\r\n<span style=\"color: #000099;\">Presentation at the Pacific Growth Equities\' <em>2006 Life Sciences Growth Conferences </em>(USA)</span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/PacificGrowthEquities_USA%20conference.pdf\" target=\"_blank\">Click here to download presentation (313kb)</a>\r\n\r\n23rd May 2006\r\n<span style=\"color: #000099;\">Roadshow presentation - company update - May 2006\r\n</span><span style=\"color: #000099;\"><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO</em> </span>\r\n</span><a href=\"/wp-content/uploads/2012/06/ASX_May23RoadshowPresentation.pdf\" target=\"_blank\">Click here to download report (323kb)</a>\r\n\r\n5th April 2006\r\n<span style=\"color: #000099;\">Presentation at US biotech conferences, 5th - 7th April 2006</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CEOUSbiotechpresentation_5April2006.pdf\" target=\"_blank\">Click here to download report (211kb)</a>\r\n\r\n14th February 2006\r\n<span style=\"color: #000099;\">Presentation to BIO-CEO Obesity Session, New York, 14th February 2006\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"New Advances in Obesity Drugs\"\r\n<a href=\"/wp-content/uploads/2012/06/BIO_CEO_OBESITY-SESSION_NY_FEB2006.pdf\" target=\"_blank\">Click here to download report (142kb)</a>\r\n\r\n8th February 2006\r\n<span style=\"color: #000099;\">Investor Roadshow Presentation, 8th February 2006 </span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/InvestorRoadshowPresentation_8Feb2006.pdf\" target=\"_blank\">Click here to download report (183kb)</a>\r\n\r\n4th November 2005\r\n<span style=\"color: #000099;\">CEO Presentation at Rodman and Renshaw Conference New York, 7 November 2005 </span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/CEOPresentationRodmanRenshaw_7Nov2005.pdf\" target=\"_blank\">Click here to download report (202kb)</a>\r\n\r\n<a href=\"http://wsw.com/webcast/rrshq7/metabolic/\" target=\"_blank\">http://wsw.com/webcast/rrshq7/metabolic/</a>\r\nClick link above for Live webcast Tuesday 8 November 2005 10am aest\r\n\r\n28th October 2005\r\n<span style=\"color: #000099;\">CEO Presentation at AGM October 2005 </span>\r\n<em>Roland Scollay PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMPresentation_28Oct2005.pdf\" target=\"_blank\">Click here to download report (168kb)</a>\r\n\r\n19th October 2005\r\n<span style=\"color: #000099;\">BBY/Jeffries Health Care and Life Sciences Conference</span>\r\n<em>Roland Scollay PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/BBY_Jeffries_Conference_Sydney19Oct05.pdf\" target=\"_blank\">Click here to download report (1mb)</a>\r\n\r\n18th October 2005\r\n<span style=\"color: #000099;\">NAASO 2005 Annual Scientific Meeting</span>\r\n<em>Caroline Herd PhD </em>\r\n\"The Effect of AOD9604 on Weight Loss in Obese Adults\"\r\n<a href=\"/wp-content/uploads/2012/06/NAASO_2005presentation.pdf\" target=\"_blank\">Click here to download report (371kb)</a>\r\n\r\n10th October 2005\r\n<span style=\"color: #000099;\">Wilson HTM Biotechnology Conference</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em>\"Products to Profits\"\r\n<a href=\"/wp-content/uploads/2012/06/WilsonHTMConference_RS_10Oct2005.pdf\" target=\"_blank\">Click here to download report (96kb)</a>\r\n\r\n7th September 2005\r\n<span style=\"color: #000099;\">Southern Cross Equities Biotechnology conference\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"DNA, Devices and Dealers\"\r\n<a href=\"/wp-content/uploads/2012/06/SouthernCrossEquitiesRS_7Sept2005.pdf\" target=\"_blank\">Click here to download report (3.63mb)</a>\r\n\r\n2nd September 2005\r\n<span style=\"color: #000099;\">Venom to Drugs 2005, Conference, Heron Island</span>\r\n<em>Daniel McIntosh </em>\r\n<a href=\"/wp-content/uploads/2012/06/ACV1_PosterVenomstoDrugs_Sept2005.pdf\" target=\"_blank\">Click here to download report (123kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">US Presentations June 2005</span>\r\n<em>Roland Scollay PhD CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/USPresentations_June%202005.pdf\" target=\"_blank\">Click here to download report (264kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Boston Bio-Relationships 2005\r\n</span><em>Roland Scollay PhD CEO\r\n</em>Presentation 1: Corporate Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005CorporatePresentation_June2005.pdf\" target=\"_blank\">Click to download report (132kb)</a>\r\n\r\nPresentation 2: Diabetes Session Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005DiabetesSession_June2005.pdf\" target=\"_blank\">Click to download report (127kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">American Diabetes Association 65th Scientific Sessions San Diego</span>\r\n<em>Prof. Gary Wittert </em>\r\nAOD9604, an Orally Active Peptide for the Treatment of Obesity: Results of a Phase 2b Study\r\n<a href=\"/wp-content/uploads/2012/06/ISW4JYRJF0/ADAposter_June2005.pdf\" target=\"_blank\">Click here to download report (106kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Share Placement Corporate Presentation June 2005</span>\r\n<em>Roland Scollay PhD CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MBPCorporatePresentation_June%202005.pdf\" target=\"_blank\">Click here to download Presentation (1.78mb)</a>\r\n\r\n2nd May 2005\r\n<span style=\"color: #000099;\">TIDES 2005 Conference Presentation, Boston</span>\r\n<em>Dr Andrea McCracken\r\n</em>Development of the Conopeptide ACV1 for the Treatment of Neuropathic Pain\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%20ACV1_2ndMay2005.pdf\" target=\"_blank\">Click here to download the Presentation (4.65mb)</a>\r\n\r\n3rd May 2004\r\n<span style=\"color: #000099;\">TIDES 2004 Conference Presentation, Las Vegas </span>\r\n<em>Dr Caroline Herd\r\n</em>AOD9604 - An Orally Active Peptide for the Treatment of Obesity\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%202004%20Conference.pdf\" target=\"_blank\">Click to download Presentation (2.33mb)</a>\r\n\r\n17th February 2003\r\n<span style=\"color: #000099;\">Conference Presentation\r\n</span><em>Mark Heffernan</em>\r\nPresentation at the Obesity and Metabolic disorders conference, London\r\n<a href=\"/wp-content/uploads/2012/06/HeffernanUK.pdf\" target=\"_blank\">Click to download Presentation (396kb)</a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<em>Please Note:\r\nThese files are provided in Adobe PDF format, requiring the Adobe PDF Reader application to view them. This application is available to download from <span style=\"text-decoration: underline;\"><strong><a href=\"http://www.adobe.com/\" target=\"_blank\">http://www.adobe.com</a></strong></span></em>\r\n\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"15\" border=\"0\" />',	'Presentations',	'',	'inherit',	'open',	'open',	'',	'133-revision-8',	'',	'',	'2012-06-18 05:35:14',	'2012-06-18 05:35:14',	'',	133,	'http://calzada-wp.urldock.com/133-revision-8/',	0,	'revision',	'',	0),
(208,	1,	'2012-06-18 05:36:51',	'2012-06-18 05:36:51',	'<h2 class=\"feSubHeading\">Presentations</h2>\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" />\r\n\r\n15th April 2011\r\n<span style=\"color: #000099;\">AGM Presentation 2010</span>\r\n<a href=\"/wp-content/uploads/2012/06/914346.pdf\" target=\"_blank\">Click here to download presentation (1.7mb)</a>\r\n\r\n18th July 2008\r\n<span style=\"color: #000099;\">Corporate Presentation: Metabolic\'s acquisition of PolyNovo\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman of Metabolic </em>and <em>Ian Griffiths, CEO of PolyNovo\r\n</em><a href=\"/wp-content/uploads/2012/06/0823-ASX-Announcement-Corporate-Presentation-Acquisition-of-PolyNovo-18-July-2008_001.pdf\">Click here to download presentation (495 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman </em>and <em>Roland Scollay, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation.pdf\" target=\"_blank\">Click here to download presentation (432 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman</em> and <em>Roland Scollay, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/32241/wmp/poxf1u5rb8\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n20th September 2007\r\n<span style=\"color: #000099;\">Update on Oral Peptide Delivery Platform\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/UpdateOralPeptideDeliveryPlatform_20Sept2007.pdf\" target=\"_blank\">Click here to download presentation ( 347 kb)</a></span>\r\n\r\n9th May 2007\r\n<span style=\"color: #003399;\">Corporate Update - May 2007</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic-Corporate-Presentation.pdf\" target=\"_blank\">Click here to download presentation (577kb)</a>\r\n\r\n24th January 2007\r\n<span style=\"color: #000099;\">Corporate Update - January 2007\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CurrentCorporatePresentation_January2007.pdf\" target=\"_blank\">Click here to download presentation (518kb)</a></span>\r\n\r\n27th November 2006\r\n<span style=\"color: #000099;\">Metabolic Domestic Roadshow - November 2006\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MetabolicDomesticRoadshow_November2006.pdf\" target=\"_blank\">Click here to download presentation (266kb)</a>\r\n\r\n30th October 2006\r\n<span style=\"color: #0000cc;\">2006 AGM:  CEO\'s presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/16722/wmp/siqi3bsv8o\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n27th October 2006\r\n<span style=\"color: #000099;\">2006 AGM: CEO\'s presentation</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMCEOPresentation_27October2006.pdf\" target=\"_blank\">Click here to download presentation (507kb) </a>\r\n\r\n12 October 2006\r\n<span style=\"color: #000099;\">Asia Pacific Life Sciences Forum (London) 12 Ocotber 2006\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em></span><span style=\"color: #000000;\"><a href=\"/wp-content/uploads/2012/06/IntersuissePresentation_October2006.pdf\" target=\"_blank\">Click here to download presentation (425kb)</a></span>\r\n\r\n28th September 2006\r\n<span style=\"color: #000099;\">UBS Global Life Sciences Conference\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<span style=\"color: #000099;\"><a href=\"/wp-content/uploads/2012/06/UBSPresentation28Sept2006.ppt\">Click here to download presentation (4.82mb)</a></span>\r\n\r\n3rd July 2006\r\n<span style=\"color: #000099;\">Investor Roadshow (UK &amp; Europe) presentation - company update - July 2006</span>\r\n<span style=\"color: #000099;\"><em><span style=\"color: #000000;\">Roland Scollay, PhD, CEO</span>\r\n</em><a href=\"/wp-content/uploads/2012/06/UKRoadshowPresentation_July2006.pdf\" target=\"_blank\">Click here to download report (301kb)</a></span>\r\n\r\n14th June 2006\r\n<span style=\"color: #000099;\">Presentation at the Pacific Growth Equities\' <em>2006 Life Sciences Growth Conferences </em>(USA)</span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/PacificGrowthEquities_USA%20conference.pdf\" target=\"_blank\">Click here to download presentation (313kb)</a>\r\n\r\n23rd May 2006\r\n<span style=\"color: #000099;\">Roadshow presentation - company update - May 2006\r\n</span><span style=\"color: #000099;\"><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO</em> </span>\r\n</span><a href=\"/wp-content/uploads/2012/06/ASX_May23RoadshowPresentation.pdf\" target=\"_blank\">Click here to download report (323kb)</a>\r\n\r\n5th April 2006\r\n<span style=\"color: #000099;\">Presentation at US biotech conferences, 5th - 7th April 2006</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CEOUSbiotechpresentation_5April2006.pdf\" target=\"_blank\">Click here to download report (211kb)</a>\r\n\r\n14th February 2006\r\n<span style=\"color: #000099;\">Presentation to BIO-CEO Obesity Session, New York, 14th February 2006\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"New Advances in Obesity Drugs\"\r\n<a href=\"/wp-content/uploads/2012/06/BIO_CEO_OBESITY-SESSION_NY_FEB2006.pdf\" target=\"_blank\">Click here to download report (142kb)</a>\r\n\r\n8th February 2006\r\n<span style=\"color: #000099;\">Investor Roadshow Presentation, 8th February 2006 </span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/InvestorRoadshowPresentation_8Feb2006.pdf\" target=\"_blank\">Click here to download report (183kb)</a>\r\n\r\n4th November 2005\r\n<span style=\"color: #000099;\">CEO Presentation at Rodman and Renshaw Conference New York, 7 November 2005 </span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/CEOPresentationRodmanRenshaw_7Nov2005.pdf\" target=\"_blank\">Click here to download report (202kb)</a>\r\n\r\n28th October 2005\r\n<span style=\"color: #000099;\">CEO Presentation at AGM October 2005 </span>\r\n<em>Roland Scollay PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMPresentation_28Oct2005.pdf\" target=\"_blank\">Click here to download report (168kb)</a>\r\n\r\n19th October 2005\r\n<span style=\"color: #000099;\">BBY/Jeffries Health Care and Life Sciences Conference</span>\r\n<em>Roland Scollay PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/BBY_Jeffries_Conference_Sydney19Oct05.pdf\" target=\"_blank\">Click here to download report (1mb)</a>\r\n\r\n18th October 2005\r\n<span style=\"color: #000099;\">NAASO 2005 Annual Scientific Meeting</span>\r\n<em>Caroline Herd PhD </em>\r\n\"The Effect of AOD9604 on Weight Loss in Obese Adults\"\r\n<a href=\"/wp-content/uploads/2012/06/NAASO_2005presentation.pdf\" target=\"_blank\">Click here to download report (371kb)</a>\r\n\r\n10th October 2005\r\n<span style=\"color: #000099;\">Wilson HTM Biotechnology Conference</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em>\"Products to Profits\"\r\n<a href=\"/wp-content/uploads/2012/06/WilsonHTMConference_RS_10Oct2005.pdf\" target=\"_blank\">Click here to download report (96kb)</a>\r\n\r\n7th September 2005\r\n<span style=\"color: #000099;\">Southern Cross Equities Biotechnology conference\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"DNA, Devices and Dealers\"\r\n<a href=\"/wp-content/uploads/2012/06/SouthernCrossEquitiesRS_7Sept2005.pdf\" target=\"_blank\">Click here to download report (3.63mb)</a>\r\n\r\n2nd September 2005\r\n<span style=\"color: #000099;\">Venom to Drugs 2005, Conference, Heron Island</span>\r\n<em>Daniel McIntosh </em>\r\n<a href=\"/wp-content/uploads/2012/06/ACV1_PosterVenomstoDrugs_Sept2005.pdf\" target=\"_blank\">Click here to download report (123kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">US Presentations June 2005</span>\r\n<em>Roland Scollay PhD CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/USPresentations_June%202005.pdf\" target=\"_blank\">Click here to download report (264kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Boston Bio-Relationships 2005\r\n</span><em>Roland Scollay PhD CEO\r\n</em>Presentation 1: Corporate Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005CorporatePresentation_June2005.pdf\" target=\"_blank\">Click to download report (132kb)</a>\r\n\r\nPresentation 2: Diabetes Session Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005DiabetesSession_June2005.pdf\" target=\"_blank\">Click to download report (127kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">American Diabetes Association 65th Scientific Sessions San Diego</span>\r\n<em>Prof. Gary Wittert </em>\r\nAOD9604, an Orally Active Peptide for the Treatment of Obesity: Results of a Phase 2b Study\r\n<a href=\"/wp-content/uploads/2012/06/ISW4JYRJF0/ADAposter_June2005.pdf\" target=\"_blank\">Click here to download report (106kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Share Placement Corporate Presentation June 2005</span>\r\n<em>Roland Scollay PhD CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MBPCorporatePresentation_June%202005.pdf\" target=\"_blank\">Click here to download Presentation (1.78mb)</a>\r\n\r\n2nd May 2005\r\n<span style=\"color: #000099;\">TIDES 2005 Conference Presentation, Boston</span>\r\n<em>Dr Andrea McCracken\r\n</em>Development of the Conopeptide ACV1 for the Treatment of Neuropathic Pain\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%20ACV1_2ndMay2005.pdf\" target=\"_blank\">Click here to download the Presentation (4.65mb)</a>\r\n\r\n3rd May 2004\r\n<span style=\"color: #000099;\">TIDES 2004 Conference Presentation, Las Vegas </span>\r\n<em>Dr Caroline Herd\r\n</em>AOD9604 - An Orally Active Peptide for the Treatment of Obesity\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%202004%20Conference.pdf\" target=\"_blank\">Click to download Presentation (2.33mb)</a>\r\n\r\n17th February 2003\r\n<span style=\"color: #000099;\">Conference Presentation\r\n</span><em>Mark Heffernan</em>\r\nPresentation at the Obesity and Metabolic disorders conference, London\r\n<a href=\"/wp-content/uploads/2012/06/HeffernanUK.pdf\" target=\"_blank\">Click to download Presentation (396kb)</a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<em>Please Note:\r\nThese files are provided in Adobe PDF format, requiring the Adobe PDF Reader application to view them. This application is available to download from <span style=\"text-decoration: underline;\"><strong><a href=\"http://www.adobe.com/\" target=\"_blank\">http://www.adobe.com</a></strong></span></em>\r\n\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"15\" border=\"0\" />',	'Presentations',	'',	'inherit',	'open',	'open',	'',	'133-revision-9',	'',	'',	'2012-06-18 05:36:51',	'2012-06-18 05:36:51',	'',	133,	'http://calzada-wp.urldock.com/133-revision-9/',	0,	'revision',	'',	0),
(209,	1,	'2012-06-18 05:39:49',	'2012-06-18 05:39:49',	'<h2 class=\"feSubHeading\">Presentations</h2>\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" />\r\n\r\n15th April 2011\r\n<span style=\"color: #000099;\">AGM Presentation 2010</span>\r\n<a href=\"/wp-content/uploads/2012/06/914346.pdf\" target=\"_blank\">Click here to download presentation (1.7mb)</a>\r\n\r\n18th July 2008\r\n<span style=\"color: #000099;\">Corporate Presentation: Metabolic\'s acquisition of PolyNovo\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman of Metabolic </em>and <em>Ian Griffiths, CEO of PolyNovo\r\n</em><a href=\"/wp-content/uploads/2012/06/0823-ASX-Announcement-Corporate-Presentation-Acquisition-of-PolyNovo-18-July-2008_001.pdf\">Click here to download presentation (495 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman </em>and <em>Roland Scollay, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation.pdf\" target=\"_blank\">Click here to download presentation (432 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman</em> and <em>Roland Scollay, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/32241/wmp/poxf1u5rb8\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n20th September 2007\r\n<span style=\"color: #000099;\">Update on Oral Peptide Delivery Platform\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/UpdateOralPeptideDeliveryPlatform_20Sept2007.pdf\" target=\"_blank\">Click here to download presentation ( 347 kb)</a></span>\r\n\r\n9th May 2007\r\n<span style=\"color: #003399;\">Corporate Update - May 2007</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic-Corporate-Presentation.pdf\" target=\"_blank\">Click here to download presentation (577kb)</a>\r\n\r\n24th January 2007\r\n<span style=\"color: #000099;\">Corporate Update - January 2007\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CurrentCorporatePresentation_January2007.pdf\" target=\"_blank\">Click here to download presentation (518kb)</a></span>\r\n\r\n27th November 2006\r\n<span style=\"color: #000099;\">Metabolic Domestic Roadshow - November 2006\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MetabolicDomesticRoadshow_November2006.pdf\" target=\"_blank\">Click here to download presentation (266kb)</a>\r\n\r\n30th October 2006\r\n<span style=\"color: #0000cc;\">2006 AGM:  CEO\'s presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/16722/wmp/siqi3bsv8o\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n27th October 2006\r\n<span style=\"color: #000099;\">2006 AGM: CEO\'s presentation</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMCEOPresentation_27October2006.pdf\" target=\"_blank\">Click here to download presentation (507kb) </a>\r\n\r\n12 October 2006\r\n<span style=\"color: #000099;\">Asia Pacific Life Sciences Forum (London) 12 Ocotber 2006\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em></span><span style=\"color: #000000;\"><a href=\"/wp-content/uploads/2012/06/IntersuissePresentation_October2006.pdf\" target=\"_blank\">Click here to download presentation (425kb)</a></span>\r\n\r\n28th September 2006\r\n<span style=\"color: #000099;\">UBS Global Life Sciences Conference\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<span style=\"color: #000099;\"><a href=\"/wp-content/uploads/2012/06/UBSPresentation28Sept2006.ppt\">Click here to download presentation (4.82mb)</a></span>\r\n\r\n3rd July 2006\r\n<span style=\"color: #000099;\">Investor Roadshow (UK &amp; Europe) presentation - company update - July 2006</span>\r\n<span style=\"color: #000099;\"><em><span style=\"color: #000000;\">Roland Scollay, PhD, CEO</span>\r\n</em><a href=\"/wp-content/uploads/2012/06/UKRoadshowPresentation_July2006.pdf\" target=\"_blank\">Click here to download report (301kb)</a></span>\r\n\r\n14th June 2006\r\n<span style=\"color: #000099;\">Presentation at the Pacific Growth Equities\' <em>2006 Life Sciences Growth Conferences </em>(USA)</span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/PacificGrowthEquities_USA%20conference.pdf\" target=\"_blank\">Click here to download presentation (313kb)</a>\r\n\r\n23rd May 2006\r\n<span style=\"color: #000099;\">Roadshow presentation - company update - May 2006\r\n</span><span style=\"color: #000099;\"><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO</em> </span>\r\n</span><a href=\"/wp-content/uploads/2012/06/ASX_May23RoadshowPresentation.pdf\" target=\"_blank\">Click here to download report (323kb)</a>\r\n\r\n5th April 2006\r\n<span style=\"color: #000099;\">Presentation at US biotech conferences, 5th - 7th April 2006</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CEOUSbiotechpresentation_5April2006.pdf\" target=\"_blank\">Click here to download report (211kb)</a>\r\n\r\n14th February 2006\r\n<span style=\"color: #000099;\">Presentation to BIO-CEO Obesity Session, New York, 14th February 2006\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"New Advances in Obesity Drugs\"\r\n<a href=\"/wp-content/uploads/2012/06/BIO_CEO_OBESITY-SESSION_NY_FEB2006.pdf\" target=\"_blank\">Click here to download report (142kb)</a>\r\n\r\n8th February 2006\r\n<span style=\"color: #000099;\">Investor Roadshow Presentation, 8th February 2006 </span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/InvestorRoadshowPresentation_8Feb2006.pdf\" target=\"_blank\">Click here to download report (183kb)</a>\r\n\r\n4th November 2005\r\n<span style=\"color: #000099;\">CEO Presentation at Rodman and Renshaw Conference New York, 7 November 2005 </span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/CEOPresentationRodmanRenshaw_7Nov2005.pdf\" target=\"_blank\">Click here to download report (202kb)</a>\r\n\r\n28th October 2005\r\n<span style=\"color: #000099;\">CEO Presentation at AGM October 2005 </span>\r\n<em>Roland Scollay PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMPresentation_28Oct2005.pdf\" target=\"_blank\">Click here to download report (168kb)</a>\r\n\r\n19th October 2005\r\n<span style=\"color: #000099;\">BBY/Jeffries Health Care and Life Sciences Conference</span>\r\n<em>Roland Scollay PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/BBY_Jeffries_Conference_Sydney19Oct05.pdf\" target=\"_blank\">Click here to download report (1mb)</a>\r\n\r\n18th October 2005\r\n<span style=\"color: #000099;\">NAASO 2005 Annual Scientific Meeting</span>\r\n<em>Caroline Herd PhD </em>\r\n\"The Effect of AOD9604 on Weight Loss in Obese Adults\"\r\n<a href=\"/wp-content/uploads/2012/06/NAASO_2005presentation.pdf\" target=\"_blank\">Click here to download report (371kb)</a>\r\n\r\n10th October 2005\r\n<span style=\"color: #000099;\">Wilson HTM Biotechnology Conference</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em>\"Products to Profits\"\r\n<a href=\"/wp-content/uploads/2012/06/WilsonHTMConference_RS_10Oct2005.pdf\" target=\"_blank\">Click here to download report (96kb)</a>\r\n\r\n7th September 2005\r\n<span style=\"color: #000099;\">Southern Cross Equities Biotechnology conference\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"DNA, Devices and Dealers\"\r\n<a href=\"/wp-content/uploads/2012/06/SouthernCrossEquitiesRS_7Sept2005.pdf\" target=\"_blank\">Click here to download report (3.63mb)</a>\r\n\r\n2nd September 2005\r\n<span style=\"color: #000099;\">Venom to Drugs 2005, Conference, Heron Island</span>\r\n<em>Daniel McIntosh </em>\r\n<a href=\"/wp-content/uploads/2012/06/ACV1_PosterVenomstoDrugs_Sept2005.pdf\" target=\"_blank\">Click here to download report (123kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">US Presentations June 2005</span>\r\n<em>Roland Scollay PhD CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/USPresentations_June-2005.pdff\" target=\"_blank\">Click here to download report (264kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Boston Bio-Relationships 2005\r\n</span><em>Roland Scollay PhD CEO\r\n</em>Presentation 1: Corporate Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005CorporatePresentation_June2005.pdf\" target=\"_blank\">Click to download report (132kb)</a>\r\n\r\nPresentation 2: Diabetes Session Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005DiabetesSession_June2005.pdf\" target=\"_blank\">Click to download report (127kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">American Diabetes Association 65th Scientific Sessions San Diego</span>\r\n<em>Prof. Gary Wittert </em>\r\nAOD9604, an Orally Active Peptide for the Treatment of Obesity: Results of a Phase 2b Study\r\n<a href=\"/wp-content/uploads/2012/06/ISW4JYRJF0/ADAposter_June2005.pdf\" target=\"_blank\">Click here to download report (106kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Share Placement Corporate Presentation June 2005</span>\r\n<em>Roland Scollay PhD CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MBPCorporatePresentation_June%202005.pdf\" target=\"_blank\">Click here to download Presentation (1.78mb)</a>\r\n\r\n2nd May 2005\r\n<span style=\"color: #000099;\">TIDES 2005 Conference Presentation, Boston</span>\r\n<em>Dr Andrea McCracken\r\n</em>Development of the Conopeptide ACV1 for the Treatment of Neuropathic Pain\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%20ACV1_2ndMay2005.pdf\" target=\"_blank\">Click here to download the Presentation (4.65mb)</a>\r\n\r\n3rd May 2004\r\n<span style=\"color: #000099;\">TIDES 2004 Conference Presentation, Las Vegas </span>\r\n<em>Dr Caroline Herd\r\n</em>AOD9604 - An Orally Active Peptide for the Treatment of Obesity\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%202004%20Conference.pdf\" target=\"_blank\">Click to download Presentation (2.33mb)</a>\r\n\r\n17th February 2003\r\n<span style=\"color: #000099;\">Conference Presentation\r\n</span><em>Mark Heffernan</em>\r\nPresentation at the Obesity and Metabolic disorders conference, London\r\n<a href=\"/wp-content/uploads/2012/06/HeffernanUK.pdf\" target=\"_blank\">Click to download Presentation (396kb)</a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<em>Please Note:\r\nThese files are provided in Adobe PDF format, requiring the Adobe PDF Reader application to view them. This application is available to download from <span style=\"text-decoration: underline;\"><strong><a href=\"http://www.adobe.com/\" target=\"_blank\">http://www.adobe.com</a></strong></span></em>\r\n\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"15\" border=\"0\" />',	'Presentations',	'',	'inherit',	'open',	'open',	'',	'133-revision-10',	'',	'',	'2012-06-18 05:39:49',	'2012-06-18 05:39:49',	'',	133,	'http://calzada-wp.urldock.com/133-revision-10/',	0,	'revision',	'',	0),
(210,	1,	'2012-06-18 05:42:08',	'2012-06-18 05:42:08',	'',	'USPresentations_June 2005',	'',	'inherit',	'open',	'open',	'',	'uspresentations_june-2005-2',	'',	'',	'2012-06-18 05:42:08',	'2012-06-18 05:42:08',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/USPresentations_June-20051.pdf',	0,	'attachment',	'application/pdf',	0),
(211,	1,	'2012-06-18 05:41:09',	'2012-06-18 05:41:09',	'<h2 class=\"feSubHeading\">Presentations</h2>\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" />\r\n\r\n15th April 2011\r\n<span style=\"color: #000099;\">AGM Presentation 2010</span>\r\n<a href=\"/wp-content/uploads/2012/06/914346.pdf\" target=\"_blank\">Click here to download presentation (1.7mb)</a>\r\n\r\n18th July 2008\r\n<span style=\"color: #000099;\">Corporate Presentation: Metabolic\'s acquisition of PolyNovo\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman of Metabolic </em>and <em>Ian Griffiths, CEO of PolyNovo\r\n</em><a href=\"/wp-content/uploads/2012/06/0823-ASX-Announcement-Corporate-Presentation-Acquisition-of-PolyNovo-18-July-2008_001.pdf\">Click here to download presentation (495 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman </em>and <em>Roland Scollay, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation.pdf\" target=\"_blank\">Click here to download presentation (432 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman</em> and <em>Roland Scollay, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/32241/wmp/poxf1u5rb8\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n20th September 2007\r\n<span style=\"color: #000099;\">Update on Oral Peptide Delivery Platform\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/UpdateOralPeptideDeliveryPlatform_20Sept2007.pdf\" target=\"_blank\">Click here to download presentation ( 347 kb)</a></span>\r\n\r\n9th May 2007\r\n<span style=\"color: #003399;\">Corporate Update - May 2007</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic-Corporate-Presentation.pdf\" target=\"_blank\">Click here to download presentation (577kb)</a>\r\n\r\n24th January 2007\r\n<span style=\"color: #000099;\">Corporate Update - January 2007\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CurrentCorporatePresentation_January2007.pdf\" target=\"_blank\">Click here to download presentation (518kb)</a></span>\r\n\r\n27th November 2006\r\n<span style=\"color: #000099;\">Metabolic Domestic Roadshow - November 2006\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MetabolicDomesticRoadshow_November2006.pdf\" target=\"_blank\">Click here to download presentation (266kb)</a>\r\n\r\n30th October 2006\r\n<span style=\"color: #0000cc;\">2006 AGM:  CEO\'s presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/16722/wmp/siqi3bsv8o\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n27th October 2006\r\n<span style=\"color: #000099;\">2006 AGM: CEO\'s presentation</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMCEOPresentation_27October2006.pdf\" target=\"_blank\">Click here to download presentation (507kb) </a>\r\n\r\n12 October 2006\r\n<span style=\"color: #000099;\">Asia Pacific Life Sciences Forum (London) 12 Ocotber 2006\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em></span><span style=\"color: #000000;\"><a href=\"/wp-content/uploads/2012/06/IntersuissePresentation_October2006.pdf\" target=\"_blank\">Click here to download presentation (425kb)</a></span>\r\n\r\n28th September 2006\r\n<span style=\"color: #000099;\">UBS Global Life Sciences Conference\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<span style=\"color: #000099;\"><a href=\"/wp-content/uploads/2012/06/UBSPresentation28Sept2006.ppt\">Click here to download presentation (4.82mb)</a></span>\r\n\r\n3rd July 2006\r\n<span style=\"color: #000099;\">Investor Roadshow (UK &amp; Europe) presentation - company update - July 2006</span>\r\n<span style=\"color: #000099;\"><em><span style=\"color: #000000;\">Roland Scollay, PhD, CEO</span>\r\n</em><a href=\"/wp-content/uploads/2012/06/UKRoadshowPresentation_July2006.pdf\" target=\"_blank\">Click here to download report (301kb)</a></span>\r\n\r\n14th June 2006\r\n<span style=\"color: #000099;\">Presentation at the Pacific Growth Equities\' <em>2006 Life Sciences Growth Conferences </em>(USA)</span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/PacificGrowthEquities_USA%20conference.pdf\" target=\"_blank\">Click here to download presentation (313kb)</a>\r\n\r\n23rd May 2006\r\n<span style=\"color: #000099;\">Roadshow presentation - company update - May 2006\r\n</span><span style=\"color: #000099;\"><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO</em> </span>\r\n</span><a href=\"/wp-content/uploads/2012/06/ASX_May23RoadshowPresentation.pdf\" target=\"_blank\">Click here to download report (323kb)</a>\r\n\r\n5th April 2006\r\n<span style=\"color: #000099;\">Presentation at US biotech conferences, 5th - 7th April 2006</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CEOUSbiotechpresentation_5April2006.pdf\" target=\"_blank\">Click here to download report (211kb)</a>\r\n\r\n14th February 2006\r\n<span style=\"color: #000099;\">Presentation to BIO-CEO Obesity Session, New York, 14th February 2006\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"New Advances in Obesity Drugs\"\r\n<a href=\"/wp-content/uploads/2012/06/BIO_CEO_OBESITY-SESSION_NY_FEB2006.pdf\" target=\"_blank\">Click here to download report (142kb)</a>\r\n\r\n8th February 2006\r\n<span style=\"color: #000099;\">Investor Roadshow Presentation, 8th February 2006 </span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/InvestorRoadshowPresentation_8Feb2006.pdf\" target=\"_blank\">Click here to download report (183kb)</a>\r\n\r\n4th November 2005\r\n<span style=\"color: #000099;\">CEO Presentation at Rodman and Renshaw Conference New York, 7 November 2005 </span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/CEOPresentationRodmanRenshaw_7Nov2005.pdf\" target=\"_blank\">Click here to download report (202kb)</a>\r\n\r\n28th October 2005\r\n<span style=\"color: #000099;\">CEO Presentation at AGM October 2005 </span>\r\n<em>Roland Scollay PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMPresentation_28Oct2005.pdf\" target=\"_blank\">Click here to download report (168kb)</a>\r\n\r\n19th October 2005\r\n<span style=\"color: #000099;\">BBY/Jeffries Health Care and Life Sciences Conference</span>\r\n<em>Roland Scollay PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/BBY_Jeffries_Conference_Sydney19Oct05.pdf\" target=\"_blank\">Click here to download report (1mb)</a>\r\n\r\n18th October 2005\r\n<span style=\"color: #000099;\">NAASO 2005 Annual Scientific Meeting</span>\r\n<em>Caroline Herd PhD </em>\r\n\"The Effect of AOD9604 on Weight Loss in Obese Adults\"\r\n<a href=\"/wp-content/uploads/2012/06/NAASO_2005presentation.pdf\" target=\"_blank\">Click here to download report (371kb)</a>\r\n\r\n10th October 2005\r\n<span style=\"color: #000099;\">Wilson HTM Biotechnology Conference</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em>\"Products to Profits\"\r\n<a href=\"/wp-content/uploads/2012/06/WilsonHTMConference_RS_10Oct2005.pdf\" target=\"_blank\">Click here to download report (96kb)</a>\r\n\r\n7th September 2005\r\n<span style=\"color: #000099;\">Southern Cross Equities Biotechnology conference\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"DNA, Devices and Dealers\"\r\n<a href=\"/wp-content/uploads/2012/06/SouthernCrossEquitiesRS_7Sept2005.pdf\" target=\"_blank\">Click here to download report (3.63mb)</a>\r\n\r\n2nd September 2005\r\n<span style=\"color: #000099;\">Venom to Drugs 2005, Conference, Heron Island</span>\r\n<em>Daniel McIntosh </em>\r\n<a href=\"/wp-content/uploads/2012/06/ACV1_PosterVenomstoDrugs_Sept2005.pdf\" target=\"_blank\">Click here to download report (123kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">US Presentations June 2005</span>\r\n<em>Roland Scollay PhD CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/USPresentations_June 2005.pdf\" target=\"_blank\">Click here to download report (264kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Boston Bio-Relationships 2005\r\n</span><em>Roland Scollay PhD CEO\r\n</em>Presentation 1: Corporate Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005CorporatePresentation_June2005.pdf\" target=\"_blank\">Click to download report (132kb)</a>\r\n\r\nPresentation 2: Diabetes Session Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005DiabetesSession_June2005.pdf\" target=\"_blank\">Click to download report (127kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">American Diabetes Association 65th Scientific Sessions San Diego</span>\r\n<em>Prof. Gary Wittert </em>\r\nAOD9604, an Orally Active Peptide for the Treatment of Obesity: Results of a Phase 2b Study\r\n<a href=\"/wp-content/uploads/2012/06/ISW4JYRJF0/ADAposter_June2005.pdf\" target=\"_blank\">Click here to download report (106kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Share Placement Corporate Presentation June 2005</span>\r\n<em>Roland Scollay PhD CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MBPCorporatePresentation_June%202005.pdf\" target=\"_blank\">Click here to download Presentation (1.78mb)</a>\r\n\r\n2nd May 2005\r\n<span style=\"color: #000099;\">TIDES 2005 Conference Presentation, Boston</span>\r\n<em>Dr Andrea McCracken\r\n</em>Development of the Conopeptide ACV1 for the Treatment of Neuropathic Pain\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%20ACV1_2ndMay2005.pdf\" target=\"_blank\">Click here to download the Presentation (4.65mb)</a>\r\n\r\n3rd May 2004\r\n<span style=\"color: #000099;\">TIDES 2004 Conference Presentation, Las Vegas </span>\r\n<em>Dr Caroline Herd\r\n</em>AOD9604 - An Orally Active Peptide for the Treatment of Obesity\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%202004%20Conference.pdf\" target=\"_blank\">Click to download Presentation (2.33mb)</a>\r\n\r\n17th February 2003\r\n<span style=\"color: #000099;\">Conference Presentation\r\n</span><em>Mark Heffernan</em>\r\nPresentation at the Obesity and Metabolic disorders conference, London\r\n<a href=\"/wp-content/uploads/2012/06/HeffernanUK.pdf\" target=\"_blank\">Click to download Presentation (396kb)</a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<em>Please Note:\r\nThese files are provided in Adobe PDF format, requiring the Adobe PDF Reader application to view them. This application is available to download from <span style=\"text-decoration: underline;\"><strong><a href=\"http://www.adobe.com/\" target=\"_blank\">http://www.adobe.com</a></strong></span></em>\r\n\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"15\" border=\"0\" />',	'Presentations',	'',	'inherit',	'open',	'open',	'',	'133-revision-11',	'',	'',	'2012-06-18 05:41:09',	'2012-06-18 05:41:09',	'',	133,	'http://calzada-wp.urldock.com/133-revision-11/',	0,	'revision',	'',	0),
(212,	1,	'2012-06-18 05:43:04',	'2012-06-18 05:43:04',	'<h2 class=\"feSubHeading\">Presentations</h2>\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" />\r\n\r\n15th April 2011\r\n<span style=\"color: #000099;\">AGM Presentation 2010</span>\r\n<a href=\"/wp-content/uploads/2012/06/914346.pdf\" target=\"_blank\">Click here to download presentation (1.7mb)</a>\r\n\r\n18th July 2008\r\n<span style=\"color: #000099;\">Corporate Presentation: Metabolic\'s acquisition of PolyNovo\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman of Metabolic </em>and <em>Ian Griffiths, CEO of PolyNovo\r\n</em><a href=\"/wp-content/uploads/2012/06/0823-ASX-Announcement-Corporate-Presentation-Acquisition-of-PolyNovo-18-July-2008_001.pdf\">Click here to download presentation (495 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman </em>and <em>Roland Scollay, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation.pdf\" target=\"_blank\">Click here to download presentation (432 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman</em> and <em>Roland Scollay, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/32241/wmp/poxf1u5rb8\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n20th September 2007\r\n<span style=\"color: #000099;\">Update on Oral Peptide Delivery Platform\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/UpdateOralPeptideDeliveryPlatform_20Sept2007.pdf\" target=\"_blank\">Click here to download presentation ( 347 kb)</a></span>\r\n\r\n9th May 2007\r\n<span style=\"color: #003399;\">Corporate Update - May 2007</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic-Corporate-Presentation.pdf\" target=\"_blank\">Click here to download presentation (577kb)</a>\r\n\r\n24th January 2007\r\n<span style=\"color: #000099;\">Corporate Update - January 2007\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CurrentCorporatePresentation_January2007.pdf\" target=\"_blank\">Click here to download presentation (518kb)</a></span>\r\n\r\n27th November 2006\r\n<span style=\"color: #000099;\">Metabolic Domestic Roadshow - November 2006\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MetabolicDomesticRoadshow_November2006.pdf\" target=\"_blank\">Click here to download presentation (266kb)</a>\r\n\r\n30th October 2006\r\n<span style=\"color: #0000cc;\">2006 AGM:  CEO\'s presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/16722/wmp/siqi3bsv8o\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n27th October 2006\r\n<span style=\"color: #000099;\">2006 AGM: CEO\'s presentation</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMCEOPresentation_27October2006.pdf\" target=\"_blank\">Click here to download presentation (507kb) </a>\r\n\r\n12 October 2006\r\n<span style=\"color: #000099;\">Asia Pacific Life Sciences Forum (London) 12 Ocotber 2006\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em></span><span style=\"color: #000000;\"><a href=\"/wp-content/uploads/2012/06/IntersuissePresentation_October2006.pdf\" target=\"_blank\">Click here to download presentation (425kb)</a></span>\r\n\r\n28th September 2006\r\n<span style=\"color: #000099;\">UBS Global Life Sciences Conference\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<span style=\"color: #000099;\"><a href=\"/wp-content/uploads/2012/06/UBSPresentation28Sept2006.ppt\">Click here to download presentation (4.82mb)</a></span>\r\n\r\n3rd July 2006\r\n<span style=\"color: #000099;\">Investor Roadshow (UK &amp; Europe) presentation - company update - July 2006</span>\r\n<span style=\"color: #000099;\"><em><span style=\"color: #000000;\">Roland Scollay, PhD, CEO</span>\r\n</em><a href=\"/wp-content/uploads/2012/06/UKRoadshowPresentation_July2006.pdf\" target=\"_blank\">Click here to download report (301kb)</a></span>\r\n\r\n14th June 2006\r\n<span style=\"color: #000099;\">Presentation at the Pacific Growth Equities\' <em>2006 Life Sciences Growth Conferences </em>(USA)</span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/PacificGrowthEquities_USA%20conference.pdf\" target=\"_blank\">Click here to download presentation (313kb)</a>\r\n\r\n23rd May 2006\r\n<span style=\"color: #000099;\">Roadshow presentation - company update - May 2006\r\n</span><span style=\"color: #000099;\"><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO</em> </span>\r\n</span><a href=\"/wp-content/uploads/2012/06/ASX_May23RoadshowPresentation.pdf\" target=\"_blank\">Click here to download report (323kb)</a>\r\n\r\n5th April 2006\r\n<span style=\"color: #000099;\">Presentation at US biotech conferences, 5th - 7th April 2006</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CEOUSbiotechpresentation_5April2006.pdf\" target=\"_blank\">Click here to download report (211kb)</a>\r\n\r\n14th February 2006\r\n<span style=\"color: #000099;\">Presentation to BIO-CEO Obesity Session, New York, 14th February 2006\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"New Advances in Obesity Drugs\"\r\n<a href=\"/wp-content/uploads/2012/06/BIO_CEO_OBESITY-SESSION_NY_FEB2006.pdf\" target=\"_blank\">Click here to download report (142kb)</a>\r\n\r\n8th February 2006\r\n<span style=\"color: #000099;\">Investor Roadshow Presentation, 8th February 2006 </span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/InvestorRoadshowPresentation_8Feb2006.pdf\" target=\"_blank\">Click here to download report (183kb)</a>\r\n\r\n4th November 2005\r\n<span style=\"color: #000099;\">CEO Presentation at Rodman and Renshaw Conference New York, 7 November 2005 </span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/CEOPresentationRodmanRenshaw_7Nov2005.pdf\" target=\"_blank\">Click here to download report (202kb)</a>\r\n\r\n28th October 2005\r\n<span style=\"color: #000099;\">CEO Presentation at AGM October 2005 </span>\r\n<em>Roland Scollay PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMPresentation_28Oct2005.pdf\" target=\"_blank\">Click here to download report (168kb)</a>\r\n\r\n19th October 2005\r\n<span style=\"color: #000099;\">BBY/Jeffries Health Care and Life Sciences Conference</span>\r\n<em>Roland Scollay PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/BBY_Jeffries_Conference_Sydney19Oct05.pdf\" target=\"_blank\">Click here to download report (1mb)</a>\r\n\r\n18th October 2005\r\n<span style=\"color: #000099;\">NAASO 2005 Annual Scientific Meeting</span>\r\n<em>Caroline Herd PhD </em>\r\n\"The Effect of AOD9604 on Weight Loss in Obese Adults\"\r\n<a href=\"/wp-content/uploads/2012/06/NAASO_2005presentation.pdf\" target=\"_blank\">Click here to download report (371kb)</a>\r\n\r\n10th October 2005\r\n<span style=\"color: #000099;\">Wilson HTM Biotechnology Conference</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em>\"Products to Profits\"\r\n<a href=\"/wp-content/uploads/2012/06/WilsonHTMConference_RS_10Oct2005.pdf\" target=\"_blank\">Click here to download report (96kb)</a>\r\n\r\n7th September 2005\r\n<span style=\"color: #000099;\">Southern Cross Equities Biotechnology conference\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"DNA, Devices and Dealers\"\r\n<a href=\"/wp-content/uploads/2012/06/SouthernCrossEquitiesRS_7Sept2005.pdf\" target=\"_blank\">Click here to download report (3.63mb)</a>\r\n\r\n2nd September 2005\r\n<span style=\"color: #000099;\">Venom to Drugs 2005, Conference, Heron Island</span>\r\n<em>Daniel McIntosh </em>\r\n<a href=\"/wp-content/uploads/2012/06/ACV1_PosterVenomstoDrugs_Sept2005.pdf\" target=\"_blank\">Click here to download report (123kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">US Presentations June 2005</span>\r\n<em>Roland Scollay PhD CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/USPresentations_June-20051.pdf\" target=\"_blank\">Click here to download report (264kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Boston Bio-Relationships 2005\r\n</span><em>Roland Scollay PhD CEO\r\n</em>Presentation 1: Corporate Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005CorporatePresentation_June2005.pdf\" target=\"_blank\">Click to download report (132kb)</a>\r\n\r\nPresentation 2: Diabetes Session Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005DiabetesSession_June2005.pdf\" target=\"_blank\">Click to download report (127kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">American Diabetes Association 65th Scientific Sessions San Diego</span>\r\n<em>Prof. Gary Wittert </em>\r\nAOD9604, an Orally Active Peptide for the Treatment of Obesity: Results of a Phase 2b Study\r\n<a href=\"/wp-content/uploads/2012/06/ISW4JYRJF0/ADAposter_June2005.pdf\" target=\"_blank\">Click here to download report (106kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Share Placement Corporate Presentation June 2005</span>\r\n<em>Roland Scollay PhD CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MBPCorporatePresentation_June%202005.pdf\" target=\"_blank\">Click here to download Presentation (1.78mb)</a>\r\n\r\n2nd May 2005\r\n<span style=\"color: #000099;\">TIDES 2005 Conference Presentation, Boston</span>\r\n<em>Dr Andrea McCracken\r\n</em>Development of the Conopeptide ACV1 for the Treatment of Neuropathic Pain\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%20ACV1_2ndMay2005.pdf\" target=\"_blank\">Click here to download the Presentation (4.65mb)</a>\r\n\r\n3rd May 2004\r\n<span style=\"color: #000099;\">TIDES 2004 Conference Presentation, Las Vegas </span>\r\n<em>Dr Caroline Herd\r\n</em>AOD9604 - An Orally Active Peptide for the Treatment of Obesity\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%202004%20Conference.pdf\" target=\"_blank\">Click to download Presentation (2.33mb)</a>\r\n\r\n17th February 2003\r\n<span style=\"color: #000099;\">Conference Presentation\r\n</span><em>Mark Heffernan</em>\r\nPresentation at the Obesity and Metabolic disorders conference, London\r\n<a href=\"/wp-content/uploads/2012/06/HeffernanUK.pdf\" target=\"_blank\">Click to download Presentation (396kb)</a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<em>Please Note:\r\nThese files are provided in Adobe PDF format, requiring the Adobe PDF Reader application to view them. This application is available to download from <span style=\"text-decoration: underline;\"><strong><a href=\"http://www.adobe.com/\" target=\"_blank\">http://www.adobe.com</a></strong></span></em>\r\n\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"15\" border=\"0\" />',	'Presentations',	'',	'inherit',	'open',	'open',	'',	'133-revision-12',	'',	'',	'2012-06-18 05:43:04',	'2012-06-18 05:43:04',	'',	133,	'http://calzada-wp.urldock.com/133-revision-12/',	0,	'revision',	'',	0),
(213,	1,	'2012-06-18 05:45:49',	'2012-06-18 05:45:49',	'',	'ADAposter_June2005',	'',	'inherit',	'open',	'open',	'',	'adaposter_june2005-2',	'',	'',	'2012-06-18 05:45:49',	'2012-06-18 05:45:49',	'',	133,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ADAposter_June20051.pdf',	0,	'attachment',	'application/pdf',	0),
(214,	1,	'2012-06-18 05:44:47',	'2012-06-18 05:44:47',	'<h2 class=\"feSubHeading\">Presentations</h2>\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" />\r\n\r\n15th April 2011\r\n<span style=\"color: #000099;\">AGM Presentation 2010</span>\r\n<a href=\"/wp-content/uploads/2012/06/914346.pdf\" target=\"_blank\">Click here to download presentation (1.7mb)</a>\r\n\r\n18th July 2008\r\n<span style=\"color: #000099;\">Corporate Presentation: Metabolic\'s acquisition of PolyNovo\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman of Metabolic </em>and <em>Ian Griffiths, CEO of PolyNovo\r\n</em><a href=\"/wp-content/uploads/2012/06/0823-ASX-Announcement-Corporate-Presentation-Acquisition-of-PolyNovo-18-July-2008_001.pdf\">Click here to download presentation (495 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman </em>and <em>Roland Scollay, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation.pdf\" target=\"_blank\">Click here to download presentation (432 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman</em> and <em>Roland Scollay, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/32241/wmp/poxf1u5rb8\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n20th September 2007\r\n<span style=\"color: #000099;\">Update on Oral Peptide Delivery Platform\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/UpdateOralPeptideDeliveryPlatform_20Sept2007.pdf\" target=\"_blank\">Click here to download presentation ( 347 kb)</a></span>\r\n\r\n9th May 2007\r\n<span style=\"color: #003399;\">Corporate Update - May 2007</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic-Corporate-Presentation.pdf\" target=\"_blank\">Click here to download presentation (577kb)</a>\r\n\r\n24th January 2007\r\n<span style=\"color: #000099;\">Corporate Update - January 2007\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CurrentCorporatePresentation_January2007.pdf\" target=\"_blank\">Click here to download presentation (518kb)</a></span>\r\n\r\n27th November 2006\r\n<span style=\"color: #000099;\">Metabolic Domestic Roadshow - November 2006\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MetabolicDomesticRoadshow_November2006.pdf\" target=\"_blank\">Click here to download presentation (266kb)</a>\r\n\r\n30th October 2006\r\n<span style=\"color: #0000cc;\">2006 AGM:  CEO\'s presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/16722/wmp/siqi3bsv8o\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n27th October 2006\r\n<span style=\"color: #000099;\">2006 AGM: CEO\'s presentation</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMCEOPresentation_27October2006.pdf\" target=\"_blank\">Click here to download presentation (507kb) </a>\r\n\r\n12 October 2006\r\n<span style=\"color: #000099;\">Asia Pacific Life Sciences Forum (London) 12 Ocotber 2006\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em></span><span style=\"color: #000000;\"><a href=\"/wp-content/uploads/2012/06/IntersuissePresentation_October2006.pdf\" target=\"_blank\">Click here to download presentation (425kb)</a></span>\r\n\r\n28th September 2006\r\n<span style=\"color: #000099;\">UBS Global Life Sciences Conference\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<span style=\"color: #000099;\"><a href=\"/wp-content/uploads/2012/06/UBSPresentation28Sept2006.ppt\">Click here to download presentation (4.82mb)</a></span>\r\n\r\n3rd July 2006\r\n<span style=\"color: #000099;\">Investor Roadshow (UK &amp; Europe) presentation - company update - July 2006</span>\r\n<span style=\"color: #000099;\"><em><span style=\"color: #000000;\">Roland Scollay, PhD, CEO</span>\r\n</em><a href=\"/wp-content/uploads/2012/06/UKRoadshowPresentation_July2006.pdf\" target=\"_blank\">Click here to download report (301kb)</a></span>\r\n\r\n14th June 2006\r\n<span style=\"color: #000099;\">Presentation at the Pacific Growth Equities\' <em>2006 Life Sciences Growth Conferences </em>(USA)</span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/PacificGrowthEquities_USA%20conference.pdf\" target=\"_blank\">Click here to download presentation (313kb)</a>\r\n\r\n23rd May 2006\r\n<span style=\"color: #000099;\">Roadshow presentation - company update - May 2006\r\n</span><span style=\"color: #000099;\"><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO</em> </span>\r\n</span><a href=\"/wp-content/uploads/2012/06/ASX_May23RoadshowPresentation.pdf\" target=\"_blank\">Click here to download report (323kb)</a>\r\n\r\n5th April 2006\r\n<span style=\"color: #000099;\">Presentation at US biotech conferences, 5th - 7th April 2006</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CEOUSbiotechpresentation_5April2006.pdf\" target=\"_blank\">Click here to download report (211kb)</a>\r\n\r\n14th February 2006\r\n<span style=\"color: #000099;\">Presentation to BIO-CEO Obesity Session, New York, 14th February 2006\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"New Advances in Obesity Drugs\"\r\n<a href=\"/wp-content/uploads/2012/06/BIO_CEO_OBESITY-SESSION_NY_FEB2006.pdf\" target=\"_blank\">Click here to download report (142kb)</a>\r\n\r\n8th February 2006\r\n<span style=\"color: #000099;\">Investor Roadshow Presentation, 8th February 2006 </span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/InvestorRoadshowPresentation_8Feb2006.pdf\" target=\"_blank\">Click here to download report (183kb)</a>\r\n\r\n4th November 2005\r\n<span style=\"color: #000099;\">CEO Presentation at Rodman and Renshaw Conference New York, 7 November 2005 </span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/CEOPresentationRodmanRenshaw_7Nov2005.pdf\" target=\"_blank\">Click here to download report (202kb)</a>\r\n\r\n28th October 2005\r\n<span style=\"color: #000099;\">CEO Presentation at AGM October 2005 </span>\r\n<em>Roland Scollay PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMPresentation_28Oct2005.pdf\" target=\"_blank\">Click here to download report (168kb)</a>\r\n\r\n19th October 2005\r\n<span style=\"color: #000099;\">BBY/Jeffries Health Care and Life Sciences Conference</span>\r\n<em>Roland Scollay PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/BBY_Jeffries_Conference_Sydney19Oct05.pdf\" target=\"_blank\">Click here to download report (1mb)</a>\r\n\r\n18th October 2005\r\n<span style=\"color: #000099;\">NAASO 2005 Annual Scientific Meeting</span>\r\n<em>Caroline Herd PhD </em>\r\n\"The Effect of AOD9604 on Weight Loss in Obese Adults\"\r\n<a href=\"/wp-content/uploads/2012/06/NAASO_2005presentation.pdf\" target=\"_blank\">Click here to download report (371kb)</a>\r\n\r\n10th October 2005\r\n<span style=\"color: #000099;\">Wilson HTM Biotechnology Conference</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em>\"Products to Profits\"\r\n<a href=\"/wp-content/uploads/2012/06/WilsonHTMConference_RS_10Oct2005.pdf\" target=\"_blank\">Click here to download report (96kb)</a>\r\n\r\n7th September 2005\r\n<span style=\"color: #000099;\">Southern Cross Equities Biotechnology conference\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"DNA, Devices and Dealers\"\r\n<a href=\"/wp-content/uploads/2012/06/SouthernCrossEquitiesRS_7Sept2005.pdf\" target=\"_blank\">Click here to download report (3.63mb)</a>\r\n\r\n2nd September 2005\r\n<span style=\"color: #000099;\">Venom to Drugs 2005, Conference, Heron Island</span>\r\n<em>Daniel McIntosh </em>\r\n<a href=\"/wp-content/uploads/2012/06/ACV1_PosterVenomstoDrugs_Sept2005.pdf\" target=\"_blank\">Click here to download report (123kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">US Presentations June 2005</span>\r\n<em>Roland Scollay PhD CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/USPresentations_June-20051.pdf\" target=\"_blank\">Click here to download report (264kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Boston Bio-Relationships 2005\r\n</span><em>Roland Scollay PhD CEO\r\n</em>Presentation 1: Corporate Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005CorporatePresentation_June2005.pdf\" target=\"_blank\">Click to download report (132kb)</a>\r\n\r\nPresentation 2: Diabetes Session Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005DiabetesSession_June2005.pdf\" target=\"_blank\">Click to download report (127kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">American Diabetes Association 65th Scientific Sessions San Diego</span>\r\n<em>Prof. Gary Wittert </em>\r\nAOD9604, an Orally Active Peptide for the Treatment of Obesity: Results of a Phase 2b Study\r\n<a href=\"/wp-content/uploads/2012/06/ISW4JYRJF0/ADAposter_June2005.pdf\" target=\"_blank\">Click here to download report (106kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Share Placement Corporate Presentation June 2005</span>\r\n<em>Roland Scollay PhD CEO</em>\r\n<a href=\"wp-content/uploads/2012/06/ADAposter_June2005.pdf\" target=\"_blank\">Click here to download Presentation (1.78mb)</a>\r\n\r\n2nd May 2005\r\n<span style=\"color: #000099;\">TIDES 2005 Conference Presentation, Boston</span>\r\n<em>Dr Andrea McCracken\r\n</em>Development of the Conopeptide ACV1 for the Treatment of Neuropathic Pain\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%20ACV1_2ndMay2005.pdf\" target=\"_blank\">Click here to download the Presentation (4.65mb)</a>\r\n\r\n3rd May 2004\r\n<span style=\"color: #000099;\">TIDES 2004 Conference Presentation, Las Vegas </span>\r\n<em>Dr Caroline Herd\r\n</em>AOD9604 - An Orally Active Peptide for the Treatment of Obesity\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%202004%20Conference.pdf\" target=\"_blank\">Click to download Presentation (2.33mb)</a>\r\n\r\n17th February 2003\r\n<span style=\"color: #000099;\">Conference Presentation\r\n</span><em>Mark Heffernan</em>\r\nPresentation at the Obesity and Metabolic disorders conference, London\r\n<a href=\"/wp-content/uploads/2012/06/HeffernanUK.pdf\" target=\"_blank\">Click to download Presentation (396kb)</a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<em>Please Note:\r\nThese files are provided in Adobe PDF format, requiring the Adobe PDF Reader application to view them. This application is available to download from <span style=\"text-decoration: underline;\"><strong><a href=\"http://www.adobe.com/\" target=\"_blank\">http://www.adobe.com</a></strong></span></em>\r\n\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"15\" border=\"0\" />',	'Presentations',	'',	'inherit',	'open',	'open',	'',	'133-revision-13',	'',	'',	'2012-06-18 05:44:47',	'2012-06-18 05:44:47',	'',	133,	'http://calzada-wp.urldock.com/133-revision-13/',	0,	'revision',	'',	0),
(215,	1,	'2012-06-18 05:46:27',	'2012-06-18 05:46:27',	'<h2 class=\"feSubHeading\">Presentations</h2>\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" />\r\n\r\n15th April 2011\r\n<span style=\"color: #000099;\">AGM Presentation 2010</span>\r\n<a href=\"/wp-content/uploads/2012/06/914346.pdf\" target=\"_blank\">Click here to download presentation (1.7mb)</a>\r\n\r\n18th July 2008\r\n<span style=\"color: #000099;\">Corporate Presentation: Metabolic\'s acquisition of PolyNovo\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman of Metabolic </em>and <em>Ian Griffiths, CEO of PolyNovo\r\n</em><a href=\"/wp-content/uploads/2012/06/0823-ASX-Announcement-Corporate-Presentation-Acquisition-of-PolyNovo-18-July-2008_001.pdf\">Click here to download presentation (495 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman </em>and <em>Roland Scollay, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation.pdf\" target=\"_blank\">Click here to download presentation (432 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman</em> and <em>Roland Scollay, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/32241/wmp/poxf1u5rb8\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n20th September 2007\r\n<span style=\"color: #000099;\">Update on Oral Peptide Delivery Platform\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/UpdateOralPeptideDeliveryPlatform_20Sept2007.pdf\" target=\"_blank\">Click here to download presentation ( 347 kb)</a></span>\r\n\r\n9th May 2007\r\n<span style=\"color: #003399;\">Corporate Update - May 2007</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic-Corporate-Presentation.pdf\" target=\"_blank\">Click here to download presentation (577kb)</a>\r\n\r\n24th January 2007\r\n<span style=\"color: #000099;\">Corporate Update - January 2007\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CurrentCorporatePresentation_January2007.pdf\" target=\"_blank\">Click here to download presentation (518kb)</a></span>\r\n\r\n27th November 2006\r\n<span style=\"color: #000099;\">Metabolic Domestic Roadshow - November 2006\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MetabolicDomesticRoadshow_November2006.pdf\" target=\"_blank\">Click here to download presentation (266kb)</a>\r\n\r\n30th October 2006\r\n<span style=\"color: #0000cc;\">2006 AGM:  CEO\'s presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/16722/wmp/siqi3bsv8o\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n27th October 2006\r\n<span style=\"color: #000099;\">2006 AGM: CEO\'s presentation</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMCEOPresentation_27October2006.pdf\" target=\"_blank\">Click here to download presentation (507kb) </a>\r\n\r\n12 October 2006\r\n<span style=\"color: #000099;\">Asia Pacific Life Sciences Forum (London) 12 Ocotber 2006\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em></span><span style=\"color: #000000;\"><a href=\"/wp-content/uploads/2012/06/IntersuissePresentation_October2006.pdf\" target=\"_blank\">Click here to download presentation (425kb)</a></span>\r\n\r\n28th September 2006\r\n<span style=\"color: #000099;\">UBS Global Life Sciences Conference\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<span style=\"color: #000099;\"><a href=\"/wp-content/uploads/2012/06/UBSPresentation28Sept2006.ppt\">Click here to download presentation (4.82mb)</a></span>\r\n\r\n3rd July 2006\r\n<span style=\"color: #000099;\">Investor Roadshow (UK &amp; Europe) presentation - company update - July 2006</span>\r\n<span style=\"color: #000099;\"><em><span style=\"color: #000000;\">Roland Scollay, PhD, CEO</span>\r\n</em><a href=\"/wp-content/uploads/2012/06/UKRoadshowPresentation_July2006.pdf\" target=\"_blank\">Click here to download report (301kb)</a></span>\r\n\r\n14th June 2006\r\n<span style=\"color: #000099;\">Presentation at the Pacific Growth Equities\' <em>2006 Life Sciences Growth Conferences </em>(USA)</span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/PacificGrowthEquities_USA%20conference.pdf\" target=\"_blank\">Click here to download presentation (313kb)</a>\r\n\r\n23rd May 2006\r\n<span style=\"color: #000099;\">Roadshow presentation - company update - May 2006\r\n</span><span style=\"color: #000099;\"><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO</em> </span>\r\n</span><a href=\"/wp-content/uploads/2012/06/ASX_May23RoadshowPresentation.pdf\" target=\"_blank\">Click here to download report (323kb)</a>\r\n\r\n5th April 2006\r\n<span style=\"color: #000099;\">Presentation at US biotech conferences, 5th - 7th April 2006</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CEOUSbiotechpresentation_5April2006.pdf\" target=\"_blank\">Click here to download report (211kb)</a>\r\n\r\n14th February 2006\r\n<span style=\"color: #000099;\">Presentation to BIO-CEO Obesity Session, New York, 14th February 2006\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"New Advances in Obesity Drugs\"\r\n<a href=\"/wp-content/uploads/2012/06/BIO_CEO_OBESITY-SESSION_NY_FEB2006.pdf\" target=\"_blank\">Click here to download report (142kb)</a>\r\n\r\n8th February 2006\r\n<span style=\"color: #000099;\">Investor Roadshow Presentation, 8th February 2006 </span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/InvestorRoadshowPresentation_8Feb2006.pdf\" target=\"_blank\">Click here to download report (183kb)</a>\r\n\r\n4th November 2005\r\n<span style=\"color: #000099;\">CEO Presentation at Rodman and Renshaw Conference New York, 7 November 2005 </span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/CEOPresentationRodmanRenshaw_7Nov2005.pdf\" target=\"_blank\">Click here to download report (202kb)</a>\r\n\r\n28th October 2005\r\n<span style=\"color: #000099;\">CEO Presentation at AGM October 2005 </span>\r\n<em>Roland Scollay PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMPresentation_28Oct2005.pdf\" target=\"_blank\">Click here to download report (168kb)</a>\r\n\r\n19th October 2005\r\n<span style=\"color: #000099;\">BBY/Jeffries Health Care and Life Sciences Conference</span>\r\n<em>Roland Scollay PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/BBY_Jeffries_Conference_Sydney19Oct05.pdf\" target=\"_blank\">Click here to download report (1mb)</a>\r\n\r\n18th October 2005\r\n<span style=\"color: #000099;\">NAASO 2005 Annual Scientific Meeting</span>\r\n<em>Caroline Herd PhD </em>\r\n\"The Effect of AOD9604 on Weight Loss in Obese Adults\"\r\n<a href=\"/wp-content/uploads/2012/06/NAASO_2005presentation.pdf\" target=\"_blank\">Click here to download report (371kb)</a>\r\n\r\n10th October 2005\r\n<span style=\"color: #000099;\">Wilson HTM Biotechnology Conference</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em>\"Products to Profits\"\r\n<a href=\"/wp-content/uploads/2012/06/WilsonHTMConference_RS_10Oct2005.pdf\" target=\"_blank\">Click here to download report (96kb)</a>\r\n\r\n7th September 2005\r\n<span style=\"color: #000099;\">Southern Cross Equities Biotechnology conference\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"DNA, Devices and Dealers\"\r\n<a href=\"/wp-content/uploads/2012/06/SouthernCrossEquitiesRS_7Sept2005.pdf\" target=\"_blank\">Click here to download report (3.63mb)</a>\r\n\r\n2nd September 2005\r\n<span style=\"color: #000099;\">Venom to Drugs 2005, Conference, Heron Island</span>\r\n<em>Daniel McIntosh </em>\r\n<a href=\"/wp-content/uploads/2012/06/ACV1_PosterVenomstoDrugs_Sept2005.pdf\" target=\"_blank\">Click here to download report (123kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">US Presentations June 2005</span>\r\n<em>Roland Scollay PhD CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/USPresentations_June-20051.pdf\" target=\"_blank\">Click here to download report (264kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Boston Bio-Relationships 2005\r\n</span><em>Roland Scollay PhD CEO\r\n</em>Presentation 1: Corporate Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005CorporatePresentation_June2005.pdf\" target=\"_blank\">Click to download report (132kb)</a>\r\n\r\nPresentation 2: Diabetes Session Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005DiabetesSession_June2005.pdf\" target=\"_blank\">Click to download report (127kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">American Diabetes Association 65th Scientific Sessions San Diego</span>\r\n<em>Prof. Gary Wittert </em>\r\nAOD9604, an Orally Active Peptide for the Treatment of Obesity: Results of a Phase 2b Study\r\n<a href=\"/wp-content/uploads/2012/06/ADAposter_June20051.pdf\" target=\"_blank\">Click here to download report (106kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Share Placement Corporate Presentation June 2005</span>\r\n<em>Roland Scollay PhD CEO</em>\r\n<a href=\"wp-content/uploads/2012/06/ADAposter_June2005.pdf\" target=\"_blank\">Click here to download Presentation (1.78mb)</a>\r\n\r\n2nd May 2005\r\n<span style=\"color: #000099;\">TIDES 2005 Conference Presentation, Boston</span>\r\n<em>Dr Andrea McCracken\r\n</em>Development of the Conopeptide ACV1 for the Treatment of Neuropathic Pain\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%20ACV1_2ndMay2005.pdf\" target=\"_blank\">Click here to download the Presentation (4.65mb)</a>\r\n\r\n3rd May 2004\r\n<span style=\"color: #000099;\">TIDES 2004 Conference Presentation, Las Vegas </span>\r\n<em>Dr Caroline Herd\r\n</em>AOD9604 - An Orally Active Peptide for the Treatment of Obesity\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%202004%20Conference.pdf\" target=\"_blank\">Click to download Presentation (2.33mb)</a>\r\n\r\n17th February 2003\r\n<span style=\"color: #000099;\">Conference Presentation\r\n</span><em>Mark Heffernan</em>\r\nPresentation at the Obesity and Metabolic disorders conference, London\r\n<a href=\"/wp-content/uploads/2012/06/HeffernanUK.pdf\" target=\"_blank\">Click to download Presentation (396kb)</a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<em>Please Note:\r\nThese files are provided in Adobe PDF format, requiring the Adobe PDF Reader application to view them. This application is available to download from <span style=\"text-decoration: underline;\"><strong><a href=\"http://www.adobe.com/\" target=\"_blank\">http://www.adobe.com</a></strong></span></em>\r\n\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"15\" border=\"0\" />',	'Presentations',	'',	'inherit',	'open',	'open',	'',	'133-revision-14',	'',	'',	'2012-06-18 05:46:27',	'2012-06-18 05:46:27',	'',	133,	'http://calzada-wp.urldock.com/133-revision-14/',	0,	'revision',	'',	0),
(216,	1,	'2012-06-18 05:48:59',	'2012-06-18 05:48:59',	'<h2 class=\"feSubHeading\">Presentations</h2>\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" />\r\n\r\n15th April 2011\r\n<span style=\"color: #000099;\">AGM Presentation 2010</span>\r\n<a href=\"/wp-content/uploads/2012/06/914346.pdf\" target=\"_blank\">Click here to download presentation (1.7mb)</a>\r\n\r\n18th July 2008\r\n<span style=\"color: #000099;\">Corporate Presentation: Metabolic\'s acquisition of PolyNovo\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman of Metabolic </em>and <em>Ian Griffiths, CEO of PolyNovo\r\n</em><a href=\"/wp-content/uploads/2012/06/0823-ASX-Announcement-Corporate-Presentation-Acquisition-of-PolyNovo-18-July-2008_001.pdf\">Click here to download presentation (495 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman </em>and <em>Roland Scollay, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation.pdf\" target=\"_blank\">Click here to download presentation (432 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman</em> and <em>Roland Scollay, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/32241/wmp/poxf1u5rb8\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n20th September 2007\r\n<span style=\"color: #000099;\">Update on Oral Peptide Delivery Platform\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/UpdateOralPeptideDeliveryPlatform_20Sept2007.pdf\" target=\"_blank\">Click here to download presentation ( 347 kb)</a></span>\r\n\r\n9th May 2007\r\n<span style=\"color: #003399;\">Corporate Update - May 2007</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic-Corporate-Presentation.pdf\" target=\"_blank\">Click here to download presentation (577kb)</a>\r\n\r\n24th January 2007\r\n<span style=\"color: #000099;\">Corporate Update - January 2007\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CurrentCorporatePresentation_January2007.pdf\" target=\"_blank\">Click here to download presentation (518kb)</a></span>\r\n\r\n27th November 2006\r\n<span style=\"color: #000099;\">Metabolic Domestic Roadshow - November 2006\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MetabolicDomesticRoadshow_November2006.pdf\" target=\"_blank\">Click here to download presentation (266kb)</a>\r\n\r\n30th October 2006\r\n<span style=\"color: #0000cc;\">2006 AGM:  CEO\'s presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/16722/wmp/siqi3bsv8o\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n27th October 2006\r\n<span style=\"color: #000099;\">2006 AGM: CEO\'s presentation</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMCEOPresentation_27October2006.pdf\" target=\"_blank\">Click here to download presentation (507kb) </a>\r\n\r\n12 October 2006\r\n<span style=\"color: #000099;\">Asia Pacific Life Sciences Forum (London) 12 Ocotber 2006\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em></span><span style=\"color: #000000;\"><a href=\"/wp-content/uploads/2012/06/IntersuissePresentation_October2006.pdf\" target=\"_blank\">Click here to download presentation (425kb)</a></span>\r\n\r\n28th September 2006\r\n<span style=\"color: #000099;\">UBS Global Life Sciences Conference\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<span style=\"color: #000099;\"><a href=\"/wp-content/uploads/2012/06/UBSPresentation28Sept2006.ppt\">Click here to download presentation (4.82mb)</a></span>\r\n\r\n3rd July 2006\r\n<span style=\"color: #000099;\">Investor Roadshow (UK &amp; Europe) presentation - company update - July 2006</span>\r\n<span style=\"color: #000099;\"><em><span style=\"color: #000000;\">Roland Scollay, PhD, CEO</span>\r\n</em><a href=\"/wp-content/uploads/2012/06/UKRoadshowPresentation_July2006.pdf\" target=\"_blank\">Click here to download report (301kb)</a></span>\r\n\r\n14th June 2006\r\n<span style=\"color: #000099;\">Presentation at the Pacific Growth Equities\' <em>2006 Life Sciences Growth Conferences </em>(USA)</span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/PacificGrowthEquities_USA%20conference.pdf\" target=\"_blank\">Click here to download presentation (313kb)</a>\r\n\r\n23rd May 2006\r\n<span style=\"color: #000099;\">Roadshow presentation - company update - May 2006\r\n</span><span style=\"color: #000099;\"><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO</em> </span>\r\n</span><a href=\"/wp-content/uploads/2012/06/ASX_May23RoadshowPresentation.pdf\" target=\"_blank\">Click here to download report (323kb)</a>\r\n\r\n5th April 2006\r\n<span style=\"color: #000099;\">Presentation at US biotech conferences, 5th - 7th April 2006</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CEOUSbiotechpresentation_5April2006.pdf\" target=\"_blank\">Click here to download report (211kb)</a>\r\n\r\n14th February 2006\r\n<span style=\"color: #000099;\">Presentation to BIO-CEO Obesity Session, New York, 14th February 2006\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"New Advances in Obesity Drugs\"\r\n<a href=\"/wp-content/uploads/2012/06/BIO_CEO_OBESITY-SESSION_NY_FEB2006.pdf\" target=\"_blank\">Click here to download report (142kb)</a>\r\n\r\n8th February 2006\r\n<span style=\"color: #000099;\">Investor Roadshow Presentation, 8th February 2006 </span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/InvestorRoadshowPresentation_8Feb2006.pdf\" target=\"_blank\">Click here to download report (183kb)</a>\r\n\r\n4th November 2005\r\n<span style=\"color: #000099;\">CEO Presentation at Rodman and Renshaw Conference New York, 7 November 2005 </span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/CEOPresentationRodmanRenshaw_7Nov2005.pdf\" target=\"_blank\">Click here to download report (202kb)</a>\r\n\r\n28th October 2005\r\n<span style=\"color: #000099;\">CEO Presentation at AGM October 2005 </span>\r\n<em>Roland Scollay PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMPresentation_28Oct2005.pdf\" target=\"_blank\">Click here to download report (168kb)</a>\r\n\r\n19th October 2005\r\n<span style=\"color: #000099;\">BBY/Jeffries Health Care and Life Sciences Conference</span>\r\n<em>Roland Scollay PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/BBY_Jeffries_Conference_Sydney19Oct05.pdf\" target=\"_blank\">Click here to download report (1mb)</a>\r\n\r\n18th October 2005\r\n<span style=\"color: #000099;\">NAASO 2005 Annual Scientific Meeting</span>\r\n<em>Caroline Herd PhD </em>\r\n\"The Effect of AOD9604 on Weight Loss in Obese Adults\"\r\n<a href=\"/wp-content/uploads/2012/06/NAASO_2005presentation.pdf\" target=\"_blank\">Click here to download report (371kb)</a>\r\n\r\n10th October 2005\r\n<span style=\"color: #000099;\">Wilson HTM Biotechnology Conference</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em>\"Products to Profits\"\r\n<a href=\"/wp-content/uploads/2012/06/WilsonHTMConference_RS_10Oct2005.pdf\" target=\"_blank\">Click here to download report (96kb)</a>\r\n\r\n7th September 2005\r\n<span style=\"color: #000099;\">Southern Cross Equities Biotechnology conference\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"DNA, Devices and Dealers\"\r\n<a href=\"/wp-content/uploads/2012/06/SouthernCrossEquitiesRS_7Sept2005.pdf\" target=\"_blank\">Click here to download report (3.63mb)</a>\r\n\r\n2nd September 2005\r\n<span style=\"color: #000099;\">Venom to Drugs 2005, Conference, Heron Island</span>\r\n<em>Daniel McIntosh </em>\r\n<a href=\"/wp-content/uploads/2012/06/ACV1_PosterVenomstoDrugs_Sept2005.pdf\" target=\"_blank\">Click here to download report (123kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">US Presentations June 2005</span>\r\n<em>Roland Scollay PhD CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/USPresentations_June-20051.pdf\" target=\"_blank\">Click here to download report (264kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Boston Bio-Relationships 2005\r\n</span><em>Roland Scollay PhD CEO\r\n</em>Presentation 1: Corporate Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005CorporatePresentation_June2005.pdf\" target=\"_blank\">Click to download report (132kb)</a>\r\n\r\nPresentation 2: Diabetes Session Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005DiabetesSession_June2005.pdf\" target=\"_blank\">Click to download report (127kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">American Diabetes Association 65th Scientific Sessions San Diego</span>\r\n<em>Prof. Gary Wittert </em>\r\nAOD9604, an Orally Active Peptide for the Treatment of Obesity: Results of a Phase 2b Study\r\n<a href=\"/wp-content/uploads/2012/06/ADAposter_June20051.pdf\" target=\"_blank\">Click here to download report (106kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Share Placement Corporate Presentation June 2005</span>\r\n<em>Roland Scollay PhD CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/ADAposter_June2005.pdf\" target=\"_blank\">Click here to download Presentation (1.78mb)</a>\r\n\r\n2nd May 2005\r\n<span style=\"color: #000099;\">TIDES 2005 Conference Presentation, Boston</span>\r\n<em>Dr Andrea McCracken\r\n</em>Development of the Conopeptide ACV1 for the Treatment of Neuropathic Pain\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%20ACV1_2ndMay2005.pdf\" target=\"_blank\">Click here to download the Presentation (4.65mb)</a>\r\n\r\n3rd May 2004\r\n<span style=\"color: #000099;\">TIDES 2004 Conference Presentation, Las Vegas </span>\r\n<em>Dr Caroline Herd\r\n</em>AOD9604 - An Orally Active Peptide for the Treatment of Obesity\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%202004%20Conference.pdf\" target=\"_blank\">Click to download Presentation (2.33mb)</a>\r\n\r\n17th February 2003\r\n<span style=\"color: #000099;\">Conference Presentation\r\n</span><em>Mark Heffernan</em>\r\nPresentation at the Obesity and Metabolic disorders conference, London\r\n<a href=\"/wp-content/uploads/2012/06/HeffernanUK.pdf\" target=\"_blank\">Click to download Presentation (396kb)</a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<em>Please Note:\r\nThese files are provided in Adobe PDF format, requiring the Adobe PDF Reader application to view them. This application is available to download from <span style=\"text-decoration: underline;\"><strong><a href=\"http://www.adobe.com/\" target=\"_blank\">http://www.adobe.com</a></strong></span></em>\r\n\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"15\" border=\"0\" />',	'Presentations',	'',	'inherit',	'open',	'open',	'',	'133-revision-15',	'',	'',	'2012-06-18 05:48:59',	'2012-06-18 05:48:59',	'',	133,	'http://calzada-wp.urldock.com/133-revision-15/',	0,	'revision',	'',	0),
(217,	1,	'2012-06-18 05:52:31',	'2012-06-18 05:52:31',	'<h2 class=\"feSubHeading\">Presentations</h2>\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" />\r\n\r\n15th April 2011\r\n<span style=\"color: #000099;\">AGM Presentation 2010</span>\r\n<a href=\"/wp-content/uploads/2012/06/914346.pdf\" target=\"_blank\">Click here to download presentation (1.7mb)</a>\r\n\r\n18th July 2008\r\n<span style=\"color: #000099;\">Corporate Presentation: Metabolic\'s acquisition of PolyNovo\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman of Metabolic </em>and <em>Ian Griffiths, CEO of PolyNovo\r\n</em><a href=\"/wp-content/uploads/2012/06/0823-ASX-Announcement-Corporate-Presentation-Acquisition-of-PolyNovo-18-July-2008_001.pdf\">Click here to download presentation (495 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman </em>and <em>Roland Scollay, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation.pdf\" target=\"_blank\">Click here to download presentation (432 kb)</a></span>\r\n\r\n2nd November 2007\r\n<span style=\"color: #000099;\">2007 AGM Presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Rob Stewart, Chairman</em> and <em>Roland Scollay, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/32241/wmp/poxf1u5rb8\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n20th September 2007\r\n<span style=\"color: #000099;\">Update on Oral Peptide Delivery Platform\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/UpdateOralPeptideDeliveryPlatform_20Sept2007.pdf\" target=\"_blank\">Click here to download presentation ( 347 kb)</a></span>\r\n\r\n9th May 2007\r\n<span style=\"color: #003399;\">Corporate Update - May 2007</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic-Corporate-Presentation.pdf\" target=\"_blank\">Click here to download presentation (577kb)</a>\r\n\r\n24th January 2007\r\n<span style=\"color: #000099;\">Corporate Update - January 2007\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CurrentCorporatePresentation_January2007.pdf\" target=\"_blank\">Click here to download presentation (518kb)</a></span>\r\n\r\n27th November 2006\r\n<span style=\"color: #000099;\">Metabolic Domestic Roadshow - November 2006\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/MetabolicDomesticRoadshow_November2006.pdf\" target=\"_blank\">Click here to download presentation (266kb)</a>\r\n\r\n30th October 2006\r\n<span style=\"color: #0000cc;\">2006 AGM:  CEO\'s presentation (AUDIO WEBCAST)\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em><a href=\"http://www.brr.com.au/event/MBP/1281/16722/wmp/siqi3bsv8o\" target=\"_blank\">Click here to listen to an audio webcast of the presentation</a></span>\r\n\r\n27th October 2006\r\n<span style=\"color: #000099;\">2006 AGM: CEO\'s presentation</span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMCEOPresentation_27October2006.pdf\" target=\"_blank\">Click here to download presentation (507kb) </a>\r\n\r\n12 October 2006\r\n<span style=\"color: #000099;\">Asia Pacific Life Sciences Forum (London) 12 Ocotber 2006\r\n</span><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO\r\n</em></span><span style=\"color: #000000;\"><a href=\"/wp-content/uploads/2012/06/IntersuissePresentation_October2006.pdf\" target=\"_blank\">Click here to download presentation (425kb)</a></span>\r\n\r\n28th September 2006\r\n<span style=\"color: #000099;\">UBS Global Life Sciences Conference\r\n</span><em>Roland Scollay, PhD, CEO</em>\r\n<span style=\"color: #000099;\"><a href=\"/wp-content/uploads/2012/06/UBSPresentation28Sept2006.ppt\">Click here to download presentation (4.82mb)</a></span>\r\n\r\n3rd July 2006\r\n<span style=\"color: #000099;\">Investor Roadshow (UK &amp; Europe) presentation - company update - July 2006</span>\r\n<span style=\"color: #000099;\"><em><span style=\"color: #000000;\">Roland Scollay, PhD, CEO</span>\r\n</em><a href=\"/wp-content/uploads/2012/06/UKRoadshowPresentation_July2006.pdf\" target=\"_blank\">Click here to download report (301kb)</a></span>\r\n\r\n14th June 2006\r\n<span style=\"color: #000099;\">Presentation at the Pacific Growth Equities\' <em>2006 Life Sciences Growth Conferences </em>(USA)</span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/PacificGrowthEquities_USA%20conference.pdf\" target=\"_blank\">Click here to download presentation (313kb)</a>\r\n\r\n23rd May 2006\r\n<span style=\"color: #000099;\">Roadshow presentation - company update - May 2006\r\n</span><span style=\"color: #000099;\"><span style=\"color: #000000;\"><em>Roland Scollay, PhD, CEO</em> </span>\r\n</span><a href=\"/wp-content/uploads/2012/06/ASX_May23RoadshowPresentation.pdf\" target=\"_blank\">Click here to download report (323kb)</a>\r\n\r\n5th April 2006\r\n<span style=\"color: #000099;\">Presentation at US biotech conferences, 5th - 7th April 2006</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/CEOUSbiotechpresentation_5April2006.pdf\" target=\"_blank\">Click here to download report (211kb)</a>\r\n\r\n14th February 2006\r\n<span style=\"color: #000099;\">Presentation to BIO-CEO Obesity Session, New York, 14th February 2006\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"New Advances in Obesity Drugs\"\r\n<a href=\"/wp-content/uploads/2012/06/BIO_CEO_OBESITY-SESSION_NY_FEB2006.pdf\" target=\"_blank\">Click here to download report (142kb)</a>\r\n\r\n8th February 2006\r\n<span style=\"color: #000099;\">Investor Roadshow Presentation, 8th February 2006 </span>\r\n<em>Roland Scollay, PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/InvestorRoadshowPresentation_8Feb2006.pdf\" target=\"_blank\">Click here to download report (183kb)</a>\r\n\r\n4th November 2005\r\n<span style=\"color: #000099;\">CEO Presentation at Rodman and Renshaw Conference New York, 7 November 2005 </span>\r\n<em>Roland Scollay, PhD, CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/CEOPresentationRodmanRenshaw_7Nov2005.pdf\" target=\"_blank\">Click here to download report (202kb)</a>\r\n\r\n28th October 2005\r\n<span style=\"color: #000099;\">CEO Presentation at AGM October 2005 </span>\r\n<em>Roland Scollay PhD, CEO </em>\r\n<a href=\"/wp-content/uploads/2012/06/AGMPresentation_28Oct2005.pdf\" target=\"_blank\">Click here to download report (168kb)</a>\r\n\r\n19th October 2005\r\n<span style=\"color: #000099;\">BBY/Jeffries Health Care and Life Sciences Conference</span>\r\n<em>Roland Scollay PhD, CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/BBY_Jeffries_Conference_Sydney19Oct05.pdf\" target=\"_blank\">Click here to download report (1mb)</a>\r\n\r\n18th October 2005\r\n<span style=\"color: #000099;\">NAASO 2005 Annual Scientific Meeting</span>\r\n<em>Caroline Herd PhD </em>\r\n\"The Effect of AOD9604 on Weight Loss in Obese Adults\"\r\n<a href=\"/wp-content/uploads/2012/06/NAASO_2005presentation.pdf\" target=\"_blank\">Click here to download report (371kb)</a>\r\n\r\n10th October 2005\r\n<span style=\"color: #000099;\">Wilson HTM Biotechnology Conference</span>\r\n<em>Roland Scollay, PhD, CEO\r\n</em>\"Products to Profits\"\r\n<a href=\"/wp-content/uploads/2012/06/WilsonHTMConference_RS_10Oct2005.pdf\" target=\"_blank\">Click here to download report (96kb)</a>\r\n\r\n7th September 2005\r\n<span style=\"color: #000099;\">Southern Cross Equities Biotechnology conference\r\n</span><em>Roland Scollay, PhD, CEO\r\n</em>\"DNA, Devices and Dealers\"\r\n<a href=\"/wp-content/uploads/2012/06/SouthernCrossEquitiesRS_7Sept2005.pdf\" target=\"_blank\">Click here to download report (3.63mb)</a>\r\n\r\n2nd September 2005\r\n<span style=\"color: #000099;\">Venom to Drugs 2005, Conference, Heron Island</span>\r\n<em>Daniel McIntosh </em>\r\n<a href=\"/wp-content/uploads/2012/06/ACV1_PosterVenomstoDrugs_Sept2005.pdf\" target=\"_blank\">Click here to download report (123kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">US Presentations June 2005</span>\r\n<em>Roland Scollay PhD CEO\r\n</em><a href=\"/wp-content/uploads/2012/06/USPresentations_June-20051.pdf\" target=\"_blank\">Click here to download report (264kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Boston Bio-Relationships 2005\r\n</span><em>Roland Scollay PhD CEO\r\n</em>Presentation 1: Corporate Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005CorporatePresentation_June2005.pdf\" target=\"_blank\">Click to download report (132kb)</a>\r\n\r\nPresentation 2: Diabetes Session Presentation\r\n<a href=\"/wp-content/uploads/2012/06/BostonBio2005DiabetesSession_June2005.pdf\" target=\"_blank\">Click to download report (127kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">American Diabetes Association 65th Scientific Sessions San Diego</span>\r\n<em>Prof. Gary Wittert </em>\r\nAOD9604, an Orally Active Peptide for the Treatment of Obesity: Results of a Phase 2b Study\r\n<a href=\"/wp-content/uploads/2012/06/ADAposter_June20051.pdf\" target=\"_blank\">Click here to download report (106kb)</a>\r\n\r\n14th June 2005\r\n<span style=\"color: #000099;\">Share Placement Corporate Presentation June 2005</span>\r\n<em>Roland Scollay PhD CEO</em>\r\n<a href=\"/wp-content/uploads/2012/06/ADAposter_June2005.pdf\" target=\"_blank\">Click here to download Presentation (1.78mb)</a>\r\n\r\n2nd May 2005\r\n<span style=\"color: #000099;\">TIDES 2005 Conference Presentation, Boston</span>\r\n<em>Dr Andrea McCracken\r\n</em>Development of the Conopeptide ACV1 for the Treatment of Neuropathic Pain\r\n<a href=\"/wp-content/uploads/2012/06/TIDES-ACV1_2ndMay2005.pdf\" target=\"_blank\">Click here to download the Presentation (4.65mb)</a>\r\n\r\n3rd May 2004\r\n<span style=\"color: #000099;\">TIDES 2004 Conference Presentation, Las Vegas </span>\r\n<em>Dr Caroline Herd\r\n</em>AOD9604 - An Orally Active Peptide for the Treatment of Obesity\r\n<a href=\"/wp-content/uploads/2012/06/TIDES%202004%20Conference.pdf\" target=\"_blank\">Click to download Presentation (2.33mb)</a>\r\n\r\n17th February 2003\r\n<span style=\"color: #000099;\">Conference Presentation\r\n</span><em>Mark Heffernan</em>\r\nPresentation at the Obesity and Metabolic disorders conference, London\r\n<a href=\"/wp-content/uploads/2012/06/HeffernanUK.pdf\" target=\"_blank\">Click to download Presentation (396kb)</a>\r\n\r\n&nbsp;\r\n\r\n&nbsp;\r\n\r\n<em>Please Note:\r\nThese files are provided in Adobe PDF format, requiring the Adobe PDF Reader application to view them. This application is available to download from <span style=\"text-decoration: underline;\"><strong><a href=\"http://www.adobe.com/\" target=\"_blank\">http://www.adobe.com</a></strong></span></em>\r\n\r\n<img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"15\" border=\"0\" />',	'Presentations',	'',	'inherit',	'open',	'open',	'',	'133-revision-16',	'',	'',	'2012-06-18 05:52:31',	'2012-06-18 05:52:31',	'',	133,	'http://calzada-wp.urldock.com/133-revision-16/',	0,	'revision',	'',	0),
(218,	1,	'2012-08-24 03:43:15',	'2012-08-24 03:43:15',	'Click on a year to view links to PDFs\n[jaccordion size=\"xsmall\" theme=\"smoothness\" active=\"0\"]\nASX Releases 2012::\n<table id=\"theTable3\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td colspan=\"2\"><img src=\"../../html/images/trans.gif\" alt=\"\" width=\"9\" height=\"1\" border=\"0\" /></td>\n</tr>\n<tr>\n<td> </td>\n<td>\n<h2 class=\"feSubHeading\">ASX Releases 2012</h2>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\"><img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" /></td>\n</tr>\n<tr>\n<td> </td>\n</tr>\n</tbody>\n</table>\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td> </td>\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/Annual-Report-2012.pdf\">Appendix 4E and 2012 Annual Report</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Appendix 4E and 2012 Annual Report</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/POlyNovo-Clinical-Trial-and-Composite-Cultured-Skin-Update.pdf\">PolyNovo Clinical Trial and Composite Cultured Skin Update</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>PolyNovo Clinical Trial and Composite Cultured Skin Update</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/Dr-David-McQuillan-to-Join-the-Calzada-Board_8-Aug-12.pdf\">Dr David McQuillan to Join the Calzada Board</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Dr David McQuillan to Join the Calzada Board</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/PolyNovo-US-Patent-Allowed_7-Aug-12.pdf\">PolyNovo US Patent Allowed</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>PolyNovo US Patent Allowed</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX-Ann_30-Jul-12.pdf\">NovoSorb Vac Human Clinical Trial Update</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>NovoSorb Vac Human Clinical Trial Update</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/132F042F2012103A223A30PM.pdf\">PolyNovo human Trial Update</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>PolyNovo human Trial Update</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/132F042F2012103A223A05PM.pdf\">AOD positive in Cartilage and Muscle Repair</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>AOD positive in Cartilage and Muscle Repair</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/132F042F2012103A213A23PM.pdf\">PolyNovo Commences Second Human Trial</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>PolyNovo Commences Second Human Trial</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/1074690.pdf\" target=\"_blank\">PolyNovo to Commence Human Trial </a></td>\n</tr>\n<tr>\n<td> </td>\n<td>PolyNovo to Commence Human Trial</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/1073489.pdf\" target=\"_blank\">PolyNovo’s US Collaboration Update</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>PolyNovo’s US Collaboration Update</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/1065480.pdf\" target=\"_blank\">Update on US Partner Collaboration </a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Update on US Partner Collaboration</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n</tbody>\n</table>\n[jacc/]\nASX Releases 2011::\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td> </td>\n<td>\n<h2 class=\"feSubHeading\">ASX Releases 2011</h2>\n</td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/1059707.pdf\" target=\"_blank\">New Applications for AOD9604</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>New Applications for AOD9604</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/Successful_Proof_of_Concept_for_Synthetic_Skin.pdf\" target=\"_blank\">Successful Proof of Concept for Synthetic Skin</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Successful Proof of Concept for Synthetic Skin</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/1030228.pdf\" target=\"_blank\">Changes to Executive Structure</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Changes to Executive Structure</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/1030275.pdf\" target=\"_blank\">Cancellation of Options </a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Cancellation of Options</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p9.pdf\" target=\"_blank\">Notice of Annual General Meeting and Proxy Form</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Notice of Annual General Meeting and Proxy Form</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/Major_Milestone_for_PolyNovo_and_NovoSorbTM.pdf\" target=\"_blank\">Major Milestone for PolyNovo and NovoSorbTM : First Human Study</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Major Milestone for PolyNovo and NovoSorbTM : First Human Study</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/1007282.pdf\" target=\"_blank\">Operational Update and Financial Result Guidance </a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Operational Update and Financial Result Guidance</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/1899_Calzada_Shareholder_Newsletter_FINAL1.pdf\" target=\"_blank\">Calzada Shareholder Newsletter</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Calzada Shareholder Newsletter</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/980299.pdf\" target=\"_blank\">Metabolic’s Osteoporosis Patent Allowed in US </a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Metabolic’s Osteoporosis Patent Allowed in US</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/979227.pdf\" target=\"_blank\">Phosphagenics Bodyshaper Update</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Phosphagenics Bodyshaper Update</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/POH_Annoucnement.pdf\" target=\"_blank\">Phosphagenics to launch new cellulite cosmetics</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Phosphagenics to launch new cellulite cosmetics</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/967193.pdf\" target=\"_blank\">Calzada Transfers Neural Regeneration Peptides Technology</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Calzada Transfers Neural Regeneration Peptides Technology</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/963942.pdf\" target=\"_blank\">First PolyNovo Patent Allowed in US</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>First PolyNovo Patent Allowed in US</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/962630.pdf\" target=\"_blank\">Burn Surgeon John Greenwood receives the inaugural Burke/Yannas prize at the American Burn Association conference</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Burn Surgeon John Greenwood receives the inaugural Burke/Yannas prize at the American Burn Association conference</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/963942.pdf\" target=\"_blank\">Board Changes</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Board Changes</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/953112.pdf\" target=\"_blank\">PolyNovo successfully completes pivotal animal study on burns device</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>PolyNovo successfully completes pivotal animal study on burns device</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/947775.pdf\" target=\"_blank\">Results for the Half Year Ended 31 December 2010</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Half year results and accounts</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/943726.pdf\">AOD9604 shows positive results in human stem cell assay for bone growth</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>AOD9604 shows positive results in human stem cell assay for bone growth</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p2.pdf\">Feasibility study extended by 12 months</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Feasibility study extended by 12 months</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p3.pdf\">Update of Black Market Sales of AOD</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Update of Black Market Sales of AOD</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p4.pdf\">Appointment of Dr Stewart Washer</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Appointment of Dr Stewart Washer</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n</tbody>\n</table>\n[jacc/]\nASX Releases 2010::\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td> </td>\n<td>\n<h2 class=\"feSubHeading\">ASX Releases 2010</h2>\n</td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p5.pdf\">Calzada sells Avexa Shares</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Calzada sells Avexa Shares</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p6.pdf\">Calzada signs Licensing Agreement with Phosphagenics</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Calzada signs Licensing Agreement with Phosphagenics</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p7.pdf\">Dr John Chiplin appointed to Calzada Board</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Dr John Chiplin appointed to Calzada Board</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p8.pdf\">Calzada - 2010 Annual Report</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Calzada - 2010 Annual Report</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=750&amp;nav_cat_id=205&amp;nav_top_id=58\">Notice of Annual General Meeting</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Notice of Annual General Meeting</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p10.pdf\">Calzada responds to claims made by Avexa Limited</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Calzada responds to claims made by Avexa Limited</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p11.pdf\">Email correspondence with Avexa – combining Avexa EGM with Avexa AGM </a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Email correspondence with Avexa – combining Avexa EGM with Avexa AGM</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p12.pdf\">Phosphagenics exercises option to licence AOD9604 to develop topical cellulite product</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Phosphagenics exercises option to licence AOD9604 to develop topical cellulite product</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p13.pdf\">Calzada to vend Metabolic into ATOS Wellness </a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Calzada to vend Metabolic into ATOS Wellness</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p14.pdf\">Change of Director\'s Interest NoticeChange of Director\'s Interest Notice</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Change of Director\'s Interest Notice</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p15.pdf\">Replacement response to the Age newspaper articleReplacement response to the Age newspaper article</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Replacement response to the Age newspaper article</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p16.pdf\">Calzada responds to The Age newspaper article</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Calzada responds to The Age newspaper article</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p17.pdf\">Half Year Report and Accounts</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Half Year Report and Accounts</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p18.pdf\">Final Director\'s Interest Notice</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Final Director\'s Interest Notice</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p19.pdf\">Initial Director\'s Interest Notice </a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Initial Director\'s Interest Notice</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p20.pdf\">Appendix 3B </a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Appendix 3B</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p21.pdf\">Calzada moves to 100% ownership of PolyNovo </a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Calzada moves to 100% ownership of PolyNovo</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p22.pdf\">Change in substantial holding Change in substantial holding </a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Change in substantial holding</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/p23.pdf\">Becoming a substantial holder from XCD </a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Becoming a substantial holder from XCD</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n</tbody>\n</table>\n[jacc/]\nASX Releases 2009::\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td> </td>\n<td>\n<h2 class=\"feSubHeading\">ASX Releases 2012</h2>\n</td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp1.pdf\">Initial Director\'s Interest Notice - Oliver Stevens</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Initial Director\'s Interest Notice - Oliver Stevens</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp2.pdf\">Initial Director\' Interest Notice - David Franklyn</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Initial Director\' Interest Notice - David Franklyn</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp3.pdf\">Initial Director\'s Interest Notice - George Cameron-Dow</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Initial Director\'s Interest Notice - George Cameron-Dow</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp4.pdf\">Initial Director\'s Interest Notice - David Kenley</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Initial Director\'s Interest Notice - David Kenley</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp5.pdf\">Changes to Company Board</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Changes to Company Board</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp6.pdf\">Appendix 3Z - I Kirkwood</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Appendix 3Z - I Kirkwood</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp7.pdf\">Appendix 3Z - Paul Lappin</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Final Directors interest Notice - P Lappin</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp8.pdf\">7 April 09 Initial Substantial Holder - Entrust </a></td>\n</tr>\n<tr>\n<td> </td>\n<td>7 April 09 Initial Substantil Holder - Entrust picks up 19.81%</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp9.pdf\">7 Aprl 09 - Ceasing o be a substantal holder - Tony Moore</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Ceasingto be a substantil holder - Tony Moore</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp10.pdf\">2 April 2009 Substantial Shareholder Notice - Tony Moore</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Tony Moore purchases substantial shareholding</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp11.pdf\">31 March 2009 Final Directors Interest Notice 3Z F. Brazil</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>31 March 2009 Final Directors Interest Notice</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp12.pdf\">Changes to Metabolic Board</a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Board Changes</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp13.pdf\">10th March 2009 Appendix 3B </a></td>\n</tr>\n<tr>\n<td> </td>\n<td>Options expiry</td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp14.pdf\">10 March 2009 - Appendix 3B</a></td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp15.pdf\">6 March 2009 - Changes to PolyNovo Board and Management</a></td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp16.pdf\">4 March 2009 - First NovoSorb Patent Granted in Australia</a></td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp17.pdf\">26 February 2009 - Appendix 4D Half Yearly Report and Accounts</a></td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp18.pdf\">23 February 2009 - Changes to Metabolic Chairman and Company Secretary</a></td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp19.pdf\">23 February 2009 - Appendix 3Z - Final Director\'s Interest Notice</a></td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp20.pdf\">2 February 2009 - Changes to Metabolic and PolyNovo Board</a></td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp21.pdf\">30 January 2009 - Appendix 3B</a></td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n<tr>\n<td colspan=\"2\"> </td>\n</tr>\n<tr>\n<td> </td>\n<td><a href=\"/wp-content/uploads/2012/06/pp22.pdf\">9th January 2009 - Change of Registered Office and Place of Business Address</a></td>\n</tr>\n</tbody>\n</table>\n[/jaccordion]',	'ASX Announcements',	'',	'inherit',	'open',	'open',	'',	'141-autosave',	'',	'',	'2012-08-24 03:43:15',	'2012-08-24 03:43:15',	'',	141,	'http://calzada-wp.urldock.com/141-autosave/',	0,	'revision',	'',	0),
(219,	1,	'2012-08-24 03:39:33',	'2012-08-24 03:39:33',	'<table>\r\n<tbody>\r\n<tr>\r\n<td>\r\n<h2 class=\"feSubHeading\">Annual Reports</h2>\r\n</td>\r\n</tr>\r\n<tr>\r\n<td>Related Files:</td>\r\n</tr>\r\n<tr>\r\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/2010_Annual_Report.pdf\">Annual Report - for Year Ended 30 June 2010</a></td>\r\n</tr>\r\n<tr>\r\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/31_December_2010_Financial_statements_FINAL.pdf\">Half Year Financial Report - for half Year Ended 31 Dec 2010</a></td>\r\n</tr>\r\n<tr>\r\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/2011_Annual_Report_Calzada_FY11_FINAL_version.pdf\">Annual Report - for Year Ended 30 June 2011</a></td>\r\n</tr>\r\n<tr>\r\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/31-December-2011-Financial-statements-Final.pdf\">Half Year Financial Report - for half Year Ended 31 Dec 2011</a></td>\r\n</tr>\r\n<tr>\r\n<td><a href=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/06/2012-Annual-Report_ONLY.pdf\">Annual Report - For Year ended 30 June 2012</a></td>\r\n</tr>\r\n</tbody>\r\n</table>',	'Financial Reports',	'',	'inherit',	'open',	'open',	'',	'143-autosave',	'',	'',	'2012-08-24 03:39:33',	'2012-08-24 03:39:33',	'',	143,	'http://calzada-wp.urldock.com/143-autosave/',	0,	'revision',	'',	0),
(220,	1,	'2012-06-18 06:03:25',	'2012-06-18 06:03:25',	'',	'Annual Report - for Year Ended 30 June 2010',	'',	'inherit',	'open',	'open',	'',	'2010_annual_report',	'',	'',	'2012-06-18 06:03:25',	'2012-06-18 06:03:25',	'',	143,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/2010_Annual_Report.pdf',	0,	'attachment',	'application/pdf',	0),
(221,	1,	'2012-06-18 06:03:47',	'2012-06-18 06:03:47',	'',	'Annual Report - for Year Ended 30 June 2011',	'',	'inherit',	'open',	'open',	'',	'2011_annual_report_calzada_fy11_final_version',	'',	'',	'2012-06-18 06:03:47',	'2012-06-18 06:03:47',	'',	143,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/2011_Annual_Report_Calzada_FY11_FINAL_version.pdf',	0,	'attachment',	'application/pdf',	0),
(222,	1,	'2012-06-18 06:03:59',	'2012-06-18 06:03:59',	'',	'Half Year Financial Report - for half Year Ended 31 Dec 2010',	'',	'inherit',	'open',	'open',	'',	'31_december_2010_financial_statements_final',	'',	'',	'2012-06-18 06:03:59',	'2012-06-18 06:03:59',	'',	143,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/31_December_2010_Financial_statements_FINAL.pdf',	0,	'attachment',	'application/pdf',	0),
(223,	1,	'2012-06-18 02:48:10',	'2012-06-18 02:48:10',	'',	'Financial Reports',	'',	'inherit',	'open',	'open',	'',	'143-revision-2',	'',	'',	'2012-06-18 02:48:10',	'2012-06-18 02:48:10',	'',	143,	'http://calzada-wp.urldock.com/143-revision-2/',	0,	'revision',	'',	0),
(224,	1,	'2012-06-18 02:47:54',	'2012-06-18 02:47:54',	'',	'ASX Announcements',	'',	'inherit',	'open',	'open',	'',	'141-revision-2',	'',	'',	'2012-06-18 02:47:54',	'2012-06-18 02:47:54',	'',	141,	'http://calzada-wp.urldock.com/141-revision-2/',	0,	'revision',	'',	0),
(225,	1,	'2012-06-18 06:10:33',	'2012-06-18 06:10:33',	'&nbsp;\n<table id=\"theTable3\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td colspan=\"2\"><img src=\"../../html/images/trans.gif\" alt=\"\" width=\"9\" height=\"1\" border=\"0\" /></td>\n</tr>\n<tr>\n<td></td>\n<td>\n<h2 class=\"feSubHeading\">ASX Releases</h2>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\"><img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" /></td>\n</tr>\n<tr>\n<td></td>\n<td id=\"theCell1\" width=\"100%\">\n<h3>ASX Releases 2012</h3>\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td></td>\n<td><a href=\"../../files/nrteUploadFiles/132F042F2012103A223A30PM.pdf\">PolyNovo human Trial Update</a></td>\n</tr>\n<tr>\n<td></td>\n<td>PolyNovo human Trial Update</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/nrteUploadFiles/132F042F2012103A223A05PM.pdf\">AOD positive in Cartilage and Muscle Repair</a></td>\n</tr>\n<tr>\n<td></td>\n<td>AOD positive in Cartilage and Muscle Repair</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/nrteUploadFiles/132F042F2012103A213A23PM.pdf\">PolyNovo Commences Second Human Trial</a></td>\n</tr>\n<tr>\n<td></td>\n<td>PolyNovo Commences Second Human Trial</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/7KV5CN9ACM/1074690.pdf\" target=\"_blank\">PolyNovo to Commence Human Trial </a></td>\n</tr>\n<tr>\n<td></td>\n<td>PolyNovo to Commence Human Trial</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/VI8KS8QBYQ/1073489.pdf\" target=\"_blank\">PolyNovo’s US Collaboration Update</a></td>\n</tr>\n<tr>\n<td></td>\n<td>PolyNovo’s US Collaboration Update</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/PE6SXJPOWV/1065480.pdf\" target=\"_blank\">Update on US Partner Collaboration </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Update on US Partner Collaboration</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n</tbody>\n</table>\n<h3>ASX Releases 2011</h3>\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=779&amp;nav_cat_id=210&amp;nav_top_id=58\" target=\"_blank\">New Applications for AOD9604</a></td>\n</tr>\n<tr>\n<td></td>\n<td>New Applications for AOD9604</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/T0LVRP791V/Successful_Proof_of_Concept_for_Synthetic_Skin.pdf\" target=\"_blank\">Successful Proof of Concept for Synthetic Skin</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Successful Proof of Concept for Synthetic Skin</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/0PN6AY3NQ1/1030228.pdf\" target=\"_blank\">Changes to Executive Structure</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Changes to Executive Structure</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/YTQSRE5DZ6/1030275.pdf\" target=\"_blank\">Cancellation of Options </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Cancellation of Options</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/LCSRNFXB5N/Notice_of_Annual_General_Meeting_and_Proxy_Form.pdf\" target=\"_blank\">Notice of Annual General Meeting and Proxy Form</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Notice of Annual General Meeting and Proxy Form</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/I5QTOLI9A9/Major_Milestone_for_PolyNovo_and_NovoSorbTM.pdf\" target=\"_blank\">Major Milestone for PolyNovo and NovoSorbTM : First Human Study</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Major Milestone for PolyNovo and NovoSorbTM : First Human Study</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/O6R74NC0D5/1007282.pdf\" target=\"_blank\">Operational Update and Financial Result Guidance </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Operational Update and Financial Result Guidance</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/AMQJC8TS9Q/1899_Calzada_Shareholder_Newsletter_FINAL.pdf\" target=\"_blank\">Calzada Shareholder Newsletter</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Calzada Shareholder Newsletter</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/4RBQ1B3DAB/980299.pdf\" target=\"_blank\">Metabolic’s Osteoporosis Patent Allowed in US </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic’s Osteoporosis Patent Allowed in US</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/2AGG3QQU8G/979227.pdf\" target=\"_blank\">Phosphagenics Bodyshaper Update</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Phosphagenics Bodyshaper Update</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/MUJND3H4D2/POH_Annoucnement.pdf\" target=\"_blank\">Phosphagenics to launch new cellulite cosmetics</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Phosphagenics to launch new cellulite cosmetics</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/NBCSI1IA7N/967193.pdf\" target=\"_blank\">Calzada Transfers Neural Regeneration Peptides Technology</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Calzada Transfers Neural Regeneration Peptides Technology</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/GXDY7II1LI/963942.pdf\" target=\"_blank\">First PolyNovo Patent Allowed in US</a></td>\n</tr>\n<tr>\n<td></td>\n<td>First PolyNovo Patent Allowed in US</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/OVUR3LRR0C/962630.pdf\" target=\"_blank\">Burn Surgeon John Greenwood receives the inaugural Burke/Yannas prize at the American Burn Association conference</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Burn Surgeon John Greenwood receives the inaugural Burke/Yannas prize at the American Burn Association conference</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/LPMGVTEWFO/962429.pdf\" target=\"_blank\">Board Changes</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Board Changes</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/6K83IAZE8C/953112.pdf\" target=\"_blank\">PolyNovo successfully completes pivotal animal study on burns device</a></td>\n</tr>\n<tr>\n<td></td>\n<td>PolyNovo successfully completes pivotal animal study on burns device</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../files/SDLHX9D51M/947775.pdf\" target=\"_blank\">Results for the Half Year Ended 31 December 2010</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Half year results and accounts</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=760&amp;nav_cat_id=210&amp;nav_top_id=58\">AOD9604 shows positive results in human stem cell assay for bone growth</a></td>\n</tr>\n<tr>\n<td></td>\n<td>AOD9604 shows positive results in human stem cell assay for bone growth</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=757&amp;nav_cat_id=210&amp;nav_top_id=58\">Feasibility study extended by 12 months</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Feasibility study extended by 12 months</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=758&amp;nav_cat_id=210&amp;nav_top_id=58\">Update of Black Market Sales of AOD</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Update of Black Market Sales of AOD</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=759&amp;nav_cat_id=210&amp;nav_top_id=58\">Appointment of Dr Stewart Washer</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Appointment of Dr Stewart Washer</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n</tbody>\n</table>\n<h3>ASX Releases 2010</h3>\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=754&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada sells Avexa Shares</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Calzada sells Avexa Shares</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=753&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada signs Licensing Agreement with Phosphagenics</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Calzada signs Licensing Agreement with Phosphagenics</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=752&amp;nav_cat_id=205&amp;nav_top_id=58\">Dr John Chiplin appointed to Calzada Board</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Dr John Chiplin appointed to Calzada Board</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=751&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada - 2010 Annual Report</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Calzada - 2010 Annual Report</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=750&amp;nav_cat_id=205&amp;nav_top_id=58\">Notice of Annual General Meeting</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Notice of Annual General Meeting</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=745&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada responds to claims made by Avexa Limited</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Calzada responds to claims made by Avexa Limited</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=744&amp;nav_cat_id=205&amp;nav_top_id=58\">Email correspondence with Avexa – combining Avexa EGM with Avexa AGM </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Email correspondence with Avexa – combining Avexa EGM with Avexa AGM</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=746&amp;nav_cat_id=205&amp;nav_top_id=58\">Phosphagenics exercises option to licence AOD9604 to develop topical cellulite product</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Phosphagenics exercises option to licence AOD9604 to develop topical cellulite product</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=743&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada to vend Metabolic into ATOS Wellness </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Calzada to vend Metabolic into ATOS Wellness</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=742&amp;nav_cat_id=205&amp;nav_top_id=58\">Change of Director\'s Interest NoticeChange of Director\'s Interest Notice</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Change of Director\'s Interest Notice</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=741&amp;nav_cat_id=205&amp;nav_top_id=58\">Replacement response to the Age newspaper articleReplacement response to the Age newspaper article</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Replacement response to the Age newspaper article</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=740&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada responds to The Age newspaper article</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Calzada responds to The Age newspaper article</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=739&amp;nav_cat_id=205&amp;nav_top_id=58\">Half Year Report and Accounts</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Half Year Report and Accounts</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=738&amp;nav_cat_id=205&amp;nav_top_id=58\">Final Director\'s Interest Notice</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Final Director\'s Interest Notice</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=737&amp;nav_cat_id=205&amp;nav_top_id=58\">Initial Director\'s Interest Notice </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Initial Director\'s Interest Notice</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=736&amp;nav_cat_id=205&amp;nav_top_id=58\">Appendix 3B </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Appendix 3B</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=735&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada moves to 100% ownership of PolyNovo </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Calzada moves to 100% ownership of PolyNovo</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=734&amp;nav_cat_id=205&amp;nav_top_id=58\">Change in substantial holding Change in substantial holding </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Change in substantial holding</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=733&amp;nav_cat_id=205&amp;nav_top_id=58\">Becoming a substantial holder from XCD </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Becoming a substantial holder from XCD</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n</tbody>\n</table>\n<h3>ASX Releases 2009</h3>\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=715&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\'s Interest Notice - Oliver Stevens</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Initial Director\'s Interest Notice - Oliver Stevens</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=714&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\' Interest Notice - David Franklyn</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Initial Director\' Interest Notice - David Franklyn</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=713&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\'s Interest Notice - George Cameron-Dow</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Initial Director\'s Interest Notice - George Cameron-Dow</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=712&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\'s Interest Notice - David Kenley</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Initial Director\'s Interest Notice - David Kenley</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=711&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Changes to Company Board</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Changes to Company Board</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=710&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Appendix 3Z - I Kirkwood</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Appendix 3Z - I Kirkwood</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=709&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Appendix 3Z - Paul Lappin</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Final Directors interest Notice - P Lappin</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=708&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">7 April 09 Initial Substantial Holder - Entrust </a></td>\n</tr>\n<tr>\n<td></td>\n<td>7 April 09 Initial Substantil Holder - Entrust picks up 19.81%</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=707&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">7 Aprl 09 - Ceasing o be a substantal holder - Tony Moore</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Ceasingto be a substantil holder - Tony Moore</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=706&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">2 April 2009 Substantial Shareholder Notice - Tony Moore</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Tony Moore purchases substantial shareholding</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=705&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">31 March 2009 Final Directors Interest Notice 3Z F. Brazil</a></td>\n</tr>\n<tr>\n<td></td>\n<td>31 March 2009 Final Directors Interest Notice</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=704&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Changes to Metabolic Board</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Board Changes</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=703&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">10th March 2009 Appendix 3B </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Options expiry</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=702&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">10 March 2009 - Appendix 3B</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=701&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">6 March 2009 - Changes to PolyNovo Board and Management</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=700&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">4 March 2009 - First NovoSorb Patent Granted in Australia</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=699&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">26 February 2009 - Appendix 4D Half Yearly Report and Accounts</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=698&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">23 February 2009 - Changes to Metabolic Chairman and Company Secretary</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=697&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">23 February 2009 - Appendix 3Z - Final Director\'s Interest Notice</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=696&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">2 February 2009 - Changes to Metabolic and PolyNovo Board</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=695&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">30 January 2009 - Appendix 3B</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../../html/s02_article/article_view.asp?id=694&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">9th January 2009 - Change of Registered Office and Place of Business Address</a></td>\n</tr>\n</tbody>\n</table>\n<h3>ASX Releases 2008</h3>\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=693&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">18th December 2008 - Metabolic invests $3.5 million for 60% of PolyNovo</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic has invested a total of $3.5 million in exchange for 60 per cent of PolyNovo Biomaterials Ltd.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=692&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">3rd December 2008 - Appendix 3B</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=691&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st December 2008 - Proposed PolyNovo acquisition terminated</a></td>\n</tr>\n<tr>\n<td></td>\n<td>This announcement advises that the proposed acquisition of PolyNovo Biomaterials Ltd has been terminated.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=690&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th November 2008 - Annual General Meeting Results</a></td>\n</tr>\n<tr>\n<td></td>\n<td>This announcement includes a summary of voting on each resolution put to shareholders at the 2008 Annual General Meeting.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=689&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th November 2008 - 2008 Annual General Meeting Presentation</a></td>\n</tr>\n<tr>\n<td></td>\n<td>This announcement contains the AGM presentation given to shareholders at the 2008 Annual General Meeting.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=688&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th November 2008 - 2008 AGM Chairman\'s Address</a></td>\n</tr>\n<tr>\n<td></td>\n<td>This announcement contains the Chairman\'s address given to shareholders at the 2008 Annual General Meeting.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=687&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">31 October 2008 - Appendix 3B</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=686&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th October 2008 - 2008 Notice of Annual General Meeting and Sample Proxy Form</a></td>\n</tr>\n<tr>\n<td></td>\n<td>The business before Metabolic\'s 2008 Annual General Meeting includes the usual agenda items as well as resolutions relating to the proposed acquisition of PolyNovo Limited.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=685&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">2nd October 2008 - Share Sale Agreement signed for acquisition of PolyNovo</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Share Sale Agreement signed for acquisition of PolyNovo</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=682&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">26th September 2008 - Metabolic Annual Report 2008</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic\'s 2008 Annual Report</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=681&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">5th September 2008 - Update on acquisition of PolyNovo</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Update on the proposed acquisition of PolyNovo</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=680&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">21st August 2008 - Appendix 4E Preliminary Final Report</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=679&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">4 August 2008 - Letter to Shareholders regarding the acquisition of PolyNovo</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Letter to Shareholders of Metabolic outlining the proposed transaction to acquire PolyNovo Biomaterials Ltd.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=678&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">18th July 2008 - Corporate Presentation: Metabolic\'s acquisition of PolyNovo</a></td>\n</tr>\n<tr>\n<td></td>\n<td>A series of slides with further detail regarding the acquisition of PolyNovo.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=677&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">18th July 2008 - Metabolic signs binding term sheet for PolyNovo</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic has signed a binding term sheet to acquire 100% of PolyNovo from its two shareholders, Xceed and CSIRO.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=676&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st July 2008 - Appendix 3B</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=675&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">20th June 2008 - Update on research and future direction </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Update on research and future direction</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=674&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">10 June 2008 - Response to Price Query</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=673&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">27th May 2008 - Appendix 3Y</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=672&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">23rd May 2008 - Appendix 3X</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Initial Director\'s Interest Notice for Mr Franklyn Brazil</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=671&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">23rd May 2008 - Appendix 3X</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Initial Director\'s Interest Notice for Mr Paul Lappin</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=667&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">21st May 2008 - Appointment of Non-Executive Directors</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic appoints two non-executive directors, Mr Franklyn Brazil and Mr Paul Lappin.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=666&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">14th May 2008 - Appendix 3Y</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=665&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">13th May 2008 - Notice of initial substantial holder - Brazil Farming Pty Ltd</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=664&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">13th May 2008 - Iain Kirkwood ceases to be a substantial shareholder</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Official notice from Iain Kirkwood advising that he has ceased as a substantial holder of Metabolic.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=663&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">12th May 2008 - Polychip Pharmaceuticals Limited ceases to be a substantial shareholder</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Official notice from Polychip Pharmaceuticals Limited (Circadian) advising the company has ceased as a substantial holder of Metabolic.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=662&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">9th May 2008 - Appendix 3B</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=661&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st May 2008 - Appendix 3X</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Initial Director\'s Interest Notice for Mr Iain Kirkwood</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=660&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">30th April 2008 - Appendix 3Z</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Final Director\'s Interest Notice for Dr Roland Scollay</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=659&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">30th April 2008 - Appointment of Non-Executive Director</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Mr Iain Kirkwood has been appointed as a non-executive director of Metabolic. Mr Kirkwood is an experienced private consultant, investor and non-executive director (of both listed and unlisted public companies).</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=658&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">29th April 2008 - Dr Roland Scollay steps down from Metabolic Board</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Dr Roland Scollay resigned as a director of the Metabolic Board. Dr Scollay will work with the Board to ensure a smooth transition and will then be leaving the Company to pursue other interests.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=657&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">8th April 2008 - Acorn ceased to be a substantial shareholder</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Official notice from Acorn Capital Limited advising the company has ceased as a substantial holder of Metabolic.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=656&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">27th February 2008 - Half Yearly Report / Half Yearly Accounts</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Financial report for the six months ended 31 December 2007.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=653&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st February 2008 - Quarterly Investor Update </a></td>\n</tr>\n<tr>\n<td></td>\n<td>This update contains a summary of Company news during the fourth quarter of 2007.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=651&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">15th January 2008 - Appendix 3B</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n</tbody>\n</table>\n<h3>ASX Releases 2007</h3>\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=649&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th December 2007 - Appendix 3B</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=636&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">2nd November 2007 - 2007 AGM: Voting Results</a></td>\n</tr>\n<tr>\n<td></td>\n<td>This announcement includes a summary of voting on each resolution put to shareholders at the 2007 Annual General Meeting.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=635&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">2nd November 2007 - 2007 AGM - Chairman\'s Address and AGM presentation</a></td>\n</tr>\n<tr>\n<td></td>\n<td>This announcement contains the full Chairman\'s address and AGM presentation given to shareholders on 2 November 2007.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=634&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">31st October 2007 - Appendix 3B</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=632&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">19th October 2007 - Quarterly Investor Update Q307 </a></td>\n</tr>\n<tr>\n<td></td>\n<td>This update contains a summary of Company news during the third quarter of 2007.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=631&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">15th October 2007 - NRP Update </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic\'s joint project with Neuren Pharmaceuticals Limited to develop NRPs has made progress. A NRP compound has been shown to be effective in animal models of motor neuron disease and peripheral neuropathy.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=629&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">28th September 2007 - 2007 Annual Report and Notice of Annual General Meeting </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic\'s 2007 Annual Report and Notice of Annual General Meeting.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=628&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">25th September 2007 - Appendix 3B</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=627&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">20th September 2007 - Update on Oral Peptide Delivery Platform</a></td>\n</tr>\n<tr>\n<td></td>\n<td>This announcement contains an update on Metabolic\'s proprietary Oral Peptide Delivery Platform including new animal data and future direction.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=626&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">10th September 2007 - Appendix 3Z</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Final Director\'s Interest Notice for Dr Arthur Emmett</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=625&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">10th September 2007 - Appendix 3Z</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Final Director\'s Interest Notice for Dr Chris Belyea</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=624&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">31st August 2007 - 2007 Appendix 4E - Preliminary Final Report</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic\'s Preliminary Final Report for the year ended 30 June 2007, including the Appendix 4E.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=623&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">30th August 2007 - Resignation of Director</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic announced the resignation of Chief Scientific Officer, Dr Chris Belyea.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=622&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">28th August 2007 - Resignation of Director</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic announced the resignationof Non-Executive Director Dr Arthur Emmett</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=621&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">17th August 2007 - Changes to Annual Report legislation </a></td>\n</tr>\n<tr>\n<td></td>\n<td>This notification was sent to Metabolic shareholders to explain new legislation changing the default option for receiving annual reports to be via a company\'s website.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=620&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">16th August 2007 - New Substantial Holder - Niako </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Official notice from Niako Investments Pty Ltd advising the company has become a substantial holder of Metabolic, with total shares representing 5.75% of issued capital as at 16th August 2007.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=619&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">14th August 2007 - Metabolic discontinues clinical trial programme for neuropathic pain drug, ACV1</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic has received new data regarding the ability of ACV1 to block the human a9a10 nicotinic acetylcholine receptor, the probable target of ACV1. The Company will focus its research and development on the Oral Peptide Delivery Platform, and will continue to search for new drugs to in-license or acquire.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=617&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">25th July 2007 - Quarterly Investor Update Q207</a></td>\n</tr>\n<tr>\n<td></td>\n<td>This update contains a summary of Company news during the second quarter of 2007.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=616&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">6th July 2007 - Appendix 3Z</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Final Director\'s Interest Notice for Dr Evert Vos</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=614&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">6th July 2007 - Resignation of Director</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic announced the resignation of Non-Executive Director Evert Vos.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=612&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">28th June 2007 - Appendix 3B</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=611&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">24th May 2007 - Appendix 3B</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=610&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">16th May 2007 - Response to Price Query</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=608&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">18th April 2007 - Appendix 3B </a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=605&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">12th April 2007 - Appendix 3X</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Initial Director\'s Interest Notice</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=604&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">12th April 2007 - Director Appointment</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic announced the appointment of Mr Don Clarke as a Non-Executive Director.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=603&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Appendix 3X</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Initial Director\'s Interest Notice</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=600&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Quarterly Investor Update Q107</a></td>\n</tr>\n<tr>\n<td></td>\n<td>This update contains a summary of Company news during the first quarter of 2007.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=599&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Appendix 3Z</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Final Director\'s Interest Notice for Mr Patrick Sutch</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=598&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Appendix 3Z</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Final Director\'s Interest Notice for Ms Robyn Baker</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=597&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">4th April 2007 - Changes to Metabolic Board</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic announced the appointment of Mr Robert Stewart as Chairman and Non-Executive Director and the resignation of Non-Executive Directors, Mr Patrick Sutch and Ms Robyn Baker.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=595&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">26th March 2007 - Metabolic\'s pain drug ACV1 enters second Phase 2 human clinical trial</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic reported the commencement of a second ACV1 Phase 2A trial in patients with neuropathic pain as well as the results of a Phase 1 extension trial for the same drug.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=594&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">26th February 2007 - Half Yearly Report / Half Yearly Accounts</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Financial report for the six months ended 31 December 2006</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=593&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">21st February 2007 - Shareholder Hotline</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Shareholders with questions regarding the OPTIONS Study are encouraged to call 1800 255 018 which is a free call within Australia. Shareholders outside Australia should call +61 2 8256 3388.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=592&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">21st February 2007 - OPTIONS Study Results</a></td>\n</tr>\n<tr>\n<td></td>\n<td>The Phase 2B trial results for Metabolic\'s drug, AOD9604, do not support the commercial viability of the drug as a treatment for obesity. Development of the drug for this condition is terminated.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=591&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">19th February 2007 - Request for trading halt</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic has been placed in a trading halt pending an announcement in relation to the results of its Phase 2B OPTIONS Study.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=590&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">8th February 2007 - Appendix 3B </a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=589&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">25th January 2007 - Appendix 3B </a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=587&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">22nd January 2007 - Quarterly Investor Update </a></td>\n</tr>\n<tr>\n<td></td>\n<td>This update contains a summary of Company news during the fourth quarter of 2006.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=586&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">12th January 2007 - Notice of Change of Interests of Substantial Holder</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Official notice from Circadian Technologies regarding the dilution of their substantial holding due to the recent share placement by Metabolic and the exercise of options.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=585&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">11th January 2007 - Appendix 3B </a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=584&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th January 2007 - Response to ASX Query</a></td>\n</tr>\n<tr>\n<td></td>\n<td>This letter from Metabolic is in response to a share price query from the ASX</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n</tbody>\n</table>\n<h3>ASX Releases 2006</h3>\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=583&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">28th December 2006 - Appendix 3B 28th December 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=582&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">20th December 2006 - Open Briefing with CEO of Metabolic </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic announced this morning the transcript from an Open Briefing with the CEO of Metabolic, regarding the completion of the Phase 2B OPTIONS Study for obesity drug AOD9604.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=581&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">19th December 2006 - Broadcast Radio Interview 19th December 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td>19th December 2006 - Audio Broadcast - CEO interviewed by Boardroom Radio: Dr Roland Scollay\'s interview by Boardroom radio has been webcast and is available at www.boardroomradio.com</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=579&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">18th December 2006 - Options Study END December 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td>The Phase 2B OPTIONS Study for Obesity drug AOD9604 has been completed on time and within budget. The number of completing subjects comfortably exceeds the statistical design goal. Results of the trial are expected to be announced in March 2007.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=580&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">18th December 2006 - Form 604 Notice of change of Interests of Substantial Holder</a></td>\n</tr>\n<tr>\n<td></td>\n<td>7th December 2006 - Form 604: Notice of Change of Interests of Substantial Holder Official notice from Acorn Capital Limited regarding the change in their substantial holding of Metabolic shares.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=578&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">15th December 2006 Notice under section 708A (5)(e)</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=577&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">15th December 2006 Appendix 3B </a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=576&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">7th December 2006 - Capital Raising December 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic raised A$10.5 million through a share placement to predominantly existing institutional shareholders. The funds raised will accelerate the oral version of ACV1 for neuropathic pain, the Oral Peptide Delivery Platform and planning for a Phase 3 obesity trial.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=575&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">7th December 2006 - Metabolic placed in trading halt</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=574&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">7th December 2006 - Metabolic\'s request for trading halt</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=573&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">5th December 2006 - Open Briefing with CEO of Metabolic</a></td>\n</tr>\n<tr>\n<td></td>\n<td>This announcement contains the transcript from an Open Briefing with the CEO of Metabolic, covering the Company\'s lead projects and strategy.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=572&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">29th November 2006 - ACV1 Clinical Trials Update November 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic announced that the Phase 2A programme for ACV1, for neuropathic pain is progressing well. The first group of patients in the first of two trials in this Phase 2A programme have been treated and the second trial is due to commence in Q107. Additionally, a separate trial to test safety of a higher dose level of ACV1 commenced in Q406.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=571&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th November 2006 - Options Study Update - 27 November 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic announced that more than 300 subjects have completed the Phase 2B OPTIONS Study so far. The last subject will complete the trial in December 2006 with results expected to be announced in March 2007.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=570&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th November 2006 - Domestic Roadshow November 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Dr Roland Scollay, CEO of Metabolic, will be meeting with various domestic brokers and analysts this week. This roadshow presentation provides an update on the Company\'s development and strategy.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=569&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd November 2006 - ACV1 PreClinical Update November 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic has made further progress with the oral version of its neuropathic pain drug ACV1. In addition, an independent study conducted in the US has identified important information about its mechanism of action.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=567&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th November 2006 - Appendix 3Y 17th November 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Appendix 3Y 17th November 2006</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=566&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th November 2006 - Appendix 3Y 17th November 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Appendix 3Y 17th November 2006</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=565&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th November 2006 - Appendix 3B 17th November 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Appendix 3B 17th November 2006</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=561&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th October 2006 - 2006 AGM: Voting Results</a></td>\n</tr>\n<tr>\n<td></td>\n<td>This announcement includes a summary of voting on each resolution put to shareholders at the Company\'s 2006 AGM.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=560&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th October 2006 - New Constitution</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Shareholders of Metabolic approved a new Constitution on 27 October 2006. The complete Constitution is included in this announcement.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=559&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th October 2006 - 2006 AGM Chairman\'s Address and CEO\'s presentation</a></td>\n</tr>\n<tr>\n<td></td>\n<td>This announcement includes the formal address given by the Chairman to shareholders at the Company\'s 2006 AGM and a presentation by the CEO.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=558&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd October 2006 - Change in Substantial Holding</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Official notice from Monash Investments regarding the change in their substantial holding of Metabolic shares.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=556&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th October 2006 - Response to ASX Query</a></td>\n</tr>\n<tr>\n<td></td>\n<td>This letter from Metabolic is is response to a share price query from the ASX.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=549&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th October 2006 - Quarterly Investor Update - 17 October 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td>This update contains a summary of Company news during the third quarter of 2006</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=548&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">12th October 2006 - Market Presentation - Intersuisse Conference October 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Dr Roland Scollay presented at the Intersuisse Life Sciences Forum (London) to increase awarenenss of Metabolic in the UK and Europe. The slide-show presentation provides an up-to-date overview of Metabolic\'s business.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=546&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">9th October 2006 - Appendix 3B 9th October 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Appendix 3B 9th October 2006</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=547&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">5th October 2006 - Obesity Trial Update - October 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td>The first 100 subjects have completed the Phase 2B OPTIONS Study including 24 weeks of daily oral dosing of obesity drug, AOD9604. The last subject will complete the trial in December 2006 with results expected to be announced in March 2007.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=545&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">28th September 2006 - UBS Global Life Sciences Conference - presentation by Dr Roland Scollay</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Dr Roland Scollay presented at the UBS Global Life Sciences Conference in New York to increase awareness of Metabolic in the US. The slide-show presentation provides and up-to-date overview of Metabolic\'s business.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=544&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th September 2006 - Metabolic\'s neuropathic pain drug, ACV1, enters Phase 2A clinical trials</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic commenced the first trial in its Phase 2A programme for ACV1, for the treatment of neuropathic pain. This first trial will target neuropathic sciatic pain and results are expected to be announced during the first six months of 2007 (H107).</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=542&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">26th September 2006 - 2006 Annual Report and Notice of Annual General Meeting</a></td>\n</tr>\n<tr>\n<td></td>\n<td>This announcement contains the Company’s 2006 Annual Report, Notice of Annual General Meeting and sample voting form.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=557&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">1st September 2006 - Quarterly rebalance of S&amp;P/ASX Indices</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Official notice that Metabolic has been removed from the S&amp;P/ASX 300 Index</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=539&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th July 2006 - Quarterly Investor Update July 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td>This update contains a summary of Company news during the second quarter of 2006.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=538&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">19th July 2006 - Obesity trial update: First subject completes treatment</a></td>\n</tr>\n<tr>\n<td></td>\n<td>The first few subjects have completed treatment including 24 weeks of daily oral dosing of AOD9604. The last subject will complete the trial in December 2006 with results expected to be announced in March 2007.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=537&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">11th July 2006 - NRP collaboration: Research on nerve protection compounds published in science journal</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Research on Neural Regeneration Peptides (NRPs) has been published in the international science journal, \'Experimental Cell Research\'. NRPs have previously shown promising effects in a rat model of nerve damage. Formal preclinical development of NRPs expected to commence in 2007.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=520&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">21 June 2006 - Metabolic\'s osteoporosis drug: additional animal data support further beneficial effects of AOD9604</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Additional animal data indicate AOD9604 has beneficial effects on trabecular bone as well as corticol bone. Two further animal studies are underway to investigate the optimal dose of AOD9604 for osteoporosis; and the possible role of the drug in treatment of osteoporosis (in addition to prevention, as previously determined).</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=465&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">14th June 2006 - Life Sciences (USA) Presentation</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Dr Roland Scollay presented at the Pacific Growth Equities\' 2006 Life Sciences Growth Conference in San Francisco to increase awareness of Metabolic in the USA. Slide-show presentation provides an up-to-date overview of Metabolic\'s business.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=466&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd May 2006 - Roadshow Presentation - company update May 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Dr Roland Scollay met with several analysts and institutions to increase local awareness of Metabolic. Slide-show presentation provides an up-to-date overview of Metabolic’s business.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=467&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">10th May 2006 - Quarterly Investor Update 10 May 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Summary of Company news during the first quarter of 2006</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=468&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">8th May 2006 - Audio Broadcast - CEO interviewed by Boardroom Radio</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Dr Roland Scollay’s interview by Boardroom radio has been audio webcast and is available at www.boardroomradio.com</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=469&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">2nd May 2006 - Metabolic completes enrolment for obesity clinical trial ahead of schedule</a></td>\n</tr>\n<tr>\n<td></td>\n<td>536 subjects have been enrolled in the Phase 2B trial, known as the “OPTIONSEstudy for obesity drug, AOD9604. This trial will now end in December 2006 and results will be announced in March 2007.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=470&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">5th April 2006 - Metabolic CEO to present at US biotech conferences</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Dr Roland Scollay presented at various biotechnology conferences and expos in the USA. Slide-show presentation provides an up-to-date overview of Metabolic’s business.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=471&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">30th March 2006 - Change in Substantial Holding</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Official notice from Monash Investments regarding the dilution of their substantial holding due to the recent share placement by Metabolic</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=472&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">24th March 2006 - Appendix 3B - New issue of options</a></td>\n</tr>\n<tr>\n<td></td>\n<td>New issue of shares and options, pursuant to the private placement on 21 March 2006</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=473&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">24th March 2006 - Notice under section 708A (5)(e)</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Official cleansing statement Eno outstanding disclosures</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=474&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">21st March 2006 - Metabolic completes A$13 million share placement</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Private placement of 30.2 million shares to international and Australian institutional investors. Funds raised will advance Metabolic’s drug pipeline for pain, osteoporosis and oral delivery platform for peptides.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=475&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th March 2006 - Trading Halt 17th March 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Official trading halt request by Metabolic</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=476&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">6th March 2006 - Clinical Trials Update</a></td>\n</tr>\n<tr>\n<td></td>\n<td>The Phase 2B trial for obesity drug, AOD9604 is progressing well, on schedule, and preparation is underway for the Phase 2A program for ACV1, for pain</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=477&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th February 2006 - Half Yearly Report / Half Yearly Accounts</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Financial report for the six months ended 31 December 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=478&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">16th February 2006 - NRP Update: Metabolic and Neuren report promising animal efficacy data in collaborative project </a></td>\n</tr>\n<tr>\n<td></td>\n<td>New compound, Neural Regeneration Peptide: NNZ-4921, has been shown to prevent or reverse peripheral neuropathy (nerve damage) in an animal study</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=479&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">15th February 2006 - CEO to present at BioCEO &amp; Investor Conference in New York</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Dr Roland Scollay participated as a panelist at the BioCEO &amp; Investor Conference in New York, and gave a presentation on Metabolic’s lead drugs AOD9604 for obesity, including details of previous trial results, and a potential new use for the drug.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=480&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">8th February 2006 - Investor Roadshow Presentation - USA</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Dr Roland Scollay presented at the Biotechnology Organisation (BIO) Conference and met with several analysts and institutions to increase awareness of Metabolic in the USA. Slide show presentation provides an up-to-date overview of Metabolic’s business.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=481&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">6th February 2006 - Metabolic Quarterly Investor Update Number 12 </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Summary of Company news during the fourth quarter of 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=482&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">1st February 2006 - Appendix 3Y - Change of Director’s Interest Notice</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Dr Roland Scollay was granted 1,000,000 options, pursuant to the Metabolic Employee Share Option Plan, approved by shareholders at the 2005 Annual General Meeting on 28 October 2005.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=483&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">1st February 2006 - Appendix 3B - New issue of options </a></td>\n</tr>\n<tr>\n<td></td>\n<td>New issue of 1,000,000 MBPAQ unquoted options, pursuant to the Metabolic Employee Share Option Plan, approved by shareholders at the 2005 Annual General Meeting on 28 October 2005.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=484&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">31st January 2006 - Potential new use in osteoporosis adds value to Metabolic\'s obesity drug</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Animal study: Orally delivered drug, AOD9604, shows an effect in preventing bone loss and maintaining bone quality in a rat model of osteoporosis.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=485&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd January 2006 - Update on Phase 2B dosing trial for obesity drug</a></td>\n</tr>\n<tr>\n<td></td>\n<td>The low dose, Phase 2B trial, known as the “OPTIONSEstudy is proceeding on schedule with recruitment on track an all ethics approvals obtained.</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n</tbody>\n</table>\n<h3>ASX Releases 2005</h3>\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=428&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">18th November 2005 - ASX Appendix 3Y Change of Director\'s Interest - A Emmett</a></td>\n</tr>\n<tr>\n<td></td>\n<td>ASX Appendix 3Y Change of Director\'s Interest - A Emmett</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=427&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">16th November 2005 - ACV1 Phase 1 results</a></td>\n</tr>\n<tr>\n<td></td>\n<td>ACV1 Phase 1 results</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=425&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">4th November 2005 - CEO Presentation Rodman Renshaw Conference 7 November 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td>CEO Presentation Rodman Renshaw Conference 7 November 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=423&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">2nd November 2005 - ASX Appendix 3B 2nd November 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td>ASX Appendix 3B 2nd November 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=422&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">31st October 2005 - ASX Appendix 3X 31st October 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td>ASX Appendix 3X 31st October 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=419&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th October 2005 - Chairman\'s Address and CEO Presentation at AGM 28th October 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Chairman\'s Address and CEO Presentation at AGM 28th October 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=421&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th October 2005 - Metabolic AGM Results 28 October 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic AGM Results 28 October 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=420&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th October 2005 - Amended Constitution of Metabolic Pharmaceuticals 28 October 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Amended Constitution of Metabolic Pharmaceuticals 28 October 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=418&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">26th October 2005 - Metabolic Quarterly Investor Update </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic Quarterly Investor Update - 26 October 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=417&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th October 2005 - Metabolic ranks number 1 as Australia\'s top innovator</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic ranks number 1 as Australia\'s top innovator</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=416&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">19th October 2005 - Metabolic CEO to present to Health Care and Life Science Conference</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic CEO to present to Health Care and Life Science Conference</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=433&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">22nd December 2005 - ASX Appendix 3Y R Scollay</a></td>\n</tr>\n<tr>\n<td></td>\n<td>ASX Appendix 3Y R Scollay</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=412&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">18th October 2005 - Metabolic starts next clinical trial of obesity drug</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic starts next clinical trial for obesity drug</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=415&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">18th October 2005 - VP Clinical Development Presentation at NAASO Conference</a></td>\n</tr>\n<tr>\n<td></td>\n<td>VP Clinical Development Presentation at NAASO Conference</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=409&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th October 2005 - Appointment of Non-Executive Director</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Appointment of Non-Executive Director</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=404&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">27th September 2005 Release of Securities from Escrow - Monash Investment Holdings P/L</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Release of Securities from Escrow - Monash Investment Holdings P/L</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=432&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">22nd December 2005 - ASX Appendix 3Y C Belyea</a></td>\n</tr>\n<tr>\n<td></td>\n<td>ASX Appendix 3Y C Belyea</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=403&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">7th September 2005 - Metabolic Pharmaceuticals CEO to present at biotechnology conference</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic Pharmaceuticals CEO to present at biotechnology conference</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=402&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">1st September 2005 - Change of Director\'s Interest - R Scollay</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Change of Director\'s Interest - R Scollay</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=401&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">26th August 2005 App 4E Preliminary Final Report</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Preliminary Final Report</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=400&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd August 2005 - Appointment of new CFO</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Appointment of new CFO</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=431&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">22nd December 2005 - ASX Appendix 3B</a></td>\n</tr>\n<tr>\n<td></td>\n<td>ASX Appendix 3B</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=399&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">15th August 2005 - Metabolic ACV1 Update 15 August 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic ACV1 Update 15th August 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=398&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">8th August 2005 - ASX Appendix 3B 8th August 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Appendix 3B - 8th August 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=395&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th Aug 2005 - Change of Director\'s Interest - A Emmett</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Change of Director\'s Interest - A Emmett</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=396&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th Aug 2005 - Change of Director\'s Interest - C Belyea</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Change of Director\'s Interest - C Belyea</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=397&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th Aug 2005 - Change of Director\'s Interest - E Vos</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Change of Director\'s Interest - E Vos</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=390&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th July 2005 - ASX Appendix 3B 28th July 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Appendix 3B - 28th July 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=430&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">25th November 2005 - ASX Appendix 3Y Change in Director\'s Interest - R Baker</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Appendix 3Y Change in Director\'s Interest - R Baker</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=386&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">21st July 2005 - SPP Announcement </a></td>\n</tr>\n<tr>\n<td></td>\n<td>Share Purchase Plan Announcement 21st July 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=385&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th July 2005 - Investor Update 5th July 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Investor Update 5th July 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=384&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th June 2005 - Notice under Section 708A of the Corps Act</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Notice under Section 708A of the Corps Act</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=383&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th June 2005 - Share Purchase Plan Offer to Shareholders</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Share Purchase Plan Offer to Shareholders</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=382&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th June 2005 - VP Corporate Development Position</a></td>\n</tr>\n<tr>\n<td></td>\n<td>VP Corporate Development Position</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=429&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th November 2005 - ASX Appendix 3Y Change in Director\'s Interest - P Sutch</a></td>\n</tr>\n<tr>\n<td></td>\n<td>ASX Appendix 3Y Change in Director\'s Interest - P Sutch</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=555&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd June 2005 - Change in Substantial Holding</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=381&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd June 2005 - Appendix 3B 23rd June 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Appendix 3B - 23rd June 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=380&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd June 2005 - ACV1 Phase 1 Clinical Trial Commences</a></td>\n</tr>\n<tr>\n<td></td>\n<td>ACV1 Phase 1 Clinical Trial Commences</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=377&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">14th June 2005 - Placement and SPP Offer</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Placement and SPP Offer</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=378&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">14th June 2005 - AusIndustry \"Commercial Ready\" Grant for ACV1</a></td>\n</tr>\n<tr>\n<td></td>\n<td>AusIndustry \"Commercial Ready\" Grant for ACV1</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=379&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">14th June 2005 - Conference Presentations June 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Conference Presentations June 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=376&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">3rd June 2005 - AOD9604 Obesity Drug Update</a></td>\n</tr>\n<tr>\n<td></td>\n<td>AOD9604 Obesity Drug Update 3rd June 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=370&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">1st June 2005 - Metabolic establishes ADR program</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic Pharmaceuticals Ltd establishes ADR Program</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=366&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">20th May 2005 - Response to ASX Query re: Share Price</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Response to ASX Query re: Share Price - 20th May 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=364&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">2nd May 2005 - ACV1 Update</a></td>\n</tr>\n<tr>\n<td></td>\n<td>ACV1 Update 2nd May 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=362&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">20th April 2005 AOD9604 Update</a></td>\n</tr>\n<tr>\n<td></td>\n<td>AOD9604 Update 20th April 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=360&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">8th March 2005 - Investor Update 8th March 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Investor Update 8th March 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=359&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">3rd March 2005 - Neuren and Metabolic Development Collaboration March 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Neuren and Metabolic Development Collaboration March 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=358&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd February 2005 US Presentations February 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td>US Presentations February 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=357&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">21st February 2005 - Half Yearly Report / Half Yearly Accounts</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Half Yearly Report / Half Yearly Accounts</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=355&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">10th February 2005 - CEO to speak on Obesity Panel at BIO CEO Conference</a></td>\n</tr>\n<tr>\n<td></td>\n<td>CEO to speak on Obesity Panel at BIO CEO Conference</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=354&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th January 2005 Metabolic appoints new Chief Executive Officer</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Metabolic appoints new Chief Executive Officer</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=353&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">13th January 2005 - ASX CEO Position</a></td>\n</tr>\n<tr>\n<td></td>\n<td>CEO Position</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n</tbody>\n</table>\n<h3>ASX Releases 2004</h3>\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=506&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">23rd December 2004 - ASX Resignation of Company Secretary</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Resignation of Company Secretary</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=505&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">17th December 2004 - ASX Change in Director\'s Interest</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Change in Director\'s Interest</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=504&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">17th December 2004 - ASX Response to Market Comments</a></td>\n</tr>\n<tr>\n<td></td>\n<td>ASX Response to Market Comments 17th December 2004</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=503&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">15th December 2004 - ASX Appendix 3B 15th November 2004</a></td>\n</tr>\n<tr>\n<td></td>\n<td>ASX Appendix 3B 15th November 2004</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=502&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">13th December 2004 - AOD9604 Phase2b Clinical Trial Successful</a></td>\n</tr>\n<tr>\n<td></td>\n<td>AOD9604 Phase 2b Clinical Trial Successful</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=501&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">13th December 2004 Successful trial results for world-first obesity drug</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Successful trial results for world-first obesity drug</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=500&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">9th December 2004 - ASX Trading Halt</a></td>\n</tr>\n<tr>\n<td></td>\n<td>ASX Trading Halt - 9th December 2004</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=499&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">29th November 2004 - AOD9604 Update on Clinical Trial Results</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Update on Clinical Trial Results 29th November 2004</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=498&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">16th November 2004 - Response to ASX Query re: Share Price</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Response to ASX Query re: Share Price</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=497&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">4th November 2004 - ASX Appendix 3B 4th November 2004</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Appendix 3B 4th November 2004</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=496&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">29th October 2004 - ASX AGM Results 29th October 2004</a></td>\n</tr>\n<tr>\n<td></td>\n<td>AGM Results 29th October 2004</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=495&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">29th October 2004 - ASX Chairman\'s Address AGM 2004</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Chairman\'s Address AGM 2004</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=494&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">30th September 2004 - Release of securities from voluntary escrow</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Release of securities from voluntary escrow</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=493&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">23rd September 2004 - 2004 Annual Report and Notice of AGM</a></td>\n</tr>\n<tr>\n<td></td>\n<td>2004 Annual Report and Notice of AGM</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=492&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">22nd September 2004 Investor Update - September 2004</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Investor Update - September 2004</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=491&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">20th September 2004 Completion of dosing in obesity trials</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Completion of dosing in obesity trials</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=490&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">24th August 2004 - Preliminary Final Report</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Appendix 4E - Preliminary Final Report</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=489&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">6th July 2004 - Increasing awareness in US markets in preparation for 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Increasing awareness in US markets in preparation for 2005</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=488&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">5th July 2004 - Cohen Research Report July 2004</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Cohen Research Report July 2004</td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"../article_view.asp?id=487&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">4th June 2004 - Investor Update</a></td>\n</tr>\n<tr>\n<td></td>\n<td>Investor Update - 4th June, 2004</td>\n</tr>\n</tbody>\n</table>\n</td>\n</tr>\n</tbody>\n</table>',	'ASX Announcements',	'',	'inherit',	'open',	'open',	'',	'141-revision-3',	'',	'',	'2012-06-18 06:10:33',	'2012-06-18 06:10:33',	'',	141,	'http://calzada-wp.urldock.com/141-revision-3/',	0,	'revision',	'',	0),
(226,	1,	'2012-06-18 06:15:53',	'2012-06-18 06:15:53',	'',	'132F042F2012103A213A23PM',	'',	'inherit',	'open',	'open',	'',	'132f042f2012103a213a23pm',	'',	'',	'2012-06-18 06:15:53',	'2012-06-18 06:15:53',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/132F042F2012103A213A23PM.pdf',	0,	'attachment',	'application/pdf',	0),
(227,	1,	'2012-06-18 06:15:55',	'2012-06-18 06:15:55',	'',	'132F042F2012103A223A05PM',	'',	'inherit',	'open',	'open',	'',	'132f042f2012103a223a05pm',	'',	'',	'2012-06-18 06:15:55',	'2012-06-18 06:15:55',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/132F042F2012103A223A05PM.pdf',	0,	'attachment',	'application/pdf',	0),
(228,	1,	'2012-06-18 06:15:59',	'2012-06-18 06:15:59',	'',	'132F042F2012103A223A30PM',	'',	'inherit',	'open',	'open',	'',	'132f042f2012103a223a30pm',	'',	'',	'2012-06-18 06:15:59',	'2012-06-18 06:15:59',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/132F042F2012103A223A30PM.pdf',	0,	'attachment',	'application/pdf',	0),
(229,	1,	'2012-06-18 06:16:14',	'2012-06-18 06:16:14',	'',	'1899_Calzada_Shareholder_Newsletter_FINAL',	'',	'inherit',	'open',	'open',	'',	'1899_calzada_shareholder_newsletter_final',	'',	'',	'2012-06-18 06:16:14',	'2012-06-18 06:16:14',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/1899_Calzada_Shareholder_Newsletter_FINAL.pdf',	0,	'attachment',	'application/pdf',	0),
(230,	1,	'2012-06-18 06:16:26',	'2012-06-18 06:16:26',	'',	'947775',	'',	'inherit',	'open',	'open',	'',	'947775',	'',	'',	'2012-06-18 06:16:26',	'2012-06-18 06:16:26',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/947775.pdf',	0,	'attachment',	'application/pdf',	0),
(231,	1,	'2012-06-18 06:16:30',	'2012-06-18 06:16:30',	'',	'953112',	'',	'inherit',	'open',	'open',	'',	'953112',	'',	'',	'2012-06-18 06:16:30',	'2012-06-18 06:16:30',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/953112.pdf',	0,	'attachment',	'application/pdf',	0),
(232,	1,	'2012-06-18 06:16:33',	'2012-06-18 06:16:33',	'',	'962429',	'',	'inherit',	'open',	'open',	'',	'962429',	'',	'',	'2012-06-18 06:16:33',	'2012-06-18 06:16:33',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/962429.pdf',	0,	'attachment',	'application/pdf',	0),
(233,	1,	'2012-06-18 06:16:36',	'2012-06-18 06:16:36',	'',	'962630',	'',	'inherit',	'open',	'open',	'',	'962630',	'',	'',	'2012-06-18 06:16:36',	'2012-06-18 06:16:36',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/962630.pdf',	0,	'attachment',	'application/pdf',	0),
(234,	1,	'2012-06-18 06:16:38',	'2012-06-18 06:16:38',	'',	'963942',	'',	'inherit',	'open',	'open',	'',	'963942',	'',	'',	'2012-06-18 06:16:38',	'2012-06-18 06:16:38',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/963942.pdf',	0,	'attachment',	'application/pdf',	0),
(235,	1,	'2012-06-18 06:16:41',	'2012-06-18 06:16:41',	'',	'967193',	'',	'inherit',	'open',	'open',	'',	'967193',	'',	'',	'2012-06-18 06:16:41',	'2012-06-18 06:16:41',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/967193.pdf',	0,	'attachment',	'application/pdf',	0),
(236,	1,	'2012-06-18 06:17:02',	'2012-06-18 06:17:02',	'',	'979227',	'',	'inherit',	'open',	'open',	'',	'979227',	'',	'',	'2012-06-18 06:17:02',	'2012-06-18 06:17:02',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/979227.pdf',	0,	'attachment',	'application/pdf',	0),
(237,	1,	'2012-06-18 06:17:06',	'2012-06-18 06:17:06',	'',	'980299',	'',	'inherit',	'open',	'open',	'',	'980299',	'',	'',	'2012-06-18 06:17:06',	'2012-06-18 06:17:06',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/980299.pdf',	0,	'attachment',	'application/pdf',	0),
(238,	1,	'2012-06-18 06:17:09',	'2012-06-18 06:17:09',	'',	'1007282',	'',	'inherit',	'open',	'open',	'',	'1007282',	'',	'',	'2012-06-18 06:17:09',	'2012-06-18 06:17:09',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/1007282.pdf',	0,	'attachment',	'application/pdf',	0),
(239,	1,	'2012-06-18 06:17:12',	'2012-06-18 06:17:12',	'',	'1030228',	'',	'inherit',	'open',	'open',	'',	'1030228',	'',	'',	'2012-06-18 06:17:12',	'2012-06-18 06:17:12',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/1030228.pdf',	0,	'attachment',	'application/pdf',	0),
(240,	1,	'2012-06-18 06:17:14',	'2012-06-18 06:17:14',	'',	'1030275',	'',	'inherit',	'open',	'open',	'',	'1030275',	'',	'',	'2012-06-18 06:17:14',	'2012-06-18 06:17:14',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/1030275.pdf',	0,	'attachment',	'application/pdf',	0),
(241,	1,	'2012-06-18 06:17:16',	'2012-06-18 06:17:16',	'',	'1065480',	'',	'inherit',	'open',	'open',	'',	'1065480',	'',	'',	'2012-06-18 06:17:16',	'2012-06-18 06:17:16',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/1065480.pdf',	0,	'attachment',	'application/pdf',	0),
(242,	1,	'2012-06-18 06:20:13',	'2012-06-18 06:20:13',	'',	'1074690',	'',	'inherit',	'open',	'open',	'',	'1074690',	'',	'',	'2012-06-18 06:20:13',	'2012-06-18 06:20:13',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/1074690.pdf',	0,	'attachment',	'application/pdf',	0),
(243,	1,	'2012-06-18 06:20:55',	'2012-06-18 06:20:55',	'',	'1073489',	'',	'inherit',	'open',	'open',	'',	'1073489',	'',	'',	'2012-06-18 06:20:55',	'2012-06-18 06:20:55',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/1073489.pdf',	0,	'attachment',	'application/pdf',	0),
(244,	1,	'2012-06-18 06:10:47',	'2012-06-18 06:10:47',	'&nbsp;\r\n<table id=\"theTable3\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td colspan=\"2\"><img src=\"../../html/images/trans.gif\" alt=\"\" width=\"9\" height=\"1\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>\r\n<h2 class=\"feSubHeading\">ASX Releases</h2>\r\n</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"><img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td id=\"theCell1\" width=\"100%\">\r\n<h3>ASX Releases 2012</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/nrteUploadFiles/132F042F2012103A223A30PM.pdf\">PolyNovo human Trial Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo human Trial Update</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/nrteUploadFiles/132F042F2012103A223A05PM.pdf\">AOD positive in Cartilage and Muscle Repair</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AOD positive in Cartilage and Muscle Repair</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/nrteUploadFiles/132F042F2012103A213A23PM.pdf\">PolyNovo Commences Second Human Trial</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo Commences Second Human Trial</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/7KV5CN9ACM/1074690.pdf\" target=\"_blank\">PolyNovo to Commence Human Trial </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo to Commence Human Trial</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/VI8KS8QBYQ/1073489.pdf\" target=\"_blank\">PolyNovo’s US Collaboration Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo’s US Collaboration Update</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/PE6SXJPOWV/1065480.pdf\" target=\"_blank\">Update on US Partner Collaboration </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update on US Partner Collaboration</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2011</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=779&amp;nav_cat_id=210&amp;nav_top_id=58\" target=\"_blank\">New Applications for AOD9604</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>New Applications for AOD9604</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/T0LVRP791V/Successful_Proof_of_Concept_for_Synthetic_Skin.pdf\" target=\"_blank\">Successful Proof of Concept for Synthetic Skin</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Successful Proof of Concept for Synthetic Skin</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/0PN6AY3NQ1/1030228.pdf\" target=\"_blank\">Changes to Executive Structure</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Changes to Executive Structure</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/YTQSRE5DZ6/1030275.pdf\" target=\"_blank\">Cancellation of Options </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Cancellation of Options</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/LCSRNFXB5N/Notice_of_Annual_General_Meeting_and_Proxy_Form.pdf\" target=\"_blank\">Notice of Annual General Meeting and Proxy Form</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Notice of Annual General Meeting and Proxy Form</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/I5QTOLI9A9/Major_Milestone_for_PolyNovo_and_NovoSorbTM.pdf\" target=\"_blank\">Major Milestone for PolyNovo and NovoSorbTM : First Human Study</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Major Milestone for PolyNovo and NovoSorbTM : First Human Study</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/O6R74NC0D5/1007282.pdf\" target=\"_blank\">Operational Update and Financial Result Guidance </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Operational Update and Financial Result Guidance</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/AMQJC8TS9Q/1899_Calzada_Shareholder_Newsletter_FINAL.pdf\" target=\"_blank\">Calzada Shareholder Newsletter</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada Shareholder Newsletter</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/4RBQ1B3DAB/980299.pdf\" target=\"_blank\">Metabolic’s Osteoporosis Patent Allowed in US </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic’s Osteoporosis Patent Allowed in US</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/2AGG3QQU8G/979227.pdf\" target=\"_blank\">Phosphagenics Bodyshaper Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Phosphagenics Bodyshaper Update</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/MUJND3H4D2/POH_Annoucnement.pdf\" target=\"_blank\">Phosphagenics to launch new cellulite cosmetics</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Phosphagenics to launch new cellulite cosmetics</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/NBCSI1IA7N/967193.pdf\" target=\"_blank\">Calzada Transfers Neural Regeneration Peptides Technology</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada Transfers Neural Regeneration Peptides Technology</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/GXDY7II1LI/963942.pdf\" target=\"_blank\">First PolyNovo Patent Allowed in US</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>First PolyNovo Patent Allowed in US</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/OVUR3LRR0C/962630.pdf\" target=\"_blank\">Burn Surgeon John Greenwood receives the inaugural Burke/Yannas prize at the American Burn Association conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Burn Surgeon John Greenwood receives the inaugural Burke/Yannas prize at the American Burn Association conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/LPMGVTEWFO/962429.pdf\" target=\"_blank\">Board Changes</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Board Changes</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/6K83IAZE8C/953112.pdf\" target=\"_blank\">PolyNovo successfully completes pivotal animal study on burns device</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo successfully completes pivotal animal study on burns device</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/SDLHX9D51M/947775.pdf\" target=\"_blank\">Results for the Half Year Ended 31 December 2010</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Half year results and accounts</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=760&amp;nav_cat_id=210&amp;nav_top_id=58\">AOD9604 shows positive results in human stem cell assay for bone growth</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AOD9604 shows positive results in human stem cell assay for bone growth</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=757&amp;nav_cat_id=210&amp;nav_top_id=58\">Feasibility study extended by 12 months</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Feasibility study extended by 12 months</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=758&amp;nav_cat_id=210&amp;nav_top_id=58\">Update of Black Market Sales of AOD</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update of Black Market Sales of AOD</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=759&amp;nav_cat_id=210&amp;nav_top_id=58\">Appointment of Dr Stewart Washer</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appointment of Dr Stewart Washer</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2010</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=754&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada sells Avexa Shares</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada sells Avexa Shares</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=753&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada signs Licensing Agreement with Phosphagenics</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada signs Licensing Agreement with Phosphagenics</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=752&amp;nav_cat_id=205&amp;nav_top_id=58\">Dr John Chiplin appointed to Calzada Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr John Chiplin appointed to Calzada Board</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=751&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada - 2010 Annual Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada - 2010 Annual Report</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=750&amp;nav_cat_id=205&amp;nav_top_id=58\">Notice of Annual General Meeting</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Notice of Annual General Meeting</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=745&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada responds to claims made by Avexa Limited</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada responds to claims made by Avexa Limited</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=744&amp;nav_cat_id=205&amp;nav_top_id=58\">Email correspondence with Avexa – combining Avexa EGM with Avexa AGM </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Email correspondence with Avexa – combining Avexa EGM with Avexa AGM</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=746&amp;nav_cat_id=205&amp;nav_top_id=58\">Phosphagenics exercises option to licence AOD9604 to develop topical cellulite product</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Phosphagenics exercises option to licence AOD9604 to develop topical cellulite product</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=743&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada to vend Metabolic into ATOS Wellness </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada to vend Metabolic into ATOS Wellness</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=742&amp;nav_cat_id=205&amp;nav_top_id=58\">Change of Director\'s Interest NoticeChange of Director\'s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=741&amp;nav_cat_id=205&amp;nav_top_id=58\">Replacement response to the Age newspaper articleReplacement response to the Age newspaper article</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Replacement response to the Age newspaper article</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=740&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada responds to The Age newspaper article</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada responds to The Age newspaper article</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=739&amp;nav_cat_id=205&amp;nav_top_id=58\">Half Year Report and Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Half Year Report and Accounts</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=738&amp;nav_cat_id=205&amp;nav_top_id=58\">Final Director\'s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=737&amp;nav_cat_id=205&amp;nav_top_id=58\">Initial Director\'s Interest Notice </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=736&amp;nav_cat_id=205&amp;nav_top_id=58\">Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=735&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada moves to 100% ownership of PolyNovo </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada moves to 100% ownership of PolyNovo</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=734&amp;nav_cat_id=205&amp;nav_top_id=58\">Change in substantial holding Change in substantial holding </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change in substantial holding</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=733&amp;nav_cat_id=205&amp;nav_top_id=58\">Becoming a substantial holder from XCD </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Becoming a substantial holder from XCD</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2009</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=715&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\'s Interest Notice - Oliver Stevens</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice - Oliver Stevens</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=714&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\' Interest Notice - David Franklyn</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\' Interest Notice - David Franklyn</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=713&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\'s Interest Notice - George Cameron-Dow</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice - George Cameron-Dow</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=712&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\'s Interest Notice - David Kenley</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice - David Kenley</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=711&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Changes to Company Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Changes to Company Board</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=710&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Appendix 3Z - I Kirkwood</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3Z - I Kirkwood</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=709&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Appendix 3Z - Paul Lappin</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Directors interest Notice - P Lappin</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=708&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">7 April 09 Initial Substantial Holder - Entrust </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>7 April 09 Initial Substantil Holder - Entrust picks up 19.81%</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=707&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">7 Aprl 09 - Ceasing o be a substantal holder - Tony Moore</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Ceasingto be a substantil holder - Tony Moore</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=706&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">2 April 2009 Substantial Shareholder Notice - Tony Moore</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Tony Moore purchases substantial shareholding</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=705&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">31 March 2009 Final Directors Interest Notice 3Z F. Brazil</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>31 March 2009 Final Directors Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=704&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Changes to Metabolic Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Board Changes</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=703&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">10th March 2009 Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Options expiry</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=702&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">10 March 2009 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=701&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">6 March 2009 - Changes to PolyNovo Board and Management</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=700&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">4 March 2009 - First NovoSorb Patent Granted in Australia</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=699&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">26 February 2009 - Appendix 4D Half Yearly Report and Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=698&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">23 February 2009 - Changes to Metabolic Chairman and Company Secretary</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=697&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">23 February 2009 - Appendix 3Z - Final Director\'s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=696&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">2 February 2009 - Changes to Metabolic and PolyNovo Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=695&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">30 January 2009 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=694&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">9th January 2009 - Change of Registered Office and Place of Business Address</a></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2008</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=693&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">18th December 2008 - Metabolic invests $3.5 million for 60% of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has invested a total of $3.5 million in exchange for 60 per cent of PolyNovo Biomaterials Ltd.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=692&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">3rd December 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=691&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st December 2008 - Proposed PolyNovo acquisition terminated</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement advises that the proposed acquisition of PolyNovo Biomaterials Ltd has been terminated.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=690&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th November 2008 - Annual General Meeting Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement includes a summary of voting on each resolution put to shareholders at the 2008 Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=689&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th November 2008 - 2008 Annual General Meeting Presentation</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the AGM presentation given to shareholders at the 2008 Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=688&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th November 2008 - 2008 AGM Chairman\'s Address</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the Chairman\'s address given to shareholders at the 2008 Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=687&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">31 October 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=686&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th October 2008 - 2008 Notice of Annual General Meeting and Sample Proxy Form</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The business before Metabolic\'s 2008 Annual General Meeting includes the usual agenda items as well as resolutions relating to the proposed acquisition of PolyNovo Limited.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=685&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">2nd October 2008 - Share Sale Agreement signed for acquisition of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Share Sale Agreement signed for acquisition of PolyNovo</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=682&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">26th September 2008 - Metabolic Annual Report 2008</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic\'s 2008 Annual Report</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=681&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">5th September 2008 - Update on acquisition of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update on the proposed acquisition of PolyNovo</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=680&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">21st August 2008 - Appendix 4E Preliminary Final Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=679&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">4 August 2008 - Letter to Shareholders regarding the acquisition of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Letter to Shareholders of Metabolic outlining the proposed transaction to acquire PolyNovo Biomaterials Ltd.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=678&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">18th July 2008 - Corporate Presentation: Metabolic\'s acquisition of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>A series of slides with further detail regarding the acquisition of PolyNovo.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=677&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">18th July 2008 - Metabolic signs binding term sheet for PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has signed a binding term sheet to acquire 100% of PolyNovo from its two shareholders, Xceed and CSIRO.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=676&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st July 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=675&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">20th June 2008 - Update on research and future direction </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update on research and future direction</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=674&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">10 June 2008 - Response to Price Query</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=673&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">27th May 2008 - Appendix 3Y</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=672&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">23rd May 2008 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice for Mr Franklyn Brazil</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=671&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">23rd May 2008 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice for Mr Paul Lappin</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=667&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">21st May 2008 - Appointment of Non-Executive Directors</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic appoints two non-executive directors, Mr Franklyn Brazil and Mr Paul Lappin.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=666&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">14th May 2008 - Appendix 3Y</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=665&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">13th May 2008 - Notice of initial substantial holder - Brazil Farming Pty Ltd</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=664&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">13th May 2008 - Iain Kirkwood ceases to be a substantial shareholder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Iain Kirkwood advising that he has ceased as a substantial holder of Metabolic.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=663&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">12th May 2008 - Polychip Pharmaceuticals Limited ceases to be a substantial shareholder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Polychip Pharmaceuticals Limited (Circadian) advising the company has ceased as a substantial holder of Metabolic.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=662&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">9th May 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=661&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st May 2008 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice for Mr Iain Kirkwood</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=660&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">30th April 2008 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Dr Roland Scollay</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=659&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">30th April 2008 - Appointment of Non-Executive Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Mr Iain Kirkwood has been appointed as a non-executive director of Metabolic. Mr Kirkwood is an experienced private consultant, investor and non-executive director (of both listed and unlisted public companies).</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=658&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">29th April 2008 - Dr Roland Scollay steps down from Metabolic Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay resigned as a director of the Metabolic Board. Dr Scollay will work with the Board to ensure a smooth transition and will then be leaving the Company to pursue other interests.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=657&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">8th April 2008 - Acorn ceased to be a substantial shareholder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Acorn Capital Limited advising the company has ceased as a substantial holder of Metabolic.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=656&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">27th February 2008 - Half Yearly Report / Half Yearly Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Financial report for the six months ended 31 December 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=653&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st February 2008 - Quarterly Investor Update </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the fourth quarter of 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=651&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">15th January 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2007</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=649&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th December 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=636&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">2nd November 2007 - 2007 AGM: Voting Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement includes a summary of voting on each resolution put to shareholders at the 2007 Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=635&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">2nd November 2007 - 2007 AGM - Chairman\'s Address and AGM presentation</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the full Chairman\'s address and AGM presentation given to shareholders on 2 November 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=634&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">31st October 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=632&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">19th October 2007 - Quarterly Investor Update Q307 </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the third quarter of 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=631&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">15th October 2007 - NRP Update </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic\'s joint project with Neuren Pharmaceuticals Limited to develop NRPs has made progress. A NRP compound has been shown to be effective in animal models of motor neuron disease and peripheral neuropathy.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=629&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">28th September 2007 - 2007 Annual Report and Notice of Annual General Meeting </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic\'s 2007 Annual Report and Notice of Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=628&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">25th September 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=627&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">20th September 2007 - Update on Oral Peptide Delivery Platform</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains an update on Metabolic\'s proprietary Oral Peptide Delivery Platform including new animal data and future direction.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=626&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">10th September 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Dr Arthur Emmett</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=625&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">10th September 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Dr Chris Belyea</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=624&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">31st August 2007 - 2007 Appendix 4E - Preliminary Final Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic\'s Preliminary Final Report for the year ended 30 June 2007, including the Appendix 4E.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=623&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">30th August 2007 - Resignation of Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the resignation of Chief Scientific Officer, Dr Chris Belyea.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=622&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">28th August 2007 - Resignation of Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the resignationof Non-Executive Director Dr Arthur Emmett</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=621&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">17th August 2007 - Changes to Annual Report legislation </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This notification was sent to Metabolic shareholders to explain new legislation changing the default option for receiving annual reports to be via a company\'s website.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=620&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">16th August 2007 - New Substantial Holder - Niako </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Niako Investments Pty Ltd advising the company has become a substantial holder of Metabolic, with total shares representing 5.75% of issued capital as at 16th August 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=619&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">14th August 2007 - Metabolic discontinues clinical trial programme for neuropathic pain drug, ACV1</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has received new data regarding the ability of ACV1 to block the human a9a10 nicotinic acetylcholine receptor, the probable target of ACV1. The Company will focus its research and development on the Oral Peptide Delivery Platform, and will continue to search for new drugs to in-license or acquire.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=617&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">25th July 2007 - Quarterly Investor Update Q207</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the second quarter of 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=616&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">6th July 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Dr Evert Vos</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=614&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">6th July 2007 - Resignation of Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the resignation of Non-Executive Director Evert Vos.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=612&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">28th June 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=611&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">24th May 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=610&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">16th May 2007 - Response to Price Query</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=608&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">18th April 2007 - Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=605&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">12th April 2007 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=604&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">12th April 2007 - Director Appointment</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the appointment of Mr Don Clarke as a Non-Executive Director.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=603&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=600&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Quarterly Investor Update Q107</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the first quarter of 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=599&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Mr Patrick Sutch</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=598&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Ms Robyn Baker</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=597&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">4th April 2007 - Changes to Metabolic Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the appointment of Mr Robert Stewart as Chairman and Non-Executive Director and the resignation of Non-Executive Directors, Mr Patrick Sutch and Ms Robyn Baker.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=595&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">26th March 2007 - Metabolic\'s pain drug ACV1 enters second Phase 2 human clinical trial</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic reported the commencement of a second ACV1 Phase 2A trial in patients with neuropathic pain as well as the results of a Phase 1 extension trial for the same drug.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=594&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">26th February 2007 - Half Yearly Report / Half Yearly Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Financial report for the six months ended 31 December 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=593&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">21st February 2007 - Shareholder Hotline</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Shareholders with questions regarding the OPTIONS Study are encouraged to call 1800 255 018 which is a free call within Australia. Shareholders outside Australia should call +61 2 8256 3388.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=592&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">21st February 2007 - OPTIONS Study Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The Phase 2B trial results for Metabolic\'s drug, AOD9604, do not support the commercial viability of the drug as a treatment for obesity. Development of the drug for this condition is terminated.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=591&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">19th February 2007 - Request for trading halt</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has been placed in a trading halt pending an announcement in relation to the results of its Phase 2B OPTIONS Study.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=590&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">8th February 2007 - Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=589&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">25th January 2007 - Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=587&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">22nd January 2007 - Quarterly Investor Update </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the fourth quarter of 2006.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=586&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">12th January 2007 - Notice of Change of Interests of Substantial Holder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Circadian Technologies regarding the dilution of their substantial holding due to the recent share placement by Metabolic and the exercise of options.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=585&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">11th January 2007 - Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=584&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th January 2007 - Response to ASX Query</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This letter from Metabolic is in response to a share price query from the ASX</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2006</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=583&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">28th December 2006 - Appendix 3B 28th December 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=582&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">20th December 2006 - Open Briefing with CEO of Metabolic </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced this morning the transcript from an Open Briefing with the CEO of Metabolic, regarding the completion of the Phase 2B OPTIONS Study for obesity drug AOD9604.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=581&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">19th December 2006 - Broadcast Radio Interview 19th December 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>19th December 2006 - Audio Broadcast - CEO interviewed by Boardroom Radio: Dr Roland Scollay\'s interview by Boardroom radio has been webcast and is available at www.boardroomradio.com</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=579&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">18th December 2006 - Options Study END December 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The Phase 2B OPTIONS Study for Obesity drug AOD9604 has been completed on time and within budget. The number of completing subjects comfortably exceeds the statistical design goal. Results of the trial are expected to be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=580&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">18th December 2006 - Form 604 Notice of change of Interests of Substantial Holder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>7th December 2006 - Form 604: Notice of Change of Interests of Substantial Holder Official notice from Acorn Capital Limited regarding the change in their substantial holding of Metabolic shares.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=578&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">15th December 2006 Notice under section 708A (5)(e)</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=577&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">15th December 2006 Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=576&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">7th December 2006 - Capital Raising December 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic raised A$10.5 million through a share placement to predominantly existing institutional shareholders. The funds raised will accelerate the oral version of ACV1 for neuropathic pain, the Oral Peptide Delivery Platform and planning for a Phase 3 obesity trial.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=575&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">7th December 2006 - Metabolic placed in trading halt</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=574&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">7th December 2006 - Metabolic\'s request for trading halt</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=573&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">5th December 2006 - Open Briefing with CEO of Metabolic</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the transcript from an Open Briefing with the CEO of Metabolic, covering the Company\'s lead projects and strategy.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=572&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">29th November 2006 - ACV1 Clinical Trials Update November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced that the Phase 2A programme for ACV1, for neuropathic pain is progressing well. The first group of patients in the first of two trials in this Phase 2A programme have been treated and the second trial is due to commence in Q107. Additionally, a separate trial to test safety of a higher dose level of ACV1 commenced in Q406.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=571&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th November 2006 - Options Study Update - 27 November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced that more than 300 subjects have completed the Phase 2B OPTIONS Study so far. The last subject will complete the trial in December 2006 with results expected to be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=570&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th November 2006 - Domestic Roadshow November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay, CEO of Metabolic, will be meeting with various domestic brokers and analysts this week. This roadshow presentation provides an update on the Company\'s development and strategy.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=569&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd November 2006 - ACV1 PreClinical Update November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has made further progress with the oral version of its neuropathic pain drug ACV1. In addition, an independent study conducted in the US has identified important information about its mechanism of action.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=567&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th November 2006 - Appendix 3Y 17th November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3Y 17th November 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=566&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th November 2006 - Appendix 3Y 17th November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3Y 17th November 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=565&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th November 2006 - Appendix 3B 17th November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B 17th November 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=561&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th October 2006 - 2006 AGM: Voting Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement includes a summary of voting on each resolution put to shareholders at the Company\'s 2006 AGM.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=560&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th October 2006 - New Constitution</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Shareholders of Metabolic approved a new Constitution on 27 October 2006. The complete Constitution is included in this announcement.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=559&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th October 2006 - 2006 AGM Chairman\'s Address and CEO\'s presentation</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement includes the formal address given by the Chairman to shareholders at the Company\'s 2006 AGM and a presentation by the CEO.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=558&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd October 2006 - Change in Substantial Holding</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Monash Investments regarding the change in their substantial holding of Metabolic shares.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=556&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th October 2006 - Response to ASX Query</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This letter from Metabolic is is response to a share price query from the ASX.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=549&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th October 2006 - Quarterly Investor Update - 17 October 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the third quarter of 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=548&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">12th October 2006 - Market Presentation - Intersuisse Conference October 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at the Intersuisse Life Sciences Forum (London) to increase awarenenss of Metabolic in the UK and Europe. The slide-show presentation provides an up-to-date overview of Metabolic\'s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=546&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">9th October 2006 - Appendix 3B 9th October 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B 9th October 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=547&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">5th October 2006 - Obesity Trial Update - October 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The first 100 subjects have completed the Phase 2B OPTIONS Study including 24 weeks of daily oral dosing of obesity drug, AOD9604. The last subject will complete the trial in December 2006 with results expected to be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=545&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">28th September 2006 - UBS Global Life Sciences Conference - presentation by Dr Roland Scollay</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at the UBS Global Life Sciences Conference in New York to increase awareness of Metabolic in the US. The slide-show presentation provides and up-to-date overview of Metabolic\'s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=544&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th September 2006 - Metabolic\'s neuropathic pain drug, ACV1, enters Phase 2A clinical trials</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic commenced the first trial in its Phase 2A programme for ACV1, for the treatment of neuropathic pain. This first trial will target neuropathic sciatic pain and results are expected to be announced during the first six months of 2007 (H107).</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=542&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">26th September 2006 - 2006 Annual Report and Notice of Annual General Meeting</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the Company’s 2006 Annual Report, Notice of Annual General Meeting and sample voting form.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=557&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">1st September 2006 - Quarterly rebalance of S&amp;P/ASX Indices</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice that Metabolic has been removed from the S&amp;P/ASX 300 Index</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=539&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th July 2006 - Quarterly Investor Update July 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the second quarter of 2006.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=538&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">19th July 2006 - Obesity trial update: First subject completes treatment</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The first few subjects have completed treatment including 24 weeks of daily oral dosing of AOD9604. The last subject will complete the trial in December 2006 with results expected to be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=537&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">11th July 2006 - NRP collaboration: Research on nerve protection compounds published in science journal</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Research on Neural Regeneration Peptides (NRPs) has been published in the international science journal, \'Experimental Cell Research\'. NRPs have previously shown promising effects in a rat model of nerve damage. Formal preclinical development of NRPs expected to commence in 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=520&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">21 June 2006 - Metabolic\'s osteoporosis drug: additional animal data support further beneficial effects of AOD9604</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Additional animal data indicate AOD9604 has beneficial effects on trabecular bone as well as corticol bone. Two further animal studies are underway to investigate the optimal dose of AOD9604 for osteoporosis; and the possible role of the drug in treatment of osteoporosis (in addition to prevention, as previously determined).</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=465&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">14th June 2006 - Life Sciences (USA) Presentation</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at the Pacific Growth Equities\' 2006 Life Sciences Growth Conference in San Francisco to increase awareness of Metabolic in the USA. Slide-show presentation provides an up-to-date overview of Metabolic\'s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=466&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd May 2006 - Roadshow Presentation - company update May 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay met with several analysts and institutions to increase local awareness of Metabolic. Slide-show presentation provides an up-to-date overview of Metabolic’s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=467&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">10th May 2006 - Quarterly Investor Update 10 May 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Summary of Company news during the first quarter of 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=468&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">8th May 2006 - Audio Broadcast - CEO interviewed by Boardroom Radio</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay’s interview by Boardroom radio has been audio webcast and is available at www.boardroomradio.com</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=469&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">2nd May 2006 - Metabolic completes enrolment for obesity clinical trial ahead of schedule</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>536 subjects have been enrolled in the Phase 2B trial, known as the “OPTIONSEstudy for obesity drug, AOD9604. This trial will now end in December 2006 and results will be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=470&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">5th April 2006 - Metabolic CEO to present at US biotech conferences</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at various biotechnology conferences and expos in the USA. Slide-show presentation provides an up-to-date overview of Metabolic’s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=471&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">30th March 2006 - Change in Substantial Holding</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Monash Investments regarding the dilution of their substantial holding due to the recent share placement by Metabolic</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=472&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">24th March 2006 - Appendix 3B - New issue of options</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>New issue of shares and options, pursuant to the private placement on 21 March 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=473&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">24th March 2006 - Notice under section 708A (5)(e)</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official cleansing statement Eno outstanding disclosures</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=474&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">21st March 2006 - Metabolic completes A$13 million share placement</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Private placement of 30.2 million shares to international and Australian institutional investors. Funds raised will advance Metabolic’s drug pipeline for pain, osteoporosis and oral delivery platform for peptides.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=475&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th March 2006 - Trading Halt 17th March 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official trading halt request by Metabolic</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=476&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">6th March 2006 - Clinical Trials Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The Phase 2B trial for obesity drug, AOD9604 is progressing well, on schedule, and preparation is underway for the Phase 2A program for ACV1, for pain</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=477&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th February 2006 - Half Yearly Report / Half Yearly Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Financial report for the six months ended 31 December 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=478&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">16th February 2006 - NRP Update: Metabolic and Neuren report promising animal efficacy data in collaborative project </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>New compound, Neural Regeneration Peptide: NNZ-4921, has been shown to prevent or reverse peripheral neuropathy (nerve damage) in an animal study</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=479&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">15th February 2006 - CEO to present at BioCEO &amp; Investor Conference in New York</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay participated as a panelist at the BioCEO &amp; Investor Conference in New York, and gave a presentation on Metabolic’s lead drugs AOD9604 for obesity, including details of previous trial results, and a potential new use for the drug.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=480&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">8th February 2006 - Investor Roadshow Presentation - USA</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at the Biotechnology Organisation (BIO) Conference and met with several analysts and institutions to increase awareness of Metabolic in the USA. Slide show presentation provides an up-to-date overview of Metabolic’s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=481&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">6th February 2006 - Metabolic Quarterly Investor Update Number 12 </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Summary of Company news during the fourth quarter of 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=482&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">1st February 2006 - Appendix 3Y - Change of Director’s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay was granted 1,000,000 options, pursuant to the Metabolic Employee Share Option Plan, approved by shareholders at the 2005 Annual General Meeting on 28 October 2005.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=483&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">1st February 2006 - Appendix 3B - New issue of options </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>New issue of 1,000,000 MBPAQ unquoted options, pursuant to the Metabolic Employee Share Option Plan, approved by shareholders at the 2005 Annual General Meeting on 28 October 2005.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=484&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">31st January 2006 - Potential new use in osteoporosis adds value to Metabolic\'s obesity drug</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Animal study: Orally delivered drug, AOD9604, shows an effect in preventing bone loss and maintaining bone quality in a rat model of osteoporosis.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=485&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd January 2006 - Update on Phase 2B dosing trial for obesity drug</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The low dose, Phase 2B trial, known as the “OPTIONSEstudy is proceeding on schedule with recruitment on track an all ethics approvals obtained.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2005</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=428&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">18th November 2005 - ASX Appendix 3Y Change of Director\'s Interest - A Emmett</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3Y Change of Director\'s Interest - A Emmett</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=427&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">16th November 2005 - ACV1 Phase 1 results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ACV1 Phase 1 results</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=425&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">4th November 2005 - CEO Presentation Rodman Renshaw Conference 7 November 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>CEO Presentation Rodman Renshaw Conference 7 November 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=423&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">2nd November 2005 - ASX Appendix 3B 2nd November 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3B 2nd November 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=422&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">31st October 2005 - ASX Appendix 3X 31st October 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3X 31st October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=419&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th October 2005 - Chairman\'s Address and CEO Presentation at AGM 28th October 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Chairman\'s Address and CEO Presentation at AGM 28th October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=421&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th October 2005 - Metabolic AGM Results 28 October 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic AGM Results 28 October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=420&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th October 2005 - Amended Constitution of Metabolic Pharmaceuticals 28 October 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Amended Constitution of Metabolic Pharmaceuticals 28 October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=418&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">26th October 2005 - Metabolic Quarterly Investor Update </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic Quarterly Investor Update - 26 October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=417&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th October 2005 - Metabolic ranks number 1 as Australia\'s top innovator</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic ranks number 1 as Australia\'s top innovator</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=416&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">19th October 2005 - Metabolic CEO to present to Health Care and Life Science Conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic CEO to present to Health Care and Life Science Conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=433&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">22nd December 2005 - ASX Appendix 3Y R Scollay</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3Y R Scollay</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=412&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">18th October 2005 - Metabolic starts next clinical trial of obesity drug</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic starts next clinical trial for obesity drug</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=415&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">18th October 2005 - VP Clinical Development Presentation at NAASO Conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>VP Clinical Development Presentation at NAASO Conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=409&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th October 2005 - Appointment of Non-Executive Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appointment of Non-Executive Director</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=404&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">27th September 2005 Release of Securities from Escrow - Monash Investment Holdings P/L</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Release of Securities from Escrow - Monash Investment Holdings P/L</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=432&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">22nd December 2005 - ASX Appendix 3Y C Belyea</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3Y C Belyea</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=403&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">7th September 2005 - Metabolic Pharmaceuticals CEO to present at biotechnology conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic Pharmaceuticals CEO to present at biotechnology conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=402&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">1st September 2005 - Change of Director\'s Interest - R Scollay</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest - R Scollay</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=401&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">26th August 2005 App 4E Preliminary Final Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Preliminary Final Report</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=400&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd August 2005 - Appointment of new CFO</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appointment of new CFO</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=431&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">22nd December 2005 - ASX Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3B</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=399&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">15th August 2005 - Metabolic ACV1 Update 15 August 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic ACV1 Update 15th August 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=398&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">8th August 2005 - ASX Appendix 3B 8th August 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B - 8th August 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=395&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th Aug 2005 - Change of Director\'s Interest - A Emmett</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest - A Emmett</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=396&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th Aug 2005 - Change of Director\'s Interest - C Belyea</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest - C Belyea</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=397&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th Aug 2005 - Change of Director\'s Interest - E Vos</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest - E Vos</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=390&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th July 2005 - ASX Appendix 3B 28th July 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B - 28th July 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=430&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">25th November 2005 - ASX Appendix 3Y Change in Director\'s Interest - R Baker</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3Y Change in Director\'s Interest - R Baker</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=386&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">21st July 2005 - SPP Announcement </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Share Purchase Plan Announcement 21st July 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=385&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th July 2005 - Investor Update 5th July 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Investor Update 5th July 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=384&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th June 2005 - Notice under Section 708A of the Corps Act</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Notice under Section 708A of the Corps Act</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=383&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th June 2005 - Share Purchase Plan Offer to Shareholders</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Share Purchase Plan Offer to Shareholders</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=382&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th June 2005 - VP Corporate Development Position</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>VP Corporate Development Position</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=429&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th November 2005 - ASX Appendix 3Y Change in Director\'s Interest - P Sutch</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3Y Change in Director\'s Interest - P Sutch</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=555&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd June 2005 - Change in Substantial Holding</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=381&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd June 2005 - Appendix 3B 23rd June 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B - 23rd June 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=380&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd June 2005 - ACV1 Phase 1 Clinical Trial Commences</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ACV1 Phase 1 Clinical Trial Commences</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=377&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">14th June 2005 - Placement and SPP Offer</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Placement and SPP Offer</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=378&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">14th June 2005 - AusIndustry \"Commercial Ready\" Grant for ACV1</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AusIndustry \"Commercial Ready\" Grant for ACV1</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=379&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">14th June 2005 - Conference Presentations June 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Conference Presentations June 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=376&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">3rd June 2005 - AOD9604 Obesity Drug Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AOD9604 Obesity Drug Update 3rd June 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=370&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">1st June 2005 - Metabolic establishes ADR program</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic Pharmaceuticals Ltd establishes ADR Program</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=366&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">20th May 2005 - Response to ASX Query re: Share Price</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Response to ASX Query re: Share Price - 20th May 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=364&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">2nd May 2005 - ACV1 Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ACV1 Update 2nd May 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=362&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">20th April 2005 AOD9604 Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AOD9604 Update 20th April 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=360&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">8th March 2005 - Investor Update 8th March 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Investor Update 8th March 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=359&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">3rd March 2005 - Neuren and Metabolic Development Collaboration March 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Neuren and Metabolic Development Collaboration March 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=358&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd February 2005 US Presentations February 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>US Presentations February 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=357&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">21st February 2005 - Half Yearly Report / Half Yearly Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Half Yearly Report / Half Yearly Accounts</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=355&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">10th February 2005 - CEO to speak on Obesity Panel at BIO CEO Conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>CEO to speak on Obesity Panel at BIO CEO Conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=354&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th January 2005 Metabolic appoints new Chief Executive Officer</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic appoints new Chief Executive Officer</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=353&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">13th January 2005 - ASX CEO Position</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>CEO Position</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2004</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=506&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">23rd December 2004 - ASX Resignation of Company Secretary</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Resignation of Company Secretary</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=505&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">17th December 2004 - ASX Change in Director\'s Interest</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change in Director\'s Interest</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=504&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">17th December 2004 - ASX Response to Market Comments</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Response to Market Comments 17th December 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=503&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">15th December 2004 - ASX Appendix 3B 15th November 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3B 15th November 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=502&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">13th December 2004 - AOD9604 Phase2b Clinical Trial Successful</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AOD9604 Phase 2b Clinical Trial Successful</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=501&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">13th December 2004 Successful trial results for world-first obesity drug</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Successful trial results for world-first obesity drug</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=500&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">9th December 2004 - ASX Trading Halt</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Trading Halt - 9th December 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=499&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">29th November 2004 - AOD9604 Update on Clinical Trial Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update on Clinical Trial Results 29th November 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=498&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">16th November 2004 - Response to ASX Query re: Share Price</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Response to ASX Query re: Share Price</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=497&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">4th November 2004 - ASX Appendix 3B 4th November 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B 4th November 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=496&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">29th October 2004 - ASX AGM Results 29th October 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AGM Results 29th October 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=495&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">29th October 2004 - ASX Chairman\'s Address AGM 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Chairman\'s Address AGM 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=494&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">30th September 2004 - Release of securities from voluntary escrow</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Release of securities from voluntary escrow</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=493&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">23rd September 2004 - 2004 Annual Report and Notice of AGM</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>2004 Annual Report and Notice of AGM</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=492&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">22nd September 2004 Investor Update - September 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Investor Update - September 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=491&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">20th September 2004 Completion of dosing in obesity trials</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Completion of dosing in obesity trials</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=490&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">24th August 2004 - Preliminary Final Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 4E - Preliminary Final Report</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=489&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">6th July 2004 - Increasing awareness in US markets in preparation for 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Increasing awareness in US markets in preparation for 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=488&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">5th July 2004 - Cohen Research Report July 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Cohen Research Report July 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=487&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">4th June 2004 - Investor Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Investor Update - 4th June, 2004</td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n</td>\r\n</tr>\r\n</tbody>\r\n</table>',	'ASX Announcements',	'',	'inherit',	'open',	'open',	'',	'141-revision-4',	'',	'',	'2012-06-18 06:10:47',	'2012-06-18 06:10:47',	'',	141,	'http://calzada-wp.urldock.com/141-revision-4/',	0,	'revision',	'',	0),
(245,	1,	'2012-06-18 06:23:26',	'2012-06-18 06:23:26',	'',	'1899_Calzada_Shareholder_Newsletter_FINAL',	'',	'inherit',	'open',	'open',	'',	'1899_calzada_shareholder_newsletter_final-2',	'',	'',	'2012-06-18 06:23:26',	'2012-06-18 06:23:26',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/1899_Calzada_Shareholder_Newsletter_FINAL1.pdf',	0,	'attachment',	'application/pdf',	0),
(246,	1,	'2012-06-18 06:23:30',	'2012-06-18 06:23:30',	'',	'Major_Milestone_for_PolyNovo_and_NovoSorbTM',	'',	'inherit',	'open',	'open',	'',	'major_milestone_for_polynovo_and_novosorbtm',	'',	'',	'2012-06-18 06:23:30',	'2012-06-18 06:23:30',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/Major_Milestone_for_PolyNovo_and_NovoSorbTM.pdf',	0,	'attachment',	'application/pdf',	0),
(247,	1,	'2012-06-18 06:23:36',	'2012-06-18 06:23:36',	'',	'Notice_of_Annual_General_Meeting_and_Proxy_Form',	'',	'inherit',	'open',	'open',	'',	'notice_of_annual_general_meeting_and_proxy_form',	'',	'',	'2012-06-18 06:23:36',	'2012-06-18 06:23:36',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting_and_Proxy_Form.pdf',	0,	'attachment',	'application/pdf',	0),
(248,	1,	'2012-06-18 06:23:39',	'2012-06-18 06:23:39',	'',	'POH_Annoucnement',	'',	'inherit',	'open',	'open',	'',	'poh_annoucnement',	'',	'',	'2012-06-18 06:23:39',	'2012-06-18 06:23:39',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/POH_Annoucnement.pdf',	0,	'attachment',	'application/pdf',	0),
(249,	1,	'2012-06-18 06:24:00',	'2012-06-18 06:24:00',	'',	'Successful_Proof_of_Concept_for_Synthetic_Skin',	'',	'inherit',	'open',	'open',	'',	'successful_proof_of_concept_for_synthetic_skin',	'',	'',	'2012-06-18 06:24:00',	'2012-06-18 06:24:00',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/Successful_Proof_of_Concept_for_Synthetic_Skin.pdf',	0,	'attachment',	'application/pdf',	0),
(250,	1,	'2012-06-18 06:21:58',	'2012-06-18 06:21:58',	'&nbsp;\r\n<table id=\"theTable3\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td colspan=\"2\"><img src=\"../../html/images/trans.gif\" alt=\"\" width=\"9\" height=\"1\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>\r\n<h2 class=\"feSubHeading\">ASX Releases</h2>\r\n</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"><img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td id=\"theCell1\" width=\"100%\">\r\n<h3>ASX Releases 2012</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/132F042F2012103A223A30PM.pdf\">PolyNovo human Trial Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo human Trial Update</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/132F042F2012103A223A05PM.pdf\">AOD positive in Cartilage and Muscle Repair</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AOD positive in Cartilage and Muscle Repair</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/132F042F2012103A213A23PM.pdf\">PolyNovo Commences Second Human Trial</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo Commences Second Human Trial</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1074690.pdf\" target=\"_blank\">PolyNovo to Commence Human Trial </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo to Commence Human Trial</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1073489.pdf\" target=\"_blank\">PolyNovo’s US Collaboration Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo’s US Collaboration Update</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1065480.pdf\" target=\"_blank\">Update on US Partner Collaboration </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update on US Partner Collaboration</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2011</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=779&amp;nav_cat_id=210&amp;nav_top_id=58\" target=\"_blank\">New Applications for AOD9604</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>New Applications for AOD9604</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/T0LVRP791V/Successful_Proof_of_Concept_for_Synthetic_Skin.pdf\" target=\"_blank\">Successful Proof of Concept for Synthetic Skin</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Successful Proof of Concept for Synthetic Skin</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/0PN6AY3NQ1/1030228.pdf\" target=\"_blank\">Changes to Executive Structure</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Changes to Executive Structure</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/YTQSRE5DZ6/1030275.pdf\" target=\"_blank\">Cancellation of Options </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Cancellation of Options</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/LCSRNFXB5N/Notice_of_Annual_General_Meeting_and_Proxy_Form.pdf\" target=\"_blank\">Notice of Annual General Meeting and Proxy Form</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Notice of Annual General Meeting and Proxy Form</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/I5QTOLI9A9/Major_Milestone_for_PolyNovo_and_NovoSorbTM.pdf\" target=\"_blank\">Major Milestone for PolyNovo and NovoSorbTM : First Human Study</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Major Milestone for PolyNovo and NovoSorbTM : First Human Study</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/O6R74NC0D5/1007282.pdf\" target=\"_blank\">Operational Update and Financial Result Guidance </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Operational Update and Financial Result Guidance</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/AMQJC8TS9Q/1899_Calzada_Shareholder_Newsletter_FINAL.pdf\" target=\"_blank\">Calzada Shareholder Newsletter</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada Shareholder Newsletter</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/4RBQ1B3DAB/980299.pdf\" target=\"_blank\">Metabolic’s Osteoporosis Patent Allowed in US </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic’s Osteoporosis Patent Allowed in US</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/2AGG3QQU8G/979227.pdf\" target=\"_blank\">Phosphagenics Bodyshaper Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Phosphagenics Bodyshaper Update</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/MUJND3H4D2/POH_Annoucnement.pdf\" target=\"_blank\">Phosphagenics to launch new cellulite cosmetics</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Phosphagenics to launch new cellulite cosmetics</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/NBCSI1IA7N/967193.pdf\" target=\"_blank\">Calzada Transfers Neural Regeneration Peptides Technology</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada Transfers Neural Regeneration Peptides Technology</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/GXDY7II1LI/963942.pdf\" target=\"_blank\">First PolyNovo Patent Allowed in US</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>First PolyNovo Patent Allowed in US</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/OVUR3LRR0C/962630.pdf\" target=\"_blank\">Burn Surgeon John Greenwood receives the inaugural Burke/Yannas prize at the American Burn Association conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Burn Surgeon John Greenwood receives the inaugural Burke/Yannas prize at the American Burn Association conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/LPMGVTEWFO/962429.pdf\" target=\"_blank\">Board Changes</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Board Changes</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/6K83IAZE8C/953112.pdf\" target=\"_blank\">PolyNovo successfully completes pivotal animal study on burns device</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo successfully completes pivotal animal study on burns device</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../files/SDLHX9D51M/947775.pdf\" target=\"_blank\">Results for the Half Year Ended 31 December 2010</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Half year results and accounts</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=760&amp;nav_cat_id=210&amp;nav_top_id=58\">AOD9604 shows positive results in human stem cell assay for bone growth</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AOD9604 shows positive results in human stem cell assay for bone growth</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=757&amp;nav_cat_id=210&amp;nav_top_id=58\">Feasibility study extended by 12 months</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Feasibility study extended by 12 months</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=758&amp;nav_cat_id=210&amp;nav_top_id=58\">Update of Black Market Sales of AOD</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update of Black Market Sales of AOD</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=759&amp;nav_cat_id=210&amp;nav_top_id=58\">Appointment of Dr Stewart Washer</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appointment of Dr Stewart Washer</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2010</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=754&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada sells Avexa Shares</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada sells Avexa Shares</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=753&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada signs Licensing Agreement with Phosphagenics</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada signs Licensing Agreement with Phosphagenics</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=752&amp;nav_cat_id=205&amp;nav_top_id=58\">Dr John Chiplin appointed to Calzada Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr John Chiplin appointed to Calzada Board</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=751&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada - 2010 Annual Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada - 2010 Annual Report</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=750&amp;nav_cat_id=205&amp;nav_top_id=58\">Notice of Annual General Meeting</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Notice of Annual General Meeting</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=745&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada responds to claims made by Avexa Limited</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada responds to claims made by Avexa Limited</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=744&amp;nav_cat_id=205&amp;nav_top_id=58\">Email correspondence with Avexa – combining Avexa EGM with Avexa AGM </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Email correspondence with Avexa – combining Avexa EGM with Avexa AGM</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=746&amp;nav_cat_id=205&amp;nav_top_id=58\">Phosphagenics exercises option to licence AOD9604 to develop topical cellulite product</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Phosphagenics exercises option to licence AOD9604 to develop topical cellulite product</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=743&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada to vend Metabolic into ATOS Wellness </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada to vend Metabolic into ATOS Wellness</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=742&amp;nav_cat_id=205&amp;nav_top_id=58\">Change of Director\'s Interest NoticeChange of Director\'s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=741&amp;nav_cat_id=205&amp;nav_top_id=58\">Replacement response to the Age newspaper articleReplacement response to the Age newspaper article</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Replacement response to the Age newspaper article</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=740&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada responds to The Age newspaper article</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada responds to The Age newspaper article</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=739&amp;nav_cat_id=205&amp;nav_top_id=58\">Half Year Report and Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Half Year Report and Accounts</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=738&amp;nav_cat_id=205&amp;nav_top_id=58\">Final Director\'s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=737&amp;nav_cat_id=205&amp;nav_top_id=58\">Initial Director\'s Interest Notice </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=736&amp;nav_cat_id=205&amp;nav_top_id=58\">Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=735&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada moves to 100% ownership of PolyNovo </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada moves to 100% ownership of PolyNovo</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=734&amp;nav_cat_id=205&amp;nav_top_id=58\">Change in substantial holding Change in substantial holding </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change in substantial holding</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=733&amp;nav_cat_id=205&amp;nav_top_id=58\">Becoming a substantial holder from XCD </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Becoming a substantial holder from XCD</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2009</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=715&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\'s Interest Notice - Oliver Stevens</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice - Oliver Stevens</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=714&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\' Interest Notice - David Franklyn</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\' Interest Notice - David Franklyn</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=713&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\'s Interest Notice - George Cameron-Dow</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice - George Cameron-Dow</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=712&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\'s Interest Notice - David Kenley</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice - David Kenley</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=711&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Changes to Company Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Changes to Company Board</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=710&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Appendix 3Z - I Kirkwood</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3Z - I Kirkwood</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=709&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Appendix 3Z - Paul Lappin</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Directors interest Notice - P Lappin</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=708&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">7 April 09 Initial Substantial Holder - Entrust </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>7 April 09 Initial Substantil Holder - Entrust picks up 19.81%</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=707&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">7 Aprl 09 - Ceasing o be a substantal holder - Tony Moore</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Ceasingto be a substantil holder - Tony Moore</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=706&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">2 April 2009 Substantial Shareholder Notice - Tony Moore</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Tony Moore purchases substantial shareholding</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=705&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">31 March 2009 Final Directors Interest Notice 3Z F. Brazil</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>31 March 2009 Final Directors Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=704&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Changes to Metabolic Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Board Changes</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=703&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">10th March 2009 Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Options expiry</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=702&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">10 March 2009 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=701&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">6 March 2009 - Changes to PolyNovo Board and Management</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=700&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">4 March 2009 - First NovoSorb Patent Granted in Australia</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=699&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">26 February 2009 - Appendix 4D Half Yearly Report and Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=698&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">23 February 2009 - Changes to Metabolic Chairman and Company Secretary</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=697&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">23 February 2009 - Appendix 3Z - Final Director\'s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=696&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">2 February 2009 - Changes to Metabolic and PolyNovo Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=695&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">30 January 2009 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=694&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">9th January 2009 - Change of Registered Office and Place of Business Address</a></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2008</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=693&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">18th December 2008 - Metabolic invests $3.5 million for 60% of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has invested a total of $3.5 million in exchange for 60 per cent of PolyNovo Biomaterials Ltd.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=692&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">3rd December 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=691&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st December 2008 - Proposed PolyNovo acquisition terminated</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement advises that the proposed acquisition of PolyNovo Biomaterials Ltd has been terminated.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=690&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th November 2008 - Annual General Meeting Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement includes a summary of voting on each resolution put to shareholders at the 2008 Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=689&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th November 2008 - 2008 Annual General Meeting Presentation</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the AGM presentation given to shareholders at the 2008 Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=688&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th November 2008 - 2008 AGM Chairman\'s Address</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the Chairman\'s address given to shareholders at the 2008 Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=687&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">31 October 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=686&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th October 2008 - 2008 Notice of Annual General Meeting and Sample Proxy Form</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The business before Metabolic\'s 2008 Annual General Meeting includes the usual agenda items as well as resolutions relating to the proposed acquisition of PolyNovo Limited.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=685&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">2nd October 2008 - Share Sale Agreement signed for acquisition of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Share Sale Agreement signed for acquisition of PolyNovo</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=682&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">26th September 2008 - Metabolic Annual Report 2008</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic\'s 2008 Annual Report</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=681&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">5th September 2008 - Update on acquisition of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update on the proposed acquisition of PolyNovo</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=680&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">21st August 2008 - Appendix 4E Preliminary Final Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=679&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">4 August 2008 - Letter to Shareholders regarding the acquisition of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Letter to Shareholders of Metabolic outlining the proposed transaction to acquire PolyNovo Biomaterials Ltd.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=678&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">18th July 2008 - Corporate Presentation: Metabolic\'s acquisition of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>A series of slides with further detail regarding the acquisition of PolyNovo.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=677&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">18th July 2008 - Metabolic signs binding term sheet for PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has signed a binding term sheet to acquire 100% of PolyNovo from its two shareholders, Xceed and CSIRO.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=676&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st July 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=675&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">20th June 2008 - Update on research and future direction </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update on research and future direction</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=674&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">10 June 2008 - Response to Price Query</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=673&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">27th May 2008 - Appendix 3Y</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=672&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">23rd May 2008 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice for Mr Franklyn Brazil</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=671&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">23rd May 2008 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice for Mr Paul Lappin</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=667&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">21st May 2008 - Appointment of Non-Executive Directors</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic appoints two non-executive directors, Mr Franklyn Brazil and Mr Paul Lappin.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=666&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">14th May 2008 - Appendix 3Y</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=665&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">13th May 2008 - Notice of initial substantial holder - Brazil Farming Pty Ltd</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=664&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">13th May 2008 - Iain Kirkwood ceases to be a substantial shareholder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Iain Kirkwood advising that he has ceased as a substantial holder of Metabolic.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=663&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">12th May 2008 - Polychip Pharmaceuticals Limited ceases to be a substantial shareholder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Polychip Pharmaceuticals Limited (Circadian) advising the company has ceased as a substantial holder of Metabolic.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=662&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">9th May 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=661&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st May 2008 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice for Mr Iain Kirkwood</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=660&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">30th April 2008 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Dr Roland Scollay</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=659&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">30th April 2008 - Appointment of Non-Executive Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Mr Iain Kirkwood has been appointed as a non-executive director of Metabolic. Mr Kirkwood is an experienced private consultant, investor and non-executive director (of both listed and unlisted public companies).</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=658&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">29th April 2008 - Dr Roland Scollay steps down from Metabolic Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay resigned as a director of the Metabolic Board. Dr Scollay will work with the Board to ensure a smooth transition and will then be leaving the Company to pursue other interests.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=657&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">8th April 2008 - Acorn ceased to be a substantial shareholder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Acorn Capital Limited advising the company has ceased as a substantial holder of Metabolic.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=656&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">27th February 2008 - Half Yearly Report / Half Yearly Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Financial report for the six months ended 31 December 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=653&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st February 2008 - Quarterly Investor Update </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the fourth quarter of 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=651&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">15th January 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2007</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=649&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th December 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=636&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">2nd November 2007 - 2007 AGM: Voting Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement includes a summary of voting on each resolution put to shareholders at the 2007 Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=635&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">2nd November 2007 - 2007 AGM - Chairman\'s Address and AGM presentation</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the full Chairman\'s address and AGM presentation given to shareholders on 2 November 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=634&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">31st October 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=632&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">19th October 2007 - Quarterly Investor Update Q307 </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the third quarter of 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=631&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">15th October 2007 - NRP Update </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic\'s joint project with Neuren Pharmaceuticals Limited to develop NRPs has made progress. A NRP compound has been shown to be effective in animal models of motor neuron disease and peripheral neuropathy.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=629&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">28th September 2007 - 2007 Annual Report and Notice of Annual General Meeting </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic\'s 2007 Annual Report and Notice of Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=628&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">25th September 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=627&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">20th September 2007 - Update on Oral Peptide Delivery Platform</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains an update on Metabolic\'s proprietary Oral Peptide Delivery Platform including new animal data and future direction.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=626&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">10th September 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Dr Arthur Emmett</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=625&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">10th September 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Dr Chris Belyea</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=624&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">31st August 2007 - 2007 Appendix 4E - Preliminary Final Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic\'s Preliminary Final Report for the year ended 30 June 2007, including the Appendix 4E.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=623&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">30th August 2007 - Resignation of Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the resignation of Chief Scientific Officer, Dr Chris Belyea.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=622&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">28th August 2007 - Resignation of Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the resignationof Non-Executive Director Dr Arthur Emmett</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=621&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">17th August 2007 - Changes to Annual Report legislation </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This notification was sent to Metabolic shareholders to explain new legislation changing the default option for receiving annual reports to be via a company\'s website.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=620&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">16th August 2007 - New Substantial Holder - Niako </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Niako Investments Pty Ltd advising the company has become a substantial holder of Metabolic, with total shares representing 5.75% of issued capital as at 16th August 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=619&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">14th August 2007 - Metabolic discontinues clinical trial programme for neuropathic pain drug, ACV1</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has received new data regarding the ability of ACV1 to block the human a9a10 nicotinic acetylcholine receptor, the probable target of ACV1. The Company will focus its research and development on the Oral Peptide Delivery Platform, and will continue to search for new drugs to in-license or acquire.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=617&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">25th July 2007 - Quarterly Investor Update Q207</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the second quarter of 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=616&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">6th July 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Dr Evert Vos</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=614&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">6th July 2007 - Resignation of Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the resignation of Non-Executive Director Evert Vos.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=612&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">28th June 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=611&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">24th May 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=610&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">16th May 2007 - Response to Price Query</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=608&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">18th April 2007 - Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=605&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">12th April 2007 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=604&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">12th April 2007 - Director Appointment</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the appointment of Mr Don Clarke as a Non-Executive Director.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=603&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=600&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Quarterly Investor Update Q107</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the first quarter of 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=599&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Mr Patrick Sutch</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=598&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Ms Robyn Baker</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=597&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">4th April 2007 - Changes to Metabolic Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the appointment of Mr Robert Stewart as Chairman and Non-Executive Director and the resignation of Non-Executive Directors, Mr Patrick Sutch and Ms Robyn Baker.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=595&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">26th March 2007 - Metabolic\'s pain drug ACV1 enters second Phase 2 human clinical trial</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic reported the commencement of a second ACV1 Phase 2A trial in patients with neuropathic pain as well as the results of a Phase 1 extension trial for the same drug.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=594&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">26th February 2007 - Half Yearly Report / Half Yearly Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Financial report for the six months ended 31 December 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=593&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">21st February 2007 - Shareholder Hotline</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Shareholders with questions regarding the OPTIONS Study are encouraged to call 1800 255 018 which is a free call within Australia. Shareholders outside Australia should call +61 2 8256 3388.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=592&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">21st February 2007 - OPTIONS Study Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The Phase 2B trial results for Metabolic\'s drug, AOD9604, do not support the commercial viability of the drug as a treatment for obesity. Development of the drug for this condition is terminated.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=591&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">19th February 2007 - Request for trading halt</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has been placed in a trading halt pending an announcement in relation to the results of its Phase 2B OPTIONS Study.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=590&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">8th February 2007 - Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=589&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">25th January 2007 - Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=587&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">22nd January 2007 - Quarterly Investor Update </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the fourth quarter of 2006.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=586&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">12th January 2007 - Notice of Change of Interests of Substantial Holder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Circadian Technologies regarding the dilution of their substantial holding due to the recent share placement by Metabolic and the exercise of options.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=585&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">11th January 2007 - Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=584&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th January 2007 - Response to ASX Query</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This letter from Metabolic is in response to a share price query from the ASX</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2006</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=583&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">28th December 2006 - Appendix 3B 28th December 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=582&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">20th December 2006 - Open Briefing with CEO of Metabolic </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced this morning the transcript from an Open Briefing with the CEO of Metabolic, regarding the completion of the Phase 2B OPTIONS Study for obesity drug AOD9604.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=581&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">19th December 2006 - Broadcast Radio Interview 19th December 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>19th December 2006 - Audio Broadcast - CEO interviewed by Boardroom Radio: Dr Roland Scollay\'s interview by Boardroom radio has been webcast and is available at www.boardroomradio.com</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=579&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">18th December 2006 - Options Study END December 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The Phase 2B OPTIONS Study for Obesity drug AOD9604 has been completed on time and within budget. The number of completing subjects comfortably exceeds the statistical design goal. Results of the trial are expected to be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=580&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">18th December 2006 - Form 604 Notice of change of Interests of Substantial Holder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>7th December 2006 - Form 604: Notice of Change of Interests of Substantial Holder Official notice from Acorn Capital Limited regarding the change in their substantial holding of Metabolic shares.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=578&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">15th December 2006 Notice under section 708A (5)(e)</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=577&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">15th December 2006 Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=576&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">7th December 2006 - Capital Raising December 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic raised A$10.5 million through a share placement to predominantly existing institutional shareholders. The funds raised will accelerate the oral version of ACV1 for neuropathic pain, the Oral Peptide Delivery Platform and planning for a Phase 3 obesity trial.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=575&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">7th December 2006 - Metabolic placed in trading halt</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=574&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">7th December 2006 - Metabolic\'s request for trading halt</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=573&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">5th December 2006 - Open Briefing with CEO of Metabolic</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the transcript from an Open Briefing with the CEO of Metabolic, covering the Company\'s lead projects and strategy.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=572&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">29th November 2006 - ACV1 Clinical Trials Update November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced that the Phase 2A programme for ACV1, for neuropathic pain is progressing well. The first group of patients in the first of two trials in this Phase 2A programme have been treated and the second trial is due to commence in Q107. Additionally, a separate trial to test safety of a higher dose level of ACV1 commenced in Q406.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=571&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th November 2006 - Options Study Update - 27 November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced that more than 300 subjects have completed the Phase 2B OPTIONS Study so far. The last subject will complete the trial in December 2006 with results expected to be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=570&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th November 2006 - Domestic Roadshow November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay, CEO of Metabolic, will be meeting with various domestic brokers and analysts this week. This roadshow presentation provides an update on the Company\'s development and strategy.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=569&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd November 2006 - ACV1 PreClinical Update November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has made further progress with the oral version of its neuropathic pain drug ACV1. In addition, an independent study conducted in the US has identified important information about its mechanism of action.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=567&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th November 2006 - Appendix 3Y 17th November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3Y 17th November 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=566&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th November 2006 - Appendix 3Y 17th November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3Y 17th November 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=565&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th November 2006 - Appendix 3B 17th November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B 17th November 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=561&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th October 2006 - 2006 AGM: Voting Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement includes a summary of voting on each resolution put to shareholders at the Company\'s 2006 AGM.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=560&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th October 2006 - New Constitution</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Shareholders of Metabolic approved a new Constitution on 27 October 2006. The complete Constitution is included in this announcement.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=559&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th October 2006 - 2006 AGM Chairman\'s Address and CEO\'s presentation</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement includes the formal address given by the Chairman to shareholders at the Company\'s 2006 AGM and a presentation by the CEO.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=558&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd October 2006 - Change in Substantial Holding</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Monash Investments regarding the change in their substantial holding of Metabolic shares.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=556&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th October 2006 - Response to ASX Query</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This letter from Metabolic is is response to a share price query from the ASX.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=549&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th October 2006 - Quarterly Investor Update - 17 October 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the third quarter of 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=548&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">12th October 2006 - Market Presentation - Intersuisse Conference October 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at the Intersuisse Life Sciences Forum (London) to increase awarenenss of Metabolic in the UK and Europe. The slide-show presentation provides an up-to-date overview of Metabolic\'s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=546&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">9th October 2006 - Appendix 3B 9th October 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B 9th October 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=547&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">5th October 2006 - Obesity Trial Update - October 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The first 100 subjects have completed the Phase 2B OPTIONS Study including 24 weeks of daily oral dosing of obesity drug, AOD9604. The last subject will complete the trial in December 2006 with results expected to be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=545&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">28th September 2006 - UBS Global Life Sciences Conference - presentation by Dr Roland Scollay</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at the UBS Global Life Sciences Conference in New York to increase awareness of Metabolic in the US. The slide-show presentation provides and up-to-date overview of Metabolic\'s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=544&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th September 2006 - Metabolic\'s neuropathic pain drug, ACV1, enters Phase 2A clinical trials</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic commenced the first trial in its Phase 2A programme for ACV1, for the treatment of neuropathic pain. This first trial will target neuropathic sciatic pain and results are expected to be announced during the first six months of 2007 (H107).</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=542&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">26th September 2006 - 2006 Annual Report and Notice of Annual General Meeting</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the Company’s 2006 Annual Report, Notice of Annual General Meeting and sample voting form.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=557&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">1st September 2006 - Quarterly rebalance of S&amp;P/ASX Indices</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice that Metabolic has been removed from the S&amp;P/ASX 300 Index</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=539&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th July 2006 - Quarterly Investor Update July 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the second quarter of 2006.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=538&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">19th July 2006 - Obesity trial update: First subject completes treatment</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The first few subjects have completed treatment including 24 weeks of daily oral dosing of AOD9604. The last subject will complete the trial in December 2006 with results expected to be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=537&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">11th July 2006 - NRP collaboration: Research on nerve protection compounds published in science journal</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Research on Neural Regeneration Peptides (NRPs) has been published in the international science journal, \'Experimental Cell Research\'. NRPs have previously shown promising effects in a rat model of nerve damage. Formal preclinical development of NRPs expected to commence in 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=520&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">21 June 2006 - Metabolic\'s osteoporosis drug: additional animal data support further beneficial effects of AOD9604</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Additional animal data indicate AOD9604 has beneficial effects on trabecular bone as well as corticol bone. Two further animal studies are underway to investigate the optimal dose of AOD9604 for osteoporosis; and the possible role of the drug in treatment of osteoporosis (in addition to prevention, as previously determined).</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=465&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">14th June 2006 - Life Sciences (USA) Presentation</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at the Pacific Growth Equities\' 2006 Life Sciences Growth Conference in San Francisco to increase awareness of Metabolic in the USA. Slide-show presentation provides an up-to-date overview of Metabolic\'s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=466&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd May 2006 - Roadshow Presentation - company update May 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay met with several analysts and institutions to increase local awareness of Metabolic. Slide-show presentation provides an up-to-date overview of Metabolic’s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=467&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">10th May 2006 - Quarterly Investor Update 10 May 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Summary of Company news during the first quarter of 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=468&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">8th May 2006 - Audio Broadcast - CEO interviewed by Boardroom Radio</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay’s interview by Boardroom radio has been audio webcast and is available at www.boardroomradio.com</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=469&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">2nd May 2006 - Metabolic completes enrolment for obesity clinical trial ahead of schedule</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>536 subjects have been enrolled in the Phase 2B trial, known as the “OPTIONSEstudy for obesity drug, AOD9604. This trial will now end in December 2006 and results will be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=470&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">5th April 2006 - Metabolic CEO to present at US biotech conferences</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at various biotechnology conferences and expos in the USA. Slide-show presentation provides an up-to-date overview of Metabolic’s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=471&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">30th March 2006 - Change in Substantial Holding</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Monash Investments regarding the dilution of their substantial holding due to the recent share placement by Metabolic</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=472&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">24th March 2006 - Appendix 3B - New issue of options</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>New issue of shares and options, pursuant to the private placement on 21 March 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=473&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">24th March 2006 - Notice under section 708A (5)(e)</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official cleansing statement Eno outstanding disclosures</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=474&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">21st March 2006 - Metabolic completes A$13 million share placement</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Private placement of 30.2 million shares to international and Australian institutional investors. Funds raised will advance Metabolic’s drug pipeline for pain, osteoporosis and oral delivery platform for peptides.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=475&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th March 2006 - Trading Halt 17th March 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official trading halt request by Metabolic</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=476&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">6th March 2006 - Clinical Trials Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The Phase 2B trial for obesity drug, AOD9604 is progressing well, on schedule, and preparation is underway for the Phase 2A program for ACV1, for pain</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=477&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th February 2006 - Half Yearly Report / Half Yearly Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Financial report for the six months ended 31 December 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=478&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">16th February 2006 - NRP Update: Metabolic and Neuren report promising animal efficacy data in collaborative project </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>New compound, Neural Regeneration Peptide: NNZ-4921, has been shown to prevent or reverse peripheral neuropathy (nerve damage) in an animal study</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=479&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">15th February 2006 - CEO to present at BioCEO &amp; Investor Conference in New York</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay participated as a panelist at the BioCEO &amp; Investor Conference in New York, and gave a presentation on Metabolic’s lead drugs AOD9604 for obesity, including details of previous trial results, and a potential new use for the drug.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=480&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">8th February 2006 - Investor Roadshow Presentation - USA</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at the Biotechnology Organisation (BIO) Conference and met with several analysts and institutions to increase awareness of Metabolic in the USA. Slide show presentation provides an up-to-date overview of Metabolic’s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=481&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">6th February 2006 - Metabolic Quarterly Investor Update Number 12 </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Summary of Company news during the fourth quarter of 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=482&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">1st February 2006 - Appendix 3Y - Change of Director’s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay was granted 1,000,000 options, pursuant to the Metabolic Employee Share Option Plan, approved by shareholders at the 2005 Annual General Meeting on 28 October 2005.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=483&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">1st February 2006 - Appendix 3B - New issue of options </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>New issue of 1,000,000 MBPAQ unquoted options, pursuant to the Metabolic Employee Share Option Plan, approved by shareholders at the 2005 Annual General Meeting on 28 October 2005.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=484&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">31st January 2006 - Potential new use in osteoporosis adds value to Metabolic\'s obesity drug</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Animal study: Orally delivered drug, AOD9604, shows an effect in preventing bone loss and maintaining bone quality in a rat model of osteoporosis.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=485&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd January 2006 - Update on Phase 2B dosing trial for obesity drug</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The low dose, Phase 2B trial, known as the “OPTIONSEstudy is proceeding on schedule with recruitment on track an all ethics approvals obtained.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2005</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=428&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">18th November 2005 - ASX Appendix 3Y Change of Director\'s Interest - A Emmett</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3Y Change of Director\'s Interest - A Emmett</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=427&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">16th November 2005 - ACV1 Phase 1 results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ACV1 Phase 1 results</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=425&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">4th November 2005 - CEO Presentation Rodman Renshaw Conference 7 November 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>CEO Presentation Rodman Renshaw Conference 7 November 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=423&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">2nd November 2005 - ASX Appendix 3B 2nd November 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3B 2nd November 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=422&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">31st October 2005 - ASX Appendix 3X 31st October 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3X 31st October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=419&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th October 2005 - Chairman\'s Address and CEO Presentation at AGM 28th October 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Chairman\'s Address and CEO Presentation at AGM 28th October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=421&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th October 2005 - Metabolic AGM Results 28 October 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic AGM Results 28 October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=420&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th October 2005 - Amended Constitution of Metabolic Pharmaceuticals 28 October 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Amended Constitution of Metabolic Pharmaceuticals 28 October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=418&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">26th October 2005 - Metabolic Quarterly Investor Update </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic Quarterly Investor Update - 26 October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=417&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th October 2005 - Metabolic ranks number 1 as Australia\'s top innovator</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic ranks number 1 as Australia\'s top innovator</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=416&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">19th October 2005 - Metabolic CEO to present to Health Care and Life Science Conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic CEO to present to Health Care and Life Science Conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=433&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">22nd December 2005 - ASX Appendix 3Y R Scollay</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3Y R Scollay</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=412&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">18th October 2005 - Metabolic starts next clinical trial of obesity drug</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic starts next clinical trial for obesity drug</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=415&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">18th October 2005 - VP Clinical Development Presentation at NAASO Conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>VP Clinical Development Presentation at NAASO Conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=409&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th October 2005 - Appointment of Non-Executive Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appointment of Non-Executive Director</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=404&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">27th September 2005 Release of Securities from Escrow - Monash Investment Holdings P/L</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Release of Securities from Escrow - Monash Investment Holdings P/L</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=432&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">22nd December 2005 - ASX Appendix 3Y C Belyea</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3Y C Belyea</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=403&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">7th September 2005 - Metabolic Pharmaceuticals CEO to present at biotechnology conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic Pharmaceuticals CEO to present at biotechnology conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=402&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">1st September 2005 - Change of Director\'s Interest - R Scollay</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest - R Scollay</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=401&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">26th August 2005 App 4E Preliminary Final Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Preliminary Final Report</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=400&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd August 2005 - Appointment of new CFO</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appointment of new CFO</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=431&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">22nd December 2005 - ASX Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3B</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=399&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">15th August 2005 - Metabolic ACV1 Update 15 August 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic ACV1 Update 15th August 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=398&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">8th August 2005 - ASX Appendix 3B 8th August 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B - 8th August 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=395&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th Aug 2005 - Change of Director\'s Interest - A Emmett</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest - A Emmett</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=396&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th Aug 2005 - Change of Director\'s Interest - C Belyea</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest - C Belyea</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=397&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th Aug 2005 - Change of Director\'s Interest - E Vos</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest - E Vos</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=390&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th July 2005 - ASX Appendix 3B 28th July 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B - 28th July 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=430&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">25th November 2005 - ASX Appendix 3Y Change in Director\'s Interest - R Baker</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3Y Change in Director\'s Interest - R Baker</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=386&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">21st July 2005 - SPP Announcement </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Share Purchase Plan Announcement 21st July 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=385&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th July 2005 - Investor Update 5th July 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Investor Update 5th July 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=384&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th June 2005 - Notice under Section 708A of the Corps Act</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Notice under Section 708A of the Corps Act</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=383&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th June 2005 - Share Purchase Plan Offer to Shareholders</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Share Purchase Plan Offer to Shareholders</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=382&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th June 2005 - VP Corporate Development Position</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>VP Corporate Development Position</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=429&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th November 2005 - ASX Appendix 3Y Change in Director\'s Interest - P Sutch</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3Y Change in Director\'s Interest - P Sutch</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=555&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd June 2005 - Change in Substantial Holding</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=381&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd June 2005 - Appendix 3B 23rd June 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B - 23rd June 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=380&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd June 2005 - ACV1 Phase 1 Clinical Trial Commences</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ACV1 Phase 1 Clinical Trial Commences</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=377&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">14th June 2005 - Placement and SPP Offer</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Placement and SPP Offer</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=378&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">14th June 2005 - AusIndustry \"Commercial Ready\" Grant for ACV1</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AusIndustry \"Commercial Ready\" Grant for ACV1</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=379&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">14th June 2005 - Conference Presentations June 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Conference Presentations June 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=376&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">3rd June 2005 - AOD9604 Obesity Drug Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AOD9604 Obesity Drug Update 3rd June 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=370&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">1st June 2005 - Metabolic establishes ADR program</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic Pharmaceuticals Ltd establishes ADR Program</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=366&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">20th May 2005 - Response to ASX Query re: Share Price</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Response to ASX Query re: Share Price - 20th May 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=364&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">2nd May 2005 - ACV1 Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ACV1 Update 2nd May 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=362&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">20th April 2005 AOD9604 Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AOD9604 Update 20th April 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=360&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">8th March 2005 - Investor Update 8th March 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Investor Update 8th March 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=359&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">3rd March 2005 - Neuren and Metabolic Development Collaboration March 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Neuren and Metabolic Development Collaboration March 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=358&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd February 2005 US Presentations February 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>US Presentations February 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=357&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">21st February 2005 - Half Yearly Report / Half Yearly Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Half Yearly Report / Half Yearly Accounts</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=355&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">10th February 2005 - CEO to speak on Obesity Panel at BIO CEO Conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>CEO to speak on Obesity Panel at BIO CEO Conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=354&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th January 2005 Metabolic appoints new Chief Executive Officer</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic appoints new Chief Executive Officer</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=353&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">13th January 2005 - ASX CEO Position</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>CEO Position</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2004</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=506&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">23rd December 2004 - ASX Resignation of Company Secretary</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Resignation of Company Secretary</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=505&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">17th December 2004 - ASX Change in Director\'s Interest</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change in Director\'s Interest</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=504&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">17th December 2004 - ASX Response to Market Comments</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Response to Market Comments 17th December 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=503&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">15th December 2004 - ASX Appendix 3B 15th November 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3B 15th November 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=502&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">13th December 2004 - AOD9604 Phase2b Clinical Trial Successful</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AOD9604 Phase 2b Clinical Trial Successful</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=501&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">13th December 2004 Successful trial results for world-first obesity drug</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Successful trial results for world-first obesity drug</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=500&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">9th December 2004 - ASX Trading Halt</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Trading Halt - 9th December 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=499&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">29th November 2004 - AOD9604 Update on Clinical Trial Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update on Clinical Trial Results 29th November 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=498&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">16th November 2004 - Response to ASX Query re: Share Price</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Response to ASX Query re: Share Price</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=497&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">4th November 2004 - ASX Appendix 3B 4th November 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B 4th November 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=496&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">29th October 2004 - ASX AGM Results 29th October 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AGM Results 29th October 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=495&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">29th October 2004 - ASX Chairman\'s Address AGM 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Chairman\'s Address AGM 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=494&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">30th September 2004 - Release of securities from voluntary escrow</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Release of securities from voluntary escrow</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=493&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">23rd September 2004 - 2004 Annual Report and Notice of AGM</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>2004 Annual Report and Notice of AGM</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=492&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">22nd September 2004 Investor Update - September 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Investor Update - September 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=491&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">20th September 2004 Completion of dosing in obesity trials</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Completion of dosing in obesity trials</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=490&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">24th August 2004 - Preliminary Final Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 4E - Preliminary Final Report</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=489&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">6th July 2004 - Increasing awareness in US markets in preparation for 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Increasing awareness in US markets in preparation for 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=488&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">5th July 2004 - Cohen Research Report July 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Cohen Research Report July 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=487&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">4th June 2004 - Investor Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Investor Update - 4th June, 2004</td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n</td>\r\n</tr>\r\n</tbody>\r\n</table>',	'ASX Announcements',	'',	'inherit',	'open',	'open',	'',	'141-revision-5',	'',	'',	'2012-06-18 06:21:58',	'2012-06-18 06:21:58',	'',	141,	'http://calzada-wp.urldock.com/141-revision-5/',	0,	'revision',	'',	0),
(251,	1,	'2012-06-18 02:54:08',	'2012-06-18 02:54:08',	'',	'Newsletters',	'',	'inherit',	'open',	'open',	'',	'155-revision-2',	'',	'',	'2012-06-18 02:54:08',	'2012-06-18 02:54:08',	'',	155,	'http://calzada-wp.urldock.com/155-revision-2/',	0,	'revision',	'',	0),
(252,	1,	'2012-06-18 09:35:22',	'2012-06-18 09:35:22',	'<table>\n<tbody>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"/wp-content/uploads/2012/06/1899_Calzada_Shareholder_Newsletter_FINAL2.pdf\">Calzada Shareholder Newsletter June 2011</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ407_1Feb2008.pdf\">February 2008 - Quarterly Investor Update - Fourth Quarter 2007</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ0307_October2007.pdf\">October 2007 - Quarterly Investor Update - Third Quarter 2007</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ0207_25July2007.pdf\">July 2007 - Quarterly Investor Update - Second Quarter 2007</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ107_5April2007.pdf\">April 2007 - Quarterly Investor Update - First Quarter 2007</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdate_22ndJanuary2007.pdf\">January 2007 - Quarterly Investor Update - Fourth Quarter 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdate_17October2006.pdf\">October 2006 - Quarterly Investor Update - Third Quarter 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"/wp-content/uploads/2012/06/ASX_InvestorQuarterlyUpdate_July2006.pdf\">July 2006 - Quarterly Investor Update - Second Quarter 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"/wp-content/uploads/2012/06/0619-ASX-Announcement-10-May-Quarterly-Update-FINAL.pdf\">May 2006 - Quarterly Investor Update - First Quarter 2006</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"/wp-content/uploads/2012/06/0605-ASX-Announcement-6-Feb-Qty-Investor-Update-FINAL.pdf\">Feb 2006 - Quarterly Investor Update - Fourth Quarter 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"/wp-content/uploads/2012/06/051026-ASX-Announcement-Quarterly-Investor-Update-Octo..pdf\">Oct 2005 - Quarterly Investor Update - Third Quarter 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"/wp-content/uploads/2012/06/ASX-Investor-Update-5-7-05.pdf\">Jul 2005 - Quarterly Investor Update - Second Quarter 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"/wp-content/uploads/2012/06/ASX-Investor-Update-8-Mar-2005.pdf\">Mar 2005 - Quarterly Investor Update - First Quarter 2005</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"/wp-content/uploads/2012/06/Investor-Update-22-September-2004.pdf\">Sep 2004 - Quarterly Investor Update - Third Quarter 2004</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"/wp-content/uploads/2012/06/ASX-Investor-Update-4-June-2004.pdf\">Jun 2004 - Quarterly Investor Update - Second Quarter 2004</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n<tr>\n<td></td>\n<td><a href=\"/wp-content/uploads/2012/06/ASX-Investor-Update-March-2004.pdf\">Mar 2004 - Quarterly Investor Update - First Quarter 2004</a></td>\n</tr>\n<tr>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td colspan=\"2\"></td>\n</tr>\n</tbody>\n</table>',	'Newsletters',	'',	'inherit',	'open',	'open',	'',	'155-autosave',	'',	'',	'2012-06-18 09:35:22',	'2012-06-18 09:35:22',	'',	155,	'http://calzada-wp.urldock.com/155-autosave/',	0,	'revision',	'',	0),
(253,	1,	'2012-06-18 06:35:09',	'2012-06-18 06:35:09',	'<table><tbody><tr><td></td>\r\n<td>\r\n<table class=\"listHeading\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\r\n<tbody><tr><td><img src=\"../html/images/trans.gif\" alt=\"\" border=\"0\" height=\"5\" width=\"1\"></td></tr>\r\n<tr><td><h2 class=\"feSubHeading\">Newsletters</h2><br>\r\n<!-- hdde:False -->\r\n</td></tr>\r\n<tr><td colspan=\"2\"><img src=\"../html/images/trans.gif\" alt=\"\" border=\"0\" height=\"5\" width=\"1\"></td></tr>\r\n</tbody></table><!-- listHeading -->\r\n<table class=\"listing\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">\r\n<tbody><tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=770&amp;nav_cat_id=159&amp;nav_top_id=58\">Calzada Shareholder Newsletter June 2011</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr><td colspan=\"2\"><div style=\"width: 1px; height: 7px; overflow: hidden;\"></div></td></tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=654&amp;nav_cat_id=159&amp;nav_top_id=58\">February 2008 - Quarterly Investor Update - Fourth Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr><td colspan=\"2\"><div style=\"width: 1px; height: 7px; overflow: hidden;\"></div></td></tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=633&amp;nav_cat_id=159&amp;nav_top_id=58\">October 2007 - Quarterly Investor Update - Third Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr><td colspan=\"2\"><div style=\"width: 1px; height: 7px; overflow: hidden;\"></div></td></tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=618&amp;nav_cat_id=159&amp;nav_top_id=58\">July 2007 - Quarterly Investor Update - Second Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr><td colspan=\"2\"><div style=\"width: 1px; height: 7px; overflow: hidden;\"></div></td></tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=601&amp;nav_cat_id=159&amp;nav_top_id=58\">April 2007 - Quarterly Investor Update - First Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr><td colspan=\"2\"><div style=\"width: 1px; height: 7px; overflow: hidden;\"></div></td></tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=588&amp;nav_cat_id=159&amp;nav_top_id=58\">January 2007 - Quarterly Investor Update - Fourth Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr><td colspan=\"2\"><div style=\"width: 1px; height: 7px; overflow: hidden;\"></div></td></tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=553&amp;nav_cat_id=159&amp;nav_top_id=58\">October 2006 - Quarterly Investor Update - Third Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr><td colspan=\"2\"><div style=\"width: 1px; height: 7px; overflow: hidden;\"></div></td></tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=540&amp;nav_cat_id=159&amp;nav_top_id=58\">July 2006 - Quarterly Investor Update - Second Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr><td colspan=\"2\"><div style=\"width: 1px; height: 7px; overflow: hidden;\"></div></td></tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=535&amp;nav_cat_id=159&amp;nav_top_id=58\">May 2006 - Quarterly Investor Update - First Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr><td colspan=\"2\"><div style=\"width: 1px; height: 7px; overflow: hidden;\"></div></td></tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=534&amp;nav_cat_id=159&amp;nav_top_id=58\">Feb 2006 - Quarterly Investor Update - Fourth Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr><td colspan=\"2\"><div style=\"width: 1px; height: 7px; overflow: hidden;\"></div></td></tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=533&amp;nav_cat_id=159&amp;nav_top_id=58\">Oct 2005 - Quarterly Investor Update - Third Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr><td colspan=\"2\"><div style=\"width: 1px; height: 7px; overflow: hidden;\"></div></td></tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=532&amp;nav_cat_id=159&amp;nav_top_id=58\">Jul 2005 - Quarterly Investor Update - Second Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr><td colspan=\"2\"><div style=\"width: 1px; height: 7px; overflow: hidden;\"></div></td></tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=531&amp;nav_cat_id=159&amp;nav_top_id=58\">Mar 2005 - Quarterly Investor Update - First Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr><td colspan=\"2\"><div style=\"width: 1px; height: 7px; overflow: hidden;\"></div></td></tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=530&amp;nav_cat_id=159&amp;nav_top_id=58\">Sep 2004 - Quarterly Investor Update - Third Quarter 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr><td colspan=\"2\"><div style=\"width: 1px; height: 7px; overflow: hidden;\"></div></td></tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=529&amp;nav_cat_id=159&amp;nav_top_id=58\">Jun 2004 - Quarterly Investor Update - Second Quarter 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr><td colspan=\"2\"><div style=\"width: 1px; height: 7px; overflow: hidden;\"></div></td></tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=528&amp;nav_cat_id=159&amp;nav_top_id=58\">Mar 2004 - Quarterly Investor Update - First Quarter 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr><td colspan=\"2\"><div style=\"width: 1px; height: 7px; overflow: hidden;\"></div></td></tr>\r\n</tbody></table><!-- listing --><!--HDDEC=t SE=F-->\r\n</td>\r\n<td></td>\r\n</tr>\r\n<!-- content buttons begin -->\r\n<tr>\r\n<td></td>\r\n<td class=\"artBtnBottom\" valign=\"top\">\r\n&nbsp;\r\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\">\r\n<tbody><tr></tr>\r\n</tbody></table>\r\n</td>',	'Newsletters',	'',	'inherit',	'open',	'open',	'',	'155-revision-3',	'',	'',	'2012-06-18 06:35:09',	'2012-06-18 06:35:09',	'',	155,	'http://calzada-wp.urldock.com/155-revision-3/',	0,	'revision',	'',	0),
(254,	1,	'2012-06-18 06:42:36',	'2012-06-18 06:42:36',	'',	'0605  ASX Announcement - 6 Feb Qty Investor Update FINAL',	'',	'inherit',	'open',	'open',	'',	'0605-asx-announcement-6-feb-qty-investor-update-final',	'',	'',	'2012-06-18 06:42:36',	'2012-06-18 06:42:36',	'',	155,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/0605-ASX-Announcement-6-Feb-Qty-Investor-Update-FINAL.pdf',	0,	'attachment',	'application/pdf',	0),
(255,	1,	'2012-06-18 06:42:40',	'2012-06-18 06:42:40',	'',	'0619 ASX Announcement - 10 May - Quarterly Update FINAL',	'',	'inherit',	'open',	'open',	'',	'0619-asx-announcement-10-may-quarterly-update-final',	'',	'',	'2012-06-18 06:42:40',	'2012-06-18 06:42:40',	'',	155,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/0619-ASX-Announcement-10-May-Quarterly-Update-FINAL.pdf',	0,	'attachment',	'application/pdf',	0),
(256,	1,	'2012-06-18 06:42:59',	'2012-06-18 06:42:59',	'',	'1899_Calzada_Shareholder_Newsletter_FINAL',	'',	'inherit',	'open',	'open',	'',	'1899_calzada_shareholder_newsletter_final-3',	'',	'',	'2012-06-18 06:42:59',	'2012-06-18 06:42:59',	'',	155,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/1899_Calzada_Shareholder_Newsletter_FINAL2.pdf',	0,	'attachment',	'application/pdf',	0),
(257,	1,	'2012-06-18 06:43:03',	'2012-06-18 06:43:03',	'',	'051026 ASX Announcement - Quarterly Investor Update - Octo.',	'',	'inherit',	'open',	'open',	'',	'051026-asx-announcement-quarterly-investor-update-octo',	'',	'',	'2012-06-18 06:43:03',	'2012-06-18 06:43:03',	'',	155,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/051026-ASX-Announcement-Quarterly-Investor-Update-Octo..pdf',	0,	'attachment',	'application/pdf',	0),
(258,	1,	'2012-06-18 06:43:06',	'2012-06-18 06:43:06',	'',	'ASX - Investor Update 4 June 2004',	'',	'inherit',	'open',	'open',	'',	'asx-investor-update-4-june-2004',	'',	'',	'2012-06-18 06:43:06',	'2012-06-18 06:43:06',	'',	155,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX-Investor-Update-4-June-2004.pdf',	0,	'attachment',	'application/pdf',	0),
(259,	1,	'2012-06-18 06:43:08',	'2012-06-18 06:43:08',	'',	'ASX - Investor Update  8 Mar 2005',	'',	'inherit',	'open',	'open',	'',	'asx-investor-update-8-mar-2005',	'',	'',	'2012-06-18 06:43:08',	'2012-06-18 06:43:08',	'',	155,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX-Investor-Update-8-Mar-2005.pdf',	0,	'attachment',	'application/pdf',	0),
(260,	1,	'2012-06-18 06:43:10',	'2012-06-18 06:43:10',	'',	'ASX - Investor Update - 5-7-05',	'',	'inherit',	'open',	'open',	'',	'asx-investor-update-5-7-05',	'',	'',	'2012-06-18 06:43:10',	'2012-06-18 06:43:10',	'',	155,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX-Investor-Update-5-7-05.pdf',	0,	'attachment',	'application/pdf',	0),
(261,	1,	'2012-06-18 06:43:13',	'2012-06-18 06:43:13',	'',	'ASX - Investor Update March 2004',	'',	'inherit',	'open',	'open',	'',	'asx-investor-update-march-2004',	'',	'',	'2012-06-18 06:43:13',	'2012-06-18 06:43:13',	'',	155,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX-Investor-Update-March-2004.pdf',	0,	'attachment',	'application/pdf',	0),
(262,	1,	'2012-06-18 06:43:17',	'2012-06-18 06:43:17',	'',	'ASX_InvestorQuarterlyUpdate_July2006',	'',	'inherit',	'open',	'open',	'',	'asx_investorquarterlyupdate_july2006',	'',	'',	'2012-06-18 06:43:17',	'2012-06-18 06:43:17',	'',	155,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX_InvestorQuarterlyUpdate_July2006.pdf',	0,	'attachment',	'application/pdf',	0),
(263,	1,	'2012-06-18 06:43:22',	'2012-06-18 06:43:22',	'',	'ASX_QuarterlyInvestorUpdate_17October2006',	'',	'inherit',	'open',	'open',	'',	'asx_quarterlyinvestorupdate_17october2006',	'',	'',	'2012-06-18 06:43:22',	'2012-06-18 06:43:22',	'',	155,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdate_17October2006.pdf',	0,	'attachment',	'application/pdf',	0),
(264,	1,	'2012-06-18 06:43:25',	'2012-06-18 06:43:25',	'',	'ASX_QuarterlyInvestorUpdate_22ndJanuary2007',	'',	'inherit',	'open',	'open',	'',	'asx_quarterlyinvestorupdate_22ndjanuary2007',	'',	'',	'2012-06-18 06:43:25',	'2012-06-18 06:43:25',	'',	155,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdate_22ndJanuary2007.pdf',	0,	'attachment',	'application/pdf',	0),
(265,	1,	'2012-06-18 06:43:30',	'2012-06-18 06:43:30',	'',	'ASX_QuarterlyInvestorUpdateQ0207_25July2007',	'',	'inherit',	'open',	'open',	'',	'asx_quarterlyinvestorupdateq0207_25july2007',	'',	'',	'2012-06-18 06:43:30',	'2012-06-18 06:43:30',	'',	155,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ0207_25July2007.pdf',	0,	'attachment',	'application/pdf',	0),
(266,	1,	'2012-06-18 06:43:34',	'2012-06-18 06:43:34',	'',	'ASX_QuarterlyInvestorUpdateQ0307_October2007',	'',	'inherit',	'open',	'open',	'',	'asx_quarterlyinvestorupdateq0307_october2007',	'',	'',	'2012-06-18 06:43:34',	'2012-06-18 06:43:34',	'',	155,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ0307_October2007.pdf',	0,	'attachment',	'application/pdf',	0),
(267,	1,	'2012-06-18 06:43:37',	'2012-06-18 06:43:37',	'',	'ASX_QuarterlyInvestorUpdateQ407_1Feb2008',	'',	'inherit',	'open',	'open',	'',	'asx_quarterlyinvestorupdateq407_1feb2008',	'',	'',	'2012-06-18 06:43:37',	'2012-06-18 06:43:37',	'',	155,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ407_1Feb2008.pdf',	0,	'attachment',	'application/pdf',	0),
(268,	1,	'2012-06-18 06:43:40',	'2012-06-18 06:43:40',	'',	'Investor Update - 22 September 2004',	'',	'inherit',	'open',	'open',	'',	'investor-update-22-september-2004',	'',	'',	'2012-06-18 06:43:40',	'2012-06-18 06:43:40',	'',	155,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/Investor-Update-22-September-2004.pdf',	0,	'attachment',	'application/pdf',	0),
(269,	1,	'2012-06-18 06:49:06',	'2012-06-18 06:49:06',	'',	'ASX_QuarterlyInvestorUpdateQ107_5April2007',	'',	'inherit',	'open',	'open',	'',	'asx_quarterlyinvestorupdateq107_5april2007',	'',	'',	'2012-06-18 06:49:06',	'2012-06-18 06:49:06',	'',	155,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ107_5April2007.pdf',	0,	'attachment',	'application/pdf',	0),
(270,	1,	'2012-06-18 06:37:42',	'2012-06-18 06:37:42',	'<table>\r\n<tbody>\r\n<tr>\r\n<td>\r\n<h2 class=\"feSubHeading\">Newsletters</h2>\r\n</td>\r\n</tr>\r\n<tr>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=770&amp;nav_cat_id=159&amp;nav_top_id=58\">Calzada Shareholder Newsletter June 2011</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=654&amp;nav_cat_id=159&amp;nav_top_id=58\">February 2008 - Quarterly Investor Update - Fourth Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=633&amp;nav_cat_id=159&amp;nav_top_id=58\">October 2007 - Quarterly Investor Update - Third Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=618&amp;nav_cat_id=159&amp;nav_top_id=58\">July 2007 - Quarterly Investor Update - Second Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=601&amp;nav_cat_id=159&amp;nav_top_id=58\">April 2007 - Quarterly Investor Update - First Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=588&amp;nav_cat_id=159&amp;nav_top_id=58\">January 2007 - Quarterly Investor Update - Fourth Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=553&amp;nav_cat_id=159&amp;nav_top_id=58\">October 2006 - Quarterly Investor Update - Third Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=540&amp;nav_cat_id=159&amp;nav_top_id=58\">July 2006 - Quarterly Investor Update - Second Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=535&amp;nav_cat_id=159&amp;nav_top_id=58\">May 2006 - Quarterly Investor Update - First Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=534&amp;nav_cat_id=159&amp;nav_top_id=58\">Feb 2006 - Quarterly Investor Update - Fourth Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=533&amp;nav_cat_id=159&amp;nav_top_id=58\">Oct 2005 - Quarterly Investor Update - Third Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=532&amp;nav_cat_id=159&amp;nav_top_id=58\">Jul 2005 - Quarterly Investor Update - Second Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=531&amp;nav_cat_id=159&amp;nav_top_id=58\">Mar 2005 - Quarterly Investor Update - First Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=530&amp;nav_cat_id=159&amp;nav_top_id=58\">Sep 2004 - Quarterly Investor Update - Third Quarter 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=529&amp;nav_cat_id=159&amp;nav_top_id=58\">Jun 2004 - Quarterly Investor Update - Second Quarter 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../html/s02_article/article_view.asp?id=528&amp;nav_cat_id=159&amp;nav_top_id=58\">Mar 2004 - Quarterly Investor Update - First Quarter 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n&nbsp;</td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td class=\"artBtnBottom\" valign=\"top\"></td>\r\n</tr>\r\n</tbody>\r\n</table>',	'Newsletters',	'',	'inherit',	'open',	'open',	'',	'155-revision-4',	'',	'',	'2012-06-18 06:37:42',	'2012-06-18 06:37:42',	'',	155,	'http://calzada-wp.urldock.com/155-revision-4/',	0,	'revision',	'',	0),
(271,	1,	'2012-06-18 06:54:45',	'2012-06-18 06:54:45',	'<table>\r\n<tbody>\r\n<tr>\r\n<td>\r\n<h2 class=\"feSubHeading\">Newsletters</h2>\r\n</td>\r\n</tr>\r\n<tr>\r\n<td><a href=\"/wp-content/uploads/2012/06/1899_Calzada_Shareholder_Newsletter_FINAL2.pdf\">Calzada Shareholder Newsletter June 2011</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ407_1Feb2008.pdf\">February 2008 - Quarterly Investor Update - Fourth Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ0307_October2007.pdf\">October 2007 - Quarterly Investor Update - Third Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ0207_25July2007.pdf\">July 2007 - Quarterly Investor Update - Second Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ107_5April2007.pdf\">April 2007 - Quarterly Investor Update - First Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdate_22ndJanuary2007.pdf\">January 2007 - Quarterly Investor Update - Fourth Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdate_17October2006.pdf\">October 2006 - Quarterly Investor Update - Third Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_InvestorQuarterlyUpdate_July2006.pdf\">July 2006 - Quarterly Investor Update - Second Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/0619-ASX-Announcement-10-May-Quarterly-Update-FINAL.pdf\">May 2006 - Quarterly Investor Update - First Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/0605-ASX-Announcement-6-Feb-Qty-Investor-Update-FINAL.pdf\">Feb 2006 - Quarterly Investor Update - Fourth Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/051026-ASX-Announcement-Quarterly-Investor-Update-Octo..pdf\">Oct 2005 - Quarterly Investor Update - Third Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX-Investor-Update-5-7-05.pdf\">Jul 2005 - Quarterly Investor Update - Second Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX-Investor-Update-8-Mar-2005.pdf\">Mar 2005 - Quarterly Investor Update - First Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/Investor-Update-22-September-2004.pdf\">Sep 2004 - Quarterly Investor Update - Third Quarter 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX-Investor-Update-4-June-2004.pdf\">Jun 2004 - Quarterly Investor Update - Second Quarter 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX-Investor-Update-March-2004.pdf\">Mar 2004 - Quarterly Investor Update - First Quarter 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>',	'Newsletters',	'',	'inherit',	'open',	'open',	'',	'155-revision-5',	'',	'',	'2012-06-18 06:54:45',	'2012-06-18 06:54:45',	'',	155,	'http://calzada-wp.urldock.com/155-revision-5/',	0,	'revision',	'',	0),
(272,	1,	'2012-06-18 06:55:51',	'2012-06-18 06:55:51',	'<table>\r\n<tbody>\r\n<tr>\r\n<td>\r\n<h2 class=\"feSubHeading\">Newsletters</h2>\r\n</td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1899_Calzada_Shareholder_Newsletter_FINAL2.pdf\">Calzada Shareholder Newsletter June 2011</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ407_1Feb2008.pdf\">February 2008 - Quarterly Investor Update - Fourth Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ0307_October2007.pdf\">October 2007 - Quarterly Investor Update - Third Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ0207_25July2007.pdf\">July 2007 - Quarterly Investor Update - Second Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdateQ107_5April2007.pdf\">April 2007 - Quarterly Investor Update - First Quarter 2007</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdate_22ndJanuary2007.pdf\">January 2007 - Quarterly Investor Update - Fourth Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_QuarterlyInvestorUpdate_17October2006.pdf\">October 2006 - Quarterly Investor Update - Third Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX_InvestorQuarterlyUpdate_July2006.pdf\">July 2006 - Quarterly Investor Update - Second Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/0619-ASX-Announcement-10-May-Quarterly-Update-FINAL.pdf\">May 2006 - Quarterly Investor Update - First Quarter 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/0605-ASX-Announcement-6-Feb-Qty-Investor-Update-FINAL.pdf\">Feb 2006 - Quarterly Investor Update - Fourth Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/051026-ASX-Announcement-Quarterly-Investor-Update-Octo..pdf\">Oct 2005 - Quarterly Investor Update - Third Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX-Investor-Update-5-7-05.pdf\">Jul 2005 - Quarterly Investor Update - Second Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX-Investor-Update-8-Mar-2005.pdf\">Mar 2005 - Quarterly Investor Update - First Quarter 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/Investor-Update-22-September-2004.pdf\">Sep 2004 - Quarterly Investor Update - Third Quarter 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX-Investor-Update-4-June-2004.pdf\">Jun 2004 - Quarterly Investor Update - Second Quarter 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/ASX-Investor-Update-March-2004.pdf\">Mar 2004 - Quarterly Investor Update - First Quarter 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>',	'Newsletters',	'',	'inherit',	'open',	'open',	'',	'155-revision-6',	'',	'',	'2012-06-18 06:55:51',	'2012-06-18 06:55:51',	'',	155,	'http://calzada-wp.urldock.com/155-revision-6/',	0,	'revision',	'',	0),
(274,	1,	'2012-06-18 02:46:52',	'2012-06-18 02:46:52',	'',	'Metabolic Pharmaceuticals Pty Ltd',	'',	'inherit',	'open',	'open',	'',	'139-revision-2',	'',	'',	'2012-06-18 02:46:52',	'2012-06-18 02:46:52',	'',	139,	'http://calzada-wp.urldock.com/139-revision-2/',	0,	'revision',	'',	0),
(275,	1,	'2012-06-18 09:40:36',	'2012-06-18 09:40:36',	'Metabolic Pharmaceuticals Pty Ltd',	'Metabolic',	'',	'inherit',	'open',	'open',	'',	'139-revision-3',	'',	'',	'2012-06-18 09:40:36',	'2012-06-18 09:40:36',	'',	139,	'http://calzada-wp.urldock.com/139-revision-3/',	0,	'revision',	'',	0),
(276,	1,	'2012-06-18 02:46:34',	'2012-06-18 02:46:34',	'',	'PolyNovo Biomaterials Pty Ltd',	'',	'inherit',	'open',	'open',	'',	'137-revision-2',	'',	'',	'2012-06-18 02:46:34',	'2012-06-18 02:46:34',	'',	137,	'http://calzada-wp.urldock.com/137-revision-2/',	0,	'revision',	'',	0),
(277,	1,	'2012-06-18 10:35:46',	'2012-06-18 10:35:46',	'<strong>2011 Annual General Meeting</strong>\n\nThe 2011 Annual General Meeting of Calzada Limited will be held at Unit 2, 320 Lorimer Street, Port Melbourne, Victoria, at 10:00am (Melbourne time)on the 15th of November 2011.\n\n<a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting_and_Proxy_Form1.pdf\" target=\"_blank\">Notice of AGM</a>\n<a href=\"/wp-content/uploads/2012/06/1046608.pdf\" target=\"_blank\">Chairmans Address</a>\n<a href=\"/wp-content/uploads/2012/06/1046682.pdf\" target=\"_blank\">Results of Meeting</a>\n<a href=\"/wp-content/uploads/2012/06/1046745.pdf\" target=\"_blank\">Notice of AGM</a>\n\n<strong>2010 Annual General Meeting</strong>\n\nThe 2010 Annual General Meeting of Calzada Limited will be held at RACV Club, 501 Bourke Street, Melbourne, Victoria, at 10:30am (Melbourne time) on the 22nd of November 2010.\n\n<a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting.pdf\" target=\"_blank\">Notice of AGM</a>\n\n<strong>2009 Annual General Meeting</strong>\n\nThe 2009 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at Level 1, 320 Lorimer St. Port Melbourne Victoria at 10:30am (Melbourne time) on Monday the 23rd of November 2009.\n\n<a href=\"/wp-content/uploads/2012/06/MPL_NOM_Final.pdf\" target=\"_blank\">Notice of AGM</a>\n\n<strong>2008 Annual General Meeting</strong>\n\nThe 2008 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at the offices of Minter Ellison Lawyers at Level 23, North Tower, Rialto, 525 Collins Street, Melbourne, Victoria at 2pm (Melbourne time) on Thursday 27 November, 2008.\n\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Results.pdf\" target=\"_blank\">Poll Results</a>\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Presentation.pdf\" target=\"_blank\">AGM Presentation</a>\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Chairman_address.pdf\" target=\"_blank\">AGM Chairman\'s Address</a>\n<a title=\"2008 Notice of AGM and Sample Proxy Form\" href=\"/wp-content/uploads/2012/06/ASX_NoticeofAGMandProxyForm_28October2008.pdf\">Notice of AGM and Sample Proxy Form</a>\n\n<strong>2007 Annual General Meeting</strong>\n\nThe 2007 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Computershare Conference Centre, Yarra Falls, 452 Johnston Street, Abbotsford, Vic  3067 on Friday, 2 November 2007.\n\n<a href=\"/wp-content/uploads/2012/06/ASX_2007AGM_Results.pdf\" target=\"_blank\">Poll Results</a>\n<a href=\"/wp-content/uploads/2012/06/2007-AGM-Chairmans-Address.pdf\" target=\"_blank\">Chairman\'s Address</a>\n<a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation1.pdf\" target=\"_blank\">AGM presentation - Full slide show</a>\n<a href=\"/wp-content/uploads/2012/06/2007-Sample-Proxy-Form.pdf\" target=\"_blank\">Sample Proxy Form</a>\n\n<strong>2006 Annual General Meeting</strong>\n\nThe 2006 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Level 23, Rialto South Tower, 525 Collins Street Melbourne on 27 October 2006\n\n<a href=\"/wp-content/uploads/2012/06/AGM-2006-Poll-Results.pdf\" target=\"_blank\">Poll Results</a>\n<a href=\"/wp-content/uploads/2012/06/AGM-2006-Chairman_s-address.pdf\" target=\"_blank\">Chairman\'s Address</a>\n<a href=\"/wp-content/uploads/2012/06/AGM-2006-Presentation.pdf\" target=\"_blank\">AGM Presentation - Full Slide Show</a>\n<a href=\"/wp-content/uploads/2012/06/2006-Notice-of-AGM-and-Proxy-Form.pdf\" target=\"_blank\">2006 Notice of Meeting and Proxy Form</a>\n\n<strong>2005 Annual General Meeting</strong>\n\nThe 2005 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 28 October, 2005.\n\n<a href=\"/wp-content/uploads/2012/06/051028b-ASX-Announcement-AGM-Results.pdf\" target=\"_blank\">Poll Results</a>\n<a href=\"/wp-content/uploads/2012/06/051028c-ASX-Announcement-AGM-address.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>\n<a href=\"/wp-content/uploads/2012/06/051028d-ASX-Announcement-AGM-preso.pdf\" target=\"_blank\">Presentation Full Slide Show</a>\n<a href=\"/wp-content/uploads/2012/06/050927-ASX-Announcement-Annual-Report-and-Notice-of-AGM-2005.pdf\" target=\"_blank\">2005 Notice of Meeting, Letter to Shareholders and Proxy Form</a>\n\n<strong>2004 Annual General Meeting</strong>\n\nThe 2004 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 29 October, 2004.\n\n<a href=\"/wp-content/uploads/2012/06/ASX-AGM-Results-29-10-04.pdf\" target=\"_blank\">Poll Results</a>\n<a href=\"/wp-content/uploads/2012/06/ASX-Chairmans-Address-AGM-2004.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>\n<a href=\"/wp-content/uploads/2012/06/ASX-Annual-Report-2004-23-9-04.pdf\" target=\"_blank\">2004 Notice of Meeting and Letter to Shareholders</a>',	'Annual General Meeting	',	'',	'inherit',	'open',	'open',	'',	'147-autosave',	'',	'',	'2012-06-18 10:35:46',	'2012-06-18 10:35:46',	'',	147,	'http://calzada-wp.urldock.com/147-autosave/',	0,	'revision',	'',	0),
(278,	1,	'2012-06-18 02:48:41',	'2012-06-18 02:48:41',	'',	'Annual General Meeting	',	'',	'inherit',	'open',	'open',	'',	'147-revision-2',	'',	'',	'2012-06-18 02:48:41',	'2012-06-18 02:48:41',	'',	147,	'http://calzada-wp.urldock.com/147-revision-2/',	0,	'revision',	'',	0),
(279,	1,	'2012-06-18 09:49:09',	'2012-06-18 09:49:09',	'',	'1046682',	'',	'inherit',	'open',	'open',	'',	'1046682',	'',	'',	'2012-06-18 09:49:09',	'2012-06-18 09:49:09',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/1046682.pdf',	0,	'attachment',	'application/pdf',	0),
(280,	1,	'2012-06-18 09:49:13',	'2012-06-18 09:49:13',	'',	'1046745',	'',	'inherit',	'open',	'open',	'',	'1046745',	'',	'',	'2012-06-18 09:49:13',	'2012-06-18 09:49:13',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/1046745.pdf',	0,	'attachment',	'application/pdf',	0),
(281,	1,	'2012-06-18 09:49:24',	'2012-06-18 09:49:24',	'',	'AGM 2006 Chairman_s address',	'',	'inherit',	'open',	'open',	'',	'agm-2006-chairman_s-address',	'',	'',	'2012-06-18 09:49:24',	'2012-06-18 09:49:24',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/AGM-2006-Chairman_s-address.pdf',	0,	'attachment',	'application/pdf',	0),
(282,	1,	'2012-06-18 09:49:29',	'2012-06-18 09:49:29',	'',	'AGM 2006 Poll Results',	'',	'inherit',	'open',	'open',	'',	'agm-2006-poll-results',	'',	'',	'2012-06-18 09:49:29',	'2012-06-18 09:49:29',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/AGM-2006-Poll-Results.pdf',	0,	'attachment',	'application/pdf',	0),
(283,	1,	'2012-06-18 09:49:42',	'2012-06-18 09:49:42',	'',	'AGM 2006 Presentation',	'',	'inherit',	'open',	'open',	'',	'agm-2006-presentation',	'',	'',	'2012-06-18 09:49:42',	'2012-06-18 09:49:42',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/AGM-2006-Presentation.pdf',	0,	'attachment',	'application/pdf',	0),
(284,	1,	'2012-06-18 09:50:12',	'2012-06-18 09:50:12',	'',	'ASX - Annual Report 2004 - 23-9-04',	'',	'inherit',	'open',	'open',	'',	'asx-annual-report-2004-23-9-04',	'',	'',	'2012-06-18 09:50:12',	'2012-06-18 09:50:12',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX-Annual-Report-2004-23-9-04.pdf',	0,	'attachment',	'application/pdf',	0),
(285,	1,	'2012-06-18 09:50:14',	'2012-06-18 09:50:14',	'',	'ASX AGM Results 29-10-04',	'',	'inherit',	'open',	'open',	'',	'asx-agm-results-29-10-04',	'',	'',	'2012-06-18 09:50:14',	'2012-06-18 09:50:14',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX-AGM-Results-29-10-04.pdf',	0,	'attachment',	'application/pdf',	0),
(286,	1,	'2012-06-18 09:50:21',	'2012-06-18 09:50:21',	'',	'ASX Chairmans Address AGM 2004',	'',	'inherit',	'open',	'open',	'',	'asx-chairmans-address-agm-2004',	'',	'',	'2012-06-18 09:50:21',	'2012-06-18 09:50:21',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX-Chairmans-Address-AGM-2004.pdf',	0,	'attachment',	'application/pdf',	0),
(287,	1,	'2012-06-18 09:50:25',	'2012-06-18 09:50:25',	'',	'ASX_2007AGM_Results',	'',	'inherit',	'open',	'open',	'',	'asx_2007agm_results',	'',	'',	'2012-06-18 09:50:25',	'2012-06-18 09:50:25',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX_2007AGM_Results.pdf',	0,	'attachment',	'application/pdf',	0),
(288,	1,	'2012-06-18 09:50:26',	'2012-06-18 09:50:26',	'',	'ASX_2008AGM_Chairman_address',	'',	'inherit',	'open',	'open',	'',	'asx_2008agm_chairman_address',	'',	'',	'2012-06-18 09:50:26',	'2012-06-18 09:50:26',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX_2008AGM_Chairman_address.pdf',	0,	'attachment',	'application/pdf',	0),
(289,	1,	'2012-06-18 09:50:29',	'2012-06-18 09:50:29',	'',	'ASX_2008AGM_Presentation',	'',	'inherit',	'open',	'open',	'',	'asx_2008agm_presentation',	'',	'',	'2012-06-18 09:50:29',	'2012-06-18 09:50:29',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX_2008AGM_Presentation.pdf',	0,	'attachment',	'application/pdf',	0),
(290,	1,	'2012-06-18 09:50:38',	'2012-06-18 09:50:38',	'',	'ASX_2008AGM_Results',	'',	'inherit',	'open',	'open',	'',	'asx_2008agm_results',	'',	'',	'2012-06-18 09:50:38',	'2012-06-18 09:50:38',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX_2008AGM_Results.pdf',	0,	'attachment',	'application/pdf',	0),
(291,	1,	'2012-06-18 09:50:44',	'2012-06-18 09:50:44',	'',	'Metabolic 2007 AGM Presentation',	'',	'inherit',	'open',	'open',	'',	'metabolic-2007-agm-presentation-2',	'',	'',	'2012-06-18 09:50:44',	'2012-06-18 09:50:44',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation1.pdf',	0,	'attachment',	'application/pdf',	0),
(292,	1,	'2012-06-18 09:50:52',	'2012-06-18 09:50:52',	'',	'MPL_NOM_Final',	'',	'inherit',	'open',	'open',	'',	'mpl_nom_final',	'',	'',	'2012-06-18 09:50:52',	'2012-06-18 09:50:52',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/MPL_NOM_Final.pdf',	0,	'attachment',	'application/pdf',	0),
(293,	1,	'2012-06-18 09:51:01',	'2012-06-18 09:51:01',	'',	'Notice_of_Annual_General_Meeting',	'',	'inherit',	'open',	'open',	'',	'notice_of_annual_general_meeting',	'',	'',	'2012-06-18 09:51:01',	'2012-06-18 09:51:01',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting.pdf',	0,	'attachment',	'application/pdf',	0),
(294,	1,	'2012-06-18 09:51:08',	'2012-06-18 09:51:08',	'',	'Notice_of_Annual_General_Meeting_and_Proxy_Form',	'',	'inherit',	'open',	'open',	'',	'notice_of_annual_general_meeting_and_proxy_form-2',	'',	'',	'2012-06-18 09:51:08',	'2012-06-18 09:51:08',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting_and_Proxy_Form1.pdf',	0,	'attachment',	'application/pdf',	0),
(295,	1,	'2012-06-18 09:51:25',	'2012-06-18 09:51:25',	'',	'2006 Notice of AGM and Proxy Form',	'',	'inherit',	'open',	'open',	'',	'2006-notice-of-agm-and-proxy-form',	'',	'',	'2012-06-18 09:51:25',	'2012-06-18 09:51:25',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/2006-Notice-of-AGM-and-Proxy-Form.pdf',	0,	'attachment',	'application/pdf',	0),
(296,	1,	'2012-06-18 09:51:28',	'2012-06-18 09:51:28',	'',	'2007 AGM Chairmans Address',	'',	'inherit',	'open',	'open',	'',	'2007-agm-chairmans-address',	'',	'',	'2012-06-18 09:51:28',	'2012-06-18 09:51:28',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/2007-AGM-Chairmans-Address.pdf',	0,	'attachment',	'application/pdf',	0),
(297,	1,	'2012-06-18 09:51:32',	'2012-06-18 09:51:32',	'',	'2007 Sample Proxy Form',	'',	'inherit',	'open',	'open',	'',	'2007-sample-proxy-form',	'',	'',	'2012-06-18 09:51:32',	'2012-06-18 09:51:32',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/2007-Sample-Proxy-Form.pdf',	0,	'attachment',	'application/pdf',	0),
(298,	1,	'2012-06-18 09:52:06',	'2012-06-18 09:52:06',	'',	'050927 ASX Announcement - Annual Report and Notice of AGM 2005',	'',	'inherit',	'open',	'open',	'',	'050927-asx-announcement-annual-report-and-notice-of-agm-2005',	'',	'',	'2012-06-18 09:52:06',	'2012-06-18 09:52:06',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/050927-ASX-Announcement-Annual-Report-and-Notice-of-AGM-2005.pdf',	0,	'attachment',	'application/pdf',	0),
(299,	1,	'2012-06-18 09:52:09',	'2012-06-18 09:52:09',	'',	'051028b ASX Announcement - AGM Results',	'',	'inherit',	'open',	'open',	'',	'051028b-asx-announcement-agm-results',	'',	'',	'2012-06-18 09:52:09',	'2012-06-18 09:52:09',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/051028b-ASX-Announcement-AGM-Results.pdf',	0,	'attachment',	'application/pdf',	0),
(300,	1,	'2012-06-18 09:52:19',	'2012-06-18 09:52:19',	'',	'051028c ASX Announcement - AGM address',	'',	'inherit',	'open',	'open',	'',	'051028c-asx-announcement-agm-address',	'',	'',	'2012-06-18 09:52:19',	'2012-06-18 09:52:19',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/051028c-ASX-Announcement-AGM-address.pdf',	0,	'attachment',	'application/pdf',	0),
(301,	1,	'2012-06-18 09:52:26',	'2012-06-18 09:52:26',	'',	'051028d ASX Announcement - AGM preso',	'',	'inherit',	'open',	'open',	'',	'051028d-asx-announcement-agm-preso',	'',	'',	'2012-06-18 09:52:26',	'2012-06-18 09:52:26',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/051028d-ASX-Announcement-AGM-preso.pdf',	0,	'attachment',	'application/pdf',	0),
(302,	1,	'2012-06-18 09:52:31',	'2012-06-18 09:52:31',	'',	'1046608',	'',	'inherit',	'open',	'open',	'',	'1046608',	'',	'',	'2012-06-18 09:52:31',	'2012-06-18 09:52:31',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/1046608.pdf',	0,	'attachment',	'application/pdf',	0),
(303,	1,	'2012-06-18 09:45:06',	'2012-06-18 09:45:06',	'<strong>2011 Annual General Meeting</strong></p>\r\n<p>The 2011 Annual General Meeting of Calzada Limited will be held at Unit 2, 320 Lorimer Street, Port Melbourne, Victoria, at 10:00am (Melbourne time)on the 15th of November 2011.<br><br><a href=\"../../files/LCSRNFXB5N/Notice_of_Annual_General_Meeting_and_Proxy_Form.pdf\" target=\"_blank\">Notice of AGM</a><br><a href=\"../../files/uploadsb/1046608.pdf\" target=\"_blank\">Chairmans Address</a><br><a href=\"../../files/uploadsb/1046682.pdf\" target=\"_blank\">Results of Meeting</a><br><a href=\"../../files/uploadsb/1046745.pdf\" target=\"_blank\">Notice of AGM</a></p>\r\n<p><strong>2010 Annual General&nbsp;Meeting<br><br></strong>The 2010 Annual General Meeting of Calzada Limited will be held at RACV Club, 501 Bourke Street, Melbourne, Victoria, at 10:30am (Melbourne time) on the 22nd of November 2010. <br><br><a href=\"../../files/K00GKTIFBQ/Notice_of_Annual_General_Meeting.pdf\" target=\"_blank\">Notice of AGM</a> </p>\r\n<p><strong>2009 Annual General&nbsp;Meeting<br><br></strong>The 2009 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at Level 1, 320 Lorimer St. Port Melbourne Victoria at 10:30am (Melbourne time) on Monday the 23rd of November 2009.<br><br><a href=\"../../files/0N5VQ1NLXE/MPL_NOM_Final.pdf\" target=\"_blank\">Notice of AGM</a> </p>\r\n<p><strong>2008 Annual General Meeting</strong></p>\r\n<p>The 2008 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at the offices of Minter Ellison Lawyers at Level 23, North Tower, Rialto, 525 Collins Street, Melbourne, Victoria at 2pm (Melbourne time) on Thursday 27 November, 2008.</p>\r\n<p><a href=\"../../files/ANOQP44V0H/ASX_2008AGM_Results.pdf\" target=\"_blank\">Poll Results</a><br><a href=\"../../files/7GBFTH7AWE/ASX_2008AGM_Presentation.pdf\" target=\"_blank\">AGM Presentation</a><br><a href=\"../../files/WWHFAIMKKW/ASX_2008AGM_Chairman_address.pdf\" target=\"_blank\">AGM Chairman\'s Address</a><br><a title=\"2008 Notice of AGM and Sample Proxy Form\" href=\"../../html/s02_article/article_view.asp?art_id=686&amp;nav_cat_id=188&amp;nav_top_id=58\">Notice of AGM and Sample Proxy Form</a></p>\r\n<p><strong>2007 Annual General Meeting</strong></p>\r\n<p>The 2007 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Computershare Conference Centre, Yarra Falls, 452 Johnston Street, Abbotsford, Vic&nbsp; 3067 on Friday, 2 November 2007.</p>\r\n<p><a href=\"../../files/8RF20GJGSL/ASX_2007AGM_Results.pdf\" target=\"_blank\">Poll Results</a><br><a href=\"../../files/PX63WWW8WU/2007%20AGM%20Chairmans%20Address.pdf\" target=\"_blank\">Chairman\'s Address</a><br><a href=\"../../files/4MA938409P/Metabolic%202007%20AGM%20Presentation.pdf\" target=\"_blank\">AGM presentation - Full slide show</a><br><a href=\"../../files/Q9Z8Z9V4YL/2007%20Sample%20Proxy%20Form.pdf\" target=\"_blank\">Sample Proxy Form</a></p>\r\n<p><strong>2006 Annual General Meeting</strong></p>\r\n<p>The 2006 Annual General Meeting of Metabolic Pharmaceuticals Limited&nbsp;was held at 10:00am at Level 23, Rialto South Tower, 525 Collins Street Melbourne on 27 October 2006</p>\r\n<p><a href=\"../../files/N1U0KMJX0Z/AGM%202006%20Poll%20Results.pdf\" target=\"_blank\">Poll Results</a><br><a href=\"../../files/P1I5S2U5YA/AGM%202006%20Chairman_s%20address.pdf\" target=\"_blank\">Chairman\'s Address</a><br><a href=\"../../files/HX9QK575PQ/AGM%202006%20Presentation.pdf\" target=\"_blank\">AGM Presentation - Full Slide Show</a><br><a href=\"../../files/G8GN8YFHO4/2006%20Notice%20of%20AGM%20and%20Proxy%20Form.pdf\" target=\"_blank\">2006 Notice of Meeting and Proxy Form</a></p>\r\n<p><strong>2005 Annual General Meeting</strong></p>\r\n<p>The 2005 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 28 October, 2005.&nbsp; </p>\r\n<p><a href=\"../../files/B04MGU1WRO/051028b%20ASX%20Announcement%20-%20AGM%20Results.pdf\" target=\"_blank\">Poll Results</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br><a href=\"../../files/TM53C9MPOY/051028c%20ASX%20Announcement%20-%20AGM%20address.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a><br><a href=\"../../files/BC8YF1BGU7/051028d%20ASX%20Announcement%20-%20AGM%20preso.pdf\" target=\"_blank\">Presentation  Full Slide Show</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br><a href=\"../../files/VAJODT5KLK/050927%20ASX%20Announcement%20-%20Annual%20Report%20and%20Notice%20of%20AGM%202005.pdf\" target=\"_blank\">2005 Notice of Meeting, Letter to Shareholders and Proxy Form</a>&nbsp;</p>\r\n<p><strong>2004 Annual General Meeting</strong></p>\r\n<p>The 2004 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 29 October, 2004.</p>\r\n<p><a href=\"../../files/7D1UQ1GLOX/ASX%20AGM%20Results%2029-10-04.pdf\" target=\"_blank\">Poll Results</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br><a href=\"../../files/3BAUIL3Q9A/ASX%20Chairmans%20Address%20AGM%202004.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>&nbsp;&nbsp;<br><a href=\"../../files/8T4IZLV1CY/ASX%20-%20Annual%20Report%202004%20-%2023-9-04.pdf\" target=\"_blank\">2004 Notice of Meeting and Letter to Shareholders</a>&nbsp;&nbsp;&nbsp;&nbsp;</p>',	'Annual General Meeting	',	'',	'inherit',	'open',	'open',	'',	'147-revision-3',	'',	'',	'2012-06-18 09:45:06',	'2012-06-18 09:45:06',	'',	147,	'http://calzada-wp.urldock.com/147-revision-3/',	0,	'revision',	'',	0),
(304,	1,	'2012-06-18 10:02:15',	'2012-06-18 10:02:15',	'<strong>2011 Annual General Meeting</strong>\r\n\r\nThe 2011 Annual General Meeting of Calzada Limited will be held at Unit 2, 320 Lorimer Street, Port Melbourne, Victoria, at 10:00am (Melbourne time)on the 15th of November 2011.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting_and_Proxy_Form1.pdf\" target=\"_blank\">Notice of AGM</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046608.pdf\" target=\"_blank\">Chairmans Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046682.pdf\" target=\"_blank\">Results of Meeting</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046745.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2010 Annual General Meeting</strong>\r\n\r\nThe 2010 Annual General Meeting of Calzada Limited will be held at RACV Club, 501 Bourke Street, Melbourne, Victoria, at 10:30am (Melbourne time) on the 22nd of November 2010.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2009 Annual General Meeting</strong>\r\n\r\nThe 2009 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at Level 1, 320 Lorimer St. Port Melbourne Victoria at 10:30am (Melbourne time) on Monday the 23rd of November 2009.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/MPL_NOM_Final.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2008 Annual General Meeting</strong>\r\n\r\nThe 2008 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at the offices of Minter Ellison Lawyers at Level 23, North Tower, Rialto, 525 Collins Street, Melbourne, Victoria at 2pm (Melbourne time) on Thursday 27 November, 2008.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Presentation.pdf\" target=\"_blank\">AGM Presentation</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Chairman_address.pdf\" target=\"_blank\">AGM Chairman\'s Address</a>\r\n<a title=\"2008 Notice of AGM and Sample Proxy Form\" href=\"../../html/s02_article/article_view.asp?art_id=686&amp;nav_cat_id=188&amp;nav_top_id=58\">Notice of AGM and Sample Proxy Form</a>\r\n\r\n<strong>2007 Annual General Meeting</strong>\r\n\r\nThe 2007 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Computershare Conference Centre, Yarra Falls, 452 Johnston Street, Abbotsford, Vic  3067 on Friday, 2 November 2007.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2007AGM_Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/2007%20AGM%20Chairmans%20Address.pdf\" target=\"_blank\">Chairman\'s Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic%202007%20AGM%20Presentation.pdf\" target=\"_blank\">AGM presentation - Full slide show</a>\r\n<a href=\"/wp-content/uploads/2012/06/2007%20Sample%20Proxy%20Form.pdf\" target=\"_blank\">Sample Proxy Form</a>\r\n\r\n<strong>2006 Annual General Meeting</strong>\r\n\r\nThe 2006 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Level 23, Rialto South Tower, 525 Collins Street Melbourne on 27 October 2006\r\n\r\n<a href=\"/wp-content/uploads/2012/06/AGM%202006%20Poll%20Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/AGM%202006%20Chairman_s%20address.pdf\" target=\"_blank\">Chairman\'s Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/AGM%202006%20Presentation.pdf\" target=\"_blank\">AGM Presentation - Full Slide Show</a>\r\n<a href=\"/wp-content/uploads/2012/06/2006%20Notice%20of%20AGM%20and%20Proxy%20Form.pdf\" target=\"_blank\">2006 Notice of Meeting and Proxy Form</a>\r\n\r\n<strong>2005 Annual General Meeting</strong>\r\n\r\nThe 2005 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 28 October, 2005.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/051028b%20ASX%20Announcement%20-%20AGM%20Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/051028c%20ASX%20Announcement%20-%20AGM%20address.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>\r\n<a href=\"/wp-content/uploads/2012/06/051028d%20ASX%20Announcement%20-%20AGM%20preso.pdf\" target=\"_blank\">Presentation Full Slide Show</a>\r\n<a href=\"/wp-content/uploads/2012/06/050927%20ASX%20Announcement%20-%20Annual%20Report%20and%20Notice%20of%20AGM%202005.pdf\" target=\"_blank\">2005 Notice of Meeting, Letter to Shareholders and Proxy Form</a>\r\n\r\n<strong>2004 Annual General Meeting</strong>\r\n\r\nThe 2004 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 29 October, 2004.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX%20AGM%20Results%2029-10-04.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX%20Chairmans%20Address%20AGM%202004.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX%20-%20Annual%20Report%202004%20-%2023-9-04.pdf\" target=\"_blank\">2004 Notice of Meeting and Letter to Shareholders</a>',	'Annual General Meeting	',	'',	'inherit',	'open',	'open',	'',	'147-revision-4',	'',	'',	'2012-06-18 10:02:15',	'2012-06-18 10:02:15',	'',	147,	'http://calzada-wp.urldock.com/147-revision-4/',	0,	'revision',	'',	0),
(305,	1,	'2012-06-18 10:04:21',	'2012-06-18 10:04:21',	'<strong>2011 Annual General Meeting</strong>\r\n\r\nThe 2011 Annual General Meeting of Calzada Limited will be held at Unit 2, 320 Lorimer Street, Port Melbourne, Victoria, at 10:00am (Melbourne time)on the 15th of November 2011.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting_and_Proxy_Form1.pdf\" target=\"_blank\">Notice of AGM</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046608.pdf\" target=\"_blank\">Chairmans Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046682.pdf\" target=\"_blank\">Results of Meeting</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046745.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2010 Annual General Meeting</strong>\r\n\r\nThe 2010 Annual General Meeting of Calzada Limited will be held at RACV Club, 501 Bourke Street, Melbourne, Victoria, at 10:30am (Melbourne time) on the 22nd of November 2010.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2009 Annual General Meeting</strong>\r\n\r\nThe 2009 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at Level 1, 320 Lorimer St. Port Melbourne Victoria at 10:30am (Melbourne time) on Monday the 23rd of November 2009.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/MPL_NOM_Final.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2008 Annual General Meeting</strong>\r\n\r\nThe 2008 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at the offices of Minter Ellison Lawyers at Level 23, North Tower, Rialto, 525 Collins Street, Melbourne, Victoria at 2pm (Melbourne time) on Thursday 27 November, 2008.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Presentation.pdf\" target=\"_blank\">AGM Presentation</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Chairman_address.pdf\" target=\"_blank\">AGM Chairman\'s Address</a>\r\n<a title=\"2008 Notice of AGM and Sample Proxy Form\" href=\"../../html/s02_article/article_view.asp?art_id=686&amp;nav_cat_id=188&amp;nav_top_id=58\">Notice of AGM and Sample Proxy Form</a>\r\n\r\n<strong>2007 Annual General Meeting</strong>\r\n\r\nThe 2007 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Computershare Conference Centre, Yarra Falls, 452 Johnston Street, Abbotsford, Vic  3067 on Friday, 2 November 2007.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2007AGM_Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/2007-AGM-Chairmans-Address.pdf\" target=\"_blank\">Chairman\'s Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic%202007%20AGM%20Presentation.pdf\" target=\"_blank\">AGM presentation - Full slide show</a>\r\n<a href=\"/wp-content/uploads/2012/06/2007%20Sample%20Proxy%20Form.pdf\" target=\"_blank\">Sample Proxy Form</a>\r\n\r\n<strong>2006 Annual General Meeting</strong>\r\n\r\nThe 2006 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Level 23, Rialto South Tower, 525 Collins Street Melbourne on 27 October 2006\r\n\r\n<a href=\"/wp-content/uploads/2012/06/AGM%202006%20Poll%20Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/AGM%202006%20Chairman_s%20address.pdf\" target=\"_blank\">Chairman\'s Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/AGM%202006%20Presentation.pdf\" target=\"_blank\">AGM Presentation - Full Slide Show</a>\r\n<a href=\"/wp-content/uploads/2012/06/2006%20Notice%20of%20AGM%20and%20Proxy%20Form.pdf\" target=\"_blank\">2006 Notice of Meeting and Proxy Form</a>\r\n\r\n<strong>2005 Annual General Meeting</strong>\r\n\r\nThe 2005 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 28 October, 2005.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/051028b%20ASX%20Announcement%20-%20AGM%20Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/051028c%20ASX%20Announcement%20-%20AGM%20address.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>\r\n<a href=\"/wp-content/uploads/2012/06/051028d%20ASX%20Announcement%20-%20AGM%20preso.pdf\" target=\"_blank\">Presentation Full Slide Show</a>\r\n<a href=\"/wp-content/uploads/2012/06/050927%20ASX%20Announcement%20-%20Annual%20Report%20and%20Notice%20of%20AGM%202005.pdf\" target=\"_blank\">2005 Notice of Meeting, Letter to Shareholders and Proxy Form</a>\r\n\r\n<strong>2004 Annual General Meeting</strong>\r\n\r\nThe 2004 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 29 October, 2004.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX%20AGM%20Results%2029-10-04.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX%20Chairmans%20Address%20AGM%202004.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX%20-%20Annual%20Report%202004%20-%2023-9-04.pdf\" target=\"_blank\">2004 Notice of Meeting and Letter to Shareholders</a>',	'Annual General Meeting	',	'',	'inherit',	'open',	'open',	'',	'147-revision-5',	'',	'',	'2012-06-18 10:04:21',	'2012-06-18 10:04:21',	'',	147,	'http://calzada-wp.urldock.com/147-revision-5/',	0,	'revision',	'',	0),
(306,	1,	'2012-06-18 10:08:18',	'2012-06-18 10:08:18',	'<strong>2011 Annual General Meeting</strong>\r\n\r\nThe 2011 Annual General Meeting of Calzada Limited will be held at Unit 2, 320 Lorimer Street, Port Melbourne, Victoria, at 10:00am (Melbourne time)on the 15th of November 2011.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting_and_Proxy_Form1.pdf\" target=\"_blank\">Notice of AGM</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046608.pdf\" target=\"_blank\">Chairmans Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046682.pdf\" target=\"_blank\">Results of Meeting</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046745.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2010 Annual General Meeting</strong>\r\n\r\nThe 2010 Annual General Meeting of Calzada Limited will be held at RACV Club, 501 Bourke Street, Melbourne, Victoria, at 10:30am (Melbourne time) on the 22nd of November 2010.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2009 Annual General Meeting</strong>\r\n\r\nThe 2009 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at Level 1, 320 Lorimer St. Port Melbourne Victoria at 10:30am (Melbourne time) on Monday the 23rd of November 2009.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/MPL_NOM_Final.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2008 Annual General Meeting</strong>\r\n\r\nThe 2008 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at the offices of Minter Ellison Lawyers at Level 23, North Tower, Rialto, 525 Collins Street, Melbourne, Victoria at 2pm (Melbourne time) on Thursday 27 November, 2008.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Presentation.pdf\" target=\"_blank\">AGM Presentation</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Chairman_address.pdf\" target=\"_blank\">AGM Chairman\'s Address</a>\r\n<a title=\"2008 Notice of AGM and Sample Proxy Form\" href=\"../../html/s02_article/article_view.asp?art_id=686&amp;nav_cat_id=188&amp;nav_top_id=58\">Notice of AGM and Sample Proxy Form</a>\r\n\r\n<strong>2007 Annual General Meeting</strong>\r\n\r\nThe 2007 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Computershare Conference Centre, Yarra Falls, 452 Johnston Street, Abbotsford, Vic  3067 on Friday, 2 November 2007.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2007AGM_Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/2007-AGM-Chairmans-Address.pdf\" target=\"_blank\">Chairman\'s Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation1.pdf\" target=\"_blank\">AGM presentation - Full slide show</a>\r\n<a href=\"/wp-content/uploads/2012/06/2007-Sample-Proxy-Form.pdf\" target=\"_blank\">Sample Proxy Form</a>\r\n\r\n<strong>2006 Annual General Meeting</strong>\r\n\r\nThe 2006 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Level 23, Rialto South Tower, 525 Collins Street Melbourne on 27 October 2006\r\n\r\n<a href=\"/wp-content/uploads/2012/06/AGM%202006%20Poll%20Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/AGM%202006%20Chairman_s%20address.pdf\" target=\"_blank\">Chairman\'s Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/AGM%202006%20Presentation.pdf\" target=\"_blank\">AGM Presentation - Full Slide Show</a>\r\n<a href=\"/wp-content/uploads/2012/06/2006%20Notice%20of%20AGM%20and%20Proxy%20Form.pdf\" target=\"_blank\">2006 Notice of Meeting and Proxy Form</a>\r\n\r\n<strong>2005 Annual General Meeting</strong>\r\n\r\nThe 2005 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 28 October, 2005.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/051028b%20ASX%20Announcement%20-%20AGM%20Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/051028c%20ASX%20Announcement%20-%20AGM%20address.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>\r\n<a href=\"/wp-content/uploads/2012/06/051028d%20ASX%20Announcement%20-%20AGM%20preso.pdf\" target=\"_blank\">Presentation Full Slide Show</a>\r\n<a href=\"/wp-content/uploads/2012/06/050927%20ASX%20Announcement%20-%20Annual%20Report%20and%20Notice%20of%20AGM%202005.pdf\" target=\"_blank\">2005 Notice of Meeting, Letter to Shareholders and Proxy Form</a>\r\n\r\n<strong>2004 Annual General Meeting</strong>\r\n\r\nThe 2004 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 29 October, 2004.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX%20AGM%20Results%2029-10-04.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX%20Chairmans%20Address%20AGM%202004.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX%20-%20Annual%20Report%202004%20-%2023-9-04.pdf\" target=\"_blank\">2004 Notice of Meeting and Letter to Shareholders</a>',	'Annual General Meeting	',	'',	'inherit',	'open',	'open',	'',	'147-revision-6',	'',	'',	'2012-06-18 10:08:18',	'2012-06-18 10:08:18',	'',	147,	'http://calzada-wp.urldock.com/147-revision-6/',	0,	'revision',	'',	0),
(307,	1,	'2012-06-18 10:13:29',	'2012-06-18 10:13:29',	'<strong>2011 Annual General Meeting</strong>\r\n\r\nThe 2011 Annual General Meeting of Calzada Limited will be held at Unit 2, 320 Lorimer Street, Port Melbourne, Victoria, at 10:00am (Melbourne time)on the 15th of November 2011.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting_and_Proxy_Form1.pdf\" target=\"_blank\">Notice of AGM</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046608.pdf\" target=\"_blank\">Chairmans Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046682.pdf\" target=\"_blank\">Results of Meeting</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046745.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2010 Annual General Meeting</strong>\r\n\r\nThe 2010 Annual General Meeting of Calzada Limited will be held at RACV Club, 501 Bourke Street, Melbourne, Victoria, at 10:30am (Melbourne time) on the 22nd of November 2010.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2009 Annual General Meeting</strong>\r\n\r\nThe 2009 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at Level 1, 320 Lorimer St. Port Melbourne Victoria at 10:30am (Melbourne time) on Monday the 23rd of November 2009.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/MPL_NOM_Final.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2008 Annual General Meeting</strong>\r\n\r\nThe 2008 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at the offices of Minter Ellison Lawyers at Level 23, North Tower, Rialto, 525 Collins Street, Melbourne, Victoria at 2pm (Melbourne time) on Thursday 27 November, 2008.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Presentation.pdf\" target=\"_blank\">AGM Presentation</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Chairman_address.pdf\" target=\"_blank\">AGM Chairman\'s Address</a>\r\n<a title=\"2008 Notice of AGM and Sample Proxy Form\" href=\"../../html/s02_article/article_view.asp?art_id=686&amp;nav_cat_id=188&amp;nav_top_id=58\">Notice of AGM and Sample Proxy Form</a>\r\n\r\n<strong>2007 Annual General Meeting</strong>\r\n\r\nThe 2007 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Computershare Conference Centre, Yarra Falls, 452 Johnston Street, Abbotsford, Vic  3067 on Friday, 2 November 2007.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2007AGM_Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/2007-AGM-Chairmans-Address.pdf\" target=\"_blank\">Chairman\'s Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation1.pdf\" target=\"_blank\">AGM presentation - Full slide show</a>\r\n<a href=\"/wp-content/uploads/2012/06/2007-Sample-Proxy-Form.pdf\" target=\"_blank\">Sample Proxy Form</a>\r\n\r\n<strong>2006 Annual General Meeting</strong>\r\n\r\nThe 2006 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Level 23, Rialto South Tower, 525 Collins Street Melbourne on 27 October 2006\r\n\r\n<a href=\"/wp-content/uploads/2012/06/AGM-2006-Poll-Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/AGM-2006-Chairman_s-address.pdf\" target=\"_blank\">Chairman\'s Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/AGM-2006-Presentation.pdf\" target=\"_blank\">AGM Presentation - Full Slide Show</a>\r\n<a href=\"/wp-content/uploads/2012/06/2006-Notice-of-AGM-and-Proxy-Form.pdf\" target=\"_blank\">2006 Notice of Meeting and Proxy Form</a>\r\n\r\n<strong>2005 Annual General Meeting</strong>\r\n\r\nThe 2005 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 28 October, 2005.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/051028b-ASX-Announcement---AGM-Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/051028c-ASX-Announcement---AGM-address.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>\r\n<a href=\"/wp-content/uploads/2012/06/051028d-ASX-Announcement---AGM-preso.pdf\" target=\"_blank\">Presentation Full Slide Show</a>\r\n<a href=\"/wp-content/uploads/2012/06/050927-ASX-Announcement---Annual-Report-and-Notice-of-AGM-2005.pdf\" target=\"_blank\">2005 Notice of Meeting, Letter to Shareholders and Proxy Form</a>\r\n\r\n<strong>2004 Annual General Meeting</strong>\r\n\r\nThe 2004 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 29 October, 2004.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX-AGM-Results-29-10-04.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX-Chairmans-Address-AGM-2004.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX---Annual-Report-2004---23-9-04.pdf\" target=\"_blank\">2004 Notice of Meeting and Letter to Shareholders</a>',	'Annual General Meeting	',	'',	'inherit',	'open',	'open',	'',	'147-revision-7',	'',	'',	'2012-06-18 10:13:29',	'2012-06-18 10:13:29',	'',	147,	'http://calzada-wp.urldock.com/147-revision-7/',	0,	'revision',	'',	0),
(308,	1,	'2012-06-18 10:14:55',	'2012-06-18 10:14:55',	'<strong>2011 Annual General Meeting</strong>\r\n\r\nThe 2011 Annual General Meeting of Calzada Limited will be held at Unit 2, 320 Lorimer Street, Port Melbourne, Victoria, at 10:00am (Melbourne time)on the 15th of November 2011.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting_and_Proxy_Form1.pdf\" target=\"_blank\">Notice of AGM</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046608.pdf\" target=\"_blank\">Chairmans Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046682.pdf\" target=\"_blank\">Results of Meeting</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046745.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2010 Annual General Meeting</strong>\r\n\r\nThe 2010 Annual General Meeting of Calzada Limited will be held at RACV Club, 501 Bourke Street, Melbourne, Victoria, at 10:30am (Melbourne time) on the 22nd of November 2010.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2009 Annual General Meeting</strong>\r\n\r\nThe 2009 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at Level 1, 320 Lorimer St. Port Melbourne Victoria at 10:30am (Melbourne time) on Monday the 23rd of November 2009.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/MPL_NOM_Final.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2008 Annual General Meeting</strong>\r\n\r\nThe 2008 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at the offices of Minter Ellison Lawyers at Level 23, North Tower, Rialto, 525 Collins Street, Melbourne, Victoria at 2pm (Melbourne time) on Thursday 27 November, 2008.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Presentation.pdf\" target=\"_blank\">AGM Presentation</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Chairman_address.pdf\" target=\"_blank\">AGM Chairman\'s Address</a>\r\n<a title=\"2008 Notice of AGM and Sample Proxy Form\" href=\"../../html/s02_article/article_view.asp?art_id=686&amp;nav_cat_id=188&amp;nav_top_id=58\">Notice of AGM and Sample Proxy Form</a>\r\n\r\n<strong>2007 Annual General Meeting</strong>\r\n\r\nThe 2007 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Computershare Conference Centre, Yarra Falls, 452 Johnston Street, Abbotsford, Vic  3067 on Friday, 2 November 2007.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2007AGM_Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/2007-AGM-Chairmans-Address.pdf\" target=\"_blank\">Chairman\'s Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation1.pdf\" target=\"_blank\">AGM presentation - Full slide show</a>\r\n<a href=\"/wp-content/uploads/2012/06/2007-Sample-Proxy-Form.pdf\" target=\"_blank\">Sample Proxy Form</a>\r\n\r\n<strong>2006 Annual General Meeting</strong>\r\n\r\nThe 2006 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Level 23, Rialto South Tower, 525 Collins Street Melbourne on 27 October 2006\r\n\r\n<a href=\"/wp-content/uploads/2012/06/AGM-2006-Poll-Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/AGM-2006-Chairman_s-address.pdf\" target=\"_blank\">Chairman\'s Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/AGM-2006-Presentation.pdf\" target=\"_blank\">AGM Presentation - Full Slide Show</a>\r\n<a href=\"/wp-content/uploads/2012/06/2006-Notice-of-AGM-and-Proxy-Form.pdf\" target=\"_blank\">2006 Notice of Meeting and Proxy Form</a>\r\n\r\n<strong>2005 Annual General Meeting</strong>\r\n\r\nThe 2005 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 28 October, 2005.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/051028b-ASX-Announcement---AGM-Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/051028c-ASX-Announcement---AGM-address.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>\r\n<a href=\"/wp-content/uploads/2012/06/051028d-ASX-Announcement---AGM-preso.pdf\" target=\"_blank\">Presentation Full Slide Show</a>\r\n<a href=\"/wp-content/uploads/2012/06/050927-ASX-Announcement---Annual-Report-and-Notice-of-AGM-2005.pdf\" target=\"_blank\">2005 Notice of Meeting, Letter to Shareholders and Proxy Form</a>\r\n\r\n<strong>2004 Annual General Meeting</strong>\r\n\r\nThe 2004 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 29 October, 2004.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX-AGM-Results-29-10-04.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX-Chairmans-Address-AGM-2004.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX-Annual-Report-2004-23-9-04.pdf\" target=\"_blank\">2004 Notice of Meeting and Letter to Shareholders</a>',	'Annual General Meeting	',	'',	'inherit',	'open',	'open',	'',	'147-revision-8',	'',	'',	'2012-06-18 10:14:55',	'2012-06-18 10:14:55',	'',	147,	'http://calzada-wp.urldock.com/147-revision-8/',	0,	'revision',	'',	0),
(309,	1,	'2012-06-18 10:16:40',	'2012-06-18 10:16:40',	'<strong>2011 Annual General Meeting</strong>\r\n\r\nThe 2011 Annual General Meeting of Calzada Limited will be held at Unit 2, 320 Lorimer Street, Port Melbourne, Victoria, at 10:00am (Melbourne time)on the 15th of November 2011.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting_and_Proxy_Form1.pdf\" target=\"_blank\">Notice of AGM</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046608.pdf\" target=\"_blank\">Chairmans Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046682.pdf\" target=\"_blank\">Results of Meeting</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046745.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2010 Annual General Meeting</strong>\r\n\r\nThe 2010 Annual General Meeting of Calzada Limited will be held at RACV Club, 501 Bourke Street, Melbourne, Victoria, at 10:30am (Melbourne time) on the 22nd of November 2010.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2009 Annual General Meeting</strong>\r\n\r\nThe 2009 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at Level 1, 320 Lorimer St. Port Melbourne Victoria at 10:30am (Melbourne time) on Monday the 23rd of November 2009.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/MPL_NOM_Final.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2008 Annual General Meeting</strong>\r\n\r\nThe 2008 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at the offices of Minter Ellison Lawyers at Level 23, North Tower, Rialto, 525 Collins Street, Melbourne, Victoria at 2pm (Melbourne time) on Thursday 27 November, 2008.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Presentation.pdf\" target=\"_blank\">AGM Presentation</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Chairman_address.pdf\" target=\"_blank\">AGM Chairman\'s Address</a>\r\n<a title=\"2008 Notice of AGM and Sample Proxy Form\" href=\"../../html/s02_article/article_view.asp?art_id=686&amp;nav_cat_id=188&amp;nav_top_id=58\">Notice of AGM and Sample Proxy Form</a>\r\n\r\n<strong>2007 Annual General Meeting</strong>\r\n\r\nThe 2007 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Computershare Conference Centre, Yarra Falls, 452 Johnston Street, Abbotsford, Vic  3067 on Friday, 2 November 2007.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2007AGM_Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/2007-AGM-Chairmans-Address.pdf\" target=\"_blank\">Chairman\'s Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation1.pdf\" target=\"_blank\">AGM presentation - Full slide show</a>\r\n<a href=\"/wp-content/uploads/2012/06/2007-Sample-Proxy-Form.pdf\" target=\"_blank\">Sample Proxy Form</a>\r\n\r\n<strong>2006 Annual General Meeting</strong>\r\n\r\nThe 2006 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Level 23, Rialto South Tower, 525 Collins Street Melbourne on 27 October 2006\r\n\r\n<a href=\"/wp-content/uploads/2012/06/AGM-2006-Poll-Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/AGM-2006-Chairman_s-address.pdf\" target=\"_blank\">Chairman\'s Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/AGM-2006-Presentation.pdf\" target=\"_blank\">AGM Presentation - Full Slide Show</a>\r\n<a href=\"/wp-content/uploads/2012/06/2006-Notice-of-AGM-and-Proxy-Form.pdf\" target=\"_blank\">2006 Notice of Meeting and Proxy Form</a>\r\n\r\n<strong>2005 Annual General Meeting</strong>\r\n\r\nThe 2005 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 28 October, 2005.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/051028b-ASX-Announcement---AGM-Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/051028c-ASX-Announcement---AGM-address.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>\r\n<a href=\"/wp-content/uploads/2012/06/051028d-ASX-Announcement---AGM-preso.pdf\" target=\"_blank\">Presentation Full Slide Show</a>\r\n<a href=\"/wp-content/uploads/2012/06/050927-ASX-Announcement-Annual-Report-and-Notice-of-AGM-2005.pdf\" target=\"_blank\">2005 Notice of Meeting, Letter to Shareholders and Proxy Form</a>\r\n\r\n<strong>2004 Annual General Meeting</strong>\r\n\r\nThe 2004 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 29 October, 2004.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX-AGM-Results-29-10-04.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX-Chairmans-Address-AGM-2004.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX-Annual-Report-2004-23-9-04.pdf\" target=\"_blank\">2004 Notice of Meeting and Letter to Shareholders</a>',	'Annual General Meeting	',	'',	'inherit',	'open',	'open',	'',	'147-revision-9',	'',	'',	'2012-06-18 10:16:40',	'2012-06-18 10:16:40',	'',	147,	'http://calzada-wp.urldock.com/147-revision-9/',	0,	'revision',	'',	0),
(310,	1,	'2012-06-18 10:23:41',	'2012-06-18 10:23:41',	'',	'ASX_NoticeofAGMandProxyForm_28October2008',	'',	'inherit',	'open',	'open',	'',	'asx_noticeofagmandproxyform_28october2008',	'',	'',	'2012-06-18 10:23:41',	'2012-06-18 10:23:41',	'',	147,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/ASX_NoticeofAGMandProxyForm_28October2008.pdf',	0,	'attachment',	'application/pdf',	0),
(311,	1,	'2012-06-18 10:17:48',	'2012-06-18 10:17:48',	'<strong>2011 Annual General Meeting</strong>\r\n\r\nThe 2011 Annual General Meeting of Calzada Limited will be held at Unit 2, 320 Lorimer Street, Port Melbourne, Victoria, at 10:00am (Melbourne time)on the 15th of November 2011.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting_and_Proxy_Form1.pdf\" target=\"_blank\">Notice of AGM</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046608.pdf\" target=\"_blank\">Chairmans Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046682.pdf\" target=\"_blank\">Results of Meeting</a>\r\n<a href=\"/wp-content/uploads/2012/06/1046745.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2010 Annual General Meeting</strong>\r\n\r\nThe 2010 Annual General Meeting of Calzada Limited will be held at RACV Club, 501 Bourke Street, Melbourne, Victoria, at 10:30am (Melbourne time) on the 22nd of November 2010.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2009 Annual General Meeting</strong>\r\n\r\nThe 2009 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at Level 1, 320 Lorimer St. Port Melbourne Victoria at 10:30am (Melbourne time) on Monday the 23rd of November 2009.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/MPL_NOM_Final.pdf\" target=\"_blank\">Notice of AGM</a>\r\n\r\n<strong>2008 Annual General Meeting</strong>\r\n\r\nThe 2008 Annual General Meeting of Metabolic Pharmaceuticals Limited will be held at the offices of Minter Ellison Lawyers at Level 23, North Tower, Rialto, 525 Collins Street, Melbourne, Victoria at 2pm (Melbourne time) on Thursday 27 November, 2008.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Presentation.pdf\" target=\"_blank\">AGM Presentation</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2008AGM_Chairman_address.pdf\" target=\"_blank\">AGM Chairman\'s Address</a>\r\n<a title=\"2008 Notice of AGM and Sample Proxy Form\" href=\"../../html/s02_article/article_view.asp?art_id=686&amp;nav_cat_id=188&amp;nav_top_id=58\">Notice of AGM and Sample Proxy Form</a>\r\n\r\n<strong>2007 Annual General Meeting</strong>\r\n\r\nThe 2007 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Computershare Conference Centre, Yarra Falls, 452 Johnston Street, Abbotsford, Vic  3067 on Friday, 2 November 2007.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX_2007AGM_Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/2007-AGM-Chairmans-Address.pdf\" target=\"_blank\">Chairman\'s Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/Metabolic-2007-AGM-Presentation1.pdf\" target=\"_blank\">AGM presentation - Full slide show</a>\r\n<a href=\"/wp-content/uploads/2012/06/2007-Sample-Proxy-Form.pdf\" target=\"_blank\">Sample Proxy Form</a>\r\n\r\n<strong>2006 Annual General Meeting</strong>\r\n\r\nThe 2006 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at 10:00am at Level 23, Rialto South Tower, 525 Collins Street Melbourne on 27 October 2006\r\n\r\n<a href=\"/wp-content/uploads/2012/06/AGM-2006-Poll-Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/AGM-2006-Chairman_s-address.pdf\" target=\"_blank\">Chairman\'s Address</a>\r\n<a href=\"/wp-content/uploads/2012/06/AGM-2006-Presentation.pdf\" target=\"_blank\">AGM Presentation - Full Slide Show</a>\r\n<a href=\"/wp-content/uploads/2012/06/2006-Notice-of-AGM-and-Proxy-Form.pdf\" target=\"_blank\">2006 Notice of Meeting and Proxy Form</a>\r\n\r\n<strong>2005 Annual General Meeting</strong>\r\n\r\nThe 2005 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 28 October, 2005.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/051028b-ASX-Announcement-AGM-Results.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/051028c-ASX-Announcement-AGM-address.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>\r\n<a href=\"/wp-content/uploads/2012/06/051028d-ASX-Announcement-AGM-preso.pdf\" target=\"_blank\">Presentation Full Slide Show</a>\r\n<a href=\"/wp-content/uploads/2012/06/050927-ASX-Announcement-Annual-Report-and-Notice-of-AGM-2005.pdf\" target=\"_blank\">2005 Notice of Meeting, Letter to Shareholders and Proxy Form</a>\r\n\r\n<strong>2004 Annual General Meeting</strong>\r\n\r\nThe 2004 Annual General Meeting of Metabolic Pharmaceuticals Limited was held at Level 23, Rialto South Tower, 525 Collins Street Melbourne at 10:00am on Friday 29 October, 2004.\r\n\r\n<a href=\"/wp-content/uploads/2012/06/ASX-AGM-Results-29-10-04.pdf\" target=\"_blank\">Poll Results</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX-Chairmans-Address-AGM-2004.pdf\" target=\"_blank\">Chairman and CEOs address to shareholders</a>\r\n<a href=\"/wp-content/uploads/2012/06/ASX-Annual-Report-2004-23-9-04.pdf\" target=\"_blank\">2004 Notice of Meeting and Letter to Shareholders</a>',	'Annual General Meeting	',	'',	'inherit',	'open',	'open',	'',	'147-revision-10',	'',	'',	'2012-06-18 10:17:48',	'2012-06-18 10:17:48',	'',	147,	'http://calzada-wp.urldock.com/147-revision-10/',	0,	'revision',	'',	0),
(312,	1,	'2012-06-19 08:05:19',	'2012-06-19 08:05:19',	'',	'Banner',	'',	'inherit',	'open',	'open',	'',	'banner',	'',	'',	'2012-06-19 08:05:19',	'2012-06-19 08:05:19',	'',	6,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/05/Banner.jpg',	0,	'attachment',	'image/jpeg',	0),
(313,	1,	'2012-06-05 19:28:03',	'2012-06-05 19:28:03',	'',	'Home',	'',	'inherit',	'open',	'open',	'',	'6-revision-7',	'',	'',	'2012-06-05 19:28:03',	'2012-06-05 19:28:03',	'',	6,	'http://calzada-wp.urldock.com/6-revision-7/',	0,	'revision',	'',	0),
(314,	1,	'2012-06-28 00:32:00',	'2012-06-28 00:32:00',	'',	'Polynovo',	'',	'publish',	'open',	'open',	'',	'polynovo',	'',	'',	'2012-07-06 00:13:19',	'2012-07-06 00:13:19',	'',	0,	'http://calzada-wp.urldock.com/?p=314',	7,	'nav_menu_item',	'',	0),
(315,	1,	'2012-06-05 19:52:12',	'2012-06-05 19:52:12',	'<h3>Mr Laurent Fossaert</h3>\r\n<h4>CHIEF EXECUTIVE OFFICER – POLYNOVO BIOMATERIALS PTY LTD</h4>\r\nLF to provide wording.\r\n\r\nXXXXX\r\n<h3></h3>\r\n<h3>Mr David Kenley</h3>\r\n<h4>CHIEF EXECUTIVE OFFICER – metabolic pharmaceuticals PTY LTD</h4>\r\nDavid Kenley has a Masters degree in Entrepreneurship &amp; Innovation, a Bachelor of Economics and is a member of the Australian Institute of Company Directors.  Over the last 25 years his career has focussed on the commercialisation of research results from Australia’s leading research institutions including CSIRO.  He has gained considerable experience in the establishment of spin-off companies and the licensing of research in many fields of science and over the last 14 years has focussed on the biotechnology sector.\r\n\r\nMr Kenley was a Director of Calzada Ltd until his resignation in early 2010 to become the CEO of Metabolic Pharmaceuticals Pty Ltd, the subsidiary established to house Calzada’s AOD and other drug development assets.\r\n\r\nPrior to this role David was the Managing Director of Xceed Capital Ltd where he worked closely with the CEO of the subsidiary, PolyNovo Biomaterials Pty Ltd, in commercialising that company’s novel biodegradable polymer technology.  He also orchestrated the restructuring and significant turnaround in financial performance of the fully owned subsidiary, Boron Molecular Pty Ltd.\r\n\r\nPreviously David was one of the Founders and the Vice President, Corporate Development of Metabolic Pharmaceuticals Ltd (now Calzada) where he worked as the 2IC until mid 2005.  He has also previously been a senior executive of Axon Instruments, Inc. (a Silicon Valley based designer and manufacturer of scientific instruments and drug discovery equipment) and Corporate Development Manager of Circadian Technologies Ltd, Australia’s first listed biotechnology company.  Over a period of nearly ten years he was Licensing &amp; Finance Manager of Sirotech Ltd, the commercial arm of CSIRO, where he managed the organisation’s licence portfolio, the largest in the southern hemisphere, and all its equity based interests.\r\n\r\nMr Kenley has significant experience in starting and growing entrepreneurial growth companies, the capital markets and in the running of publicly listed entities.\r\n<h3 id=\"greenwood\">A/Prof John Greenwood AM</h3>\r\n<h4>Chief Medical Officer</h4>\r\n<strong>Director, Adult Burns Service, Royal Adelaide Hospital</strong>\r\n<strong>Director, Skin Engineering Laboratory, Hanson Institute</strong>\r\n<strong>Associate Professor, Department of Surgery, University of Adelaide</strong>\r\n\r\nAssociate Professor John Greenwood AM is an English-trained plastic surgeon who works full-time in burn care as the Medical Director of the Adult Burn Centre of the Royal Adelaide Hospital in Adelaide, South Australia. This is currently the only ABA/ACS Verified Burn Centre outside the United States. His other posts include Director of the Skin Engineering Laboratory (one of only two Australian laboratories licensed by the Therapeutic Goods Administration (TGA – Australia’s equivalent of the FDA) for the commercial processing of cultured skin cellular products, and Associate Professor in the Discipline of Surgery, School of Medicine, University of Adelaide.\r\n\r\nHe has been working on the development of skin replacement products utilising the NovoSorb biodegradable polyurethane platform since 2004, following a structured programme of studies, both <em>in-vitro</em> and <em>in-vivo</em>, collecting data and generating impressive results which have been rewarded with approval for human trials in Australia.\r\n\r\nHe is a member of both the American Burn Association and the Australian and New Zealand Burn Association and an international editor for the Journal of Burn Care and Research. Although a single-handed burn surgeon, his laboratory and clinical research programmes and general insights have been rewarded with 81 publications including 6 book chapters and 51 papers in peer-reviewed journals. His recent work with the polymer BTM earned him the inaugural Burke-Yannas Bioengineering Award, presented at the ABA Meeting in Chicago earlier this year.\r\n\r\nIn addition to his basic medical degree (MBChB – Bachelor of Medicine, Bachelor of Surgery), he holds a Bachelor of Science with honours degree by thesis in anatomy and a Doctor of Medicine post-graduate degree, also by thesis. His other qualifications are specialist plastic surgery fellowships with the Intercollegiate Board of the Colleges of Surgery of England, Scotland and Ireland and more recently specialist plastic surgery fellowship of the Royal Australasian College of Surgeons. The post-nominal immediately after his name (AM) is membership of the Order of Australia, an honour bestowed on him by the Queen following his work leading Australia’s only Burns Assessment Team after the carnage of the 2002 Bali Bombings which killed 202 civilians.\r\n<h3>Dr Tim Moore</h3>\r\n<h4>Principal Scientist</h4>\r\nDr. Moore completed a Bachelor of Applied Science (Chemistry) degree at Swinburne University of Technology, followed by an honours degree and PhD degree. Dr. Moore’s PhD dissertation was in the field of biodegradable polyurethanes; the title was “Design and Synthesis of Biodegradable Thermoplastic Polyurethanes for Tissue Engineering”.\r\n\r\nDr. Moore has been involved with PolyNovo since its inception and is a co-inventor of some of the variants of NovoSorb™. He has been working on the development of biodegradable polymers for medical devices for over ten years. His main area of expertise is in polyurethanes and the development of biomaterials for use in medical devices. He developed a novel range of biodegradable chain extenders which is included in several of PolyNovo’s patent applications. Dr. Moore is involved in project management and product development in PolyNovo’s leading applications. Dr. Moore is also responsible for the maintenance of PolyNovo’s extensive Intellectual Property Portfolio. He is co-author on a number of peer-reviewed papers and patent applications. He was a co-recipient of the CSIRO Molecular Science Divisional Strategic Action Plan Award for Innovation (2004) and of the CSIRO medal in Research Achievement category (2005).\r\n<h3>Mr Chris Mews (CPA, ACIS)</h3>\r\n<h4>Company Secretary/Chief Financial Officer</h4>\r\nMr Mews was appointed Company Secretary of Calzada Ltd on 16th April 2009 and was appointed Chief Financial Officer on 1st September 2009.\r\n\r\nMr Mews has been involved in the financial services industry for over 10 years.  Mr Mews is a Certified Practicing Accountant and Chartered Company Secretary and has been Company Secretary and Chief Financial Officer of various listed and unlisted companies.',	'Management & Staff',	'',	'inherit',	'open',	'open',	'',	'15-revision-6',	'',	'',	'2012-06-05 19:52:12',	'2012-06-05 19:52:12',	'',	15,	'http://calzada-wp.urldock.com/15-revision-6/',	0,	'revision',	'',	0),
(316,	1,	'2012-06-11 05:13:20',	'2012-06-11 05:13:20',	'<table>\r\n<tbody>\r\n<tr>\r\n<td>\r\n<h2>Calzada Limited</h2>\r\n<img class=\"alignnone size-thumbnail wp-image-123\" title=\"calzada_logo\" src=\"/wp-content/uploads/2012/05/calzada_logo\" alt=\"contact Calzada\" /></td>\r\n</tr>\r\n<tr>\r\n<td>Wendy Townsend\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia&nbsp;\r\n\r\n&nbsp;</td>\r\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\r\n<strong>Fax:</strong>+61 (0) 3 8681 4099\r\n<strong>Email:</strong><a href=\"mailTo:wtownsend@calzada.com.au\">wtownsend@calzada.com.au</a></td>\r\n</tr>\r\n<tr>\r\n<td>\r\n<h2>PolyNovo Biomaterials Pty Ltd</h2>\r\n<img class=\"alignnone size-full wp-image-124\" title=\"polynovo\" src=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/polynovologo.jpg\" alt=\"\" width=\"225\" height=\"120\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td>Chief Executive Officer\r\nMr. Laurent Fossaert\r\nPolyNovo Biomaterials Pty Ltd\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia&nbsp;\r\n\r\n&nbsp;</td>\r\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\r\n<strong>Fax:</strong>+61 (0) 3 8681 4099\r\n<strong>Email:</strong><a href=\"mailTo:info@polynovo.com\">info@polynovo.com</a></td>\r\n</tr>\r\n<tr>\r\n<td>\r\n<h2>Metabolic Pharmaceuticals Limited</h2>\r\n<img class=\"alignnone size-full wp-image-126\" title=\"metaboliclogo\" src=\"/wp-content/uploads/2012/05/metaboliclogo.jpg\" alt=\"metaboloic\" width=\"225\" height=\"120\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td>Chief Executive Officer\r\nMr. David Kenley\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia</td>\r\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\r\n<strong>Fax:</strong>+61 (0) 3 8681 4099</td>\r\n</tr>\r\n</tbody>\r\n</table>',	'Contact Us',	'',	'inherit',	'open',	'open',	'',	'27-revision-7',	'',	'',	'2012-06-11 05:13:20',	'2012-06-11 05:13:20',	'',	27,	'http://calzada-wp.urldock.com/27-revision-7/',	0,	'revision',	'',	0),
(317,	1,	'2012-06-28 00:35:35',	'2012-06-28 00:35:35',	'<table>\r\n<tbody>\r\n<tr>\r\n<td>\r\n<h2>Calzada Limited</h2>\r\n<img class=\"alignnone size-thumbnail wp-image-123\" title=\"calzada_logo\" src=\"/wp-content/uploads/2012/05/calzada_logo\" alt=\"contact Calzada\" /></td>\r\n</tr>\r\n<tr>\r\n<td>Wendy Townsend\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia&nbsp;</td>\r\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\r\n<strong>Fax:</strong>+61 (0) 3 8681 4099\r\n<strong>Email:</strong><a href=\"mailTo:wtownsend@calzada.com.au\">wtownsend@calzada.com.au</a></td>\r\n</tr>\r\n<tr>\r\n<td>\r\n<h2>PolyNovo Biomaterials Pty Ltd</h2>\r\n<img class=\"alignnone size-full wp-image-124\" title=\"polynovo\" src=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/polynovologo.jpg\" alt=\"\" width=\"225\" height=\"120\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td>Chief Executive Officer\r\nMr. Laurent Fossaert\r\nPolyNovo Biomaterials Pty Ltd\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia&nbsp;</td>\r\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\r\n<strong>Fax:</strong>+61 (0) 3 8681 4099\r\n<strong>Email:</strong><a href=\"mailTo:info@polynovo.com\">info@polynovo.com</a></td>\r\n</tr>\r\n<tr>\r\n<td>\r\n<h2>Metabolic Pharmaceuticals Pty Ltd</h2>\r\n<img class=\"alignnone size-full wp-image-126\" title=\"metaboliclogo\" src=\"/wp-content/uploads/2012/05/metaboliclogo.jpg\" alt=\"metaboloic\" width=\"225\" height=\"120\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td>Chief Executive Officer\r\nMr. David Kenley\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia</td>\r\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\r\n<strong>Fax:</strong>+61 (0) 3 8681 4099</td>\r\n</tr>\r\n</tbody>\r\n</table>',	'Contact Us',	'',	'inherit',	'open',	'open',	'',	'27-revision-8',	'',	'',	'2012-06-28 00:35:35',	'2012-06-28 00:35:35',	'',	27,	'http://calzada-wp.urldock.com/27-revision-8/',	0,	'revision',	'',	0),
(318,	1,	'2012-06-28 00:45:45',	'2012-06-28 00:45:45',	'<table>\r\n<tbody>\r\n<tr>\r\n<td>\r\n<h2>Calzada Limited</h2>\r\n<img class=\"alignnone size-thumbnail wp-image-123\" title=\"calzada_logo\" src=\"/wp-content/uploads/2012/05/calzada_logo\" alt=\"contact Calzada\" /></td>\r\n</tr>\r\n<tr>\r\n<td>Wendy Townsend\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia</td>\r\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\r\n<strong>Fax:</strong>+61 (0) 3 8681 4099\r\n<strong>Email:</strong><a href=\"mailTo:wtownsend@calzada.com.au\">wtownsend@calzada.com.au</a></td>\r\n</tr>\r\n<tr>\r\n<td>\r\n<h2>PolyNovo Biomaterials Pty Ltd</h2>\r\n<img class=\"alignnone size-full wp-image-124\" title=\"polynovo\" src=\"http://calzada-wp.urldock.com/wp-content/uploads/2012/05/polynovologo.jpg\" alt=\"\" width=\"225\" height=\"120\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td>Chief Executive Officer\r\nMr. Laurent Fossaert\r\nPolyNovo Biomaterials Pty Ltd\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia</td>\r\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\r\n<strong>Fax:</strong>+61 (0) 3 8681 4099\r\n<strong>Email:</strong><a href=\"mailTo:info@polynovo.com\">info@polynovo.com</a></td>\r\n</tr>\r\n<tr>\r\n<td>\r\n<h2>Metabolic Pharmaceuticals Pty Ltd</h2>\r\n<img class=\"alignnone size-full wp-image-126\" title=\"metaboliclogo\" src=\"/wp-content/uploads/2012/05/metaboliclogo.jpg\" alt=\"metaboloic\" width=\"225\" height=\"120\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td>Chief Executive Officer\r\nMr. David Kenley\r\n2/320 Lorimer Street\r\nPort Melbourne VIC 3207\r\nAustralia</td>\r\n<td><strong>Phone:</strong>+61 (0) 3 8681 4050\r\n<strong>Fax:</strong>+61 (0) 3 8681 4099\r\n<strong>Email:<a href=\"mailto:dkenley@calzada.com.au\">dkenley@calzada.com.au</a></strong></td>\r\n</tr>\r\n</tbody>\r\n</table>',	'Contact Us',	'',	'inherit',	'open',	'open',	'',	'27-revision-9',	'',	'',	'2012-06-28 00:45:45',	'2012-06-28 00:45:45',	'',	27,	'http://calzada-wp.urldock.com/27-revision-9/',	0,	'revision',	'',	0),
(319,	1,	'2012-06-28 01:04:17',	'2012-06-28 01:04:17',	'',	'1059707',	'',	'inherit',	'open',	'open',	'',	'1059707',	'',	'',	'2012-06-28 01:04:17',	'2012-06-28 01:04:17',	'',	141,	'http://calzada-wp.urldock.com/wp-content/uploads/2012/06/1059707.pdf',	0,	'attachment',	'application/pdf',	0),
(320,	1,	'2012-06-18 06:32:16',	'2012-06-18 06:32:16',	'&nbsp;\r\n<table id=\"theTable3\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td colspan=\"2\"><img src=\"../../html/images/trans.gif\" alt=\"\" width=\"9\" height=\"1\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>\r\n<h2 class=\"feSubHeading\">ASX Releases</h2>\r\n</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"><img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td id=\"theCell1\" width=\"100%\">\r\n<h3>ASX Releases 2012</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/132F042F2012103A223A30PM.pdf\">PolyNovo human Trial Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo human Trial Update</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/132F042F2012103A223A05PM.pdf\">AOD positive in Cartilage and Muscle Repair</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AOD positive in Cartilage and Muscle Repair</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/132F042F2012103A213A23PM.pdf\">PolyNovo Commences Second Human Trial</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo Commences Second Human Trial</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1074690.pdf\" target=\"_blank\">PolyNovo to Commence Human Trial </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo to Commence Human Trial</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1073489.pdf\" target=\"_blank\">PolyNovo’s US Collaboration Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo’s US Collaboration Update</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1065480.pdf\" target=\"_blank\">Update on US Partner Collaboration </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update on US Partner Collaboration</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2011</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=779&amp;nav_cat_id=210&amp;nav_top_id=58\" target=\"_blank\">New Applications for AOD9604</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>New Applications for AOD9604</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/Successful_Proof_of_Concept_for_Synthetic_Skin.pdf\" target=\"_blank\">Successful Proof of Concept for Synthetic Skin</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Successful Proof of Concept for Synthetic Skin</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1030228.pdf\" target=\"_blank\">Changes to Executive Structure</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Changes to Executive Structure</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1030275.pdf\" target=\"_blank\">Cancellation of Options </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Cancellation of Options</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting_and_Proxy_Form.pdf\" target=\"_blank\">Notice of Annual General Meeting and Proxy Form</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Notice of Annual General Meeting and Proxy Form</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/Major_Milestone_for_PolyNovo_and_NovoSorbTM.pdf\" target=\"_blank\">Major Milestone for PolyNovo and NovoSorbTM : First Human Study</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Major Milestone for PolyNovo and NovoSorbTM : First Human Study</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1007282.pdf\" target=\"_blank\">Operational Update and Financial Result Guidance </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Operational Update and Financial Result Guidance</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1899_Calzada_Shareholder_Newsletter_FINAL1.pdf\" target=\"_blank\">Calzada Shareholder Newsletter</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada Shareholder Newsletter</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/980299.pdf\" target=\"_blank\">Metabolic’s Osteoporosis Patent Allowed in US </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic’s Osteoporosis Patent Allowed in US</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/979227.pdf\" target=\"_blank\">Phosphagenics Bodyshaper Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Phosphagenics Bodyshaper Update</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/POH_Annoucnement.pdf\" target=\"_blank\">Phosphagenics to launch new cellulite cosmetics</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Phosphagenics to launch new cellulite cosmetics</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/967193.pdf\" target=\"_blank\">Calzada Transfers Neural Regeneration Peptides Technology</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada Transfers Neural Regeneration Peptides Technology</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/963942.pdf\" target=\"_blank\">First PolyNovo Patent Allowed in US</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>First PolyNovo Patent Allowed in US</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/962630.pdf\" target=\"_blank\">Burn Surgeon John Greenwood receives the inaugural Burke/Yannas prize at the American Burn Association conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Burn Surgeon John Greenwood receives the inaugural Burke/Yannas prize at the American Burn Association conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/963942.pdf\" target=\"_blank\">Board Changes</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Board Changes</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/953112.pdf\" target=\"_blank\">PolyNovo successfully completes pivotal animal study on burns device</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo successfully completes pivotal animal study on burns device</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/947775.pdf\" target=\"_blank\">Results for the Half Year Ended 31 December 2010</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Half year results and accounts</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=760&amp;nav_cat_id=210&amp;nav_top_id=58\">AOD9604 shows positive results in human stem cell assay for bone growth</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AOD9604 shows positive results in human stem cell assay for bone growth</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=757&amp;nav_cat_id=210&amp;nav_top_id=58\">Feasibility study extended by 12 months</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Feasibility study extended by 12 months</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=758&amp;nav_cat_id=210&amp;nav_top_id=58\">Update of Black Market Sales of AOD</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update of Black Market Sales of AOD</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=759&amp;nav_cat_id=210&amp;nav_top_id=58\">Appointment of Dr Stewart Washer</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appointment of Dr Stewart Washer</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2010</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=754&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada sells Avexa Shares</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada sells Avexa Shares</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=753&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada signs Licensing Agreement with Phosphagenics</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada signs Licensing Agreement with Phosphagenics</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=752&amp;nav_cat_id=205&amp;nav_top_id=58\">Dr John Chiplin appointed to Calzada Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr John Chiplin appointed to Calzada Board</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=751&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada - 2010 Annual Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada - 2010 Annual Report</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=750&amp;nav_cat_id=205&amp;nav_top_id=58\">Notice of Annual General Meeting</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Notice of Annual General Meeting</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=745&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada responds to claims made by Avexa Limited</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada responds to claims made by Avexa Limited</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=744&amp;nav_cat_id=205&amp;nav_top_id=58\">Email correspondence with Avexa – combining Avexa EGM with Avexa AGM </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Email correspondence with Avexa – combining Avexa EGM with Avexa AGM</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=746&amp;nav_cat_id=205&amp;nav_top_id=58\">Phosphagenics exercises option to licence AOD9604 to develop topical cellulite product</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Phosphagenics exercises option to licence AOD9604 to develop topical cellulite product</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=743&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada to vend Metabolic into ATOS Wellness </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada to vend Metabolic into ATOS Wellness</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=742&amp;nav_cat_id=205&amp;nav_top_id=58\">Change of Director\'s Interest NoticeChange of Director\'s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=741&amp;nav_cat_id=205&amp;nav_top_id=58\">Replacement response to the Age newspaper articleReplacement response to the Age newspaper article</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Replacement response to the Age newspaper article</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=740&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada responds to The Age newspaper article</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada responds to The Age newspaper article</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=739&amp;nav_cat_id=205&amp;nav_top_id=58\">Half Year Report and Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Half Year Report and Accounts</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=738&amp;nav_cat_id=205&amp;nav_top_id=58\">Final Director\'s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=737&amp;nav_cat_id=205&amp;nav_top_id=58\">Initial Director\'s Interest Notice </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=736&amp;nav_cat_id=205&amp;nav_top_id=58\">Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=735&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada moves to 100% ownership of PolyNovo </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada moves to 100% ownership of PolyNovo</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=734&amp;nav_cat_id=205&amp;nav_top_id=58\">Change in substantial holding Change in substantial holding </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change in substantial holding</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=733&amp;nav_cat_id=205&amp;nav_top_id=58\">Becoming a substantial holder from XCD </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Becoming a substantial holder from XCD</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2009</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=715&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\'s Interest Notice - Oliver Stevens</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice - Oliver Stevens</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=714&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\' Interest Notice - David Franklyn</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\' Interest Notice - David Franklyn</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=713&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\'s Interest Notice - George Cameron-Dow</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice - George Cameron-Dow</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=712&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\'s Interest Notice - David Kenley</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice - David Kenley</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=711&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Changes to Company Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Changes to Company Board</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=710&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Appendix 3Z - I Kirkwood</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3Z - I Kirkwood</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=709&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Appendix 3Z - Paul Lappin</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Directors interest Notice - P Lappin</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=708&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">7 April 09 Initial Substantial Holder - Entrust </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>7 April 09 Initial Substantil Holder - Entrust picks up 19.81%</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=707&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">7 Aprl 09 - Ceasing o be a substantal holder - Tony Moore</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Ceasingto be a substantil holder - Tony Moore</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=706&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">2 April 2009 Substantial Shareholder Notice - Tony Moore</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Tony Moore purchases substantial shareholding</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=705&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">31 March 2009 Final Directors Interest Notice 3Z F. Brazil</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>31 March 2009 Final Directors Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=704&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Changes to Metabolic Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Board Changes</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=703&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">10th March 2009 Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Options expiry</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=702&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">10 March 2009 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=701&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">6 March 2009 - Changes to PolyNovo Board and Management</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=700&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">4 March 2009 - First NovoSorb Patent Granted in Australia</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=699&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">26 February 2009 - Appendix 4D Half Yearly Report and Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=698&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">23 February 2009 - Changes to Metabolic Chairman and Company Secretary</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=697&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">23 February 2009 - Appendix 3Z - Final Director\'s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=696&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">2 February 2009 - Changes to Metabolic and PolyNovo Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=695&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">30 January 2009 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=694&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">9th January 2009 - Change of Registered Office and Place of Business Address</a></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2008</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=693&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">18th December 2008 - Metabolic invests $3.5 million for 60% of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has invested a total of $3.5 million in exchange for 60 per cent of PolyNovo Biomaterials Ltd.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=692&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">3rd December 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=691&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st December 2008 - Proposed PolyNovo acquisition terminated</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement advises that the proposed acquisition of PolyNovo Biomaterials Ltd has been terminated.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=690&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th November 2008 - Annual General Meeting Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement includes a summary of voting on each resolution put to shareholders at the 2008 Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=689&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th November 2008 - 2008 Annual General Meeting Presentation</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the AGM presentation given to shareholders at the 2008 Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=688&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th November 2008 - 2008 AGM Chairman\'s Address</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the Chairman\'s address given to shareholders at the 2008 Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=687&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">31 October 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=686&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th October 2008 - 2008 Notice of Annual General Meeting and Sample Proxy Form</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The business before Metabolic\'s 2008 Annual General Meeting includes the usual agenda items as well as resolutions relating to the proposed acquisition of PolyNovo Limited.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=685&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">2nd October 2008 - Share Sale Agreement signed for acquisition of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Share Sale Agreement signed for acquisition of PolyNovo</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=682&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">26th September 2008 - Metabolic Annual Report 2008</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic\'s 2008 Annual Report</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=681&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">5th September 2008 - Update on acquisition of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update on the proposed acquisition of PolyNovo</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=680&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">21st August 2008 - Appendix 4E Preliminary Final Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=679&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">4 August 2008 - Letter to Shareholders regarding the acquisition of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Letter to Shareholders of Metabolic outlining the proposed transaction to acquire PolyNovo Biomaterials Ltd.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=678&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">18th July 2008 - Corporate Presentation: Metabolic\'s acquisition of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>A series of slides with further detail regarding the acquisition of PolyNovo.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=677&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">18th July 2008 - Metabolic signs binding term sheet for PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has signed a binding term sheet to acquire 100% of PolyNovo from its two shareholders, Xceed and CSIRO.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=676&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st July 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=675&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">20th June 2008 - Update on research and future direction </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update on research and future direction</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=674&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">10 June 2008 - Response to Price Query</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=673&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">27th May 2008 - Appendix 3Y</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=672&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">23rd May 2008 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice for Mr Franklyn Brazil</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=671&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">23rd May 2008 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice for Mr Paul Lappin</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=667&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">21st May 2008 - Appointment of Non-Executive Directors</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic appoints two non-executive directors, Mr Franklyn Brazil and Mr Paul Lappin.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=666&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">14th May 2008 - Appendix 3Y</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=665&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">13th May 2008 - Notice of initial substantial holder - Brazil Farming Pty Ltd</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=664&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">13th May 2008 - Iain Kirkwood ceases to be a substantial shareholder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Iain Kirkwood advising that he has ceased as a substantial holder of Metabolic.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=663&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">12th May 2008 - Polychip Pharmaceuticals Limited ceases to be a substantial shareholder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Polychip Pharmaceuticals Limited (Circadian) advising the company has ceased as a substantial holder of Metabolic.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=662&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">9th May 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=661&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st May 2008 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice for Mr Iain Kirkwood</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=660&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">30th April 2008 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Dr Roland Scollay</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=659&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">30th April 2008 - Appointment of Non-Executive Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Mr Iain Kirkwood has been appointed as a non-executive director of Metabolic. Mr Kirkwood is an experienced private consultant, investor and non-executive director (of both listed and unlisted public companies).</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=658&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">29th April 2008 - Dr Roland Scollay steps down from Metabolic Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay resigned as a director of the Metabolic Board. Dr Scollay will work with the Board to ensure a smooth transition and will then be leaving the Company to pursue other interests.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=657&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">8th April 2008 - Acorn ceased to be a substantial shareholder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Acorn Capital Limited advising the company has ceased as a substantial holder of Metabolic.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=656&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">27th February 2008 - Half Yearly Report / Half Yearly Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Financial report for the six months ended 31 December 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=653&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st February 2008 - Quarterly Investor Update </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the fourth quarter of 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=651&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">15th January 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2007</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=649&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th December 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=636&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">2nd November 2007 - 2007 AGM: Voting Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement includes a summary of voting on each resolution put to shareholders at the 2007 Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=635&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">2nd November 2007 - 2007 AGM - Chairman\'s Address and AGM presentation</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the full Chairman\'s address and AGM presentation given to shareholders on 2 November 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=634&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">31st October 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=632&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">19th October 2007 - Quarterly Investor Update Q307 </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the third quarter of 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=631&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">15th October 2007 - NRP Update </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic\'s joint project with Neuren Pharmaceuticals Limited to develop NRPs has made progress. A NRP compound has been shown to be effective in animal models of motor neuron disease and peripheral neuropathy.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=629&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">28th September 2007 - 2007 Annual Report and Notice of Annual General Meeting </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic\'s 2007 Annual Report and Notice of Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=628&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">25th September 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=627&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">20th September 2007 - Update on Oral Peptide Delivery Platform</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains an update on Metabolic\'s proprietary Oral Peptide Delivery Platform including new animal data and future direction.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=626&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">10th September 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Dr Arthur Emmett</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=625&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">10th September 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Dr Chris Belyea</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=624&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">31st August 2007 - 2007 Appendix 4E - Preliminary Final Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic\'s Preliminary Final Report for the year ended 30 June 2007, including the Appendix 4E.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=623&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">30th August 2007 - Resignation of Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the resignation of Chief Scientific Officer, Dr Chris Belyea.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=622&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">28th August 2007 - Resignation of Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the resignationof Non-Executive Director Dr Arthur Emmett</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=621&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">17th August 2007 - Changes to Annual Report legislation </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This notification was sent to Metabolic shareholders to explain new legislation changing the default option for receiving annual reports to be via a company\'s website.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=620&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">16th August 2007 - New Substantial Holder - Niako </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Niako Investments Pty Ltd advising the company has become a substantial holder of Metabolic, with total shares representing 5.75% of issued capital as at 16th August 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=619&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">14th August 2007 - Metabolic discontinues clinical trial programme for neuropathic pain drug, ACV1</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has received new data regarding the ability of ACV1 to block the human a9a10 nicotinic acetylcholine receptor, the probable target of ACV1. The Company will focus its research and development on the Oral Peptide Delivery Platform, and will continue to search for new drugs to in-license or acquire.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=617&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">25th July 2007 - Quarterly Investor Update Q207</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the second quarter of 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=616&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">6th July 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Dr Evert Vos</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=614&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">6th July 2007 - Resignation of Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the resignation of Non-Executive Director Evert Vos.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=612&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">28th June 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=611&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">24th May 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=610&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">16th May 2007 - Response to Price Query</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=608&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">18th April 2007 - Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=605&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">12th April 2007 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=604&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">12th April 2007 - Director Appointment</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the appointment of Mr Don Clarke as a Non-Executive Director.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=603&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=600&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Quarterly Investor Update Q107</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the first quarter of 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=599&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Mr Patrick Sutch</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=598&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Ms Robyn Baker</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=597&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">4th April 2007 - Changes to Metabolic Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the appointment of Mr Robert Stewart as Chairman and Non-Executive Director and the resignation of Non-Executive Directors, Mr Patrick Sutch and Ms Robyn Baker.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=595&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">26th March 2007 - Metabolic\'s pain drug ACV1 enters second Phase 2 human clinical trial</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic reported the commencement of a second ACV1 Phase 2A trial in patients with neuropathic pain as well as the results of a Phase 1 extension trial for the same drug.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=594&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">26th February 2007 - Half Yearly Report / Half Yearly Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Financial report for the six months ended 31 December 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=593&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">21st February 2007 - Shareholder Hotline</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Shareholders with questions regarding the OPTIONS Study are encouraged to call 1800 255 018 which is a free call within Australia. Shareholders outside Australia should call +61 2 8256 3388.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=592&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">21st February 2007 - OPTIONS Study Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The Phase 2B trial results for Metabolic\'s drug, AOD9604, do not support the commercial viability of the drug as a treatment for obesity. Development of the drug for this condition is terminated.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=591&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">19th February 2007 - Request for trading halt</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has been placed in a trading halt pending an announcement in relation to the results of its Phase 2B OPTIONS Study.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=590&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">8th February 2007 - Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=589&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">25th January 2007 - Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=587&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">22nd January 2007 - Quarterly Investor Update </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the fourth quarter of 2006.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=586&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">12th January 2007 - Notice of Change of Interests of Substantial Holder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Circadian Technologies regarding the dilution of their substantial holding due to the recent share placement by Metabolic and the exercise of options.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=585&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">11th January 2007 - Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=584&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th January 2007 - Response to ASX Query</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This letter from Metabolic is in response to a share price query from the ASX</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2006</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=583&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">28th December 2006 - Appendix 3B 28th December 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=582&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">20th December 2006 - Open Briefing with CEO of Metabolic </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced this morning the transcript from an Open Briefing with the CEO of Metabolic, regarding the completion of the Phase 2B OPTIONS Study for obesity drug AOD9604.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=581&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">19th December 2006 - Broadcast Radio Interview 19th December 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>19th December 2006 - Audio Broadcast - CEO interviewed by Boardroom Radio: Dr Roland Scollay\'s interview by Boardroom radio has been webcast and is available at www.boardroomradio.com</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=579&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">18th December 2006 - Options Study END December 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The Phase 2B OPTIONS Study for Obesity drug AOD9604 has been completed on time and within budget. The number of completing subjects comfortably exceeds the statistical design goal. Results of the trial are expected to be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=580&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">18th December 2006 - Form 604 Notice of change of Interests of Substantial Holder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>7th December 2006 - Form 604: Notice of Change of Interests of Substantial Holder Official notice from Acorn Capital Limited regarding the change in their substantial holding of Metabolic shares.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=578&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">15th December 2006 Notice under section 708A (5)(e)</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=577&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">15th December 2006 Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=576&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">7th December 2006 - Capital Raising December 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic raised A$10.5 million through a share placement to predominantly existing institutional shareholders. The funds raised will accelerate the oral version of ACV1 for neuropathic pain, the Oral Peptide Delivery Platform and planning for a Phase 3 obesity trial.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=575&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">7th December 2006 - Metabolic placed in trading halt</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=574&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">7th December 2006 - Metabolic\'s request for trading halt</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=573&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">5th December 2006 - Open Briefing with CEO of Metabolic</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the transcript from an Open Briefing with the CEO of Metabolic, covering the Company\'s lead projects and strategy.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=572&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">29th November 2006 - ACV1 Clinical Trials Update November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced that the Phase 2A programme for ACV1, for neuropathic pain is progressing well. The first group of patients in the first of two trials in this Phase 2A programme have been treated and the second trial is due to commence in Q107. Additionally, a separate trial to test safety of a higher dose level of ACV1 commenced in Q406.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=571&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th November 2006 - Options Study Update - 27 November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced that more than 300 subjects have completed the Phase 2B OPTIONS Study so far. The last subject will complete the trial in December 2006 with results expected to be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=570&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th November 2006 - Domestic Roadshow November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay, CEO of Metabolic, will be meeting with various domestic brokers and analysts this week. This roadshow presentation provides an update on the Company\'s development and strategy.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=569&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd November 2006 - ACV1 PreClinical Update November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has made further progress with the oral version of its neuropathic pain drug ACV1. In addition, an independent study conducted in the US has identified important information about its mechanism of action.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=567&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th November 2006 - Appendix 3Y 17th November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3Y 17th November 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=566&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th November 2006 - Appendix 3Y 17th November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3Y 17th November 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=565&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th November 2006 - Appendix 3B 17th November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B 17th November 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=561&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th October 2006 - 2006 AGM: Voting Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement includes a summary of voting on each resolution put to shareholders at the Company\'s 2006 AGM.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=560&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th October 2006 - New Constitution</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Shareholders of Metabolic approved a new Constitution on 27 October 2006. The complete Constitution is included in this announcement.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=559&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th October 2006 - 2006 AGM Chairman\'s Address and CEO\'s presentation</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement includes the formal address given by the Chairman to shareholders at the Company\'s 2006 AGM and a presentation by the CEO.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=558&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd October 2006 - Change in Substantial Holding</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Monash Investments regarding the change in their substantial holding of Metabolic shares.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=556&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th October 2006 - Response to ASX Query</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This letter from Metabolic is is response to a share price query from the ASX.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=549&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th October 2006 - Quarterly Investor Update - 17 October 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the third quarter of 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=548&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">12th October 2006 - Market Presentation - Intersuisse Conference October 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at the Intersuisse Life Sciences Forum (London) to increase awarenenss of Metabolic in the UK and Europe. The slide-show presentation provides an up-to-date overview of Metabolic\'s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=546&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">9th October 2006 - Appendix 3B 9th October 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B 9th October 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=547&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">5th October 2006 - Obesity Trial Update - October 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The first 100 subjects have completed the Phase 2B OPTIONS Study including 24 weeks of daily oral dosing of obesity drug, AOD9604. The last subject will complete the trial in December 2006 with results expected to be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=545&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">28th September 2006 - UBS Global Life Sciences Conference - presentation by Dr Roland Scollay</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at the UBS Global Life Sciences Conference in New York to increase awareness of Metabolic in the US. The slide-show presentation provides and up-to-date overview of Metabolic\'s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=544&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th September 2006 - Metabolic\'s neuropathic pain drug, ACV1, enters Phase 2A clinical trials</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic commenced the first trial in its Phase 2A programme for ACV1, for the treatment of neuropathic pain. This first trial will target neuropathic sciatic pain and results are expected to be announced during the first six months of 2007 (H107).</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=542&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">26th September 2006 - 2006 Annual Report and Notice of Annual General Meeting</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the Company’s 2006 Annual Report, Notice of Annual General Meeting and sample voting form.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=557&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">1st September 2006 - Quarterly rebalance of S&amp;P/ASX Indices</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice that Metabolic has been removed from the S&amp;P/ASX 300 Index</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=539&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th July 2006 - Quarterly Investor Update July 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the second quarter of 2006.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=538&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">19th July 2006 - Obesity trial update: First subject completes treatment</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The first few subjects have completed treatment including 24 weeks of daily oral dosing of AOD9604. The last subject will complete the trial in December 2006 with results expected to be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=537&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">11th July 2006 - NRP collaboration: Research on nerve protection compounds published in science journal</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Research on Neural Regeneration Peptides (NRPs) has been published in the international science journal, \'Experimental Cell Research\'. NRPs have previously shown promising effects in a rat model of nerve damage. Formal preclinical development of NRPs expected to commence in 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=520&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">21 June 2006 - Metabolic\'s osteoporosis drug: additional animal data support further beneficial effects of AOD9604</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Additional animal data indicate AOD9604 has beneficial effects on trabecular bone as well as corticol bone. Two further animal studies are underway to investigate the optimal dose of AOD9604 for osteoporosis; and the possible role of the drug in treatment of osteoporosis (in addition to prevention, as previously determined).</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=465&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">14th June 2006 - Life Sciences (USA) Presentation</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at the Pacific Growth Equities\' 2006 Life Sciences Growth Conference in San Francisco to increase awareness of Metabolic in the USA. Slide-show presentation provides an up-to-date overview of Metabolic\'s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=466&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd May 2006 - Roadshow Presentation - company update May 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay met with several analysts and institutions to increase local awareness of Metabolic. Slide-show presentation provides an up-to-date overview of Metabolic’s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=467&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">10th May 2006 - Quarterly Investor Update 10 May 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Summary of Company news during the first quarter of 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=468&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">8th May 2006 - Audio Broadcast - CEO interviewed by Boardroom Radio</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay’s interview by Boardroom radio has been audio webcast and is available at www.boardroomradio.com</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=469&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">2nd May 2006 - Metabolic completes enrolment for obesity clinical trial ahead of schedule</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>536 subjects have been enrolled in the Phase 2B trial, known as the “OPTIONSEstudy for obesity drug, AOD9604. This trial will now end in December 2006 and results will be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=470&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">5th April 2006 - Metabolic CEO to present at US biotech conferences</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at various biotechnology conferences and expos in the USA. Slide-show presentation provides an up-to-date overview of Metabolic’s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=471&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">30th March 2006 - Change in Substantial Holding</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Monash Investments regarding the dilution of their substantial holding due to the recent share placement by Metabolic</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=472&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">24th March 2006 - Appendix 3B - New issue of options</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>New issue of shares and options, pursuant to the private placement on 21 March 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=473&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">24th March 2006 - Notice under section 708A (5)(e)</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official cleansing statement Eno outstanding disclosures</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=474&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">21st March 2006 - Metabolic completes A$13 million share placement</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Private placement of 30.2 million shares to international and Australian institutional investors. Funds raised will advance Metabolic’s drug pipeline for pain, osteoporosis and oral delivery platform for peptides.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=475&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th March 2006 - Trading Halt 17th March 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official trading halt request by Metabolic</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=476&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">6th March 2006 - Clinical Trials Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The Phase 2B trial for obesity drug, AOD9604 is progressing well, on schedule, and preparation is underway for the Phase 2A program for ACV1, for pain</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=477&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th February 2006 - Half Yearly Report / Half Yearly Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Financial report for the six months ended 31 December 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=478&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">16th February 2006 - NRP Update: Metabolic and Neuren report promising animal efficacy data in collaborative project </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>New compound, Neural Regeneration Peptide: NNZ-4921, has been shown to prevent or reverse peripheral neuropathy (nerve damage) in an animal study</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=479&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">15th February 2006 - CEO to present at BioCEO &amp; Investor Conference in New York</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay participated as a panelist at the BioCEO &amp; Investor Conference in New York, and gave a presentation on Metabolic’s lead drugs AOD9604 for obesity, including details of previous trial results, and a potential new use for the drug.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=480&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">8th February 2006 - Investor Roadshow Presentation - USA</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at the Biotechnology Organisation (BIO) Conference and met with several analysts and institutions to increase awareness of Metabolic in the USA. Slide show presentation provides an up-to-date overview of Metabolic’s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=481&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">6th February 2006 - Metabolic Quarterly Investor Update Number 12 </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Summary of Company news during the fourth quarter of 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=482&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">1st February 2006 - Appendix 3Y - Change of Director’s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay was granted 1,000,000 options, pursuant to the Metabolic Employee Share Option Plan, approved by shareholders at the 2005 Annual General Meeting on 28 October 2005.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=483&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">1st February 2006 - Appendix 3B - New issue of options </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>New issue of 1,000,000 MBPAQ unquoted options, pursuant to the Metabolic Employee Share Option Plan, approved by shareholders at the 2005 Annual General Meeting on 28 October 2005.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=484&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">31st January 2006 - Potential new use in osteoporosis adds value to Metabolic\'s obesity drug</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Animal study: Orally delivered drug, AOD9604, shows an effect in preventing bone loss and maintaining bone quality in a rat model of osteoporosis.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=485&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd January 2006 - Update on Phase 2B dosing trial for obesity drug</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The low dose, Phase 2B trial, known as the “OPTIONSEstudy is proceeding on schedule with recruitment on track an all ethics approvals obtained.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2005</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=428&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">18th November 2005 - ASX Appendix 3Y Change of Director\'s Interest - A Emmett</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3Y Change of Director\'s Interest - A Emmett</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=427&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">16th November 2005 - ACV1 Phase 1 results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ACV1 Phase 1 results</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=425&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">4th November 2005 - CEO Presentation Rodman Renshaw Conference 7 November 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>CEO Presentation Rodman Renshaw Conference 7 November 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=423&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">2nd November 2005 - ASX Appendix 3B 2nd November 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3B 2nd November 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=422&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">31st October 2005 - ASX Appendix 3X 31st October 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3X 31st October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=419&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th October 2005 - Chairman\'s Address and CEO Presentation at AGM 28th October 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Chairman\'s Address and CEO Presentation at AGM 28th October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=421&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th October 2005 - Metabolic AGM Results 28 October 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic AGM Results 28 October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=420&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th October 2005 - Amended Constitution of Metabolic Pharmaceuticals 28 October 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Amended Constitution of Metabolic Pharmaceuticals 28 October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=418&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">26th October 2005 - Metabolic Quarterly Investor Update </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic Quarterly Investor Update - 26 October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=417&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th October 2005 - Metabolic ranks number 1 as Australia\'s top innovator</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic ranks number 1 as Australia\'s top innovator</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=416&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">19th October 2005 - Metabolic CEO to present to Health Care and Life Science Conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic CEO to present to Health Care and Life Science Conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=433&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">22nd December 2005 - ASX Appendix 3Y R Scollay</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3Y R Scollay</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=412&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">18th October 2005 - Metabolic starts next clinical trial of obesity drug</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic starts next clinical trial for obesity drug</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=415&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">18th October 2005 - VP Clinical Development Presentation at NAASO Conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>VP Clinical Development Presentation at NAASO Conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=409&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th October 2005 - Appointment of Non-Executive Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appointment of Non-Executive Director</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=404&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">27th September 2005 Release of Securities from Escrow - Monash Investment Holdings P/L</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Release of Securities from Escrow - Monash Investment Holdings P/L</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=432&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">22nd December 2005 - ASX Appendix 3Y C Belyea</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3Y C Belyea</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=403&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">7th September 2005 - Metabolic Pharmaceuticals CEO to present at biotechnology conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic Pharmaceuticals CEO to present at biotechnology conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=402&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">1st September 2005 - Change of Director\'s Interest - R Scollay</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest - R Scollay</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=401&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">26th August 2005 App 4E Preliminary Final Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Preliminary Final Report</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=400&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd August 2005 - Appointment of new CFO</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appointment of new CFO</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=431&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">22nd December 2005 - ASX Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3B</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=399&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">15th August 2005 - Metabolic ACV1 Update 15 August 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic ACV1 Update 15th August 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=398&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">8th August 2005 - ASX Appendix 3B 8th August 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B - 8th August 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=395&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th Aug 2005 - Change of Director\'s Interest - A Emmett</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest - A Emmett</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=396&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th Aug 2005 - Change of Director\'s Interest - C Belyea</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest - C Belyea</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=397&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th Aug 2005 - Change of Director\'s Interest - E Vos</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest - E Vos</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=390&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th July 2005 - ASX Appendix 3B 28th July 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B - 28th July 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=430&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">25th November 2005 - ASX Appendix 3Y Change in Director\'s Interest - R Baker</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3Y Change in Director\'s Interest - R Baker</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=386&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">21st July 2005 - SPP Announcement </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Share Purchase Plan Announcement 21st July 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=385&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th July 2005 - Investor Update 5th July 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Investor Update 5th July 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=384&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th June 2005 - Notice under Section 708A of the Corps Act</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Notice under Section 708A of the Corps Act</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=383&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th June 2005 - Share Purchase Plan Offer to Shareholders</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Share Purchase Plan Offer to Shareholders</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=382&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th June 2005 - VP Corporate Development Position</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>VP Corporate Development Position</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=429&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th November 2005 - ASX Appendix 3Y Change in Director\'s Interest - P Sutch</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3Y Change in Director\'s Interest - P Sutch</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=555&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd June 2005 - Change in Substantial Holding</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=381&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd June 2005 - Appendix 3B 23rd June 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B - 23rd June 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=380&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd June 2005 - ACV1 Phase 1 Clinical Trial Commences</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ACV1 Phase 1 Clinical Trial Commences</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=377&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">14th June 2005 - Placement and SPP Offer</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Placement and SPP Offer</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=378&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">14th June 2005 - AusIndustry \"Commercial Ready\" Grant for ACV1</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AusIndustry \"Commercial Ready\" Grant for ACV1</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=379&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">14th June 2005 - Conference Presentations June 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Conference Presentations June 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=376&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">3rd June 2005 - AOD9604 Obesity Drug Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AOD9604 Obesity Drug Update 3rd June 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=370&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">1st June 2005 - Metabolic establishes ADR program</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic Pharmaceuticals Ltd establishes ADR Program</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=366&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">20th May 2005 - Response to ASX Query re: Share Price</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Response to ASX Query re: Share Price - 20th May 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=364&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">2nd May 2005 - ACV1 Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ACV1 Update 2nd May 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=362&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">20th April 2005 AOD9604 Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AOD9604 Update 20th April 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=360&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">8th March 2005 - Investor Update 8th March 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Investor Update 8th March 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=359&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">3rd March 2005 - Neuren and Metabolic Development Collaboration March 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Neuren and Metabolic Development Collaboration March 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=358&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd February 2005 US Presentations February 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>US Presentations February 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=357&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">21st February 2005 - Half Yearly Report / Half Yearly Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Half Yearly Report / Half Yearly Accounts</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=355&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">10th February 2005 - CEO to speak on Obesity Panel at BIO CEO Conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>CEO to speak on Obesity Panel at BIO CEO Conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=354&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th January 2005 Metabolic appoints new Chief Executive Officer</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic appoints new Chief Executive Officer</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=353&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">13th January 2005 - ASX CEO Position</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>CEO Position</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2004</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=506&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">23rd December 2004 - ASX Resignation of Company Secretary</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Resignation of Company Secretary</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=505&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">17th December 2004 - ASX Change in Director\'s Interest</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change in Director\'s Interest</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=504&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">17th December 2004 - ASX Response to Market Comments</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Response to Market Comments 17th December 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=503&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">15th December 2004 - ASX Appendix 3B 15th November 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3B 15th November 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=502&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">13th December 2004 - AOD9604 Phase2b Clinical Trial Successful</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AOD9604 Phase 2b Clinical Trial Successful</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=501&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">13th December 2004 Successful trial results for world-first obesity drug</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Successful trial results for world-first obesity drug</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=500&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">9th December 2004 - ASX Trading Halt</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Trading Halt - 9th December 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=499&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">29th November 2004 - AOD9604 Update on Clinical Trial Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update on Clinical Trial Results 29th November 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=498&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">16th November 2004 - Response to ASX Query re: Share Price</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Response to ASX Query re: Share Price</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=497&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">4th November 2004 - ASX Appendix 3B 4th November 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B 4th November 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=496&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">29th October 2004 - ASX AGM Results 29th October 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AGM Results 29th October 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=495&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">29th October 2004 - ASX Chairman\'s Address AGM 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Chairman\'s Address AGM 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=494&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">30th September 2004 - Release of securities from voluntary escrow</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Release of securities from voluntary escrow</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=493&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">23rd September 2004 - 2004 Annual Report and Notice of AGM</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>2004 Annual Report and Notice of AGM</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=492&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">22nd September 2004 Investor Update - September 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Investor Update - September 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=491&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">20th September 2004 Completion of dosing in obesity trials</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Completion of dosing in obesity trials</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=490&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">24th August 2004 - Preliminary Final Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 4E - Preliminary Final Report</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=489&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">6th July 2004 - Increasing awareness in US markets in preparation for 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Increasing awareness in US markets in preparation for 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=488&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">5th July 2004 - Cohen Research Report July 2004</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Cohen Research Report July 2004</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=487&amp;nav_cat_id=166&amp;nav_top_id=58&amp;dsb=1745\">4th June 2004 - Investor Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Investor Update - 4th June, 2004</td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n</td>\r\n</tr>\r\n</tbody>\r\n</table>',	'ASX Announcements',	'',	'inherit',	'open',	'open',	'',	'141-revision-6',	'',	'',	'2012-06-18 06:32:16',	'2012-06-18 06:32:16',	'',	141,	'http://calzada-wp.urldock.com/141-revision-6/',	0,	'revision',	'',	0),
(321,	1,	'2012-06-28 01:06:17',	'2012-06-28 01:06:17',	'&nbsp;\r\n<table id=\"theTable3\" width=\"100%\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td colspan=\"2\"><img src=\"../../html/images/trans.gif\" alt=\"\" width=\"9\" height=\"1\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>\r\n<h2 class=\"feSubHeading\">ASX Releases</h2>\r\n</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"><img src=\"../../html/images/trans.gif\" alt=\"\" width=\"1\" height=\"10\" border=\"0\" /></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td id=\"theCell1\" width=\"100%\">\r\n<h3>ASX Releases 2012</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/132F042F2012103A223A30PM.pdf\">PolyNovo human Trial Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo human Trial Update</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/132F042F2012103A223A05PM.pdf\">AOD positive in Cartilage and Muscle Repair</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AOD positive in Cartilage and Muscle Repair</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/132F042F2012103A213A23PM.pdf\">PolyNovo Commences Second Human Trial</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo Commences Second Human Trial</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1074690.pdf\" target=\"_blank\">PolyNovo to Commence Human Trial </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo to Commence Human Trial</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1073489.pdf\" target=\"_blank\">PolyNovo’s US Collaboration Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo’s US Collaboration Update</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1065480.pdf\" target=\"_blank\">Update on US Partner Collaboration </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update on US Partner Collaboration</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2011</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/AOD9604.pdf\" target=\"_blank\">New Applications for AOD9604</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>New Applications for AOD9604</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/Successful_Proof_of_Concept_for_Synthetic_Skin.pdf\" target=\"_blank\">Successful Proof of Concept for Synthetic Skin</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Successful Proof of Concept for Synthetic Skin</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1030228.pdf\" target=\"_blank\">Changes to Executive Structure</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Changes to Executive Structure</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1030275.pdf\" target=\"_blank\">Cancellation of Options </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Cancellation of Options</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/Notice_of_Annual_General_Meeting_and_Proxy_Form.pdf\" target=\"_blank\">Notice of Annual General Meeting and Proxy Form</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Notice of Annual General Meeting and Proxy Form</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/Major_Milestone_for_PolyNovo_and_NovoSorbTM.pdf\" target=\"_blank\">Major Milestone for PolyNovo and NovoSorbTM : First Human Study</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Major Milestone for PolyNovo and NovoSorbTM : First Human Study</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1007282.pdf\" target=\"_blank\">Operational Update and Financial Result Guidance </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Operational Update and Financial Result Guidance</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/1899_Calzada_Shareholder_Newsletter_FINAL1.pdf\" target=\"_blank\">Calzada Shareholder Newsletter</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada Shareholder Newsletter</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/980299.pdf\" target=\"_blank\">Metabolic’s Osteoporosis Patent Allowed in US </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic’s Osteoporosis Patent Allowed in US</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/979227.pdf\" target=\"_blank\">Phosphagenics Bodyshaper Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Phosphagenics Bodyshaper Update</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/POH_Annoucnement.pdf\" target=\"_blank\">Phosphagenics to launch new cellulite cosmetics</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Phosphagenics to launch new cellulite cosmetics</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/967193.pdf\" target=\"_blank\">Calzada Transfers Neural Regeneration Peptides Technology</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada Transfers Neural Regeneration Peptides Technology</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/963942.pdf\" target=\"_blank\">First PolyNovo Patent Allowed in US</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>First PolyNovo Patent Allowed in US</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/962630.pdf\" target=\"_blank\">Burn Surgeon John Greenwood receives the inaugural Burke/Yannas prize at the American Burn Association conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Burn Surgeon John Greenwood receives the inaugural Burke/Yannas prize at the American Burn Association conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/963942.pdf\" target=\"_blank\">Board Changes</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Board Changes</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/953112.pdf\" target=\"_blank\">PolyNovo successfully completes pivotal animal study on burns device</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>PolyNovo successfully completes pivotal animal study on burns device</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"/wp-content/uploads/2012/06/947775.pdf\" target=\"_blank\">Results for the Half Year Ended 31 December 2010</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Half year results and accounts</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=760&amp;nav_cat_id=210&amp;nav_top_id=58\">AOD9604 shows positive results in human stem cell assay for bone growth</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>AOD9604 shows positive results in human stem cell assay for bone growth</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=757&amp;nav_cat_id=210&amp;nav_top_id=58\">Feasibility study extended by 12 months</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Feasibility study extended by 12 months</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=758&amp;nav_cat_id=210&amp;nav_top_id=58\">Update of Black Market Sales of AOD</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update of Black Market Sales of AOD</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=759&amp;nav_cat_id=210&amp;nav_top_id=58\">Appointment of Dr Stewart Washer</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appointment of Dr Stewart Washer</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2010</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=754&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada sells Avexa Shares</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada sells Avexa Shares</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=753&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada signs Licensing Agreement with Phosphagenics</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada signs Licensing Agreement with Phosphagenics</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=752&amp;nav_cat_id=205&amp;nav_top_id=58\">Dr John Chiplin appointed to Calzada Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr John Chiplin appointed to Calzada Board</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=751&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada - 2010 Annual Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada - 2010 Annual Report</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=750&amp;nav_cat_id=205&amp;nav_top_id=58\">Notice of Annual General Meeting</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Notice of Annual General Meeting</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=745&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada responds to claims made by Avexa Limited</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada responds to claims made by Avexa Limited</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=744&amp;nav_cat_id=205&amp;nav_top_id=58\">Email correspondence with Avexa – combining Avexa EGM with Avexa AGM </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Email correspondence with Avexa – combining Avexa EGM with Avexa AGM</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=746&amp;nav_cat_id=205&amp;nav_top_id=58\">Phosphagenics exercises option to licence AOD9604 to develop topical cellulite product</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Phosphagenics exercises option to licence AOD9604 to develop topical cellulite product</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=743&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada to vend Metabolic into ATOS Wellness </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada to vend Metabolic into ATOS Wellness</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=742&amp;nav_cat_id=205&amp;nav_top_id=58\">Change of Director\'s Interest NoticeChange of Director\'s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=741&amp;nav_cat_id=205&amp;nav_top_id=58\">Replacement response to the Age newspaper articleReplacement response to the Age newspaper article</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Replacement response to the Age newspaper article</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=740&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada responds to The Age newspaper article</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada responds to The Age newspaper article</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=739&amp;nav_cat_id=205&amp;nav_top_id=58\">Half Year Report and Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Half Year Report and Accounts</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=738&amp;nav_cat_id=205&amp;nav_top_id=58\">Final Director\'s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=737&amp;nav_cat_id=205&amp;nav_top_id=58\">Initial Director\'s Interest Notice </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=736&amp;nav_cat_id=205&amp;nav_top_id=58\">Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=735&amp;nav_cat_id=205&amp;nav_top_id=58\">Calzada moves to 100% ownership of PolyNovo </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Calzada moves to 100% ownership of PolyNovo</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=734&amp;nav_cat_id=205&amp;nav_top_id=58\">Change in substantial holding Change in substantial holding </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change in substantial holding</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?art_id=733&amp;nav_cat_id=205&amp;nav_top_id=58\">Becoming a substantial holder from XCD </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Becoming a substantial holder from XCD</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2009</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=715&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\'s Interest Notice - Oliver Stevens</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice - Oliver Stevens</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=714&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\' Interest Notice - David Franklyn</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\' Interest Notice - David Franklyn</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=713&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\'s Interest Notice - George Cameron-Dow</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice - George Cameron-Dow</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=712&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Initial Director\'s Interest Notice - David Kenley</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice - David Kenley</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=711&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Changes to Company Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Changes to Company Board</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=710&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Appendix 3Z - I Kirkwood</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3Z - I Kirkwood</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=709&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Appendix 3Z - Paul Lappin</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Directors interest Notice - P Lappin</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=708&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">7 April 09 Initial Substantial Holder - Entrust </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>7 April 09 Initial Substantil Holder - Entrust picks up 19.81%</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=707&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">7 Aprl 09 - Ceasing o be a substantal holder - Tony Moore</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Ceasingto be a substantil holder - Tony Moore</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=706&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">2 April 2009 Substantial Shareholder Notice - Tony Moore</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Tony Moore purchases substantial shareholding</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=705&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">31 March 2009 Final Directors Interest Notice 3Z F. Brazil</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>31 March 2009 Final Directors Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=704&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">Changes to Metabolic Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Board Changes</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=703&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">10th March 2009 Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Options expiry</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=702&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">10 March 2009 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=701&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">6 March 2009 - Changes to PolyNovo Board and Management</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=700&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">4 March 2009 - First NovoSorb Patent Granted in Australia</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=699&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">26 February 2009 - Appendix 4D Half Yearly Report and Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=698&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">23 February 2009 - Changes to Metabolic Chairman and Company Secretary</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=697&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">23 February 2009 - Appendix 3Z - Final Director\'s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=696&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">2 February 2009 - Changes to Metabolic and PolyNovo Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=695&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">30 January 2009 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../../html/s02_article/article_view.asp?id=694&amp;nav_cat_id=189&amp;nav_top_id=58&amp;dsb=1717\">9th January 2009 - Change of Registered Office and Place of Business Address</a></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2008</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=693&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">18th December 2008 - Metabolic invests $3.5 million for 60% of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has invested a total of $3.5 million in exchange for 60 per cent of PolyNovo Biomaterials Ltd.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=692&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">3rd December 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=691&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st December 2008 - Proposed PolyNovo acquisition terminated</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement advises that the proposed acquisition of PolyNovo Biomaterials Ltd has been terminated.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=690&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th November 2008 - Annual General Meeting Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement includes a summary of voting on each resolution put to shareholders at the 2008 Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=689&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th November 2008 - 2008 Annual General Meeting Presentation</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the AGM presentation given to shareholders at the 2008 Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=688&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th November 2008 - 2008 AGM Chairman\'s Address</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the Chairman\'s address given to shareholders at the 2008 Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=687&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">31 October 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=686&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">28th October 2008 - 2008 Notice of Annual General Meeting and Sample Proxy Form</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The business before Metabolic\'s 2008 Annual General Meeting includes the usual agenda items as well as resolutions relating to the proposed acquisition of PolyNovo Limited.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=685&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">2nd October 2008 - Share Sale Agreement signed for acquisition of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Share Sale Agreement signed for acquisition of PolyNovo</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=682&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">26th September 2008 - Metabolic Annual Report 2008</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic\'s 2008 Annual Report</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=681&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">5th September 2008 - Update on acquisition of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update on the proposed acquisition of PolyNovo</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=680&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">21st August 2008 - Appendix 4E Preliminary Final Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=679&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">4 August 2008 - Letter to Shareholders regarding the acquisition of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Letter to Shareholders of Metabolic outlining the proposed transaction to acquire PolyNovo Biomaterials Ltd.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=678&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">18th July 2008 - Corporate Presentation: Metabolic\'s acquisition of PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>A series of slides with further detail regarding the acquisition of PolyNovo.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=677&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">18th July 2008 - Metabolic signs binding term sheet for PolyNovo</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has signed a binding term sheet to acquire 100% of PolyNovo from its two shareholders, Xceed and CSIRO.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=676&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st July 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=675&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">20th June 2008 - Update on research and future direction </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Update on research and future direction</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=674&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">10 June 2008 - Response to Price Query</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=673&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">27th May 2008 - Appendix 3Y</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=672&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">23rd May 2008 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice for Mr Franklyn Brazil</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=671&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">23rd May 2008 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice for Mr Paul Lappin</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=667&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">21st May 2008 - Appointment of Non-Executive Directors</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic appoints two non-executive directors, Mr Franklyn Brazil and Mr Paul Lappin.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=666&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">14th May 2008 - Appendix 3Y</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=665&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">13th May 2008 - Notice of initial substantial holder - Brazil Farming Pty Ltd</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=664&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">13th May 2008 - Iain Kirkwood ceases to be a substantial shareholder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Iain Kirkwood advising that he has ceased as a substantial holder of Metabolic.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=663&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">12th May 2008 - Polychip Pharmaceuticals Limited ceases to be a substantial shareholder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Polychip Pharmaceuticals Limited (Circadian) advising the company has ceased as a substantial holder of Metabolic.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=662&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">9th May 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=661&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st May 2008 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice for Mr Iain Kirkwood</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=660&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">30th April 2008 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Dr Roland Scollay</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=659&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">30th April 2008 - Appointment of Non-Executive Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Mr Iain Kirkwood has been appointed as a non-executive director of Metabolic. Mr Kirkwood is an experienced private consultant, investor and non-executive director (of both listed and unlisted public companies).</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=658&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">29th April 2008 - Dr Roland Scollay steps down from Metabolic Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay resigned as a director of the Metabolic Board. Dr Scollay will work with the Board to ensure a smooth transition and will then be leaving the Company to pursue other interests.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=657&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">8th April 2008 - Acorn ceased to be a substantial shareholder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Acorn Capital Limited advising the company has ceased as a substantial holder of Metabolic.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=656&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">27th February 2008 - Half Yearly Report / Half Yearly Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Financial report for the six months ended 31 December 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=653&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">1st February 2008 - Quarterly Investor Update </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the fourth quarter of 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=651&amp;nav_cat_id=188&amp;nav_top_id=58&amp;dsb=1732\">15th January 2008 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2007</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=649&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th December 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=636&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">2nd November 2007 - 2007 AGM: Voting Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement includes a summary of voting on each resolution put to shareholders at the 2007 Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=635&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">2nd November 2007 - 2007 AGM - Chairman\'s Address and AGM presentation</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the full Chairman\'s address and AGM presentation given to shareholders on 2 November 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=634&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">31st October 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=632&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">19th October 2007 - Quarterly Investor Update Q307 </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the third quarter of 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=631&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">15th October 2007 - NRP Update </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic\'s joint project with Neuren Pharmaceuticals Limited to develop NRPs has made progress. A NRP compound has been shown to be effective in animal models of motor neuron disease and peripheral neuropathy.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=629&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">28th September 2007 - 2007 Annual Report and Notice of Annual General Meeting </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic\'s 2007 Annual Report and Notice of Annual General Meeting.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=628&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">25th September 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=627&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">20th September 2007 - Update on Oral Peptide Delivery Platform</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains an update on Metabolic\'s proprietary Oral Peptide Delivery Platform including new animal data and future direction.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=626&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">10th September 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Dr Arthur Emmett</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=625&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">10th September 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Dr Chris Belyea</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=624&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">31st August 2007 - 2007 Appendix 4E - Preliminary Final Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic\'s Preliminary Final Report for the year ended 30 June 2007, including the Appendix 4E.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=623&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">30th August 2007 - Resignation of Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the resignation of Chief Scientific Officer, Dr Chris Belyea.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=622&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">28th August 2007 - Resignation of Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the resignationof Non-Executive Director Dr Arthur Emmett</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=621&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">17th August 2007 - Changes to Annual Report legislation </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This notification was sent to Metabolic shareholders to explain new legislation changing the default option for receiving annual reports to be via a company\'s website.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=620&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">16th August 2007 - New Substantial Holder - Niako </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Niako Investments Pty Ltd advising the company has become a substantial holder of Metabolic, with total shares representing 5.75% of issued capital as at 16th August 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=619&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">14th August 2007 - Metabolic discontinues clinical trial programme for neuropathic pain drug, ACV1</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has received new data regarding the ability of ACV1 to block the human a9a10 nicotinic acetylcholine receptor, the probable target of ACV1. The Company will focus its research and development on the Oral Peptide Delivery Platform, and will continue to search for new drugs to in-license or acquire.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=617&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">25th July 2007 - Quarterly Investor Update Q207</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the second quarter of 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=616&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">6th July 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Dr Evert Vos</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=614&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">6th July 2007 - Resignation of Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the resignation of Non-Executive Director Evert Vos.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=612&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">28th June 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=611&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">24th May 2007 - Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=610&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">16th May 2007 - Response to Price Query</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=608&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">18th April 2007 - Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=605&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">12th April 2007 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=604&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">12th April 2007 - Director Appointment</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the appointment of Mr Don Clarke as a Non-Executive Director.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=603&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Appendix 3X</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Initial Director\'s Interest Notice</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=600&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Quarterly Investor Update Q107</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the first quarter of 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=599&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Mr Patrick Sutch</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=598&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th April 2007 - Appendix 3Z</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Final Director\'s Interest Notice for Ms Robyn Baker</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=597&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">4th April 2007 - Changes to Metabolic Board</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced the appointment of Mr Robert Stewart as Chairman and Non-Executive Director and the resignation of Non-Executive Directors, Mr Patrick Sutch and Ms Robyn Baker.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=595&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">26th March 2007 - Metabolic\'s pain drug ACV1 enters second Phase 2 human clinical trial</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic reported the commencement of a second ACV1 Phase 2A trial in patients with neuropathic pain as well as the results of a Phase 1 extension trial for the same drug.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=594&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">26th February 2007 - Half Yearly Report / Half Yearly Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Financial report for the six months ended 31 December 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=593&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">21st February 2007 - Shareholder Hotline</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Shareholders with questions regarding the OPTIONS Study are encouraged to call 1800 255 018 which is a free call within Australia. Shareholders outside Australia should call +61 2 8256 3388.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=592&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">21st February 2007 - OPTIONS Study Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The Phase 2B trial results for Metabolic\'s drug, AOD9604, do not support the commercial viability of the drug as a treatment for obesity. Development of the drug for this condition is terminated.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=591&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">19th February 2007 - Request for trading halt</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has been placed in a trading halt pending an announcement in relation to the results of its Phase 2B OPTIONS Study.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=590&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">8th February 2007 - Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=589&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">25th January 2007 - Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=587&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">22nd January 2007 - Quarterly Investor Update </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the fourth quarter of 2006.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=586&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">12th January 2007 - Notice of Change of Interests of Substantial Holder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Circadian Technologies regarding the dilution of their substantial holding due to the recent share placement by Metabolic and the exercise of options.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=585&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">11th January 2007 - Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=584&amp;nav_cat_id=176&amp;nav_top_id=58&amp;dsb=1736\">5th January 2007 - Response to ASX Query</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This letter from Metabolic is in response to a share price query from the ASX</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2006</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=583&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">28th December 2006 - Appendix 3B 28th December 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=582&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">20th December 2006 - Open Briefing with CEO of Metabolic </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced this morning the transcript from an Open Briefing with the CEO of Metabolic, regarding the completion of the Phase 2B OPTIONS Study for obesity drug AOD9604.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=581&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">19th December 2006 - Broadcast Radio Interview 19th December 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>19th December 2006 - Audio Broadcast - CEO interviewed by Boardroom Radio: Dr Roland Scollay\'s interview by Boardroom radio has been webcast and is available at www.boardroomradio.com</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=579&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">18th December 2006 - Options Study END December 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The Phase 2B OPTIONS Study for Obesity drug AOD9604 has been completed on time and within budget. The number of completing subjects comfortably exceeds the statistical design goal. Results of the trial are expected to be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=580&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">18th December 2006 - Form 604 Notice of change of Interests of Substantial Holder</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>7th December 2006 - Form 604: Notice of Change of Interests of Substantial Holder Official notice from Acorn Capital Limited regarding the change in their substantial holding of Metabolic shares.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=578&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">15th December 2006 Notice under section 708A (5)(e)</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=577&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">15th December 2006 Appendix 3B </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=576&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">7th December 2006 - Capital Raising December 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic raised A$10.5 million through a share placement to predominantly existing institutional shareholders. The funds raised will accelerate the oral version of ACV1 for neuropathic pain, the Oral Peptide Delivery Platform and planning for a Phase 3 obesity trial.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=575&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">7th December 2006 - Metabolic placed in trading halt</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=574&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">7th December 2006 - Metabolic\'s request for trading halt</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td></td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=573&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">5th December 2006 - Open Briefing with CEO of Metabolic</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the transcript from an Open Briefing with the CEO of Metabolic, covering the Company\'s lead projects and strategy.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=572&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">29th November 2006 - ACV1 Clinical Trials Update November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced that the Phase 2A programme for ACV1, for neuropathic pain is progressing well. The first group of patients in the first of two trials in this Phase 2A programme have been treated and the second trial is due to commence in Q107. Additionally, a separate trial to test safety of a higher dose level of ACV1 commenced in Q406.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=571&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th November 2006 - Options Study Update - 27 November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic announced that more than 300 subjects have completed the Phase 2B OPTIONS Study so far. The last subject will complete the trial in December 2006 with results expected to be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=570&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th November 2006 - Domestic Roadshow November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay, CEO of Metabolic, will be meeting with various domestic brokers and analysts this week. This roadshow presentation provides an update on the Company\'s development and strategy.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=569&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd November 2006 - ACV1 PreClinical Update November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic has made further progress with the oral version of its neuropathic pain drug ACV1. In addition, an independent study conducted in the US has identified important information about its mechanism of action.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=567&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th November 2006 - Appendix 3Y 17th November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3Y 17th November 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=566&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th November 2006 - Appendix 3Y 17th November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3Y 17th November 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=565&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th November 2006 - Appendix 3B 17th November 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B 17th November 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=561&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th October 2006 - 2006 AGM: Voting Results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement includes a summary of voting on each resolution put to shareholders at the Company\'s 2006 AGM.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=560&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th October 2006 - New Constitution</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Shareholders of Metabolic approved a new Constitution on 27 October 2006. The complete Constitution is included in this announcement.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=559&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th October 2006 - 2006 AGM Chairman\'s Address and CEO\'s presentation</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement includes the formal address given by the Chairman to shareholders at the Company\'s 2006 AGM and a presentation by the CEO.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=558&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd October 2006 - Change in Substantial Holding</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Monash Investments regarding the change in their substantial holding of Metabolic shares.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=556&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th October 2006 - Response to ASX Query</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This letter from Metabolic is is response to a share price query from the ASX.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=549&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th October 2006 - Quarterly Investor Update - 17 October 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the third quarter of 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=548&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">12th October 2006 - Market Presentation - Intersuisse Conference October 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at the Intersuisse Life Sciences Forum (London) to increase awarenenss of Metabolic in the UK and Europe. The slide-show presentation provides an up-to-date overview of Metabolic\'s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=546&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">9th October 2006 - Appendix 3B 9th October 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B 9th October 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=547&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">5th October 2006 - Obesity Trial Update - October 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The first 100 subjects have completed the Phase 2B OPTIONS Study including 24 weeks of daily oral dosing of obesity drug, AOD9604. The last subject will complete the trial in December 2006 with results expected to be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=545&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">28th September 2006 - UBS Global Life Sciences Conference - presentation by Dr Roland Scollay</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at the UBS Global Life Sciences Conference in New York to increase awareness of Metabolic in the US. The slide-show presentation provides and up-to-date overview of Metabolic\'s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=544&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th September 2006 - Metabolic\'s neuropathic pain drug, ACV1, enters Phase 2A clinical trials</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic commenced the first trial in its Phase 2A programme for ACV1, for the treatment of neuropathic pain. This first trial will target neuropathic sciatic pain and results are expected to be announced during the first six months of 2007 (H107).</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=542&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">26th September 2006 - 2006 Annual Report and Notice of Annual General Meeting</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This announcement contains the Company’s 2006 Annual Report, Notice of Annual General Meeting and sample voting form.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=557&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">1st September 2006 - Quarterly rebalance of S&amp;P/ASX Indices</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice that Metabolic has been removed from the S&amp;P/ASX 300 Index</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=539&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th July 2006 - Quarterly Investor Update July 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>This update contains a summary of Company news during the second quarter of 2006.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=538&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">19th July 2006 - Obesity trial update: First subject completes treatment</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The first few subjects have completed treatment including 24 weeks of daily oral dosing of AOD9604. The last subject will complete the trial in December 2006 with results expected to be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=537&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">11th July 2006 - NRP collaboration: Research on nerve protection compounds published in science journal</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Research on Neural Regeneration Peptides (NRPs) has been published in the international science journal, \'Experimental Cell Research\'. NRPs have previously shown promising effects in a rat model of nerve damage. Formal preclinical development of NRPs expected to commence in 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=520&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">21 June 2006 - Metabolic\'s osteoporosis drug: additional animal data support further beneficial effects of AOD9604</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Additional animal data indicate AOD9604 has beneficial effects on trabecular bone as well as corticol bone. Two further animal studies are underway to investigate the optimal dose of AOD9604 for osteoporosis; and the possible role of the drug in treatment of osteoporosis (in addition to prevention, as previously determined).</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=465&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">14th June 2006 - Life Sciences (USA) Presentation</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at the Pacific Growth Equities\' 2006 Life Sciences Growth Conference in San Francisco to increase awareness of Metabolic in the USA. Slide-show presentation provides an up-to-date overview of Metabolic\'s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=466&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd May 2006 - Roadshow Presentation - company update May 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay met with several analysts and institutions to increase local awareness of Metabolic. Slide-show presentation provides an up-to-date overview of Metabolic’s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=467&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">10th May 2006 - Quarterly Investor Update 10 May 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Summary of Company news during the first quarter of 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=468&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">8th May 2006 - Audio Broadcast - CEO interviewed by Boardroom Radio</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay’s interview by Boardroom radio has been audio webcast and is available at www.boardroomradio.com</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=469&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">2nd May 2006 - Metabolic completes enrolment for obesity clinical trial ahead of schedule</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>536 subjects have been enrolled in the Phase 2B trial, known as the “OPTIONSEstudy for obesity drug, AOD9604. This trial will now end in December 2006 and results will be announced in March 2007.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=470&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">5th April 2006 - Metabolic CEO to present at US biotech conferences</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at various biotechnology conferences and expos in the USA. Slide-show presentation provides an up-to-date overview of Metabolic’s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=471&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">30th March 2006 - Change in Substantial Holding</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official notice from Monash Investments regarding the dilution of their substantial holding due to the recent share placement by Metabolic</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=472&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">24th March 2006 - Appendix 3B - New issue of options</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>New issue of shares and options, pursuant to the private placement on 21 March 2006</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=473&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">24th March 2006 - Notice under section 708A (5)(e)</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official cleansing statement Eno outstanding disclosures</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=474&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">21st March 2006 - Metabolic completes A$13 million share placement</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Private placement of 30.2 million shares to international and Australian institutional investors. Funds raised will advance Metabolic’s drug pipeline for pain, osteoporosis and oral delivery platform for peptides.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=475&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">17th March 2006 - Trading Halt 17th March 2006</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Official trading halt request by Metabolic</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=476&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">6th March 2006 - Clinical Trials Update</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The Phase 2B trial for obesity drug, AOD9604 is progressing well, on schedule, and preparation is underway for the Phase 2A program for ACV1, for pain</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=477&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">27th February 2006 - Half Yearly Report / Half Yearly Accounts</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Financial report for the six months ended 31 December 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=478&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">16th February 2006 - NRP Update: Metabolic and Neuren report promising animal efficacy data in collaborative project </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>New compound, Neural Regeneration Peptide: NNZ-4921, has been shown to prevent or reverse peripheral neuropathy (nerve damage) in an animal study</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=479&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">15th February 2006 - CEO to present at BioCEO &amp; Investor Conference in New York</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay participated as a panelist at the BioCEO &amp; Investor Conference in New York, and gave a presentation on Metabolic’s lead drugs AOD9604 for obesity, including details of previous trial results, and a potential new use for the drug.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=480&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">8th February 2006 - Investor Roadshow Presentation - USA</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay presented at the Biotechnology Organisation (BIO) Conference and met with several analysts and institutions to increase awareness of Metabolic in the USA. Slide show presentation provides an up-to-date overview of Metabolic’s business.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=481&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">6th February 2006 - Metabolic Quarterly Investor Update Number 12 </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Summary of Company news during the fourth quarter of 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=482&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">1st February 2006 - Appendix 3Y - Change of Director’s Interest Notice</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Dr Roland Scollay was granted 1,000,000 options, pursuant to the Metabolic Employee Share Option Plan, approved by shareholders at the 2005 Annual General Meeting on 28 October 2005.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=483&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">1st February 2006 - Appendix 3B - New issue of options </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>New issue of 1,000,000 MBPAQ unquoted options, pursuant to the Metabolic Employee Share Option Plan, approved by shareholders at the 2005 Annual General Meeting on 28 October 2005.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=484&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">31st January 2006 - Potential new use in osteoporosis adds value to Metabolic\'s obesity drug</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Animal study: Orally delivered drug, AOD9604, shows an effect in preventing bone loss and maintaining bone quality in a rat model of osteoporosis.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=485&amp;nav_cat_id=164&amp;nav_top_id=58&amp;dsb=1738\">23rd January 2006 - Update on Phase 2B dosing trial for obesity drug</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>The low dose, Phase 2B trial, known as the “OPTIONSEstudy is proceeding on schedule with recruitment on track an all ethics approvals obtained.</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n</tbody>\r\n</table>\r\n<h3>ASX Releases 2005</h3>\r\n<table class=\"listing\" style=\"width: 100%;\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\r\n<tbody>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=428&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">18th November 2005 - ASX Appendix 3Y Change of Director\'s Interest - A Emmett</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3Y Change of Director\'s Interest - A Emmett</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=427&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">16th November 2005 - ACV1 Phase 1 results</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ACV1 Phase 1 results</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=425&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">4th November 2005 - CEO Presentation Rodman Renshaw Conference 7 November 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>CEO Presentation Rodman Renshaw Conference 7 November 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=423&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">2nd November 2005 - ASX Appendix 3B 2nd November 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3B 2nd November 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=422&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">31st October 2005 - ASX Appendix 3X 31st October 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3X 31st October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=419&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th October 2005 - Chairman\'s Address and CEO Presentation at AGM 28th October 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Chairman\'s Address and CEO Presentation at AGM 28th October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=421&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th October 2005 - Metabolic AGM Results 28 October 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic AGM Results 28 October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=420&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th October 2005 - Amended Constitution of Metabolic Pharmaceuticals 28 October 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Amended Constitution of Metabolic Pharmaceuticals 28 October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=418&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">26th October 2005 - Metabolic Quarterly Investor Update </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic Quarterly Investor Update - 26 October 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=417&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th October 2005 - Metabolic ranks number 1 as Australia\'s top innovator</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic ranks number 1 as Australia\'s top innovator</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=416&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">19th October 2005 - Metabolic CEO to present to Health Care and Life Science Conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic CEO to present to Health Care and Life Science Conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=433&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">22nd December 2005 - ASX Appendix 3Y R Scollay</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3Y R Scollay</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=412&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">18th October 2005 - Metabolic starts next clinical trial of obesity drug</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic starts next clinical trial for obesity drug</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=415&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">18th October 2005 - VP Clinical Development Presentation at NAASO Conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>VP Clinical Development Presentation at NAASO Conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=409&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th October 2005 - Appointment of Non-Executive Director</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appointment of Non-Executive Director</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=404&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">27th September 2005 Release of Securities from Escrow - Monash Investment Holdings P/L</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Release of Securities from Escrow - Monash Investment Holdings P/L</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=432&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">22nd December 2005 - ASX Appendix 3Y C Belyea</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3Y C Belyea</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=403&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">7th September 2005 - Metabolic Pharmaceuticals CEO to present at biotechnology conference</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic Pharmaceuticals CEO to present at biotechnology conference</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=402&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">1st September 2005 - Change of Director\'s Interest - R Scollay</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest - R Scollay</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=401&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">26th August 2005 App 4E Preliminary Final Report</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Preliminary Final Report</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=400&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">23rd August 2005 - Appointment of new CFO</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appointment of new CFO</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=431&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">22nd December 2005 - ASX Appendix 3B</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>ASX Appendix 3B</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=399&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">15th August 2005 - Metabolic ACV1 Update 15 August 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Metabolic ACV1 Update 15th August 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=398&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">8th August 2005 - ASX Appendix 3B 8th August 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B - 8th August 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=395&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th Aug 2005 - Change of Director\'s Interest - A Emmett</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest - A Emmett</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=396&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th Aug 2005 - Change of Director\'s Interest - C Belyea</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest - C Belyea</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=397&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th Aug 2005 - Change of Director\'s Interest - E Vos</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Change of Director\'s Interest - E Vos</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=390&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">28th July 2005 - ASX Appendix 3B 28th July 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3B - 28th July 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=430&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">25th November 2005 - ASX Appendix 3Y Change in Director\'s Interest - R Baker</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Appendix 3Y Change in Director\'s Interest - R Baker</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=386&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">21st July 2005 - SPP Announcement </a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Share Purchase Plan Announcement 21st July 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=385&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">5th July 2005 - Investor Update 5th July 2005</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Investor Update 5th July 2005</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=384&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th June 2005 - Notice under Section 708A of the Corps Act</a></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td>Notice under Section 708A of the Corps Act</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"2\"></td>\r\n</tr>\r\n<tr>\r\n<td></td>\r\n<td><a href=\"../article_view.asp?id=383&amp;nav_cat_id=141&amp;nav_top_id=58&amp;dsb=1740\">24th June 2005 - Share Purchase Plan Offer to